357
JANUARY 2012 • VOLUME 12-01 PHARMACISTS’ EDITION Nova Scotia Formulary Updates New Products New Diabetic Products – PRP New Exception Status Benefits Calcitonin Intranasal Criteria Code Non-Insured Products Transition Fees Changes to the Nova Scotia Formulary on the Pharmacare Website Included with this Bulletin Prescriber List – January 2012 Nova Scotia Formulary Updates New Products The following product was reviewed by the Canadian Drug Expert Committee (CDEC), and will be listed as a benefit, effective February 2, 2012. PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR Twynsta® (telmisartan/ amlodipine) 40/5mg Tab 40/10mg Tab 80/5mg Tab 80/10mg Tab 02371022 02371030 02371049 02371057 DNP DNP DNP DNP SF SF SF SF BOE BOE BOE BOE Decision Highlights Telmisartan is an agiotensin II receptor blocker and amlodipine is a calcium channel blocker. Telmisartan/amlodipine fixed dose combination (FDC), at both the lowest and highest recommended doses, was demonstrated to be bioequivelant to the same doses of its individual components given separately. The following products are new listings to the Nova Scotia Formulary, effective February 2, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated. PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR AC Girlz Chamber (replacing AeroChamber AC-Girlz) 96899963 DNP FC TMI AC Boyz Chamber (replacing AeroChamber AC-Boyz) 96899962 DNP FC TMI ASATAB 325mg EC Tab 02352427 DNP SFC ODN

Nova Scotia Formulary Updates

Embed Size (px)

Citation preview

JANUARY 2012 • VOLUME 12-01 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Products

New Diabetic Products – PRP

New Exception Status Benefits

Calcitonin Intranasal Criteria Code

Non-Insured Products

Transition Fees

Changes to the Nova Scotia Formulary on the Pharmacare Website

Included with this Bulletin

Prescriber List – January 2012

Nova Scotia Formulary Updates New Products The following product was reviewed by the Canadian Drug Expert Committee (CDEC), and will be listed as a benefit, effective February 2, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Twynsta® (telmisartan/amlodipine)

40/5mg Tab 40/10mg Tab 80/5mg Tab 80/10mg Tab

02371022 02371030 02371049 02371057

DNP DNP DNP DNP

SF SF SF SF

BOE BOE BOE BOE

Decision Highlights

Telmisartan is an agiotensin II receptor blocker and amlodipine is a calcium channel blocker.

Telmisartan/amlodipine fixed dose combination (FDC), at both the lowest and highest recommended doses, was demonstrated to be bioequivelant to the same doses of its individual components given separately.

The following products are new listings to the Nova Scotia Formulary, effective February 2, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

AC Girlz Chamber (replacing AeroChamber AC-Girlz)

96899963 DNP FC TMI

AC Boyz Chamber (replacing AeroChamber AC-Boyz)

96899962 DNP FC TMI

ASATAB 325mg EC Tab 02352427 DNP SFC ODN

PAGE 2 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

New Products continued…

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS

MFR

Bisacodyl-ODAN 5mg Tab 02273411 DNP C ODN

Chloral hydrate -ODAN 100mg/mL Syr 02247621 DNP SFC ODN Citrodan (magnesium citrate) 50mg/mL O/L 80001809 DNP C ODN

Diamicron® MR 60mg Tab 02356422 DNP SFD SEV

Erythromycin Opthalmic Ointment 0.5% 02326663 DNPMO SF SGQ

JAMP-K8 (potassium chloride)

600mg (8mEq) SR Tab 80013005 DNP SFC JPC

JAMP-K20 (potassium chloride)

1500mg (20mgEq) SR Tab

80013007 DNP SFC JPC

ODAN K-20 (potassium chloride)

1500mg (20mgEq) SR Tab

80004415 DNP SFC ODN

The following products are new listings to the Nova Scotia Formulary, effective February 2, 2012. The benefit status and MRP within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT DIN MRP (EFFECTIVE FEB 23, 2012)

PRESCRIBER BENEFIT STATUS MFR

valsartan 40mg tab

CO Valsartan 40mg Tab 02337487 0.4657 DNP SF COB

Sandoz Valsartan 40mg Tab 02356740 0.4657 DNP SF SDZ

Teva-Valsartan 40mg Tab 02356643 0.4657 DNP SF TEV

Diovan® 40mg Tab 02270528 0.4657 DNP SF NVR

PAGE 3 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

New Diabetic Products – PRP The following products are new listings to the Nova Scotia Formulary, effective February 2, 2012. The benefit status and PRP within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT DIN/PIN PRP PRESCRIBER BENEFIT STATUS MFR

BGStar® Test Strips (50) 97799464 0.7400 DNP SFD SAV

BGStar® Test Strips (100) 97799465 0.6750 DNP SFD SAV

BGStar® Lancets (100) 97799466 0.0500 DNP SFD SAV New Exception Status Benefits The following products were reviewed by the Atlantic Expert Advisory Committee (AEAC) and will be listed as exception status benefits, with the following criteria, effective February 2, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

CO Etidronate 200mg Tab 02248686 DNP E (SFC) COB

MYLAN-Etidronate 200mg Tab 02245330 DNP E (SFC) MYL

CO Etidrocal Kit 400mg/500mg Tab 02263866 DNP E (SFC) COB

Etidrocal Kit 400mg/500mg Tab 02353210 DNP E (SFC) SAS

MYLAN-Eti-Cal Carepac 400mg/500mg Tab 02247323 DNP E (SFC) MYL

Novo-Etidronatecal Kit 400mg/500mg Tab 02324199 DNP E (SFC) TEV

Didrocal® Kit 400mg/500mg Tab 02176017 DNP E (SFC) WNC

Criteria for the treatment of osteoporosis associated with documented fragility fracture when alendronate, risedronate and raloxifene are not tolerated or are contraindicated

for the treatment of osteoporosis without documented fragility fracture when the patient is at high 10 year fracture risk (>20% major osteoporotic fracture over 10 years) as indicated by the radiologist on a BMD report, and alendronate, risedronate and raloxifene are not tolerated or are contraindicated

other requests reviewed on a case by case basis Decision Highlights The committee recommended that etidronate be listed with the same criteria as

calcitonin as there is very little evidence of benefit and it is not a first line agent.

PAGE 4 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

New Exception Status Benefits continued…

PRODUCT DIN MRP (EFFECTIVE FEB. 23, 2012)

PRESCRIBER BENEFIT STATUS MFR

Novo-Methylphenidate ER-C 18mg Tab

02315068 1.4276 D E (F) TEV

Novo-Methylphenidate ER-C 27mg Tab

02315076 1.6475 D E (F) TEV

Novo-Methylphenidate ER-C 36mg Tab

02315084 1.8674 D E (F) TEV

Novo-Methylphenidate ER-C 54mg tab

02315092 2.3072 D E (F) TEV

Criteria for patients 6-25 years of age diagnosed with attention deficit hyperactivity disorder (ADHD) who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

- patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

- prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics, general practitioners or other prescribers with expertise in ADHD AND

- have been tried on immediate release or slow release methylphenidate with unsatisfactory results

Decision Highlights The Committee recommended that generic methylphenidate extended release be added to the formulary with the same restrictive criteria as Biphentin®.

Both products are once daily methylphenidate alternatives and generic methylphenidate ER is not more expensive than Biphentin®.

It was recommended to increase the upper age limit to 25 years to allow for psychosocial needs as patients transition into adulthood.

PAGE 5 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

New Exception Status Benefits continued… The following products were reviewed by the Atlantic Expert Advisory Committee (AEAC), and will be listed with the following new criteria, effective February 2, 2012.

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Biphentin® (methylphenidate)

10mg Cap 15mg Cap 20mg Cap 30mg Cap 40mg Cap 50mg Cap 60mg Cap 80mg Cap

02277166 02277131 02277158 02277174 02277182 02277190 02277204 02277212

D D D D D D D D

E (F) E (F) E (F) E (F) E (F) E (F) E (F) E (F)

PFR PFR PFR PFR PFR PFR PFR PFR

Criteria for patients 6-25 years of age diagnosed with attention deficit hyperactivity disorder (ADHD) who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

- patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

- prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics, general practitioners or other prescribers with expertise in ADHD AND

- have been tried on immediate release or slow release methylphenidate with unsatisfactory results

Decision Highlights It was recommended to increase the upper age limit to 25 years to allow for psychosocial needs as patients transition into adulthood.

PAGE 6 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

New Exception Status Benefits continued… The following product was reviewed by the Canadian Drug Expert Committee (CDEC), and will be listed with the following new criteria, effective February 2, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Aclasta® (zoledronic acid) 5mg/100mL Inj 02269198 DNP E (SFC) NVR

Criteria for the treatment of Paget’s disease for women with postmenopausal osteoporosis for whom bisphosphonates are

contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia) and have at least two of the following: - age > 75 years - a prior fragility fracture - a bone mineral density (BMD) T-score ≤-2.5

Decision Highlights Aclasta® (zoledronic acid) is an injectable bisphosphonate agent. There is insufficient evidence that zoledronic acid offers a therapeutic

advantage over oral bisphosphonates, including alendronate. The cost of zolendronic acid is approximately five times that of generic

alendronate. There may be a small proportion of women who are otherwise eligible for

funding of oral bisphosphonates but who are unable to take oral bisphosphonates and who may benefit from annual intravenous bisphosphonate therapy.

The following products were reviewed by the Atlantic Pharmacare Review Committee (APRC) and will be listed as exception status benefits, with the following criteria, effective February 2, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Saizen® (somatropin)

6mg/cartridge 12mg/cartridge 20mg/cartridge

02350122 02350130 02350149

DNP DNP DNP

E (SF) E (SF) E (SF)

EMD EMD EMD

Criteria For the treatment of growth hormone deficiency in patients with Turner Syndrome, upon the request of an endocrinologist or prescriber with a specialty in endocrinology

PAGE 7 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

Calcitonin Intranasal Criteria Code Please note that effective immediately, Criteria Code 90 is available for use for calcitonin intranasal, for the following criteria only:

for the treatment of pain associated with osteoporotic fragility fractures, bone metastases or pathological fractures (short term up to 3 months)

The code will be limited for use to a maximum of 3 months, once per year. The prescriber may submit a request to the Pharmacare office for consideration for beneficiaries who require therapy beyond 3 months. Non-Insured Products The following products were reviewed by the Atlantic Pharmacare Review Committee (APRC), and were not recommended to be listed as insured benefits under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS

MFR

ASATAB 80mg Chewable Tab 02280167 N/A Not Insured ODN

Ferodan (ferrous sulphate)

150mg/5mL Syrup

00758469 N/A Not Insured ODN

Ferodan Infant Drops (ferrous sulphate)

75mg/mL 02237385 N/A Not Insured ODN

PEG 3350 (polyethylene glycol 3350)

100% powder for solution

02358034 N/A Not Insured MSC

Ni-ODAN (nicotinic acid) 500mg ER Tab 00779806 N/A Not Insured ODN

Lidodan Endotracheal (lidocaine)

10mg/ACT liquid

02231147 N/A Not Insured ODN

The following products were reviewed by the Atlantic Expert Advisory Committee (AEAC) and were not recommended to be listed as benefits under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Niaspan FCT® (nicotinic acid)

500mg ER Tab 750mg ER Tab 1000mg ER Tab

02309254 02309262 02309289

N/A N/A N/A

Not Insured Not Insured Not Insured

SNV SNV SNV

Decision Highlights Niaspan FCT® (nicotinic acid) is more expensive than other alternatives without demonstrated superiority.

PAGE 8 OF 8 PHARMACISTS’ EDITION

VOLUME 12-01

Non-Insured Products continued… The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and were not recommended to be listed as benefits under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Revolade® (eltrombopag olamine)

25mg Tab 50mg Tab

02361825 02361833

N/A N/A

Not Insured Not Insured

GSK GSK

Decision Highlights Eltrombopag olamine is a thrombopoietin receptor agonist. In the three double-blind, randomized placebo-controlled trials of patients with

chronic immune thrombocytopenic purpura (ITP), the primary outcome was platelet response, which the Committee considered less clinically relevant than bleeding events.

There are no head-to-head randomized controlled trials comparing eltrombopag with individual comparator treatments for ITP.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Abstral® (fentanyl citrate)

100mcg SL Tab 200mcg SL Tab 300mcg SL Tab 400mcg SL Tab 600mcg SL Tab

02364174 02364182 02364190 02364204 02364212

N/A N/A N/A N/A N/A

Not Insured Not Insured Not Insured Not Insured Not Insured

PAL PAL PAL PAL PAL

Decision Highlights Fentanyl is a µ-opioid receptor antagonist. There are no randomized controlled trials directly comparing fentanyl citrate

sublingual tablets with other less costly opioids available for the management of breakthrough cancer pain.

The cost of fentanyl citrate sublingual tablets greatly exceeds the costs of other available oral opioids.

Transition Fees for the Period of January 1, 2012 to March 31, 2012 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.25 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees. Changes to the Nova Scotia Formulary on the Pharmacare Website Beginning February 2, 2012, the Nova Scotia Formulary will be available on the Nova Scotia Pharmacare website (www.nspharmacare.ca) only in PDF file format. It will continue to be updated monthly. To view PDF files, you need to have Adobe Acrobat Reader installed on your computer. This software is free from the Adobe Web Site. Instructions to download the software, as well as how to search for text in PDF documents, will be provided on the Formulary link.

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

PRESCRIBER LIST – JANUARY 2012

PHYSICIANS

SURNAME TOWN/CITY CPSNSAAL ALI, ABDULLA S 13820 ABBASIAN, ALI SYDNEY 14003 ABBASS, ALLAN A HALIFAX 11867 ABBOTT, EDWARD C HALIFAX 2149 ABDELGADIR, IBRAHIM M ANTIGONISH 15710 ABEL, RACHEL SYDNEY 13484 ABENHEIMER, MARTIN S SYDNEY 6313 ABEYSEKERA, R AMHERST 10449 ABIDI, SABINA HALIFAX 12384 ABONOWARA, ABDULGANI HALIFAX 13826 ABRAHAM, ROBERT J HAMMONDS PLAINS 7645 ABRAHAM, SUMA R TRURO 14001 ABRIEL, DAVID L MAHONE BAY 6371 ABU-WASEL, BASSAM HALIFAX 15643 ABUD, LELY MAHONE BAY 14322 ACHENBACH, JILLIAN M HALIFAX 14623 ACKERMANN, MICHAEL J SHERBROOKE 7806 ACOTT, PHILIP D HALIFAX 10757 ACTON, DAVID C KENTVILLE 7903 ADAMS, HELIKA D SHUBENACADIE 6094 ADAMS, JAMES H DARTMOUTH 4530 ADAMSON, HENRY HALIFAX 7930 ADDIE, BRIAN F EASTERN PASSAGE 13014 ADELASOYE, OLUREMI F NEW GLASGOW 15193 AGO, C T HALIFAX 12606 *AHMAD, AMER R WINDSOR 8002 AHMAD, ASMA R HALIFAX 11192 AHMAD, KHALIL DARTMOUTH 6419 AHMAD, SIRAJ HALIFAX 2893 AHMED, AHMED A HALIFAX 14876 AHMED, TAHIRA S HALIFAX 8129 AIKMAN, PETER J HALIFAX 11875 AINAMO, JYRI S KINGSTON 10743 AIRES, LIANA HALIFAX 12385 AKHTAR, SYED N DARTMOUTH 2610 AKINSOLA, OLUWATOSIN SYDNEY 15497 AL BUGAMI, METEB M HALIFAX 14396 AL KARMI, RANI N SYDNEY 15222 AL-DHAMIN, AMMAR S HALIFAX 15424 AL-KUWAITI, NOORA H 14729 AL-MANAHI, RASHA N NEW GLASGOW 15735 AL-NASSAR, RAFID S NEW GLASGOW 15727 AL-SHAMI, EMAN YARMOUTH 15440 ALAGHBAND-RAD, JAVAD HALIFAX 14290 ALANSARI, NABEEL M CHARLOTTETOWN 15680 ALAS, JUAN P SPRINGHILL 12598 ALBISTON, BRIGIT J BRIDGEWATER 13927 ALDA, MARTIN HALIFAX 12049 ALDRIDGE, DAVID J SYDNEY 11966 ALEXANDER, DAVID I HALIFAX 4551 ALEXIADIS, MARIA HALIFAX 7820 ALI, IDRIS M HALIFAX 7524 ALI, IMTIAZ S HALIFAX 10890 ALI, JAVED E SYDNEY 10745 ALI, SYED Z SYDNEY 14757 ALIAN, WAEL ABD E 13832

SURNAME TOWN/CITY CPSNSALLAN, PATRICIA L ANTIGONISH 6540 *ALLANACH, WILLIAM W 11631 ALLEN, ALEXANDER C HALIFAX 4406 ALLEN, CHRISTOPHER T HALIFAX 4626 ALLEN, DOUGLAS L HALIFAX 4576 ALLEN, MAUREEN A ANTIGONISH 12065 ALLEN, VICTORIA M HALIFAX 10776 ALOYSIUS, JEYARANEE HALIFAX 13532 ALTENKIRK, GARY B TRURO 12100 ALWAYN, IAN P HALIFAX 14599 ALZAIDI, ABDULAZIZ 12904 ALZRIGHE, MOHAMED DARTMOUTH 13428 AMIR-KHALKHALI, B HALIFAX 12391 AMIRAULT, JOHN D HALIFAX 4678 AMIT, MINOLI N ANTIGONISH 6267 ANDERSON, CHARLES C UPPER TANTALLON 6803 ANDERSON, DAVID R HALIFAX 10655 ANDERSON, K ERIC C HALIFAX 12122 ANDERSON, KAREN E HALIFAX 7211 ANDERSON, PETER A HALIFAX 6986 ANDREA, GLENN C HALIFAX 10287 ANDREW, MELISSA K HALIFAX 12658 ANDREWS, DAVID M HALIFAX 3337 ANNAMALAI, SIVAKUMAR SYDNEY 14882 ANSARI, SHOAIB R SYDNEY 14544 ANTONY, S SHEET HARBOUR 13764 APOSTOLIDES, COSTA HALIFAX 12123 AQUINO, EMMANUEL P DARTMOUTH 23 ARAB, MARTHA A HALIFAX 11056 ARCHIBALD, CURTIS HALIFAX 14125 ARCHIBALD, GREGORY C HALIFAX 12371 ARCHIBALD, J FRED HALIFAX 4543 ARCHIBALD, JOHN DAVID NEW GLASGOW 3560 ARCHIBALD, JOHN M SYDNEY 4226 *ARCHIBALD, SHAUNA M HALIFAX 13502 ARMSON, BRIAN A HALIFAX 6363 ARMSTRONG, DUNCAN S HALIFAX 4950 ARORA, GAGAN AMHERST 14813 ASHFAQ, SIRAJUDDIN HALIFAX 3307 ASHOUR, IMAN 13355 ASHTON, BRIAN D BEDFORD 11076 ASIM, HAMMAD H MIRA ROAD 13702 ASPIN, JOHN D HALIFAX 12898 ATIA, JOHN N AMHERST 15064 ATIYAH, ABDULRAZZAK O NEW WATERFORD 10778 ATKINSON, ANTHONY R BRIDGEWATER 6221 ATKINSON, BRADLEY C SHEET HARBOUR 10859 ATKINSON, CHRISTINA M DARTMOUTH 12525 ATKINSON, SUSAN M HALIFAX 10249 ATKINSON, VICTORIA E 12659 AUCOIN, JOSEPH C CHETICAMP 3030 AUCOIN, MARCEL D CHETICAMP 11506 AUDAIN, COLIN V HALIFAX 14113 AUDAIN, VINCENT P HALIFAX 3363 AVERY, CHANDRA M HALIFAX 14479 AWALT, ERIN J HALIFAX 13835

* Refer to page 24 for alternate Pharmacare prescriber number. 2

SURNAME TOWN/CITY CPSNSAWAN, SHAHID I AMHERST 6620 AWWAD, BAHAA E ANTIGONISH 15742 AYLMER, ANNE P HALIFAX 7699 AYLMER, DAVID A TRURO 10332 AYOUB, HAIFA H GUYSBOROUGH 15159 AZER, RAED NEW WATERFORD 11516 AZIZ, SAHAR DARTMOUTH 14104 BADI, FATHI F DARTMOUTH 15459 BADLEY, BERNARD W HALIFAX 5027 BADRELDIN, MOHAMED 12532 BAGNELL, ALEXA L HALIFAX 13453 BAGNELL, PHILIP SCOTT HALIFAX 11632 BAHL, GAURAV HALIFAX 15213 *BAILLY, GREGORY G HALIFAX 11633 BAINS, RAVINDER S HALIFAX 12660 BAKOWSKY, VOLODKO S HALIFAX 11077 BALSER, ERIC F MIDDLETON 12076 BALYS, RICHARD L DARTMOUTH 14222 BANCE, MANOHAR L HALIFAX 12588 BANDER, MAREK S DIGBY 10294 BANJO, OLUFEMI YARMOUTH 15673 BANKS, JOHN V DARTMOUTH 6556 BANKS, MICHAEL R HALIFAX 3558 BARCLAY, SPENCER L TRENTON 3891 BARKOVA, EVA HALIFAX 14408 BARKWELL, ROBERT G ANNAPOLIS ROYAL 11732 BARNES, DAVID C HALIFAX 7067 BARNES, PENELOPE J HALIFAX 10389 BARRY, ANNE E KENTVILLE 6818 *BARSS, DAVID H BRIDGEWATER 4395 BARTON, WILLIAM F DARTMOUTH 4085 BASECQZ, GUY NEW GLASGOW 15705 BASKETT, ROGER J HALIFAX 11634 BASKETT, THOMAS F HALIFAX 6071 BASS, STEPHANIE MUSQ. HARBOUR 13278 BASTA, MAGDY N HALIFAX 11763 BATA, IQBAL R HALIFAX 7662 BATA, NAZLIN I HALIFAX 7458 BAUER, CHRISTOPHER A WOLFVILLE 15391 BAXTER, EDITH M HALIFAX 13580 BAXTER, MARY L DARTMOUTH 12538 BEATON, BLAINE G LUNENBURG 7166 BEAUPRIE, IAN G HALIFAX 7762 BEDARD, RICHARD J SYDNEY 4566 BEED, STEPHEN D ENFIELD 8086 BEGIN, PAUL A OXFORD 6931 BEGUM, REHANA WOLFVILLE 14039 BELEN, JAIME O INVERNESS 3950 BELL, BARBARA A GUYSBOROUGH 12490 BELL, DAVID G HALIFAX 6920 BELL, HELEN F TRURO 4970 BELL, MARILYNNE L HALIFAX 4863 BELLIVEAU, ADELE M DARTMOUTH 10067 BELLIVEAU, DANIEL J HALIFAX 12566 BENDOR-SAMUEL, R HALIFAX 12115 BENNE, MARGARET E GREENFIELD 14310 BENNE, TOBIAS H GREENFIELD 14311 BENNETT, MARK S INVERNESS 10234 BENSTEAD, TIMOTHY J HALIFAX 7091 BENT, ALFRED E BROOKFIELD 13800 BENT, KEVIN P HALIFAX 12053 BENTLEY, JAMES R HALIFAX 10886

SURNAME TOWN/CITY CPSNSBERESFORD, J P HALIFAX 4712 BERGER, CHRISTOPHER BEDFORD 12344 BERGHUIS, HAROLD P TRURO 11184 BERGIN, DEIRDRE B BEDFORD 12884 BERGIN, FIONA A HALIFAX 10079 BERGIN, SIOBHAN M DARTMOUTH 10618 BERMAN, JASON HALIFAX 13915 BERNSTEIN, MARK L HALIFAX 14220 BERRY, ROBERT F HALIFAX 11078 BESSENYEI, ANETT HALIFAX 14703 BETHUNE, DREW C HALIFAX 6401 BETHUNE, GRAEME H HALIFAX 4745 *BEUKES, E GERHARD DIGBY 15399 BEVERIDGE, WILLIAM K KENTVILLE 7986 BEYDOUN, HUSSEIN HALIFAX 11244 BHALLA, SUMEER K 14625 BHAN, VIRENDER HALIFAX 7700 BHANOT, RAJ MOUNT UNIACKE 7628 BHASKARA, SREENIVASA LOWER SACKVILLE 10944 BHATIA, ANUJ TORONTO 15144 BHATTACHARJEE, D NORTH SYDNEY 2862 BHATTACHARYYA, AMAL DARTMOUTH 2238 BIDDULPH, MICHAEL PLEASANTVILLE 13018 BIENKOWSKI, HALINA J AMHERST 8105 BIENKOWSKI, KRZYSZTOF AMHERST 7585 BIERNACKA, MAGDALENA NEW GLASGOW 14062 BILO, JOHN M KENTVILLE 11885 BILSKI-PIOTROWSKI, M HALIFAX 10476 BIRD, RODERICK A SYDNEY 4064 BIRD, SALLY J HALIFAX 14867 BIRNIE, WILLIAM A HALIFAX 6833 BISHOP, ALLEN J KENTVILLE 6009 BISSON, GAIL M SYDNEY 6770 BLACK, JOHN D DIGBY 4382 BLACK, KAREN J HALIFAX 11080 BLACK, KATHARINE A DARTMOUTH 10988 BLACKADAR, ANDREW LIVERPOOL 13388 BLACKIE, BARBARA J HALIFAX 11886 BLAIKIE, PETER G PUGWASH 10477 BLAIR, DAVID M TRURO 6097 BLAIR, WILLIAM H BARRINGTON PASS 6264 BLAKE, KIM HALIFAX 11760 BLANCHARD, MARK C HALIFAX 12442 BLASZKOW-PORANEK, B HALIFAX 7883 BLINN, ALAIN J METEGHAN CNTR 15671 BLOIS, BEAU TRURO 15162 BLOOM, NANCY A HALIFAX 14577 BLOOM, SETH A HALIFAX 14367 BOBADILLA-MARTINEZ, J AMHERST 12572 BOILEAU, LOUIS O HALIFAX 13417 BOLIVAR, PATRICIA E KENTVILLE 11410 BOLLEDDULA, K HALIFAX 14058 BONANG, LISA M MUSQ. HARBOUR 10781 BOND, DAVID M DARTMOUTH 15183 BONNINGTON, SIMON P ANNAPOLIS ROYAL 15210 BOOD, TIMOTHY W HALIFAX 7186 BOOTH, A WILLIAM ANTIGONISH 6893 BORGAONKAR, JOY N HALIFAX 11977 BORST, SJOERD A HALIFAX 15346 BORTOLUSSI, ROBERT A HALIFAX 4880 BOSMA, MARK A HALIFAX 12395 BOTROUS, MARY BEDFORD 15045

* Refer to page 24 for alternate Pharmacare prescriber number. 3

SURNAME TOWN/CITY CPSNSBOTTEN, DAVID L HALIFAX 12936 BOUCHER, CHARLES B CLEVELAND 4998 BOUDREAU, ANDRE DARTMOUTH 14794 BOUDREAU, CINDY L YARMOUTH 6897 BOUDREAU, D TODD STELLARTON 13706 BOURKE, KEVIN E HALIFAX 7321 BOUTCHER, PAUL A KENTVILLE 14707 BOUTILIER, CAROL M GLACE BAY 7138 BOUTILIER, NICOLE A WESTVILLE 12882 BOUTILIER, ROBERT G FALL RIVER 11635 BOUZAYEN, RENDA HALIFAX 12511 BOWDEN, LOIS A PORT WILLIAMS 7703 BOWEN, A SCOTT L AMHERST 12891 BOWER, NEIL L TRURO 7777 BOWES, DAVID M HALIFAX 13842 BOWES, VERNON F HALIFAX 2775 BOWIE, DENNIS M HALIFAX 4059 *BOYD, GORDON J HALIFAX 10782 BRADLEY, BILL R DARTMOUTH 10279 BRADLEY, CHRISTINE 13581 BRADY, JOLENE N HALIFAX 13179 BRAKE, DAVID J SYDNEY 10082 BRAKE, JONATHAN A EASTERN PASSAGE 14380 BREITLING, MAGNUS K HALIFAX 15383 BRENNAN, ELIZABETH B ANTIGONISH 10419 BRENNAN, MICHAEL B ANTIGONISH 10070 BRENNAN, PETER G HALIFAX 10357 BRIEN, DONALD M MIRA ROAD 11997 BRISSEAU, GUY F HALIFAX 10771 BRNA, PAULA M DARTMOUTH 13086 BROCK, JO-ANN K HALIFAX 13285 BRODAREC, IVAN YARMOUTH 10672 BROMLEY, PETER J LOWER SACKVILLE 10783 BROOKS, ANN BEDFORD 7092 BROOKS, JANE C MIDDLETON 12003 BROOKS, SIMON A BEDFORD 7080 BROSKY, GERALD M HALIFAX 7671 BROWN, BASIL S HALIFAX 2870 BROWN, CHARLES A KENTVILLE 2406 BROWN, DONALD C HALIFAX 5008 BROWN, MICHAEL PETER HALIFAX 13390 BROWN, ROBERT L HALIFAX 2137 BROWN, TIMOTHY HALIFAX 12129 BROWN, WANDA G TRURO 8123 BROWN, WAYNE C MUSQ. HARBOUR 4203 BROWNSTONE, ROBERT M HALIFAX 12534 BRUNET, AILEEN S DARTMOUTH 14203 BRYDIE, ALAN O HALIFAX 13380 BRYDIE, SARAH E HALIFAX 14294 BUCHHOLZ, KENNETH P ANNAPOLIS ROYAL 6212 *BUCKLEY, NIALL J WINDSOR 7794 BUDDEN, HEIDI L SYDNEY 13554 BUDUHAN, GORDON HALIFAX 15105 BUFFETT, BERNARD R NEILS HARBOUR 6911 BUFFETT, LAWRENCE M DARTMOUTH 2266 BUHARIWALLA, FAROKH R SYDNEY 6729 BULAJIC, RANKA B MIRA ROAD 15421 BULLOCK, GRAHAM L HALIFAX 8097 BULLOCK, MARTIN J HALIFAX 11393 BURCH, KAREN A KENTVILLE 14600 BURDEN, GEORGE M ELMSDALE 4957 BURGE, FREDERICK I HALIFAX 8102

SURNAME TOWN/CITY CPSNSBURGESS, GINA M HALIFAX 10084 BURGESS, LORRAINE T KENTVILLE 7319 BURKE, BRIAN J PORT WILLIAMS 10085 BURKE, JOHN W HALIFAX 11786 BURNS LACHANCE, J HAMMONDS PLAINS 14247 BURNS, A GEORGE LOUISBOURG 12242 BURNS, EMMA C HALIFAX 14136 BURNSTEIN, MATTHEW D HALIFAX 6752 BURRELL, STEVEN C HALIFAX 11249 BURRILL, RANDY S PICTOU 6802 BURTON, ELIZABETH A HALIFAX 14137 BUSAHMEN, WALEED E DARTMOUTH 15457 BUSH, ROBERT P TATAMAGOUCHE 10087 BUSSEY, CHRISTY C HALIFAX 14414 BUSSEY, LYNN ANN L HALIFAX 13424 BUSTIN, ROBIN G BERWICK 6204 BUTLER, CLAY K GLACE BAY 10657 BUTLER, GREGORY J CANNING 6129 BUTLER, TREVOR KENTVILLE 12667 BUTT, ROBINETTE D HAMMONDS PLAINS 13196 BUZAID, AMIN SYDNEY 14883 CADEGAN, PERRY K GLACE BAY 4526 CAIN, EDWARD J HALIFAX 4924 CAIN, MICHELLE R YARMOUTH 11197 CAINES, JUDY S HALIFAX 4790 CAJEE, ISMAIL HALIFAX 10696 CALKIN, CYNTHIA V HALIFAX 10785 CALNEN, CHARLOTTE A HALIFAX 12668 CALVERLEY, VIRGINIA C HALIFAX 7148 CAMERON, CATHERINE J SCOTSBURN 7596 CAMERON, ESTELLE E SYDNEY 4828 CAMERON, IAN A SHERBROOKE 4996 CAMERON, JEAN M ANTIGONISH 7404 CAMERON, KENNETH M DARTMOUTH 4962 CAMERON, MARIANNE C HALIFAX 14653 CAMERON, STEWART M HALIFAX 7748 CAMPBELL, DONALD M DARTMOUTH 4055 CAMPBELL, GENEVIEVE M DARTMOUTH 6678 CAMPBELL, GLENN R HALIFAX 11889 CAMPBELL, JOHN M 12398 CAMPBELL, MARY-ANNE SYDNEY 7335 CAMPBELL, SAMUEL G HALIFAX 11499 CARANDANG, CARLO G HALIFAX 13965 CARBYN, KEVIN M HALIFAX 10484 CAREY, AIDAN G LOWER SACKVILLE 7459 CARPENTER, FREDERICK TRURO 6243 CARR, BRENDAN S HALIFAX 10381 CARREY, NORMAND J HALIFAX 11501 CARRILLO, MONICA SYDNEY 13266 CARSLEY, HOLLY H TATAMAGOUCHE 13496 CARTER, ALEXANDRA J HALIBUT BAY 14782 CARTER, JOHN E HALIFAX 12487 CARTER, LORNA J DARTMOUTH 6190 CARVER, DANIEL J HALIFAX 7320 CASEY, J STEPHANIE HALIFAX 6773 CASEY, PATRICK J HALIFAX 11636 CASSIDY, BEVERLEY D WOLFVILLE 10464 CASSIDY, KERI-LEIGH HALIFAX 12912 CEPICA ANGEL, DENISA FALL RIVER 13019 CERVIN, CATHERINE K HALIFAX 7670 CHADWICK, JOHN A SYDNEY 2623 CHALATI, BACHAR TRURO 13140

* Refer to page 24 for alternate Pharmacare prescriber number. 4

SURNAME TOWN/CITY CPSNSCHALMERS, RONALD A TRURO 4058 CHALONER, WOUNA M SHELBURNE 12589 CHAMPION, JEFFREY A DARTMOUTH 7170 CHANDLER, JAMES D YARMOUTH 7706 CHANDLER, JULIE E YARMOUTH 7502 CHAO, ERIC D HAMMONDS PLAINS 15428 CHARBONNEAU, R 14630 CHARLEBOIS, PAUL B HALIFAX 13212 CHATURVEDI, PRABHAT K GLACE BAY 3252 CHAWLA, RAKESH HAMMONDS PLAINS 13696 CHAWLA, VISHAL HALIFAX 12670 CHEAH, KEE S BEDFORD 3833 CHEEVERS, PAUL M YARMOUTH 13689 *CHEHIL, SONIA HALIFAX 11891 CHEN, ROBERT HALIFAX 11379 CHENG, CALVINO K HALIFAX 13973 CHENG, NATALIE Y DARTMOUTH 15488 CHENGAPA, VINNIE K HALIFAX 10369 CHERNIN, ANDREA L HAMMONDS PLAINS 10152 CHEVERIE, DONALD J DARTMOUTH 6850 CHIASSON, JOHN D ANTIGONISH 6117 CHIASSON, MEREDITH D FALL RIVER 14111 CHIASSON, MICHEL T CHETICAMP 13124 CHILDS, CHRISTOPHER M BEDFORD 3288 CHISHOLM, BLANCHE T HALIFAX 10601 CHISHOLM, JANICE D HALIFAX 12399 CHISHOLM, KENNETH C HALIFAX 7567 CHOBOTUK, TARA D 14632 CHOKSHI, RASHMIKANT G SYDNEY 2981 CHOW, CARLYLE S BADDECK 3035 CHOW, LINDA Y HALIFAX 12074 CHOWDHURY, DHIMAN HALIFAX 11591 CHOWDHURY, SMRITI HALIFAX 11587 CHRISTIANS, NEIL J SYDNEY 13507 CHRISTIE, KEVIN 13910 CHRISTIE, SEAN D HALIFAX 11414 CHUI, SAI-TAO LOWER SACKVILLE 2723 CHUN, SAMUEL S DARTMOUTH 11561 CHURCH, CHRISTOPHER L BRIDGEWATER 10758 CHURCH, RHONDA L BRIDGEWATER 10937 CIACH, MICHELLE BEDFORD 14141 CLAGUE, NICHOLAS P TRURO 10934 CLARK, ALEXANDER J HALIFAX 15152 *CLARK, DONALD F KENTVILLE 11531 CLARKE, ADAM C KENTVILLE 11893 CLARKE, BARRY S HALIFAX 7633 CLARKE, BRIAN A HALIFAX 13585 CLARKE, DAVID B HALIFAX 11566 CLARKE, GREGORY V KENTVILLE 12335 CLARKE, JAMES R HALIFAX 12672 CLARKE, KAREN A HALIFAX 7733 CLIFTON, NEIL A ANTIGONISH 12619 CLONEY, JACQUELINE F LOWER SACKVILLE 4959 CLORY, MICHAEL B BEDFORD 10698 CLOUTIER, LOUISE WOLFVILLE 4416 COADY, CATHERINE M HALIFAX 10254 COAKLEY, ARTHUR G BADDECK 11491 COGSWELL, ESTHER M KENTVILLE 10787 COHEN, ROBERT E SYDNEY 3862 COISH, CHARLES NORTH SYDNEY 12554 COLE, BASILON C NEW GLASGOW 6603 COLE, ELIZABETH M WINDSOR 11976

SURNAME TOWN/CITY CPSNSCOLES, CHAD P HALIFAX 11640 COLES, JOYCE K HATCHETT LAKE 14226 COLLICUTT, JAMES A SYDNEY 11025 COLLINS, JAMES A PORT HAWKESBURY 4556 COLP, JEFFREY N HATCHET LAKE 10489 COLTER, KIMBERLEY A DARTMOUTH 11087 COLWELL, BRUCE D HALIFAX 11234 COLWELL, JOHN R BRIDGEWATER 12639 COMEAU, ALBAN L SAULNIERVILLE 4995 *CONNELL, CATHY A HALIFAX 8106 CONNELLY, ALAN B KENTVILLE 3572 CONNIDIS, STEPHANIE A HALIFAX 10402 CONNORS, LORI A BEDFORD 13847 CONRAD, SARAH L LUNENBURG 14693 CONROD, CHERYL K SYDNEY 7588 CONTER, HOWARD S HALIFAX 7109 CONYERS, ROOP ANNAPOLIS ROYAL 14553 COOK, CHRISTOPHER T TRURO 13460 COOK, MICHAEL W TRURO 4565 COOK, STEVEN T TRURO 3861 COOKEY, BENEDICT J DARTMOUTH 4063 COOLEN, JILLIAN D HALIFAX 14251 COONAN, THOMAS J HALIFAX 4480 COOPER ROSEN, ETHEL G DARTMOUTH 6505 COOPER, PHILLIP W ANTIGONISH 10963 COOPER, ROBERT J PICTOU 12476 *CORKUM, THOMAS P DARTMOUTH 3719 CORSTEN, PETER G HALIFAX 11088 COSH, SARAH M LIVERPOOL 14804 COTE, M CHRISTENA HALIFAX 7324 COTTREAU, ALISON M YARMOUTH 7349 COUBAN, STEPHEN HALIFAX 11560 COUPER, JANET A HD ST MARG BAY 10554 COUTURE, DOMINIQUE J YARMOUTH 10582 COUTURE, SOPHIE DARTMOUTH 13968 COVERT, ALAN A HALIFAX 3698 COVERT, CAROLINE R HALIFAX 14063 COVERT, SABRINA K KENTVILLE 13023 COVINGTON, NANCY I HALIFAX 4547 COX, CHRISTOPHER P HALIFAX 14477 COX, J JOSEPH SYDNEY 13563 COX, JAFNA L HALIFAX 10252 COX, JAMIE R FALMOUTH 13467 COX, KAREN A CHESTER 12921 CRAGG, FRANK J SYDNEY 7747 CRAIG, CATHERINE M DARTMOUTH 11159 CRAIG, PATRICIA A NEW GLASGOW 10007 CRAM, JENNIFER E ANNAPOLIS ROYAL 14868 CRASWELL, DONALD F MIDDLETON 3342 *CRAWFORD, KIM R LIVERPOOL 6952 CRAWLEY, FRANCES J WINDSOR 7602 CREIGHTON, DAVID A DARTMOUTH 6990 CREIGHTON, PAULA GLACE BAY 13137 CRITCHLEY, CAROL A MIRA ROAD 4820 CROCKER, JOHN F HALIFAX 2629 CRON, CHARLES C HALIFAX 3583 CROOKS, BRUCE N HALIFAX 13135 CROOKS, HARRIS G HATCHET LAKE 4521 CROSBIE, STEPHEN H NORTH SYDNEY 7575 CROSBY, AMANDA R STILLWATER LAKE 14634 CROSBY, JEAN D SYDNEY 6121 CROSKERRY, PATRICK G GLEN HAVEN 7090

* Refer to page 24 for alternate Pharmacare prescriber number. 5

SURNAME TOWN/CITY CPSNSCROWELL, DENISE M HALIFAX 13045 CROWELL, RICHARD H HALIFAX 6223 CRUESS, ALAN F HALIFAX 13217 CRUZ, ARTURO M DARTMOUTH 6815 CUDMORE, DAVID P ANTIGONISH 6376 CULLIGAN, W BRENT HALIFAX 12400 CUMMINGS, ELIZABETH A HALIFAX 11177 CURLEY, MICHAEL A HALIFAX 13292 CURLEY, WILLIAM F TRURO 10895 CURRIE, THOMAS B SYDNEY 11332 CURRY, PHILIP L SYDNEY RIVER 7408 CURRY, STEPHEN A HALIFAX 10642 CURTIS, GARY M TRURO 3037 CURTIS, HEATHER A HALIFAX 13293 CURTIS, JOHN C BEDFORD 4913 CURTIS, JOYCE B HALIFAX 4766 CURWIN, JULIE M SYDNEY 12871 CUSSEN, MICHAEL J NEWPORT 7034 CUTLER, SUSAN E NEW GLASGOW 14635 CWAJNA, WLADYSLAWA HALIFAX 10791 D'ANJOU, CATHERINE M HALIFAX 13848 D'ARCY, DIANE L HALIFAX 7537 D'ENTREMONT, JULITE L BRIDGEWATER 14638 D'ENTREMONT, LIONEL J METEGHAN CNTR 4767 D'EON, JACQUELINE R PUBNICO 10491 D'INTINO, ANNE F SYDNEY 6510 D'INTINO, YOLANDA M SYDNEY 6852 DABBOUR, SAM HALIFAX 13024 DAKIN HACHE, KELLY A HALIFAX 12401 DAMACEN, HARVEY HALIFAX 14859 DARVESH, SULTAN HALIFAX 7965 DAS, BIJON HALIFAX 12673 *DAUPHINEE-BENTLEY, P K PARRSBORO 14109 DAVEY, COLIN F LOWER SACKVILLE 10021 DAVID, YASMINE HALIFAX 3318 DAVIDSON, DION L KENTVILLE 13945 DAVIS, DONNA J HALIFAX 10792 DAVIS, GEORGE R DARTMOUTH 4463 DAVIS, IAN R HALIFAX 11869 DAVIS, JOANN E HALIFAX 11257 DAVIS, MARY L HALIFAX 11193 DAVIS, PHILIP J HALIFAX 3699 DAWOOD, ISIS HALIFAX 13757 DAYAL-GOSINE, LYSTRA R HALIFAX 3229 DE BOER, CORNELIS TRURO 11324 DE SAINT SARDOS, A BRIDGEWATER 14759 DE, SABE K BEDFORD 12402 DEARMAN, LISA M WOLFVILLE 10094 DEBAIE, DARALYN M HALIFAX 14636 DECOSTE, REBECCA HALIFAX 12403 DELANEY, SUSAN M DARTMOUTH 12404 DELISLE, ISABELLE M HALIFAX 7637 DELIU, ENVER HALIFAX 12575 DELVA, M DIANNE HALIFAX 14516 DELVA, NICHOLAS J HALIFAX 14275 DEMCOE, ALISTAIR R 14706 DEMIAN, HANY A HALIFAX 14593 DEMPSEY, IAN M DARTMOUTH 11534 DEMPSTER, JEFFREY J HALIFAX 12548 DEROCHE, STEVEN A PETIT DE GRAT 15688 DESHWAL, NATASHA A BEDFORD 11258 DESORMEAU, LEON M ANTIGONISH 6318

SURNAME TOWN/CITY CPSNSDESORMEAUX, YVON ELMSDALE 12944 DESROSIERS, JACQUES G HALIFAX 7469 *DEVARAJAN, S HALIFAX 10365 DEVEAU, JOEY METEGHAN CNTR 15150 DEVITT, JAMES H HAMMONDS PLAINS 12353 *DHAR, NEELMA HALIFAX 7549 DHARA, ARUNDHATI HALIFAX 15173 DHAWAN, BALCHANDRA YARMOUTH 15439 DIAS, E BERNICE GLACE BAY 11377 DIAZ, PEDRO E LOWER SACKVILLE 13816 DICKIESON, ANDREW W HALIFAX 12137 DICKINSON, JOHN D HALIFAX 11558 *DICKSON, GENA E BERWICK 7062 DIEFENBACH, KATHRYN L AYLESFORD 6209 DILL, ALAN S ANNAPOLIS ROYAL 3580 DINGLE, MARGARET A HALIFAX 4958 DINI, EZIO M HALIFAX 12991 DIPCHAND, CHRISTINE S HALIFAX 10795 DIQUINZIO, CLAUDIO HALIFAX 10001 DOANE, FRANK R HALIFAX 4827 DOANE, PAUL H HALIFAX 4043 DOBEK, ISABELLA CHESTER 10297 DOBEK, LUKE HALIFAX 14224 DOBSON, DIANA C NORTH SYDNEY 4242 DOBSON, GREGORY R HALIFAX 11837 DOBSON, REBECCA L HALIFAX 6652 DOCHEV, ATANAS BRIDGEWATER 14270 DODD, FAITH SYDNEY 14519 DOLHANTY, DOROTHY A MIRA ROAD 10099 DONKERVOORT, LAURA V DILIGENT RIVER 15074 DOOLEY, JOSEPH M HALIFAX 6365 DORAN, WILLIAM WOLFVILLE 13433 DORREEN, MARK S HALIFAX 12237 DOUCET, ALBERT D LIVERPOOL 4705 DOUCET, ROBYN T HALIFAX 15231 DOUCETTE, PAUL B DARTMOUTH 12358 DOUGLAS, ANDREW C PICTOU 6361 DOW, MICHELLE M METEGHAN CNTR 7571 DOYLE, CRYSTAL R FALL RIVER 15049 DOYLE, MARY A SYDNEY 7194 DRAKE, WENDY T HATCHET LAKE 11416 DRAPEAU, DENNIS J HALIFAX 12406 DRUCKER, ARIK M HALIFAX 13027 DRYSDALE, SCOTT M HALIFAX 10100 DRYSDALE-BUHR, C HALIFAX 7135 DU TOIT, DANIEL J BRIDGEWATER 15435 DUFFY, ANNE C HALIFAX 11384 DUGAS, GISELLE J METEGHAN CNTR 14329 DUGAS, ISABELLE SYDNEY 12989 DUGGAN, MARY C HEBRON 3960 DUKE, STEPHEN M DARTMOUTH 14266 DUNBAR, MICHAEL J HALIFAX 10495 DUNN, MICHAEL V KENTVILLE 7772 DUNN, REX S SYDNEY 4942 DUPERE, DAVID HAMMONDS PLAINS 11097 DURLING, RONALD R PETITE RIVIERE 4379 DYACK, COLIN SCOTSBURN 2636 DYACK, SARAH GLEN HAVEN 12524 DYKEMAN, M T DARTMOUTH 7898 DZIERZANOWSKI, MARTIN TRURO 12408 DZIEWALTOWSKA, B HALIFAX 10578 EARLE, LYNDA M LIVERPOOL 13557

* Refer to page 24 for alternate Pharmacare prescriber number. 6

SURNAME TOWN/CITY CPSNSEASTON, ALEXANDER S HALIFAX 13537 EDGAR, DAWN C HALIFAX 10056 EDMONDS, DIANE E PLEASANTVILLE 11725 EGAR, SUSANNE E INVERNESS 14964 EISENER, BEVERLEY M DARTMOUTH 6233 EL-BATNIGI, NEMER HALIFAX 13075 EL-HAWARY, RON HALIFAX 13963 EL-NAGGAR, WALID HALIFAX 14805 EL-ZUBEIDI, WASSIM NEW GLASGOW 14419 ELKOUT, LOTFIA HALIFAX 13827 ELLERKER, MARK R GLACE BAY 12272 ELLERKER, STEPHANIE P GLACE BAY 12274 ELLIOTT, CHRISTOPHER R NEW GLASGOW 4207 *ELLIOTT, DAVID C HALIFAX 6447 ELLIS, CATHERINE L HATCHET LAKE 10498 ELLIS, STEPHEN D TRURO 10796 ELLSMERE, JAMES C HALIFAX 12139 ELMEZUGHI, AHMED S HANWELL 15065 ELNAGAR, ISLAM S HALIFAX 14597 ENGLISH, KELTIE J LOWER SACKVILLE 7682 ENRIGHT, WILLIAM M WINDSOR 6498 EPSTEIN, IAN L HALIFAX 13593 ERNEST, GARY P LIVERPOOL 6238 ESPINAL MONTOYA, V SYDNEY 14584 ESSER, MICHAEL HALIFAX 14767 ETCHES, SELENE M HALIFAX 13594 ETTEHAD DABAGH, M PARRSBORO 15725 EVANS, MICHAEL D HALIFAX 7354 EWING, KAREN D BASS RIVER 11340 FAHIM, MOHAMMAD NEW GLASGOW 14298 FAIRFIELD, SONIA SYDNEY 14150 FALVEY, DENIS M ROSE BAY 4843 FARINA, DANA M HALIFAX 11420 FARINHOLT, HEIDI-MARIE NEW GLASGOW 15669 FAROOQ, MOHAMMAD SYDNEY 4396 FARRELL, E STEPHEN NEW WATERFORD 4630 FARRELL, GERALD E NEW GLASGOW 6193 FARRELL, SCOTT A HALIFAX 7756 FASHIR, BAROUDI M SYDNEY 13796 FASHORANTI, O PUGWASH 10984 FAY, DONALD F HALIFAX 6262 FELDERHOF, CATHARINA PICTOU 4528 FELDERHOF, RICHARD P NEW GLASGOW 3721 FELTMATE, MARY F TRURO 12874 *FERGUSON, CRAIG A BRIDGEWATER 12374 FERGUSON, G BRIAN AMHERST 6216 FERGUSON, JEANNE M ROSS FERRY 11694 FERGUSON, LINDA M TRURO 7976 FERGUSON, MURDO TRURO 8090 FERGUSON-LOSIER, N DARTMOUTH 10798 FERNANDEZ, CONRAD V HALIFAX 10866 FERNANDEZ, LOUIS A HALIFAX 4273 FEWER, KAREN A MIDDLE MUSQ. 11544 FIELD, DEANNA J TRURO 13923 FIELD, SIMON W HALIFAX 13167 FIELDUS, WARREN HALIFAX 13595 FIGUEROA PEREZ, M DARTMOUTH 13791 FILLITER, BRUCE D DARTMOUTH 4550 FINKLE, SIMON N HALIFAX 11262 FINLAYSON, ALEXANDER HALIFAX 7006 FINLAYSON, LAURA A BEDFORD 7253 FINLEY, G ALLEN HALIFAX 7059

SURNAME TOWN/CITY CPSNSFINLEY, JOHN P HALIFAX 4861 FINNAMORE, RYAN E HALIFAX 13759 FITZ-CLARKE, JOHN R HALIFAX 11052 FITZGERALD, JAMES M LOWER SACKVILLE 3866 FLAVELLE, SHAUNA C HALIFAX 14428 FLECKENSTEIN, MARTIN H NEW MINAS 7579 FLEETWOOD, IAN G HALIFAX 12960 FLEMING, MICHAEL FALL RIVER 4981 FLEMMING, BRUCE K HALIFAX 4896 FLETCHER, MARK A DARTMOUTH 11024 FLINN, ROGER M PORT WILLIAMS 3708 FLYNN, MICHAEL S HALIFAX 7156 FOLEY, ANITA A GUYSBOROUGH 4533 FOLEY, BRIAN SYDNEY 8153 FOLINSBEE, CATHERINE D TRURO 6837 FORAN, JOCELYN PORT WILLIAMS 11908 FORBES, CYNTHIA A FALL RIVER 13184 FORBES, JOHN G WESTVILLE 4692 FOROUZESH, BAHRAM SYDNEY 15442 FORSHNER, DAVID D PUGWASH 4187 FORT, STEPHEN HALIFAX 13377 FORWARD, KEVIN R HALIFAX 7734 FOSTER, D LYNETTE BEDFORD 14834 FOUAD, MAGDY A NEW GLASGOW 10432 FOX, HILDA M FALL RIVER 4179 FOX, JONATHAN R FALL RIVER 11789 FOX, ROY A WAVERLEY 4140 FOX, SCOTT 13656 FOYLE, ANNETTE FALL RIVER 4719 FOYLE, CATHARINE DARTMOUTH 14877 FRABONI, THERESA L HALIFAX 12382 FRAGER, GERALDINE HALIFAX 11334 FRAGOSO, ZAIDA LOWER SACKVILLE 13001 FRASER, HUGHIE F CONQUERALL MILLS 15201 FRASER, JAMES D HALIFAX 10615 FRASER, JOHN R HALIFAX 4889 FRASER, LOUIS H WINDSOR 11984 FRASER, MARGARET A SYDNEY 14731 FRASER, MARY-ANNE ENFIELD 7841 FRASER, ROBERT B HALIFAX 7933 FRASER, RONALD I TRURO 11402 FRASER, ZACHARY R DARTMOUTH 4717 FREER, JANYA M HALIFAX 15507 FRENT, GILDA A HALIFAX 10351 FRETER, SUSAN H HALIFAX 12306 FRIEL, PATRICK H YARMOUTH 6547 FRIZZLE, TENA A AMHERST 12574 FUHRMANN, MARLENE B ANTIGONISH 6736 FULLER, PENELOPE J ANTIGONISH 7246 FUREY, ELIZABETH A HALIFAX 14433 FUREY, WILLIAM SCOTT HALIFAX 13597 FYNN, JOHN K AMHERST 14252 GADIR, YOUSIF HAMMONDS PLAINS 12469 GAGNON, LINDA L DARTMOUTH 6870 GAJEWSKI, JERZY B HALIFAX 7302 GALLACHER, WILLIAM HALIFAX 8083 GALLAGHER, KATHLEEN M BEDFORD 8019 GALLANT, CHRISTOPHER DARTMOUTH 7256 GALLANT, PAULA M KENTVILLE 10049 GALLANT, STEVE J ANTIGONISH 8038 GALLIVAN, GLENN G ANTIGONISH 10290 GALLIVAN, MICHAEL P GLACE BAY 7222

* Refer to page 24 for alternate Pharmacare prescriber number. 7

SURNAME TOWN/CITY CPSNSGAMMELL, LISA SYDNEY 13301 GANDHI, KARAMCHAND J BRIDGEWATER 3465 GARCIA DEL BUSTO, E BADDECK 14687 GARDNER, ANGUS J SYDNEY 4042 GARDNER, MARTIN J HALIFAX 6196 GARVEY, BRIAN M CANNING 4450 GASKIN, DAVID A HALIFAX 13265 GASS, DAVID A HALIFAX 4884 GATIEN, JOHN G HALIFAX 3641 GAZIT, VERED HALIFAX 15117 GEBRE-HEYWOT, T GRAND LAKE 11339 GEE, SHIRL A HAMMONDS PLAINS 11269 GELDENHUYS, LAURETTE HALIFAX 12097 GELLRICH, PASCAL HALIFAX 14753 GENGE, ROLAND J BADDECK 4356 GEORGE, P KENTVILLE 3226 GEORGE, RONALD B HALIFAX 12677 GEORGE, SHAUN R BERWICK 10280 GEORGE, STAN P HALIFAX 12876 GERGES, MAGED F HALIFAX 14250 GERMANUS, FATEN S BARRINGTON PASS. 15739 GHAFFARI, SEYED R BRIDGEWATER 14906 GHANEM, YAZAN M PICTOU 14881 GHENEA, IRINA NORTH SYDNEY 12555 *GIACOMANTONIO, C HALIFAX 10105 GIACOMANTONIO, JAMES HALIFAX 6112 GIACOMANTONIO, N HALIFAX 11243 GIBBON, STEPHEN B HALIFAX 4049 GIBSON, RICHARD J DARTMOUTH 6276 GIFFIN, BARRY D MIDDLE MUSQ. 7389 GILL, RICHARD K HALIFAX 4758 GILLESPIE, LAURIE H YARMOUTH 14330 GILLIATT, ERICA P HALIFAX 10107 GILLIS, AMY E STELLARTON 13598 GILLIS, AMY E HALIFAX 14874 GILLIS, GRANT G HALIFAX 10801 *GILLIS, JOHN M DARTMOUTH 12636 GILLIS, L JANE HALIFAX 13391 GILLIS, LISA A EASTERN PASSAGE 13575 GILMOUR, DONNA T HALIFAX 12245 GINN, JOHN L DARTMOUTH 11241 GINTHER, DAVID G HALIFAX 7994 GIORNO, ANDREW M SYDNEY 14979 GLASGOW, DANIEL F SYDNEY 4585 GLASGOW, MICHAEL J TATAMAGOUCHE 7370 GLAUDE, SIMON-PIERRE SYDNEY FORKS 15644 GLAZEBROOK, K HALIFAX 11100 GLAZEBROOK, MARK A HALIFAX 11101 GLENN, JOHN J HALIFAX 4505 GOBRAN, GEHAD HALIFAX 13514 GODDARD, PETER AYLESFORD 2781 GODDARD, TOM A WOLFVILLE 11961 GODKIN, TIMOTHY A HALIFAX 11827 GOLD, ELISABETH HALIFAX 7785 GOLDCHTAUB, VALERI NEW GLASGOW 14808 GOODINE, GRANT A LAWRENCETOWN 6948 GOODMAN, MARNI NEW MINAS 13419 GOODWIN, JANICE R DARTMOUTH 10108 GORDON, ALFRED DARTMOUTH 5146 GORDON, ANN K KENTVILLE 15380 GORDON, EDWARD G DARTMOUTH 11533 GORDON, JANET E HALIFAX 11488

SURNAME TOWN/CITY CPSNSGORDON, KEVIN E HALIFAX 7708 GORMAN, MARY C ANTIGONISH 6630 GORMAN, WAYNE M YARMOUTH 4057 GOSSE, G CRAIG BEDFORD 6999 GOW, NINA M HALIFAX 7802 GOWAN, SUSAN E HALIFAX 6686 GRACIE, GLEN A SYDNEY 4048 GRADSTEIN, JANNEKE S AMHERST 14285 GRADSTEIN, ROETKA HALIFAX 14384 GRAHAM, CHRISTOPHER HALIFAX 6742 GRAHAM, DAVID J GLEN MARGARET 4615 GRAHAM, JOHANNA H HALIFAX 10502 GRAHAM, JOHN P HALIFAX 6090 GRAHAM, ROBERT D TRURO 4973 GRANDY, ELWOOD C WINDSOR 6526 GRANT, DAVID A KENTVILLE 6525 GRANT, DOUGLAS A HALIFAX 11649 GRANT, IAN A HALIFAX 11811 GRANT, JOHN D WOLFVILLE 7359 GRANTMYRE, JOHN E HALIFAX 6528 GRAVEN, MICHAEL A HALIFAX 13716 GRAVES, GILLIAN R HALIFAX 6030 GRAY, ALLISON J HALIFAX 12543 GRAY, CHRISTOPHER J HALIFAX 12678 GRAY, GERALD E HALIFAX 4515 GREEN, PETER J HALIFAX 11270 GREEN, ROBERT S HALIFAX 11613 GREGOIRE, M HALIFAX 13603 GREGOIRE, TRIXIE L HALIFAX 13121 GREGOR, RONALD D HALIFAX 3746 GREGUS, VOJTECH DARTMOUTH 10289 GRIFFIN, LESLIE B HALIFAX 11102 GRIFFIN, LISA J BEDFORD 13730 GRIMSHAW, ROBERT N HALIFAX 10299 GROSS, MICHAEL HALIFAX 7278 GRUCHY, STEVEN E HALIFAX 13922 GUBITZ, GORDON HALIFAX 11528 GUERIN, JOHN M HALIFAX 15681 *GUNDOGAN, MUNIRE HALIFAX 14249 GUNN, DAVID LIVERPOOL 13303 GUNN, ROBERT F KENTVILLE 4659 GUPTA, JAGDISH S SYDNEY 2964 GUPTA, REKHA HALIFAX 6152 GUPTILL, M ELIZABETH BRIDGEWATER 4991 GURUSAMY, DEEPA COLDBROOK 14103 GUY, TREVOR J SYDNEY 13856 HAASE, DAVID A HALIFAX 6790 HABIB, EMAD 12523 HABIBA, AYMAN A SYDNEY 14587 HACHE, A JOHN HALIFAX 12680 HACK, IMRAN NEW GLASGOW 6249 HACKMANN, THOMAS HALIFAX 10057 HACKSHAW, CHRISTIAN M MAHONE BAY 14607 HADDAD, SUSAN J BEDFORD 15121 HADLAW, VIOLETTA A PORT WILLIAMS 10638 HAFIDH, MAKY SYDNEY 14235 HAIDER, UMAR HALIFAX 12949 HAIGH, DONALD DARTMOUTH 11620 HAJEK, TOMAS HALIFAX 13551 HALDANE, DAVID J HALIFAX 7068 HALEEM, SAIMA SYDNEY 13681 HALEES, WALID Y ANTIGONISH 14752

* Refer to page 24 for alternate Pharmacare prescriber number. 8

SURNAME TOWN/CITY CPSNSHALIK, JERRY J YARMOUTH 10008 HALL, ALLEN H CARLETON 1346 HALL, RICHARD I HALIFAX 6950 HALL, STEPHANIE DARTMOUTH 13149 HALPERIN, SCOTT A HALIFAX 6843 HAMILTON, GILLIAN R HALIFAX 12413 HAMILTON, JOHN R ANTIGONISH 6462 *HAMILTON, KEITH R HALIFAX 6202 HAMILTON, LINDA D HALIFAX 11427 HAMILTON, ROGER D WOLFVILLE 10568 HAMM, CHARLES P KENTVILLE 13079 HAMMEL, KENNETH H NEW GLASGOW 13952 HAMSON, ANDREW C HALIFAX 10315 HANADA, EDWIN Y HALIFAX 11428 *HANCOCK FRIESEN, C HALIFAX 11829 HANCOCK, CAROLINE A ANNAPOLIS ROYAL 11830 HANCOCK, JENNIFER N HALIFAX 13987 HANCOCK, MARK J L'ARDOISE 15717 HANLEY, W ERIC HALIFAX 6996 HANLY, JOHN G HALIFAX 7356 HANNA, ADALA HALIFAX 15349 HANNA, MARY H HALIFAX 15491 HANSON, SONYA DARTMOUTH 12479 HANSPAL, RAJVINDER S SYDNEY 15093 HAQ, SHEIRA NEW WATERFORD 13128 HAQUE, SHAMIM ANTIGONISH 14878 HARDING, ROY A WINDSOR JUNCTION 8128 HARLESS, WILLIAM W SYDNEY 15675 HAROON, BABAR A HALIFAX 15360 HARRIGAN, LYNNE A KENTVILLE 7615 HARRIS, ANDREW S HALIFAX 11430 HARRIS, COLIN J KENTVILLE 13606 HARRISON, DEAN AMHERST 13164 HART, RENEE S DARTMOUTH 12887 HART, ROBERT D HALIFAX 12415 HARVEY, WILLIAM L ELMSDALE 11650 HASAN, AZRA SYDNEY 14154 HASEGAWA, WANDA S HALIFAX 14008 HASSAN, ABDALLA A BRIDGEWATER 11812 HASSAN, ANSAR 11904 HASSAN, SAMEH M DARTMOUTH 14836 HATCHETTE, TODD F HALIFAX 11970 HATFIELD, PETER W HALIFAX 8067 HATHEWAY, RONALD J BRIDGEWATER 7279 HAWKINS, ANN E HALIFAX 6029 HAWORTH, DAMIAN J HAMMONDS PLAINS 13276 HAYDEN, DAVID S BRIDGEWATER 11108 HAYES, VONDA M HALIFAX 3735 HAYNE, ORMILLE A HALIFAX 2763 HAZELTON, LARA D HALIFAX 11109 HEATHCOTE, JOHN G HALIFAX 13665 HEBB, ARTHUR M DARTMOUTH 5167 HEBB, MATTHEW O 13037 HECKLER, LISA V HALIFAX 14688 HEEDE, SANTA HALIFAX 15706 HEELAN, JOHN A HALIFAX 10372 HEFFERNAN, LEROY P KENTVILLE 3292 HEGARTY, RAYMOND ANTIGONISH 12503 *HEGAZY, ADHAM M ANTIGONISH 15429 HEIKAL, RUBY BEDFORD 14044 HEISLER, BENJAMIN E KENTVILLE 11272 HELYER, LUCY K HALIFAX 12249

SURNAME TOWN/CITY CPSNSHEMANI, RAZI H YARMOUTH 15701 HENDERSON, J DAVID TRURO 13506 HENDERSON, JANE M HALIFAX 7558 HENDY, AYMAN M HALIFAX 15738 HENNEBERRY, RYAN J WAVERLEY 12683 HENNENFENT, BRETT W LUNENBURG 11625 HENTELEFF, HARRY J HALIFAX 11215 HENZLER, DIETRICH HALIFAX 14520 HERGETT, SUSAN C WOLFVILLE 10109 HERING, RAMM HALIFAX 14446 HERMAN, SHAUNA P STILLWATER LAKE 14157 HERMANN, LAURA L WINNIPEG 14689 HERNANDEZ, MARIA D AMHERST 13677 HERNANDEZ, PAUL HALIFAX 11354 HEUGHAN, DAVID M BADDECK 14691 HEWINS, EDWARD A KENTVILLE 10068 HEWLETT, THOMAS J SYDNEY 10902 HICKCOX, SAMUEL E HALIFAX 13983 HICKEY, D PAUL NORTH SYDNEY 3908 HICKEY, JOHN S ANTIGONISH 4255 HICKEY, MICHAEL A HALIFAX 15657 HICKS, SHAWN D HALIFAX 15487 HIGGINS, TERRANCE F HALIFAX 3557 HILLIARD, JENNIFER Y KENTVILLE 15084 HILLIS, MICHAEL T PORT WILLIAMS 10930 HILLYARD, JEREMY W ANTIGONISH 11489 HIMMELMAN, DONALD W PLEASANTVILLE 3814 *HINDLER, LIONEL R SHUBENACADIE 10670 HIPWELL, ALEXANDER E DARTMOUTH 6704 HIRSCH, DAVID J HALIFAX 6645 HIRSCH, GREGORY M HALIFAX 11342 HOFFMAN, DANIEL B PICTOU 8016 HOFNER, GRAZYNA W TRURO 10807 HOLLAND, STEWART DARTMOUTH 4434 HOLLENHORST, HELMUT HALIFAX 13763 HOLMES, ANDREW I BADDECK 11007 HONG, PAUL HALIFAX 13673 HOOGERBOORD, C PRINCE ALBERT 15629 HOPKINS, GARY W DARTMOUTH 7529 HORNE, S GABRIELLE HALIFAX 11154 HORNER, GORDON W DARTMOUTH 4593 HORREY, KATHLEEN A HALIFAX 12148 *HORTON, NATALIE L YARMOUTH 10210 HORTON, ROBERT P HALIFAX 10948 HOSEIN, JALAL WELLINGTON 4075 HOSKIN-MOTT, ANN E HALIFAX 6176 HOUCK, LESLIE V TRURO 12946 HOUSTOUN, ANNE HALIFAX 7130 HOWARD, JANE A ANTIGONISH 14211 HOWARD, JANET L DARTMOUTH 6716 HOWARD, JASON J HALIFAX 14873 HOWATT, ERIC B KENTVILLE 7036 HOWE, DAVID H PARRSBORO 11520 HOWLETT, TODD C DARTMOUTH 11029 HUANG, WEEI-YUARN HALIFAX 13921 HUBER, ADAM M HALIFAX 12383 HUBLALL, RONALD V YARMOUTH 15206 HUDEC, MARY-ANN HALIFAX 10312 HUGHES, DANIEL M HALIFAX 6720 HUMAYUN, MUHAMMAD DARTMOUTH 4180 *HUMPHREY, ANDREW B HALIFAX 10111 HUNG, ORLANDO R HALIFAX 7225

* Refer to page 24 for alternate Pharmacare prescriber number. 9

SURNAME TOWN/CITY CPSNSHURLEY, KATRINA F HALIFAX 13039 HUSSAIN, KHALID M SYDNEY 13396 HUSSEIN, ABIR H YARMOUTH 15726 HUTCHISON, MARY E NORTH SYDNEY 4541 HYDORN, THOMAS G AMHERST 7510 HYMAN, MICHAEL P GRANVILLE FERRY 12608 HYNDMAN, JOHN C HALIFAX 4173 IBRAHIM, WAEL STELLARTON 15484 IGNACIO, BAYANI S SYDNEY MINES 2823 IGNACIO, EUGENE E SYDNEY MINES 6894 IGOE, MICHAEL P NORTH SYDNEY 7426 ILES, SIAN E HALIFAX 6846 IMRAN, S ALI HALIFAX 12473 IMRIE, DAVID D HALIFAX 3754 ING, VINCENT W HALIFAX 2747 INGARFIELD, HEATHER L HALIFAX 10877 INGHAM, ANDREW B HALIFAX 11980 IQBAL, MIRZA N YARMOUTH 14976 IRWIN, MANDI R HALIFAX 14741 ISAC, FOUAD A YARMOUTH 4611 ISSEKUTZ, ANDREW C HALIFAX 6037 ISSEKUTZ, THOMAS B HALIFAX 6306 IZZARD, J BRAD DARTMOUTH 11655 JABEEN, SHAIFTA BEDFORD 13474 JACKMAN, CHRISTOPHER HALIFAX 14253 JACKSON, PETER D SYDNEY 5583 JACKSON, SIMON D HALIFAX 10240 JAIN, SHERRY HALIFAX 14262 JALA, VIKRAM R NEW GLASGOW 14611 JAMES, SHERRY L LOWER SACKVILLE 13861 JAMIESON, CHRISTOPHER HALIFAX 11525 JANGAARD, KRISTA A HALIFAX 10703 JANKE, EDWIN M YARMOUTH 6173 JANSEN, GREGORY W BRIDGEWATER 7301 JARVIE, ANDREW HALIFAX 13801 JARVIS, CARL W HALIFAX 10808 *JARVIS, JOLENE E HUBBARDS 13225 JAYABARATHAN, AJANTHA HALIFAX 10264 JAZRAWI, BASHAR L STELLARTON 15495 JEANS-MINGO, L AULAYNE NEW GLASGOW 7406 JEFFREY, CAM A TRURO 13646 JELLEMA, DICK HD ST MARGS BAY 11331 JENKINS, JOHN T LUNENBURG 10507 JENSEN, JOHN J SYDNEY 13979 JEYAKUMAR, ALWIN HALIFAX 14057 JHA, UMESH C HALIFAX 4778 *JHIRAD, RONEN H MIRA ROAD 15130 JIWANI, ALMAS A BERWICK 14328 JOHNSON, ALPHONSE J HALIFAX 3094 JOHNSON, ERNEST B HALIFAX 1887 JOHNSON, HEATHER O BRIDGEWATER 12492 JOHNSON, JOHN K HALIFAX 11777 JOHNSON, KEVIN W BRIDGEWATER 12491 JOHNSON, KRISTINE A HALIFAX 11364 JOHNSON, LIANE B HALIFAX 11277 JOHNSON, PAUL M HALIFAX 11433 JOHNSTON, BARBARA L HALIFAX 7293 JOHNSTON, C FALL RIVER 13482 *JOHNSTON, DAVID G HALIFAX 6955 JOHNSTON, DENNIS W HALIFAX 5179 JOHNSTON, J MARK KENTVILLE 11656 JOHNSTON, MICHAEL R HALIFAX 14321

SURNAME TOWN/CITY CPSNSJOHNSTONE, JAMES E HALIFAX 14730 JOLLIMORE, JASON V TRURO 12152 JOLLYMORE, BRIAN D WOLFVILLE 8120 JOLLYMORE, GEORGE C CHESTER 2093 *JONASSON, JAMES D KINGSTON 15039 JONES, BRENT D HALIFAX 13242 JONES, BRONWEN A BLACK POINT 10026 JONES, CHRISTOPHER T HALIFAX 15642 JONES, GORDON R HALIFAX 4474 JONES, HEATHER D HALIFAX 13252 JONES, LORI M HALIFAX 14989 JONES, SARAH D UPPER TANTALLON 14434 JONES-LOCKE, DIANA C TRURO 8063 JONY, LOUAI TRURO 12481 JORGENSEN, SALLY MAHONE BAY 7740 JOSEPH, MARY K CANNING 12515 JOSEPH, PAUL K HALIFAX 7851 JOSEPHSON, E BRUCE HALIFAX 11761 JOSHI, CHANGULANDA NEW GLASGOW 13432 JOST, ELLEN HALIFAX 13721 *JOTA, JOSE M WESTVILLE 15077 JOY, ANDREA E EASTERN PASSAGE 11833 JOY, GRAHAM A EASTERN PASSAGE 11112 JOYCE, BRENDA M HALIFAX 7922 JUNEK, WADE HALIFAX 6299 JURGA, MILAN ANTIGONISH 11630 KADIR, NAJEEB A AMHERST 13807 KAHWASH, EIAD D HALIFAX 14802 KAIPRATH, SOUMINI NEW GLASGOW 13529 KAISER, STEPHANIE HALIFAX 13161 KAJETANOWICZ, ANDRZEJ SYDNEY 10442 KAJETANOWICZ, DANUTA SYDNEY RIVER 8070 KALER, SHARONA A HALIFAX 14718 KALYAN, SANGEETA BRIDGEWATER 15147 KANAAN, HASSAN D SYDNEY 15100 KANAGASABAI, S COLDBROOK 15729 KANELLAKOS, GEORGE W HALIFAX 13240 KAPILAN, PRIYADHARSINI BEDFORD 13803 KAPUR, FARAH FALL RIVER 11371 KAPUR, SANDEEP HALIFAX 10864 KARIVELIL, JOSHY A SPRINGHILL 14317 KASINA, RAFAL A WINDSOR 7714 KAUL, SANJEEV AMHERST 14218 KAWCHUK, JANET HALIFAX 8028 KAWCHUK, TERRY P HALIFAX 7076 KAZIMIRSKI, JUDITH C FALMOUTH 3601 KAZIMIRSKI, MARK WINDSOR 3602 KEATING, M HALIFAX 14161 KEELER, JOHN E SHELBURNE 6898 KEENAN, ROBERT J HALIFAX 14853 KELLAND, ALISON A CHESTER 4646 KELLS, CATHERINE M HALIFAX 7709 KELLY, CATHERINE L LUNENBURG 6592 KELLY, COLLEEN M HALIFAX 7755 KENT, BLAINE A HALIFAX 11659 KEOUGH, VALERIE J HALIFAX 12154 KEOUGH-RYAN, TAMMY M HALIFAX 11279 KESHEN, AARON HALIFAX 13610 KEW, ANDREA K HALIFAX 12688 KHALIFA, ABDUL M PORT MORIEN 2567 KHALIL, HISHAM A BEDFORD 15236 *KHALIL, TAREK H HALIFAX 14851

* Refer to page 24 for alternate Pharmacare prescriber number. 10

SURNAME TOWN/CITY CPSNSKHAN, AARON Y DARTMOUTH 10723 KHAN, ASIF A NEW GLASGOW 15353 KHAN, FAREEHA S ESKASONI 13865 KHAN, GHULAM Z DARTMOUTH 14293 KHAN, M NAEEM HALIFAX 12881 KHAN, MUHAMMAD A SYDNEY RIVER 13864 KHODADAD, KIAN K SYDNEY 15676 KHOROVETS, ANDREI ANTIGONISH 14579 KIBERD, BRYCE A HALIFAX 10734 KIDWAI, BAKHTIAR J HALIFAX 12993 KIESER, KATHARINA E HALIFAX 11662 KILCOLLINS, CALVIN T WINDSOR 4552 KILLEEN, RONALD A LOWER SACKVILLE 4517 KING, DAVID B HALIFAX 3995 KING, ELIZABETH A ANNAPOLIS ROYAL 13274 KING, YVONNE KENTVILLE 6001 KINLEY, C EDDY HALIFAX 7453 KINLEY, JACQUELINE L HALIFAX 13152 KINNEAR, HILARY A DARTMOUTH 11910 KINSLEY, GRANT CHURCH POINT 13771 KIRBY, JEFFREY C HALIFAX 4920 KIRBY, RONALD L HALIFAX 4482 *KIRBY, SARAH HALIFAX 10941 KIRK, DUNCAN GRANT STELLARTON 4228 KIRKPATRICK, DAVID A HALIFAX 6084 KIRKPATRICK, JOHN H NORTH SYDNEY 6529 KIRMANI, SALEEM AMHERST 15133 KIS, JOANNA HALIFAX 13828 KISHTA, WALEED E HALIFAX 15180 KITAMURA, KELLY M HALIFAX 11403 KLASSEN, BRIAN D 11437 KLASSEN, DENNIS R HALIFAX 12287 KLAUS, ERNST MARKUS HALIFAX 15583 KLIMEK, MAREK 10641 KLONOWSKA, M DARTMOUTH 10444 KLONOWSKA-PHILLIPS, M DARTMOUTH 13198 KLYNSTRA, SANDRA J BOUTILIERS POINT 6877 KNIGHT, DEBORAH C DARTMOUTH 4914 *KNOTT, Z MAREK SYDNEY MINES 10355 KODAGODA, DAYANANDA SYDNEY 11604 KOHLSMITH, DOUGLAS J SYDNEY MINES 7257 KOILPILLAI, C HALIFAX 6588 KOLLER, KATALIN E HALIFAX 13310 KOLYSHER, PAULA L HALIFAX 11913 KOOKA, DARA M GLACE BAY 3480 KOSHI, EDVIN HALIFAX 12691 KOVACS, GEORGE HALIFAX 8084 KOWALCZYK, AMIE J HALIFAX 15654 KOWALCZYK, EARL S HALIFAX 15658 KOZEL, VITIA V TRURO 10238 *KOZOUSEK, VLADIMIR HALIFAX 7504 KRAWCZYK, JOHN G NEW GLASGOW 13450 KROL-LASS, JUSTYNA AMHERST 14512 KRONFLI, RISK N BEDFORD 10676 KRONICK, JONATHAN B HALIFAX 13160 KRUEGER-NAUG, A HALIFAX 14164 KUMAR-CHUGH, PREM HALIFAX 7042 KUNCHERIA, JOY NORTH SYDNEY 10764 KUTCHER, STAN P HALIFAX 11229 KWAPISZ, MYRON M HALIFAX 14333 KWASNIK, ANNE M NEW GLASGOW 13449 KYDD, RICHARD W BRIDGEWATER 6219

SURNAME TOWN/CITY CPSNSKYSELA, ALENIA R YARMOUTH 15185 LACAS, ALETHEA D HALIFAX 15176 LACUESTA, GINA A HALIFAX 12052 LAFKOVICI, VLADIMIR BEAR RIVER 10460 LAFLEUR, EDITH P DARTMOUTH 12158 LAFRANCE, MONIQUE S INVERNESS 12157 LAKOSHA, HESHAM HALIFAX 12514 LAMBETH, MICHELLE A DARTMOUTH 12083 LANG, BIANCA HALIFAX 6779 LANG, H BENNO HALIFAX 10816 LANG, MARIA T UPPER TANTALLON 7430 LANGDON, REX L HALIFAX 5208 *LANGE, JENNIFER A SYDNEY 13866 LANGILLE, DONALD B HALIFAX 4371 LANGILLE, KENNETH R AYLESFORD 15741 *LANGLEY, CHRISTINE E BEDFORD 10627 LANGLEY, JOANNE M HALIFAX 7944 LANGLEY, RICHARD G HALIFAX 10037 LANGLEY, STEPHANIE A NORTH SYDNEY 11283 LAPPIN, SUSAN F LOWER SACKVILLE 7551 LARKIN, TARA L NEW GLASGOW 15095 LAROCHE, G ROBERT HALIFAX 6397 LARYEA, MARIE A HALIFAX 12418 LASKOWSKI, ALEXANDRA HALIFAX 12376 LASKOWSKI, DEREK HALIFAX 12560 LASSEY, STEVE PICTOU 11802 LATOUR, ANNE H SYDNEY 11841 LAUGHREN, JAMES J 14685 LAUNCELOTT, GORDON O HALIFAX 6032 LAURIA-HORNER, BIANCA HALIFAX 7075 LAVALLEY, WILLIAM G CHESTER 7515 LAW, ANNI E BADDECK 7065 LAW, JOHN A HALIFAX 11230 LAW, JOYCE 14167 LAWAL, WAHEED O SYDNEY 15674 LAWAND, CHRISTOPHER SYDNEY 13868 LAWEN, JOSEPH G HALIFAX 4967 LAWLESS, JILL M TIMBERLEA 13748 LAWRENCE, GILLIAN AMHERST 2742 LAZARIC, DANIEL M PORT WILLIAMS 11117 LAZIER, LORRAINE L FALMOUTH 10124 LAZOVSKIS, JURIS SYDNEY 13220 LEAHEY, J LORNE HALIFAX 6323 LEAHEY, SHELAGH M YARMOUTH 4512 LEAHY, JAMES R WINDSOR 6093 LEBLANC, CONSTANCE H HALIFAX 7741 LEBLANC, JOHN C HALIFAX 7991 LEBLANC, MARTIN R HALIFAX 13869 LEBLANC, RAYMOND P HALIFAX 6033 LEBLANC, ROBIN B DARTMOUTH 11664 LEBRUN, GERALD P HALIFAX 3328 LECKEY, NAIDA L LOWER SACKVILLE 10981 LECKEY, RICHARD N BEDFORD 11118 LEDDIN, DESMOND J HALIFAX 7749 LEE, GEORGE T HALIFAX 10237 LEE, MIN S HALIFAX 12160 LEE, PETER C DARTMOUTH 12161 LEE, PETER T NEW GLASGOW 6211 LEE, TONY C HALIFAX 15712 LEE, WILLIAM R DARTMOUTH 6293 LEE, WINIFRED W DARTMOUTH 12133 LEFEBVRE, GUY CALEDONIA 11618

* Refer to page 24 for alternate Pharmacare prescriber number. 11

SURNAME TOWN/CITY CPSNSLEFEL, OLEG YARMOUTH 15227 LEGARE, JEAN-FRANCOIS HALIFAX 11285 LEGAY, DOUGLAS A DARTMOUTH 7030 LEGERE, PAUL W YARMOUTH 8049 LEHMANN, CHRISTIAN HALIFAX 14316 LEIGHTON, MARGARET M HALIFAX 4831 LEIGHTON, ROSS K HALIFAX 6876 LENNOX, A SCOTT BRIDGEWATER 14780 LESSARD, PIERRE L CANNING 11359 LEVERMAN, JENNIFER L HALIFAX 13470 LEWANDOWSKI, ROBERT GLACE BAY 12006 LEWINGTON, DANIELLE C HACKETTS COVE 12101 LEWINGTON, RICHARD B HACKETTS COVE 12102 LEWIS, LORRAINE N DARTMOUTH 7325 LEWIS, VALERIE L HALIFAX 10583 LEY, DAVID C RESERVE MINES 10819 LIBBUS, YVONNE E SYDNEY 10820 LIGHTFOOT, C HALIFAX 13871 LINCOLN, MAXIMILLIAN C NEW GLASGOW 15096 LINDENER, MARGO HALIFAX 7136 LINDENSMITH, JORIN M DARTMOUTH 12420 LITTLEJOHN, PETER W NEW WATERFORD 4299 LITZ, D SHARON HALIFAX 6369 LIVINGSTON, PATRICIA L HALIFAX 7879 LIVINGSTONE, JAMES B BRIDGEWATER 6189 LIWSKI, ROBERT S HALIFAX 13313 LLOYD, R GRAYSON PORT WILLIAMS 13615 LO, CHARLES D HALIFAX 6312 LO, FRANK L HALIFAX 6329 LOANE, THOMAS D HALIFAX 6403 LOCKE, TREVOR A TRURO 8064 LODGE, RICHARD HALIFAX 12311 LOGAN, HEATHER 12693 LOGAN, KARL J HALIFAX 15198 LOGAN, VANCE H W. PORTERS LAKE 6134 LOK, RAYMOND T INVERNESS 6601 LOOK, DIDIER S HALIFAX 13872 LOPEZ BLANCO, A SYDNEY 15390 LORENZ, KONSTANTIN HALIFAX 14341 LOSHAJ, RYVE TRURO 14314 LOVE, MICHAEL P HALIFAX 13150 LOVERIDGE, PETER L GLENWOOD 4309 LOWE, WILLIAM M COLDBROOK 6012 LOWRY, BRIGITTE H NEW WATERFORD 11726 LUDMAN, MARK D HALIFAX 13258 *LUTWICK, RENEE E BEDFORD 7124 LYMBURNER, DANA L HAMMONDS PLAINS 15002 LYNCH, MARY E HALIFAX 6524 LYNK, ANDREW D SYDNEY 6539 LYNK, MARY E NEW WATERFORD 3919 LYONS, BRIAN J YARMOUTH 10938 M-SHENDEREY, INNA YARMOUTH 15135 MACAULAY, ANDRIA J TRURO 13461 MACAULAY, BRUCE D HALIFAX 11120 MACAULAY, PETER M COLE HARBOUR 7328 MACAULAY, ROBERT J BEDFORD 12239 MACCARA, ANNE S PICTOU 6341 MACCARA, MELANIE L NEW GLASGOW 10129 MACCORMICK, ELIZABETH SYDNEY MINES 6374 MACCORMICK, KEITH R WOLFVILLE 7565 MACCORMICK, RONALD E SYDNEY 4997 MACCORMICK, SHAUN A TRURO 6710

SURNAME TOWN/CITY CPSNSMACDONALD, ALLAN S SYDNEY 2099 MACDONALD, ANGUS C BADDECK 2096 MACDONALD, CARLA DARTMOUTH 11598 MACDONALD, DANIEL J TATAMAGOUCHE 13873 MACDONALD, DAVID A HALIFAX 12162 MACDONALD, DIANNE D HALIFAX 4963 MACDONALD, DONALD G SHEET HARBOUR 7159 MACDONALD, H PAUL STELLARTON 3880 MACDONALD, ILDIKO L BEDFORD 12542 MACDONALD, J GERARD AMHERST 6131 MACDONALD, JENNIFER L LIVERPOOL 13151 MACDONALD, JENNIFER L TRURO 13192 MACDONALD, JOANNE L HALIFAX 7924 MACDONALD, JOHN W DARTMOUTH 3569 MACDONALD, JON K NEW GLASGOW 4821 MACDONALD, KAREN A ANTIGONISH 12892 *MACDONALD, KAREN A HALIFAX 6899 *MACDONALD, MARION N STELLARTON 4446 MACDONALD, NANCY L HALIFAX 6322 MACDONALD, NONI E HALIFAX 12209 MACDONALD, PAUL J SYDNEY 7834 MACDONALD, RHEA C INVERNESS 13617 MACDONALD, SCOTT M FALL RIVER 13489 MACDONALD, SHANNON L HALIFAX 13046 MACDONALD, WILLIAM M NORTH SYDNEY 6342 MACDOUGALL, A HALIFAX 13479 MACDOUGALL, BRADLEY WESTVILLE 15005 MACDOUGALL, C HALIFAX 6913 MACDOUGALL, PETER C HALIFAX 12324 MACDOUGALL, RYAN F HALIFAX 14439 MACDOUGALL, STEVEN G MIRA ROAD 6719 MACDUFF, BLAIR A ANTIGONISH 14006 MACEACHERN, JOHN R BERWICK 6004 MACEACHERN, RON T NEW GLASGOW 12842 MACFARLANE, AMY E FALL RIVER 14036 MACFARLANE, ROBYN J HALIFAX 14061 MACGIBBON, S LOIS BEDFORD 14831 *MACGILLIVRAY, B JEAN ANTIGONISH 14288 MACGREGOR, JANICE M HALIFAX 10011 MACHEL, TERESA M WINDSOR 7463 MACHEL, WIESLAW J WINDSOR 7833 MACINNIS, BRIAN L BERWICK 6821 MACINTOSH, BERNARD H NORTH SYDNEY 14440 MACINTOSH, DONALD G HALIFAX 12261 *MACINTOSH, REBECCA F HALIFAX 12253 *MACINTYRE, JANET K HALIFAX 12422 MACINTYRE, LISA A FALL RIVER 10521 MACKAY, IAN E TRURO 13619 MACKAY, ROSE L SYDNEY 12694 MACKAY, THOMAS J HALIFAX 15063 *MACKEAN, GERALD L HALIFAX 4661 MACKEAN-RIPLEY, SUSAN DARTMOUTH 14650 MACKENZIE, MICHAEL A ANTIGONISH 6241 MACKENZIE, ROBERT J ALBERT BRIDGE 14170 MACKILLOP, JAMES H SYDNEY 6680 MACKINNON, DAVID A MIDDLETON 4975 MACKINNON, HEATHER A HALIFAX 7783 MACKNIGHT, CHRIS R HALIFAX 10131 *MACLACHLAN, A JAMES PICTOU 12911 MACLACHLAN, DIANE E GLACE BAY 14800 MACLACHLAN, JOHN R WOLFVILLE 4708 MACLACHLAN, RICHARD A HALIFAX 4378

* Refer to page 24 for alternate Pharmacare prescriber number. 12

SURNAME TOWN/CITY CPSNSMACLEAN, ALEX HALIFAX 14388 MACLEAN, C BERNARD INVERNESS 1892 MACLEAN, DAPHNE A ANTIGONISH 13917 MACLEAN, DAVID S ST JOHNS 15128 MACLEAN, GREGOR W NEW GLASGOW 7331 MACLEAN, JAMES D GLACE BAY 13875 MACLEAN, MICHELE HALIFAX 12352 MACLEAN, MOIRA J BEDFORD 15716 MACLEAN, PAUL D MIDDLETON 4060 MACLEAN, RHONDA A HALIFAX 12423 MACLEAN, STEPHEN W BEDFORD 11394 MACLEAN-FRASER, ERIN ANTIGONISH 14497 MACLELLAN, DAWN L HALIFAX 11444 MACLELLAN, ROCHELLE L LOWER SACKVILLE 14530 MACLENNAN, MARTIN T DARTMOUTH 11982 MACLEOD, ALISON D KENTVILLE 13620 MACLEOD, SUSAN E SYDNEY 14522 MACLEOD, WAYNE HALIFAX 12496 MACMANUS, BRIAN J HALIFAX 6918 MACMULLIN, ELWOOD C SYDNEY 4994 MACNAUGHTON, JANET E WOLFVILLE 6917 MACNEIL, DAVID R BEDFORD 7342 MACNEIL, DOROTHY E SYDNEY 6271 MACNEIL, IAIN P ELMSDALE 7954 MACNEIL, MALCOLM L ARICHAT 6516 MACNEIL, MARY V HALIFAX 11567 *MACNEIL, MEAGAN A HALIFAX 14652 MACNEILL, JAMES R HALIFAX 3874 MACNEILL, JUDITH L HALIFAX 10523 MACNEILL, KARA E NEW GLASGOW 13047 MACNEILL, ROBERT B BEN EOIN 6571 MACPHEE, SHANNON DARTMOUTH 12867 MACPHERSON, MARILYN P TRURO 10685 MACPHERSON, RAYMA D DARTMOUTH 6375 MACQUARRIE, DONALD C HALIFAX 13315 MACQUARRIE, KIRK J HALIFAX 10826 MACQUARRIE, ROBYN M HD OF CHEZZETCO. 14172 MACVICAR, G NEIL ALBERT BRIDGE 8041 MACVICAR, JOAN H BEDFORD 6650 MADER, JUDITH A HALIFAX 10352 MADHVANI, ASHWIN K YARMOUTH 6045 MADIGAN, MAUREEN A PORT WILLIAMS 13701 MAGEE, J FERGALL HALIFAX 14028 MAGEE, KIRK HALIFAX 11373 MAGUIRE, HUGH P TRURO 11074 MAHANEY, GORDON R DARTMOUTH 3875 MAHAR, ROBERT K HALIFAX 4944 MAHARAJ, MANDAT SYDNEY 10440 MAHDI, GAMAL E HALIFAX 15083 MAHENDRARAJAH, R GUYSBOROUGH 13743 MAHER, LAUREN H WEYMOUTH 14598 MAHMOUD-AHMED, A SYDNEY 14223 MAIANSKI, IRIT R FERGUSONS COVE 14879 MAIANSKI, ZIV FERGUSONS COVE 15320 MAIDMENT, P DIANE EAST LAHAVE 10524 MAILMAN, TIMOTHY L HALIFAX 10827 MAJAESS, GEORGE G HALIFAX 7568 MAKHAN, WINSTON M STELLARTON 3724 MAKKAR, NINA TRURO 11125 MALAK, EMAD Y DARTMOUTH 14271 MALAN, J ETIENNE NEW GLASGOW 14854 MALDONADO GONZALEZ, D HALIFAX 15652

SURNAME TOWN/CITY CPSNSMALEKI, BABAK HALIFAX 13316 MALIAKKAL, RITA K L'ARDOISE 14869 MALIK, HATIM G SYDNEY 3387 MALIK, SAIRA DARTMOUTH 10603 MALIK, SHAHID L SYDNEY 13487 MALLERY, LAURIE H HALIFAX 10250 MALLOY, SUSAN J HALIFAX 7340 MALONEY, PAUL A ANTIGONISH 14902 MALONEY, WILLIAM J HALIFAX 7172 MALTBY, CATHERINE C PORT WILLIAMS 7691 MANGAT, NAVDEEP DIGBY 15009 MANKAVIL KOVILVEETIL, A HALIFAX 15648 MANN, COLIN G BRIDGEWATER 8026 MANN, OLGA E HALIFAX 4857 MANN, OTTO HALIFAX 4069 MANNING, J DAVID HALIFAX 10286 MANOS, DARIA HALIFAX 12696 MANOS, SARAH H HALIFAX 13080 MANSOOR, SAMINA SYDNEY 15141 MARAIS, ABRAHAM J YARMOUTH 14071 MARCHAND, DEBORAH J PORT HAWKESBURY 6814 MARCHE, JANET E HALIFAX 12513 MARE, FRANS YARMOUTH 15695 MARIER, GISELE BRIDGEWATER 10525 MARIOTTI, CARLO U HALIFAX 11666 MARSH, LORNE A HALIFAX 4918 *MARSHALL, ARTHUR D BRIDGEWATER 11289 MARSHALL, CINDY LOWER SACKVILLE 10526 MARSHALL, GENA M HALIFAX 11290 MARSTERS, DAVID W PORT WILLIAMS 4822 MARTEL, ROBERT F GRAND PRE 6511 MARTELL, DAVID R LUNENBURG 11667 MARTIN, KARYN L HALIFAX 14174 MARVAL-OSPINO, HEIZER HALIFAX 13878 MASON, WILLIAM F HALIFAX 1895 MASOUMI-RAVANDI, M BROOKFIELD 14481 MASSOUD, EMAD A HALIFAX 11357 MATEOS-CORRAL, DIMAS HALIFAX 15410 MATHESON, HUGH B HALIFAX 6520 MATHESON, LESLIE J HALIFAX 6751 MATHESON, TIMOTHY HAMMONDS PLAINS 14175 MATHISEN, BRIT L BRIDGEWATER 7314 MATSUSAKI, RONALD H DIGBY 14550 MATZ, ALEXANDER M YARMOUTH 12600 MAWDSLEY, SCOTT D DARTMOUTH 11291 MAXAN, EMILY E HALIFAX 14176 MAXNER, CHARLES E HALIFAX 6762 MAYER, A LISL HALIFAX 10830 MAYER, KRISTINE L SYDNEY RIVER 11442 MAYNES, DOUGLAS F HALIFAX 3879 MCADOO, KERI K NEW MINAS 11808 MCALLISTER, AMY L BEDFORD 15012 MCARTHUR, ALASTAIR KENTVILLE 7201 MCASLAN, K LYNN HALIFAX 6642 MCAULEY, PAUL MAHONE BAY 7358 MCBEATH, RODERICK I KENTVILLE 6172 MCBRIDE, GRAEME N DARTMOUTH 15013 MCBURNEY, ROBERT D OTTAWA 15751 MCCANN, D BURTON HALIFAX 7782 MCCARTHY, JOHN-PAUL KENTVILLE 13879 MCCARTHY, LEANNE S HALIFAX 13880 MCCARTHY, STEPHEN C TRURO 6228

* Refer to page 24 for alternate Pharmacare prescriber number. 13

SURNAME TOWN/CITY CPSNSMCCARVILLE, CLIFFORD J DARTMOUTH 10831 MCCLELLAND, BRUCE BEDFORD 10693 MCCORMICK, KATE M DARTMOUTH 7536 MCCORMICK, SAMUEL A ANNAPOLIS ROYAL 14864 MCCORMICK, WILLIAM O LOWER SACKVILLE 6331 MCCRACKEN, L JOAN WOLFVILLE 4730 MCCROSSIN, J MURRAY AMHERST 10438 MCCULLOCH, DONNA M HALIFAX 10566 MCCURDY, JEFFREY D HALIFAX 14442 MCDONALD, ANDREA J HALIFAX 11651 MCDONALD, GORDON J 13882 MCDONALD, LINDSAY 14443 MCDONALD, LORI J HALIFAX 14484 MCFARLANE, BRIAN A PUGWASH 13817 MCGIBNEY, KIERON D TRURO 15186 *MCGORY, RODNEY W SYDNEY RIVER 13048 MCGRAIL, J SIMON DARTMOUTH 13967 MCGRATH, FIONA M HALIFAX 11758 MCGUIRE, PAUL B KINGSTON 4231 MCINTOSH, MARION C SYDNEY RIVER 2777 MCINTYRE, ALLAN J HALIFAX 4680 MCINTYRE, PAUL F HALIFAX 4735 MCKEEN, DOLORES M HALIFAX 11555 MCKELVEY, J ROGER DARTMOUTH 13154 MCKENNA, CHRISTINE J HALIFAX 12372 MCKENNA, PATRICIA J ANTIGONISH 4061 MCKENNEY, RODERICK N TRURO 8130 MCKEOUGH, MICHEL F SYDNEY MINES 6553 MCKIGGAN, JOHN J HALIFAX 2341 MCKINNON, GENEVIEVE M HALIFAX 13883 MCLAREN, RICHARD G GLEN HAVEN 14327 *MCLAUGHLIN, MICHAEL A DARTMOUTH 12348 MCLEAN, ANGUS D PORT WILLIAMS 10141 MCLEAN, JAMES R HUBBARDS 10303 MCLEOD, LYNNE HALIFAX 11445 MCLEOD, R BRUCE PORT WILLIAMS 7673 MCLERNON, SARAH LYNN TANTALLON 13375 MCMAHON, LYNNE E DOMINION 12167 MCMILLAN, DOUGLAS D HALIFAX 13262 MCMILLAN, MERLE K KENTVILLE 14286 MCMULLEN, MARK A TANTALLON 11925 MCMULLEN, SARAH HALIFAX 14344 MCNAB, JOHN W FALL RIVER 4988 MCNALLY, CATHERINE E KENTVILLE 13123 MCNALLY, GREGORY T HEBBVILLE 7866 MCNEELY, P DANIEL HALIFAX 11669 MCNEIL, JOHN O TRURO 7151 MCNEIL, KEVIN S GLACE BAY 6220 MCNEIL, NANCY L DARTMOUTH 11446 MCNEIL, SHELLY A HALIFAX 11128 MCNEILL, LAURIE K BRIDGEWATER 13416 *MCPARLAND, COLUMBA P HALIFAX 10636 MCPHEE, DERRICK M HALIFAX 10586 MCPHERSON, JOHN W CAMBRIDGE STN 14490 MCROBERT, ELIZABETH A HALIFAX 7843 MCTIMONEY, MICHELLE C HALIFAX 11712 MCVEIGH, SONJA A FERGUSONS COVE 14237 MCVEY, JENNIFER HALIFAX 12700 MEADOWS-YOUNGER, M TRURO 13906 MEARS, PAUL DARTMOUTH 13049 MEEHAN, CATHERYNE N PORTUGUESE COVE 14267 MENARD, PATRICIA A ANTIGONISH 10587

SURNAME TOWN/CITY CPSNSMENDEZ, IVAR M HALIFAX 11194 MENG, CHEN BRIDGEWATER 12429 MERCER, CHRISTINA L BERWICK 11670 MERRIMEN, JENNIFER L GLEN HAVEN 13053 MERRITT, ROBERT B PORTERS LAKE 8089 MERRYWEATHER, R JULIA CANNING 12440 MERSHATI, ABDELWAHAB DARTMOUTH 11701 MIAN, IRFAN TORONTO 11476 MICHAEL, LILIANE F BEDFORD 14353 MICHAEL, ROGER T HALIFAX 3086 MIGAS, MARIA HALIFAX 14537 MILBURN, CHRISTOPHER R SYDNEY 12369 MILES, GRAHAM C ANTIGONISH 6947 MILLER, MERVYN D SYDNEY 11375 MILLER, ROBERT A HALIFAX 6072 MILLER, ROBERT A HALIFAX 11751 MILLER, ROBERT M HALIFAX 4787 MILLER, STEPHEN G FALL RIVER 10834 MILLIGAN, SCOTT R SYDNEY 11926 MILLIKEN, HEATHER I DARTMOUTH 11813 MILLIKEN, JACQUELINE H BRIDGEWATER 3471 MILLS, PHILIP J DARTMOUTH 11214 MILNE, ANDREW D HALIFAX 13319 MILNE, DAVID G HAMMONDS PLAINS 13199 MILNE, P RONALD HALIFAX 14083 *MINDRUM, CHRISTA R NEW MINAS 15397 MINODIN, MIKE O BEDFORD 13478 MINOR, SAMUEL F BEDFORD 14217 MISHRA, ADITYA V HALIFAX 6919 MISHRA, HARSH V HALIFAX 6714 MISTRY, DIPAN N HALIFAX 15677 MITCHELL, ALEXANDER D DARTMOUTH 13051 MITCHELL, DAVID A ANTIGONISH 7160 MITCHELL, MICHAEL J HALIFAX 6845 MITCHELL, VICTORIA P HALIFAX 6478 MOELLER, JEREMY J DARTMOUTH 13623 MOGAN, NORAH K LIVERPOOL 12855 MOHAMED, AHMED YARMOUTH 13508 MOHAMED, ISMAIL S HALIFAX 15441 MOHANDAS, RAJENDER N ANTIGONISH 7659 MOHSIN, HINA BEDFORD 12895 MOKASHI, ARATI HALIFAX 13389 MOLINARI, MICHELE HALIFAX 13994 MONG, IRENE E BEDFORD 15640 MONTGOMERIE, HUGH S ELMSDALE 3546 MONTGOMERY, GAGE B ELMSDALE 6385 MONTGOMERY, KATHY P HALIFAX 6827 MOON, JENNI HALIFAX 11043 MOORE, IRENE M AYLESFORD 6787 MOORHOUSE, PAIGE A HALIFAX 13043 MORASH, ANGELA H HALIFAX 14473 MORASH, GARRY W LIVERPOOL 4840 MORGAN, MATTHEW E BEDFORD 12703 MORGAN, NEAL BRIDGEWATER 14614 MORGAN, PAUL F PORT WILLIAMS 11769 MORIARTY, MARY F DARTMOUTH 4824 MORLEY, CHARLOTTE M HALIFAX 7581 MORRIS, DAVID P HALIFAX 12970 MORRIS, IAN HALIFAX 4697 MORRIS, KELLY A AMHERST 14664 MORRIS, STEVEN F HALIFAX 10414 MORRISON, DEBRA HALIFAX 10319

* Refer to page 24 for alternate Pharmacare prescriber number. 14

SURNAME TOWN/CITY CPSNSMORRISON, EARL G MARION BRIDGE 10900 MORRISON, JASON M HALIFAX 14861 MORRISON, NANCY J HALIFAX 7570 MORSE, DAVID W LUNENBURG 15134 *MORSE, EWART A BRIDGEWATER 4062 *MORZYCKI, WOJCIECH HALIFAX 10705 MOSES, BRIAN G YARMOUTH 13624 MOSS, CHRISTOPHER J TATAMAGOUCHE 7193 MOSS, PHILIPPA A TATAMAGOUCHE 7701 MOUNTAIN, ANITA D HALIFAX 13625 MUGGAH, JENNIFER J PORT WILLIAMS 6081 MUHSIN, MUNIR DARTMOUTH 15094 MUIR, AVA J DARTMOUTH 14180 MUIR, JOHN G HALIFAX 7443 MUIR, SARAH A HALIFAX 10239 MUISE, ROLAND J YARMOUTH 4689 MUISE, THOMAS A YARMOUTH 7150 MUKHI, ALFIN N HALIFAX 13918 MULHALL, DAVID R KENTVILLE 7677 MULHERIN, MICHAEL T PORT WILLIAMS 11293 MULLAN, ROBERT D KENTVILLE 6354 MULLAN, TERENCE J BEDFORD 7562 MULLEN, TIMOTHY J HALIFAX 15666 MULLINS, ROSALIND J HALIFAX 13626 MULROY, LIAM A HALIFAX 7580 MUNRO, ALISTAIR EASTERN PASSAGE 6319 MUNROE, TANYA M TRURO 12289 MUNSHI, AUTAR K SYDNEY 6453 MURAD, KHULOOD J SYDNEY 14539 MURAD, MOAZZAM SYDNEY 13386 MURDOCH, JOHN L DARTMOUTH 6910 MURPHY, CHERYL L HALIFAX 12173 MURPHY, CHRISTOPHER A YARMOUTH 13393 MURPHY, GEORGE F LOWER SACKVILLE 6847 MURPHY, JOANNE S HALIFAX 8088 MURPHY, KARMA N YARMOUTH 13947 MURPHY, MICHELE G ANTIGONISH 3928 MURPHY, NANCY HALIFAX 11451 MURPHY, PAUL F SYDNEY 4716 MURPHY, THOMAS B YARMOUTH 3355 MURRAY, JOCK A HALIFAX 10907 MURRAY, JOHN G TRURO 2687 MURRAY, JONATHAN A AVONPORT 13697 MURRAY, KENNETH R NEILS HARBOUR 3873 MURRAY, KERRY A KINGSTON 13627 MURRAY, KIM P DARTMOUTH 6728 MURRAY, MICHAEL R TRURO 6887 MURRAY, ROYA R TRURO 6718 MURRAY, SCOTT J HALIFAX 7437 MURRAY, SHAWN K HALIFAX 11132 MUSGRAVE, BRUCE L KENTVILLE 15401 MUTHIAH, KARUPPAN PERTH-ANDOVER 13742 MUTHU, M SARAVANA DARTMOUTH 10463 MUTHU, SARASA ANTIGONISH 10584 MYATT, GERALD L BEDFORD 4945 MYATT, GREGORY A MIRA ROAD 10027 NABI, NAEEM U BEDFORD 15189 NADEEM, SYED N HALIFAX 13434 NADER, NABIL AMHERST 12499 *NADOUR, JALAA TRURO 14580 NAEEM, MEHMOODA NORTH SYDNEY 14886 NAGIAH, THEEPA S DARTMOUTH 14031

SURNAME TOWN/CITY CPSNSNAGPAL, SABINA HALIFAX 14677 NANJI, AMIN A HALIFAX 14026 NAPIER, ROBERT LUKE HALIFAX 14503 NAQVI, MAHMOOD ALI SYDNEY 5317 NASEEM, IRAM I SYDNEY RIVER 13718 NASH, MICHAEL B KENTVILLE 13733 NASSAR, BASSAM A HALIFAX 8096 NASSER, JOSEPH G HALIFAX 7870 NATARAJAN, NANDINI M HALIFAX 13462 NATHAN, VIJI WINDSOR 13746 NAULT, YVONNE D ST PETERS 10329 NEILSON, GRAINNE E HALIFAX 10893 NESTEL, ANTHONY W BRIDGEWATER 11985 NESTEL, MAGDALENA D BRIDGEWATER 11986 NETTE, FARRELL L KENTVILLE 13629 NEU, ROLF-DIETER HALIFAX 4233 NEUMANN, ANNA BEDFORD 14181 NEWCOMB, PAULETTE F BEDFORD 7560 NEWHOOK, TRACY L KENTVILLE 11672 NEWTON, PAUL X BRIDGEWATER 4992 NGAN, JOHNSON C HALIFAX 7063 NICHOLS, BLAIR A WOLFVILLE 4539 NICHOLSON, BRIAN M ANTIGONISH 11673 NICHOLSON, DANIEL J MINEVILLE 6912 NICHOLSON, JENNIFER M UPPER LAHAVE 15089 NICHOLSON, JOHN D DARTMOUTH 10146 NICHOLSON, RAE A PICTOU 3576 NICOLELA, MARCELO T HALIFAX 12034 NOLAN, MAUREEN C HALIFAX 10868 NORMAN, BRIAN P HALIFAX 14287 NORMAN, RICHARD W TANTALLON 4936 NORMORE, WAYNE J BEDFORD 11329 NORTHGRAVE, STACEY A SYDNEY 11674 NOVIKOVA, OLGA ANTIGONISH 13523 NOWLAN, CLAIRE N EASTERN PASSAGE 11983 NTAMBAZI, MATTHEW YARMOUTH 14930 NUNN, DAVID J KENTVILLE 7710 NUNN, ROBERT T HALIFAX 7346 NUTH, LAURA L DARTMOUTH 10452 O'BLENES, STACY B HALIFAX 11133 O'BRIEN, BRIAN D HALIFAX 15056 *O'BRIEN, BRIAN J GLACE BAY 4629 O'BRIEN, DANIEL M HALIFAX 7661 O'BRIEN, DAVID A DARTMOUTH 12175 O'BRIEN, M KATHLEEN HALIFAX 10055 O'CONNELL, JENNIFER M HAMMONDS PLAINS 14413 O'CONNOR, JOHN F DARTMOUTH 3360 O'DONOVAN, CLAIRE M HALIFAX 10635 O'GRADY, PATRICK G NORTH SYDNEY 10147 O'HEARN, BRUCE M HALIFAX 4234 O'MALLEY, VINCENT P KENTVILLE 7882 O'NEIL, BARBARA A NEW GERMANY 12434 O'NEIL, LEONARD S HALIFAX 4940 O'NEILL, CARMEN A BRIDGEWATER 7729 O'NEILL, MARIE-THERESE A HALIFAX 10373 O'NEILL, MARY C HALIFAX 12273 O'NEILL, MICHELLE E SYDNEY 12705 O'SULLIVAN, EOGHAN F SHELBURNE 11031 OEI, IEN T SYDNEY 6602 OGUNTADE, JOHN A YARMOUTH 15422 OKAFOR, LIVINUS O NEW GLASGOW 14783 OLIVER, ROBERT A DARTMOUTH 4844

* Refer to page 24 for alternate Pharmacare prescriber number. 15

SURNAME TOWN/CITY CPSNSOMOTO, DANIEL M SYDNEY 14974 OPITZ, SILKE A KENTVILLE 14513 ORLIK, BENJAMIN C HALIFAX 13889 *ORLIK, HERBERT HALIFAX 4118 ORNSTEIN, AMY HALIFAX 13472 ORR, ANDREW C HALIFAX 7467 ORRELL, KEVIN G MIRA ROAD 6338 ORRELL, LIAM F SYDNEY 6895 ORRELL, SEAN E SYDNEY 6207 ORTIZ, ANA M DARTMOUTH 12615 ORTIZ-ALVAREZ, OLIVA ANTIGONISH 13790 ORTIZ-DOMINQUEZ, TANIA HALIFAX 14702 OTLEY, ANTHONY R HALIFAX 10580 OWEN, STEPHEN M BRIDGEWATER 4867 OXNER, JAMES H DARTMOUTH 3554 OXNER, WILLIAM M HALIFAX 11134 OZERE, CHRISTOPHER P DARTMOUTH 10031 PACIS, RUTH B DARTMOUTH 11779 PADMORE, DAVE E TRURO 10871 PAHIL, RAJBIR S SYDNEY 12247 PAJER, KATHLEEN A HALIFAX 15720 PALETA, JOHN HUBBARDS 15195 PALETZ, JUSTIN L HALIFAX 7017 PALMER, BRUCE W KENTVILLE 6519 PANEK, ROMUALD HALIFAX 10749 PARISH, BARBARA M BERWICK 10228 PARK, THOMAS R NEW GLASGOW 4953 PARKASH, RAJENDER HALIFAX 3976 PARKASH, RATIKA HALIFAX 13694 PARKASH, RAVI HALIFAX 12218 PARKASH, SANDHYA HALIFAX 13062 PARKER, DEBORAH J HALIFAX 14182 PARMINDER, RANJIT K SYDNEY RIVER 4211 PARSONS, ARTHUR H HALIFAX 3356 PASTERNAK, SYLVIA HALIFAX 12438 PATEL, NAVINCHANDRA M LOUISBOURG 4219 PATEL, SUNIL T HALIFAX 12282 PATERSON, ROBERT A DARTMOUTH 7093 PATIL, JAYWANT J HALIFAX 4869 PATRICK, WARD D HALIFAX 11173 PATRIQUIN, MARIA J HALIFAX 12535 PATTERSON, MICHAEL D KENTVILLE 14004 PAULICK, BILL C YARMOUTH 10276 PEALING, ROBERT D GREENFIELD 15463 PEARCE, PATRICIA A HALIFAX 4639 *PEIN, CHO Y LOWER SACKVILLE 2387 PELLEY, LORRAINE V SHUBENACADIE 11541 PELLOW, TANYA R HALIFAX 12707 PELTEKIAN, KEVORK M HALIFAX 7972 PENN, JEFFREY R TRURO 10998 PENNELL, MARK L WOLFVILLE 11395 PENNEY, LYNETTE S HALIFAX 14498 PENNOCK, KEVIN STILLWATER LAKE 13357 PEREIRA, ETHEL E HALIFAX 5324 PEREIRA, LEO V ANTIGONISH 7849 PERES, AMOS HALIFAX 13162 PERK, MASIS TRURO 10576 PESTELL, DEBBIE L BEDFORD 15215 *PETERS, CURT S HALIFAX 13634 PETERS, LAURA M GRAND LAKE 11362 PETERS, SUSAN NEW GLASGOW 15160 PETERSEN, AGNIESZKA E MIRA ROAD 15682

SURNAME TOWN/CITY CPSNSPETRIE, DANIEL W HALIFAX 14450 PETRIE, DAVID A HALIFAX 8054 PETROPOLIS, PETER N HALIFAX 6972 PHILLIPS, BRUCE A TRURO 10149 PHILLIPS, STEPHEN J HALIFAX 7473 PHILLIPS, WAYNE L WOLFVILLE 4235 PHILPOTT, STEPHANIE L SHUBENACADIE 12541 PHOTOPOULOS, SPIRO HALIFAX 12849 PICCININI, HELENA P HALIFAX 10766 PICKETT, BRYAN M BEDFORD 12332 PICKETT, GWYNEDD E HALIFAX 14809 PICKETT, WAYNE E BEDFORD 10150 PIERCE, MARIANNE E HALIFAX 14745 PILLAI, N GOPALAKRISHNA INVERNESS 2871 PINTO, TERESA HALIFAX 13056 PITTMAN, CARLA E DARTMOUTH 12307 PLAXTON, E KIM HALIFAX 6693 PLUTA, PAUL L PORT HAWKESBURY 10042 POGOSYAN, MARYNA ROTHESAY 14024 POHLMANN-EDEN, B HALIFAX 14586 POIRIER, ANGELA M HALIFAX 10340 POLLETT, HARRY F NORTH SYDNEY 2873 PONNAMBALAM, CHRIS DARTMOUTH 7908 PONTON-BELTRAN, C AMHERST 12118 PORTER, GEOFFREY A HALIFAX 12526 POTTLE, M KENT HALIFAX 6932 POTTLE, ROBERT A DARTMOUTH 10416 POULOS, PETER H NORTH SYDNEY 6343 POULOS, ROBERT KIRK DARTMOUTH 10043 POWELL, KIMBERLEY D KENTVILLE 11298 POWER, MICHAEL T HAMMONDS PLAINS 12180 POYAH, PENELOPE S HALIFAX 13326 PRABHU, UMESH H YARMOUTH 10458 PREMACHANDRA, P BARRINGTON PASS. 15106 PREMSAGAR, SAROJADEVI HALIFAX 13173 PREMSAGAR, VICKESH HALIFAX 13226 PRETTY, BRUCE R PROSPECT BAY 4097 PRICE, JUDY M HALIFAX 13058 PRICE, NANCY A PORT WILLIAMS 7723 PRICE, VICTORIA E HALIFAX 13761 PRINGLE, CHRISTOPHER R HALIFAX 10323 PRINSLOO, ETIENNE SYDNEY 13766 PROCTOR, IRMA J BRIDGEWATER 10756 PROKAI, KAREN A HALIFAX 11845 PROPPER, LUKAS HALIFAX 13437 PROPPEROVA, IVA HALIFAX 14186 PSOOY, BRIAN J HALIFAX 11679 PUGH, CHERYL P BRIDGEWATER 13498 PUGH, J CHRISTIAN BRIDGEWATER 13495 PUGSLEY, DONALD C BROOKFIELD 6214 PUPPALA, VENKATA K SYDNEY 15158 PURDY, KERRI S HALIFAX 13892 PURDY, R ALLAN HALIFAX 4909 PUTHENPARUMPIL, JACOB HALIFAX 13378 QADRY, SYED M HALIFAX 14289 QANUNGO, M TARIQ PORT HAWKESBURY 14568 QUINN, BRYAN B SYDNEY 4351 QURAISHI, ATA-UR-REHMAN HALIFAX 13362 QURESHI, ALIA TORONTO 15678 RAAFAT, SAWSAN ANTIGONISH 14309 RAFFERTY, JAMES L CALEDONIA 12208 RAFIE, IHSAN YARMOUTH 15048

* Refer to page 24 for alternate Pharmacare prescriber number. 16

SURNAME TOWN/CITY CPSNSRAFIQ, SURAIYA TRURO 13234 RAFUSE, PAUL E HALIFAX 10701 RAGHAVAN, SAI L PORTERS LAKE 10689 RAHMAN, FAISAL ANTIGONISH 13700 RAHMAN, ZIA SHELBURNE 15156 RAHNAVARDI, KATAYOUN DARTMOUTH 14621 RAICHE-MARSDEN, M DARTMOUTH 10537 RAIZAH, ABDULLAH F HALIFAX 13829 RAJARAMAN, MURALI M HALIFAX 7840 RAJARATHNA, MALLIKA P SPRINGHILL 14107 RAJDA, MALGORZATA HALIFAX 10620 RAJDA, MIROSLAW HALIFAX 10654 RAMER, SARAH A HALIFAX 12445 RAMESSAR, ELENA YARMOUTH 14084 RAMESSAR, JOHN A YARMOUTH 13174 RAMSEY, MICHAEL S HALIFAX 3682 RAMSEY, SUZANNE E HALIFAX 10539 RANDELL, L CHRISTOPHER YARMOUTH 12250 RANJI, MOSTAFA BERWICK 15477 RANSOM, THOMAS P HALIFAX 12845 RAO, SANJAY K KENTVILLE 15664 RAPPARD, SCOTT C DARTMOUTH 7306 RASHID, MOHSIN HALIFAX 12045 RASIC, DANIEL T HALIFAX 14390 RASTIKERDAR, ALI DARTMOUTH 15501 RATUSHNY, JEFFREY V BRIDGEWATER 14454 RAYMOND, ESTHER R MAHONE BAY 11225 RAYSON, DANIEL HALIFAX 10063 READ, ROBERT M HALIFAX 5339 REARDON, GERALD P HALIFAX 4370 REARDON, PATRICK M HALIFAX 4469 REBELLO, ROSARIO HALIFAX 12312 REBELO, RAUL A GLACE BAY 3662 RECEVEUR, DARRYN S HALIFAX 15388 REHAN, FOUZIA MUSQ. HARBOUR 14078 REHMAN, WASEEMA SYDNEY 14090 REID, DANIEL S DARTMOUTH 3547 *RENAULT, PAUL S HALIFAX 6512 RENDON, RICARDO A HALIFAX 12650 REX, GREGORY HALIFAX 13144 REYNOLDS, JASON H BEDFORD 12183 REYNOLDS, PAUL E HALIFAX 6758 RHEAUME, DORIANNE E HALIFAX 12582 RICHARDSON, C GLEN HALIFAX 11457 *RIDEOUT, ANDREA N HALIFAX 13442 RIDEOUT, CAROLYN M ANTIGONISH 12950 RIDING, TIMOTHY J BRIDGEWATER 13991 RIDLER, ANNE C HALIFAX 14190 RIIVES, MAI L HALIFAX 11593 *RILEY, CHRISTINE A HALIFAX 7192 RILEY, MARK E SHELBURNE 6826 RING, MELANIE S BEDFORD 7815 RITCEY, SUSAN G MIRA ROAD 10236 RITCHIE, JULIA ANTIGONISH 12859 RITENOUR, RUSTY J HALIFAX 13328 RITTENBERG, DAVID A HALIFAX 13480 RITTENBERG, PAULA V HALIFAX 13475 RITTER, JOHN A SYDNEY 12553 RIVAS, JUAN H LOWER SACKVILLE 12926 RIZK, SOHA R DARTMOUTH 15197 ROBBINS, MEGAN 13329 ROBERTS, DELYTH M HAMMONDS PLAINS 10153

SURNAME TOWN/CITY CPSNSROBERTS, KENNETH F HALIFAX 14457 ROBERTSON, C S 12447 ROBERTSON, HEATHER E BRIDGEWATER 7240 ROBERTSON, JILL D HALIFAX 14459 ROBERTSON, NANCY L BEDFORD 7696 ROBINSON, DALE K MONCTON 13533 ROBINSON, K SUE HALIFAX 7397 ROBINSON, KATHERINE A HALIFAX 7988 ROBITAILLE, JOHANE M HALIFAX 11568 ROCKER, GRAEME M HALIFAX 10876 ROCKWOOD, KENNETH J HALIFAX 10256 ROGERS, JAMIE B TRURO 10155 ROGERS, JOHN C SYDNEY 7784 *ROHLAND, TERRY A PUBNICO 4960 RONDEAU, RONALD L OXFORD 4676 *ROPER, FIONA M BEDFORD 6567 ROSE, HEATHER P WEST PENNANT 12185 ROSENBERG, EDWIN M HALIFAX 2404 ROSS, ANDREW A HALIFAX 7676 ROSS, BARBARA J PORT WILLIAMS 10763 ROSS, DAWN L HALIFAX 6537 ROSS, EDWARD C DARTMOUTH 3347 ROSS, JOHN A HALIFAX 8079 ROSS, JONATHAN G BEDFORD 15153 ROSS, VALERIE A HALIFAX 7556 ROWE, DONALD G TRURO 10233 ROWE, JUDY A HALIFAX 11661 ROWICKA, MARGARET D HALIFAX 10156 ROWICKA, MONIKA M NEW GLASGOW 14714 ROXBURGH, BRIAN M SYDNEY 7263 ROY, ARUP MICHAEL NEW GLASGOW 15486 ROY, GREGORY L DARTMOUTH 4525 *RUBENS, MARK J DARTMOUTH 7738 RUBIO-REYES, CARLOS A AMHERST 12570 RUDD, MICHAEL W KENTVILLE 12647 RUDDY, JAMES KENTVILLE 11791 RUGGLES, LESLEY ANTIGONISH 7519 RUTLEDGE, ROBERT D HALIFAX 10952 RUZICKOVA, MARTINA HALIFAX 12982 RYAN, MICHAEL T MIRA ROAD 6780 SAAD, EMILE BEAVER BANK 13806 SADEK, IRENE HALIFAX 10884 SADEK, JOSEPH A HALIFAX 12304 SADLER, LAURA K UPPER TANTALLON 14472 SADLER, MARGOT C ANTIGONISH 10159 SADLER, ROBERT MARK HALIFAX 7566 SAHA, AMAL K HALIFAX 13558 SALAH, JOAN C NORTH SYDNEY 12712 SALAMEH, MUWAFFAQ ANTIGONISH 14304 SALAT, PETER KENTVILLE 13781 SALAZAR, S RAMON WOLFVILLE 13747 SALIH, RASHA HALIFAX 12614 SALSMAN, KENNETH R AYLESFORD 14509 SAMAD, ARIF HALIFAX 10647 SAMPSON, MARIA T HALIFAX 12004 SAMPSON, MARK E SYDNEY 8027 SANDERS, DAVID H DARTMOUTH 2605 SAPP, GEORGE A CHESTER 2617 SAPP, HEIDI L HALIFAX 11140 SAPP, JOHN L HALIFAX 11141 SARDIWALLA, ISMAIL SYDNEY 14925 SARIC, AMRA HALIFAX 13132

* Refer to page 24 for alternate Pharmacare prescriber number. 17

SURNAME TOWN/CITY CPSNSSARIC, DJEMSO DARTMOUTH 13564 SARWAL, SHAILINI R HALIFAX 12361 SAUNDERS, W DAVID HALIFAX 6927 SAVA, CRISTINA M NEW GLASGOW 14352 SAVA, CRISTINA M NEW GLASGOW 14352 SAVVOPOULOS, STAVROS DARTMOUTH 12713 SAWLER, MARGARET R WAVERLEY 12341 *SAXON, MICHELE P MIDDLETON 14658 SCHAFFNER, JOHN P PORT WILLIAMS 4694 *SCHALLER, GERALD H HALIFAX 4522 SCHEFFLER, MATTHIAS HALIFAX 15375 SCHELEW, BENJAMIN L HALIFAX 8125 SCHERBARTH, SANDRA E SYDNEY 12448 SCHLECH, WALTER F HALIFAX 6316 SCHLOSSER, GISELA E TATAMAGOUCHE 13126 SCHMIDT, MATTHIAS H HALIFAX 11539 SCHMIDT, MICHAEL K HALIFAX 14521 SCHMIT, PIERRE J HALIFAX 14056 SCHNARE, KEVIN P NEW GLASGOW 7168 SCHOFFER, KERRIE L HALIFAX 12187 SCHWARTZ, STACEY A HALIFAX 7940 SCHWARZ, ROBERT D HALIFAX 4789 SCOTT, DONALD J BRIDGEWATER 3843 SCOTT, HEATHER M HALIFAX 10592 SCOTT, JEANETTE M HALIFAX 15458 SCOTT, JEFFREY W HALIFAX 10664 SCOTT, ROBERT C NEW MINAS 10949 SCOTT, TRACY A HALIFAX 11213 *SCOVIL, ROBERT J HUBLEY 6725 SCOVIL, SUSAN J BEDFORD 15431 SEAMAN, DONALD M KENTVILLE 5413 SEAMAN, JAMES G KENTVILLE 3720 SEAMAN, SARAH J DARTMOUTH 13064 SEAMONE, CHRISTOPHER D HALIFAX 6410 SEBASTIAN, ANTONYPILLAI MIRA ROAD 12450 SEBASTIAN, MALEAKAL S NEW GLASGOW 2832 SEETHARAMDOO, PATRICK LOWER SACKVILLE 4041 SEGATO, PETER M WOLFVILLE 14068 SEKULA, ZYGMUNT P HALIFAX 10029 SEMENOV, IGOR AMHERST 15449 SEMSAR, ALIREZA SPRINGHILL 15170 SENTHILLMOHAN, S PORT HAWKESBURY 12381 SEQUEIRA, S PREM NEW GLASGOW 14236 SERS, ROBERT N ANTIGONISH 4671 SETAYESH, A RAMIN MUSQ. HARBOUR 14573 SETHI, SHILPA MIDDLE MUSQ. 15448 SHAABAN, HANI MIRA ROAD 12552 SHAARBAF, RAID HALIFAX 14089 SHAFFELBURG, MICHAEL D KENTVILLE 11142 SHAHEEN, UZMA YARMOUTH 13562 SHAHI, BAHRAM NEW GLASGOW 15184 SHANKAR, JAI J HALIFAX 15350 SHARMA, SHIKHI TRURO 13719 SHARMA, SUSHIL K TRURO 13235 SHARRATT, GEOFFREY P HALIFAX 10737 SHATSHAT, SOUAD M HALIFAX 11461 SHAW, EMILY J HALIFAX 13334 SHAWWA, ALLAM A HALIFAX 12377 SHEA, SARAH E HALIFAX 7125 SHEEHAN, STEPHEN D HAMMONDS PLAINS 8020 SHEEHY, DAVID N SHUBENACADIE 6711 SHEHZAD, ANEES A SYDNEY 13065

SURNAME TOWN/CITY CPSNSSHEN, KHALED A TRURO 14345 SHENDEREY, ALEXANDER YARMOUTH 14346 SHEPPARD, DUANE G DARTMOUTH 11972 SHERIDAN, WILLIAM J HALIFAX 7039 SHETTAR, CHANNABASAV YARMOUTH 12903 SHETTY, BANAKESARI N YARMOUTH 10744 SHIH, WARREN DARTMOUTH 10846 SHIMON, LAITH D SYDNEY 11612 SHIRLEY, MARGARET A BRIDGEWATER 8060 SHIVAKUMAR, SUDEEP S HALIFAX 13335 SHORT, CHRISTINE HALIFAX 11143 SHOULDICE, ELIZABETH 13885 SHRAFAT, NADEEM SYDNEY 13754 SHUBA, LESYA M HALIFAX 12453 SHUKLA, ROMESH C HALIFAX 4905 SHUKLA, SHASHI P HALIFAX 6040 SHULLAIH, ZAKI O SYDNEY 14478 SIBLEY, STEPHANIE R KINGSTON 15659 SIDDIQUI, MUGHINA A ANTIGONISH 14361 SIDHOM, MARY HALIFAX 10746 SILBURT, BRUCE S HALIFAX 12088 SILVER, M MARGARET ANTIGONISH 4663 SILVER, MICHAEL E ANTIGONISH 10162 SIMMS, MATTHEW HALIFAX 13336 SIMPSON, CHARLES D HALIFAX 6723 SIMPSON, CHARLES D HALIFAX 13641 SINCLAIR, MICHAEL G KENTVILLE 13712 SINGH, JAGMOHAN K TRURO 10999 SINGH, JASPAL KENTVILLE 8140 SINGH, SARBAN HALIFAX 12569 SINGH, SARBJIT TRURO 10164 SINGLETON, KATHLEEN M HALIFAX 10633 SINHA, DINESH P HALIFAX 3848 SIVAKUMAR, SARASWATI SYDNEY 14620 SIVANANTH, P KENTVILLE 13751 SJAUS, ANA HALIFAX 13066 SKIDMORE, DAVID L HALIFAX 13775 SKINNER, EDISON B PICTOU 5376 SLATER, JENNIFER L HALIFAX 14736 SLAYTER, IAN M ANTIGONISH 13443 *SLIPP, FRANK E TRURO 3570 SMITH, AARON C WESTVILLE 14747 SMITH, ANDREW NEIL DARTMOUTH 12455 SMITH, CATHRYN L WINDSOR 6458 SMITH, CHERYL D SCOTSBURN 11700 *SMITH, CORTNEY M HALIFAX 14195 SMITH, DAVID Y TRURO 4400 SMITH, DEBORAH J HALIFAX 6614 SMITH, ERIC J HATCHET LAKE 10060 SMITH, JAMIE A 14754 SMITH, JOHN D MINEVILLE 4818 SMITH, MATTHEW 14462 SMITH, MURDOCK A SYDNEY 3339 *SMITH, PAULA F POINT EDWARD 7804 SMITH, PETER K DARTMOUTH 7202 *SMITH, PHILIP M SYDNEY 7120 SMITH, PRESTON A HALIFAX 14342 SMITH, SHANE A HALIFAX 15143 SNAIR, PATTI J HALIFAX 13755 SNEDDON, KADRE A BEDFORD 15420 SNOW, STEPHANIE L HALIFAX 13899 SNOW, WILLIAM M SYDNEY 3701

* Refer to page 24 for alternate Pharmacare prescriber number. 18

SURNAME TOWN/CITY CPSNSSODER, CHRISTIAN M HALIFAX 6180 SOKOLENKO, MARINA HALIFAX 12106 SOLIMAN, EHAB STELLARTON 12203 SOMERS, PATRICK A HALIFAX 12265 SOMMER, MARKUS PORT WILLIAMS 14371 SOMMERFREUND, RAFI D LONDON 15418 SOMMERS, JACK G BEDFORD 4337 SOMMERS, JANET M TRURO 13839 SOMMERS, RYAN B TRURO 14209 SONIER, PAUL W CHETICAMP 12057 SOOCHAN, DIANA C HALIFAX 14712 SORHAINDO, MARK A FALL RIVER 11705 SOROKA, STEVEN D HALIFAX 12271 SOTO-MORENO, LOURDES YARMOUTH 15715 SOUDEK, DUSAN DARTMOUTH 7945 SOUSSOU, DAVID GLACE BAY 14890 SPENCER, GORDON J GLACE BAY 10550 SPENCER, KEVIN D OTTAWA 15721 SPICER, FINLAY R HALIFAX 7333 SPIESS, STEVEN D LOWER SACKVILLE 10728 SPRACKLIN, ANN E BRIDGEWATER 11944 SRIRANGARAJAN, RAMANI PORT HAWKESBURY 13405 SRIVATSA, KOUSTHUB K TRURO 14919 SSEGUYA-LWANGA, DAVID SYDNEY 13208 ST PETERS, CRAIG B HALIFAX 11145 STACEY, COOPER B DARTMOUTH 14499 *STALKER, ROBERT E HALIFAX 4823 STANISH, WILLIAM D HALIFAX 3564 STARODUB, JAMES P HALIFAX 15692 STEELE, CURTIS A HALIFAX 7848 STEELE, LEONE DARTMOUTH 8068 STEEVES, ALEXANDER L MAHONE BAY 3702 STEEVES, BRIAN R ANTIGONISH 3884 STEIN, JOHN D HALIFAX 15069 STENDER, MARK W HALIFAX 12050 STERN, RICHARD B PORT WILLIAMS 6053 STEVENS, SARAH C HALIFAX 7609 *STEWART, GRAHAM M UPR KENNETCOOK 11360 STEWART, JACQUELINE HALIFAX 15627 STEWART, JAMES A LUNENBURG 6568 STEWART, JOHN W DARTMOUTH 2153 STEWART, KEIR M HALIFAX 11850 STEWART, ROBERT L HALIFAX 13642 STINSON, DORA A HALIFAX 4362 STODDART, TODD A BRIDGEWATER 11946 STOKES, AIDAN HALIFAX 3752 STOKES, ROBERT BADDECK 4560 STONE, R CRAIG SYDNEY 10230 STRASFELD, MAURICE NEW GLASGOW 12333 STRAUB, DEBORAH NEW GLASGOW 10710 STRONG, JULIE K HALIFAX 6767 STURGE, CECIL C VALLEY 13737 STURMY, STEPHEN P ANTIGONISH 4535 STYLES, JANET K HALIFAX 13900 STYLES, JANET K HALIFAX 13900 SUBHANI, KHAJA N HALIFAX 3597 SULLIVAN, JOHN A HALIFAX 4238 SULLIVAN, JOHN H CANSO 4612 SULLIVAN, TANIA T ANTIGONISH 13367 SULLIVAN, WAYNE H HALIFAX 4386 SUNDARARAJAN, K WOLFVILLE 15460 SUNDIN, JAN O BRIDGEWATER 10663

SURNAME TOWN/CITY CPSNSSURETTE, JOEL Y YARMOUTH 13338 SUTHERLAND, GEORGE R ANTIGONISH 6748 SUTHERLAND, WILLIAM E BADDECK 15363 SUTTON, COLIN G GRAND LAKE 11556 SUTTON, EVELYN D HALIFAX 7689 SWAIN, ANN E PORT WILLIAMS 11465 SWICA, LESZEK STELLARTON 10555 SWIFT, ALEXANDER HALIFAX 13156 SWIFT, ELENA R BEDFORD 13143 SWINAMER, DEANNA L HALIFAX 12298 SZCZESNY, KRYSTIAN M AMHERST 7411 SZERB, JENNIFER J HALIFAX 6904 SZUDEK, EWA A HALIFAX 7884 T'IEN, WALLACE DARTMOUTH 7084 TAHA, DORIS MIRA ROAD 15111 TAIANI, E JOHN NEW MINAS 4979 TAIT, GLENDON R HALIFAX 15414 TAN, ALEXANDER HALIFAX 12720 TANTON, RONALD T HALIFAX 4635 TARAKJI, AHMAD R YARMOUTH 13671 TARGETT, MATTHEW M KENTVILLE 14466 TATLIDIL, CUNEYT DARTMOUTH 13069 TAYLOR CLARKE, REBECCA PORT WILLIAMS 11687 TAYLOR, BRETT W HALIFAX 11503 TAYLOR, GRETTA LUNENBURG 13214 TAYLOR, J E SCOTT BEDFORD 6923 TAYLOR, JOHNATHAN DARTMOUTH 13810 TAYLOR, LINDSAY E HALIFAX 15190 TAYLOR, ROSEMARIE A LOWER SACKVILLE 4807 TAYLOR, STEVEN MARK HALIFAX 12858 TAYLOR, TRUDY A HALIFAX 13654 TEEHAN, MICHAEL D HALIFAX 6974 TEODORESCU, OTILIA HALIFAX 13493 THANAMAYOORAN, S SYDNEY 12839 THERIAULT, DIANE M DARTMOUTH 7498 THERIAULT, P SCOTT HALIFAX 10190 THOMPSON, DEBORAH L HALIFAX 4781 THOMPSON, KAREN M PORT WILLIAMS 15697 THOMPSON, KRISTA L UPPER TANTALLON 11220 THOMPSON, SUSAN E RIVERVIEW 11204 THOMSON, CAROLYN J HALIFAX 8107 THONI, ANDREA J E LAWRENCETOWN 12594 THORNE, SUSAN F LIVERPOOL 10166 THURGOOD, ANN HALIFAX 11178 TIBBO, PHILIP G HALIFAX 10605 TILLEY, DAVID L HALIFAX 7629 TITLE, LAWRENCE M HALIFAX 10320 TO, DINH VU DARTMOUTH 13421 TOBIN, CHERYL LEANNE SYDNEY 15647 TODD, CRYSTAL F NEW MINAS 13341 TODD, ROBERT J SYDNEY 12722 TOLBA, MARWAN BEDFORD 13210 TOMA, TAMER S DARTMOUTH 15196 TOMLINSON, H MARY M DARTMOUTH 8147 TOOR, JASPREET K HALIFAX 15502 TOP, KARINA A HALIFAX 13860 TOPLACK, CHRISTINA M WOLFVILLE 10972 TOPP, TREVOR J HALIFAX 10405 TOREN, ANDREW J HALIFAX 15646 TOROK, MARIA T BEDFORD 14510 TOWNSEND, CLARENCE H NEW GLASGOW 13767 TRAGER, MORRIS E HALIFAX 4252

* Refer to page 24 for alternate Pharmacare prescriber number. 19

SURNAME TOWN/CITY CPSNSTRAVERS, ANDREW H HALIFAX 13492 TREMAINE, ROBERT D HALIFAX 6522 TRENHOLM, ARTHUR D HALIFAX 3714 TRITES, JONATHAN R HALIFAX 12599 *TRUEMAN, GILLIAN M BERWICK 6086 TUGWELL, BARNA D DARTMOUTH 13440 TULIPAN, TANYA M HALIFAX 14819 TURNBULL, GEOFFREY K HALIFAX 6496 TURNER, CHARLES G WINDSOR 4825 TUTERT, MARGARET L MOUNT UNIACKE 6840 TWEED, ANNE E MAHONE BAY 4616 TYNSKI, GREGORY F KENTVILLE 7561 UDOLU, OWHOEDE J SYDNEY 15408 UHOEGBU, CHIMDI U SYDNEY 15723 UREN, KELLY J KENTVILLE 14022 URSULIAK, ZENOVIA J HUBBARDS 12723 USMAN, MUHAMMAD SYDNEY 14483 VAIR, DONALD B HALIFAX 6246 VAKHARIA, NARENDRA R HALIFAX 10851 VAN AARDT, RENIER G TRURO 11796 VAN BOXEL, PAUL J AMHERST 12583 VAN EYK, NANCY A HALIFAX 13732 VAN ONSELEN, EUGENE SAULNIERVILLE 13939 VAN ZANTEN, SANDER J HALIFAX 7993 VANAST, WALTER J LERY 14279 VANDENHOF, MICHIEL C HALIFAX 6206 VANDORPE, ROBERT A HALIFAX 6694 VARMA, DIVYA J DARTMOUTH 11689 VATS, ARUN R GREENWOOD 10660 VAUGHAN, PETER W HALIFAX 12990 VEASEY, DUNCAN A CENTREVILLE 14347 VEASEY, JACK B EASTERN PASSAGE 13097 VEERASSAMY, SHALINI HALIFAX 14202 VEINOT NASH, JANET L HALIFAX 6091 VELJKOVIC, ANDREA N KENTVILLE 13647 VENUGOPAL, VIKRAM DARTMOUTH 10420 VERMA, BHARTI HALIFAX 7022 VERRYN STUART, IAN T KENTVILLE 4664 VERSNICK, ERIC J TRURO 11470 VIENNEAU, THERESA L NEW GLASGOW 13990 VINCENT, FRANKLYN A HALIFAX 13714 VINCER, MICHAEL J HALIFAX 6791 VIRICK, MOHAN S BLACKETTS LAKE 2160 VITALE, WILLIAM R HALIFAX 6474 VLATTEN, ARNIM HALIFAX 13344 VOHRA, MANOJ VALLEY 7828 WADDEN, ANN M DARTMOUTH 6916 WADDEN, MICHAEL R KENTVILLE 11314 WADDEN, ROBERT A HALIFAX 10174 WAJEEH, MOHAMMED YARMOUTH 13185 WAJSTAUB, SANDRA SYDNEY 15661 WALENTYNOWICZ, M HALIFAX 11163 WALKER, C ROBIN HALIFAX 14248 WALKER, HARMANNUS C GLACE BAY 4613 WALLACE, TIMOTHY AMHERST 13715 WALLING, KEITH E LOWER SACKVILLE 2538 WALLING, SIMON A HALIFAX 10367 WALSH, MARK J HALIFAX 11691 WALSH, NOREEN M HALIFAX 7422 WAMBULWA, CHARLES M SHELBURNE 15118 WANLESS, IAN R HALIFAX 14066 WARREN, ANDREW E HALIFAX 11496

SURNAME TOWN/CITY CPSNSWARREN, JOANN L TRURO 12357 WARREN, KATHERINE J WINDSOR 11471 WARREN, RICHARD DARTMOUTH 13402 WASILEWSKI, LESZEK J E LAWRENCETOWN 12591 WATSON, ADRIENNE N HALIFAX 13788 WATSON, ANDREW C MAHONE BAY 3093 WATSON, KRISTA P MAHONE BAY 13148 WATSON, MARY-LYNN HALIFAX 8047 WATSON, MATTHEW T DARTMOUTH 12604 WATSON, WADE T HALIFAX 13926 WATSON-CREED, GAYNOR DARTMOUTH 13976 WATSON-JESSOME, JANE HALIFAX 13392 WATT, DOUGLAS A SYDNEY MINES 6907 WATT, GARTH B HALIFAX 11198 WATTS, PETER W KENTVILLE 3801 WAWER, ANDREW R NORTH SYDNEY 6732 *WAWER, URSULA B BEDFORD 7825 *WAWRZYSZYN, BENIGNA HALIFAX 10680 WAWRZYSZYN, JANUSZ SYDNEY 7204 WEAGLE, EVERETT D BRIDGEWATER 7792 WEAVER, DONALD F HALIFAX 12975 WEBSTER, DAVID M YARMOUTH 10675 WEBSTER, SUSAN D DARTMOUTH 10271 WEEREN, CHRISTOPHER G HALIFAX 10558 WELCH, JOHN PHILIP HALIFAX 2863 WELLS, PHILIP J STEWIACKE 7913 WELLWOOD, ALISON M WOLFVILLE 14502 WELLWOOD, HEATHER M WOLFVILLE 4376 WENNING, JOAN B HALIFAX 6114 WERNER, DIETRICH BRIDGEWATER 14239 WERTLEN, WINSTON G YARMOUTH 12299 *WESCOTT, DON D ANTIGONISH 12026 WEST, KENNETH A HALIFAX 10990 WEST, MICHAEL L HALIFAX 7989 WESTBY, DONALD M WEYMOUTH 6662 WHATLEY, GORDON S HALIFAX 6422 WHITBY, DAVID HALIFAX 2167 WHITE, CELINA D AMHERST 6400 WHITE, DARRELL J HALIFAX 11073 WHITE, KIMBERLEY D HALIFAX 12899 WHITE, MAUREEN E HALIFAX 7366 WHITE, MICHAEL L BEDFORD 4645 WHITE, ROBYN A 13903 WHITE, ROSEMARY A HALIFAX 4380 WHYNOT, LESLEY M HAMMONDS PLAINS 11158 WHYTE, ROBIN HALIFAX 10330 WIEBE, ALISON W DARTMOUTH 12021 WIEDER, JANA HALIFAX 7195 WIGHTMAN, HOWARD A KENTVILLE 6530 WIGNALL, GEOFFREY R 12728 WILE, IONA HANTSPORT 10018 WILKE, DEREK R HALIFAX 11149 WILKIE, ALLAN V PORT WILLIAMS 12038 WILLIAMS, ALBERT R HALIFAX 13345 WILLIAMS, GEOFFREY S HALIFAX 13071 WILLIAMS, JASON G HALIFAX 12464 WILLIAMS, JULIE HALIFAX 13400 WILLIAMS, LACI A HALIFAX 15033 WILLIAMS, LARA J HALIFAX 13346 WILLIAMS, STACEY P HALIFAX 12199 WILLIAMS, TRACEY L TRURO 12200 WILSON, DAVID H SHELBURNE 6414

* Refer to page 24 for alternate Pharmacare prescriber number. 20

SURNAME TOWN/CITY CPSNSWILSON, DIANE B LUNENBURG 11626 WILSON, EVA ADRIANA HALIFAX 14722 WILSON, KENNETH L HALIFAX 6245 WILSON, RODNEY D HALIFAX 11740 WINSOR, WENDY A HALIFAX 13535 WISNIOWSKI, LEO E BEDFORD 10740 WITTER, TOBIAS HALIFAX 14351 WOJCIK, RONALD W HAMMONDS PLAINS 7129 WONG, DANIEL 12201 WONG, DAVE SYDNEY 11695 WONG, JILL M HALIFAX 12193 WONG, KENNY K HALIFAX 11953 WONG, KIM HALIFAX 15618 WONG, LORI ANN HALIFAX 11809 WOO, DANIEL KENTVILLE 12730 WOOD, DAVID C HALIFAX 7421 WOOD, ELLEN P HALIFAX 12020 WOOD, JEREMY R HALIFAX 7086 WOOD, LORI A HALIFAX 12527 WOOD, WILLIAM C BRIDGEWATER 12220 *WOODFORD, TIMOTHY J LIVERPOOL 6934 WOODS, ERIC R YARMOUTH 6908 WORKMAN, STEPHEN R HALIFAX 11203 WORNELL, PHILIP A TRURO 12465 WORTH, GLEN G SYDNEY 10207 WREN, PATRICIA L HALIFAX 6407 WRIGHT, ALISTAIR STUART HALIFAX 13904 WRIGHT, BRUCE A BRIDGEWATER 7711 WRIGHT, S ELIZABETH BEDFORD 12531 WU, KWONG Y HALIFAX 6083 WURSTER, CHARLES L FALL RIVER 11955 WYBENGA, MILTON P BROOKFIELD 7357 WYMAN, CHESTER R YARMOUTH 3563 XENOYANNIS, GEORGE L HALIFAX 15347 XU, ZHAOLIN HALIFAX 10573

SURNAME TOWN/CITY CPSNSYABSLEY, REGINALD H HALIFAX 2828 YAFAI, ABDUL-AZIZ KINGSTON 4604 YAMADA, DREW C HALIFAX 14470 YANCHAR, NATALIE L HALIFAX 12078 YAZER, ERIKA E HALIFAX 14936 YAZER, HAROLD HALIFAX 3709 YEADON, DEREK E WINDSOR 4602 YEE, KENNY Y BARRINGTON PASS. 10996 YEPES, HORACIO SYDNEY 13361 YEUNG, GORDON K HALIFAX 13905 YHAP, MARGARET C HALIFAX 4503 YOELL, CHRISTOPHER W NEW MINAS 10858 YOSHIDA, LIANNE M HALIFAX 13494 YOU, CHOONG K HALIFAX 3772 YOUNG, DAVID C HALIFAX 11765 YOUNG, GORDON V PICTOU 4223 YOUNG, MICHAEL J HALIFAX 12234 YOUNIS, TALLAL H HALIFAX 13515 YUNG, JASON D DARTMOUTH 12466 ZAMAN, KHAWAR-UZ DARTMOUTH 10762 ZAREMBA, EWELINA HALIFAX 14723 ZAREMBA, JOZEF AMHERST 10650 ZBUK, RANDALL S HALIFAX 14726 ZED, JOANNA M HALIFAX 7781 ZEMERLI, FATIMA Z SYDNEY 14397 ZHANG, LU HALIFAX 13707 ZILBERT, ARTHUR W DARTMOUTH 4389 ZINCK, M SUZANNE HALIFAX 13989 ZITNER, DAVID HALIFAX 4241 ZIVIC-DELIU, LJILJANA HALIFAX 13553 ZWICKER, CHRISTINE L PORTERS LAKE 11232 ZWICKER, DANIEL M LUNENBURG 4548 ZWICKER, DEBORAH A SYDNEY 11151 ZWICKER, HOLLY J UPPER TANTALLON 11473

21

MIDWIVES

SURNAME

TOWN/CITY

PRESCRIBER NUMBER

ASHE, AMANDA ANTIGONISH 2 BEVAN, MELISSA ANTIGONISH 11 CHISHOLM, KELLY DARTMOUTH 4 DIETZE, MAREN LUNENBURG 1 GODWIN, RACHEL DARTMOUTH 7 NIBLETT, LESLIE BRIDGEWATER 3 PICKART, THERESA KETCH HARBOUR 5 ROBB, KAREN DARTMOUTH 6

* Refer to page 24 for alternate Pharmacare prescriber number. 22

NURSE PRACTITIONERS

SURNAME

TOWN/CITY

PROVIDER NUMBER

ANDERSON, MARY A INVERNESS 720999 BENNETT, C RENATE CALEDONIA 722688 BENOIT, MARY R HALIFAX 716831 BILLARD, ARLENE GLACE BAY 728347 BLOIS, DEBORAH PARRSBORO 716883 BRACE, LENORA PICTOU 727529 BROOKS, ELAINE HALIFAX 719148 BURGESS, CARLA HALIFAX 725610 CAMPBELL, TRUDY HALIFAX 729559 CARTWRIGHT, LOIS NEILS HARBOUR 727237 CHAPMAN, KRISTINA HALIFAX 732304 CHUBBS, DAWN O NEW GERMANY 729855 CLEVELAND, CHARLOTTE UPPER TANTALLON 728934 COCKERSELL, KEITH G HALIFAX 726244 CORBETT, DIANNE YARMOUTH 732280 COULTER, LYNN HALIFAX 717468 CURRIE, BARBARA HALIFAX 724553 D'ENTREMONT, DUANA L PUBNICO 723502 DAY, CONSTANCE DIGBY 727784 DEMAINE, DAPHNE DIGBY 733654 DICKS, DEBORAH MUSQ. HARBOUR 718179 DUKE, SANDRA HALIFAX 727896 EDGECOMBE, NANCY HALIFAX 731523 EDWARDS, JO-ANN HALIFAX 725096 ELLIS, ERICA SPRINGHILL 729695 FAIRBANKS-SMITH, HEIDI RIVER HEBERT 729880 FORREST, JENNIFER LOWER SACKVILLE 727298 GARDEN-JAYASINGHE, J LANTZ 724009 GIFFIN, LORRI BEDFORD 726083 GILBERT, LILLA HALIFAX 732220 GORMAN, NICOLE E BEDFORD 733677 GRANT, DONNA HALIFAX 723558 GREEK, SHANNON BEDFORD 731311 GREEN, JACQUELINE L PICTOU 730576 GREENE, CARLA SPRINGHILL 728871 HART, DEBORAH LEITCHES CREEK 729988 HARVEY, JACINTA M BERWICK 719783 HEBERT, KIM FLETCHERS LAKE 722784 HENDRIKSEN, J BADDECK 725417 HICKEY, DEANA SHELBURNE 729007 HIRSCH, GERALYNN HALIFAX 719144 HODGSON, ELIZABETH HALIFAX 717847 HUQ, SALINA MIDDLE SACKVILLE 730621 *INGS, DAVID JASON SYDNEY 729444 KELLY, NIKKI M HALIFAX 729636 KENNEDY, SHERYL HALIFAX 732325 KETTLE, SONIA HAMMONDS PLAINS 727677 KNICKLE, KRISSINDA A LUNENBURG 729085 KNICKLE, KRISTA LUNENBURG 727256 LAKE, TRACY L DARTMOUTH 729426 LAMARCHE, KIM FREEPORT 728963 LANDRY, DAVID HALIFAX 726953 LANE, TRICIA HALIFAX 728879 LAWLOR, DIANA STILLWATER LAKE 726144 LEBLANC, MEGAN G MIDDLE W. PUBNICO 731724

SURNAME

TOWN/CITY

PROVIDER NUMBER

LEGG, KAREN MIDDLE SACKVILLE 725254 LOVE, ANNETTE HALIFAX 730718 LOWE, DAWN WINDSOR 729116 MACCALLUM, KIMBERLY A DARTMOUTH 726974 MACDONALD, DARA LEE NEW GLASGOW 724184 MACDONALD, GEORGANN CLARKS HARBOUR 733145 MACDONALD, LENA M ANTIGONISH 728483 MACDONALD, NANCY J CHESTER 729882 MACEACHERN, CLARE M MABOU 724720 MACISAAC, JANET PORT HAWKES. 716862 MACKAY, MICHELLE HAMMONDS PLAINS 727655 MACLEAN, KRISTAL PICTOU 727294 MACPHERSON, DARLA SACKVILLE 728028 MACRAE, HELEN FREEPORT 719963 MCCOWAN, SUSAN T HALIFAX 729587 MCGRAY, SHEILA J NEWPORT 718357 MCKEE, D BEVERLY WOLFVILLE 731807 MCNAMARA, CHRISTINA HALIFAX 726229 MCNAMARA-MORSE, D MIDDLETON 726489 MEAGHER, ANDELA D HALIFAX 726471 MILLER, CAROLE-ANN HALIFAX 730408 MILLER, LYNN PUGWASH 726049 MISENER, CATHERINE HALIFAX 720151 MISNER, DEBBEE COLDBROOK 722259 MITCHELL, CAROLYN BEDFORD 728359 MURPHY, RALEEN HALIFAX 731829 NEARING, SHANNON HALIFAX 721891 NEWTON, KIMBERLY J TATAMAGOUCHE 730467 NICHOLS, NATALIE DARTMOUTH 722227 O'CONNELL, TERRILEE METEGHAN CENTRE 730274 OLDFORD, DEBORAH DARTMOUTH 723924 PHALEN-KELLY, KELLY J BEDFORD 725360 PLANETTA, CYNTHIA SYDNEY 720682 ROACH, DEBORAH A GLACE BAY 721406 RUTHERFORD, MARILYN STILLWATER LAKE 731400 SAILE, AXEL S LUNENBURG 730455 SAMSON GAGNON, B L'ARDOISE 728286 SANREGRET, TAMBREY DIGBY 733413 SEYMOUR, FRANCES ADVOCATE HRBR 727069 SMITH, CHERYL AMHERST 721194 SNIDER, KAREN FREEPORT 730457 STODDART, MELISSA E AYLESFORD 731062 STOREY, SANDRA L HALIFAX 730043 TAYLOR, PAULA HAMMONDS PLAINS 722367 THIBEAU, MELANIE Z HEBRON 728231 TINNING, AMANDA HALIFAX 732355 TONER, SANDRA GEORGES RIVER 723718 VENEDAM-MARCHAND, C ANTIGONISH 724485 WELCHER, SOHANI HALIFAX 726424 WHITE-YOUNG, LEEANN MIDDLETON 729608 WITHROW, KAREN HALIFAX 730171 WOOD, MARSHA HAMMONDS PLAINS 721622 YATES, GILLIAN PROSPECT 719141 YEATES, PAULA HALIFAX 726671

NOTE: To become an authorized Nurse Practitioner under the Nova Scotia Pharmacare Programs, a practitioner must be licensed with the College of Registered Nurses of Nova Scotia and part of a valid “Collaborative Practice Agreement”.

* Refer to page 24 for alternate Pharmacare prescriber number. 23

PRESCRIBING OPTOMETRISTS

SURNAME

TOWN/CITY

PROVIDER NUMBER

AMBIZAS, HELEN SYDNEY 50174 BAIRD, MICHAEL H LOWER SACKVILLE 50164 BALDOCK, ALAN J AMHERST 50146 BAYER, CHERYL YARMOUTH 50216 BLACKMORE, STEPHANIE DARTMOUTH 50220 BOUDREAU, L AMHERST 50222 BUCHANAN-DORRANCE, J HALIFAX 50152 BURNS, BARRY PORT HAWKES. 50115 CAREW, ALPHONSE S LOWER SACKVILLE 50107 CARTON, TOM LUNENBURG 50194 CHAFE, JOHN R SYDNEY 50117 CHOW, FREDDIE K HALIFAX 50185 CHUTE, MARK ELMSDALE 50170 COX, M AVILA BEDFORD 50160 CULLEN, ANDREA SYDNEY 50221 CURRIE, DEBRA A LOWER SACKVILLE 50137 D'ENTREMONT, NAOMI STE-ANNE-DU-RUISS 50231 DAVIS, CARL W HALIFAX 50108 DEBLY, MIRIAM J HALIFAX 50132 DECOSTE, JOLENE ANTIGONISH 50179 DENMAN, MARNI HALIFAX 50225 DOBBELSTEYN, DAVID M HALIFAX 50058 DOBSON, ANGELA C BEDFORD 50144 DOMAN, CAROL A BEDFORD 50186 DUFFEY, MICHAEL P MIDDLETON 50060 FLEMING, JOHN SYDNEY 50062 FLYNN, KRISTA WOLFVILLE 50203 FRENCH, VICTORIA HALIFAX 50209 FURFARO, MELISSA ANTIGONISH 50235 GAGNON, PAUL J GREENWOOD 50224 GALLIE, LEAH HALIFAX 50208 GAUDET, PAULA M LOWER SACKVILLE 50142 GILLAM, DAVID TRURO 50118 GRAY, PAUL J HALIFAX 50066 HAWKINS, K ANDREA ELMSDALE 50169 ISABELLE, GLENN D MAHONE BAY 50070 KEPES, MARK HALIFAX 50232 KILLORAN, JODY A DARTMOUTH 50183 KINNEY, BRETT MIDDLETON 50205 LACEY, LISA M YARMOUTH 50195 LAI, ELIZABETH BEDFORD 50207 LANDRY, REMI DIEPPE 50227 LANG, GAETAN L HALIFAX 50124 LAVANDIER, ANDRE BRIDGEWATER 50143 LAWRENCE, THOMAS D BRIDGEWATER 50072 LEGER, JEAN - GUY SPRINGHILL 50131 LEVESQUE, YVES LIVERPOOL 50145 LU, CHARLES C DARTMOUTH 50157 MACDONALD, RHETLAND HALIFAX 50198 MACDONNELL, DEIDRE L HALIFAX 50187 MACDOUGALL, HEATHER TRURO 50111

SURNAME

TOWN/CITY

PROVIDER NUMBER

MACDUFF, J REID WINDSOR 50079 MACINNIS, SHAUN DARTMOUTH 50210 MACKINNON, LAWRENCE NEW GLASGOW 50121 MACLEOD, JOHN G NEW GLASGOW 50080 MAILLET, JULIE HALIFAX 50215 MAILLET, TIM UPPER TANTALLON 50196 MAKARAN, ROSEMARY RIVERVIEW 50190 MALIK, PAMELA BRIDGEWATER 50082 MANCHANDA, AMITPAL DARTMOUTH 50128 MANDELMAN, TOBY BEDFORD 50083 MARTIN, JUDY A SPRYFIELD 50085 MCCARTHY, IAN AMHERST 50214 MCGINTY, EUAN HAMMONDS PLAINS 50226 MCINTOSH, SCOTT DARTMOUTH 50191 MCKAY, SHARI L SYDNEY 50189 MCKEE, KATHERINE T WOLFVILLE 50155 MCMANUIS, CATHERINE M YARMOUTH 50086 * MCMULLIN, LAURA DARTMOUTH 50234 MOORE, SUZANNE HALIFAX 50181 MUNRO, JILLIAN WOLFVILLE 50239 NAUGLE, MICHAEL MONCTON 50223 NEARING, MEGAN HALIFAX 50233 OULAHEN, MICHAEL G DARTMOUTH 50112 PARKASH, RAMAN HALIFAX 50184 PERRY, CRYSTAL HALIFAX 50213 POTHIER, SHELDON J WOLFVILLE 50113 POTTER, CHARLOTTE M NEW GLASGOW 50201 POTTLE, J THOMAS GLACE BAY 50094 RAY, JANET E FALL RIVER 50095 READY, SARAH FALL RIVER 50236 REID, MELANIE NEW GLASGOW 50228 REID, NATHAN NEW GLASGOW 50229 RICHARD, SERGE MONCTON 50158 ROHLAND, GUY A YARMOUTH 50211 RYBA, EDWARD J SYDNEY 50098 SAMPSON, JOHANNA L ST PETERS 50126 SAMSON, NATHANIEL SYDNEY 50200 SANGSTER, JEFFREY O HALIFAX 50161 SAYWOOD, ANGELA K FALL RIVER 50202 SCOTT, ALLISON DARTMOUTH 50204 SEALE, ROBBI K YARMOUTH 50154 SHEPPARD, ERIN L BEDFORD 50188 SMIT, HENRY M TRURO 50100 SMITH, JACQUELYN HALIFAX 50178 SMITH, RYAN LANTZ 50238 TELSTAD, LYLE SCOTSBURN 50193 WAGG, RAYMOND P NEW GLASGOW 50102 WEBBER, ANDREW J FALL RIVER 50182 WILKINSON, SARA DIGBY 50192 WILSON, DAVID JOHN UPPER TANTALLON 50237 WINSLADE, TIMOTHY C WOLFVILLE 50105

24

ALTERNATE PRESCRIBER NUMBERS

The College of Physicians and Surgeons of Nova Scotia (CSPNS) license number is generally used as the physician prescriber number when billing the Pharmacare Programs. However, for some physicians, an alternative number has been assigned and should be used for Pharmacare billing purposes. SURNAME

TOWN/CITY

PRESCRIBER NUMBER

AGO, C HALIFAX 5678081 ALLAN, PATRICIA ANTIGONISH 6542 ARCHIBALD, JOHN SYDNEY 5386 BAHL, GAURAV HALIFAX 152130 BARRY, ANNE KENTVILLE 898 BETHUNE, GRAEME HALIFAX 5365 BOWIE, DENNIS HALIFAX 4059A BUCHHOLZ, KENNETH ANNAPOLIS ROYAL 16212 CHEEVERS, PAUL YARMOUTH 13889 CLARK, ALEXANDER HALIFAX 4390 COMEAU, ALBAN SAULNIERVILLE 4955 COOPER, ROBERT PICTOU 4956 CRASWELL, DONALD MIDDDLETON 15342 DAS, BIJON HALIFAX 126730 DESROSIERS, JACQUES HALIFAX 546 DEVITT, JAMES HAMMONDS PLAINS 9749 DICKINSON, JOHN HALIFAX 8012 ELLIOTT, CHRISTOPHER NEW GLASGOW 42077 FELTMATE, MARY TRURO 6393 GHENEA, IRINA NORTH SYDNEY 8205 GILLIS, GRANT HALIFAX 10808 GUERIN, JOHN HALIFAX 156810 HAMILTON, JOHN ANTIGONISH 5428 HANADA, EDWIN HALIFAX 11428A HEGARTY, RAYMOND ANTIGONISH 4298 HIMMELMAN, DONALD PLEASANTVILLE 5036 HORREY, KATHLEEN HALIFAX 9777 HUMAYUN, MUHAMMAD DARTMOUTH 306176 HUQ, SALINA MIDDLE SACKVILLE 30621 JARVIS, CARL HALIFAX 10801 JHA, UMESH HALIFAX 5239 JOHNSTON, C FALL RIVER 13982 JOLLYMORE, GEORGE CHESTER 5407 JOST, ELLEN HALIFAX 7175 KHALIL, HISHAM BEDFORD 15581 KIRBY, RONALD HALIFAX 529 KNIGHT, DEBORAH DARTMOUTH 49142 KOZEL, VITIA TRURO 10038 LANGDON, REX HALIFAX 15208 LANGILLE, KENNETH AYLESFORD 4538 LUDMAN, MARK HALIFAX 7704

SURNAME

TOWN/CITY

PRESCRIBER NUMBER

MACDONALD, KAREN ANTIGONISH 6899A MACDONALD, KAREN HALIFAX 6899 MACGIBBON, S LOIS BEDFORD 148310 MACINTOSH, DONALD HALIFAX 12264 MACINTOSH, REBECCA HALIFAX 6610 MACKAY, THOMAS HALIFAX 3781 MACKNIGHT, CHRIS HALIFAX 8253 MACNEIL, MARY HALIFAX 8014 MARSH, LORNE HALIFAX 5368 MCGIBNEY, KEIRON TRURO 151860 MCLAREN, RICHARD TRURO 4492 MCMANUIS, CATHERINE YARMOUTH 41 MCNEILL, LAURIE BRIDGEWATER 2634 MILNE, P RONALD HALIFAX 7635 MORSE, DAVID LUNENBURG 3878 MORSE, EWART BRIDGEWATER 5372 NADER, NABIL AMHERST 12499A O'BRIEN, BRIAN HALIFAX 4915 ORLIK, BENJAMIN HALIFAX 138890 PEARCE, PATRICIA HALIFAX 1639 PESTELL, DEBBIE BEDFORD 152150 REID, DANIEL DARTMOUTH 13574 RICHARDSON, C GLEN HALIFAX 11457A RIIVES, MAI HALIFAX 7311 ROGERS, JOHN SYDNEY 7784A RONDEAU, RONALD OXFORD 46761 ROY, GREGORY DARTMOUTH 5252 SAWLER, MARGARET WAVERLEY 123410 SCHAFFNER, JOHN PORT WILLIAMS 5758 SCOTT, TRACY HALIFAX 8076 SLAYTER, IAN ANTIGONISH 4401 SMITH, CHERYL SCOTSBURN 8053 SMITH, MURDOCK SYDNEY 5256 SMITH, PETER DARTMOUTH 17200 STACEY, COOPER DARTMOUTH 4969 STEVENS, SARAH HALIFAX 7600A TRITES, JONATHAN HALIFAX 104853 WAWER, ANDREW NORTH SYDNEY 5219 WAWER, URSULA BEDFORD 17825 WERTLEN, WINSTON YARMOUTH 1973 WOOD, WILLIAM BRIDGEWATER 4838

FEBRUARY 2012 • VOLUME 12-03 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

OxyContin®/OxyNEO® Communication

Exception Status Drugs

New Products

New Ostomy Products

Product Name and Manufacturer Change

Non-Insured Products

Transition Fees

Changes to the Nova Scotia Formulary on the Pharmacare Website

Nova Scotia Formulary Updates

OxyContin®/OxyNEO® Communication

The Atlantic Expert Advisory Committee (AEAC) has reviewed OxyNEO® and recommended that it not be listed on the Nova Scotia Pharmacare Formulary.

Effective March 1, 2012, under the Nova Scotia Pharmacare Programs, there will be no new starts for OxyContin® or OxyNEO®. Nova Scotia Pharmacare beneficiaries who are currently receiving OxyContin ® (who have received coverage in the 3 months prior to March 1, 2012) will be eligible to receive coverage of OxyNEO®.

The Nova Scotia Pharmacare Program will consider requests for long acting oxycodone (OxyContin® or OxyNeo®) on a case-by-case basis for cancer or palliative pain when other alternatives on the Formulary have failed or are not appropriate.

OxyNEO® is not interchangeable with OxyContin®. Nova Scotia Pharmacare beneficiaries changing to OxyNEO® will require a new prescription if their physician deems it appropriate to continue, but will not need a new Exception Status Drug Request as their approved coverage for OxyContin® will apply to OxyNEO®. As well, all existing part-fill prescriptions for OxyContin® will have to be rewritten for OxyNEO® for patients who are currently on OxyContin® once the supply of OxyContin® is depleted.

A comprehensive review of oxycodone is being done. The results of this study will address the appropriate place in therapy for oxycodone products for pain management.

Exception Status Drugs

Certain drugs are only eligible for coverage under the Pharmacare Programs when an individual meets criteria developed by the Atlantic or Canadian Expert Advisory Committees. A list of drugs is included in the Nova Scotia Formulary as Appendix III, “Criteria for Coverage of Exception Status Drugs” and they are indicated by “E” in the benefit status column of the Formulary.

PAGE 2 OF 4PHARMACISTS’ EDITION

VOLUME 12-03

Exception Status Drugs Continued…

Copies of the standard exception status drug (ESD) request form, Pharmacist ESD request form, and special forms for specific drugs are included in the Formulary, and can also be found on the Nova Scotia Pharmacare website at www.nspharmacare.ca.

Requests for Coverage

To request coverage, the prescriber should mail or fax a completed request form or letter to the Pharmacare office. Pharmacists may complete an exception status form on behalf of the beneficiary; however, the form must be signed by the prescriber. Prescribers may also contact the Pharmacare office and speak directly to an Exception Status Drug Analyst or a Pharmacist Consultant to request coverage. The prescriber must provide the following information as part of the request:

beneficiary identification, including Nova Scotia Health Card number diagnosis drug requested criteria met other pertinent information

If the Pharmacist is the prescriber of a medication that requires special authorization for payment, the Pharmacist may submit a request for coverage for review. The request must include all of the above, as well as clearly indicate:

that the Pharmacist is the prescriber of the medication the Pharmacist’s name and NSCP license number the pharmacy name and provider number the mailing address (for written confirmation of response)

Written confirmation of the outcome of the review is provided to the prescriber of the medication. It is, therefore, very important that Pharmacists provide an appropriate mailing address on each request, to ensure that the confidential response is delivered to them or other designated pharmacy staff.

Coverage for non-benefit drugs may also be considered for coverage in exceptional circumstances following a written request from the prescriber. Prescribers may also contact the Pharmacare office and speak directly to a Pharmacist Consultant to request coverage.

Notification

Beneficiaries are notified only if the request is approved. Beneficiaries may bring this letter to the pharmacy to verify that coverage has been approved or the Pharmacist may simply bill the claim on-line for immediate response. The prescriber is notified in all cases (if coverage is authorized, if the request is refused because the criteria for coverage is not met, or if more information is required). The notification will include the name and strength of the drug approved as well as the term for coverage.

PAGE 3 OF 4PHARMACISTS’ EDITION

VOLUME 12-03

Exception Status Drugs Continued…

Billing

Once authorization is approved, the claim for the exception status drug is billed on-line to the Pharmacare Programs. Usual copayment and deductible rules apply. If the beneficiary has received the drug while awaiting authorization and the request is eventually approved, the beneficiary can seek reimbursement if the original receipt is forwarded to the Pharmacare Office within six months of the date purchased. Likewise, coverage may also be backdated to a maximum of three months or the first of the month of registration (whichever is less).

New Products

The following products are new listings to the Nova Scotia Formulary, effective February 27, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT STRENGTH DIN/PIN PRESCRIBERBENEFIT

STATUSMFR

Botox® 50 unit/vial Inj 00999443 DNP E (SF) ALL

Hydromorph Contin® 4.5mg Cap 02359502 D SFC PFR

Hydromorph Contin® 9mg Cap 02359510 D SFC PFR

pms-Mirtazepine 15mg Tab 02273942 DNP SFC PMS

pms-Quetiapine 50mg Tab 02361892 DNP SF PMS

Synthroid® 0.137mg Tab 02233852 DNP SF ABB

New Ostomy Products

The following products are new listings to the Nova Scotia Formulary, effective February 27, 2012.

PRODUCT DIN/PINPRODUCTNUMBER

PRESCRIBERBENEFITSTATUS

MFR

Mouldable Rings (3.0mm) 95098252 12030 DNP SFC COLMouldable Rings (4.2mm) 95098251 12042 DNP SFC COL

PAGE 4 OF 4PHARMACISTS’ EDITION

VOLUME 12-03

Product Name and Manufacturer Change

Please note that effective immediately, the following product has undergone a name and manufacturer change. The DIN for this product remains the same.

PRODUCT MFR DIN NEW PRODUCT NAME NEW MFR

Lanoxin 0.05mg/mL Elx PMS 02242320 Toloxin 0.05mg/mL Sol MMT

Non-Insured Products

The following products were reviewed by the Atlantic Expert Advisory Committee (AEAC) and were not recommended to be listed as benefits under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBERBENEFITSTATUS

MFR

TOBI® 300mg/5mL Sol 02239630 N/A Not Insured NVRTOBI® Podhaler® 28mg Cap 02365154 N/A Not insured NVR

Decision Highlights Current available evidence does not clearly show superiority of any one formulation over another with regards to efficacy or safetyTOBI is approximately ten times the cost of IV tobramycinA well designed comparative trial is required to justify the increased cost of TOBI compared to the IV tobramycin formulation

Transition Fees for the Period of January 1, 2012 to March 31, 2012

According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.25 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

Changes to the Nova Scotia Formulary on the Pharmacare Website

Beginning February 2, 2012, the Nova Scotia Formulary will only appear on the Nova Scotia Pharmacare website (www.nspharmacare.ca) in Portable Document Format (PDF). It will continue to be updated monthly. In order to view PDF files, you need to have Adobe® Reader installed on your computer. Instructions to download this free software is provided on the Formulary site.

To search for specific text and page content in the PDF version of the Formulary you can: Right click the document and choose “Find” from the pop-up menu. In the upper right of the window, enter your search term and click the arrows to navigate to each instance. Perform a more complex search for whole words, phrases, comments, and other options by doing either of the following:

In a web browser, click the binoculars at the left of the window. If the binoculars are not there, right click the document and choose “Show Navigation Pane Buttons” In the Adobe® Reader application, choose Edit > Advanced Search

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 1 of 77

Generic Name and Strength DIN Brand MFR MRP PRPacebutolol HCl 100mg tab 02286246 Acebutolol 100mg tab SAS 0.1342

02147602 Apo-Acebutolol 100mg tab APX 0.134202237885 MYLAN-Acebutolol (Type S) 100mg tab MYL 0.134202237721 MYLAN-Acebutolol 100mg tab MYL 0.134202204517 Novo-Acebutolol 100mg tab TEV 0.134202165546 Nu-Acebutolol 100mg tab NXP 0.134201910140 Rhotral 100mg tab SDZ 0.134201926543 Sectral 100mg tab (discontinued) SAV 0.1342

acebutolol HCl 200mg tab 02286254 Acebutolol 200mg tab SAS 0.201402147610 Apo-Acebutolol 200mg tab APX 0.201402237886 MYLAN-Acebutolol (Type S) 200mg tab MYL 0.201402237722 MYLAN-Acebutolol 200mg tab MYL 0.201402204525 Novo-Acebutolol 200mg tab TEV 0.201402165554 Nu-Acebutolol 200mg tab NXP 0.201401910159 Rhotral 200mg tab SDZ 0.201401926551 Sectral 200mg tab SAV 0.2014

acebutolol HCl 400mg tab 02286262 Acebutolol 400mg tab SAS 0.400802147629 Apo-Acebutolol 400mg tab APX 0.400802237887 MYLAN-Acebutolol (Type S) 400mg tab MYL 0.400802237723 MYLAN-Acebutolol 400mg tab MYL 0.400802204533 Novo-Acebutolol 400mg tab TEV 0.400802165562 Nu-Acebutolol 400mg tab NXP 0.400801910167 Rhotral 400mg tab SDZ 0.400801926578 Sectral 400mg tab SAV 0.4008

acetaminophen 325mg & oxycodone 5mg tab

02324628 Apo-Oxycodone/Acet 5/325mg tab APX 0.1285

01916548 Endocet tab BRI 0.128502361361 Oxycodone/Acet 5/325mg tab SAS 0.128501916475 Percocet tab BRI 0.128500608165 ratio-Oxycocet tab TEV 0.128502307898 Sandoz-Oxycodone Acet tab SDZ 0.1285

acetazolamide 250mg tab 00545015 Acetazolamide tablets 250mg AAP 0.1343acetylcysteine 200mg/mL inj 02243098 Acetylcysteine 200mg/mL inj SDZ 0.6800

02091526 Mucomyst 200mg/mL inj WLS 0.6800acetylsalicylic acid 325mg EC tab 00010332 Entrophen 325mg EC tab PDP 0.0280

00216666 Novasen 325mg EC tab TEV 0.028002284529 pms-ASA 325mg EC tab PMS 0.0280

acetylsalicylic acid 650mg EC tab 00010340 Entrophen 650mg EC tab PDP 0.035200229296 Novasen 650mg EC tab TEV 0.0352

acetylsalicylic acid 330mg, butalbital 50mg, caffeine 40mg & codeine phosphate 15mg cap

00176192 Fiorinal C1/4 cap NVR 0.6210

00608203 ratio-Tecnal C1/4 cap TEV 0.6210acetylsalicylic acid 330mg, butalbital 50mg, caffeine 40mg & codeine phosphate 30mg cap

00176206 Fiorinal C1/2 cap NVR 0.7607

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 2 of 77

Generic Name and Strength DIN Brand MFR MRP PRPacetylsalicylic acid 330mg, butalbital 50mg, caffeine 40mg & codeine phosphate 30mg cap

00608181 ratio-Tecnal C1/2 cap TEV 0.7607

acetylsalicylic acid 330mg, butalbital 50mg & caffeine 40mg cap

00226327 Fiorinal cap NVR 0.5794

00608238 ratio-Tecnal cap TEV 0.5794acyclovir 200mg tab 02286556 Acyclovir 200mg tab SAS 0.6397

02207621 Apo-Acyclovir 200mg tab APX 0.639702242784 MYLAN-Acyclovir 200mg tab MYL 0.639702285959 Novo-Acyclovir 200mg tab TEV 0.639702197405 Nu-Acyclovir 200mg tab NXP 0.639702078627 ratio-Acyclovir 200mg tab TEV 0.639700634506 Zovirax 200mg tab GSK 0.6397

acyclovir 400mg tab 02286564 Acyclovir 400mg tab SAS 1.270002207648 Apo-Acyclovir 400mg tab APX 1.270002242463 MYLAN-Acyclovir 400mg tab MYL 1.270002285967 Novo-Acyclovir 400mg tab TEV 1.270002197413 Nu-Acyclovir 400mg tab NXP 1.270002078635 ratio-Acyclovir 400mg tab TEV 1.270001911627 Zovirax 400mg tab GSK 1.2700

acyclovir 800mg tab 02286572 Acyclovir 800mg tab SAS 2.027702207656 Apo-Acyclovir 800mg tab APX 2.027702242464 MYLAN-Acyclovir 800mg tab MYL 2.027702285975 Novo-Acyclovir 800mg tab TEV 2.027702197421 Nu-Acyclovir 800mg tab NXP 2.027702078651 ratio-Acyclovir 800mg tab TEV 2.027701911635 Zovirax 800mg tab GSK 2.0277

alendronate 10mg tab (exception status) 02248728 Apo-Alendronate 10mg tab APX 0.797802201011 Fosamax 10mg tab FRS 0.797802270129 MYLAN-Alendronate 10mg tab MYL 0.797802288087 Sandoz Alendronate 10mg tab SDZ 0.797802247373 Teva-Alendronate 10mg tab TEV 0.7978

alendronate 40mg tab (exception status) 02258102 CO Alendronate 40mg tab COB 2.609702201038 Fosamax 40mg tab FRS 2.6097

alendronate 70mg tab (exception status) 02352966 Alendronate 70mg tab SAS 4.023002299712 Alendronate-FC 70mg tab PHL 4.023002248730 Apo-Alendronate 70mg tab APX 4.023002258110 CO Alendronate 70mg tab COB 4.023002245329 Fosamax 70mg tab FRS 4.023002286335 MYLAN-Alendronate 70mg tab MYL 4.023002284006 pms-Alendronate-FC 70mg tab PMS 4.023002275279 ratio-Alendronate 70mg tab (discontinued) TEV 4.023002288109 Sandoz Alendronate 70mg tab SDZ 4.023002261715 Teva-Alendronate 70mg tab TEV 4.0230

allopurinol 100mg tab 00402818 Zyloprim 100mg tab AAP 0.0847

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 3 of 77

Generic Name and Strength DIN Brand MFR MRP PRPallopurinol 200mg tab 00479799 Zyloprim 200mg tab AAP 0.1411allopurinol 300mg tab 00402796 Zyloprim 300mg tab AAP 0.2306alprazolam 0.25mg tab 02349191 Alprazolam 0.25mg tab SAS 0.0760

00865397 Apo-Alpraz 0.25mg tab APX 0.076002137534 MYLAN-Alprazolam 0.25mg tab MYL 0.076001913484 Novo-Alprazol 0.25mg tab TEV 0.076000548359 Xanax 0.25mg tab PFI 0.0760

alprazolam 0.5mg tab 02349205 Alprazolam 0.5mg tab SAS 0.092000865400 Apo-Alpraz 0.5mg tab APX 0.092002137542 MYLAN-Alprazolam 0.5mg tab MYL 0.092001913492 Novo-Alprazol 0.5mg tab TEV 0.092000548367 Xanax 0.5mg tab PFI 0.0920

amantadine HCl 100mg cap 02139200 MYLAN-Amantadine 100mg cap MYL 0.517901990403 pms-Amantadine 100mg cap PMS 0.5179

amantadine HCl 10mg/mL o/l 02022826 pms-Amantadine 10mg/mL syrup PMS 0.1090amcinonide 0.1% cr 02192284 Cyclocort 0.1% cr STI 0.1953

02247098 ratio-Amcinonide 0.1% cr TEV 0.195302246714 Taro-Amcinonide 0.1% cr TAR 0.1953

amcinonide 0.1% lot 02192276 Cyclocort 0.1% lot STI 0.261502247097 ratio-Amcinonide 0.1% lot TEV 0.2615

amcinonide 0.1% oint 02192268 Cyclocort 0.1% oint STI 0.314702247096 ratio-Amcinonide 0.1% oint TEV 0.3147

amiloride 5mg tab 02249510 Midamor 5mg tab AAP 0.2948amiodarone 200mg tab 02364336 Amiodarone 200mg tab SAS 0.8236

02246194 Apo-Amiodarone 200mg tab APX 0.823602036282 Cordarone 200mg tab WAY 0.823602240604 MYLAN-Amiodarone 200mg tab MYL 0.823602239835 Novo-Amiodarone 200mg tab TEV 0.823602245781 phl-Amiodarone 200mg tab PHL 0.823602242472 pms-Amiodarone 200mg tab PMS 0.823602240071 ratio-Amiodarone 200mg tab TEV 0.823602243836 Sandoz Amiodarone 200mg tab SDZ 0.8236

amitriptyline 10mg tab 00335053 Elavil 10mg tab AAP 0.0721amitriptyline 25mg tab 00335061 Elavil 25mg tab AAP 0.1314amitriptyline 50mg tab 00335088 Elavil 50mg tab AAP 0.2547amitriptyline 75mg tab 00754129 Elavil 75mg tab AAP 0.3943amlodipine 5mg tab 02331284 Amlodipine 5mg tab SAS 0.5127

02273373 Apo-Amlodipine 5mg tab APX 0.512702297485 CO Amlodipine 5mg tab COB 0.512702280132 GD-Amlodipine 5mg tab GMD 0.512702331071 Jamp-Amlodipine 5mg tab JPC 0.512702371715 Mar-Amlodipine 5mg tab MAR 0.512702362651 MINT-Amlodipine 5mg tab MNT 0.512702272113 MYLAN-Amlodipine 5mg tab MYL 0.5127

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 4 of 77

Generic Name and Strength DIN Brand MFR MRP PRPamlodipine 5mg tab 00878928 Norvasc 5mg tab PFI 0.5127

02250497 Novo-Amlodipine 5mg tab TEV 0.512702326779 phl-Amlodipine 5mg tab PHL 0.512702284065 pms-Amlodipine 5mg tab PMS 0.512702321858 RAN-Amlodipine 5mg tab RAN 0.512702259605 ratio-Amlodipine 5mg tab TEV 0.512702284383 Sandoz Amlodipine 5mg tab SDZ 0.512702357712 Septa-Amlodipine 5mg tab SPT 0.5127

amlodipine 10mg tab 02331292 Amlodipine 10mg tab SAS 0.761002273381 Apo-Amlodipine 10mg tab APX 0.761002297493 CO Amlodipine 10mg tab COB 0.761002280140 GD-Amlodipine 10mg tab GMD 0.761002331098 Jamp-Amlodipine 10mg tab JPC 0.761002371723 Mar-Amlodipine 10mg tab MAR 0.761002362678 MINT-Amlodipine 10mg tab MNT 0.761002272121 MYLAN-Amlodipine 10mg tab MYL 0.761000878936 Norvasc 10mg tab PFI 0.761002250500 Novo-Amlodipine 10mg tab TEV 0.761002326787 phl-Amlodipine 10mg tab PHL 0.761002284073 pms-Amlodipine 10mg tab PMS 0.761002321866 RAN-Amlodipine 10mg tab RAN 0.761002259613 ratio-Amlodipine 10mg tab TEV 0.761002284391 Sandoz Amlodipine 10mg tab SDZ 0.761002357720 Septa-Amlodipine 10mg tab SPT 0.7610

amlodipine 5mg & atorvastatine 10mg tab 02273233 Caduet 5/10mg tab PFI 1.248002362759 GD-Amlodipine/Atorvastatin 5/10mg tab GMD 1.2480

amlodipine 5mg & atorvastatine 20mg tab 02273241 Caduet 5/20mg tab PFI 1.393602362767 GD-Amlodipine/Atorvastatin 5/20mg tab GMD 1.3936

amlodipine 5mg & atorvastatine 40mg tab 02273268 Caduet 5/40mg tab PFI 1.448202362775 GD-Amlodipine/Atorvastatin 5/40mg tab GMD 1.4482

amlodipine 5mg & atorvastatine 80mg tab 02273276 Caduet 5/80mg tab PFI 1.448202362783 GD-Amlodipine/Atorvastatin 5/80mg tab GMD 1.4482

amlodipine 10mg & atorvastatine 10mg tab 02273284 Caduet 10/10mg tab PFI 1.570402362791 GD-Amlodipine/Atorvastatin 10/10mg tab GMD 1.5704

amlodipine 10mg & atorvastatine 20mg tab 02273292 Caduet 10/20mg tab PFI 1.716002362805 GD-Amlodipine/Atorvastatin 10/20mg tab GMD 1.7160

amlodipine 10mg & atorvastatine 40mg tab 02273306 Caduet 10/40mg tab PFI 1.770602362813 GD-Amlodipine/Atorvastatin 10/40mg tab GMD 1.7706

amlodipine 10mg & atorvastatine 80mg tab 02273314 Caduet 10/80mg tab PFI 1.770602362821 GD-Amlodipine/Atorvastatin 10/80mg tab GMD 1.7706

amoxicillin & enzyme inhibitor 125mg/5mL susp

02243986 Apo-Amoxi Clav 125mg/5mL susp APX 0.0517

01916882 Clavulin-125F 125mg/5mL susp GSK 0.051702244646 ratio-Aclavulanate 125mg/5mL susp TEV 0.0517

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 5 of 77

Generic Name and Strength DIN Brand MFR MRP PRPamoxicillin & enzyme inhibitor 250mg/5mL susp

02243987 Apo-Amoxi Clav 250mg/5mL susp APX 0.0869

01916874 Clavulin-250F 250mg/5mL susp GSK 0.086902244647 ratio-Aclavulanate 250mg/5mL susp TEV 0.0869

amoxicillin & enzyme inhibitor 400mg/5mL susp

02288559 Apo-Amoxi Clav 400mg/5mL susp APX 0.1969

02238830 Clavulin-400 400mg/5mL susp GSK 0.1969amoxicillin & enzyme inhibitor 250mg tab 02243350 Apo-Amoxi Clav 250mg tab APX 0.9375amoxicillin & enzyme inhibitor 500mg tab 02243351 Apo-Amoxi Clav 500mg tab APX 0.6673

01916858 Clavulin-500F 500mg tab GSK 0.667302243771 ratio-Aclavulanate 500mg tab TEV 0.6673

amoxicillin & enzyme inhibitor 875mg tab 02245623 Apo-Amoxi Clav 875mg tab APX 0.888102238829 Clavulin-875 (875mg) tab GSK 0.888102248138 Novo-Clavamoxin-875 (875mg) tab TEV 0.888102247021 ratio-Aclavulanate 875mg tab TEV 0.8881

amoxicillin 250mg cap 02352710 Amoxicillin 250mg cap SAS 0.175000628115 Apo-Amoxi 250mg cap APX 0.175002238171 MYLAN-Amoxicillin 250mg cap MYL 0.175000406724 Novamoxin 250mg cap TEV 0.175000865567 Nu-Amoxi 250mg cap NXP 0.175002230243 pms-Amoxicillin 250mg cap PMS 0.1750

amoxicillin 500mg cap 02352729 Amoxicillin 500mg cap SAS 0.341700628123 Apo-Amoxi 500mg cap APX 0.341702238172 MYLAN-Amoxicillin 500mg cap MYL 0.341700406716 Novamoxin 500mg cap TEV 0.341700865575 Nu-Amoxi 500mg cap NXP 0.341702230244 pms-Amoxicillin 500mg cap PMS 0.3417

amoxicillin 250mg chewable tab 02352737 Amoxicillin 250mg chew tab (discontinued) SAS 0.613802036355 Novamoxin 250mg chew tab TEV 0.6138

amoxicillin 25mg/mL o/l 02352745 Amoxicillin 125mg susp SAS 0.035302352761 Amoxicillin Sugar-Reduced 25mg/mL o/l SAS 0.035300628131 Apo-Amoxi 25mg/mL o/l APX 0.035300628131 Apo-Amoxi Sugar Free 25mg/mL o/l APX 0.035300452149 Novamoxin 25mg/mL o/l TEV 0.035301934171 Novamoxin Sugar-Reduced 25mg/mL o/l TEV 0.035300865540 Nu-Amoxi 25mg/mL o/l NXP 0.035302230245 pms-Amoxicillin 25mg/mL o/l PMS 0.0353

amoxicillin 50mg/mL o/l 02352753 Amoxicillin 250mg susp SAS 0.054002352788 Amoxicillin Sugar-Reduced 50mg/mL o/l SAS 0.054000628158 Apo-Amoxi 50mg/mL o/l APX 0.054000628158 Apo-Amoxi Sugar Free 50mg/mL o/l APX 0.054000452130 Novamoxin 50mg/mL o/l TEV 0.054001934163 Novamoxin Sugar-Reduced 50mg/mL o/l TEV 0.054000865559 Nu-Amoxi 50mg/mL o/l NXP 0.054002230246 pms-Amoxicillin 50mg/mL o/l PMS 0.0540

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 6 of 77

Generic Name and Strength DIN Brand MFR MRP PRPampicillin 250mg cap 00020877 Novo-Ampicillin 250mg cap TEV 0.3657ampicillin 500mg cap 00020885 Novo-Ampicillin 500mg cap TEV 0.7091anagrelide 0.5mg cap (exception status) 02236859 Agrylin 0.5mg cap SHI 2.6361

02253054 MYLAN-Anagrelide 0.5mg cap MYL 2.636102260107 Sandoz Anagrelide 0.5mg cap SDZ 2.6361

atenolol 25mg tab 02247182 phl-Atenolol 25mg tab PHL 0.175802246581 pms-Atenolol 25mg tab PMS 0.1758

atenolol 50mg tab 00773689 Apo-Atenol 50mg tab APX 0.236402255545 CO Atenolol 50mg tab COB 0.236402367564 Jamp-Atenolol 50mg tab JPC 0.236402371987 Mar-Atenolol 50mg tab MAR 0.236402368021 MINT-Atenol 50mg tab MNT 0.236402146894 MYLAN-Atenolol 50mg tab MYL 0.236401912062 Novo-Atenol 50mg tab TEV 0.236400886114 Nu-Atenol 50mg tab NXP 0.236402238316 phl-Atenolol 50mg tab PHL 0.236402237600 pms-Atenolol 50mg tab PMS 0.236402267985 RAN-Atenol 50mg tab RAN 0.236402171791 ratio-Atenolol 50mg tab TEV 0.236402231731 Sandoz Atenolol 50mg tab SDZ 0.236402039532 Tenormin 50mg tab AZE 0.2364

atenolol 100mg tab 00773697 Apo-Atenol 100mg tab APX 0.388702255553 CO Atenolol 100mg tab COB 0.388702367572 Jamp-Atenolol 100mg tab JPC 0.388702371995 Mar-Atenolol 100mg tab MAR 0.388702368048 MINT-Atenol 100mg tab MNT 0.388702147432 MYLAN-Atenolol 100mg tab MYL 0.388701912054 Novo-Atenol 100mg tab TEV 0.388700886122 Nu-Atenol 100mg tab NXP 0.388702238318 phl-Atenolol 100mg tab PHL 0.388702237601 pms-Atenolol 100mg tab PMS 0.388702267993 RAN-Atenolol 100mg tab RAN 0.388702171805 ratio-Atenolol 100mg tab TEV 0.388702231733 Sandoz Atenolol 100mg tab SDZ 0.388702039540 Tenormin 100mg tab AZE 0.3887

atenolol 50mg & chlorthalidone 25mg tab 02248763 Apo-Atenidone 50/25mg tab APX 0.319702302918 Novo-Atenolthalidone 50/25mg tab TEV 0.319702049961 Tenoretic 50/25mg tab AZE 0.3197

atenolol 100mg & chlorthalidone 25mg tab 02248764 Apo-Atenidone 100/25mg tab APX 0.711702302926 Novo-Atenolthalidone 100/25mg tab TEV 0.711702049988 Tenoretic 100/25mg tab AZE 0.7117

atorvastatin 10mg tab 02295261 Apo-Atorvastatin 10mg tab APX 0.582402348705 Atorvastatin 10mg tab (SAS) SAS 0.582402310899 CO Atorvastatin 10mg tab COB 0.582402288346 GD-Atorvastatin 10mg tab GMD 0.5824

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 7 of 77

Generic Name and Strength DIN Brand MFR MRP PRPatorvastatin 10mg tab 02302675 Novo-Atorvastatin 10mg tab TEV 0.5824

02313448 pms-Atorvastatin 10mg tab PMS 0.582402313707 RAN-Atorvastatin 10mg tab RAN 0.582402350297 ratio-Atorvastatin 10mg tab TEV 0.582402324946 Sandoz Atorvastatin 10mg tab SDZ 0.5824

atorvastatin 20mg tab 02295288 Apo-Atorvastatin 20mg tab APX 0.728002348713 Atorvastatin 20mg tab (SAS) SAS 0.728002310902 CO Atorvastatin 20mg tab COB 0.728002288354 GD-Atorvastatin 20mg tab GMD 0.728002302683 Novo-Atorvastatin 20mg tab TEV 0.728002313456 pms-Atorvastatin 20mg tab PMS 0.728002313715 RAN-Atorvastatin 20mg tab RAN 0.728002350319 ratio-Atorvastatin 20mg tab TEV 0.728002324954 Sandoz Atorvastatin 20mg tab SDZ 0.7280

atorvastatin 40mg tab 02295296 Apo-Atorvastatin 40mg tab APX 0.782602348721 Atorvastatin 40mg tab (SAS) SAS 0.782602310910 CO Atorvastatin 40mg tab COB 0.782602288362 GD-Atorvastatin 40mg tab GMD 0.782602302691 Novo-Atorvastatin 40mg tab TEV 0.782602313464 pms-Atorvastatin 40mg tab PMS 0.782602313723 RAN-Atorvastatin 40mg tab RAN 0.782602350327 ratio-Atorvastatin 40mg tab TEV 0.782602324962 Sandoz Atorvastatin 40mg tab SDZ 0.7826

atorvastatin 80mg tab 02295318 Apo-Atorvastatin 80mg tab APX 0.782602348748 Atorvastatin 80mg tab (SAS) SAS 0.782602310929 CO Atorvastatin 80mg tab COB 0.782602288370 GD-Atorvastatin 80mg tab GMD 0.782602302713 Novo-Atorvastatin 80mg tab TEV 0.782602313472 pms-Atorvastatin 80mg tab PMS 0.782602313758 RAN-Atorvastatin 80mg tab RAN 0.782602350335 ratio-Atorvastatin 80mg tab TEV 0.782602324970 Sandoz Atorvastatin 80mg tab SDZ 0.7826

azathioprine 50mg tab 02242907 Apo-Azathioprine 50mg tab APX 0.384702343002 Azathioprine 50mg tab SAS 0.384700004596 Imuran 50mg tab GSK 0.384702231491 MYLAN-Azathioprine 50mg tab MYL 0.384702236819 Novo-Azathioprine 50mg tab TEV 0.3847

azithromycin 250mg tab (exception status) 02247423 Apo-Azithromycin 250mg tab APX 1.976002330881 Azithromycin 250mg tab SAS 1.976002255340 CO Azithromycin 250mg tab COB 1.976002274531 GD-Azithromycin 250mg tab GMD 1.976002278359 MYLAN-Azithromycin 250mg tab MYL 1.976002267845 Novo-Azithromycin 250mg tab TEV 1.976002278588 phl-Azithromycin 250mg tab PHL 1.976002261634 pms-Azithromycin 250mg tab PMS 1.9760

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 8 of 77

Generic Name and Strength DIN Brand MFR MRP PRPazithromycin 250mg tab (exception status) 02275287 ratio-Azithromycin 250mg tab TEV 1.9760

02265826 Sandoz Azithromycin 250mg tab SDZ 1.976002212021 Zithromax 250mg tab PFI 1.9760

azithromycin 600mg tab (exception status) 02330911 Azithromycin 600mg tab SAS 6.000002256088 CO Azithromycin 600mg tab COB 6.000002261642 pms-Azithromycin 600mg tab PMS 6.000002231143 Zithromax 600mg tab PFI 6.0000

azithromycin pos 100mg/5mL susp (exception status)

02315157 Novo-Azithromycin Pediatric 100mg/5mL susp TEV 0.4272

02274388 pms-Azithromycin POS 100mg/5mL susp PMS 0.427202332388 Sandoz Azithromycin POS 100mg/5mL susp SDZ 0.427202223716 Zithromax POS 100mg/5mL susp PFI 0.4272

azithromycin pos 200mg/5mL susp (exception status)

02315165 Novo-Azithromycin Pediatric 200mg/5mL susp TEV 0.6052

02274396 pms-Azithromycin POS 200mg/5mL susp PMS 0.605202332396 Sandoz Azithromycin POS 200mg/5mL susp SDZ 0.605202223724 Zithromax POS 200mg/5mL susp PFI 0.6052

baclofen 10mg tab 02139332 Apo-Baclofen 10mg tab APX 0.274602287021 Baclofen 10mg tab SAS 0.274600455881 Lioresal 10mg tab NVR 0.274602088398 MYLAN-Baclofen 10mg tab MYL 0.274602136090 Nu-Baclo 10mg tab NXP 0.274602236963 phl-Baclofen 10mg tab PHL 0.274602063735 pms-Baclofen 10mg tab PMS 0.274602236507 ratio-Baclofen 10mg tab TEV 0.2746

baclofen 20mg tab 02139391 Apo-Baclofen 20mg tab APX 0.534402287048 Baclofen 20mg tab SAS 0.534400636576 Lioresal DS 20mg tab NVR 0.534402088401 MYLAN-Baclofen 20mg tab MYL 0.534402136104 Nu-Baclo 20mg tab NXP 0.534402236964 phl-Baclofen 20mg tab PHL 0.534402063743 pms-Baclofen 20mg tab PMS 0.534402236508 ratio-Baclofen 20mg tab TEV 0.5344

beclomethasone dipropionate 50mcg/dose aqueous nasal spray

02238796 Apo-Beclo 50mcg/dose aq nasal sp APX 0.0613

02172712 MYLAN-Beclo 50mcg/dose aq nasal sp MYL 0.061302238577 Nu-Beclomethasone 50mcg/dose aq nasal sp NXP 0.0613

benazepril 5mg tab 02290332 Benazepril 5mg tab AAP 0.605200885835 Lotensin 5mg tab NVR 0.6052

benazepril 10mg tab 02290340 Benazepril 10mg tab AAP 0.715600885843 Lotensin 10mg tab NVR 0.7156

benazepril 20mg tab 02273918 Benazepril 20mg tab AAP 0.821100885851 Lotensin 20mg tab NVR 0.8211

benztropine mesylate 2mg tab 00426857 Apo-Benztropine 2mg tab APX 0.045000587265 pms-Benztropine 2mg tab PMS 0.0450

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 9 of 77

Generic Name and Strength DIN Brand MFR MRP PRPbenzydamine 0.15% oral rinse (exception status)

02239044 Apo-Benzydamine 0.15% oral rinse APX 0.0290

02310422 Novo-Benzydamine 0.15% oral rinse TEV 0.029002229777 pms-Benzydamine 0.15% oral rinse PMS 0.0290

betahistine 16mg tab (exception status) 02280191 Novo-Betahistine 16mg tab TEV 0.409102243878 Serc 16mg tab SPH 0.4091

betahistine 24mg tab (exception status) 02280205 Novo-Betahistine 24mg tab TEV 0.573002247998 Serc 24mg tab SPH 0.5730

betamethasone 6mg/mL inj 02237835 Betaject 6mg/mL inj SDZ 9.530000028096 Celestone soluspan 6mg/mL inj SCH 9.5300

betamethasone & gentamicin oph/otic sol 00682217 Garasone oph/otic sol SCH 1.201202244999 Sandoz Pentasone oph/otic sol SDZ 1.2012

betamethasone 17 valerate 0.05% cr 00716618 Betaderm 0.05% cr TAR 0.0606betamethasone 17 valerate 0.1% cr 00716626 Betaderm 0.1% cr TAR 0.0903betamethasone dipropionate 0.05% cr 00323071 Diprosone 0.05% cr SCH 0.2048

01925350 Taro-Sone 0.05% cr TAR 0.2048betamethasone dipropionate 0.05% glycol cr 00688622 Diprolene 0.05% glycol cr SCH 0.6224

00849650 ratio-Topilene 0.05% glycol cr TEV 0.6224betamethasone dipropionate 0.05% glycol lot

00862975 Diprolene 0.05% glycol lot SCH 0.5620

01927914 ratio-Topilene 0.05% glycol lot TEV 0.5620betamethasone dipropionate 0.05% glycol oint

00629367 Diprolene 0.05% glycol oint SCH 0.6224

00849669 ratio-Topilene 0.05% glycol oint TEV 0.6224betamethasone dipropionate 0.05% lot 00417246 Diprosone 0.05% lot SCH 0.2376

00809187 ratio-Topisone 0.05% lot TEV 0.2376betamethasone dipropionate 0.05% oint 00344923 Diprosone 0.05% oint SCH 0.2590

00805009 ratio-Topisone 0.05% oint TEV 0.2590bethamethasone dipropionate 0.05% & salicylic acid 2% lot

00578428 Diprosalic 0.05%/2% lot SCH 0.4228

02245688 ratio-Topisalic 0.05%/2% lot TEV 0.4228bicalutamide 50mg tab 02296063 Apo-Bicalutamide 50mg tab APX 2.6500

02325985 Bicalutamide 50mg tab AHC 2.650002184478 Casodex 50mg tab AZE 2.650002274337 CO Bicalutamide 50mg tab COB 2.650002357216 Jamp-Bicalutamide 50mg tab JPC 2.650002302403 MYLAN-Bicalutamide 50mg tab MYL 2.650002270226 Novo-Bicalutamide 50mg tab TEV 2.650002275589 pms-Bicalutamide 50mg tab PMS 2.650002277700 ratio-Bicalutamide 50mg tab TEV 2.650002276089 Sandoz Bicalutamide 50mg tab SDZ 2.6500

bisoprolol 5mg tab 02256134 Apo-Bisoprolol 5mg tab APX 0.220502267470 Novo-Bisoprolol 5mg tab TEV 0.220502302632 pms-Bisoprolol 5mg tab PMS 0.220502247439 Sandoz Bisoprolol 5mg tab SDZ 0.2205

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 10 of 77

Generic Name and Strength DIN Brand MFR MRP PRPbisoprolol 10mg tab 02256177 Apo-Bisoprolol 10mg tab APX 0.3654

02267489 Novo-Bisoprolol 10mg tab TEV 0.365402302640 pms-Bisoprolol 10mg tab PMS 0.365402247440 Sandoz Bisoprolol 10mg tab SDZ 0.3654

brimonidine 0.2% oph sol 02236876 Alphagan 0.2% oph sol ALL 1.320002260077 Apo-Brimonidine 0.2% oph sol APX 1.320002246284 pms-Brimonidine 0.2% oph sol PMS 1.320002243026 ratio-Brimonidine 0.2% oph sol TEV 1.320002305429 Sandoz Brimonidine 0.2% oph sol SDZ 1.3200

bromazepam 1.5mg tab 02177153 Apo-Bromazepam 1.5mg tab APX 0.0693bromazepam 3mg tab 02177161 Apo-Bromazepam 3mg tab APX 0.0600

00518123 Lectopam 3mg tab HLR 0.060002230584 Novo-Bromazepam 3mg tab TEV 0.0600

bromazepam 6mg tab 02177188 Apo-Bromazepam 6mg tab APX 0.087600518131 Lectopam 6mg tab HLR 0.087602230585 Novo-Bromazepam 6mg tab TEV 0.0876

bromocriptine mesylate 2.5mg tab 02087324 Apo-Bromocriptine 2.5mg tab APX 0.545302231702 pms-Bromocriptine 2.5mg tab PMS 0.5453

bromocriptine mesylate 5mg cap 02230454 Apo-Bromocriptine 5mg cap APX 0.971102236949 pms-Bromocriptine 5mg cap PMS 0.9711

budesonide 64mcg/dose aqueous nasal spray

02241003 MYLAN-Budesonide 64mcg/mL aq nasal spray MYL 0.0843

02231923 Rhinocort 64mcg/mL aq nasal spray AZE 0.0843bupropion 100mg SR tab 02325373 pms-Bupropion 100mg SR tab PMS 0.3733

02285657 ratio-Bupropion 100mg SR tab TEV 0.373302275074 Sandoz Bupropion 100mg SR tab SDZ 0.3733

bupropion 150mg SR tab 02313421 pms-Bupropion 150mg SR tab PMS 0.369902285665 ratio-Bupropion 150mg SR tab TEV 0.369902275082 Sandoz Bupropion 150mg SR tab SDZ 0.369902237825 Wellbutrin 150mg SR tab BVL 0.3699

buspirone HCl 10mg tab 02211076 Apo-Buspirone 10mg tab APX 0.434000603821 Buspar 10mg tab (discontinued) BRI 0.434002231492 Novo-Buspirone 10mg tab TEV 0.434002207672 Nu-Buspirone 10mg tab NXP 0.434002230942 pms-Buspirone 10mg tab PMS 0.4340

butorphanol 10mg/mL nasal sp 02242504 Apo-Butorphanol nasal sp APX 2.2908cabergoline 0.5mg tab (exception status) 02301407 CO Cabergoline 0.5mg tab COB 8.8550

02242471 Dostinex 0.5mg tab SQI 8.8550calcitonin 200iu/dose nasal spray (exception status)

02247585 Apo-Calcitonin 200iu/dose nasal spray APX 1.7254

02240775 Miacalcin 200iu/dose nasal spray NVR 1.725402261766 Sandoz Calcitonin NS 200iu/dose nasal spray SDZ 1.7254

candesartan 8mg tab 02365359 Apo-Candesartan 8mg tab APX 0.460002239091 Atacand 8mg tab AZE 0.460002326965 Sandoz Candesartan 8mg tab SDZ 0.4600

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 11 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcandesartan 16mg tab 02365367 Apo-Candesartan 16mg tab APX 0.4600

02239092 Atacand 16mg tab AZE 0.460002326973 Sandoz Candesartan 16mg tab SDZ 0.4600

captopril 12.5mg tab 00893595 Apo-Capto 12.5mg tab APX 0.212002163551 MYLAN-Captopril 12.5mg tab MYL 0.212001913824 Nu-Capto 12.5mg tab NXP 0.2120

captopril 25mg tab 00893609 Apo-Capto 25mg tab APX 0.300000546283 Capoten 25mg tab BRI 0.300002163578 MYLAN-Captopril 25mg tab MYL 0.300001942972 Novo-Captoril 25mg tab TEV 0.300001913832 Nu-Capto 25mg tab NXP 0.3000

captopril 50mg tab 00893617 Apo-Capto 50mg tab APX 0.559000546291 Capoten 50mg tab (discontinued) BRI 0.559002163586 MYLAN-Captopril 50mg tab MYL 0.559001942980 Novo-Captoril 50mg tab TEV 0.559001913840 Nu-Capto 50mg tab NXP 0.5590

captopril 100mg tab 00893625 Apo-Capto 100mg tab APX 1.039502163594 MYLAN-Captopril 100mg tab MYL 1.039501942999 Novo-Captoril 100mg tab TEV 1.039501913859 Nu-Capto 100mg tab NXP 1.039502230206 pms-Captopril 100mg tab PMS 1.0395

carbamazepine 200mg tab 00402699 Apo-Carbamazepine 200mg tab APX 0.079500782718 Novo-Carbamaz 200mg tab TEV 0.079500010405 Tegretol 200mg tab NVR 0.0795

carbamazepine 100mg chewable tab 02231542 pms-Carbamazepine 100mg chewable tab PMS 0.065402261855 Sandoz Carbamazepine 100mg chewable tab SDZ 0.065402244403 Taro-Carbamazepine 100mg chewable tab TAR 0.065400369810 Tegretol 100mg chewable tab NVR 0.0654

carbamazepine 200mg chewable tab 02231540 pms-Carbamazepine 200mg chewable tab PMS 0.129002261863 Sandoz Carbamazepine 200mg chewable tab SDZ 0.129002244404 Taro-Carbamazepine 200mg chewable tab TAR 0.129000665088 Tegretol 200mg chewable tab NVR 0.1290

carbamazepine 200mg cr tab 02241882 MYLAN-Carbamazepine 200mg CR tab MYL 0.160102231543 pms-Carbamazepine 200mg Cr tab PMS 0.160102261839 Sandoz Carbamazepine 200mg Cr tab SDZ 0.160100773611 Tegretol 200mg Cr tab NVR 0.1601

carbamazepine 400mg cr tab 02241883 MYLAN-Carbamazepine 400mg Cr tab MYL 0.320102231544 pms-Carbamazepine 400mg Cr tab PMS 0.320102261847 Sandoz Carbamazepine 400mg Cr tab SDZ 0.320100755583 Tegretol 400mg Cr tab NVR 0.3201

carvedilol 3.125mg tab (exception status) 02247933 Apo-Carvedilol 3.125mg tab APX 0.800102364913 Carvedilol 3.125mg tab SAS 0.800102347512 MYLAN-Carvedilol 3.125mg tab MYL 0.800102248752 phl-Carvedilol 3.125mg tab PHL 0.8001

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 12 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcarvedilol 3.125mg tab (exception status) 02245914 pms-Carvedilol 3.125mg tab PMS 0.8001

02268027 RAN-Carvedilol 3.125mg tab RAN 0.800102252309 ratio-Carvedilol 3.125mg tab TEV 0.800102338068 Zym-Carvedilol 3.125mg tab ZYM 0.8001

carvedilol 6.25mg tab (exception status) 02247934 Apo-Carvedilol 6.25mg tab APX 0.800102364921 Carvedilol 6.25mg tab SAS 0.800102347520 MYLAN-Carvedilol 6.25mg tab MYL 0.800102248753 phl-Carvedilol 6.25mg tab PHL 0.800102245915 pms-Carvedilol 6.25mg tab PMS 0.800102268035 RAN-Carvedilol 6.25mg tab RAN 0.800102252317 ratio-Carvedilol 6.25mg tab TEV 0.800102338092 Zym-Carvedilol 6.25mg tab ZYM 0.8001

carvedilol 12.5mg tab (exception status) 02247935 Apo-Carvedilol 12.5mg tab APX 0.800102364948 Carvedilol 12.5mg tab SAS 0.800102347555 MYLAN-Carvedilol 12.5mg tab MYL 0.800102248754 phl-Carvedilol 12.5mg tab PHL 0.800102245916 pms-Carvedilol 12.5mg tab PMS 0.800102268043 RAN-Carvedilol 12.5mg tab RAN 0.800102252325 ratio-Carvedilol 12.5mg tab TEV 0.800102338106 Zym-Carvedilol 12.5mg tab ZYM 0.8001

carvedilol 25mg tab (exception status) 02247936 Apo-Carvedilol 25mg tab APX 0.800102364956 Carvedilol 25mg tab SAS 0.800102347571 MYLAN-Carvedilol 25mg tab MYL 0.800102248755 phl-Carvedilol 25mg tab PHL 0.800102245917 pms-Carvedilol 25mg tab PMS 0.800102268051 RAN-Carvedilol 25mg tab RAN 0.800102252333 ratio-Carvedilol 25mg tab TEV 0.800102338114 Zym-Carvedilol 25mg tab ZYM 0.8001

cefadroxil 500mg cap 02240774 Apo-Cefadroxil 500mg cap APX 0.842102235134 Novo-Cefadroxil 500mg cap TEV 0.8421

cefazolin sodium 500mg/vial inj 02308932 Cefazolin Sodium 500mg/vial inj SDZ 4.000002108119 Cefazolin Sodium 500mg/vial inj TEV 4.0000

cefazolin sodium 1g/vial inj 02308959 Cefazolin Sodium 1g/vial inj SDZ 6.000002297205 Cefazolin Sodium 1g/vial inj APX 6.000002108127 Cefazolin Sodium 1g/vial inj TEV 6.0000

cefprozil 125mg/5mL o/l 02293943 Apo-Cefprozil 125mg/5mL o/l APX 0.067702163675 Cefzil 125mg/5mL o/l BRI 0.067702329204 RAN-Cefprozil 125mg/5mL o/l RAN 0.067702303426 Sandoz Cefprozil 125mg/5mL o/l SDZ 0.0677

cefprozil 250mg/5mL o/l 02293951 Apo-Cefprozil 250mg/5mL o/l APX 0.135402163683 Cefzil 250mg/5mL o/l BRI 0.135402293579 RAN-Cefprozil 250mg/5mL o/l RAN 0.135402303434 Sandoz Cefprozil 250mg/5mL o/l SDZ 0.1354

cefprozil 250mg tab 02292998 Apo-Cefprozil 250mg tab APX 0.6931

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 13 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcefprozil 250mg tab 02163659 Cefzil 250mg tab BRI 0.6931

02293528 RAN-Cefprozil 250mg tab RAN 0.693102302179 Sandoz Cefprozil 250mg tab SDZ 0.6931

cefprozil 500mg tab 02293005 Apo-Cefprozil 500mg tab APX 1.359002163667 Cefzil 500mg tab BRI 1.359002293536 RAN-Cefprozil 500mg tab RAN 1.359002302187 Sandoz Cefprozil 500mg tab SDZ 1.3590

ceftriaxone 0.25g/vial inj 02292866 Ceftriaxone 0.25g/vial inj APX 7.525000657387 Rocephin 0.25g/vial inj HLR 7.5250

ceftriaxone 1g/vial inj 02292874 Ceftriaxone 1g/vial inj (APX) APX 23.800002292270 Ceftriaxone 1g/vial inj (SDZ) SDZ 23.800000657417 Rocephin 1g/vial inj (discontinued) HLR 23.8000

ceftriaxone 2g/vial inj 02292882 Ceftriaxone 2g/vial inj (APX) APX 46.900002292289 Ceftriaxone 2g/vial inj (SDZ) SDZ 46.9000

cefuroxime axetil 250mg tab 02244393 Apo-Cefuroxime 250mg tab APX 0.723702212277 Ceftin 250mg tab GSK 0.723702242656 ratio-Cefuroxime 250mg tab TEV 0.7237

cefuroxime axetil 500mg tab 02244394 Apo-Cefuroxime 500mg tab APX 1.433702212285 Ceftin 500mg tab GSK 1.433702242657 ratio-Cefuroxime 500mg tab TEV 1.4337

celecoxib 100mg cap 02239941 Celebrex 100mg cap PFI 0.2625celecoxib 200mg cap 02239942 Celebrex 200mg cap PFI 0.5250cephalexin monohydrate 25mg o/l 00342106 Novo-Lexin 125mg/5mL susp TEV 0.0860cephalexin monohydrate 50mg o/l 00342092 Novo-Lexin 250mg/5mL susp TEV 0.1351cephalexin monohydrate 250mg tab 00768723 Apo-Cephalex 250mg tab APX 0.2250

00583413 Novo-Lexin 250mg tab TEV 0.225000865877 Nu-Cephalex 250mg tab NXP 0.2250

cephalexin monohydrate 500mg tab 00768715 Apo-Cephalex 500mg tab APX 0.450000583421 Novo-Lexin 500mg tab TEV 0.450000865885 Nu-Cephalex 500mg tab NXP 0.4500

cetirizine 10mg tab (exception status) 02231603 APC-Cetirizine 10mg tab APX 0.408302231603 Apo-Cetirizine 10mg tab APX 0.408302315955 Extra Strength Allergy Relief 10mg tab PDP 0.408302223554 Reactine 10mg tab JNJ 0.4083

chlordiazepoxide HCl 5mg & clidinium Br 2.5mg cap

00618454 Apo-Chlorax 5mg/2.5mg cap APX 0.2211

00115630 Librax 5mg/2.5mg cap VLN 0.2211chloroquine phosphate 250mg tab 00021261 Novo-Chloroquine 250mg tab TEV 0.4010chlorpromazine 25mg/mL inj 00743518 Chlorpromazine 25mg/mL inj SDZ 1.1100cilazapril 1mg tab 02291134 Apo-Cilazapril 1mg tab APX 0.2492

02350963 Cilazapril 1mg tab SAS 0.249201911465 Inhibace 1mg tab (discontinued) HLR 0.249202283778 MYLAN-Cilazapril 1mg tab MYL 0.249202266350 Novo-Cilazapril 1mg tab TEV 0.2492

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 14 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcilazapril 1mg tab 02280442 pms-Cilazapril 1mg tab PMS 0.2492cilazapril 2.5mg tab 02291142 Apo-Cilazapril 2.5mg tab APX 0.2872

02350971 Cilazapril 2.5mg tab SAS 0.287201911473 Inhibace 2.5mg tab HLR 0.287202283786 MYLAN-Cilazapril 2.5mg tab MYL 0.287202266369 Novo-Cilazapril 2.5mg tab TEV 0.287202280450 pms-Cilazapril 2.5mg tab PMS 0.2872

cilazapril 5mg tab 02291150 Apo-Cilazapril 5mg tab APX 0.333602350998 Cilazapril 5mg tab SAS 0.333601911481 Inhibace 5mg tab HLR 0.333602283794 MYLAN-Cilazapril 5mg tab MYL 0.333602266377 Novo-Cilazapril 5mg tab TEV 0.333602280469 pms-Cilazapril 5mg tab PMS 0.3336

cilazapril 5mg & hydrochlorothiazide 12.5mg tab

02284987 Apo-Cilazapril/HCTZ 5mg/12.5mg tab APX 0.4170

02181479 Inhibace Plus 5mg/12.5mg tab HLR 0.417002313731 Novo-Cilazapril/HCTZ 5mg/12.5mg tab TEV 0.4170

cimetidine 200mg tab 00584215 Apo-Cimetidine 200mg tab APX 0.0860cimetidine 300mg tab 00487872 Apo-Cimetidine 300mg tab APX 0.0860

02227444 MYLAN-Cimetidine 300mg tab MYL 0.086000865818 Nu-Cimet 300mg tab NXP 0.0860

cimetidine 400mg tab 00600059 Apo-Cimetidine 400mg tab APX 0.135002227452 MYLAN-Cimetidine 400mg tab MYL 0.135000865826 Nu-Cimet 400mg tab NXP 0.1350

cimetidine 600mg tab 00600067 Apo-Cimetidine 600mg tab APX 0.172002227460 MYLAN-Cimetidine 600mg tab MYL 0.172000865834 Nu-Cimet 600mg tab NXP 0.1720

cimetidine 800mg tab 00749494 Apo-Cimetidine 800mg tab APX 0.2530ciprofloxacin 0.3% oph sol (exception status)

02263130 Apo-Ciproflox 0.3% oph sol APX 0.791501945270 Ciloxan 0.3% oph sol ALC 0.791502253933 pms-Ciprofloxacin 0.3% oph sol PMS 0.7915

ciprofloxacin 250mg tab (exception status) 02229521 Apo-Ciproflox 250mg tab APX 0.989702155958 Cipro 250mg tab BAY 0.989702353318 Ciprofloxacin 250mg tab SAS 0.989702247339 CO Ciprofloxacin 250mg tab COB 0.989702317427 MINT-Ciprofloxacin 250mg tab MNT 0.989702245647 MYLAN-Ciprofloxacin 250mg tab MYL 0.989702161737 Novo-Ciprofloxacin 250mg tab TEV 0.989702248437 pms-Ciprofloxacin 250mg tab PMS 0.989702303728 RAN-Ciproflox 250mg tab RAN 0.989702246825 ratio-Ciprofloxacin 250mg tab TEV 0.989702248756 Sandoz Ciprofloxacin 250mg tab SDZ 0.9897

ciprofloxacin 500mg tab (exception status) 02229522 Apo-Ciproflox 500mg tab APX 1.116602155966 Cipro 500mg tab BAY 1.116602353326 Ciprofloxacin 500mg tab SAS 1.1166

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 15 of 77

Generic Name and Strength DIN Brand MFR MRP PRPciprofloxacin 500mg tab (exception status) 02247340 CO Ciprofloxacin 500mg tab COB 1.1166

02317435 MINT-Ciprofloxacin 500mg tab MNT 1.116602245648 MYLAN-Ciprofloxacin 500mg tab MYL 1.116602161745 Novo-Ciprofloxacin 500mg tab TEV 1.116602248438 pms-Ciprofloxacin 500mg tab PMS 1.116602303736 RAN-Ciproflox 500mg tab RAN 1.116602246826 ratio-Ciprofloxacin 500mg tab TEV 1.116602248757 Sandoz Ciprofloxacin 500mg tab SDZ 1.1166

ciprofloxacin 750mg tab (exception status) 02229523 Apo-Ciproflox 750mg tab APX 2.044702155974 Cipro 750mg tab BAY 2.044702353334 Ciprofloxacin 750mg tab SAS 2.044702247341 CO Ciprofloxacin 750mg tab COB 2.044702317443 MINT-Ciprofloxacin 750mg tab MNT 2.044702245649 MYLAN-Ciprofloxacin 750mg tab MYL 2.044702161753 Novo-Ciprofloxacin 750mg tab TEV 2.044702248439 pms-Ciprofloxacin 750mg tab PMS 2.044702303744 RAN-Ciproflox 750mg tab RAN 2.044702246827 ratio-Ciprofloxacin 750mg tab TEV 2.044702248758 Sandoz Ciprofloxacin 750mg tab SDZ 2.0447

citialopram 10mg tab 02273543 phl-Citalopram 10mg tab PHL 0.446402270609 pms-Citalopram 10mg tab PMS 0.4464

citalopram 20mg tab 02246056 Apo-Citalopram 20mg tab APX 0.532702239607 Celexa 20mg tab VLH 0.532702353660 Citalopram 20mg tab SAS 0.532702306239 Citalopram-Odan 20mg tab ODN 0.532702248050 CO Citalopram 20mg tab COB 0.532702313405 Jamp-Citalopram 20mg tab JPC 0.532702304686 MINT-Citalopram 20mg tab MNT 0.532702246594 MYLAN-Citalopram 20mg tab MYL 0.532702293218 Novo-Citalopram 20mg tab TEV 0.532702248944 phl-Citalopram 20mg tab PHL 0.532702248010 pms-Citalopram 20mg tab PMS 0.532702285622 RAN-Citalo 20mg tab RAN 0.532702252112 ratio-Citalopram 20mg tab TEV 0.532702248170 Sandoz Citalopram 20mg tab SDZ 0.532702355272 Septa-Citalopram 20mg tab SPT 0.5327

citalopram 40mg tab 02246057 Apo-Citalopram 40mg tab APX 0.532702239608 Celexa 40mg tab VLH 0.532702353679 Citalopram 40mg tab SAS 0.532702306247 Citalopram-Odan 40mg tab ODN 0.532702248051 CO Citalopram 40mg tab COB 0.532702313413 Jamp-Citalopram 40mg tab JPC 0.532702304694 MINT-Citalopram 40mg tab MNT 0.532702246595 MYLAN-Citalopram 40mg tab MYL 0.532702293226 Novo-Citalopram 40mg tab TEV 0.5327

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 16 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcitalopram 40mg tab 02248945 phl-Citalopram 40mg tab PHL 0.5327

02248011 pms-Citalopram 40mg tab PMS 0.532702285630 RAN-Citalo 40mg tab RAN 0.532702252120 ratio-Citalopram 40mg tab TEV 0.532702248171 Sandoz Citalopram 40mg tab SDZ 0.532702355280 Septa-Citalopram 40mg tab SPT 0.5327

clarithromycin 250mg tab (exception status) 02274744 Apo-Clarithromycin 250mg tab APX 1.100501984853 Biaxin BID 250mg tab ABB 1.100502248856 MYLAN-Clarithromycin 250mg tab MYL 1.100502247573 pms-Clarithromycin 250mg tab PMS 1.100502361426 RAN-Clarithromycin 250mg tab RAN 1.100502247818 ratio-Clarithromycin 250mg tab TEV 1.100502266539 Sandoz Clarithromycin 250mg tab SDZ 1.1005

clarithromycin 500mg tab (exception status) 02274752 Apo-Clarithromycin 500mg tab APX 1.629302126710 Biaxin BID 500mg tab ABB 1.629302248857 MYLAN-Clarithromycin 500mg tab MYL 1.629302247574 pms-Clarithromycin 500mg tab PMS 1.629302361434 RAN-Clarithromycin 500mg tab RAN 1.629302247819 ratio-Clarithromycin 500mg tab TEV 1.629302266547 Sandoz Clarithromycin 500mg tab SDZ 1.6293

clindamycin 150mg/mL (bulk) inj 02230535 Clindamycin 150mg/mL (bulk) inj SDZ 3.325000260436 Dalacin C Phos 150mg/mL (bulk) inj PFI 3.3250

clindamycin 150mg cap 02245232 Apo-Clindamycin 150mg cap APX 0.376500030570 Dalacin C 150mg cap PFI 0.376502258331 MYLAN-Clindamycin 150mg cap MYL 0.376502241709 Novo-Clindamycin 150mg cap TEV 0.3765

clindamycin 300mg cap 02245233 Apo-Clindamycin 300mg cap APX 0.752902182866 Dalacin C 300mg cap PFI 0.752902258358 MYLAN-Clindamycin 300mg cap MYL 0.752902241710 Novo-Clindamycin 300mg cap TEV 0.7529

clindamycin 150mg/mL inj 02230540 Clindamycin 150mg/mL inj SDZ 3.325000260436 Dalacin C Phos 150mg/mL inj PFI 3.3250

clindamycin 1% top sol 00582301 Dalacin T 1% top sol PFI 0.226002266938 Taro-Clindamycin 1% top sol TAR 0.2260

clobazam 10mg tab 02244638 Apo-Clobazam 10mg tab APX 0.215302221799 Frisium 10mg tab OVN 0.215302238334 Novo-Clobazam 10mg tab TEV 0.215302244474 pms-Clobazam 10mg tab PMS 0.2153

clobetasol 17-propionate 0.05% cr 02213265 Dermovate 0.05% cr TPH 0.260502024187 MYLAN-Clobetasol 0.05% cr MYL 0.260502093162 Novo-Clobetasol 0.05% cr TEV 0.260502232191 pms-Clobetasol 0.05% cr PMS 0.260501910272 ratio-Clobetasol 0.05% cr TEV 0.260502245523 Taro-Clobetasol 0.05% cr TAR 0.2605

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 17 of 77

Generic Name and Strength DIN Brand MFR MRP PRPclobetasol 17-propionate 0.05% oint 02213273 Dermovate 0.05% oint TPH 0.2605

02026767 MYLAN-Clobetasol 0.05% oint MYL 0.260502126192 Novo-Clobetasol 0.05% oint TEV 0.260502309548 pms-Clobetasol 0.05% oint PMS 0.260502232193 pms-Clobetasol 0.05% oint (discontinued) PMS 0.260501910280 ratio-Clobetasol 0.05% oint TEV 0.260502245524 Taro-Clobetasol 0.05% oint TAR 0.2605

clobetasol 17-propionate 0.05% scalp lot 02213281 Dermovate 0.05% scalp lot TPH 0.227402216213 Gen-Clobetasol 0.05% scalp lot MYL 0.227402232195 pms-Clobetasol 0.05% scalp lot PMS 0.227401910299 ratio-Clobetasol 0.05% scalp lot TEV 0.227402245522 Taro-Clobetasol 0.05% scalp lot TAR 0.2274

clomipramine 10mg tab 00330566 Anafranil 10mg tab ORX 0.129002040786 Apo-Clomipramine 10mg tab APX 0.129002244816 CO Clomipramine 10mg tab COB 0.1290

clomipramine 25mg tab 00324019 Anafranil 25mg tab ORX 0.175802040778 Apo-Clomipramine 25mg tab APX 0.175802244817 CO Clomipramine 25mg tab COB 0.1758

clomipramine 50mg tab 00402591 Anafranil 50mg tab ORX 0.323702040751 Apo-Clomipramine 50mg tab APX 0.323702244818 CO Clomipramine 50mg tab COB 0.3237

clonazepam 0.5mg tab 02177889 Apo-Clonazepam 0.5mg tab APX 0.079302270641 CO Clonazepam 0.5mg tab COB 0.079302230950 MYLAN-Clonazepam 0.5mg tab MYL 0.079302239024 Novo-Clonazepam 0.5mg tab TEV 0.079302236948 phl-Clonazepam-R 0.5mg tab PHL 0.079302048701 pms-Clonazepam 0.5mg tab PMS 0.079302207818 pms-Clonazepam-R 0.5mg tab PMS 0.079302103656 ratio-Clonazepam 0.5mg tab (discontinued) TEV 0.079300382825 Rivotril 0.5mg tab HLR 0.079302233960 Sandoz Clonazepam 0.5mg tab SDZ 0.079302345676 Zym-Clonazepam 0.5mg tab ZYM 0.0793

clonazepam 1mg tab 02145235 phl-Clonazepam 1mg tab PHL 0.186002048728 pms-Clonazepam 1mg tab PMS 0.1860

clonazepam 2mg tab 02177897 Apo-Clonazepam 2mg tab APX 0.136702270676 CO Clonazepam 2mg tab COB 0.136702230951 MYLAN-Clonazepam 2mg tab MYL 0.136702239025 Novo-Clonazepam 2mg tab TEV 0.136702145243 phl-Clonazepam 2mg tab PHL 0.136702048736 pms-Clonazepam 2mg tab PMS 0.136702103737 ratio-Clonazepam 2mg tab (discontinued) TEV 0.136700382841 Rivotril 2mg tab HLR 0.136702233985 Sandoz Clonazepam 2mg tab SDZ 0.136702303337 Zym-Clonazepam 2mg tab ZYM 0.1367

clonidine HCl 0.025mg tab 02248732 Apo-Clonidine 0.025mg tab APX 0.1817

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 18 of 77

Generic Name and Strength DIN Brand MFR MRP PRPclonidine HCl 0.025mg tab 02361299 Clonidine 0.025mg tab (discontinued) SAS 0.1817

00519251 Dixarit 0.025mg tab BOE 0.181702304163 Novo-Clonidine 0.025mg tab TEV 0.1817

clonidine HCl 0.1mg tab 00868949 Apo-Clonidine 0.1mg tab APX 0.176500259527 Catapres 0.1mg tab BOE 0.176502361302 Clonidine 0.1mg tab (discontinued) SAS 0.176502046121 Novo-Clonidine 0.1mg tab TEV 0.176501913786 Nu-Clonidine 0.1mg tab NXP 0.1765

clonidine HCl 0.2mg tab 00868957 Apo-Clonidine 0.2mg tab APX 0.314900291889 Catapres 0.2mg tab BOE 0.314902361310 Clonidine 0.2mg tab (discontinued) SAS 0.314902046148 Novo-Clonidine 0.2mg tab TEV 0.314901913220 Nu-Clonidine 0.2mg tab NXP 0.3149

clorazepate dipotassium 3.75mg cap 00860689 Apo-Clorazepate 3.75mg cap APX 0.1476clorazepate dipotassium 7.5mg cap 00860700 Apo-Clorazepate 7.5mg cap APX 0.1810clorazepate dipotassium 15mg cap 00860697 Apo-Clorazepate 15mg cap APX 0.3259clotrimazole 1% cr 02150867 Canesten 1% cr YNO 0.0884

00812382 Clotrimaderm 1% cr TAR 0.0884clotrimazole 1% vag cr 02150891 Canesten 1% vag cr YNO 0.1750

00812366 Clotrimaderm 1% vag cr TAR 0.1750clotrimazole 2% vag cr 02150905 Canesten 2% vag cr YNO 0.3500

00812374 Clotrimaderm 2% vag cr TAR 0.3500cloxacillin 250mg cap 00618292 Apo-Cloxi 250mg cap (discontinued) APX 0.3515

00337765 Novo-Cloxin 250mg cap TEV 0.3515cloxacillin 500mg cap 00618284 Apo-Cloxi 500mg cap (discontinued) APX 0.6646

00337773 Novo-Cloxin 500mg cap TEV 0.6646cloxacillin 25mg/mL o/l 00644633 Apo-Cloxi 25mg/mL o/l (discontinued) APX 0.0855

00337757 Novo-Cloxin 25mg/mL o/l TEV 0.0855cromoglycate sodium 1% unit dose inh sol 02046113 pms-Sodium cromoglycate 1% neb sol PMS 0.8350cromoglycate sodium 2% nasal sol 01950541 Rhinaris-CS Anti-Allergic nasal mist PMS 0.5292cromoglycate sodium 2% oph sol 02009277 Cromolyn 2% oph sol PDP 0.9500

02230621 Opticrom 2% oph sol ALL 0.9500cyanocobalamin 100mcg/mL inj 02241500 Vitamin B12 100mcg/mL inj SDZ 1.4500cyclobenzaprine HCl 10mg tab 02177145 Apo-Cyclobenzaprine 10mg tab APX 0.3765

02287064 Cyclobenzaprine 10mg tab SAS 0.376502231353 MYLAN-Cyclobenzaprine 10mg tab MYL 0.376502080052 Novo-Cycloprine 10mg tab TEV 0.376502171848 Nu-Cyclobenzaprine 10mg tab NXP 0.376502249359 phl-Cyclobenzaprine 10mg tab PHL 0.376502212048 pms-Cyclobenzaprine 10mg tab PMS 0.3765

cyclosporine 25mg cap (exception status) 02150689 Neoral 25mg cap NVR 1.305002247073 Sandoz Cyclosporine 25mg cap SDZ 1.3050

cyclosporine 50mg cap (exception status) 02150662 Neoral 50mg cap NVR 2.545002247074 Sandoz Cyclosporine 50mg cap SDZ 2.5450

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 19 of 77

Generic Name and Strength DIN Brand MFR MRP PRPcyclosporine 100mg cap (exception status) 02150670 Neoral 100mg cap NVR 5.0900

02242821 Sandoz Cyclosporine 100mg cap SDZ 5.0900cyclosporine 100mg/mL o/l (exception status)

02244324 Apo-Cyclosporine 100mg/mL o/l APX 3.7708

02150697 Neoral 100mg/mL o/l NVR 3.7708cyproterone 50mg tab 00704431 Androcur 50mg tab PMS 1.5283

02245898 Cyproterone 50mg tab AAP 1.5283deferoxamine 500mg/vial inj 01981242 Desferal 500mg/vial inj NVR 8.1750

02241600 Desferrioxamine 500mg/vial inj HOS 8.175002242055 pms-Deferoxamine 500mg/vial inj PMS 8.1750

desipramine 10mg tab 02216248 Apo-Desipramine 10mg tab APX 0.3804desipramine 25mg tab 02216256 Apo-Desipramine 25mg tab APX 0.3804desipramine 50mg tab 02216264 Apo-Desipramine 50mg tab APX 0.6704desipramine 75mg tab 02216272 Apo-Desipramine 75mg tab APX 0.8915desipramine 100mg tab 02216280 Apo-Desipramine 100mg tab APX 0.8915desmopressin 0.1mg tab (exception status) 02284030 Apo-Desmopressin 0.1mg tab APX 0.5287

00824305 DDAVP 0.1mg tab FEI 0.528702287730 Novo-Desmopressin 0.1mg tab TEV 0.528702304368 pms-Desmopressin 0.1mg tab PMS 0.5287

desmopressin 0.2mg tab (exception status) 02284049 Apo-Desmopressin 0.2mg tab APX 1.057300824143 DDAVP 0.2mg tab FEI 1.057302287749 Novo-Desmopressin 0.2mg tab TEV 1.057302304376 pms-Desmopressin 0.2mg tab PMS 1.0573

desmopressin 60mcg SL tab (exception status)

02284995 DDAVP Melt 60mcg SL tab FEI 0.5287

desmopressin 120mcg SL tab (exception status)

02285002 DDAVP Melt 120mcg SL tab FEI 1.0573

desogestrel 150mcg and ethiny estradiol 30mcg tab (21)

02317192 Apri 21 tab 21 day APX 0.4375

02042487 Marvelon 21 tab 21 day ORG 0.4375desogestrel 150mcg and ethiny estradiol 30mcg tab (28)

02317206 Apri 28 tab 28 day APX 0.3281

02042479 Marvelon 28 tab 28 day ORG 0.3281desonide 0.05% cr 02229315 pms-Desonide 0.05% cr PMS 0.3349desonide 0.05% oint 02229323 pms-Desonide 0.05% oint PMS 0.3177dexamethasone 0.5mg tab 02261081 Apo-Dexamethasone 0.5mg tab APX 0.1970

01964976 pms-Dexamethasone 0.5mg tab PMS 0.1970dexamethasone 0.75mg tab 01964968 pms-Dexamethasone 0.75mg tab PMS 0.4500dexamethasone 4mg tab 02250055 Apo-Dexamethasone 4mg tab APX 0.7673

00489158 Dexasone 4mg tab VLN 0.767301964070 pms-Dexamethasone 4mg tab PMS 0.7673

dexamethasone 4mg/mL inj 01977547 Dexamethasone 4mg/mL inj CYI 1.606000664227 Dexamethasone 4mg/mL inj SDZ 1.6060

dexamethasone 0.1% oph/otic sol 00739839 Sandoz Dexamethasone 0.1% oph/otic sol SDZ 1.4060

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 20 of 77

Generic Name and Strength DIN Brand MFR MRP PRPdexamethasone, framycetin sulfate & gramicidin oph/otic sol

02247920 Sandoz Opticort oph/otic sol SDZ 1.4675

02224623 Sofracort oph/otic sol SAV 1.4675diazepam 5mg tab 00362158 Apo-Diazepam 5mg tab APX 0.0650

00013285 Valium 5mg tab HLR 0.0650diazepam 10mg tab 00405337 Apo-Diazepam 10mg tab APX 0.0867diazepam 5mg/mL inj 00399728 Diazepam 5mg/mL inj SDZ 0.7850diclofenac sodium 25mg EC tab 00839175 Apo-Diclo 25mg EC tab APX 0.1167

00808539 Novo-Difenac 25mg EC tab TEV 0.116700886017 Nu-Diclo 25mg EC tab NXP 0.116702302616 pms-Diclofenac 25mg EC tab PMS 0.116702261952 Sandoz Diclofenac 25mg EC tab SDZ 0.1167

diclofenac sodium 50mg EC tab 00839183 Apo-Diclo 50mg EC tab APX 0.233302352397 Diclofenac Sodium 50mg tab SAS 0.233300808547 Novo-Difenac 50mg EC tab TEV 0.233300886025 Nu-Diclo 50mg EC tab NXP 0.233302302624 pms-Diclofenac 50mg EC tab PMS 0.233302261960 Sandoz Diclofenac 50mg EC tab SDZ 0.233300514012 Voltaren 50mg EC tab NVR 0.2333

diclofenac sodium 75mg SR tab 02162814 Apo-Diclo 75mg SR tab APX 0.350002352400 Diclofenac Sodium 75mg SR tab SAS 0.350002158582 Novo-Difenac 75mg SR tab TEV 0.350002231504 pms-Diclofenac 75mg SR tab PMS 0.350002261901 Sandoz Diclofenac 75mg SR tab SDZ 0.350000782459 Voltaren 75mg SR tab NVR 0.3500

diclofenac sodium 100mg SR tab 02091194 Apo-Diclo 100mg SR tab APX 0.661402048698 Novo-Difenac 100mg SR tab TEV 0.661402231505 pms-Diclofenac 100mg SR tab PMS 0.661402261944 Sandoz Diclofenac 100mg SR tab SDZ 0.661400590827 Voltaren 100mg SR tab NVR 0.6614

diclofenac sodium 50mg supp 02231506 pms-Diclofenac 50mg supp PMS 0.533702261928 Sandoz Diclofenac 50mg supp SDZ 0.533700632724 Voltaren 50mg supp NVR 0.5337

diclofenac sodium 100mg supp 02231508 pms-Diclofenac 100mg supp PMS 0.718402261936 Sandoz Diclofenac 100mg supp SDZ 0.718400632732 Voltaren 100mg supp NVR 0.7184

diflunisal 250mg tab 02039486 Apo-Diflunisal 250mg tab APX 0.175002048493 Novo-Diflunisal 250mg tab TEV 0.1750

diflunisal 500mg tab 02039494 Apo-Diflunisal 500mg tab APX 0.3500dihydroergotamine 1mg/mL inj 00027243 Dihydroergotamine 1mg/mL inj STR 3.7933

02241163 Dihydroergotamine 1mg/mL inj SDZ 3.7933diltiazem 120mg CD cap 02230997 Apo-Diltiaz 120mg CD cap APX 0.5914

02097249 Cardizem 120mg CD cap BVL 0.591402242538 Novo-Diltazem 120mg CD cap TEV 0.5914

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 21 of 77

Generic Name and Strength DIN Brand MFR MRP PRPdiltiazem 120mg CD cap 02231052 Nu-Diltiaz 120mg CD cap NXP 0.5914

02355752 pms-Diltiazem CD 120mg cap PMS 0.591402229781 ratio-Diliazem 120mg CD cap TEV 0.591402243338 Sandoz Diltiazem 120mg CD cap SDZ 0.5914

diltiazem 180mg CD cap 02230998 Apo-Diltiaz 180mg CD cap APX 0.785002097257 Cardizem 180mg CD cap BVL 0.785002242539 Novo-Diltazem 180mg CD cap TEV 0.785002231053 Nu-Diltiaz 180mg CD cap NXP 0.785002355760 pms-Diltiazem CD 180mg cap PMS 0.785002229782 ratio-Diliazem 180mg CD cap TEV 0.785002243339 Sandoz Diltiazem 180mg CD cap SDZ 0.7850

diltiazem 240mg CD cap 02230999 Apo-Diltiaz 240mg CD cap APX 1.041202097265 Cardizem 240mg CD cap BVL 1.041202242540 Novo-Diltazem 240mg CD cap TEV 1.041202231054 Nu-Diltiaz 240mg CD cap NXP 1.041202355779 pms-Diltiazem CD 240mg cap PMS 1.041202229783 ratio-Diliazem 240mg CD cap TEV 1.041202243340 Sandoz Diltiazem 240mg CD cap SDZ 1.0412

diltiazem 300mg CD cap 02229526 Apo-Diltiaz 300mg CD cap APX 1.301502097273 Cardizem 300mg CD cap BVL 1.301502242541 Novo-Diltazem 300mg CD cap TEV 1.301502355787 pms-Diltiazem CD 300mg cap PMS 1.301502229784 ratio-Diliazem 300mg CD cap TEV 1.301502243341 Sandoz Diltiazem 300mg CD cap SDZ 1.3015

diltiazem 120mg ER cap 02291037 Apo-Diltiaz TZ 120mg ER cap APX 0.341302271605 Novo-Diltiazem HCL 120mg ER cap TEV 0.341302245918 Sandoz Diltiazem T 120mg ER cap SDZ 0.341302231150 Tiazac 120mg ER cap BVL 0.3413

diltiazem 180mg ER cap 02291045 Apo-Diltiaz TZ 180mg ER cap APX 0.462202271613 Novo-Diltiazem HCL 180mg ER cap TEV 0.462202245919 Sandoz Diltiazem T 180mg ER cap SDZ 0.462202231151 Tiazac 180mg ER cap BVL 0.4622

diltiazem 240mg ER cap 02291053 Apo-Diltiaz TZ 240mg ER cap APX 0.613102271621 Novo-Diltiazem HCL 240mg ER cap TEV 0.613102245920 Sandoz Diltiazem T 240mg ER cap SDZ 0.613102231152 Tiazac 240mg ER cap BVL 0.6131

diltiazem 300mg ER cap 02291061 Apo-Diltiaz TZ 300mg ER cap APX 0.755102271648 Novo-Diltiazem HCL 300mg ER cap TEV 0.755102245921 Sandoz Diltiazem T 300mg ER cap SDZ 0.755102231154 Tiazac 300mg ER cap BVL 0.7551

diltiazem 360mg ER cap 02291088 Apo-Diltiaz TZ 360mg ER cap APX 0.924502271656 Novo-Diltiazem HCL 360mg ER cap TEV 0.924502245922 Sandoz Diltiazem T 360mg ER cap SDZ 0.924502231155 Tiazac 360mg ER cap BVL 0.9245

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 22 of 77

Generic Name and Strength DIN Brand MFR MRP PRPdiltiazem HCl 30mg tab 00771376 Apo-Diltiaz 30mg tab APX 0.2075

00862924 Novo-Diltazem 30mg tab TEV 0.207500886068 Nu-Diltiaz 30mg tab NXP 0.2075

diltiazem HCl 60mg tab 00771384 Apo-Diltiaz 60mg tab APX 0.363700862932 Novo-Diltazem 60mg tab TEV 0.363700886076 Nu-Diltiaz 60mg tab NXP 0.3637

dimenhydrinate 10mg/mL IV inj 00392731 Dimenhydrinate 10mg/mL IV amp SDZ 0.3520dimenhydrinate 50mg/mL IM inj 00392537 Dimenhydrinate 50mg/mL IM inj SDZ 1.1500

00013579 Gravol I 50mg/mL IM inj CHU 1.1500dimethyl sulfoxide 500mg/g (50%) irr sol 02243231 Dimethyl Sulfoxide 50% irr sol SDZ 1.1840

00493392 Rimso 50% irr sol BCH 1.1840dipyridamole 25mg tab 00895644 Apo-Dipyridamole-FC 25mg tab APX 0.2633dipyridamole 50mg tab 00895652 Apo-Dipyridamole-FC 50mg tab APX 0.2932

00067393 Persantine 50mg tab BOE 0.2932dipyridamole 75mg tab 00895660 Apo-Dipyridamole-FC 75mg tab APX 0.4397

00452092 Persantine 75mg tab BOE 0.4397divalproex sodium 125mg tab 02239698 Apo-Divalproex 125mg tab APX 0.1179

00596418 Epival 125mg tab ABB 0.117902239701 Novo-Divalproex 125mg tab TEV 0.117902239517 Nu-Divalproex 125mg tab NXP 0.1179

divalproex sodium 250mg tab 02239699 Apo-Divalproex 250mg tab APX 0.212000596426 Epival 250mg tab ABB 0.212002239702 Novo-Divalproex 250mg tab TEV 0.212002239518 Nu-Divalproex 250mg tab NXP 0.2120

divalproex sodium 500mg tab 02239700 Apo-Divalproex 500mg tab APX 0.424100596434 Epival 500mg tab ABB 0.424102239703 Novo-Divalproex 500mg tab TEV 0.424102239519 Nu-Divalproex 500mg tab NXP 0.4241

dobutamine 12.5mg/mL inj 02242010 Dobutamine 12.5mg/mL inj SDZ 1.4885domperidone maleate 10mg tab 02103613 Apo-Domperidone 10mg tab APX 0.1496

02350440 Domperidone 10mg tab SAS 0.149602278669 MYLAN-Domperidone 10mg tab MYL 0.149602157195 Novo-Domperidone 10mg tab TEV 0.149602231477 Nu-Domperidone 10mg tab NXP 0.149602236466 pms-Domperidone 10mg tab PMS 0.149602268078 RAN-Domperidone 10mg tab RAN 0.149601912070 ratio-Domperidone 10mg tab TEV 0.1496

dorzolamide HCI 2% oph sol 02316307 Sandoz Dorzolamide 2% oph sol SDZ 1.517602216205 Trusopt 2% oph sol MSD 1.5176

dorzolamide HCI 2% & timolol maleate 0.5% oph sol

02299615 Apo-Dorzo-Timop 2%/0.5% oph sol APX 2.2968

02240113 Cosopt 2%/0.5% oph sol MSD 2.296802344351 Sandoz Dorzolamide/Timolol 2/0.5% oph sol SDZ 2.2968

doxazosin 1mg tab 02240588 Apo-Doxazosin 1mg tab APX 0.2273

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 23 of 77

Generic Name and Strength DIN Brand MFR MRP PRPdoxazosin 1mg tab 01958100 Cardura-1 1mg tab PFI 0.2273

02240498 MYLAN-Doxazosin 1mg tab MYL 0.227302242728 Novo-Doxazosin 1mg tab TEV 0.227302244527 pms-Doxazosin 1mg tab PMS 0.2273

doxazosin 2mg tab 02240589 Apo-Doxazosin 2mg tab APX 0.272601958097 Cardura-2 2mg tab PFI 0.272602240499 MYLAN-Doxazosin 2mg tab MYL 0.272602242729 Novo-Doxazosin 2mg tab TEV 0.272602244528 pms-Doxazosin 2mg tab PMS 0.2726

doxazosin 4mg tab 02240590 Apo-Doxazosin 4mg tab APX 0.354501958119 Cardura-4 4mg tab PFI 0.354502240500 MYLAN-Doxazosin 4mg tab MYL 0.354502242730 Novo-Doxazosin 4mg tab TEV 0.354502244529 pms-Doxazosin 4mg tab PMS 0.3545

doxepin HCl 10mg cap 02049996 Apo-Doxepin 10mg cap APX 0.188900024325 Sinequan 10mg cap ERF 0.1889

doxepin HCl 25mg cap 02050005 Apo-Doxepin 25mg cap APX 0.214001913425 Novo-Doxepin 25mg cap TEV 0.214000024333 Sinequan 25mg cap ERF 0.2140

doxepin HCl 50mg cap 02050013 Apo-Doxepin 50mg cap APX 0.397101913433 Novo-Doxepin 50mg cap TEV 0.397100024341 Sinequan 50mg cap ERF 0.3971

doxepin HCl 75mg cap 02050021 Apo-Doxepin 75mg cap APX 0.430201913441 Novo-Doxepin 75mg cap TEV 0.430200400750 Sinequan 75mg cap ERF 0.4302

doxepin HCl 100mg cap 02050048 Apo-Doxepin 100mg cap APX 0.565801913468 Novo-Doxepin 100mg cap TEV 0.565800326925 Sinequan 100mg cap ERF 0.5658

doxepin HCl 150mg cap 01913476 Novo-Doxepin 150mg cap TEV 0.8678doxycycline 100mg cap 00740713 Apo-Doxy 100mg cap APX 0.5860

02351234 Doxycycline 100mg cap SAS 0.586000725250 Novo-Doxylin 100mg cap TEV 0.586002044668 Nu-Doxycycline 100mg cap NXP 0.586000024368 Vibramycin 100mg cap PFI 0.5860

doxycycline 100mg tab (Vibra-tabs) 00874256 Apo-Doxy 100mg tab APX 0.586002351242 Doxycycline 100mg tab SAS 0.586002158574 Novo-Doxylin 100mg tab TEV 0.5860

enalapril 2.5mg tab 02020025 Apo-Enalapril 2.5mg tab APX 0.312802291878 CO Enalapril 2.5mg tab COB 0.312802300036 MYLAN-Enalapril 2.5mg tab MYL 0.312802300680 Novo-Enalapril 2.5mg tab TEV 0.312802352230 RAN-Enalapril 2.5mg tab RAN 0.312802299933 Sandoz Enalapril 2.5mg tab SDZ 0.312800851795 Vasotec 2.5mg tab FRS 0.3128

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 24 of 77

Generic Name and Strength DIN Brand MFR MRP PRPenalapril 5mg tab 02019884 Apo-Enalapril 5mg tab APX 0.3702

02291886 CO Enalapril 5mg tab COB 0.370202300044 MYLAN-Enalapril 5mg tab MYL 0.370202233005 Novo-Enalapril 5mg tab TEV 0.370202352249 RAN-Enalapril 5mg tab RAN 0.370202299941 Sandoz Enalapril 5mg tab SDZ 0.370200708879 Vasotec 5mg tab FRS 0.3702

enalapril 10mg tab 02019892 Apo-Enalapril 10mg tab APX 0.444702291894 CO Enalapril 10mg tab COB 0.444702300052 MYLAN-Enalapril 10mg tab MYL 0.444702233006 Novo-Enalapril 10mg tab TEV 0.444702352257 RAN-Enalapril 10mg tab RAN 0.444702299968 Sandoz Enalapril 10mg tab SDZ 0.444700670901 Vasotec 10mg tab FRS 0.4447

enalapril 20mg tab 02019906 Apo-Enalapril 20mg tab APX 0.536702291908 CO Enalapril 20mg tab COB 0.536702300060 MYLAN-Enalapril 20mg tab MYL 0.536702233007 Novo-Enalapril 20mg tab TEV 0.536702352265 RAN-Enalapril 20mg tab RAN 0.536702299976 Sandoz Enalapril 20mg tab SDZ 0.536700670928 Vasotec 20mg tab FRS 0.5367

enalapril 5mg & hydrochlorothiazide 12.5mg tab

02352923 Apo-Enalapril Maleate/HCTZ 5/12.5mg tab APX 0.4941

02300222 Novo-Enalapril/HCTZ 5/12.5mg tab TEV 0.4941enalapril 10mg & hydrochlorothiazide 25mg tab

02352931 Apo-Enalapril Maleate/HCTZ 10/25mg tab APX 0.8368

02300230 Novo-Enalapril/HCTZ 10/25mg tab TEV 0.836800657298 Vaseretic 10/25mg tab FRS 0.8368

erythromycin base 250mg cap 00726672 Apo-Erythro-EC 250mg cap AAP 0.423200607142 ERYC 250mg cap PFI 0.4232

erythromycin base 333mg cap 01925938 Apo-Erythro-EC 333mg cap AAP 0.470100873454 ERYC 333mg cap PFI 0.4701

erythromycin ethylsuccinate 600mg tab 00637416 Erythro-ES 600mg tab AAP 0.3649erythromycin ethylsuccinate 40mg/mL o/l 00605859 Novo-Rythro EES 200mg/5mL susp TEV 0.0923erythromycin ethylsuccinate 80mg/mL o/l 00652318 Novo-Rythro EES 400mg/5mL susp TEV 0.1398estradiol 50mcg/day patch (exception status)

02244000 Estradot 50mcg/day patch NVR 2.412502246967 Sandoz Estradiol Derm 50mcg/day patch SDZ 2.4125

estradiol 75mcg/day patch (exception status)

02244001 Estradot 75mcg/day patch NVR 2.587502246968 Sandoz Estradiol Derm 75mcg/day patch SDZ 2.5875

estradiol 100mcg/day patch (exception status)

02244002 Estradot 100mcg/day patch NVR 2.7375

02246969 Sandoz Estradiol Derm 100mcg/day patch SDZ 2.7375etidronate 200mg tab 02248686 CO Etidronate 200mg tab COB 0.8257

02245330 MYLAN-Etidronate 200mg tab MYL 0.8257

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 25 of 77

Generic Name and Strength DIN Brand MFR MRP PRPetidronic disodium 400mg & calcium carbonate 500mg tab, sequential kit

02263866 CO Etidrocal sequential kit COB 19.9900

02176017 Didrocal sequential kit WNC 19.990002353210 Etidrocal kit SAS 19.990002247323 MYLAN-Eti-Cal Carepac sequential kit MYL 19.990002324199 Novo-Etidrocal sequential kit TEV 19.9900

etodolac 200mg cap 02232317 Etodolac 200mg cap AAP 0.3500etodolac 300mg cap 02232318 Etodolac 300mg cap AAP 0.3500famciclovir 125mg tab 02292025 Apo-Famciclovir 125mg tab APX 1.3940

02305682 CO Famciclovir 125mg tab COB 1.394002229110 Famvir 125mg tab NVR 1.394002278081 pms-Famciclovir 125mg tab PMS 1.394002278634 Sandoz Famciclovir 125mg tab SDZ 1.3940

famciclovir 250mg tab 02292041 Apo-Famciclovir 250mg tab APX 1.873302305690 CO Famciclovir 250mg tab COB 1.873302229129 Famvir 250mg tab NVR 1.873302278103 pms-Famciclovir 250mg tab PMS 1.873302278642 Sandoz Famciclovir 250mg tab SDZ 1.8733

famciclovir 500mg tab 02292068 Apo-Famciclovir 500mg tab APX 2.772602305704 CO Famciclovir 500mg tab COB 2.772602177102 Famvir 500mg tab NVR 2.772602278111 pms-Famciclovir 500mg tab PMS 2.772602278650 Sandoz Famciclovir 500mg tab SDZ 2.7726

famotidine 20mg tab 01953842 Apo-Famotidine 20mg tab APX 0.180002351102 Famotidine 20mg tab SAS 0.180002196018 MYLAN-Famotidine 20mg tab MYL 0.180002022133 Novo-Famotidine 20mg tab TEV 0.180002024195 Nu-Famotidine 20mg tab NXP 0.180000710121 Pepcid 20mg tab FRS 0.1800

famotidine 40mg tab 01953834 Apo-Famotidine 40mg tab APX 0.360002351110 Famotidine 40mg tab SAS 0.360002196026 MYLAN-Famotidine 40mg tab MYL 0.360002022141 Novo-Famotidine 40mg tab TEV 0.360002024209 Nu-Famotidine 40mg tab NXP 0.360000710113 Pepcid 40mg tab FRS 0.3600

famotidine 10mg/mL inj 02247745 Famotidine Omega 10mg/mL inj OMG 1.8295famotidine 10mg/mL inj (pf) 02247735 Famotidine Omega (PF) 10mg/mL inj OMG 1.6740felodipine 5mg tab (Plendil) 00851779 Plendil 5mg tab AZE 0.5097

02280264 Sandoz Felodipine 5mg tab SDZ 0.5097felodipine 10mg tab (Plendil) 00851787 Plendil 10mg tab AZE 0.7647

02280272 Sandoz Felodipine 10mg tab SDZ 0.7647felodipine 5mg tab (Renedil) 02221993 Renedil 5mg tab SAV 0.5097

02280264 Sandoz Felodipine 5mg tab SDZ 0.5097felodipine 10mg tab (Renedil) 02222000 Renedil 10mg tab SAV 0.7647

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 26 of 77

Generic Name and Strength DIN Brand MFR MRP PRPfelodipine 10mg tab (Renedil) 02280272 Sandoz Felodipine 10mg tab SDZ 0.7647fenofibrate 67mg cap 02243180 Apo-Feno-Micro 67mg cap APX 0.4325

02243551 Novo-Fenofibrate Micronized 67mg cap TEV 0.4325fenofibrate 100mg tab 02246859 Apo-Feno-Super 100mg tab APX 0.5407

02241601 Lipidil Supra 100mg tab SPH 0.540702289083 Novo-Fenofibrate S 100mg tab TEV 0.540702288044 Sandoz Fenofibrate S 100mg tab SDZ 0.5407

fenofibrate 160mg tab 02246860 Apo-Feno-Super 160mg tab APX 0.498502241602 Lipidil Supra 160mg tab SPH 0.498502289091 Novo-Fenofibrate S 160mg tab TEV 0.498502288052 Sandoz Fenofibrate S 160mg tab SDZ 0.4985

fenofibrate 200mg cap 02239864 Apo-Feno-Micro 200mg cap APX 1.089002286092 Fenofibrate Micro 200mg cap SAS 1.089002146959 Lipidil Micro 200mg cap SPH 1.089002240210 MYLAN-Fenofibrate Micro 200mg cap MYL 1.089002243552 Novo-Fenofibrate Micronized 200mg cap TEV 1.089002273551 pms-Fenofibrate Micro 200mg cap PMS 1.089002250039 ratio-Fenofibrate MC 200mg cap TEV 1.0890

fentanyl 12mcg/hr patch (exception status) 02341379 pms-Fentanyl MTX 12mcg/hr patch PMS 2.231002330105 RAN-Fentanyl MTX 12mcg/hr patch RAN 2.231002311925 ratio-Fentanyl 12mcg/hr patch TEV 2.231002327112 Sandoz Fentanyl 12mcg/hr patch SDZ 2.2310

fentanyl 25mcg/hr patch (exception status) 02275813 Duragesic MAT 25mcg/hr patch JAN 4.598402314630 Novo-Fentanyl 25mcg/hr patch TEV 4.598402341387 pms-Fentanyl MTX 25mcg/hr patch PMS 4.598402249391 RAN-Fentanyl 25mcg/hr patch RAN 4.598402330113 RAN-Fentanyl MTX 25mcg/hr patch RAN 4.598402282941 ratio-Fentanyl 25mcg/hr patch TEV 4.598402327120 Sandoz Fentanyl 25mcg/hr patch SDZ 4.5984

fentanyl 50mcg/hr patch (exception status) 02275821 Duragesic MAT 50mcg/hr patch JAN 8.653602314649 Novo-Fentanyl 50mcg/hr patch TEV 8.653602341395 pms-Fentanyl MTX 50mcg/hr patch PMS 8.653602249413 RAN-Fentanyl 50mcg/hr patch RAN 8.653602330121 RAN-Fentanyl MTX 50mcg/hr patch RAN 8.653602282968 ratio-Fentanyl 50mcg/hr patch TEV 8.653602327147 Sandoz Fentanyl 50mcg/hr patch SDZ 8.6536

fentanyl 75mcg/hr patch (exception status) 02275848 Duragesic MAT 75mcg/hr patch JAN 12.171202314657 Novo-Fentanyl 75mcg/hr patch TEV 12.171202341409 pms-Fentanyl MTX 75mcg/hr patch PMS 12.171202249421 RAN-Fentanyl 75mcg/hr patch RAN 12.171202330148 RAN-Fentanyl MTX 75mcg/hr patch RAN 12.171202282976 ratio-Fentanyl 75mcg/hr patch TEV 12.171202327155 Sandoz Fentanyl 75mcg/hr patch SDZ 12.1712

fentanyl 100mcg/hr patch (exception status) 02275856 Duragesic MAT 100mcg/hr patch JAN 15.1496

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 27 of 77

Generic Name and Strength DIN Brand MFR MRP PRPfentanyl 100mcg/hr patch (exception status) 02314665 Novo-Fentanyl 100mcg/hr patch TEV 15.1496

02341417 pms-Fentanyl MTX 100mcg/hr patch PMS 15.149602249448 RAN-Fentanyl 100mcg/hr patch RAN 15.149602330156 RAN-Fentanyl MTX 100mcg/hr patch RAN 15.149602282984 ratio-Fentanyl 100mcg/hr patch TEV 15.149602327163 Sandoz Fentanyl 100mcg/hr patch SDZ 15.1496

finasteride 5mg tab 02354462 CO Finasteride 5mg tab COB 0.746402355043 Finasteride 5mg tab AHC 0.746402357224 Jamp-Finasteride 5mg tab JPC 0.746402356058 MYLAN-Finasteride 5mg tab MYL 0.746402348500 Novo-Finasteride 5mg tab TEV 0.746402310112 pms-Finasteride 5mg tab PMS 0.746402010909 Proscar 5mg tab FRS 0.746402306905 ratio-Finasteride 5mg tab TEV 0.746402322579 Sandoz Finasteride 5mg tab SDZ 0.7464

flecainide 50mg tab 02275538 Flecainide 50mg tab AAP 0.429301966197 Tambocor 50mg tab GWP 0.4293

flecainide 100mg tab 02275546 Flecainide 100mg tab AAP 0.858501966200 Tambocor 100mg tab GWP 0.8585

floctafenine 200mg tab 02244680 Floctafenine 200mg tab AAP 0.1167floctafenine 400mg tab 02244681 Floctafenine 400mg tab AAP 0.2333fluconazole 50mg tab 02237370 Apo-Fluconazole 50mg tab APX 3.1266

02281260 CO Fluconazole 50mg tab COB 3.126602245292 MYLAN-Fluconazole 50mg tab MYL 3.126602236978 Novo-Fluconazole 50mg tab TEV 3.126602245643 pms-Fluconazole 50mg tab PMS 3.1266

fluconazole 100mg tab 02237371 Apo-Fluconazole 100mg tab APX 5.546602281279 CO Fluconazole 100mg tab COB 5.546602245293 MYLAN-Fluconazole 100mg tab MYL 5.546602236979 Novo-Fluconazole 100mg tab TEV 5.546602245644 pms-Fluconazole 100mg tab PMS 5.5466

fluconazole 150mg cap 02241895 Apo-Fluconazole 150mg cap APX 7.072502282348 pms-Fluconazole 150mg cap PMS 7.0725

flunarizine 5mg cap 02246082 Flunarizine 5mg cap AAP 0.7817fluocinonide 0.05% cr 02161923 Lidex 0.05% cr VAL 0.2443

00716863 Lyderm 0.05% cr TPH 0.2443fluocinonide 0.05% gel 02236997 Lyderm 0.05% gel TPH 0.3418

02161974 Topsyn 0.05% gel MDS 0.3418fluocinonide 0.05% oint 02161966 Lidex 0.05% oint VAL 0.3035

02236996 Lyderm 0.05% oint TPH 0.3035fluorometholone 0.1% oph sol 00247855 FML Liquifilm 0.1% oph sol ALL 1.9411

02238568 pms-Fluorometholone 0.1% oph sol PMS 1.9411fluoxetine 10mg cap 02216353 Apo-Fluoxetine 10mg cap APX 0.8650

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 28 of 77

Generic Name and Strength DIN Brand MFR MRP PRPfluoxetine 10mg cap 02242177 CO Fluoxetine 10mg cap COB 0.8650

02286068 Fluoxetine 10mg cap SAS 0.865002237813 MYLAN-Fluoxetine 10mg cap MYL 0.865002216582 Novo-Fluoxetine 10mg cap TEV 0.865002192756 Nu-Fluoxetine 10mg cap NXP 0.865002223481 phl-Fluoxetine 10mg cap PHL 0.865002177579 pms-Fluoxetine 10mg cap PMS 0.865002018985 Prozac 10mg cap LIL 0.865002241371 ratio-Fluoxetine 10mg cap TEV 0.865002243486 Sandoz Fluoxetine 10mg cap SDZ 0.865002302659 Zym-Fluoxetine 10mg cap ZYM 0.8650

fluoxetine 20mg cap 02216361 Apo-Fluoxetine 20mg cap APX 0.735702242178 CO Fluoxetine 20mg cap COB 0.735702286076 Fluoxetine 20mg cap SAS 0.735702237814 MYLAN-Fluoxetine 20mg cap MYL 0.735702216590 Novo-Fluoxetine 20mg cap TEV 0.735702192764 Nu-Fluoxetine 20mg cap NXP 0.735702223503 phl-Fluoxetine 20mg cap PHL 0.735702177587 pms-Fluoxetine 20mg cap PMS 0.735700636622 Prozac 20mg cap LIL 0.735702241374 ratio-Fluoxetine 20mg cap TEV 0.735702243487 Sandoz Fluoxetine 20mg cap SDZ 0.735702302667 Zym-Fluoxetine 20mg cap ZYM 0.7357

fluphenazine decanoate 25mg/mL inj 02091275 pms-Fluphenazine 25mg/mL inj (discontinued) PMS 4.6320flurbiprofen 50mg tab 00647942 Ansaid 50mg tab (discontinued) PFI 0.1750

01912046 Apo-Flurbiprofen 50mg tab APX 0.175002100509 Novo-Flurprofen 50mg tab TEV 0.175002020661 Nu-Flurbiprofen 50mg tab NXP 0.1750

flurbiprofen 100mg tab 00600792 Ansaid 100mg tab (discontinued) PFI 0.303901912038 Apo-Flurbiprofen 100mg tab APX 0.303902100517 Novo-Flurprofen 100mg tab TEV 0.303902020688 Nu-Flurbiprofen 100mg tab NXP 0.3039

flutamide 250mg tab 02238560 Apo-Flutamide 250mg tab APX 1.353000637726 Euflex 250mg tab SCH 1.353002230089 Novo-Flutamide 250mg tab TEV 1.353002230104 pms-Flutamide 250mg tab PMS 1.3530

fluvoxamine 50mg tab 02231329 Apo-Fluvoxamine 50mg tab APX 0.342802255529 CO Fluvoxamine 50mg tab COB 0.342801919342 Luvox 50mg tab SPH 0.342802239953 Novo-Fluvoxamine 50mg tab TEV 0.342802231192 Nu-Fluvoxamine 50mg tab NXP 0.342802240682 pms-Fluvoxamine 50mg tab PMS 0.342802218453 ratio-Fluvoxamine 50mg tab TEV 0.3428

fluvoxamine 100mg tab 02231330 Apo-Fluvoxamine 100mg tab APX 0.616302255537 CO Fluvoxamine 100mg tab COB 0.6163

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 29 of 77

Generic Name and Strength DIN Brand MFR MRP PRPfluvoxamine 100mg tab 01919369 Luvox 100mg tab SPH 0.6163

02239954 Novo-Fluvoxamine 100mg tab TEV 0.616302231193 Nu-Fluvoxamine 100mg tab NXP 0.616302240683 pms-Fluvoxamine 100mg tab PMS 0.616302218461 ratio-Fluvoxamine 100mg tab TEV 0.6163

fosinopril 10mg tab 02266008 Apo-Fosinopril 10mg tab APX 0.348402331004 Jamp-Fosinopril 10mg tab JPC 0.348401907107 Monopril 10mg tab BRI 0.348402262401 MYLAN-Fosinopril 10mg tab MYL 0.348402247802 Novo-Fosinopril10mg tab TEV 0.348402294524 RAN-Fosinopril 10mg tab RAN 0.3484

fosinopril 20mg tab 02266016 Apo-Fosinopril 20mg tab APX 0.419002331012 Jamp-Fosinopril20mg tab JPC 0.419001907115 Monopril 20mg tab BRI 0.419002262428 MYLAN-Fosinopril 20mg tab MYL 0.419002247803 Novo-Fosinopril 20mg tab TEV 0.419002294532 RAN-Fosinopril 20mg tab RAN 0.4190

furosemide 20mg tab 00396788 Apo-Furosemide 20mg tab APX 0.037302351420 Furosemide 20mg tab SAS 0.037302224690 Lasix 20mg tab SAV 0.037300337730 Novo-Semide 20mg tab TEV 0.0373

furosemide 40mg tab 00362166 Apo-Furosemide 40mg tab APX 0.055802351439 Furosemide 40mg tab SAS 0.055802224704 Lasix 40mg tab SAV 0.055800337749 Novo-Semide 40mg tab TEV 0.0558

furosemide 80mg tab 00707570 Apo-Furosemide 80mg tab APX 0.122002351447 Furosemide 80mg tab SAS 0.122000765953 Novo-Semide 80mg tab TEV 0.1220

gabapentin 100mg cap 02244304 Apo-Gabapentin 100mg cap APX 0.166902321203 Auro-Gabapentin 100mg cap ARO 0.166902256142 CO Gabapentin 100mg cap COB 0.166902353245 Gabapentin 100mg cap SAS 0.166902285819 GD-Gabapentin 100mg cap GMD 0.166902248259 MYLAN-Gabapentin 100mg cap MYL 0.166902084260 Neurontin 100mg cap PFI 0.166902244513 Novo-Gabapentin 100mg cap TEV 0.166902246314 phl-Gabapentin 100mg cap PHL 0.166902243446 pms-Gabapentin 100mg cap PMS 0.166902319055 RAN-Gabapentin 100mg cap RAN 0.166902260883 ratio-Gabapentin 100mg cap (discontinued) TEV 0.1669

gabapentin 300mg cap 02244305 Apo-Gabapentin 300mg cap APX 0.406002321211 Auro-Gabapentin 300mg cap ARO 0.406002256150 CO Gabapentin 300mg cap COB 0.406002353253 Gabapentin 300mg cap SAS 0.406002285827 GD-Gabapentin 300mg cap GMD 0.4060

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 30 of 77

Generic Name and Strength DIN Brand MFR MRP PRPgabapentin 300mg cap 02248260 MYLAN-Gabapentin 300mg cap MYL 0.4060

02084279 Neurontin 300mg cap PFI 0.406002244514 Novo-Gabapentin 300mg cap TEV 0.406002246315 phl-Gabapentin 300mg cap PHL 0.406002243447 pms-Gabapentin 300mg cap PMS 0.406002319063 RAN-Gabapentin 300mg cap RAN 0.406002260891 ratio-Gabapentin 300mg cap (discontinued) TEV 0.4060

gabapentin 400mg cap 02244306 Apo-Gabapentin 400mg cap APX 0.483802321238 Auro-Gabapentin 400mg cap ARO 0.483802256169 CO Gabapentin 400mg cap COB 0.483802353261 Gabapentin 400mg cap SAS 0.483802285835 GD-Gabapentin 400mg cap GMD 0.483802248261 MYLAN-Gabapentin 400mg cap MYL 0.483802084287 Neurontin 400mg cap PFI 0.483802244515 Novo-Gabapentin 400mg cap TEV 0.483802246316 phl-Gabapentin 400mg cap PHL 0.483802243448 pms-Gabapentin 400mg cap PMS 0.483802319071 RAN-Gabapentin 400mg cap RAN 0.483802260905 ratio-Gabapentin 400mg cap TEV 0.4838

gabapentin 600mg tab 02293358 Apo-Gabapentin 600mg tab APX 0.725702285843 GD-Gabapentin 600mg tab GMD 0.725702239717 Neurontin 600mg tab PFI 0.725702248457 Novo-Gabapentin 600mg tab TEV 0.7257

gabapentin 800mg tab 02293366 Apo-Gabapentin 800mg tab APX 0.967602285851 GD-Gabapentin 800mg tab GMD 0.967602239718 Neurontin 800mg tab PFI 0.967602247346 Novo-Gabapentin 800mg tab TEV 0.9676

galantamine 8mg ER cap (exception status) 02316943 PAT-Galantamine ER 8mg cap PPH 1.994402266717 Reminyl ER 8mg cap JAN 1.9944

galantamine 16mg ER cap (exception status)

02316951 PAT-Galantamine ER 16mg cap PPH 1.9944

02266725 Reminyl ER 16mg cap JAN 1.9944galantamine 24mg ER cap (exception status)

02316978 PAT-Galantamine ER 24mg cap PPH 1.9944

02266733 Reminyl ER 24mg cap JAN 1.9944gemfibrozil 300mg cap 01979574 Apo-Gemfibrozil 300mg cap APX 0.1963

00599026 Lopid 300mg cap PFI 0.196302185407 MYLAN-Gemfibrozil 300mg cap MYL 0.196302241704 Novo-Gemfibrozil 300mg cap TEV 0.196302058456 Nu-Gemfibrozil 300mg cap NXP 0.196302239951 pms-Gemfibrozil 300mg cap PMS 0.1963

gemfibrozil 600mg tab 01979582 Apo-Gemfibrozil 600mg tab APX 0.515702230476 MYLAN-Gemfibrozil 600mg tab MYL 0.515702142074 Novo-Gemfibrozil 600mg tab TEV 0.515702058464 Nu-Gemfibrozil 600mg tab NXP 0.5157

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 31 of 77

Generic Name and Strength DIN Brand MFR MRP PRPgemfibrozil 600mg tab 02230183 pms-Gemfibrozil 600mg tab PMS 0.5157gentamicin 40mg/mL inj 02242652 Gentamicin 40mg/mL inj SDZ 2.9650gentamicin 0.3% oph oint 02230888 Sandoz Gentamicin 0.3% oph oint SDZ 1.5000gentamicin 0.3% oph sol 00512192 Garamycin 0.3% oph sol SCH 0.4060

02229440 Sandoz Gentamicin 0.3% oph sol SDZ 0.4060gentamicin 0.3% otic sol 00512184 Garamycin 0.3% otic sol SCH 1.0320

02229441 Sandoz Gentamicin 0.3% otic sol SDZ 1.0320gliclazide 80mg tab 02245247 Apo-Gliclazide 80mg tab APX 0.1490

00765996 Diamicron 80mg tab SEV 0.149002287072 Gliclazide 80mg tab SAS 0.149002229519 MYLAN-Gliclazide 80mg tab MYL 0.149002238103 Novo-Gliclazide 80mg tab TEV 0.1490

gliclazide MR 30mg tab 02297795 Apo-Gliclazide 30mg MR tab AAP 0.152402242987 Diamicron 30mg MR tab SEV 0.1524

glucose testing strips 97799824 Accu-Chek Advantage (100) BOM 0.740097799823 Accu-Chek Advantage (50) BOM 0.740097799814 Accu-Chek AVIVA (100) BOM 0.740097799815 Accu-Chek AVIVA (50) BOM 0.740097799962 Accu-Chek Compact (102) BOM 0.740097799963 Accu-Chek Compact (51) BOM 0.740097799497 Accu-Chek Mobile BG Test Strip Cassette (100) BOM 0.740097799496 Accu-Chek Mobile BG Test Strip Cassette (50) BOM 0.740097799748 Ascensia Breeze 2 Disc (100) BDD 0.740097799749 Ascensia Breeze 2 Disc (50) BDD 0.740097799702 Ascensia Contour (100) BDD 0.740097799703 Ascensia Contour (50) BDD 0.740097799564 EZ Oracle (100) THI 0.738197799829 FreeStyle (100) MID 0.733597799827 FreeStyle (50) MID 0.740097799597 FreeStyle Lite (100) MID 0.733597799596 FreeStyle Lite (50) MID 0.740097799770 iTest (50) AUT 0.691097799583 NovaMax (100) NBM 0.740097799584 NovaMax (50) NBM 0.740097799582 On-Call Plus (100) ACO 0.630097799580 On-Call Plus (25) ACO 0.700097799581 On-Call Plus (50) ACO 0.670097799475 One Touch Verio Test Strips (100) LFS 0.694397799476 One Touch Verio Test Strips (50) LFS 0.740097799976 One-Touch (100) LFS 0.738197799977 One-Touch (50) LFS 0.740097799982 One-Touch FastTake (100) LFS 0.738197799983 One-Touch FastTake (50) LFS 0.740097799985 One-Touch Ultra (100) LFS 0.738197799986 One-Touch Ultra (50) LFS 0.7400

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 32 of 77

Generic Name and Strength DIN Brand MFR MRP PRPglucose testing strips 97799840 Precision Xtra (100) MID 0.7325

97799841 Precision Xtra (50) MID 0.740097799601 Sidekick Blood Glucose HOM 0.444497799532 TRUEtest (100) HOM 0.574197799531 TRUEtest (50) HOM 0.574297799602 TrueTrack (100) HOM 0.385997799603 TrueTrack (50) HOM 0.4444

glyburide 2.5mg tab 01913654 Apo-Glyburide 2.5mg tab APX 0.039302224550 Diabeta 2.5mg tab SAV 0.039302350459 Glyburide 2.5mg tab SAS 0.039300808733 MYLAN-Glybe 2.5mg tab MYL 0.039301913670 Novo-Glyburide 2.5mg tab TEV 0.039302020734 Nu-Glyburide 2.5mg tab NXP 0.039301900927 ratio-Glyburide 2.5mg tab TEV 0.039302248008 Sandoz Glyburide 2.5mg tab SDZ 0.0393

glyburide 5mg tab 01913662 Apo-Glyburide 5mg tab APX 0.068302224569 Diabeta 5mg tab SAV 0.068300720941 Euglucon 5mg tab PMS 0.068302350467 Glyburide 5mg tab SAS 0.068300808741 MYLAN-Glybe 5mg tab MYL 0.068301913689 Novo-Glyburide 5mg tab TEV 0.068302020742 Nu-Glyburide 5mg tab NXP 0.068302236734 pms-Glyburide 5mg tab PMS 0.068301900935 ratio-Glyburide 5mg tab TEV 0.068302248009 Sandoz Glyburide 5mg tab SDZ 0.0683

granisetron 1 mg tab (exception status) 02308894 Granisetron 1mg tab AAP 14.648002185881 Kytril 1mg tab HLR 14.6480

haloperidol 0.5mg tab 00396796 Apo-Haloperidol 0.5mg tab APX 0.036000363685 Novo-Peridol 0.5mg tab TEV 0.0360

haloperidol 1mg tab 00396818 Apo-Haloperidol 1mg tab APX 0.061400363677 Novo-Peridol 1mg tab TEV 0.0614

haloperidol 2mg tab 00396826 Apo-Haloperidol 2mg tab APX 0.105000363669 Novo-Peridol 2mg tab TEV 0.1050

haloperidol 5mg tab 00396834 Apo-Haloperidol 5mg tab APX 0.148700363650 Novo-Peridol 5mg tab TEV 0.1487

haloperidol 10mg tab 00463698 Apo-Haloperidol 10mg tab APX 0.133000713449 Novo-Peridol 10mg tab TEV 0.1330

haloperidol LA 50mg/mL inj 02130297 Haloperidol LA 50mg/mL inj SDZ 7.3600haloperidol LA 100mg/mL inj 02130300 Haloperidol LA 100mg/mL inj SDZ 14.7167hydralazine HCl 10mg tab 00441619 Apo-Hydralazine 10mg tab APX 0.1347hydralazine HCl 25mg tab 00441627 Apo-Hydralazine 25mg tab APX 0.2314hydralazine HCl 50mg tab 00441635 Apo-Hydralazine 50mg tab APX 0.3633hydrochlorothiazide 12.5mg tab 02327856 Apo-Hydro 12.5mg tab APX 0.0322

02274086 pms-Hydrochlorothiazide 12.5mg tab PMS 0.0322

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 33 of 77

Generic Name and Strength DIN Brand MFR MRP PRPhydrochlorothiazide 25mg tab 00326844 Apo-Hydro 25mg tab APX 0.0395

02360594 Hydrochlorothiazide 25mg tab SAS 0.039500021474 Novo-Hydrazide 25mg tab TEV 0.039502247386 pms-Hydrochlorothiazide 25mg tab PMS 0.0395

hydrochlorothiazide 50mg tab 00312800 Apo-Hydro 50mg tab APX 0.055102360608 Hydrochlorothiazide 50mg tab SAS 0.055100021482 Novo-Hydrazide 50mg tab TEV 0.055102247387 pms-Hydrochlorothiazide 50mg tab PMS 0.0551

hydrochlorothiazide 100mg tab 00644552 Apo-Hydro 100mg tab APX 0.1232hydrochlorothiazide 50mg & amiloride HCl 5mg tab

00784400 Apo-Amilzide 50mg/5mg tab APX 0.1476

02257378 MYLAN-Amilazide 50mg/5mg tab MYL 0.147601937219 Novamilor 50mg/5mg tab TEV 0.147600886106 Nu-Amilzide 50mg/5mg tab NXP 0.1476

hydrochlorothiazide 25mg & spironolactone 25mg tab

00180408 Aldactazide 25/25mg tab PFI 0.1216

00613231 Novo-Spirozine 25/25mg tab TEV 0.1216hydrochlorothiazide 50mg & spironolactone 50mg tab

00594377 Aldactazide 50/50mg tab PFI 0.2571

00657182 Novo-Spirozine 50/50mg tab TEV 0.2571hydrochlorothiazide 25mg & triamterene 50mg tab

00441775 Apo-Triazide 25/50mg tab APX 0.0608

00532657 Novo-Triamzide 25/50mg tab TEV 0.060800865532 Nu-Triazide 25/50mg tab NXP 0.0608

hydrocortisone & antiinfectives oph oint 02242485 Sandoz Cortimyxin oph oint SDZ 3.6143hydrocortisone 0.5% oint 02128446 Anodan-HC 0.5% oint ODN 0.4130

00505773 Anusol-HC 0.5% oint JNJ 0.413002247691 Sandoz Anuzinc HC 0.5% oint SDZ 0.4130

hydrocortisone 10mg supp 02236399 Anodan-HC 10mg supp ODN 0.607500476285 Anusol-HC 10mg supp JNJ 0.607502242798 Sandoz Anuzinc HC 10mg supp SDZ 0.6075

hydrocortisone valerate 0.2% cr 02242984 Hydroval 0.2% cr TPH 0.1211hydrocortisone, framycetin sulfate & cinchocaine HCl oint

02247322 Proctol oint ODN 0.5960

02223252 Proctosedyl oint AXC 0.596002226383 ratio-Proctosone oint TEV 0.596002242527 Sandoz Proctomyxin HC oint SDZ 0.5960

hydrocortisone, framycetin sulfate & cinchocaine HCl supp

02247882 Proctol supp ODN 0.7925

02223260 Proctosedyl supp AXC 0.792502226391 ratio-Proctosone supp TEV 0.792502242528 Sandoz Proctomyxin HC supp SDZ 0.7925

hydrocortisone, pramoxine oint 00505781 Anugesic-HC oint JNJ 0.731702234466 Proctodan-HC oint ODN 0.731702247692 Sandoz Anuzinc HC Plus oint SDZ 0.7317

hydrocortisone, pramoxine supp 00476242 Anugesic-HC supp JNJ 1.0875

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 34 of 77

Generic Name and Strength DIN Brand MFR MRP PRPhydrocortisone, pramoxine supp 02240851 Proctodan-HC supp ODN 1.0875

02242797 Sandoz Anuzinc HC Plus supp SDZ 1.0875hydromorphone 2mg/mL inj 00627100 Dilaudid 2mg/mL inj PFR 1.1380

02145901 Hydromorphone 2mg/mL inj SDZ 1.1380hydromorphone 10mg/mL inj 00622133 Dilaudid HP 10mg/mL inj PFR 2.7500

02145928 Hydromorphone HP 10mg/mL inj SDZ 2.7500hydromorphone 20mg/mL inj 02146118 Dilaudid HP Plus 20mg/mL inj PFR 4.5100

02145936 Hydromorphone HP 20mg/mL inj SDZ 4.5100hydromorphone 50mg/mL inj 02145863 Dilaudid XP 50mg/mL inj PFR 10.4950

02146126 Hydromorphone HP 50mg/mL inj SDZ 10.4950hydromorphone 1mg/mL oral sol 00786535 Dilaudid 1mg/mL oral sol PFR 0.0665

01916386 pms-Hydromorphone 1mg/mL oral sol PMS 0.0665hydromorphone HCl 1mg tab 00705438 Dilaudid 1mg tab PFR 0.0959

00885444 pms-Hydromorphone 1mg tab PMS 0.0959hydromorphone HCl 2mg tab 00125083 Dilaudid 2mg tab PFR 0.1417

00885436 pms-Hydromorphone 2mg tab PMS 0.1417hydromorphone HCl 4mg tab 00125121 Dilaudid 4mg tab PFR 0.2240

00885401 pms-Hydromorphone 4mg tab PMS 0.2240hydromorphone HCl 8mg tab 00786543 Dilaudid 8mg tab PFR 0.3528

00885428 pms-Hydromorphone 8mg tab PMS 0.3528hydroxychloroquine 200mg tab 02246691 Apo-Hydroxyquine 200mg tab APX 0.2620

02252600 MYLAN-Hydroxychloroquine 200mg tab MYL 0.262002017709 Plaquenil 200mg tab SAV 0.2620

hydroxyurea 500mg cap 02247937 Apo-Hydroxyurea 500mg cap (discontinued) APX 1.020300465283 Hydrea 500mg cap BRI 1.020302343096 Hydroxyurea 500mg cap SAS 1.020302242920 MYLAN-Hydroxyurea 500mg cap MYL 1.0203

hydroxyzine HCl 10mg cap (exception status)

00646059 Apo-Hydroxyzine 10mg cap APX 0.1116

00738824 Novo-Hydroxyzin 10mg cap TEV 0.1116hydroxyzine HCl 25mg cap (exception status)

00646024 Apo-Hydroxyzine 25mg cap APX 0.1425

00738832 Novo-Hydroxyzin 25mg cap TEV 0.1425hydroxyzine HCl 50mg cap (exception status)

00646016 Apo-Hydroxyzine 50mg cap APX 0.2068

00738840 Novo-Hydroxyzin 50mg cap TEV 0.2068ibuprofen 300mg tab 00441651 Apo-Ibuprofen 300mg tab APX 0.1087

02242632 Motrin IB 300mg tab JNJ 0.1087ibuprofen 400mg tab 00506052 APC-Ibuprofen 400mg tab APX 0.0372

00506052 Apo-Ibuprofen 400mg tab APX 0.037202317338 Jamp-Ibuprofen 400mg tab JPC 0.037202242658 Motrin IB 400mg tab JNJ 0.037200629340 Novo-Profen 400mg tab TEV 0.0372

ibuprofen 600mg tab 00585114 Apo-Ibuprofen 600mg tab APX 0.131300629359 Novo-Profen 600mg tab TEV 0.1313

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 35 of 77

Generic Name and Strength DIN Brand MFR MRP PRPibuprofen 600mg tab 02020726 Nu-Ibuprofen 600mg tab NXP 0.1313idoxuridine 0.1% sol 02237187 Sandoz Idoxuridine 0.1% sol SDZ 4.9900imipramine 25mg tab 00312797 Imipramine 25mg tab AAP 0.2682imipramine 50mg tab 00326852 Imipramine 50mg tab AAP 0.5232indomethacin 25mg cap 00611158 Apo-Indomethacin 25mg cap APX 0.0871

00337420 Novo-Methacin 25mg cap TEV 0.087100865850 Nu-Indo 25mg cap NXP 0.0871

indomethacin 50mg cap 00611166 Apo-Indomethacin 50mg cap APX 0.151100337439 Novo-Methacin 50mg cap TEV 0.151100865869 Nu-Indo 50mg cap NXP 0.1511

indomethacin 50mg supp 02231799 Sandoz Indomethacin 50mg supp SDZ 0.8400indomethacin 100mg supp 01934139 ratio-Indomethacin 100mg supp TEV 0.8920

02231800 Sandoz Indomethacin 100mg supp SDZ 0.8920ipratropium bromide 200mcg/mL & salbutamol 1mg/mL unit dose inh sol (exception status)

02231675 Combivent UD inh sol BOE 0.2936

02272695 MYLAN-Combo Sterinebs UD inh sol MYL 0.293602243789 ratio-IPRA SAL UD inh sol TEV 0.2936

ipratropium bromide 125mcg/mL unit dose inh sol (2mL) (exception status)

02231135 pms-Ipratropium 125mcg/mL UD inh sol PMS 0.2765

02097176 ratio-Ipratropium 125mcg/mL UD inh sol TEV 0.2765ipratropium bromide 250mcg/mL inh sol (20mL) (exception status)

02126222 Apo-Ipravent 250mcg/mL inh sol (20mL) APX 0.5530

02239131 MYLAN-Ipratropium 250mcg/mL inh sol (20mL) MYL 0.553002210479 Novo-Ipramide 250mcg/mL inh sol (20mL) TEV 0.553002231136 pms-Ipratropium 250mcg/mL inh sol (20mL) PMS 0.5530

ipratropium bromide 250mcg/mL unit dose inh sol (1mL) (exception status)

02216221 MYLAN-Ipratropium 250mcg/mL UD inh sol(1mL) MYL 0.5530

02231244 pms-Ipratropium 250mcg/mL UD inh sol (1mL) PMS 0.553002097168 ratio-Ipratropium 250mcg/mL UD inh sol (1mL) TEV 0.5530

ipratropium bromide 250mcg/mL unit dose inh sol (2mL) (exception status)

02216221 MYLAN-Ipratropium 250mcg/mL UD inh sol(2mL) MYL 0.5530

02231245 pms-Ipratropium 250mcg/mL UD inh sol (2mL) PMS 0.553002097168 ratio-Ipratropium 250mcg/mL UD inh sol (2mL) TEV 0.5530

ipratropium bromide 0.3% nasal spray (21mcg/dose)

02163705 Atrovent 0.3% nasal spray BOE 0.0508

02239627 pms-Ipratropium 0.3% nasal spray PMS 0.0508ipratropium bromide 0.6% nasal spray (42mcg/dose)

02246084 Apo-Ipravent 0.6% nasal spray APX 0.1355

02163713 Atrovent 0.6% nasal spray BOE 0.1355irbesartan 75mg tab 02237923 Avapro 75mg tab BRI 0.4839

02328070 CO Irbesartan 75mg tab COB 0.483902317060 pms-Irbesartan 75mg tab PMS 0.483902316390 ratio-Irbesartan 75mg tab TEV 0.483902328461 Sandoz Irbesartan 75mg SDZ 0.483902315971 Teva-Irbesartan 75mg tab TEV 0.4839

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 36 of 77

Generic Name and Strength DIN Brand MFR MRP PRPirbesartan 150mg tab 02237924 Avapro 150mg tab BRI 0.4839

02328089 CO Irbesartan 150mg tab COB 0.483902317079 pms-Irbesartan 150mg tab PMS 0.483902316404 ratio-Irbesartan 150mg tab TEV 0.483902328488 Sandoz Irbesartan 150mg tab SDZ 0.483902315998 Teva-Irbesartan 150mg tab TEV 0.4839

irbesartan 300mg tab 02237925 Avapro 300mg tab BRI 0.483902328100 CO Irbesartan 300mg tab COB 0.483902317087 pms-Irbesartan 300mg tab PMS 0.483902316412 ratio-Irbesartan 300mg tab TEV 0.483902328496 Sandoz Irbesartan 300mg tab SDZ 0.483902316005 Teva-Irbesartan 300mg tab TEV 0.4839

irbesartan 150mg & hydrochlorothiazide 12.5mg tab

02241818 Avalide 150/12.5mg tab BRI 0.4839

02357399 CO Irbesartan/HCT 150/12.5mg tab COB 0.483902328518 pms-Irbesartan-HCTZ 150/12.5 mg tab PMS 0.483902363208 RAN-Irbesartan HCTZ 150/12.5mg tab RAN 0.483902330512 ratio-Irbesartan HCTZ 150/12.5 mg tab TEV 0.483902337428 Sandoz Irbesartan HCT 150/12.5mg tab SDZ 0.483902316013 Teva-Irbesartan/HCTZ 150/12.5mg tab TEV 0.4839

irbesartan 300mg & hydrochlorothiazide 12.5mg tab

02241819 Avalide 300/12.5mg tab BRI 0.4839

02357402 CO Irbesartan/HCT 300/12.5mg tab COB 0.483902328526 pms-Irbesartan-HCTZ 300/12.5 mg tab PMS 0.483902363216 RAN-Irbesartan HCTZ 300/12.5mg tab RAN 0.483902330520 ratio-Irbesartan HCTZ 300/12.5 mg tab TEV 0.483902337436 Sandoz Irbesartan HCT 300/12.5mg tab SDZ 0.483902316021 Teva-Irbesartan/HCTZ 300/12.5mg tab TEV 0.4839

irbesartan 300mg & hydrochlorothiazide 25mg tab

02280213 Avalide 300/25mg tab BRI 0.4806

02357410 CO Irbesartan/HCT 300/25mg tab COB 0.480602328534 pms-Irbesartan-HCTZ 300/25 mg tab PMS 0.480602363224 RAN-Irbesartan HCTZ 300/25mg tab RAN 0.480602330539 ratio-Irbesartan HCTZ 300/25 mg tab TEV 0.480602337444 Sandoz Irbesartan HCT 300/25mg tab SDZ 0.480602316048 Teva-Irbesartan/HCTZ 300/25mg tab TEV 0.4806

isosorbide dinitrate 5mg SL tab 00670944 ISDN 5mg tab AAP 0.0674isosorbide dinitrate 10mg tab 00441686 ISDN 10mg tab AAP 0.0397isosorbide dinitrate 30mg tab 00441694 ISDN 30mg tab AAP 0.0930isosorbide mononitrate 60mg SR tab 02272830 Apo-ISMN 60mg SR tab APX 0.4950

02126559 Imdur 60mg ER tab AZE 0.495002301288 pms-ISMN 60mg SR tab PMS 0.4950

isotretinoin 10mg cap 00582344 Accutane 10mg cap HLR 0.931302257955 Clarus 10mg cap MYL 0.9313

isotretinoin 40mg cap 00582352 Accutane 40mg cap HLR 1.9003

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 37 of 77

Generic Name and Strength DIN Brand MFR MRP PRPisotretinoin 40mg cap 02257963 Clarus 40mg cap MYL 1.9003ketoconazole 2% cr 02245662 Ketoderm 2% cr TPH 0.3166ketoconazole 200mg tab 02237235 Apo-Ketoconazole 200mg tab APX 1.1835

02231061 Novo-Ketoconazole 200mg tab TEV 1.183502122197 Nu-Ketocon 200mg tab NXP 1.1835

ketoprofen 50mg cap 00790427 Apo-Keto 50mg cap AAP 0.1750ketoprofen 50mg EC tab 00790435 Apo-Keto-E 50mg EC tab AAP 0.1750ketoprofen 100mg EC tab 00842664 Apo-Keto-E 100mg EC tab AAP 0.3500ketoprofen 200mg SR tab 02172577 Apo-Keto 200mg SR tab AAP 0.7000ketorolac 30mg/mL inj 02239944 Ketorolac 30mg/mL inj SDZ 4.3000ketorolac 0.5% oph sol 01968300 Acular 0.5% oph sol ALL 1.6000

02245821 Apo-Ketorolac 0.5% oph sol APX 1.600002247461 ratio-Ketorolac 0.5% oph sol TEV 1.6000

ketotifen fumarate 1mg tab 02230730 Novo-Ketotifen 1mg tab TEV 0.687400577308 Zaditen 1mg tab TEV 0.6874

ketotifen fumarate 1mg/5mL syr 02176084 Novo-Ketotifen 1mg/5mL inj TEV 0.1330lactulose 667mg/mL o/l (exception status) 02242814 Apo-Lactulose 667mg/mL o/l APX 0.0145

02295881 Jamp-Lactulose 667mg/mL o/l JPC 0.014500854409 ratio-Lactulose 667mg/mL o/l TEV 0.014502331551 Teva-Lactulose 667mg/mL o/l TEV 0.0145

lamotrigine 25mg tab 02245208 Apo-Lamotrigine 25mg tab APX 0.149702142082 Lamictal 25mg tab GSK 0.149702343010 Lamotrigine 25mg tab SAS 0.149702265494 MYLAN-Lamotrigine 25mg tab MYL 0.149702248232 Novo-Lamotrigine 25mg tab TEV 0.149702246897 pms-Lamotrigine 25mg tab PMS 0.149702243352 ratio-Lamotrigine 25mg tab TEV 0.1497

lamotrigine 100mg tab 02245209 Apo-Lamotrigine 100mg tab APX 0.597602142104 Lamictal 100mg tab GSK 0.597602343029 Lamotrigine 100mg tab SAS 0.597602265508 MYLAN-Lamotrigine 100mg tab MYL 0.597602248233 Novo-Lamotrigine 100mg tab TEV 0.597602246898 pms-Lamotrigine 100mg tab PMS 0.597602243353 ratio-Lamotrigine 100mg tab TEV 0.5976

lamotrigine 150mg tab 02245210 Apo-Lamotrigine 150mg tab APX 0.880702142112 Lamictal 150mg tab GSK 0.880702343037 Lamotrigine 150mg tab SAS 0.880702265516 MYLAN-Lamotrigine 150mg tab MYL 0.880702248234 Novo-Lamotrigine 150mg tab TEV 0.880702246899 pms-Lamotrigine 150mg tab PMS 0.880702246963 ratio-Lamotrigine 150mg tab TEV 0.8807

lancets 97799689 Abbott Thin (200) MID 0.044597799691 Abbott Thin 28g (100) MID 0.050097799494 Accu-Chek Fastclix Lancets (102) BOM 0.0500

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 38 of 77

Generic Name and Strength DIN Brand MFR MRP PRPlancets 97799495 Accu-Chek Fastclix Lancets (204) BOM 0.0500

97799817 Accu-Chek Multiclix (102) BOM 0.050097799816 Accu-Chek Multiclix (204) BOM 0.050097799946 Accu-Chek Softclix (100) BOM 0.050097799945 Accu-Chek Softclix (200) BOM 0.050097799942 Accu-Chek Softclix Pro (200) BOM 0.050097799917 Ascensia Microlet BDD 0.050097799918 Ascensia Microlet (100) BDD 0.050097799882 BD Ultra-Fine 33g (100) BTD 0.050097799540 EZ Health (100) THI 0.050097799825 Finger Stix (200) BDD 0.050097799826 FreeStyle (100) MID 0.050097799766 iTest 28g (100) AUT 0.046597799767 iTest 33g (100) AUT 0.040497799592 Medlance Plus Lite 25g (200) MPD 0.050097799591 Medlance Plus Universal 21G (200) MPD 0.050097799810 MPD Thin MPD 0.031897799807 MPD Ultra Thin (100) MPD 0.031897799501 One Touch Delica (100) LFS 0.050097799765 One-Touch Sure Soft (200) LFS 0.050097799970 One-Touch Ultra Soft (100) LFS 0.050097799948 Safe-T-Pro (200) BOM 0.0500

lansoprazole 15mg cap (exception status) 02293811 Apo-Lansoprazole 15mg DR cap APX 0.800002357682 Lansoprazole 15mg DR cap SAS 0.800002353830 MYLAN-Lansoprazole 15mg DR cap MYL 0.800002280515 Novo-Lansoprazole 15mg DR cap TEV 0.800002165503 Prevacid 15mg cap ABB 0.8000

lansoprazole 30mg cap (exception status) 02293838 Apo-Lansoprazole 30mg DR cap APX 0.800002357690 Lansoprazole 30mg DR cap SAS 0.800002353849 MYLAN-Lansoprazole 30mg DR cap MYL 0.800002280523 Novo-Lansoprazole 30mg DR cap TEV 0.800002165511 Prevacid 30mg cap ABB 0.8000

latanopost 50mcg/mL oph sol 02296527 Apo-Latanoprost 0.005% oph sol APX 4.404802373041 GD-Latanoprost 0.005% oph sol GMD 4.404802231493 Xalatan 0.005% oph sol PFI 4.4048

leflunomide 10mg tab (exception status) 02256495 Apo-Leflunomide 10mg tab APX 4.296802241888 Arava 10mg tab SAV 4.296802351668 Leflunomide 10mg tab SAS 4.296802319225 MYLAN-Leflunomide 10mg tab MYL 4.296802261251 Novo-Leflunomide 10mg tab TEV 4.296802288265 pms-Leflunomide 10mg tab PMS 4.296802283964 Sandoz Leflunomide 10mg tab SDZ 4.2968

leflunomide 20mg tab (exception status) 02256509 Apo-Leflunomide 20mg tab APX 4.296802241889 Arava 20mg tab SAV 4.296802351676 Leflunomide 20mg tab SAS 4.2968

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 39 of 77

Generic Name and Strength DIN Brand MFR MRP PRPleflunomide 20mg tab (exception status) 02319233 MYLAN-Leflunomide 20mg tab MYL 4.2968

02261278 Novo-Leflunomide 20mg tab TEV 4.296802288273 pms-Leflunomide 20mg tab PMS 4.296802283972 Sandoz Leflunomide 20mg tab SDZ 4.2968

letrozole 2.5 tab 02231384 Femara 2.5mg tab NVR 2.361302338459 Letrozole 2.5mg tab (AHC) AHC 2.361302348969 Letrozole 2.5mg tab (COB) COB 2.361302347997 Letrozole 2.5mg tab (TEV) TEV 2.361302322315 MED-Letrozole 2.5mg tab GMP 2.361302309114 pms-Letrozole 2.5mg tab PMS 2.361302344815 Sandoz Letrozole 2.5mg tab SDZ 2.3613

levetiracetam 250mg tab (exception status) 02285924 Apo-Levetiracetam 250mg tab APX 0.800002274183 CO Levetiracetam 250mg tab COB 0.800002247027 Keppra 250mg tab UCB 0.800002353342 Levetiracetam 250mg tab SAS 0.800002296101 pms-Levetiracetam 250mg tab PMS 0.8000

levetiracetam 500mg tab (exception status) 02285932 Apo-Levetiracetam 500mg tab APX 0.975002274191 CO Levetiracetam 500mg tab COB 0.975002247028 Keppra 500mg tab UCB 0.975002353350 Levetiracetam 500mg tab SAS 0.975002296128 pms-Levetiracetam 500mg tab PMS 0.9750

levetiracetam 750mg tab (exception status) 02285940 Apo-Levetiracetam 750mg tab APX 1.350002274205 CO Levetiracetam 750mg tab COB 1.350002247029 Keppra 750mg tab UCB 1.350002353369 Levetiracetam 750mg tab SAS 1.350002296136 pms-Levetiracetam 750mg tab PMS 1.3500

levobunolol HCl 0.25% oph sol 02031159 ratio-Levobunolol 0.25% oph sol TEV 1.176002241715 Sandoz Levobunolol 0.25% oph sol (discontinued) SDZ 1.1760

levobunolol HCl 0.5% oph sol 00637661 Betagan 0.5% oph sol ALL 1.316002237991 pms-Levobunolol 0.5% oph sol PMS 1.316002031167 ratio-Levobunolol 0.5% oph sol TEV 1.316002241716 Sandoz Levobunolol 0.5% oph sol SDZ 1.3160

levodopa 100mg & carbidopa 10mg tab 02195933 Apo-Levocarb 100/10mg tab APX 0.187702244494 Novo-Levocarbidopa 100/10mg tab TEV 0.187702182831 Nu-Levocarb 100/10mg tab NXP 0.187700355658 Sinemet 100/10mg tab FRS 0.1877

levodopa 100mg & carbidopa 25mg tab 02195941 Apo-Levocarb 100/25mg tab APX 0.280302244495 Novo-Levocarbidopa 100/25mg tab TEV 0.280302182823 Nu-Levocarb 100/25mg tab NXP 0.280300513997 Sinemet 100/25mg tab FRS 0.2803

levodopa 250mg & carbidopa 25mg tab 02195968 Apo-Levocarb 250/25mg tab APX 0.312902244496 Novo-Levocarbidopa 250/25mg tab TEV 0.312900328219 Sinemet 250/25mg tab FRS 0.3129

levodopa 100mg & carbidopa 25mg cr tab 02272873 Apo-Levocarb CR 100/25mg tab AAP 0.5562

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 40 of 77

Generic Name and Strength DIN Brand MFR MRP PRPlevodopa 100mg & carbidopa 25mg cr tab 02028786 Sinemet CR 100/25mg tab FRS 0.5562levodopa 200mg & carbidopa 50mg cr tab 02245211 Levocarb CR 200/50 tab AAP 1.0850

00870935 Sinemet CR 200/50 tab FRS 1.0850levofloxacin 250mg tab (exception status) 02284707 Apo-Levofloxacin 250mg tab APX 2.1186

02315424 CO Levofloxacin 250mg tab COB 2.118602236841 Levaquin 250mg tab JAN 2.118602313979 MYLAN-Levofloxacin 250mg tab MYL 2.118602248262 Novo-Levofloxacin 250mg tab TEV 2.118602284677 pms-Levofloxacin 250mg tab PMS 2.118602298635 Sandoz Levofloxacin 250mg tab SDZ 2.1186

levofloxacin 500mg tab (exception status) 02284715 Apo-Levofloxacin 500mg tab APX 2.414202315432 CO Levofloxacin 500mg tab COB 2.414202236842 Levaquin 500mg tab JAN 2.414202313987 MYLAN-Levofloxacin 500mg tab MYL 2.414202248263 Novo-Levofloxacin 500mg tab TEV 2.414202284685 pms-Levofloxacin 500mg tab PMS 2.414202298643 Sandoz Levofloxacin 500mg tab SDZ 2.4142

levonorgestrel 0.10mg & ethinyl estradiol 0.02mg tab (21)

02236974 Alesse 21 Day WAY 0.4636

02298538 Aviane 21 Day APX 0.4636levonorgestrel 0.10mg & ethinyl estradiol 0.02mg tab (28)

02236975 Alesse 28 Day WAY 0.3477

02298546 Aviane 28 Day APX 0.3477levonorgestrel 0.15mg & ethinyl estradiol 0.03mg tab (21)

02042320 Min-Ovral 21 Day WAY 0.4636

02295946 Portia 21 Day APX 0.4636levonorgestrel 0.15mg & ethinyl estradiol 0.03mg tab (28)

02042339 Min-Ovral 28 Day WAY 0.3477

02295954 Portia 28 Day APX 0.3477lidocaine 5% oint 02083795 Lidodan 5% oint ODN 0.3967

00001961 Xylocaine 5% oint AZE 0.3967lisinopril 5mg tab 02217481 Apo-Lisinopril 5mg tab APX 0.5387

02271443 CO Lisinopril 5mg tab COB 0.538702274833 MYLAN-Lisinopril 5mg tab MYL 0.538702285061 Novo-Lisinopril (Type P) 5mg tab TEV 0.538702285118 Novo-Lisinopril (Type Z) 5mg tab TEV 0.538702292203 pms-Lisinopril 5mg tab PMS 0.538700839388 Prinivil 5mg tab FRS 0.538702294230 RAN-Lisinopril 5mg tab RAN 0.538702256797 ratio-Lisinopril P 5mg tab TEV 0.538702299879 ratio-Lisinopril Z 5mg tab TEV 0.538702289199 Sandoz Lisinopril 5mg tab SDZ 0.538702049333 Zestril 5mg tab AZE 0.5387

lisinopril 10mg tab 02217503 Apo-Lisinopril 10mg tab APX 0.647302271451 CO Lisinopril 10mg tab COB 0.6473

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 41 of 77

Generic Name and Strength DIN Brand MFR MRP PRPlisinopril 10mg tab 02274841 MYLAN-Lisinopril 10mg tab MYL 0.6473

02285088 Novo-Lisinopril P 10mg tab TEV 0.647302285126 Novo-Lisinopril Z 10mg tab TEV 0.647302292211 pms-Lisinopril 10mg tab PMS 0.647300839396 Prinivil 10mg tab FRS 0.647302294249 RAN-Lisinopril 10mg tab RAN 0.647302256800 ratio-Lisinopril P 10mg tab TEV 0.647302299887 ratio-Lisinopril Z 10mg tab TEV 0.647302289202 Sandoz Lisinopril 10mg tab SDZ 0.647302049376 Zestril 10mg tab AZE 0.6473

lisinopril 20mg tab 02217511 Apo-Lisinopril 20mg tab APX 0.777902271478 CO Lisinopril 20mg tab COB 0.777902274868 MYLAN-Lisinopril 20mg tab MYL 0.777902285096 Novo-Lisinopril P 20mg tab TEV 0.777902285134 Novo-Lisinopril Z 20mg tab TEV 0.777902292238 pms-Lisinopril 20mg tab PMS 0.777900839418 Prinivil 20mg tab FRS 0.777902294257 RAN-Lisinopril 20mg tab RAN 0.777902256819 ratio-Lisinopril P 20mg tab TEV 0.777902299895 ratio-Lisinopril Z 20mg tab TEV 0.777902289229 Sandoz Lisinopril 20mg tab SDZ 0.777902049384 Zestril 20mg tab AZE 0.7779

lisinopril 10mg & hydrochlorothiazide 12.5mg tab

02261979 Apo-Lisinopril/HCTZ 10/12.5mg tab APX 0.3429

02362945 Lisinopril/HCTZ 10/12.5mg (Type Z) tab SAS 0.342902297736 MYLAN-Lisinopril/HCTZ 10/12.5mg tab MYL 0.342902302136 Novo-Lisinopril/HCTZ (Type P) 10/12.5mg tab TEV 0.342902301768 Novo-Lisinopril/HCTZ (Type Z) 10/12.5mg tab TEV 0.342902108194 Prinzide 10/12.5mg tab FRS 0.342902103729 Zestoretic 10/12.5mg tab AZE 0.3429

lisinopril 20mg & hydrochlorothiazide 12.5mg tab

02261987 Apo-Lisinopril/HCTZ 20/12.5mg tab APX 0.4120

02362953 Lisinopril/HCTZ 20/12.5mg (Type Z) tab SAS 0.412002297744 MYLAN-Lisinopril/HCTZ 20/12.5mg tab MYL 0.412002302144 Novo-Lisinopril/HCTZ (Type P) 20/12.5mg tab TEV 0.412002301776 Novo-Lisinopril/HCTZ (Type Z) 20/12.5mg tab TEV 0.412000884413 Prinzide 20/12.5mg tab FRS 0.412002045737 Zestoretic 20/12.5mg tab AZE 0.4120

lisinopril 20mg & hydrochlorothiazide 25mg tab

02261995 Apo-Lisinopril/HCTZ 20/25mg tab APX 0.4120

02362961 Lisinopril/HCTZ 20/25mg (Type Z) tab SAS 0.412002297752 MYLAN-Lisinopril/HCTZ 20/25mg tab MYL 0.412002302152 Novo-Lisinopril/HCTZ (Type P) 20/25mg tab TEV 0.412002301784 Novo-Lisinopril/HCTZ (Type Z) 20/25mg tab TEV 0.412002045729 Zestoretic 20/25mg tab AZE 0.4120

lithium 300mg SR tab 02266695 Lithmax SR 300mg tab AAP 0.2708

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 42 of 77

Generic Name and Strength DIN Brand MFR MRP PRPlithium 600mg cap 02011239 Carbolith 600mg cap VLN 0.1530

02216159 pms-Lithium Carbonate 600mg cap PMS 0.1530lithium 300mg cap (Carbolith) 02242838 Apo-Lithium Carbonate 300mg cap APX 0.0443

00236683 Carbolith 300mg cap VLN 0.044302216140 pms-Lithium Carbonate 300mg cap PMS 0.0443

lithium 150mg cap (Carbolith) 02242837 Apo-Lithium Carbonate 150mg cap APX 0.046400461733 Carbolith 150mg cap VLN 0.046402216132 pms-Lithium Carbonate 150mg cap PMS 0.0464

lithium 300mg cap (Lithane) 02242838 Apo-Lithium Carbonate 300mg cap APX 0.044300406775 Lithane 300mg cap ERF 0.0443

lithium 150mg cap (Lithane) 02242837 Apo-Lithium Carbonate 150mg cap APX 0.046402013231 Lithane 150mg cap ERF 0.0464

loperamide 2mg caplet 02212005 APC-Loperamide 2mg caplet (discontinued) APX 0.143402212005 Apo-Loperamide 2mg caplet APX 0.143402183862 Imodium 2mg caplet JNJ 0.143402132591 Novo-Loperamide 2mg caplet TEV 0.143402228351 pms-Loperamide 2mg caplet PMS 0.143402257564 Sandoz Loperamide 2mg caplet SDZ 0.1434

loperamide HCl 0.2mg/mL o/l 02016095 pms-Loperamide 0.2mg/mL o/l PMS 0.1072loratadine 10mg tab (exception status) 02243880 APC-Loratadine 10mg tab APX 0.6267

02243880 Apo-Loratadine 10mg tab APX 0.626700782696 Claritin 10mg tab SCH 0.6267

lorazepam 0.5mg tab 00655740 Apo-Lorazepam 0.5mg tab APX 0.035902041413 Ativan 0.5mg tab WAY 0.035902351072 Lorazepam 0.5mg tab SAS 0.035900711101 Novo-Lorazem 0.5mg tab TEV 0.035900728187 pms-Lorazepam 0.5mg tab PMS 0.0359

lorazepam 1mg tab 00655759 Apo-Lorazepam 1mg tab APX 0.044702041421 Ativan 1mg tab WAY 0.044702351080 Lorazepam 1mg tab SAS 0.044700637742 Novo-Lorazem 1mg tab TEV 0.044700728195 pms-Lorazepam 1mg tab PMS 0.0447

lorazepam 2mg tab 00655767 Apo-Lorazepam 2mg tab APX 0.069902041448 Ativan 2mg tab WAY 0.069902351099 Lorazepam 2mg tab SAS 0.069900637750 Novo-Lorazem 2mg tab TEV 0.069900728209 pms-Lorazepam 2mg tab PMS 0.0699

lorazepam 4mg/mL inj 02243278 Lorazepam 4mg/mL inj SDZ 2.9900lovastatin 20mg tab 02220172 Apo-Lovastatin 20mg tab APX 0.8264

02248572 CO Lovastatin 20mg tab COB 0.826402353229 Lovastatin 20mg tab SAS 0.826400795860 Mevacor 20mg tab FRS 0.826402243127 MYLAN-Lovastatin 20mg tab MYL 0.826402246542 Novo-Lovastatin 20mg tab TEV 0.8264

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 43 of 77

Generic Name and Strength DIN Brand MFR MRP PRPlovastatin 20mg tab 02246013 pms-Lovastatin 20mg tab PMS 0.8264

02245822 ratio-Lovastatin 20mg tab TEV 0.826402247056 Sandoz Lovastatin 20mg tab SDZ 0.8264

lovastatin 40mg tab 02220180 Apo-Lovastatin 40mg tab APX 1.509402248573 CO Lovastatin 40mg tab COB 1.509402353237 Lovastatin 40mg tab SAS 1.509400795852 Mevacor 40mg tab FRS 1.509402243129 MYLAN-Lovastatin 40mg tab MYL 1.509402246543 Novo-Lovastatin 40mg tab TEV 1.509402246014 pms-Lovastatin 40mg tab PMS 1.509402245823 ratio-Lovastatin 40mg tab TEV 1.509402247057 Sandoz Lovastatin 40mg tab SDZ 1.5094

loxapine 5mg tab 02230837 Xylac 5mg tab PMS 0.1789loxapine 10mg tab 02230838 Xylac 10mg tab PMS 0.2978loxapine 25mg tab 02230839 Xylac 25mg tab PMS 0.4617loxapine 50mg tab 02230840 Xylac 50mg tab PMS 0.6154maprotiline 25mg tab 02158612 Novo-Maprotiline 25mg tab TEV 0.5687maprotiline 50mg tab 02158620 Novo-Maprotiline 50mg tab TEV 1.0769maprotiline 75mg tab 02158639 Novo-Maprotiline 75mg tab TEV 1.4707medroxyprogesterone acetate 2.5mg tab 02244726 Apo-Medroxy 2.5mg tab APX 0.0642

02221284 Novo-Medrone 2.5mg tab TEV 0.064200708917 Provera 2.5mg tab PFI 0.0642

medroxyprogesterone acetate 5mg tab 02244727 Apo-Medroxy 5mg tab APX 0.127002221292 Novo-Medrone 5mg tab TEV 0.127000030937 Provera 5mg tab PFI 0.1270

medroxyprogesterone acetate 10mg tab 02277298 Apo-Medroxy 10mg tab APX 0.257702221306 Novo-Medrone 10mg tab TEV 0.257700729973 Provera 10mg tab PFI 0.2577

medroxyprogesterone acetate 100mg tab 02267640 Apo-Medroxy 100mg tab APX 0.915300030945 Provera 100mg tab PFI 0.9153

medroxyprogesterone acetate 150mg/mL inj 00585092 Depo-Provera 150mg/mL inj PFI 22.000002322250 Medroxyprogesterone Acetate 150mg/mL inj SDZ 22.0000

mefenamic acid 250mg cap 02229452 Apo-Mefenamic 250mg cap AAP 0.5412megestrol 40mg tab 02195917 Megestrol 40mg tab AAP 1.0930megestrol 40mg tab 02195925 Megestrol 160mg tab AAP 4.6254meloxicam 7.5mg tab 02248973 Apo-Meloxicam 7.5mg tab APX 0.3204

02250012 CO Meloxicam 7.5mg tab COB 0.320402353148 Meloxicam 7.5mg tab SAS 0.320402242785 Mobicox 7.5mg tab BOE 0.320402255987 MYLAN-Meloxicam 7.5mg tab MYL 0.320402258315 Novo-Meloxicam 7.5mg tab TEV 0.320402248607 phl-Meloxicam 7.5mg tab PHL 0.320402248267 pms-Meloxicam 7.5mg tab PMS 0.320402247889 ratio-Meloxicam 7.5mg tab TEV 0.3204

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 44 of 77

Generic Name and Strength DIN Brand MFR MRP PRPmeloxicam 15mg tab 02248974 Apo-Meloxicam 15mg tab APX 0.3697

02250020 CO Meloxicam 15mg tab COB 0.369702353156 Meloxicam 15mg tab SAS 0.369702242786 Mobicox 15mg tab BOE 0.369702255995 MYLAN-Meloxicam 15mg tab MYL 0.369702258323 Novo-Meloxicam 15mg tab TEV 0.369702248608 phl-Meloxicam 15mg tab PHL 0.369702248268 pms-Meloxicam 15mg tab PMS 0.369702248031 ratio-Meloxicam 15mg tab TEV 0.3697

metformin HCl 500mg tab 02167786 Apo-Metformin 500mg tab APX 0.095302257726 CO Metformin 500mg tab COB 0.095302099233 Glucophage 500mg tab SAV 0.095302242794 Metformin 500mg tab MEL 0.095302353377 Metformin 500mg tab SAS 0.095302148765 MYLAN-Metformin 500mg tab MYL 0.095302045710 Novo-Metformin 500mg tab TEV 0.095302162822 Nu-Metformin 500mg tab NXP 0.095302223562 pms-Metformin 500mg tab PMS 0.095302269031 RAN-Metformin 500mg tab RAN 0.095302242974 ratio-Metformin 500mg tab TEV 0.095302246820 Sandoz Metformin FC 500mg tab SDZ 0.0953

metformin HCl 850mg tab 02229785 Apo-Metformin 850mg tab APX 0.153602257734 Co Metformin 850mg tab COB 0.153602162849 Glucophage 850mg tab SAV 0.153602353385 Metformin 850mg tab SAS 0.153602229656 MYLAN-Metformin 850mg tab MYL 0.153602230475 Novo-Metformin 850mg tab TEV 0.153602229517 Nu-Metformin 850mg tab NXP 0.153602242589 pms-Metformin 850mg tab PMS 0.153602269058 RAN-Metformin 850mg tab RAN 0.153602242931 ratio-Metformin 850mg tab TEV 0.153602246821 Sandoz Metformin FC 850mg tab SDZ 0.1536

methotrexate 2.5mg tab 02182963 Apo-Methotrexate 2.5mg tab APX 0.632502170698 Methotrexate 2.5mg tab WAY 0.632502244798 ratio-Methotrexate Sodium 2.5mg tab TEV 0.6325

methotrimeprazine 2mg tab 02238403 Apo-Methoprazine 2mg tab APX 0.0685methotrimeprazine 5mg tab 02238404 Apo-Methoprazine 5mg tab APX 0.0991methotrimeprazine 25mg tab 02238405 Apo-Methoprazine 25mg tab APX 0.2547methotrimeprazine 50mg tab 02238406 Apo-Methoprazine 50mg tab APX 0.3857methyldopa 125mg tab 00360252 Methyldopa 125mg tab AAP 0.1074methyldopa 250mg tab 00360260 Methyldopa 250mg tab AAP 0.1555methyldopa 500mg tab 00426830 Methyldopa 500mg tab AAP 0.2753methylphenidate 10mg tab 02249324 Apo-Methylphenidate 10mg tab APX 0.1453

00584991 pms-Methylphenidate 10mg tab PMS 0.1453

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 45 of 77

Generic Name and Strength DIN Brand MFR MRP PRPmethylphenidate 10mg tab 00005606 Ritalin 10mg tab NVR 0.1453methylphenidate 20mg tab 02249332 Apo-Methylphenidate 20mg tab APX 0.2461

00585009 pms-Methylphenidate 20mg tab PMS 0.246100005614 Ritalin 20mg tab NVR 0.2461

methylphenidate 20mg SR tab 02266687 Apo-Methylphenidate 20mg SR tab APX 0.282000632775 Ritalin 20mg SR tab NVR 0.282002320312 Sandoz Methylphenidate 20mg SR tab SDZ 0.2820

methylprednisolone acetate 40mg/vial inj 01934333 Depo-Medrol 40mg/mL inj PFI 4.515002245407 Methylprednisolone Acetate 40mg/mL inj SDZ 4.5150

methylprednisolone acetate 80mg/vial inj 01934341 Depo-Medrol 80mg/mL inj PFI 6.990002245408 Methylprednisolone Acetate 80mg/mL inj SDZ 6.9900

methylprednisolone acetate 40mg/vial inj (pf)

00030759 Depo-Medrol 40mg/mL inj (PF) PFI 4.7250

02245400 Methylprednisolone Acetate 40mg/mL inj (PF) SDZ 4.7250methylprednisolone acetate 80mg/vial inj (pf)

00030767 Depo-Medrol 80mg/mL inj (PF) PFI 9.0300

02245406 Methylprednisolone Acetate 80mg/mL inj (PF) SDZ 9.0300methylprednisolone sodium succinate 40mg/vial inj

02231893 Methylprednisolone Sod. Succ. 40mg/vial inj TEV 3.6000

methylprednisolone sodium succinate 125mg/vial inj

02231894 Methylprednisolone Sod. Succ. 125mg/vial inj TEV 8.5000

methylprednisolone sodium succinate 500mg/vial inj

02231895 Methylprednisolone Sod Succ 500mg/vial inj TEV 20.1820

00030678 Solu-Medrol 500mg/vial inj PFI 20.1820methylprednisolone sodium succinate 1g/vial inj

02241229 Methylprednisolone Sod Succ 1g/vial inj TEV 31.0000

00036137 Solu-Medrol 1g/vial inj PFI 31.0000metoclopramide HCl 5mg tab 00842826 Apo-Metoclop 5mg tab APX 0.0556

02143275 Nu-Metoclopramide 5mg tab NXP 0.055602230431 pms-Metoclopramide 5mg tab PMS 0.0556

metoclopramide HCl 10mg tab 00842834 Apo-Metoclop 10mg tab APX 0.058302143283 Nu-Metoclopramide 10mg tab NXP 0.058302230432 pms-Metoclopramide 10mg tab PMS 0.0583

metoclopramide HCl 1mg o/l 02230433 pms-Metoclopramide 1mg/mL liq PMS 0.0486metoprolol tartrate 50mg tab 00618632 Apo-Metoprolol 50mg tab APX 0.1074

00749354 Apo-Metoprolol-L 50mg tab APX 0.107400397423 Lopresor 50mg tab NVR 0.107402350394 Metoprolol Film-Coated 50mg tab SAS 0.107402174545 MYLAN-Metoprolol (Type L) 50mg tab MYL 0.107400648035 Novo-Metoprol (pink) 50mg tab TEV 0.107400865605 Nu-Metop 50mg tab NXP 0.107402230803 pms-Metoprolol-L 50mg tab PMS 0.107402354187 Sandoz Metoprolol (Type L) 50mg tab SDZ 0.107402247875 Sandoz Metoprolol (Type L) 50mg tab SDZ 0.1074

metoprolol tartrate 100mg tab 00618640 Apo-Metoprolol 100mg tab APX 0.222300751170 Apo-Metoprolol-L 100mg tab APX 0.2223

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 46 of 77

Generic Name and Strength DIN Brand MFR MRP PRPmetoprolol tartrate 100mg tab 00397431 Lopresor 100mg tab NVR 0.2223

02350408 Metoprolol Film-Coated 100mg tab SAS 0.222302174553 MYLAN-Metoprolol (Type L) 100mg tab MYL 0.222300648043 Novo-Metoprol (blue) 100mg tab TEV 0.222300865613 Nu-Metop 100mg tab NXP 0.222302230804 pms-Metoprolol-L 100mg tab PMS 0.222302247876 Sandoz Metoprolol (Type L) 100mg tab SDZ 0.222302354195 Sandoz Metoprolol (Type L) 100mg tab SDZ 0.2223

metoprolol tartrate 100mg SR tab 02285169 Apo-Metoprolol 100mg SR tab APX 0.131200658855 Lopresor 100mg SR tab NVR 0.131202303396 Sandoz Metoprolol 100mg SR tab SDZ 0.1312

metoprolol tartrate 200mg SR tab 02285177 Apo-Metoprolol 200mg SR tab APX 0.249900534560 Lopresor 200mg SR tab NVR 0.249902303418 Sandoz Metoprolol 200mg SR tab SDZ 0.2499

metronidazole 250mg tab 00545066 Metronidazole 250mg tab AAP 0.0646mexiletine 100mg cap 02230359 Novo-Mexiletine 100mg cap TEV 1.0203mexiletine 200mg cap 02230360 Novo-Mexiletine 200mg cap TEV 1.3663miconazole 2% vag cr 02231106 Micozole 2% vag cr TAR 0.1511

02084309 Monistat 7 2% vag cr JNJ 0.1511midazolam 1mg/mL inj 02240285 Midazolam 1mg/mL inj SDZ 0.7800midazolam 5mg/mL inj 02240286 Midazolam 5mg/mL inj SDZ 4.1000midodrine 2.5mg tab 02278677 Midodrine 2.5mg tab AAP 0.3675midodrine 5mg tab 02278685 Midodrine 5mg tab AAP 0.6109minocycline HCl 50mg cap 02084090 Apo-Minocycline 50mg cap APX 0.5350

02173514 Minocin 50mg cap (discontinued) STI 0.535002287226 Minocycline 50mg cap SAS 0.535002230735 MYLAN-Minocycline 50mg cap MYL 0.535002108143 Novo-Minocycline 50mg cap TEV 0.535002294419 pms-Minocycline 50mg cap PMS 0.535002237313 Sandoz Minocycline 50mg cap SDZ 0.5350

minocycline HCl 100mg cap 02084104 Apo-Minocycline 100mg cap APX 1.033202173506 Minocin 100mg cap (discontinued) STI 1.033202287234 Minocycline 100mg cap SAS 1.033202230736 MYLAN-Minocycline 100mg cap MYL 1.033202108151 Novo-Minocycline 100mg cap TEV 1.033202294427 pms-Minocycline 100mg cap PMS 1.033202237314 Sandoz Minocycline 100mg cap SDZ 1.0332

mirtazapine 30mg tab 02286629 Apo-Mirtazapine 30mg tab APX 0.520802256118 MYLAN-Mirtazapine 30mg tab MYL 0.520802259354 Novo-Mirtazapine 30mg tab TEV 0.520802252279 phl-Mirtazapine 30mg tab PHL 0.520802248762 pms-Mirtazapine 30mg tab PMS 0.520802270927 ratio-Mirtazapine 30mg tab TEV 0.520802243910 Remeron 30mg tab ORG 0.5208

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 47 of 77

Generic Name and Strength DIN Brand MFR MRP PRPmirtazapine 30mg tab 02250608 Sandoz Mirtazapine 30mg tab SDZ 0.5208

02325187 Zym-Mirtazapine 30mg tab ZYM 0.5208mirtazapine 15mg RD tab 02299801 Auro-Mirtazapine OD 15mg tab ARO 0.1607

02279894 Novo-Mirtazapine 15mg OD tab TEV 0.160702248542 Remeron 15mg RD tab ORG 0.1607

mirtazapine 30mg RD tab 02299828 Auro-Mirtazapine OD 30mg tab ARO 0.321302279908 Novo-Mirtazapine 30mg OD tab TEV 0.321302248543 Remeron 30mg RD tab ORG 0.3213

mirtazapine 45mg RD tab 02299836 Auro-Mirtazapine OD 45mg tab ARO 0.482002279916 Novo-Mirtazapine 45mg OD tab TEV 0.482002248544 Remeron 45mg RD tab ORG 0.4820

misoprostol 100mcg tab 02244022 Misoprostol 100mcg tab AAP 0.2804misoprostol 200mcg tab 02244023 Misoprostol 200mcg tab AAP 0.4669moclobemide 100mg tab 02232148 Apo-Moclobemide 100mg tab APX 0.2520

02239746 Novo-Moclobemide 100mg tab TEV 0.252002237111 Nu-Moclobemide 100mg tab NXP 0.2520

moclobemide 150mg tab 02232150 Apo-Moclobemide 150mg tab APX 0.242300899356 Manerix 150mg tab MVL 0.242302239747 Novo-Moclobemide 150mg tab TEV 0.242302237112 Nu-Moclobemide 150mg tab NXP 0.2423

moclobemide 300mg tab 02240456 Apo-Moclobemide 300mg tab APX 0.475802166747 Manerix 300mg tab MVL 0.475802239748 Novo-Moclobemide 300mg tab TEV 0.4758

mometasone 0.1% cr 00851744 Elocom 0.1% cr SCH 0.526302367157 Taro-Mometasone 0.1% cr TAR 0.5263

mometasone 0.1% lot 00871095 Elocom 0.1% lot SCH 0.312302266385 Taro-Mometasone 0.1% lot TAR 0.3123

mometasone 0.1% oint 00851736 Elocom 0.1% oint SCH 0.270102248130 ratio-Mometasone 0.1% oint TEV 0.270102264749 Taro-Mometasone 0.1% oint TAR 0.2701

montelukast 4mg granules 02358611 Sandoz Montelukast 4mg granules SDZ 0.145802247997 Singulair 4mg/pkt granules FRS 0.1458

montelukast 4mg chewable tab 02354977 pms-Montelukast 4mg chewtab PMS 0.583302330385 Sandoz Montelukast 4mg chewtab SDZ 0.583302243602 Singulair 4mg chewtab FRS 0.583302355507 Teva-Montelukast 4mg chewtab TEV 0.5833

montelukast 5mg chewable tab 02354985 pms-Montelukast 5mg chewtab PMS 0.644002330393 Sandoz Montelukast 5mg chewtab SDZ 0.644002238216 Singulair 5mg chewtab FRS 0.644002355515 Teva-Montelukast 5mg chewtab TEV 0.6440

montelukast 10mg chewable tab 02373947 pms-Montelukast FC 10mg tab PMS 0.945902328593 Sandoz Montelukast 10mg tab SDZ 0.945902238217 Singulair 10mg tab FRS 0.945902355523 Teva-Montelukast 10mg tab TEV 0.9459

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 48 of 77

Generic Name and Strength DIN Brand MFR MRP PRPmorphine sulfate 15mg SR tab 02350815 Morphine SR 15mg tab SAS 0.3751

02015439 MS Contin 15mg SR tab PFR 0.375102302764 Novo-Morphine 15mg SR tab TEV 0.375102244790 Sandoz Morphine 15mg SR tab SDZ 0.3751

morphine sulfate 30mg SR tab 02350890 Morphine SR 30mg tab SAS 0.566402014297 MS Contin 30mg SR tab PFR 0.566402302772 Novo-Morphine 30mg SR tab TEV 0.566402244791 Sandoz Morphine 30mg SR tab SDZ 0.5664

morphine sulfate 60mg SR tab 02350912 Morphine SR 60mg tab SAS 0.998402014300 MS Contin 60mg SR tab PFR 0.998402302780 Novo-Morphine 60mg SR tab TEV 0.998402245286 pms-Morphine Sulfate 60mg SR tab (discontinued) PMS 0.998402244792 Sandoz Morphine 60mg SR tab SDZ 0.9984

morphine sulfate 100mg SR tab 02350920 Morphine SR 100mg tab SAS 1.936402014319 MS Contin 100mg SR tab PFR 1.936402302799 Novo-Morphine 100mg SR tab TEV 1.9364

morphine sulfate 200mg SR tab 02350947 Morphine SR 200mg tab SAS 3.600002014327 MS Contin 200mg SR tab PFR 3.600002302802 Novo-Morphine 200mg SR tab TEV 3.6000

morphine sulfate 10mg/mL inj 00392588 Morphine Sulfate 10mg/mL inj SDZ 0.9900morphine sulfate 15mg/mL inj 00392561 Morphine Sulfate 15mg/mL inj SDZ 1.0050mupirocin 2% oint 01916947 Bactroban 2% oint GSK 0.3453

02279983 Taro-Mupirocin 2% oint TAR 0.3453nabumetone 500mg tab 02238639 Apo-Nabumetone 500mg tab APX 0.1750

02244563 MYLAN-Nabumetone 500mg tab MYL 0.175002343282 Nabumetone 500mg tab SAS 0.175002240867 Novo-Nabumetone 500mg tab TEV 0.1750

nabumetone 750mg tab 02240868 Novo-Nabumetone 750mg tab TEV 0.3500nadolol 40mg tab 00782505 Apo-Nadol 40mg tab APX 0.2465

02126753 Novo-Nadolol 40mg tab TEV 0.2465nadolol 80mg tab 00782467 Apo-Nadol 80mg tab APX 0.3515

02126761 Novo-Nadolol 80mg tab TEV 0.3515nadolol 160mg tab 00782475 Apo-Nadol 160mg tab APX 1.2046naproxen 125mg tab 00522678 Apo-Naproxen 125mg tab APX 0.0781naproxen 250mg tab 00522651 Apo-Naproxen 250mg tab APX 0.1068

02350750 Naproxen 250mg tab SAS 0.106800565350 Novo-Naprox 250mg tab TEV 0.106800865648 Nu-Naprox 250mg tab NXP 0.1068

naproxen 375mg tab 00600806 Apo-Naproxen 375mg tab APX 0.145802350769 Naproxen 375mg tab SAS 0.145800627097 Novo-Naprox 375mg tab TEV 0.145800865656 Nu-Naprox 375mg tab NXP 0.1458

naproxen 500mg tab 00592277 Apo-Naproxen 500mg tab APX 0.211002350777 Naproxen 500mg tab SAS 0.2110

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 49 of 77

Generic Name and Strength DIN Brand MFR MRP PRPnaproxen 500mg tab 00589861 Novo-Naprox 500mg tab TEV 0.2110

00865664 Nu-Naprox 500mg tab NXP 0.2110naproxen 250mg EC tab 02246699 Apo-Naproxen 250mg EC tab APX 0.1639

02162792 Naprosyn-E 250mg EC tab HLR 0.163902350785 Naproxen 250mg EC tab SAS 0.163902243312 Novo-Naprox 250mg EC tab TEV 0.1639

naproxen 375mg EC tab 02246700 Apo-Naproxen 375mg EC tab APX 0.214902243432 MYLAN-Naproxen 375mg EC tab MYL 0.214902162415 Naprosyn-E 375mg EC tab HLR 0.214902350793 Naproxen 375mg EC tab SAS 0.214902243313 Novo-Naprox 375mg EC tab TEV 0.214902294702 pms-Naproxen 375mg EC tab PMS 0.2149

naproxen 500mg EC tab 02246701 Apo-Naproxen 500mg EC tab APX 0.350002241024 MYLAN-Naproxen 500mg EC tab MYL 0.350002162423 Naprosyn-E 500mg EC tab HLR 0.350002350807 Naproxen 500mg EC tab SAS 0.350002243314 Novo-Naprox 500mg EC tab TEV 0.350002294710 pms-Naproxen 500mg EC tab PMS 0.3500

naproxen 750mg SR tab 02177072 Apo-Naproxen 750mg SR tab (discontinued) APX 0.700002162466 Naprosyn 750mg SR tab HLR 0.7000

naproxen sodium 275mg tab 02162725 Anaprox 275mg tab HLR 0.175000784354 Apo-Napro-Na 275mg tab APX 0.175002351013 Naproxen Sodium 275mg tab SAS 0.175000778389 Novo-Naprox Sodium 275mg tab TEV 0.1750

naproxen sodium 550mg tab 02162717 Anaprox DS 550mg tab HLR 0.350001940309 Apo-Napro-Na DS 550mg tab APX 0.350002351021 Naproxen Sodium DS 550mg tab SAS 0.350002026600 Novo-Naprox Sodium 550mg tab TEV 0.3500

naproxen 500mg supp 02017237 pms-Naproxen 500mg supp PMS 0.9639naratriptan 1mg tab (exception status) 02237820 Amerge 1mg tab GSK 8.4338

02314290 Novo-Naratriptan 1mg tab TEV 8.4338naratriptan 2.5mg tab (exception status) 02237821 Amerge 2.5mg tab GSK 6.1438

02314304 Novo-Naratriptan 2.5mg tab TEV 6.143802322323 Sandoz Naratriptan 2.5mg tab SDZ 6.1438

nifedipine 5mg cap 00725110 Nifedipine 5mg cap AAP 0.3992nifedipine 10mg tab 00755907 Nifedipine 10mg tab AAP 0.5292nifedipine 30mg ER tab 02155907 Adalat XL 30mg tab BAY 0.8639

02349167 MYLAN-Nifedipine 30mg ER tab MYL 0.8639nifedipine 60mg ER tab 02155990 Adalat XL 60mg tab BAY 1.2511

02321149 MYLAN-Nifedipine 60mg ER tab MYL 1.2511nitrofurantoin 50mg cap 02231015 Novo-Furantoin 50mg cap TEV 0.3984nitroglycerin 0.4mg/dose pumpspray 02231441 Nitrolingual 0.4mg/dose pumpspray SAV 0.0423

02238998 Rho-Nitro 0.4mg/dose pumpspray SDZ 0.0423nizatidine 150mg cap 02220156 Apo-Nizatidine 150mg cap APX 0.1800

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 50 of 77

Generic Name and Strength DIN Brand MFR MRP PRPnizatidine 150mg cap 00778338 Axid 150mg cap MMT 0.1800

02240457 Novo-Nizatidine 150mg cap TEV 0.180002177714 pms-Nizatidine 150mg cap PMS 0.1800

nizatidine 300mg cap 02220164 Apo-Nizatidine 300mg cap APX 0.360000778346 Axid 300mg cap MMT 0.360002240458 Novo-Nizatidine 300mg cap TEV 0.360002177722 pms-Nizatidine 300mg cap PMS 0.3600

norfloxacin 400mg tab (exception status) 02229524 Apo-Norflox 400mg tab APX 1.371602269627 CO Norfloxacin 400mg tab COB 1.371602237682 Novo-Norfloxacin 400mg tab TEV 1.371602246596 pms-Norfloxacin 400mg tab PMS 1.3716

nortriptyline 10mg cap 02223511 Apo-Nortriptyline 10mg cap APX 0.090000015229 Aventyl 10mg cap PHL 0.090002231781 Novo-Nortriptyline 10mg cap TEV 0.090002223139 Nu-Nortriptyline 10mg cap NXP 0.090002177692 pms-Nortriptyline 10mg cap PMS 0.0900

nortriptyline 25mg cap 02223538 Apo-Nortriptyline 25mg cap APX 0.181000015237 Aventyl 25mg cap PHL 0.181002231782 Novo-Nortriptyline 25mg cap TEV 0.181002223147 Nu-Nortriptyline 25mg cap NXP 0.181002177706 pms-Nortriptyline 25mg cap PMS 0.1810

nystatin 100,000iu o/l 02194201 ratio-Nystatin 100,000iu/mL oral drops TEV 0.0740octreotide 50mcg/mL inj 02248639 Octreotide Acetate Omega 50mcg/mL inj HOS 2.0360

00839191 Sandostatin 50mcg/mL inj NVR 2.0360octreotide 100mcg/mL inj 02248640 Octreotide Acetate Omega 100mcg/mL inj HOS 3.8440

00839205 Sandostatin 100mcg/mL inj NVR 3.8440octreotide 200mcg/mL inj 02248642 Octreotide Acetate Omega 200mcg/mL inj HOS 7.3928

02049392 Sandostatin 200mcg/mL inj NVR 7.3928octreotide 500mcg/mL inj 02248641 Octreotide Acetate Omega 500mcg/mL inj HOS 18.0640

00839213 Sandostatin 500mcg/mL inj NVR 18.0640ofloxacin 300mg tab (exception status) 02231531 Ofloxacin 300mg tab AAP 1.6626ofloxacin 400mg tab (exception status) 02231532 Ofloxacin 400mg tab AAP 1.6626ofloxacin 0.3% oph sol (exception status) 02248398 Apo-Ofloxacin 0.3% oph sol APX 0.9784

02143291 Ocuflox 0.3% oph sol ALL 0.978402252570 pms-Ofloxacin 0.3% oph sol PMS 0.9784

olanzapine 2.5mg tab (exception status) 02281791 Apo-Olanzapine 2.5mg tab APX 0.718902337878 MYLAN-Olanzapine 2.5mg tab MYL 0.718902276712 Novo-Olanzapine 2.5mg tab TEV 0.718902303116 pms-Olanzapine 2.5mg tab PMS 0.718902310341 Sandoz Olanzapine 2.5mg tab SDZ 0.718902229250 Zyprexa 2.5mg tab LIL 0.7189

olanzapine 5mg tab (exception status) 02281805 Apo-Olanzapine 5mg tab APX 1.437802337886 MYLAN-Olanzapine 5mg tab MYL 1.437802276720 Novo-Olanzapine 5mg tab TEV 1.4378

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 51 of 77

Generic Name and Strength DIN Brand MFR MRP PRPolanzapine 5mg tab (exception status) 02303159 pms-Olanzapine 5mg tab PMS 1.4378

02310368 Sandoz Olanzapine 5mg tab SDZ 1.437802229269 Zyprexa 5mg tab LIL 1.4378

olanzapine 7.5mg tab (exception status) 02281813 Apo-Olanzapine 7.5mg tab APX 2.156602337894 MYLAN-Olanzapine 7.5mg tab MYL 2.156602276739 Novo-Olanzapine 7.5mg tab TEV 2.156602303167 pms-Olanzapine 7.5mg tab PMS 2.156602310376 Sandoz Olanzapine 7.5mg tab SDZ 2.156602229277 Zyprexa 7.5mg tab LIL 2.1566

olanzapine 10mg tab (exception status) 02281821 Apo-Olanzapine 10mg tab APX 2.875502337908 MYLAN-Olanzapine 10mg tab MYL 2.875502276747 Novo-Olanzapine 10mg tab TEV 2.875502303175 pms-Olanzapine 10mg tab PMS 2.875502310384 Sandoz Olanzapine 10mg tab SDZ 2.875502229285 Zyprexa 10mg tab LIL 2.8755

olanzapine 15mg tab (exception status) 02281848 Apo-Olanzapine 15mg tab APX 4.313202337916 MYLAN-Olanzapine 15mg tab MYL 4.313202276755 Novo-Olanzapine 15mg tab TEV 4.313202303183 pms-Olanzapine 15mg tab PMS 4.313202310392 Sandoz Olanzapine 15mg tab SDZ 4.313202238850 Zyprexa 15mg tab LIL 4.3132

olanzapine ODT 5mg tab (exception status) 02327562 CO Olanzapine ODT 5mg tab COB 1.429802321343 Novo-Olanzapine OD 5mg tab TEV 1.429802303191 pms-Olanzapine ODT 5mg tab PMS 1.429802327775 Sandoz Olanzapine ODT 5mg tab SDZ 1.429802243086 Zyprexa Zydis 5mg tab LIL 1.4298

olanzapine ODT 10mg tab (exception status)

02360624 Apo-Olanzapine ODT 10mg tab APX 2.8572

02327570 CO Olanzapine ODT 10mg tab COB 2.857202321351 Novo-Olanzapine OD 10mg tab TEV 2.857202303205 pms-Olanzapine ODT 10mg tab PMS 2.857202327783 Sandoz Olanzapine ODT 10mg tab SDZ 2.857202243087 Zyprexa Zydis 10mg tab LIL 2.8572

olanzapine ODT 15mg tab (exception status)

02360632 Apo-Olanzapine ODT 15mg tab APX 4.2844

02327589 CO Olanzapine ODT 15mg tab COB 4.284402321378 Novo-Olanzapine OD 15mg tab TEV 4.284402303213 pms-Olanzapine ODT 15mg tab PMS 4.284402327791 Sandoz Olanzapine ODT 15mg tab SDZ 4.284402243088 Zyprexa Zydis 15mg tab LIL 4.2844

olanzapine ODT 20mg tab (exception status)

02360640 Apo-Olanzapine ODT 20mg tab APX 5.9377

02327597 CO Olanzapine ODT 20mg tab COB 5.937702321386 Novo-Olanzapine OD 20mg tab TEV 5.937702327805 Sandoz Olanzapine ODT 20mg tab SDZ 5.9377

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 52 of 77

Generic Name and Strength DIN Brand MFR MRP PRPolanzapine ODT 20mg tab (exception status)

02243089 Zyprexa Zydis 20mg tab LIL 5.9377

omeprazole 10mg cap 02119579 Losec 10mg cap AZE 0.550002329425 MYLAN-Omeprazole 10mg cap MYL 0.550002296438 Sandoz Omeprazole 10mg cap SDZ 0.5500

omeprazole 20mg cap 02245058 Apo-Omeprazole 20mg cap APX 1.100000846503 Losec 20mg cap AZE 1.100002329433 MYLAN-Omeprazole 20mg cap MYL 1.100002348691 Omeprazole 20mg cap SAS 1.100002320851 pms-Omeprazole 20mg cap PMS 1.100002296446 Sandoz Omeprazole 20mg cap SDZ 1.1000

omeprazole 10mg cap/tab 02230737 Losec 10mg tab AZE 0.816602329425 MYLAN-Omeprazole 10mg cap MYL 0.8166

omeprazole 20mg cap/tab 02245058 Apo-Omeprazole 20mg cap APX 1.100002190915 Losec 20mg tab AZE 1.100002329433 MYLAN-Omeprazole 20mg cap MYL 1.100002295415 Novo-Omeprazole Delayed-Release 20mg tab TEV 1.100002348691 Omeprazole 20mg cap SAS 1.100002310260 pms-Omeprazole DR 20mg tap PMS 1.100002260867 ratio-Omeprazole 20mg tab TEV 1.1000

ondansetron 4mg tab (exception status) 02288184 Apo-Ondansetron 4mg tab APX 4.089902296349 CO Ondansetron 4mg tab COB 4.089902313685 Jamp-Ondansetron 4mg tab JPC 4.089902305259 MINT- Ondansetron 4mg tab MNT 4.089902297868 MYLAN-Ondansetron 4mg tab MYL 4.089902264056 Novo-Ondansetron 4mg tab TEV 4.089902306212 Ondansetron-Odan 4mg tab ODN 4.089902278618 phl-Ondansetron 4mg tab PHL 4.089902258188 pms-Ondansetron 4mg tab PMS 4.089902312247 RAN-Ondansetron 4mg tab RAN 4.089902278529 ratio-Ondansetron 4mg tab TEV 4.089902274310 Sandoz Ondansetron 4mg tab SDZ 4.089902213567 Zofran 4mg tab GSK 4.0899

ondansetron 8mg tab (exception status) 02288192 Apo-Ondansetron 8mg tab APX 8.177702296357 CO Ondansetron 8mg tab COB 8.177702313693 Jamp-Ondansetron 8mg tab JPC 8.177702305267 MINT-Ondansetron 8mg tab MNT 8.177702297876 MYLAN-Ondansetron 8mg tab MYL 8.177702264064 Novo-Ondansetron 8mg tab TEV 8.177702306220 Ondansetron-Odan 8mg tab ODN 8.177702278626 phl-Ondansetron 8mg tab PHL 8.177702258196 pms-Ondansetron 8mg tab PMS 8.177702312255 RAN-Ondansetron 8mg tab RAN 8.177702278537 ratio-Ondansetron 8mg tab TEV 8.177702274329 Sandoz Ondansetron 8mg tab SDZ 8.1777

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 53 of 77

Generic Name and Strength DIN Brand MFR MRP PRPondansetron 8mg tab (exception status) 02213575 Zofran 8mg tab GSK 8.1777ondansetron 4mg ODT tab (exception status)

02239372 Zofran 4mg ODT tab GSK 4.0899

ondansetron 8mg ODT tab (exception status)

02239373 Zofran 8mg ODT tab GSK 8.1777

ondansetron 4mg/5mL o/l (exception status) 02291967 Ondansetron 4mg/5mL o/l AAP 1.585802229639 Zofran 4mg/5mL o/l GSK 1.5858

orciprenaline 2mg/mL syr 02236783 Apo-Orciprenaline 2mg/mL syr APX 0.0574oxazepam 15mg tab 00402745 Apo-Oxazepam 15mg tab APX 0.0550oxazepam 30mg tab 00402737 Apo-Oxazepam 30mg tab APX 0.0750oxcarbazepine 150mg tab (exception status) 02284294 Apo-Oxcarbazepine 150mg tab APX 0.6209

02242067 Trileptal 150mg tab NVR 0.6209oxcarbazepine 300mg tab (exception status) 02284308 Apo-Oxcarbazepine 300mg tab APX 1.2414

02242068 Trileptal 300mg tab NVR 1.2414oxcarbazepine 600mg tab (exception status) 02284316 Apo-Oxcarbazepine 600mg tab APX 2.4826

02242069 Trileptal 600mg tab NVR 2.4826oxybutynin 5mg tab 02163543 Apo-Oxybutynin 5mg tab APX 0.2485

02230800 MYLAN-Oxybutynin 5mg tab MYL 0.248502230394 Novo-Oxybutynin 5mg tab TEV 0.248502158590 Nu-Oxybutyn 5mg tab NXP 0.248502350238 Oxybutynin 5mg tab SAS 0.248502240550 pms-Oxbytynin 5mg tab PMS 0.2485

oxybutynin 1mg/mL o/l 02223376 pms-Oxybutynin 1mg/mL o/l PMS 0.1183oxycodone 5mg tab (Supeudol) 02319977 pms-Oxycodone 5mg tab PMS 0.1776

00789739 Supeudol 5mg tab SDZ 0.1776oxycodone 10mg tab (Supeudol) 02319985 pms-Oxycodone 10mg tab PMS 0.2760

00443948 Supeudol 10mg tab SDZ 0.2760oxycodone 5mg tab (Oxy-IR) 02231934 Oxy-IR 5mg tab PFR 0.1776

02319977 pms-Oxycodone 5mg tab PMS 0.1776oxycodone 10mg tab (Oxy-IR) 02240131 Oxy-IR 10mg tab PFR 0.2760

02319985 pms-Oxycodone 10mg tab PMS 0.2760oxycodone 20mg tab 02240132 Oxy-IR 20mg tab PFR 0.4358

02319993 pms-Oxycodone 20mg tab PMS 0.4358pantoprazole 20mg EC tab (exception status)

02292912 Apo-Pantoprazole 20mg DR tab APX 1.2750

02285479 Novo-Pantoprazole 20mg DR tab TEV 1.275002241804 Pantoloc 20mg DR tab NYC 1.275002305038 RAN-Pantoprazole 20mg DR tab RAN 1.275002308681 ratio-Pantoprazole 20mg DR tab (discontinued) TEV 1.275002301075 Sandoz Pantoprazole 20mg DR tab SDZ 1.2750

pantoprazole 40mg EC tab (exception status)

02292920 Apo-Pantoprazole 40mg DR tab APX 0.8087

02300486 CO Pantoprazole 40mg DR tab COB 0.808702299585 MYLAN-Pantoprazole 40mg DR tab MYL 0.808702285487 Novo-Pantoprazole 40mg DR tab TEV 0.8087

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 54 of 77

Generic Name and Strength DIN Brand MFR MRP PRPpantoprazole 40mg EC tab (exception status)

02229453 Pantoloc 40mg DR tab NYC 0.8087

02307871 pms-Pantoprazole 40mg DR tab PMS 0.808702305046 RAN-Pantoprazole 40mg DR tab RAN 0.808702308703 ratio-Pantoprazole 40mg DR tab (discontinued) TEV 0.808702301083 Sandoz Pantoprazole 40mg DR tab SDZ 0.8087

paroxetine 20mg tab 02240908 Apo-Paroxetine 20mg tab APX 0.722202262754 CO Paroxetine 20mg tab COB 0.722202248013 MYLAN-Paroxetine 20mg tab MYL 0.722202248557 Novo-Paroxetine 20mg tab TEV 0.722202282852 Paroxetine 20mg tab SAS 0.722201940481 Paxil 20mg tab GSK 0.722202248451 phl-Paroxetine 20mg tab PHL 0.722202247751 pms-Paroxetine 20mg tab PMS 0.722202247811 ratio-Paroxetine 20mg tab TEV 0.722202269430 Sandoz Paroxetine 20mg tab SDZ 0.7222

paroxetine 30mg tab 02240909 Apo-Paroxetine 30mg tab APX 0.767302262762 CO Paroxetine 30mg tab COB 0.767302248014 MYLAN-Paroxetine 30mg tab MYL 0.767302248558 Novo-Paroxetine 30mg tab TEV 0.767302282860 Paroxetine 30mg tab SAS 0.767301940473 Paxil 30mg tab GSK 0.767302248452 phl-Paroxetine 30mg tab PHL 0.767302247752 pms-Paroxetine 30mg tab PMS 0.767302247812 ratio-Paroxetine 30mg tab TEV 0.767302269449 Sandoz Paroxetine 30mg tab SDZ 0.7673

penicillin V potassium 300mg tab 00642215 Apo-Pen VK 300mg tab APX 0.071000021202 Novo-Pen-VK 300mg tab TEV 0.071000717568 Nu-Pen VK 300mg tab NXP 0.0710

penicillin V potassium 60mg/mL o/l 00642231 Apo-Pen VK 60mg/mL o/l APX 0.061800391603 Novo-Pen-VK 60mg/mL o/l TEV 0.0618

pentoxifylline 400mg tab (exception status) 02230090 Apo-Pentoxifylline 400mg SR tab APX 0.584602221977 Trental 400mg tab SAV 0.5846

perphenazine 4mg tab 00335126 Perphenazine 4mg tab AAP 0.0823pethidine 50mg/mL inj 00725765 Meperidine 50mg/mL inj SDZ 0.9600pethidine 75mg/mL inj 00725757 Meperidine 75mg/mL inj SDZ 1.0100pethidine 100mg/mL inj 00725749 Meperidine 100mg/mL inj SDZ 1.0700phenylephrine 10mg/mL inj 02241980 Neo-Synephrine 10mg/mL inj HOS 2.2600

01953583 Phenylephrine 10mg/mL inj SDZ 4.4300phenytoin 25mg/mL susp 00023450 Dilantin-125 25mg/mL susp PFI 0.0311

02250896 Taro-Phenytoin 25mg/mL susp TAR 0.0311pimozide 2mg tab 02245432 Apo-Pimozide 2mg tab APX 0.3093

00313815 Orap 2mg tab PHL 0.3093pimozide 4mg tab 02245433 Apo-Pimozide 4mg tab APX 0.4136

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 55 of 77

Generic Name and Strength DIN Brand MFR MRP PRPpimozide 4mg tab 00313823 Orap 4mg tab PHL 0.4136pindolol 5mg tab 00755877 Apo-Pindol 5mg tab APX 0.2283

00869007 Novo-Pindol 5mg tab TEV 0.228300886149 Nu-Pindol 5mg tab NXP 0.228302231536 pms-Pindolol 5mg tab PMS 0.228302261782 Sandoz Pindolol 5mg tab SDZ 0.228300417270 Visken 5mg tab NVR 0.2283

pindolol 10mg tab 00755885 Apo-Pindol 10mg tab APX 0.396500869015 Novo-Pindol 10mg tab TEV 0.396500886009 Nu-Pindol 10mg tab NXP 0.396502231537 pms-Pindolol 10mg tab PMS 0.396502261790 Sandoz Pindolol 10mg tab SDZ 0.396500443174 Visken 10mg tab NVR 0.3965

pindolol 15mg tab 00755893 Apo-Pindol 15mg tab APX 0.580400869023 Novo-Pindol 15mg tab TEV 0.580400886130 Nu-Pindol 15mg tab NXP 0.580402231539 pms-Pindolol 15mg tab PMS 0.580402261804 Sandoz Pindolol 15mg tab SDZ 0.580400417289 Visken 15mg tab NVR 0.5804

pioglitazone 15mg tab (exception status) 02242572 Actos 15mg tab LIL 0.951302302942 Apo-Pioglitazone 15mg tab APX 0.951302302861 CO Pioglitazone 15mg tab COB 0.951302326477 MINT-Pioglitazone 15mg tab MNT 0.951302298279 MYLAN-Pioglitazone 15mg tab MYL 0.951302274914 Novo-Pioglitazone 15mg tab TEV 0.951302307669 phl-Pioglitazone 15mg tab PHL 0.951302303124 pms-Pioglitazone 15mg tab PMS 0.951302301423 ratio-Pioglitazone 15mg tab TEV 0.951302297906 Sandoz Pioglitazone 15mg tab SDZ 0.951302320754 Zym-Pioglitazone 15mg tab ZYM 0.9513

pioglitazone 30mg tab (exception status) 02242573 Actos 30mg tab LIL 1.332802302950 Apo-Pioglitazone 30mg tab APX 1.332802302888 CO Pioglitazone 30mg tab COB 1.332802365529 Jamp-Pioglitazone 30mg tab JPC 1.332802326485 MINT-Pioglitazone 30mg tab MNT 1.332802298287 MYLAN-Pioglitazone 30mg tab MYL 1.332802274922 Novo-Pioglitazone 30mg tab TEV 1.332802307677 phl-Pioglitazone 30mg tab PHL 1.332802339587 Pioglitazone 30mg tab AHC 1.332802303132 pms-Pioglitazone 30mg tab PMS 1.332802301431 ratio-Pioglitazone 30mg tab TEV 1.332802297914 Sandoz Pioglitazone 30mg tab SDZ 1.332802320762 Zym-Pioglitazone 30mg tab ZYM 1.3328

pioglitazone 45mg tab (exception status) 02242574 Actos 45mg tab LIL 2.004002302977 Apo-Pioglitazone 45mg tab APX 2.0040

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 56 of 77

Generic Name and Strength DIN Brand MFR MRP PRPpioglitazone 45mg tab (exception status) 02302896 CO Pioglitazone 45mg tab COB 2.0040

02365537 Jamp-Pioglitazone 45mg tab JPC 2.004002326493 MINT-Pioglitazone 45mg tab MNT 2.004002298295 MYLAN-Pioglitazone 45mg tab MYL 2.004002274930 Novo-Pioglitazone 45mg tab TEV 2.004002307723 phl-Pioglitazone 45mg tab PHL 2.004002339595 Pioglitazone 45mg tab AHC 2.004002303140 pms-Pioglitazone 45mg tab PMS 2.004002301458 ratio-Pioglitazone 45mg tab TEV 2.004002297922 Sandoz Pioglitazone 45mg tab SDZ 2.004002320770 Zym-Pioglitazone 45mg tab ZYM 2.0040

piroxicam 10mg cap 00642886 Apo-Piroxicam 10mg cap APX 0.350000695718 Novo-Pirocam 10mg cap TEV 0.350000865761 Nu-Pirox 10mg cap NXP 0.3500

piroxicam 20mg cap 00642894 Apo-Piroxicam 20mg cap APX 0.700000695696 Novo-Pirocam 20mg cap TEV 0.700000865788 Nu-Pirox 20mg cap NXP 0.7000

piroxicam 20mg supp 02154463 pms-Piroxicam 20mg supp PMS 2.2329polymixin b sulfate, neomycin sulfate & gramicidin oph/otic sol

00807435 Optimyxin Plus oph/otic sol SDZ 0.8230

polymyxin b sulfate, neomycin sulfate & hydrocortisone otic sol

01912828 Cortisporin otic sol GSK 1.1400

02230386 Sandoz Cortimyxin otic sol SDZ 1.1400potassium chloride 1.33mEq/mL o/l 01918303 K-10 1.33mEq/mL o/l GSK 0.0158

02238604 pms-Potassium Chloride 1.33mEq/mL o/l PMS 0.0158pramipexole 0.25mg tab 02292378 Apo-Pramipexole 0.25mg tab APX 0.4205

02297302 CO Pramipexole 0.25mg tab COB 0.420502237145 Mirapex 0.25mg tab BOE 0.420502269309 Novo-Pramipexole 0.25mg tab TEV 0.420502290111 pms-Pramipexole 0.25mg tab PMS 0.420502315262 Sandoz Pramipexole 0.25mg tab SDZ 0.4205

pramipexole 1mg tab 02292394 Apo-Pramipexole 1mg tab APX 0.841102297329 CO Pramipexole 1mg tab COB 0.841102237146 Mirapex 1mg tab BOE 0.841102269325 Novo-Pramipexole 1mg tab TEV 0.841102290146 pms-Pramipexole 1mg tab PMS 0.841102315289 Sandoz Pramipexole 1mg tab SDZ 0.8411

pramipexole 1.5mg tab 02292408 Apo-Pramipexole 1.5mg tab APX 0.841102297337 CO Pramipexole 1.5mg tab COB 0.841102237147 Mirapex 1.5mg tab BOE 0.841102269333 Novo-Pramipexole 1.5mg tab TEV 0.841102290154 pms-Pramipexole 1.5mg tab PMS 0.841102315297 Sandoz Pramipexole 1.5mg tab SDZ 0.8411

pravastatin 10mg tab 02243506 Apo-Pravastatin 10mg tab APX 0.953002248182 CO Pravastatin 10mg tab COB 0.9530

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 57 of 77

Generic Name and Strength DIN Brand MFR MRP PRPpravastatin 10mg tab 02330954 Jamp-Pravastatin 10mg tab JPC 0.9530

02317451 MINT-Pravastatin 10mg tab MNT 0.953002257092 MYLAN-Pravastatin 10mg tab MYL 0.953002247008 Novo-Pravastatin 10mg tab TEV 0.953002244350 Nu-Pravastatin 10mg tab NXP 0.953002249766 phl-Pravastatin 10mg tab PHL 0.953002247655 pms-Pravastatin 10mg tab PMS 0.953000893749 Pravachol 10mg tab BRI 0.953002356546 Pravastatin 10mg tab SAS 0.953002284421 RAN-Pravastatin 10mg tab RAN 0.953002247856 Sandoz Pravastatin 10mg tab SDZ 0.9530

pravastatin 20mg tab 02243507 Apo-Pravastatin 20mg tab APX 1.124302248183 CO Pravastatin 20mg tab COB 1.124302330962 Jamp-Pravastatin 20mg tab JPC 1.124302317478 MINT-Pravastatin 20mg tab MNT 1.124302257106 MYLAN-Pravastatin 20mg tab MYL 1.124302247009 Novo-Pravastatin 20mg tab TEV 1.124302244351 Nu-Pravastatin 20mg tab NXP 1.124302249774 phl-Pravastatin 20mg tab PHL 1.124302247656 pms-Pravastatin 20mg tab PMS 1.124300893757 Pravachol 20mg tab BRI 1.124302356554 Pravastatin 20mg tab SAS 1.124302284448 RAN-Pravastatin 20mg tab RAN 1.124302247857 Sandoz Pravastatin 20mg tab SDZ 1.1243

pravastatin 40mg tab 02243508 Apo-Pravastatin 40mg tab APX 1.354302248184 CO Pravastatin 40mg tab COB 1.354302330970 Jamp-Pravastatin 40mg tab JPC 1.354302317486 MINT-Pravastatin 40mg tab MNT 1.354302257114 MYLAN-Pravastatin 40mg tab MYL 1.354302247010 Novo-Pravastatin 40mg tab TEV 1.354302244352 Nu-Pravastatin 40mg tab NXP 1.354302249782 phl-Pravastatin 40mg tab PHL 1.354302247657 pms-Pravastatin 40mg tab PMS 1.354302222051 Pravachol 40mg tab BRI 1.354302356562 Pravastatin 40mg tab SAS 1.354302284456 RAN-Pravastatin 40mg tab RAN 1.354302247858 Sandoz Pravastatin 40mg tab SDZ 1.3543

prazosin HCl 1mg tab 00882801 Apo-Prazo 1mg tab APX 0.205501934198 Novo-Prazin 1mg tab TEV 0.205501913794 Nu-Prazo 1mg tab NXP 0.2055

prazosin HCl 2mg tab 00882828 Apo-Prazo 2mg tab APX 0.279101934201 Novo-Prazin 2mg tab TEV 0.279101913808 Nu-Prazo 2mg tab NXP 0.2791

prazosin HCl 5mg tab 00882836 Apo-Prazo 5mg tab APX 0.380601934228 Novo-Prazin 5mg tab TEV 0.3806

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 58 of 77

Generic Name and Strength DIN Brand MFR MRP PRPprazosin HCl 5mg tab 01913816 Nu-Prazo 5mg tab NXP 0.3806prednisolone acetate 0.12% oph susp 00299405 Pred Mild 0.12% oph susp ALL 1.3450

01916181 Sandoz Prednisolone 0.12% oph susp SDZ 1.3450prednisolone acetate 1% oph susp 00301175 Pred Forte 1% oph susp ALL 1.9400

00700401 ratio-Prednisolone 1% oph susp TEV 1.940001916203 Sandoz Prednisolone 1% oph susp SDZ 1.9400

prednisolone sodium phosphare 1mg/mL o/l 02230619 Pediapred oral sol SAV 0.093602245532 pms-Prednisolone oral sol PMS 0.0936

prednisone 1mg tab 00598194 Apo-Prednisone 1mg tab APX 0.107200271373 Winpred 1mg tab VLN 0.1072

prednisone 5mg tab 00312770 Apo-Prednisone 5mg tab APX 0.040100021695 Novo-Prednisone 5mg tab TEV 0.0401

prednisone 50mg tab 00550957 Apo-Prednisone 50mg tab APX 0.173500232378 Novo-Prednisone 50mg tab TEV 0.1735

primidone 125mg tab 00399310 Primidone 125mg tab AAP 0.0600primidone 250mg tab 00396761 Primidone 250mg tab AAP 0.0944prochlorperazine 5mg tab 00886440 Apo-Prochlorazine 5mg tab APX 0.1659prochlorperazine 10mg tab 00886432 Apo-Prochlorazine 10mg tab APX 0.2025prochlorperazine 5mg/mL inj 00789747 Prochlorperazine 5mg/mL inj SDZ 1.0450procyclidine HCl 5mg tab 00587354 pms-Procyclidine 5mg tab PMS 0.1396procyclidine HCl 0.5mg/mL o/l 00587362 pms-Procyclidine 0.5mg/mL elx PMS 0.2730propafenone 150mg tab 02243324 Apo-Propafenone 150mg tab APX 0.4275

02245372 MYLAN-Propafenone 150mg tab MYL 0.427502294559 pms-Propafenone 150mg tab PMS 0.427502343053 Propafenone 150mg tab SAS 0.427500603708 Rythmol 150mg tab ABB 0.4275

propafenone 300mg tab 02243325 Apo-Propafenone 300mg tab APX 0.753702245373 MYLAN-Propafenone 300mg tab MYL 0.753702294575 pms-Propafenone 300mg tab PMS 0.753702343061 Propafenone 300mg tab SAS 0.753700603716 Rythmol 300mg tab ABB 0.7537

propranolol 10mg tab 00402788 Apo-Propranolol 10mg tab APX 0.019200496480 Novo-Pranol 10mg tab TEV 0.0192

propranolol 20mg tab 00663719 Apo-Propranolol 20mg tab APX 0.034600740675 Novo-Pranol 20mg tab TEV 0.0346

propranolol 40mg tab 00402753 Apo-Propranolol 40mg tab APX 0.034800496499 Novo-Pranol 40mg tab TEV 0.0348

propranolol 80mg tab 00402761 Apo-Propranolol 80mg tab APX 0.058500496502 Novo-Pranol 80mg tab TEV 0.0585

propranolol 120mg tab 00504335 Apo-Propranolol 120mg tab APX 0.3091quetiapine 25mg tab 02313901 Apo-Quetiapine 25mg tab APX 0.2033

02316080 CO Quetiapine 25mg tab COB 0.203302330415 Jamp-Quetiapine 25mg tab JPC 0.203302307804 MYLAN-Quetiapine 25mg tab MYL 0.2033

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 59 of 77

Generic Name and Strength DIN Brand MFR MRP PRPquetiapine 25mg tab 02284235 Novo-Quetiapine 25mg tab TEV 0.2033

02299054 phl-Quetiapine 25mg tab PHL 0.203302296551 pms-Quetiapine 25mg tab PMS 0.203302353164 Quetiapine 25mg tab SAS 0.203302311704 ratio-Quetiapine 25mg tab (discontinued) TEV 0.203302313995 Sandoz Quetiapine 25mg tab SDZ 0.203302236951 Seroquel 25mg tab AZE 0.2033

quetiapine 100mg tab 02313928 Apo-Quetiapine 100mg tab APX 0.542402316099 CO Quetiapine 100mg tab COB 0.542402330423 Jamp-Quetiapine 100mg tab JPC 0.542402307812 MYLAN-Quetiapine 100mg tab MYL 0.542402284243 Novo-Quetiapine 100mg tab TEV 0.542402299062 phl-Quetiapine 100mg tab PHL 0.542402296578 pms-Quetiapine 100mg tab PMS 0.542402353172 Quetiapine 100mg tab SAS 0.542402311712 ratio-Quetiapine 100mg tab (discontinued) TEV 0.542402314002 Sandoz Quetiapine 100mg tab SDZ 0.542402236952 Seroquel 100mg tab AZE 0.5424

quetiapine 200mg tab 02313936 Apo-Quetiapine 200mg tab APX 1.089102316110 CO Quetiapine 200mg tab COB 1.089102330458 Jamp-Quetiapine 200mg tab JPC 1.089102307839 MYLAN-Quetiapine 200mg tab MYL 1.089102284278 Novo-Quetiapine 200mg tab TEV 1.089102299089 phl-Quetiapine 200mg tab PHL 1.089102296594 pms-Quetiapine 200mg tab PMS 1.089102353199 Quetiapine 200mg tab SAS 1.089102311747 ratio-Quetiapine 200mg tab (discontinued) TEV 1.089102314010 Sandoz Quetiapine 200mg tab SDZ 1.089102236953 Seroquel 200mg tab AZE 1.0891

quetiapine 300mg tab 02313944 Apo-Quetiapine 300mg tab APX 1.589202316129 CO Quetiapine 300mg tab COB 1.589202330466 Jamp-Quetiapine 300mg tab JPC 1.589202307847 MYLAN-Quetiapine 300mg tab MYL 1.589202284286 Novo-Quetiapine 300mg tab TEV 1.589202299097 phl-Quetiapine 300mg tab PHL 1.589202296608 pms-Quetiapine 300mg tab PMS 1.589202353202 Quetiapine 300mg tab SAS 1.589202311755 ratio-Quetiapine 300mg tab (discontinued) TEV 1.589202314029 Sandoz Quetiapine 300mg tab SDZ 1.589202244107 Seroquel 300mg tab AZE 1.5892

quinine sulfate 200mg cap 00021008 Novo-Quinine 200mg cap TEV 0.2390quinine sulfate 300mg cap 00021016 Novo-Quinine 300mg cap TEV 0.3750rabeprazole 10mg EC tab 02345579 Apo-Rabeprazole 10mg EC tab APX 0.2675

02296632 Novo-Rabeprazole 10mg EC tab TEV 0.267502243796 Pariet 10mg EC tab JAN 0.2675

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 60 of 77

Generic Name and Strength DIN Brand MFR MRP PRPrabeprazole 10mg EC tab 02310805 pms-Rabeprazole 10mg EC tab PMS 0.2675

02356511 Rabeprazole EC 10mg tab SAS 0.267502298074 RAN-Rabeprazole 10mg EC tab RAN 0.267502314177 Sandoz Rabeprazole 10mg EC tab SDZ 0.2675

rabeprazole 20mg EC tab 02345587 Apo-Rabeprazole 20mg EC tab APX 0.535102296640 Novo-Rabeprazole 20mg EC tab TEV 0.535102243797 Pariet 20mg EC tab JAN 0.535102310813 pms-Rabeprazole 20mg EC tab PMS 0.535102356538 Rabeprazole EC 20mg tab SAS 0.535102298082 RAN-Rabeprazole 20mg EC tab RAN 0.535102314185 Sandoz Rabeprazole 20mg EC tab SDZ 0.5351

raloxifene 60mg tab (exception status) 02279215 Apo-Raloxifene 60mg tab APX 1.375202239028 Evista 60mg tab LIL 1.375202312298 Novo-Raloxifene 60mg tab TEV 1.375202358921 pms-Raloxifene 60mg tab PMS 1.3752

ramipril 1.25mg cap/tab 02221829 Altace 1.25mg cap SAV 0.277302251515 Apo-Ramipril 1.25mg cap APX 0.277302295482 CO Ramipril 1.25mg cap COB 0.277302331101 Jamp-Ramipril 1.25mg cap JPC 0.277302301148 MYLAN-Ramipril 1.25mg cap MYL 0.277302295369 pms-Ramipril 1.25mg cap PMS 0.277302310503 RAN-Ramipril 1.25mg cap RAN 0.277302287692 ratio-Ramipril 1.25mg cap TEV 0.277302291398 Sandoz Ramipril 1.25mg tab SDZ 0.2773

ramipril 2.5mg cap/tab 02221837 Altace 2.5mg cap SAV 0.320002251531 Apo-Ramipril 2.5mg cap APX 0.320002295490 CO Ramipril 2.5mg cap COB 0.320002331128 Jamp-Ramipril 2.5mg cap JPC 0.320002301156 MYLAN-Ramipril 2.5mg cap MYL 0.320002247945 Novo-Ramipril 2.5mg cap TEV 0.320002247917 pms-Ramipril 2.5mg cap PMS 0.320002310511 RAN-Ramipril 2.5mg cap RAN 0.320002287706 ratio-Ramipril 2.5mg cap TEV 0.320002291401 Sandoz Ramipril 2.5mg tab SDZ 0.3200

ramipril 5mg cap/tab 02221845 Altace 5mg cap SAV 0.320002251574 Apo-Ramipril 5mg cap APX 0.320002295504 CO Ramipril 5mg cap COB 0.320002331136 Jamp-Ramipril 5mg cap JPC 0.320002301164 MYLAN-Ramipril 5mg cap MYL 0.320002247946 Novo-Ramipril 5mg cap TEV 0.320002247918 pms-Ramipril 5mg cap PMS 0.320002310538 RAN-Ramipril 5mg cap RAN 0.320002287714 ratio-Ramipril 5mg cap (discontinued) TEV 0.320002291428 Sandoz Ramipril 5mg tab SDZ 0.3200

ramipril 10mg cap/tab 02221853 Altace 10mg cap SAV 0.4053

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 61 of 77

Generic Name and Strength DIN Brand MFR MRP PRPramipril 10mg cap/tab 02251582 Apo-Ramipril 10mg cap APX 0.4053

02295512 CO Ramipril 10mg cap COB 0.405302331144 Jamp-Ramipril 10mg cap JPC 0.405302301172 MYLAN-Ramipril 10mg cap MYL 0.405302247947 Novo-Ramipril 10mg cap TEV 0.405302247919 pms-Ramipril 10mg cap PMS 0.405302310546 RAN-Ramipril 10mg cap RAN 0.405302287722 ratio-Ramipril 10mg cap (discontinued) TEV 0.405302291436 Sandoz Ramipril 10mg tab SDZ 0.4053

ramipril 15mg cap 02281112 Altace 15mg cap SAV 0.813202325381 Apo-Ramipril 15mg cap APX 0.813202311194 ratio-Ramipril 15mg cap (discontinued) TEV 0.8132

ramipril 2.5mg & hydrochlorothiazide 12.5mg tab

02283131 Altace HCT 2.5/12.5mg SAV 0.2250

02342138 pms-Ramipril-HCTZ 2.5/12.5mg tab PMS 0.2250ramipril 5mg & hydrochlorothiazide 12.5mg tab

02283158 Altace HCT 5/12.5mg SAV 0.2263

02342146 pms-Ramipril-HCTZ 5/12.5mg tab PMS 0.2263ramipril 5mg & hydrochlorothiazide 25mg tab

02283174 Altace HCT 5/25mg tab SAV 0.226302342162 pms-Ramipril-HCTZ 5/25mg tab PMS 0.2263

ramipril 10mg & hydrochlorothiazide 12.5mg tab

02283166 Altace HCT 10/12.5mg tab SAV 0.2865

02342154 pms-Ramipril-HCTZ 10/12.5mg tab PMS 0.2865ramipril 10mg & hydrochlorothiazide 25mg tab

02283182 Altace HCT 10/25mg tab SAV 0.2865

02342170 pms-Ramipril-HCTZ 10/25mg tab PMS 0.2865ranitidine 150mg tab 00733059 Apo-Ranitidine 150mg tab APX 0.1800

02248570 CO Ranitidine 150mg tab COB 0.180002367378 Myl-Ranitidine 150mg tab MYL 0.180002207761 MYLAN-Ranitidine 150mg tab MYL 0.180000828564 Novo-Ranidine 150mg tab TEV 0.180000865737 Nu-Ranit 150mg tab NXP 0.180002242453 pms-Ranitidine 150mg tab PMS 0.180002336480 RAN-Ranitidine 150mg tab RAN 0.180002353016 Ranitidine 150mg tab SAS 0.180000828823 ratio-Ranitidine 150mg tab TEV 0.180002243229 Sandoz Ranitidine 150mg tab SDZ 0.180002212331 Zantac 150mg tab GSK 0.1800

ranitidine 300mg tab 00733067 Apo-Ranitidine 300mg tab APX 0.360002248571 CO Ranitidine 300mg tab COB 0.360002367386 Myl-Ranitidine 300mg tab MYL 0.360002207788 MYLAN-Ranitidine 300mg tab MYL 0.360000828556 Novo-Ranidine 300mg tab TEV 0.360000865745 Nu-Ranit 300mg tab NXP 0.360002242454 pms-Ranitidine 300mg tab PMS 0.360002336502 RAN-Ranitidine 300mg tab RAN 0.3600

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 62 of 77

Generic Name and Strength DIN Brand MFR MRP PRPranitidine 300mg tab 02353024 Ranitidine 300mg tab SAS 0.3600

00828688 ratio-Ranitidine 300mg tab TEV 0.360002243230 Sandoz Ranitidine 300mg tab SDZ 0.360002212358 Zantac 300mg tab GSK 0.3600

ranitidine 25mg/mL inj 02256711 Ranitidine 25mg/mL inj SDZ 1.331002212366 Zantac 25mg/mL inj GSK 1.3310

ranitidine 15mg/mL o/l 02280833 Apo-Ranitidine 15mg/mL o/l APX 0.093202242940 Novo-Ranidine 15mg/mL o/l TEV 0.093202212374 Zantac 15mg/mL o/l (discontinued) GSK 0.0932

rifampin 150mg cap 02091887 Rifadin 150mg cap SAV 0.655200393444 Rofact 150mg cap VLN 0.6552

rifampin 300mg cap 02092808 Rifadin 300mg cap SAV 1.031100343617 Rofact 300mg cap VLN 1.0311

risedronate 5mg tab (exception status) 02242518 Actonel 5mg tab WNC 1.389702298376 Novo-Risedronate 5mg tab TEV 1.3897

risedronate 30mg tab (exception status) 02239146 Actonel 30mg tab WNC 9.003402298384 Novo-Risedronate 30mg tab TEV 9.0034

risedronate 35mg tab (exception status) 02246896 Actonel 35mg tab WNC 4.720002353687 Apo-Risedronate 35mg tab APX 4.720002298392 Novo-Risedronate 35mg tab TEV 4.720002302209 pms-Risedronate 35mg tab PMS 4.720002319861 ratio-Risedronate 35mg tab TEV 4.720002327295 Sandoz-Risedronate 35mg tab SDZ 4.7200

risperidone 0.25mg tab 02282119 Apo-Risperidone 0.25mg tab APX 0.210302282585 CO Risperidone 0.25mg tab COB 0.210302359529 Jamp-Risperidone 0.25mg tab JPC 0.210302371766 Mar-Risperidone 0.25mg tab MAR 0.210302359790 MINT Risperidone 0.25mg tab MNT 0.210302282240 MYLAN-Risperidone 0.25mg tab MYL 0.210302282690 Novo-Risperidone 0.25mg tab TEV 0.210302258439 phl-Risperidone 0.25mg tab PHL 0.210302252007 pms-Risperidone 0.25mg tab PMS 0.210302280906 RAN-Risperidone 0.25mg tab RAN 0.210302328305 RBX-Risperidone 0.25mg tab RAN 0.210302240551 Risperdal 0.25mg tab JAN 0.210302356880 Risperidone 0.25mg tab SAS 0.210302303655 Sandoz Risperidone 0.25mg tab SDZ 0.2103

risperidone 0.5mg tab 02282127 Apo-Risperidone 0.5mg tab APX 0.352202282593 CO Risperidone 0.5mg tab COB 0.352202359537 Jamp-Risperidone 0.5mg tab JPC 0.352202371774 Mar-Risperidone 0.5mg tab MAR 0.352202359804 MINT Risperidone 0.5mg tab MNT 0.352202282259 MYLAN-Risperidone 0.5mg tab MYL 0.352202264188 Novo-Risperidone 0.5mg tab TEV 0.3522

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 63 of 77

Generic Name and Strength DIN Brand MFR MRP PRPrisperidone 0.5mg tab 02258447 phl-Risperidone 0.5mg tab PHL 0.3522

02252015 pms-Risperidone 0.5mg tab PMS 0.352202280914 RAN-Risperidone 0.5mg tab RAN 0.352202328313 RBX-Risperidone 0.5mg tab RAN 0.352202240552 Risperdal 0.5mg tab JAN 0.352202356899 Risperidone 0.5mg tab SAS 0.352202303663 Sandoz Risperidone 0.5mg tab SDZ 0.3522

risperidone 1mg tab 02282135 Apo-Risperidone 1mg tab APX 0.486602282607 CO Risperidone 1mg tab COB 0.486602359545 Jamp-Risperidone 1mg tab JPC 0.486602371782 Mar-Risperidone 1mg tab MAR 0.488602359812 MINT Risperidone 1mg tab MNT 0.486602282267 MYLAN-Risperidone 1mg tab MYL 0.486602264196 Novo-Risperidone 1mg tab TEV 0.486602258455 phl-Risperidone 1mg tab PHL 0.486602252023 pms-Risperidone 1mg tab PMS 0.486602280922 RAN-Risperidone 1mg tab RAN 0.486602328321 RBX-Risperidone 1mg tab RAN 0.486602025280 Risperdal 1mg tab JAN 0.486602356902 Risperidone 1mg tab SAS 0.486602279800 Sandoz Risperidone 1mg tab SDZ 0.4866

risperidone 2mg tab 02282143 Apo-Risperidone 2mg tab APX 0.971402282615 CO Risperidone 2mg tab COB 0.971402359553 Jamp-Risperidone 2mg tab JPC 0.971402371790 Mar-Risperidone 2mg tab MAR 0.971402359820 MINT Risperidone 2mg tab MNT 0.971402282275 MYLAN-Risperidone 2mg tab MYL 0.971402264218 Novo-Risperidone 2mg tab TEV 0.971402258463 phl-Risperidone 2mg tab PHL 0.971402252031 pms-Risperidone 2mg tab PMS 0.971402280930 RAN-Risperidone 2mg tab RAN 0.971402328348 RBX-Risperidone 2mg tab RAN 0.971402025299 Risperdal 2mg tab JAN 0.971402356910 Risperidone 2mg tab SAS 0.971402279819 Sandoz Risperidone 2mg tab SDZ 0.9714

risperidone 3mg tab 02282151 Apo-Risperidone 3mg tab APX 1.457202282623 CO Risperidone 3mg tab COB 1.457202359561 Jamp-Risperidone 3mg tab JPC 1.457202371804 Mar-Risperidone 3mg tab MAR 1.457202359839 MINT Risperidone 3mg tab MNT 1.457202282283 MYLAN-Risperidone 3mg tab MYL 1.457202264226 Novo-Risperidone 3mg tab TEV 1.457202258471 phl-Risperidone 3mg tab PHL 1.457202252058 pms-Risperidone 3mg tab PMS 1.457202280949 RAN-Risperidone 3mg tab RAN 1.4572

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 64 of 77

Generic Name and Strength DIN Brand MFR MRP PRPrisperidone 3mg tab 02328364 RBX-Risperidone 3mg tab RAN 1.4572

02025302 Risperdal 3mg tab JAN 1.457202356929 Risperidone 3mg tab SAS 1.457202279827 Sandoz Risperidone 3mg tab SDZ 1.4572

risperidone 4mg tab 02282178 Apo-Risperidone 4mg tab APX 1.943002282631 CO Risperidone 4mg tab COB 1.943002359588 Jamp-Risperidone 4mg tab JPC 1.943002371812 Mar-Risperidone 4mg tab MAR 1.943002359847 MINT Risperidone 4mg tab MNT 1.943002282291 MYLAN-Risperidone 4mg tab MYL 1.943002264234 Novo-Risperidone 4mg tab TEV 1.943002258498 phl-Risperidone 4mg tab PHL 1.943002252066 pms-Risperidone 4mg tab PMS 1.943002280957 RAN-Risperidone 4mg tab RAN 1.943002328372 RBX-Risperidone 4mg tab RAN 1.943002025310 Risperdal 4mg tab JAN 1.943002356937 Risperidone 4mg tab SAS 1.943002279835 Sandoz Risperidone 4mg tab SDZ 1.9430

risperidone ODT 1mg tab 02291789 pms-Risperidone ODT 1mg tab PMS 0.772502247705 Risperdal M-tab (1mg) JAN 0.7725

risperidone ODT 2mg tab 02291797 pms-Risperidone ODT 2mg tab PMS 1.528102247706 Risperdal M-tab (2mg) JAN 1.5281

risperidone 1mg/mL o/l 02280396 Apo-Risperidone 1mg/mL o/l APX 0.548802279266 pms-Risperidone 1mg/mL o/l PMS 0.548802236950 Risperdal 1mg/mL o/l JAN 0.5488

rivastigmine 1.5mg cap (exception status) 02336715 Apo-Rivastigmine 1.5mg cap APX 1.042402242115 Exelon 1.5mg cap NVR 1.042402332809 MYLAN-Rivastigmine 1.5mg cap MYL 1.042402305984 Novo-Rivastigmine 1.5mg cap TEV 1.042402306034 pms-Rivastigmine 1.5mg cap PMS 1.042402311283 ratio-Rivastigmine 1.5mg cap TEV 1.042402324563 Sandoz Rivastigmine 1.5mg cap SDZ 1.0424

rivastigmine 3mg cap (exception status) 02336723 Apo-Rivastigmine 3mg cap APX 1.042402242116 Exelon 3mg cap NVR 1.042402332817 MYLAN-Rivastigmine 3mg cap MYL 1.042402305992 Novo-Rivastigmine 3mg cap TEV 1.042402306042 pms-Rivastigmine 3mg cap PMS 1.042402311291 ratio-Rivastigmine 3mg cap TEV 1.042402324571 Sandoz Rivastigmine 3mg cap SDZ 1.0424

rivastigmine 4.5mg cap (exception status) 02336731 Apo-Rivastigmine 4.5mg cap APX 1.042402242117 Exelon 4.5mg cap NVR 1.042402332825 MYLAN-Rivastigmine 4.5mg cap MYL 1.042402306018 Novo-Rivastigmine 4.5mg cap TEV 1.042402306050 pms-Rivastigmine 4.5mg cap PMS 1.042402311305 ratio-Rivastigmine 4.5mg cap TEV 1.0424

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 65 of 77

Generic Name and Strength DIN Brand MFR MRP PRPrivastigmine 4.5mg cap (exception status) 02324598 Sandoz Rivastigmine 4.5mg cap SDZ 1.0424rivastigmine 6mg cap (exception status) 02336758 Apo-Rivastigmine 6mg cap APX 1.0424

02242118 Exelon 6mg cap NVR 1.042402332833 MYLAN-Rivastigmine 6mg cap MYL 1.042402306026 Novo-Rivastigmine 6mg cap TEV 1.042402306069 pms-Rivastigmine 6mg cap PMS 1.042402311313 ratio-Rivastigmine 6mg cap TEV 1.042402324601 Sandoz Rivastigmine 6mg cap SDZ 1.0424

ropinirole 0.25mg tab 02316846 CO Ropinirole 0.25mg tab COB 0.113502326590 pms-Ropinirole 0.25mg tab PMS 0.113502232565 ReQuip 0.25mg tab GSK 0.113502353040 Ropinirole 0.25mg tab SAS 0.1135

ropinirole 1mg tab 02316854 CO Ropinirole 1mg tab COB 0.454102326612 pms-Ropinirole 1mg tab PMS 0.454102232567 ReQuip 1mg tab GSK 0.454102353059 Ropinirole 1mg tab SAS 0.4541

ropinirole 2mg tab 02316862 CO Ropinirole 2mg tab COB 0.499602326620 pms-Ropinirole 2mg tab PMS 0.499602232568 ReQuip 2mg tab GSK 0.499602353067 Ropinirole 2mg tab SAS 0.4996

ropinirole 5mg tab 02316870 CO Ropinirole 5mg tab COB 1.375402326639 pms-Ropinirole 5mg tab PMS 1.375402232569 ReQuip 5mg tab NVR 1.375402353075 Ropinirole 5mg tab SAS 1.3754

salbutamol 100mcg/dose oral inh 02232570 Airomir 100mcg/dose oral inh GWP 0.032502245669 Apo-Salvent CFC Free 100mcg/dose oral inh APX 0.032502241497 Ventolin HFA 100mcg/dose oral inh GSK 0.0325

salbutamol 5mg/mL inh sol (exception status)

02069571 pms-Salbutamol 5mg/mL inh sol 10mL PMS 0.4012

00860808 ratio-Salbutamol 5mg/mL inh sol 10mL TEV 0.401202154412 Sandoz Salbutamol 5mg/mL inh sol 10mL SDZ 0.401202213486 Ventolin 5mg/mL inh sol 10mL GSK 0.4012

salbutamol 2mg tab 02146843 Apo-Salvent 2mg tab APX 0.1274salbutamol 4mg tab 02146851 Apo-Salvent 4mg tab APX 0.2134salbutamol 0.5mg/mL unit dose inh sol (exception status)

02208245 pms-Salbutamol 0.5mg/mL UD inh sol PMS 0.0334

02239365 ratio-Salbutamol 0.5mg/mL UD inh sol TEV 0.0334salbutamol 1mg/mL unit dose inh sol (exception status)

01926934 MYLAN-Salbutamol 1mg/mL UD inh sol MYL 0.0669

02208229 pms-Salbutamol 1mg/mL UD inh sol PMS 0.066901986864 ratio-Salbutamol 1mg/mL UD inh sol TEV 0.066902213419 Ventolin 1mg/mL UD inh sol GSK 0.0669

salbutamol 2mg/mL unit dose inh sol (exception status)

02173360 MYLAN-Salbutamol 2mg/mL UD inh sol MYL 0.1337

02208237 pms-Salbutamol 2mg/mL UD inh sol PMS 0.1337

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 66 of 77

Generic Name and Strength DIN Brand MFR MRP PRPsalbutamol 2mg/mL unit dose inh sol (exception status)

02239366 ratio-Salbutamol 2mg/mL UD inh sol TEV 0.1337

02213427 Ventolin 2mg/mL UD inh sol GSK 0.1337scopolamine 20mg/mL inj 02229868 Hyoscine Butylbromide 20mg/mL inj SDZ 4.5150selegiline 5mg tab 02230641 Apo-Selegiline 5mg tab APX 1.2650

02231036 MYLAN-Selegiline 5mg tab MYL 1.265002068087 Novo-Selegiline 5mg tab TEV 1.265002230717 Nu-Selegiline 5mg tab NXP 1.2650

sertraline 25mg cap 02238280 Apo-Sertraline 25mg cap APX 0.321602287390 CO Sertraline 25mg cap COB 0.321602273683 GD-Sertraline 25mg cap GMD 0.321602242519 MYLAN-Sertraline 25mg cap MYL 0.321602240485 Novo-Sertraline 25mg cap TEV 0.321602245824 phl-Sertraline 25mg cap PHL 0.321602244838 pms-Sertraline 25mg cap PMS 0.321602245787 ratio-Sertraline 25mg cap (discontinued) TEV 0.321602245159 Sandoz Sertraline 25mg cap SDZ 0.321602353520 Sertraline 25mg cap SAS 0.321602132702 Zoloft 25mg cap PFI 0.3216

sertraline 50mg cap 02238281 Apo-Sertraline 50mg cap APX 0.643202287404 CO Sertraline 50mg cap COB 0.643202273691 GD-Sertraline 50mg cap GMD 0.643202242520 MYLAN-Sertraline 50mg cap MYL 0.643202240484 Novo-Sertraline 50mg cap TEV 0.643202245825 phl-Sertraline 50mg cap PHL 0.643202244839 pms-Sertraline 50mg cap PMS 0.643202245788 ratio-Sertraline 50mg cap (discontinued) TEV 0.643202245160 Sandoz Sertraline 50mg cap SDZ 0.643202353539 Sertraline 50mg cap SAS 0.643201962817 Zoloft 50mg cap PFI 0.6432

sertraline 100mg cap 02238282 Apo-Sertraline 100mg cap APX 0.674002287412 CO Sertraline 100mg cap COB 0.674002273705 GD-Sertraline 100mg cap GMD 0.674002242521 MYLAN-Sertraline 100mg cap MYL 0.674002240481 Novo-Sertraline 100mg cap TEV 0.674002245826 phl-Sertraline 100mg cap PHL 0.674002244840 pms-Sertraline 100mg cap PMS 0.674002245789 ratio-Sertraline 100mg cap (discontinued) TEV 0.674002245161 Sandoz Sertraline 100mg cap SDZ 0.674002353547 Sertraline 100mg cap SAS 0.674001962779 Zoloft 100mg cap PFI 0.6740

sildenafil 20mg tab 02319500 ratio-Sildenafil-R 20mg tab TEV 7.439902279401 Revatio 20mg tab PFI 7.4399

simvastatin 5mg tab 02247011 Apo-Simvastatin 5mg tab APX 0.411402248103 CO Simvastatin 5mg tab COB 0.4114

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 67 of 77

Generic Name and Strength DIN Brand MFR MRP PRPsimvastatin 5mg tab 02331020 Jamp-Simvastatin 5mg tab JPC 0.4114

02246582 MYLAN-Simvastatin 5mg tab MYL 0.411402250144 Novo-Simvastatin 5mg tab TEV 0.411402281546 phl-Simvastatin 5mg tab PHL 0.411402269252 pms-Simvastatin 5mg tab PMS 0.411402329131 RAN-Simvastatin 5mg tab RAN 0.411402284723 Simvastatin 5mg tab SAS 0.411400884324 Zocor 5mg tab FRS 0.4114

simvastatin 10mg tab 02247012 Apo-Simvastatin 10mg tab APX 0.809302248104 CO Simvastatin 10mg tab COB 0.809302331039 Jamp-Simvastatin 10mg tab JPC 0.809302246583 MYLAN-Simvastatin 10mg tab MYL 0.809302250152 Novo-Simvastatin 10mg tab TEV 0.809302281554 phl-Simvastatin 10mg tab PHL 0.809302269260 pms-Simvastatin 10mg tab PMS 0.809302329158 RAN-Simvastatin 10mg tab RAN 0.809302247068 ratio-Simvastatin 10mg tab TEV 0.809302247828 Sandoz Simvastatin 10mg tab SDZ 0.809302284731 Simvastatin 10mg tab SAS 0.809300884332 Zocor 10mg tab FRS 0.8093

simvastatin 20mg tab 02247013 Apo-Simvastatin 20mg tab APX 1.000202248105 CO Simvastatin 20mg tab COB 1.000202331047 Jamp-Simvastatin 20mg tab JPC 1.000202246737 MYLAN-Simvastatin 20mg tab MYL 1.000202250160 Novo-Simvastatin 20mg tab TEV 1.000202281562 phl-Simvastatin 20mg tab PHL 1.000202269279 pms-Simvastatin 20mg tab PMS 1.000202329166 RAN-Simvastatin 20mg tab RAN 1.000202247069 ratio-Simvastatin 20mg tab (discontinued) TEV 1.000202247830 Sandoz Simvastatin 20mg tab SDZ 1.000202284758 Simvastatin 20mg tab SAS 1.000200884340 Zocor 20mg tab FRS 1.0002

simvastatin 40mg tab 02247014 Apo-Simvastatin 40mg tab APX 1.000202248106 CO Simvastatin 40mg tab COB 1.000202331055 Jamp-Simvastatin 40mg tab JPC 1.000202246584 MYLAN-Simvastatin 40mg tab MYL 1.000202250179 Novo-Simvastatin 40mg tab TEV 1.000202281570 phl-Simvastatin 40mg tab PHL 1.000202269287 pms-Simvastatin 40mg tab PMS 1.000202329174 RAN-Simvastatin 40mg tab RAN 1.000202247070 ratio-Simvastatin 40mg tab (discontinued) TEV 1.000202247831 Sandoz Simvastatin 40mg tab SDZ 1.000202284766 Simvastatin 40mg tab SAS 1.000200884359 Zocor 40mg tab FRS 1.0002

simvastatin 80mg tab 02247015 Apo-Simvastatin 80mg tab APX 1.0002

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 68 of 77

Generic Name and Strength DIN Brand MFR MRP PRPsimvastatin 80mg tab 02248107 CO Simvastatin 80mg tab COB 1.0002

02331063 Jamp-Simvastatin 80mg tab JPC 1.000202246585 MYLAN-Simvastatin 80mg tab MYL 1.000202250187 Novo-Simvastatin 80mg tab TEV 1.000202281589 phl-Simvastatin 80mg tab PHL 1.000202269295 pms-Simvastatin 80mg tab PMS 1.000202329182 RAN-Simvastatin 80mg tab RAN 1.000202247071 ratio-Simvastatin 80mg tab TEV 1.000202247833 Sandoz Simvastatin 80mg tab SDZ 1.000202284774 Simvastatin 80mg tab SAS 1.000202240332 Zocor 80mg tab FRS 1.0002

sodium aurothiomalate 10mg/mL inj 01927620 Myochrysine 10mg/mL inj SAV 9.660002245456 Sodium Aurothiomalate 10mg/mL inj SDZ 9.6600

sodium aurothiomalate 25mg/mL inj 02245457 Sodium Aurothiomalate 25mg/mL inj SDZ 11.7100sodium aurothiomalate 50mg/mL inj 01927604 Myochrysine 50mg/mL inj SAV 18.2100

02245458 Sodium Aurothiomalate 50mg/mL inj SDZ 18.2100sodium chloride, hypertonic 5% oph sol 00750824 MURO-128 5% oph sol BSH 0.5633

02245735 Sandoz Sodium Chloride 5% oph sol SDZ 0.5633sotalol 80mg tab 02210428 Apo-Sotalol 80mg tab APX 0.5932

02270625 CO Sotalol 80mg tab COB 0.593202229778 MYLAN-Sotalol 80mg tab MYL 0.593202231181 Novo-Sotalol 80mg tab TEV 0.593202200996 Nu-Sotalol 80mg tab NXP 0.593202238326 pms-Sotalol 80mg tab PMS 0.593202084228 ratio-Sotalol 80mg tab TEV 0.593202257831 Sandoz Sotalol 80mg tab SDZ 0.5932

sotalol 160mg tab 02167794 Apo-Sotalol 160mg tab APX 0.649202270633 CO Sotalol 160mg tab COB 0.649202229779 MYLAN-Sotalol 160mg tab MYL 0.649202231182 Novo-Sotalol 160mg tab TEV 0.649202163772 Nu-Sotalol 160mg tab NXP 0.649202238327 pms-Sotalol 160mg tab PMS 0.649202084236 ratio-Sotalol 160mg tab TEV 0.649202257858 Sandoz Sotalol 160mg tab SDZ 0.6492

spironolactone 25mg tab 00028606 Aldactone 25mg tab PFI 0.119400613215 Novo-Spiroton 25mg tab TEV 0.1194

spironolactone 100mg tab 00285455 Aldactone 100mg tab PFI 0.278000613223 Novo-Spiroton 100mg tab TEV 0.2780

sucralfate 1g tab 02125250 Apo-Sucralfate 1g tab APX 0.219902045702 Novo-Sucralate 1g tab TEV 0.219902134829 Nu-Sucralfate 1g tab NXP 0.219902100622 Sulcrate 1g tab AXC 0.2199

sufentanil citrate 50mcg/mL inj 02244147 Sufentanil Citrate 50mcg/mL inj SDZ 6.8300sulfamethoxazole 400mg & trimethoprim 80mg tab

00445274 Apo-Sulfatrim 400/80mg tab APX 0.0482

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 69 of 77

Generic Name and Strength DIN Brand MFR MRP PRPsulfamethoxazole 400mg & trimethoprim 80mg tab

00510637 Novo-Trimel 400/80mg tab TEV 0.0482

00865710 Nu-Cotrimox 400/80mg tab NXP 0.0482sulfamethoxazole 800mg & trimethoprim 160mg tab

00445282 Apo-Sulfatrim 800/160mg DS tab APX 0.1221

00510645 Novo-Trimel 800/160mg DS tab TEV 0.122100865729 Nu-Cotrimox 800/160mg DS tab NXP 0.1221

sulfamethoxazole 40mg & trimethoprim 8mg/mL o/l

00726540 Novo-Trimel 40/8mg susp TEV 0.0911

sulfinpyrazone 200mg tab 00441767 Sulfinpyrazone 200mg tab AAP 0.3252sulindac 150mg tab 00778354 Apo-Sulin 150mg tab APX 0.3500

00745588 Novo-Sundac 150mg tab TEV 0.350002042576 Nu-Sulindac 150mg tab NXP 0.3500

sulindac 200mg tab 00778362 Apo-Sulin 200mg tab APX 0.350000745596 Novo-Sundac 200mg tab TEV 0.350002042584 Nu-Sulindac 200mg tab NXP 0.3500

sumatriptan 50mg tab (exception status) 02268388 Apo-Sumatriptan 50mg tab APX 7.135002257890 CO Sumatriptan 50mg tab COB 7.135002212153 Imitrex DF 50mg tab GSK 7.135002268914 MYLAN-Sumatriptan 50mg tab MYL 7.135002286823 Novo-Sumatriptan DF 50mg tab TEV 7.135002256436 pms-Sumatriptan 50mg tab PMS 7.135002263025 Sandoz Sumatriptan 50mg tab SDZ 7.135002286521 Sumatriptan 50mg tab SAS 7.1350

sumatriptan 100mg tab (exception status) 02268396 Apo-Sumatriptan 100mg tab APX 7.860002257904 CO Sumatriptan 100mg tab COB 7.860002212161 Imitrex DF 100mg tab GSK 7.860002268922 MYLAN-Sumatriptan 100mg tab MYL 7.860002239367 Novo-Sumatriptan 100mg tab TEV 7.860002286831 Novo-Sumatriptan DF 100mg tab TEV 7.860002256444 pms-Sumatriptan 100mg tab PMS 7.860002263033 Sandoz Sumatriptan 100mg tab SDZ 7.860002286548 Sumatriptan 100mg tab SAS 7.8600

sumatriptan 12mg/mL inj (exception status) 02212188 Imitrex 6mg/0.5mL inj GSK 61.720002361698 Sumatriptan SUN 6mg/0.5mL inj TAR 61.7200

tamoxifen citrate 10mg tab 00812404 Apo-Tamox 10mg tab APX 0.175002088428 MYLAN-Tamoxifen 10mg tab MYL 0.175000851965 Novo-Tamoxifen 10mg tab TEV 0.1750

tamoxifen citrate 20mg tab 00812390 Apo-Tamox 20mg tab APX 0.350002089858 MYLAN-Tamoxifen 20mg tab MYL 0.350002048485 Nolvadex-D 20mg tab AZE 0.350000851973 Novo-Tamoxifen 20mg tab TEV 0.3500

temazepam 15mg cap 02225964 Apo-Temazepam 15mg cap APX 0.079902244814 CO Temazepam 15mg cap COB 0.079902230095 Novo-Temazepam 15mg cap TEV 0.0799

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 70 of 77

Generic Name and Strength DIN Brand MFR MRP PRPtemazepam 15mg cap 02243023 ratio-Temazepam 15mg cap TEV 0.0799

00604453 Restoril 15mg cap ORX 0.0799temazepam 30mg cap 02225972 Apo-Temazepam 30mg cap APX 0.0968

02244815 CO Temazepam 30mg cap COB 0.096802230102 Novo-Temazepam 30mg cap TEV 0.096802243024 ratio-Temazepam 30mg cap TEV 0.096800604461 Restoril 30mg cap ORX 0.0968

tenoxicam 20mg tab 02230661 Tenoxicam 20mg tab AAP 0.7000terazosin 1mg tab 02234502 Apo-Terazosin 1mg tab APX 0.2989

00818658 Hytrin 1mg tab ABB 0.298902233047 Nu-Terazosin 1mg tab NXP 0.298902243518 pms-Terazosin 1mg tab PMS 0.298902218941 ratio-Terazosin 1mg tab TEV 0.298902350475 Terazosin 1mg tab SAS 0.298902230805 Teva-Terazosin 1mg tab TEV 0.2989

terazosin 2mg tab 02234503 Apo-Terazosin 2mg tab APX 0.380000818682 Hytrin 2mg tab ABB 0.380002233048 Nu-Terazosin 2mg tab NXP 0.380002243519 pms-Terazosin 2mg tab PMS 0.380002218968 ratio-Terazosin 2mg tab TEV 0.380002350483 Terazosin 2mg tab SAS 0.380002230806 Teva-Terazosin 2mg tab TEV 0.3800

terazosin 5mg tab 02234504 Apo-Terazosin 5mg tab APX 0.516000818666 Hytrin 5mg tab ABB 0.516002233049 Nu-Terazosin 5mg tab NXP 0.516002243520 pms-Terazosin 5mg tab PMS 0.516002218976 ratio-Terazosin 5mg tab TEV 0.516002350491 Terazosin 5mg tab SAS 0.516002230807 Teva-Terazosin 5mg tab TEV 0.5160

terazosin 10mg tab 02234505 Apo-Terazosin 10mg tab APX 0.755300818674 Hytrin 10mg tab ABB 0.755302233050 Nu-Terazosin 10mg tab NXP 0.755302243521 pms-Terazosin 10mg tab PMS 0.755302218984 ratio-Terazosin 10mg tab TEV 0.755302350505 Terazosin 10mg tab SAS 0.755302230808 Teva-Terazosin 10mg tab TEV 0.7553

terbinafine 250mg tab (exception status) 02239893 Apo-Terbinafine 250mg tab APX 1.854502320134 Auro-Terbinafine 250mg tab ARO 1.854502254727 CO Terbinafine 250mg tab COB 1.854502031116 Lamisil 250mg tab NVR 1.854502242503 MYLAN-Terbinafine 250mg tab MYL 1.854502240346 Novo-Terbinafine 250mg tab TEV 1.854502294273 pms-Terbinafine 250mg tab PMS 1.854502262177 Sandoz Terbinafine 250mg tab SDZ 1.854502353121 Terbinafine 250mg tab SAS 1.8545

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 71 of 77

Generic Name and Strength DIN Brand MFR MRP PRPtestosterone cypionate 100mg/mL inj 00030783 Depo-Testosterone 100mg/mL inj PFI 2.3580

02246063 Testosterone Cypionate 100mg/mL inj SDZ 2.3580testosterone undercanoate 40mg cap 00782327 Andriol 40mg cap SCH 0.7649

02322498 pms-Testosterone 40mg cap PMS 0.7649tetracycline 250mg cap 00580929 Tetra 250mg cap AAP 0.0713theophylline 200mg SR tab 02230086 Novo-Theophyl SR 200mg tab TEV 0.1040theophylline 300mg SR tab 02230087 Novo-Theophyl SR 300mg tab TEV 0.1400thiamine (vit B1) 100mg/mL inj 02193221 Thiamiject 100mg/mL inj (OMG) OMG 1.1880

02243525 Thiamine 100mg/mL inj CYI 1.1880tiaprofenic acid 200mg tab 02136112 Apo-Tiaprofenic 200mg tab APX 0.2333

02179679 Novo-Tiaprofenic 200mg tab TEV 0.2333tiaprofenic acid 300mg tab 02136120 Apo-Tiaprofenic 300mg tab APX 0.3500

02179687 Novo-Tiaprofenic 300mg tab TEV 0.350002146886 Nu-Tiaprofenic 300mg tab NXP 0.3500

ticlopidine 250mg tab (exception status) 02237701 Apo-Ticlopidine 250mg tab APX 0.688502239744 MYLAN-Ticlopidine 250mg tab MYL 0.688502236848 Novo-Ticlopidine 250mg tab TEV 0.688502243587 Sandoz Ticlopidine 250mg tab (discontinued) SDZ 0.688502343045 Ticlopidine 250mg tab SAS 0.6885

timolol maleate 0.25% oph sol 00755826 Apo-Timop 0.25% oph sol APX 1.550000893773 MYLAN-Timolol 0.25% oph sol MYL 1.550002083353 pms-Timolol 0.25% oph sol PMS 1.550002166712 Sandoz Timolol 0.25% oph sol SDZ 1.5500

timolol maleate 0.5% oph sol 00755834 Apo-Timop 0.5% oph sol APX 1.457600893781 MYLAN-Timolol 0.5% oph sol (discontinued) MYL 1.457602083345 pms-Timolol 0.5% oph sol PMS 1.457602166720 Sandoz Timolol 0.5% oph sol SDZ 1.457600451207 Timoptic 0.5% oph sol FRS 1.4576

timolol maleate 5mg tab 00755842 Apo-Timol 5mg tab APX 0.181701947796 Novo-Timol 5mg tab TEV 0.181702044609 Nu-Timolol 5mg tab NXP 0.1817

timolol maleate 10mg tab 00755850 Apo-Timol 10mg tab APX 0.283501947818 Novo-Timol 10mg tab TEV 0.283502044617 Nu-Timolol 10mg tab NXP 0.2835

timolol maleate 20mg tab 00755869 Apo-Timol 20mg tab APX 0.567001947826 Novo-Timol 20mg tab TEV 0.5670

tizanidine 4mg tab (exception status) 02259893 Apo-Tizanidine 4mg tab APX 0.368602272059 MYLAN-Tizanidine 4mg tab MYL 0.368602239170 Zanaflex 4mg tab SQI 0.3686

tobramycin 10mg/mL inj 02241209 Tobramycin 10mg/mL inj SDZ 2.3150tobramycin 40mg/mL inj 02241210 Tobramycin 40mg/mL inj SDZ 3.2100tobramycin 0.3% oph sol 02239577 pms-Tobramycin 0.3% oph sol (discontinued) PMS 1.0480

02241755 Sandoz Tobramycin 0.3% oph sol SDZ 1.048000513962 Tobrex 0.3% oph sol ALC 1.0480

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 72 of 77

Generic Name and Strength DIN Brand MFR MRP PRPtolbutamide 500mg tab 00312762 Tolbutamide 500mg tab AAP 0.1182topiramate 25mg tab (exception status) 02279614 Apo-Topiramate 25mg tab APX 0.5005

02287765 CO Topiramate 25mg tab COB 0.500502315645 MINT-Topiramate 25mg tab MNT 0.500502263351 MYLAN-Topiramate 25mg tab MYL 0.500502248860 Novo-Topiramate 25mg tab TEV 0.500502271184 phl-Topiramate 25mg tab PHL 0.500502262991 pms-Topiramate 25mg tab PMS 0.500502260050 SandozTopiramate 25mg tab SDZ 0.500502230893 Topamax 25mg tab JAN 0.500502356856 Topiramate 25mg tab SAS 0.500502325136 Zym-Topiramate 25mg tab ZYM 0.5005

topiramate 100mg tab (exception status) 02279630 Apo-Topiramate 100mg tab APX 0.948602287773 CO Topiramate 100mg tab COB 0.948602315653 MINT-Topiramate 100mg tab MNT 0.948602263378 MYLAN-Topiramate 100mg tab MYL 0.948602248861 Novo-Topiramate 100mg tab TEV 0.948602271192 phl-Topiramate 100mg tab PHL 0.948602263009 pms-Topiramate 100mg tab PMS 0.948602260069 Sandoz Topiramate 100mg tab SDZ 0.948602230894 Topamax 100mg tab JAN 0.948602356864 Topiramate 100mg tab SAS 0.948602325144 Zym-Topiramate 100mg tab ZYM 0.9486

topiramate 200mg tab (exception status) 02279649 Apo-Topiramate 200mg tab APX 1.416602287781 CO Topiramate 200mg tab COB 1.416602315661 MINT-Topiramate 200mg tab MNT 1.416602263386 MYLAN-Topiramate 200mg tab MYL 1.416602248862 Novo-Topiramate 200mg tab TEV 1.416602271206 phl-Topiramate 200mg tab PHL 1.416602263017 pms-Topiramate 200mg tab PMS 1.416602267837 Sandoz Topiramate 200mg tab SDZ 1.416602230896 Topamax 200mg tab JAN 1.416602356872 Topiramate 200mg tab SAS 1.416602325152 Zym-Topiramate 200mg tab ZYM 1.4166

trazodone 50mg tab 02147637 Apo-Trazodone 50mg tab APX 0.221402231683 MYLAN-Trazodone 50mg tab MYL 0.221402144263 Novo-Trazodone 50mg tab TEV 0.221402165384 Nu-Trazodone 50mg tab NXP 0.221402236941 phl-Trazodone 50mg tab PHL 0.221401937227 pms-Trazodone 50mg tab PMS 0.221402348772 Trazodone 50mg tab SAS 0.2214

trazodone 100mg tab 02147645 Apo-Trazodone 100mg tab APX 0.395602231684 MYLAN-Trazodone 100mg tab MYL 0.395602144271 Novo-Trazodone 100mg tab TEV 0.395602165392 Nu-Trazodone 100mg tab NXP 0.3956

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 73 of 77

Generic Name and Strength DIN Brand MFR MRP PRPtrazodone 100mg tab 02236942 phl-Trazodone 100mg tab PHL 0.3956

01937235 pms-Trazodone 100mg tab PMS 0.395602348780 Trazodone 100mg tab SAS 0.3956

trazodone 150mg tab 02147653 Apo-Trazodone 150mg tab APX 0.581202144298 Novo-Trazodone 150mg tab TEV 0.581202165406 Nu-Trazodone-D 150mg tab NXP 0.581202348799 Trazodone 150mg tab SAS 0.5812

triamcinolone acetonide 0.1% oral paste 01964054 Oracort 0.1% Paste TAR 0.9267triamcinolone 10mg/mL inj 01999761 Kenalog-10 10mg/mL inj WSQ 2.6760

02229540 Triamcinolone 10mg/mL inj SDZ 2.6760triamcinolone 40mg/mL inj 01999869 Kenalog-40 40mg/mL inj WSQ 4.7700

01977563 Triamcinolone 40mg/mL inj CYI 4.770002229550 Triamcinolone 40mg/mL inj SDZ 4.7700

trifluoperazine 1mg tab 00345539 Trifluoperazine 1mg tab AAP 0.1454trifluoperazine 2mg tab 00312754 Trifluoperazine 2mg tab AAP 0.1908trifluoperazine 5mg tab 00312746 Trifluoperazine 5mg tab AAP 0.2526trifluoperazine 10mg tab 00326836 Trifluoperazine 10mg tab AAP 0.3028trifluridine 1% oph sol 02248529 Sandoz Trifluridine 1% oph sol SDZ 3.0625

00687456 Viroptic 1% oph sol THR 3.0625trimebutine 200mg tab 00803499 Modulon 200mg tab AXC 0.5680

02245664 Trimebutine 200mg tab AAP 0.5680trimethoprim 100mg tab 02243116 Trimethoprim 100mg tab AAP 0.2785trimethoprim 200mg tab 02243117 Trimethoprim 200mg tab AAP 0.5722trimipramine 12.5mg tab 00740799 Trimipramine 12.5mg tab AAP 0.2340trimipramine 25mg tab 00740802 Trimipramine 25mg tab AAP 0.3012trimipramine 50mg tab 00740810 Trimipramine 50mg tab AAP 0.5896trimipramine 75mg cap 02070987 Trimipramine 75mg tab AAP 0.7936trimipramine 100mg tab 00740829 Trimipramine 100mg tab AAP 1.0062tryptophan 500mg tab (exception status) 02248538 Apo-Tryptophan 500mg tab APX 0.3563

02240333 ratio-Tryptophan 500mg tab TEV 0.356302029456 Tryptan 500mg tab VLN 0.3563

tryptophan 1g tab (exception status) 02248539 Apo-Tryptophan 1g tab APX 0.712602237250 ratio-Tryptophan 1g tab TEV 0.712600654531 Tryptan 1g tab VLN 0.7126

tryptophan 500mg cap (exception status) 02248540 Apo-Tryptophan 500mg cap APX 0.356302240334 ratio-Tryptophan 500mg cap TEV 0.356300718149 Tryptan 500mg cap VLN 0.3563

ursodiol 250mg tab (exception status) 02273497 pms-Ursodiol C 250mg tab PMS 0.989402238984 Urso 250mg tab AXC 0.9894

ursodiol 500mg tab (exception status) 02273500 pms-Ursodiol C 500mg tab PMS 1.876802245894 Urso DS 500mg tab AXC 1.8768

valacyclovir 500mg tab 02295822 Apo-Valacyclovir 500mg tab APX 1.357102331748 CO-Valacyclovir 500mg tab COB 1.357102351579 MYLAN-Valacyclovir 500mg tab MYL 1.3571

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 74 of 77

Generic Name and Strength DIN Brand MFR MRP PRPvalacyclovir 500mg tab 02298457 pms-Valacyclovir 500mg tab PMS 1.3571

02219492 Valtrex 500mg tab GSK 1.3571valproic acid 250mg cap 02238048 Apo-Valproic 250mg cap APX 0.2225

00443840 Depakene 250mg cap ABB 0.222502184648 MYLAN-Valproic 250mg cap MYL 0.222502100630 Novo-Valproic 250mg cap TEV 0.222502237830 Nu-Valproic 250mg cap NXP 0.222502230768 pms-Valproic 250mg cap PMS 0.222502140047 ratio-Valproic 250mg cap (discontinued) TEV 0.2225

valproic acid 500mg EC cap 02218321 Novo-Valproic 500mg EC cap TEV 0.519702229628 pms-Valproic 500mg EC cap PMS 0.5197

valproic acid 50mg/mL syr 02238370 Apo-Valproic 50mg/mL syr APX 0.046400443832 Depakene 50mg/mL syr ABB 0.046402236807 pms-Valproic 50mg/mL syr PMS 0.046402140063 ratio-Valproic 50mg/mL syr TEV 0.0464

valsartan 80mg tab 02337495 CO Valsartan 80mg tab COB 0.478602244781 Diovan 80mg tab NVR 0.478602363100 RAN-Valsartan 80mg tab RAN 0.478602356759 Sandoz Valsartan 80mg tab SDZ 0.478602356651 Teva-Valsartan 80mg tab TEV 0.4786

valsartan 160mg tab 02337509 CO Valsartan 160mg tab COB 0.479702244782 Diovan 160mg tab NVR 0.479702363119 RAN-Valsartan 160mg tab RAN 0.479702356767 Sandoz Valsartan 160mg tab SDZ 0.479702356678 Teva-Valsartan 160mg tab TEV 0.4797

valsartan 320mg tab 02337517 CO Valsartan 320mg tab COB 0.466302289504 Diovan 320mg tab NVR 0.466302356775 Sandoz Valsartan 320mg tab SDZ 0.466302356686 Teva-Valsartan 320mg tab TEV 0.4663

valsartan 80mg & hydrochlorothiazide 12.5mg tab

02241900 Diovan-HCT 80/12.5mg tab NVR 0.4772

02356694 Sandoz Valsartan/HCT 80/12.5mg tab SDZ 0.477202356996 Teva-Valsartan/HCTZ 80/12.5mg tab TEV 0.4772

valsartan 160mg & hydrochlorothiazide 12.5mg tab

02241901 Diovan-HCT 160/12.5mg tab NVR 0.4788

02356708 Sandoz Valsartan/HCT 160/12.5mg tab SDZ 0.478802357003 Teva-Valsartan/HCTZ 160/12.5mg tab TEV 0.4788

valsartan 160mg & hydrochlorothiazide 25mg tab

02246955 Diovan-HCT 160/25mg tab NVR 0.4776

02356716 Sandoz Valsartan/HCT 160/25mg tab SDZ 0.477602357011 Teva-Valsartan/HCTZ 160/25mg tab TEV 0.4776

valsartan 320mg & hydrochlorothiazide 12.5mg tab

02308908 Diovan-HCT 320/12.5 tab NVR 0.4804

02356724 Sandoz Valsartan/HCT 320/12.5mg tab SDZ 0.480402357038 Teva-Valsartan/HCTZ 320/12.5mg tab TEV 0.4804

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 75 of 77

Generic Name and Strength DIN Brand MFR MRP PRPvalsartan 320mg & hydrochlorothiazide 25mg tab

02308916 Diovan-HCT 320/25mg tab NVR 0.4776

02356732 Sandoz Valsartan/HCT 320/25mg tab SDZ 0.477602357046 Teva-Valsartan/HCTZ 320/25mg tab TEV 0.4776

vancomycin HCI 500mg/vial inj 02230191 Sterile Vancomycin HCI 500mg/vial inj HOS 33.689302342855 Val-Vanco 500mg/vial inj VAL 33.6893

vancomycin HCI 1g/vial inj 02230192 Sterile Vancomycin HCI 1g/vial inj HOS 64.004202342863 Val-Vanco 1000mg/vial inj VAL 64.0042

vancomycin 500mg/vial inj 02241820 pms-Vancomycin 500mg/vial inj PMS 33.6893vancomycin 1g/vial inj 02241821 pms-Vancomycin 1g/vial inj PMS 64.0042venlafaxine 37.5mg ER cap 02331683 Apo-Venlafaxine 37.5mg XR cap APX 0.3632

02304317 CO Venlafaxine 37.5mg XR cap COB 0.363202237279 Effexor 37.5mg XR cap WAY 0.363202310279 MYLAN-Venlafaxine 37.5mg XR cap MYL 0.363202275023 Novo-Venlafaxine 37.5mg XR cap TEV 0.363202278545 pms-Venlafaxine 37.5mg XR cap PMS 0.363202273969 ratio-Venlafaxine 37.5mg XR cap TEV 0.363202310317 Sandoz Venlafaxine 37.5mg XR cap SDZ 0.363202354713 Venlafaxine 37.5mg XR cap SAS 0.3632

venlafaxine 75mg ER cap 02331691 Apo-Venlafaxine 75mg XR cap APX 0.726402304325 CO Venlafaxine 75mg XR cap COB 0.726402237280 Effexor 75mg XR cap WAY 0.726402310287 MYLAN-Venlafaxine 75mg XR cap MYL 0.726402275031 Novo-Venlafaxine 75mg XR cap TEV 0.726402278553 pms-Venlafaxine 75mg XR cap PMS 0.726402273977 ratio-Venlafaxine 75mg XR cap TEV 0.726402310325 Sandoz Venlafaxine 75mg XR cap SDZ 0.726402354721 Venlafaxine 75mg XR cap SAS 0.7264

venlafaxine 150mg ER cap 02331705 Apo-Venlafaxine 150mg XR cap APX 0.766902304333 CO Venlafaxine 150mg XR cap COB 0.766902237282 Effexor 150mg XR cap WAY 0.766902310295 MYLAN-Venlafaxine 150mg XR cap MYL 0.766902275058 Novo-Venlafaxine 150mg XR cap TEV 0.766902278561 pms-Venlafaxine 150mg XR cap PMS 0.766902273985 ratio-Venlafaxine 150mg XR cap TEV 0.766902310333 Sandoz Venlafaxine 150mg XR cap SDZ 0.766902354748 Venlafaxine 150mg XR cap SAS 0.7669

verapamil HCl 80mg tab 00782483 Apo-Verap 80mg tab APX 0.273502237921 MYLAN-Verapamil 80mg tab MYL 0.273500886033 Nu-Verap 80mg tab NXP 0.2735

verapamil HCl 120mg tab 00782491 Apo-Verap 120mg tab APX 0.425002237922 MYLAN-Verapamil 120mg tab MYL 0.425000886041 Nu-Verap 120mg tab NXP 0.4250

verapamil 180mg SR tab 02246894 Apo-Verap 180mg SR tab APX 0.619801934317 Isoptin 180mg SR tab ABB 0.6198

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 76 of 77

Generic Name and Strength DIN Brand MFR MRP PRPverapamil 180mg SR tab 02210355 MYLAN-Verapamil 180mg SR tab MYL 0.6198verapamil 240mg SR tab 02246895 Apo-Verap 240mg SR tab APX 0.8266

00742554 Isoptin 240mg SR tab ABB 0.826602210363 MYLAN-Verapamil 240mg SR tab MYL 0.826602211920 Novo-Veramil 240mg SR tab TEV 0.826602237791 pms-Verapamil 240mg SR tab PMS 0.8266

warfarin 1mg tab 02242924 Apo-Warfarin 1mg tab APX 0.127301918311 Coumadin 1mg tab BRI 0.127302244462 MYLAN-Warfarin 1mg tab MYL 0.127302265273 Novo-Warfarin 1mg tab TEV 0.127302242680 Taro-Warfarin 1mg tab TAR 0.127302344025 Warfarin 1mg tab SAS 0.1273

warfarin 2mg tab 02242925 Apo-Warfarin 2mg tab APX 0.134601918338 Coumadin 2mg tab BRI 0.134602244463 MYLAN-Warfarin 2mg tab MYL 0.134602265281 Novo-Warfarin 2mg tab TEV 0.134602242681 Taro-Warfarin 2mg tab TAR 0.134602344033 Warfarin 2mg tab SAS 0.1346

warfarin 2.5mg tab 02242926 Apo-Warfarin 2.5mg tab APX 0.107801918346 Coumadin 2.5mg tab BRI 0.107802244464 MYLAN-Warfarin 2.5mg tab MYL 0.107802265303 Novo-Warfarin 2.5mg tab TEV 0.107802242682 Taro-Warfarin 2.5mg tab TAR 0.107802344041 Warfarin 2.5mg tab SAS 0.1078

warfarin 3mg tab 02245618 Apo-Warfarin 3mg tab APX 0.166902240205 Coumadin 3mg tab BRI 0.166902287498 MYLAN-Warfarin 3mg tab MYL 0.166902265311 Novo-Warfarin 3mg tab TEV 0.166902242683 Taro-Warfarin 3mg tab TAR 0.166902344068 Warfarin 3mg tab SAS 0.1669

warfarin 4mg tab 02242927 Apo-Warfarin 4mg tab APX 0.166902007959 Coumadin 4mg tab BRI 0.166902244465 MYLAN-Warfarin 4mg tab MYL 0.166902265338 Novo-Warfarin 4mg tab TEV 0.166902242684 Taro-Warfarin 4mg tab TAR 0.166902344076 Warfarin 4mg tab SAS 0.1669

warfarin 5mg tab 02242928 Apo-Warfarin 5mg tab APX 0.108001918354 Coumadin 5mg tab BRI 0.108002244466 MYLAN-Warfarin 5mg tab MYL 0.108002265346 Novo-Warfarin 5mg tab TEV 0.108002242685 Taro-Warfarin 5mg tab TAR 0.108002344084 Warfarin 5mg tab SAS 0.1080

warfarin 6mg tab 02240206 Coumadin 6mg tab BRI 0.175302287501 MYLAN-Warfarin 6mg tab MYL 0.175302242686 Taro-Warfarin 6mg tab TAR 0.1753

REIMBURSEMENT LIST - February 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective February 1, 2012 Page 77 of 77

Generic Name and Strength DIN Brand MFR MRP PRPwarfarin 7.5mg tab 02287528 MYLAN-Warfarin 7.5mg tab MYL 0.3014

02242697 Taro-Warfarin 7.5mg tab TAR 0.301402344106 Warfarin 7.5mg tab SAS 0.3014

warfarin 10mg tab 02242929 Apo-Warfarin 10mg tab APX 0.193701918362 Coumadin 10mg tab BRI 0.193702244467 MYLAN-Warfarin 10mg tab MYL 0.193702242687 Taro-Warfarin 10mg tab TAR 0.193702344114 Warfarin 10mg tab SAS 0.1937

zolmitriptan 2.5mg tab (exception status) 02369036 MYLAN-Zolmitriptan 2.5mg tab MYL 5.486702324229 pms-Zolmitriptan 2.5mg tab PMS 5.486702362988 Sandoz Zolmitriptan 2.5mg tab SDZ 5.486702313960 Teva-Zolmitriptan 2.5mg tab TEV 5.486702238660 Zomig 2.5mg tab AZE 5.4867

zolmitriptan ODT 2.5mg tab (exception status)

02324768 pms-Zolmitriptan ODT 2.5mg tab PMS 5.4867

02362996 Sandoz Zolmitriptan ODT 2.5mg tab SDZ 5.486702342545 Teva-Zolmitriptan OD 2.5mg tab TEV 5.486702243045 Zomig Rapimelt 2.5mg tab AZE 5.4867

zopiclone 5mg tab 02245077 Apo-Zopiclone 5mg tab APX 0.223102271931 CO Zopiclone 5mg tab COB 0.223102216167 Imovane 5mg tab SAV 0.223102296616 MYLAN-Zopiclone 5mg tab MYL 0.223102251450 Novo-Zopiclone 5mg tab TEV 0.223102294052 phl-Zopiclone 5mg tab PHL 0.223102243426 pms-Zopiclone 5mg tab PMS 0.223102267918 RAN-Zopiclone 5mg tab RAN 0.223102246534 ratio-Zopiclone 5mg tab TEV 0.223102257572 Sandoz Zopiclone 5mg tab SDZ 0.223102344122 Zopiclone 5mg tab SAS 0.2231

FEBRUARY 2012 • VOLUME 12-02 PHARMACISTS’ EDITION

Palliative Home Care Drug Program Included with this Bulletin

Palliative Home Care Medication Authorization Form

Direct Deposit Form

Palliative Home Care Drug Program Coverage of palliative care symptom control medications helps to ensure individuals followed by the palliative care program and who choose end of life care at home are able to do so. As a result, effective February 1, 2012, the province has introduced the Palliative Home Care Drug Coverage Program. This program will cover the full cost of drugs intended for use in end of life care at home. In order to be eligible for the program, patients must reside in Nova Scotia and have a valid health card number. Eligibility will be determined by a palliative care nurse or palliative care physician. Once patients are approved for coverage, the nurse or physician will complete a Medication Authorization form and forward to the community pharmacist. This form lists all of the approved medication classifications that will be covered under the program for the patient. Only medications that are in the classifications on the form will be eligible. A valid prescription is required for medications that can be purchased over the counter. A copy of the form is included with this bulletin. The form provides authorization for the pharmacy to bill the cost of the approved medications, and is good for six months from the date of issue. The pharmacy will bill the Department of Health and Wellness directly for all approved medications. Pharmacies will be reimbursed for the total cost submitted for any claims dated February 1, 2012 or later. Pharmacare pricing policies, such as PRP, will not apply and the drugs will not be subject to exception status criteria. There will be no cost to the patient for approved medications. In order to be reimbursed, pharmacies must complete the pharmacy contact information on the form and must submit a copy of the Medication Authorization form, along with the original prescription receipts to:

Palliative Home Care Drug Coverage Program c/o Pharmaceutical Services, Department of Health and Wellness

1690 Hollis Street, PO Box 488 Halifax, NS

B3J 2R8

PAGE 2 OF 2 PHARMACISTS’ EDITION

VOLUME 12-02

. Palliative Home Care Drug Coverage Continued… To ensure efficient processing of claims, pharmacies are encouraged to sign up for payment of claims through direct deposit. Although pharmacies may already be set up for direct payment for other Pharmacare Programs, a separate authorization is required for the Palliative Care Drug Program. A copy of the direct deposit form is included with this bulletin. A webinar information session is being planned for the near future. Further details will be provided as they become available. Please contact Pharmaceutical Services at 902-424-1596 with any questions.

Palliative Care Drug Program Pharmaceutical Services, Department of Health and Wellness 1690 Hollis Street PO Box 488 Halifax NS B3J 2R8 Phone: 902 424-1596

PALLIATIVE HOME CARE DRUG COVERAGE MEDICATION AUTHORIZATION

Client Information

Name HCN

DOB

Address

Community Pharmacy Information

Name of Pharmacy Phone

Contact Person Fax

Address

Billing Instructions

Bill the Department of Health and Wellness for the out of pocket costs for following medications ONLY:

Analgesics opioid analgesics, NSAID,

acetaminophen

Dermatological Agents corticosteroids, antifungal,

antipruritic, antibiotic

Respiratory Agents cough preparations, bronchodilators,

antihistamines

Gastrointestinal Agents

antidiarrheal, antiemetic (including octreotide), antispasmodic, laxatives,

PPI, H2 blockers

CNS Agents anticonvulsants, antidepressants,

antipsychotics, stimulants, sedatives and hypnotics

Cardiovascular Agents antiarrythmics, nitrates, beta blockers,

calcium channel blockers, diuretics, ACE inhibitors, ARB

Corticosteroids for dermatologic and systemic use,

inhaled corticosteroids

Coagulating Agents warfarin, heparin, LMWH

Anti-infective Agents (for dermatologic and systemic use)

antibiotics, antivirals, antifungals

Hemorrhoid Therapy

Diabetes Agents Bone Metabolism Regulators bisphosphonates

This authorization is valid for SIX MONTHS from the date written. Any medications after that date or additional medications will require a new authorization form. Authorized by DHA

(Palliative Care Nurse or Palliative Care Physician-Print Name)

Date Phone Fax Please submit invoices with original prescription receipts and a copy of this Authorization to:

Palliative Care Drug Program Pharmaceutical Services, Department of Health and Wellness 1690 Hollis Street PO Box 488 Halifax NS B3J 2R8 Phone: 902 424-1596

PALLIATIVE HOME CARE DRUG COVERAGE MEDICATION AUTHORIZATION

Client Information

Name HCN

DOB

Address

Community Pharmacy Information

Name of Pharmacy Phone

Contact Person Fax

Address

Billing Instructions

Bill the Department of Health and Wellness for the out of pocket costs for following medications ONLY:

Analgesics opioid analgesics, NSAID,

acetaminophen

Dermatological Agents corticosteroids, antifungal,

antipruritic, antibiotic

Respiratory Agents cough preparations, bronchodilators,

antihistamines

Gastrointestinal Agents

antidiarrheal, antiemetic (including octreotide), antispasmodic, laxatives,

PPI, H2 blockers

CNS Agents anticonvulsants, antidepressants,

antipsychotics, stimulants, sedatives and hypnotics

Cardiovascular Agents antiarrythmics, nitrates, beta blockers,

calcium channel blockers, diuretics, ACE inhibitors, ARB

Corticosteroids for dermatologic and systemic use,

inhaled corticosteroids

Coagulating Agents warfarin, heparin, LMWH

Anti-infective Agents (for dermatologic and systemic use)

antibiotics, antivirals, antifungals

Hemorrhoid Therapy

Diabetes Agents Bone Metabolism Regulators bisphosphonates

This authorization is valid for SIX MONTHS from the date written. Any medications after that date or additional medications will require a new authorization form. Authorized by DHA

(Palliative Care Nurse or Palliative Care Physician-Print Name)

Date Phone Fax Please submit invoices with original prescription receipts and a copy of this Authorization to:

Authorized signature:

Printed name:

Title:

Date:

orY Y Y Y / M M / D D

Canadian Banking

Bank Account Information for Deposits

Please attach a blank cheque with your bank information on it. Write void across the front.

Type of Account: m Chequing m Savings

Authorize Electronic Funds PaymentsI authorize the Department of Finance to deposit, by electronic fund transfer, payments owed to me by the Province of Nova Scotia and, if necessary, to debit entries and adjustments for amounts deposited electronically in error. The department will deposit the payments in the banking account designated above. I recognize that if I give incomplete or inaccurate information on this form, payments may be made to the wrong account.

For accounts without cheques, have your bank complete the following:

Type of Account: m Chequing m Savings

Name of bank or other financial institution:

Address of branch where account is held:

Transit No.: Institution No.:

Account No.:

Teller Stamp:

or

ChequeNo. TransitNo. InstitutionNo. AccountNo.

NameP.O.BoxCity,CanadaH0H0H0

Pay to the order of ________________________________________ $ ___________________

_________________________________________________________________________ Dollars

Signature

E x a m p l E

“000” “00000” 000 0000 000

ChequeNo. 0000

Void

Direct Deposit Authorization for Electronic Funds Transfer (EFT) Use this form to

m Start direct deposit payments m Change information previously submitted.

Effective date:

Contact informationVendor number (if known):

Name of company or person to receive payment:

Street Address:

Contact person: Phone:

Title or position: Fax:

Confirmation of DepositsYour statement of account from your bank will show payments from The Province of Nova Scotia. If you give us your e-mail address, we will send you e-mail confirmation whenever we deposit a payment to your account.

E-mail address for confirmation of deposit: OR

m I do not wish to receive confirmation.

Fax or mail completed form and voided cheque to Attention: Vendor Master Fax number: (902) 424-8601

Mailing address: Department of Finance, 5th Floor, Government Accounting PO Box 187, Halifax, Nova Scotia, Canada B3J 2N3

Questions? Call (902) 424-5998 or e-mail [email protected] Re

vise

d F

eb, 2

010

FEBRUARY 2012 • VOLUME 12-03 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

OxyContin®/OxyNEO® Communication

Exception Status Drugs

New Products

New Ostomy Products

Product Name and Manufacturer Change

Non-Insured Products

Transition Fees

Changes to the Nova Scotia Formulary on the Pharmacare Website

Nova Scotia Formulary Updates OxyContin®/OxyNEO® Communication The Atlantic Expert Advisory Committee (AEAC) has reviewed OxyNEO® and recommended that it not be listed on the Nova Scotia Pharmacare Formulary. Effective March 1, 2012, under the Nova Scotia Pharmacare Programs, there will be no new starts for OxyContin® or OxyNEO®. Nova Scotia Pharmacare beneficiaries who are currently receiving OxyContin ® (who have received coverage in the 3 months prior to March 1, 2012) will be eligible to receive coverage of OxyNEO®. The Nova Scotia Pharmacare Program will consider requests for long acting oxycodone (OxyContin® or OxyNeo®) on a case-by-case basis for cancer or palliative pain when other alternatives on the Formulary have failed or are not appropriate. OxyNEO® is not interchangeable with OxyContin®. Nova Scotia Pharmacare beneficiaries changing to OxyNEO® will require a new prescription if their physician deems it appropriate to continue, but will not need a new Exception Status Drug Request as their approved coverage for OxyContin® will apply to OxyNEO®. As well, all existing part-fill prescriptions for OxyContin® will have to be rewritten for OxyNEO® for patients who are currently on OxyContin® once the supply of OxyContin® is depleted. A comprehensive review of oxycodone is being done. The results of this study will address the appropriate place in therapy for oxycodone products for pain management. Exception Status Drugs Certain drugs are only eligible for coverage under the Pharmacare Programs when an individual meets criteria developed by the Atlantic or Canadian Expert Advisory Committees. A list of drugs is included in the Nova Scotia Formulary as Appendix III, “Criteria for Coverage of Exception Status Drugs” and they are indicated by “E” in the benefit status column of the Formulary.

PAGE 2 OF 4 PHARMACISTS’ EDITION

VOLUME 12-03

Exception Status Drugs Continued… Copies of the standard exception status drug (ESD) request form, Pharmacist ESD request form, and special forms for specific drugs are included in the Formulary, and can also be found on the Nova Scotia Pharmacare website at www.nspharmacare.ca. Requests for Coverage To request coverage, the prescriber should mail or fax a completed request form or letter to the Pharmacare office. Pharmacists may complete an exception status form on behalf of the beneficiary; however, the form must be signed by the prescriber. Prescribers may also contact the Pharmacare office and speak directly to an Exception Status Drug Analyst or a Pharmacist Consultant to request coverage. The prescriber must provide the following information as part of the request:

beneficiary identification, including Nova Scotia Health Card number diagnosis drug requested criteria met other pertinent information

If the Pharmacist is the prescriber of a medication that requires special authorization for payment, the Pharmacist may submit a request for coverage for review. The request must include all of the above, as well as clearly indicate:

that the Pharmacist is the prescriber of the medication the Pharmacist’s name and NSCP license number the pharmacy name and provider number the mailing address (for written confirmation of response)

Written confirmation of the outcome of the review is provided to the prescriber of the medication. It is, therefore, very important that Pharmacists provide an appropriate mailing address on each request, to ensure that the confidential response is delivered to them or other designated pharmacy staff. Coverage for non-benefit drugs may also be considered for coverage in exceptional circumstances following a written request from the prescriber. Prescribers may also contact the Pharmacare office and speak directly to a Pharmacist Consultant to request coverage. Notification Beneficiaries are notified only if the request is approved. Beneficiaries may bring this letter to the pharmacy to verify that coverage has been approved or the Pharmacist may simply bill the claim on-line for immediate response. The prescriber is notified in all cases (if coverage is authorized, if the request is refused because the criteria for coverage is not met, or if more information is required). The notification will include the name and strength of the drug approved as well as the term for coverage.

PAGE 3 OF 4 PHARMACISTS’ EDITION

VOLUME 12-03

Exception Status Drugs Continued… Billing Once authorization is approved, the claim for the exception status drug is billed on-line to the Pharmacare Programs. Usual copayment and deductible rules apply. If the beneficiary has received the drug while awaiting authorization and the request is eventually approved, the beneficiary can seek reimbursement if the original receipt is forwarded to the Pharmacare Office within six months of the date purchased. Likewise, coverage may also be backdated to a maximum of three months or the first of the month of registration (whichever is less). New Products The following products are new listings to the Nova Scotia Formulary, effective February 27, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Botox® 50 unit/vial Inj 00999443 DNP E (SF) ALL

Hydromorph Contin® 4.5mg Cap 02359502 D SFC PFR

Hydromorph Contin® 9mg Cap 02359510 D SFC PFR

pms-Mirtazepine 15mg Tab 02273942 DNP SFC PMS

pms-Quetiapine 50mg Tab 02361892 DNP SF PMS

Synthroid® 0.137mg Tab 02233852 DNP SF ABB

New Ostomy Products The following products are new listings to the Nova Scotia Formulary, effective February 27, 2012.

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Mouldable Rings (3.0mm) 95098252 12030 DNP SFC COL Mouldable Rings (4.2mm) 95098251 12042 DNP SFC COL

PAGE 4 OF 4 PHARMACISTS’ EDITION

VOLUME 12-03

Product Name and Manufacturer Change Please note that effective immediately, the following product has undergone a name and manufacturer change. The DIN for this product remains the same. PRODUCT MFR DIN NEW PRODUCT NAME NEW MFR

Lanoxin 0.05mg/mL Elx PMS 02242320 Toloxin 0.05mg/mL Sol MMT Non-Insured Products The following products were reviewed by the Atlantic Expert Advisory Committee (AEAC) and were not recommended to be listed as benefits under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

TOBI® 300mg/5mL Sol 02239630 N/A Not Insured NVR TOBI® Podhaler® 28mg Cap 02365154 N/A Not insured NVR

Decision Highlights Current available evidence does not clearly show superiority of any one formulation over another with regards to efficacy or safety

TOBI is approximately ten times the cost of IV tobramycin A well designed comparative trial is required to justify the increased cost of

TOBI compared to the IV tobramycin formulation Transition Fees for the Period of January 1, 2012 to March 31, 2012 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.25 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees. Changes to the Nova Scotia Formulary on the Pharmacare Website Beginning February 2, 2012, the Nova Scotia Formulary will only appear on the Nova Scotia Pharmacare website (www.nspharmacare.ca) in Portable Document Format (PDF). It will continue to be updated monthly. In order to view PDF files, you need to have Adobe® Reader installed on your computer. Instructions to download this free software is provided on the Formulary site. To search for specific text and page content in the PDF version of the Formulary you can:

Right click the document and choose “Find” from the pop-up menu. In the upper right of the window, enter your search term and click the arrows to navigate to each instance.

Perform a more complex search for whole words, phrases, comments, and other options by doing either of the following:

In a web browser, click the binoculars at the left of the window. If the binoculars are not there, right click the document and choose “Show Navigation Pane Buttons”

In the Adobe® Reader application, choose Edit > Advanced Search

APRIL 2012 • VOLUME 12-04 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

Cholinesterase Inhibitors (ChEI) Exception Status Criteria and Process Revisions

Palliative Home Care Drug Coverage Program Update

Nova Scotia Pharmacare Programs

Transition Fees

Understanding Generic Drugs

Included with this Bulletin

New ChEI Request Forms Generic Drugs: Your Questions Answered Similarities and Differences Between Brand Name and Generic Drugs What are Bioavailability and Bioequivelance?

Nova Scotia Formulary Updates

Cholinesterase Inhibitors (ChEI) Exception Status Criteria and Process Revisions This bulletin is to advise of changes to the exception status criteria and process for reimbursement of ChEI under the Nova Scotia Provincial Pharmacare Programs. These changes will be effective April 1, 2012. Exception Status Criteria Change A review of the ChEI was undertaken in order to ensure that the exception status criteria are in line with the current medical evidence. As a result, several changes to the current exception status criteria were recommended. Effective April 1, 2012 the exception status criteria will change to the following: Donepezil, Galantamine, Rivastigmine For the treatment of mild to moderate probable Alzheimer’s disease or possible Alzheimer’s disease with vascular component, with Lewy bodies who meet the following criteria:

• a Mini-Mental State Examination (MMSE) score of 10 to 30 AND • a Functional Assessment Staging Test (FAST) score of 4 to 5

Initial requests for reimbursement will be considered for a maximum 4 month approval; subsequent requests may be considered for a maximum 12 month approval. Requests to switch from one agent in the class to another will not be considered beyond the initial 4 month approval The following qualitative information will also be requested: At initial re-assessment:

• Is this patient benefitting from drug therapy? Yes / No Please Describe

At subsequent re-assessment:

• Is the patient benefitting from drug therapy? Yes / No

PAGE 2 OF 5 PHARMACISTS’ EDITION

VOLUME 12-04

Exception Status Criteria Change Continued… Switching Agents Currently Nova Scotia Pharmacare accepts requests to change from one agent to another at any point in therapy; however, the literature demonstrates that intolerance to an agent is identified early in therapy. Therefore switching will only be permitted during the first four month approval period. It was noted that there is no definitive evidence that these drugs, when given at equipotent doses, will have differences in their adverse effects. Target Symptoms Target symptoms will no longer be required; however physicians will be asked at the initial and subsequent reassessments if, in their opinion, the patient is benefiting from drug therapy. Exception Status Forms Please note that the ChEI request forms have been updated, with the number of forms reduced from four to two, with one for initiation of therapy and one for continuation of therapy. PATIENT SPECIFIC RENEWAL FORMS WILL NO LONGER BE AUTOMATICALLY MAILED TO THE PHYSICIAN’S OFFICE. It will be the responsibility of the physician to acquire and complete a renewal request form. Requests must be submitted on the appropriate exception status request form. Copies are attached to this bulletin and are also available under “Exception Status Drugs” on the website at www.nspharmacare.ca. Functional Assessment and Staging Tool (FAST) The Functional Assessment and Staging Tool (FAST) score is a measure of a patient’s functional ability.

Adapted from: Reisberg, B. Functional Assessment Staging (FAST). Psychopharmacology Bulletin 1988;24(4):653-9

FAST STAGE FUNCTIONAL IMPAIRMENT DUE TO COGNITIVE DEFICIT (NOT PHYSICAL)

4 Mild IADLs: needs assistance (Instrumental Activities of Daily Living include complex tasks such as managing money and medications, shopping, cooking, driving, housekeeping, using telephone)

5 Moderate Re-wearing clothes; requires assistance in such basic tasks of daily life as choosing proper clothing. Patient can no longer function independently.

6 Moderately Severe

ADLs: needs assistance, especially with dressing and bathing (i.e. unable to bathe properly; inability to handle the mechanics of toileting); eventually experiences urinary and fecal incontinence (Activities of Daily Living include dressing, washing, toileting, feeding, mobility)

7 Severe Non-verbal, non-ambulatory

PAGE 3 OF 5 PHARMACISTS’ EDITION

VOLUME 12-04

Stage 4: Patients with mild Alzheimer’s disease may demonstrate problems with recent memory, which impairs their ability to manage their instrumental activities of daily living (IADL).

These patients may still be quite capable of managing their own basic activities of daily living (ADL).

This would be associated with a FAST of 4.

Stage 5: Patient exhibits deficient performance in such basic tasks of daily life such as choosing proper clothing, and assistance is required for independent community living. Functional Impairment is due to cognitive deficit and not a physical deficit.

• The caregiver must help the patient choose appropriate clothing for the occasion or season. (e.g. the patient will wear incongruous clothing)

• Over the course of this stage some patients may begin to forget to bathe regularly, unless reminded.

• Patients at this stage are still capable of putting on their clothing properly, once it has been selected for them. They are also capable of bathing themselves although they may have been reminded to bathe.

• This should represent a change from previous behaviour.

Note: Patients with moderate Alzheimer’s disease will have more difficulty with their IADL and may require cueing to manage their basic ADL (e.g., assistance to choose proper clothing) but are able to complete the task with some degree of independence. This would be associated with a FAST of 5.

Stage 6: Decreased ability to dress, bathe, and toilet independently

Substage 6(a): Decreased ability to put on clothing properly. Patient requires actual physical assistance in putting on clothing properly. As the illness advances, increasing assistance from caregivers is needed to help the patients clothe themselves properly (e.g. putting on clothing in the proper sequence, putting shoes on proper feet, buttoning or zipping clothing).

Substage 6(b): Decreased ability to bathe independently. Ability to properly adjust the bathwater, enter and exit the bath, wash properly, and completely dry oneself declines. Patient may have a fear of bathing.

Substage 6(c): Decreased ability to perform mechanics of toileting independently. Patients at this stage begin to forget to flush the toilet. They may also begin to forget to wipe themselves or wipe themselves improperly when toileting. The caregiver begins to assist the patient in the mechanics of toileting.

Substage 6(d): Urinary incontinence and 6(e): Fecal Incontinence. This is in the absence of infection or other genitourinary tract, or gastrointestinal, pathology. The patient has episodes of incontinence. Note: If there is a reason unrelated to Alzheimer’s dementia that a patient meets the criteria for a score of 6 on the FAST scale (e.g., they have urinary incontinence secondary to pre-existing stress incontinence, or dressing difficulties due to arthritis), that criterion should be ignored when determining the patient’s FAST stage.

Adapted from: www.calgaryhealthregion.ca/.../e02form102591functionalassessmentstaging.doc and Sclan and Reisberg, International Psychogeratrics Vol4. Supp 1. 1992.

PAGE 4 OF 5 PHARMACISTS’ EDITION

VOLUME 12-04

Palliative Home Care Drug Coverage Program Update In the February 2012 Pharmacare News Bulletin, we provided details of the Palliative Home Care Drug Coverage Program. This program was effective February 1, 2012, and covers the full cost of drugs intended for use in end-of-life care at home. A complete list of the eligible medications is now available on the members only section of the Pharmacy Association of Nova Scotia (PANS) website. After April 1, 2012, only those medications that are on the list will be paid under the program. Pharmacies are also reminded that:

A valid prescription is required for medications that can be purchased over-the-counter, and an official prescription receipt is required for reimbursement.

The program does not provide coverage for any supplies or medical equipment.

Please contact Pharmaceutical Services at 902-424-1596 with any questions regarding the program. Nova Scotia Pharmacare Programs Nova Scotia Pharmacare Programs run from April 1st to March 31st each year. Eligibility for each program varies but participants must be a permanent resident of Nova Scotia and have a valid Nova Scotia Health Card. Seniors’ Pharmacare Program There are no premium or copayment increases in the Seniors’ Pharmacare Program this year. The premium remains at $424 and the copayment remains at 30% per prescription to a maximum of $382 per year. Renewal packages have been sent to all seniors currently enrolled in the Seniors’ Pharmacare Program. For specific information on the Seniors’ Pharmacare Program, please call either 496-7002 or toll free 1-800-544-6191. Information may also be accessed from the website at www.nspharmacare.ca Family Pharmacare Program Nova Scotia Family Pharmacare Program is available to all Nova Scotia residents who are not currently enrolled in another Pharmacare Program (except the Drug Assistance for Cancer Patients). Residents may also enroll in Family Pharmacare as secondary insurance if they already have private insurance. There are no upfront costs or premiums when registering with the Nova Scotia Family Pharmacare Program. Annual deductible and copayment maximums are determined by family size and income. For specific information on the Family Pharmacare Program, please call either 496-5667 or toll-free1-877-330-0323. Information may also be accessed from the website at www.nspharmacare.ca Transition Fees for the period of April 1, 2012 to March 31, 2013 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.75 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

PAGE 5 OF 5 PHARMACISTS’ EDITION

VOLUME 12-04

Understanding Generic Drugs The Canadian Agency for Drugs and Technologies and Health (CADTH) has developed handouts for both patients and health professionals, which help to answer common questions about generic drugs. You can access these handouts through the following links: http://www.cadth.ca/resources/generics Generic Drugs: Your Questions Answered: http://www.cadth.ca/en/resources/generics/your-questions-answered Similarities and Differences Between Brand Name and Generic Drugs: http://www.cadth.ca/en/resources/generics/similarities What are Bioavailability and Bioequivelance?: http://www.cadth.ca/media/pdf/Generic_prof_supplement_en.pdf For your convenience, copies of these handouts have been included with this bulletin.

03/2012

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

First Request for Cholinesterase Inhibitor Please provide the following to support your request for initial 4 month coverage of a cholinesterase inhibitor

P A T I E N T I N F O R M A T I O N

PATIENT SURNAME

PATIENT GIVEN NAME

HEALTH CARD NUMBER

DATE OF BIRTH

PATIENT ADDRESS

D I A G N O S T I C I N F O R M A T I O N - C O M P L E T E A L L The cause of the patient’s dementia is (check as appropriate):

Probable Alzheimer’s Disease Possible Alzheimer’s Disease with vascular component Possible Alzheimer’s Disease with Lewy bodies Possible Alzheimer’s Disease with other – specify: _________________________

MMSE Score ___________ Date ___________ FAST Score _________ Date __________

FAST Stage Functional Impairment due to cognitive deficit (NOT PHYSICAL DEFICIT)

4 Mild IADLs: needs assistance (Instrumental Activities of Daily Living include complex tasks such as managing money and medications, shopping, cooking, driving, housekeeping, using telephone)

5 Moderate Re-wearing clothes; requires assistance in such basic tasks of daily life as choosing proper clothing. Assistance is required for independent community living.

6 Severe ADLs: needs hands-on assistance, especially with dressing and bathing, due to cognitive impairment; eventually experiences urinary and fecal incontinence (Activities of Daily Living include dressing, washing, toileting, feeding, mobility)

7 Very Severe (End Stage)

Non-verbal, non-ambulatory

Only patients with a FAST score of 4 or 5 are eligible for coverage for cholinesterase inhibitors. Adapted from: Reisberg, B. Functional Assessment Staging. Psychopharmacology Bulletin. 1988.

C H O L I N E S T E R A S E I N H I B I T O R

Has this patient been on a cholinesterase inhibitor before? YES since ___________ NO Is this a switch to a different agent due to intolerance? YES NO If “YES”, please describe the intolerance: A switch to a second cholinesterase inhibitor agent will only be considered for reimbursement during the first four month approval period.

Cholinesterase inhibitor requested and starting dosage

Donepezil (Aricept®) Dosage: _______________________________

Galantamine (Reminyl ER®

and generics) Dosage: _______________________________

Rivastigmine (Exelon® and generics) Dosage: _______________________________

PHYSICIAN NAME & ADDRESS:

CPSNS # PHYSICIAN SIGNATURE DATE

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1 Fax: (902) 468-9402

03/2012

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Renewal of a Cholinesterase Inhibitor Please provide the following to support your request for renewal of a cholinesterase inhibitor

P A T I E N T I N F O R M A T I O N

PATIENT SURNAME

PATIENT GIVEN NAME

HEALTH CARD NUMBER

DATE OF BIRTH

PATIENT ADDRESS

MMSE & FAST (complete both)

MMSE Score ___________ Date ___________ FAST Score _________ Date __________

FAST Stage Functional Impairment due to cognitive deficit (NOT PHYSICAL DEFICIT)

4 Mild IADLs: needs assistance (Instrumental Activities of Daily Living include complex tasks such as managing money and medications, shopping, cooking, driving, housekeeping, using telephone)

5 Moderate Re-wearing clothes; requires assistance in such basic tasks of daily life as choosing proper clothing. Assistance is required for independent community living.

6 Severe ADLs: needs hands-on assistance, especially with dressing and bathing, due to cognitive impairment; eventually experiences urinary and fecal incontinence (Activities of Daily Living include dressing, washing, toileting, feeding, mobility)

7 Very Severe (End Stage)

Non-verbal, non-ambulatory

Only patients with a FAST score of 4 or 5 are eligible for coverage for cholinesterase inhibitors. Adapted from: Reisberg, B. Functional Assessment Staging. Psychopharmacology Bulletin. 1988.

E V I D E N C E O F B E N E F I T

Is the patient benefitting from this drug? YES or NO

Only for initial re-assessment. Not required for subsequent annual re-assessments. Please describe: * benefit can be based on caregiver report or cognitive testing; consider cognitive, functional, behavioural, social and leisure domains

When is it time to consider discontinuing the cholinesterase inhibitor?

If MMSE <10 OR FAST ≥6 (not eligible for coverage) OR

there is no initial improvement after 3-6 months of drug therapy OR

the patient has a rapid decline in cognitive or functional symptoms OR

rapid decline in MMSE (>3points in 6 months) or FAST

C H O L I N E S T E R A S E I N H I B I T O R

Cholinesterase inhibitor being continued and current dosage

Donepezil (Aricept®) Dosage: _______________________________

Galantamine (Reminyl ER®

and generics) Dosage: _______________________________

Rivastigmine (Exelon® and generics) Dosage: _______________________________

PHYSICIAN NAME & ADDRESS:

CPSNS # PHYSICIAN SIGNATURE DATE

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1 Fax: (902) 468-9402

MAY 2012 • VOLUME 12-05 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

Pharmacy Provider Numbers Criteria Update: Olanzapine Criteria Update: Terbinafine Criteria Update: Revlimid® New Exception Status Benefits New Products New Diabetic Products Non-Insured Products Palliative Home Care Drug Coverage Program Transition Fees

Nova Scotia Formulary Updates Pharmacy Provider Numbers Effective immediately, pharmacies must provide their provider number when calling Nova Scotia Pharmacare. No patient information will be released, including eligibility, status of ESD requests, claims, and billing information, unless the provider number is given. This is to ensure that we are protecting and safeguarding confidential information. Thank you for your cooperation. Criteria Update: Olanzapine Please note that effective immediately, the exception status criteria for olanzapine ODT will change to be consistent with the olanzapine tablet criteria:

Product Strength DIN Prescriber Benefit Status MFR

Olanzapine ODT (Zyprexa® Zydis® and generic brands)

5mg 10mg 15mg 20mg

DNP DNP DNP DNP

E (SF) E (SF) E (SF) E (SF)

Criteria For the treatment of schizophrenia and related psychotic disorders upon the written request of a psychiatrist, either first line or upon failure of other antipsychotic agents

For the acute treatment of manic or mixed episodes in bipolar I disorder in patients with intolerance or a history of failure to one other atypical antipsychotic

For maintenance therapy in patients with bipolar disease who are currently stabilized on olanzapine

Decision Highlights

Olanzapine ODT is similar in price to the regular olanzapine tablets

PAGE 2 OF 5 PHARMACISTS’ EDITION

VOLUME 12-05

Criteria Update: Terbinafine The following product was reviewed by the Atlantic Expert Advisory Committee (AEAC) and will be listed with the following new criteria, effective May 4, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Terbinafine (Lamisil® and generic brands)

250mg Tab DNP E (SF)

Criteria For the treatment of severe onychomycosis caused by dermatophyte fungi (Suggested treatment periods: 6 weeks for fingernails and 12 weeks for toenails. Longer periods of time will be considered on a case by case basis)

For the treatment of dermatophyte infection unresponsive to other treatments or unlikely to respond to other treatments due to the site or severity of the infection

Criteria Update: Revlimid® The following products were reviewed by the Cancer Systemic Therapy Policy Committee (CSTPC) and will be listed with the following new criteria, effective May 4, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Revlimid® (lenalidomide)

5mg Cap 10mg Cap 15mg Cap 25mg Cap

02304899 02304902 02317699 02317710

DNP DNP DNP DNP

E (SFC) E (SFC) E (SFC) E (SFC)

CEL CEL CEL CEL

Criteria In combination with dexamethasone in adult patients with progressive multiple myeloma (MM) after at least one previous treatment, not resistant to dexamethasone, documented measurable disease and an ECOG performance status of 0-2

As a single agent in adult myelodysplastic syndrome (MDS) patients with transfusion dependent anemia due to low or intermediate-1 risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenic abnormalities

PAGE 3 OF 5 PHARMACISTS’ EDITION

VOLUME 12-05

New Exception Status Benefits Effective May 4, 2012, the following strength of Risperdal Consta® will be added as an exception status benefit with the following already existing criteria:

Product Strength DIN Prescriber Benefit Status MFR

Risperdal Consta® (risperidone)

12.5mg/Vial Inj 02298465 DNP E (SF) JAN

Criteria For patients having problems with compliance on an oral antipsychotic or For patients who are currently receiving conventional depot antipsychotic and are

experiencing significant side effects (EPS or TD) or lack of efficacy Decision Highlights Other strengths of Risperdal Consta® are currently listed on the provincial

formulary as exception status. The 12.5mg strength has a similar (slightly less) price per mg. Utilization is

expected to be low with few clinical indications for use. The following product was reviewed by the Canadian Systemic Therapy Policy Committee (CSTPC) and will be listed with the following criteria, effective May 4, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Zytiga® (abiraterone acetate)

250mg Tab 02371065 DNP E (SFC) JAN

Criteria In combination with prednisone for metastatic castration resistant prostate cancer patients with histologically confirmed prostate cancer, ECOG performance status of 0-2 and progression after previous treatment with docetaxel

New Products The following products are new listings to the Nova Scotia Formulary, effective May 4, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

MINT-Citalopram 10mg Tab 02370077 DNP SFC MNT MINT-Atenol 25mg Tab 02368013 DNP SF MNT

PAGE 4 OF 5 PHARMACISTS’ EDITION

VOLUME 12-05

New Diabetic Products The following products are new listings to the Nova Scotia Formulary, effective May 4, 2012, benefit status and PRP within the Nova Scotia Pharmacare Programs are indicated.

PRODUCT DIN/PIN PRP PRESCRIBER BENEFIT STATUS MFR

Rapid Response® Blood Glucose Test Strips (50’s) 97799451 0.7100 DNP SFC BTX MyGlucoHealth® Glucose Test Strips (50’s) 97799458 0.6730 DNP SFC EHS

Non-Insured Products The following products were reviewed by the Canadian Drug Expert Committee (CDEC), and were not recommended to be listed as insured benefits under the Nova Scotia Pharmacare Programs.

Product Strength DIN Prescriber Benefit Status MFR

Brilinta® (ticagrelor)

90mg Tab 02368544 N/A Not Insured AZE

Decision Highlights Ticagrelor is a selective and reversibly bound antagonist of the adenosine diphosphate P2Y12 receptor.

The pre-specified subgroup analysis (by region), in one large randomized controlled trial of patients with acute coronary syndromes, did not provide evidence of the superiority of ticagrelor compared with clopidogrel in North American patient population to support a higher price for ticagrelor.

Product Strength DIN Prescriber Benefit Status MFR

Onsolis® (fentanyl citrate buccal soluble film)

200mcg Film 400mcg Film 600mcg Film 800mcg Film 1200mcg Film

02350661 02350688 02350696 02350718 02350726

N/A N/A N/A N/A N/A

Not Insured Not Insured Not Insured Not Insured Not Insured

MVL MVL MVL MVL MVL

Decision Highlights Fentanyl citrate buccal soluble film has a Health Canada indication for the management of breakthrough pain in cancer patients aged 18 years and older who are already receiving and are tolerant to 60mg per day morphine equivalents for a week or longer.

There are no randomized controlled trials directly comparing fentanyl citrate buccal soluble film with other less costly opioids for the management of breakthrough cancer pain.

The cost of fentanyl citrate buccal soluble film greatly exceeds that of other available oral opioids.

PAGE 5 OF 5 PHARMACISTS’ EDITION

VOLUME 12-05

Non-Insured Products Continued... The following product was not recommended to be listed as a benefit, however, will be funded through the HIV Program at the QEII Health Sciences Centre.

Product Strength DIN Prescriber Benefit Status MFR

Edurant® (rilpivirine hydrochloride)

25mg Tab 02370603 N/A Not Insured JAN

Palliative Home Care Drug Coverage Program In the February 2012 Pharmacare News Bulletin, we provided details of the Palliative Home Care Drug Coverage Program. This program was effective February 1, 2012, and covers the full cost of drugs intended for use in end-of-life care at home. A complete list of the eligible medications is now available on the members only section of the Pharmacy Association of Nova Scotia (PANS) website. After April 1, 2012, only those medications that are on the list will be paid under the program. Pharmacies are also reminded that:

A valid prescription is required for medications that can be purchased over-the-counter, and an official prescription receipt is required for reimbursement.

The program does not provide coverage for any supplies or medical equipment.

Please contact Pharmaceutical Services at 902-424-1596 with any questions regarding the program. Transition Fees for the period of April 1, 2012 to March 31, 2013 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.75 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

JUNE 2012 • VOLUME 12-06 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Exception Status Benefits

Criteria Updates: Xeloda®, Gleevec®

Non-Insured Products

Transition Fees

Included with this Bulletin

Request for Coverage of Dabigatran (Pradax®) Form

Pradax® Information Sheet

Nova Scotia Formulary Updates New Exception Status Benefits The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and will be listed as exception status benefits, with the following criteria, effective June 1, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Banzel® (rufinamide)

100mg Tab 200mg Tab 400mg Tab

02369613 02369621 02369648

DNP DNP DNP

E(SF) E(SF) E(SF)

EIS EIS EIS

Criteria For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome for patients who meet all of the following criteria:

- Are under the care of a physician experienced in treating Lennox-Gastaut syndrome-associated seizures, AND

- Are currently receiving two or more antiepileptic drugs, AND

- In whom less costly antiepileptic drugs are ineffective or not appropriate

Decision Highlights

The mechanism by which rufinamide exerts its antiepileptic effect is unknown. It is structurally unrelated to other currently available antiepileptic drugs.

Rufinamide has a Health Canada indication for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children aged four years and older, and adults.

PAGE 2 OF 5 PHARMACISTS’ EDITION

VOLUME 12-06

New Exception Status Benefits continued…

Product Strength DIN Prescriber Benefit Status MFR

Pradax® (dabigatran)

110mg Cap 150mg Cap

02312441 02358808

DNP DNP

E(SF) E(SF)

BOE BOE

Criteria Inclusion Criteria: At-risk1 patients with non-valvular atrial fibrillation (AF) who require dabigatran for the prevention of stroke and systemic embolism AND in whom:

- Anticoagulation is inadequate2 following a reasonable trial3 on warfarin; OR

- Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)

Exclusion Criteria:

Patients with impaired renal function4 (creatinine clearance or estimated glomerular filtration rate < 30 mL/min) OR ≥ 75 years of age and without documented stable renal function5 OR hemodynamically significant rheumatic valvular heart disease6, especially mitral stenosis; OR prosthetic heart valves

1. At risk patients with non valvular atrial fibrillation are defined as those with a CHADS2 score of ≥ 1.

2. Inadequate anticoagulation is defined as INR testing results that are outside the desired INR range for at least 35% of the tests during the monitoring period (i.e. adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).

3. A reasonable trial on warfarin is defined as at least two months of therapy.

4. Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see Pradax® (dabigatran) Product Monograph).

5. Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate that is maintained for at least three months (i.e. 30-49 mL/min for 110 mg twice daily dosing or ≥ 50 mL/min for 150 mg twice daily dosing).

6. There is currently no data to support that dabigatran provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves, so dabigatran is not recommended in these populations.

*Please Note: Patients starting dabigatran should have ready access to appropriate medical services to manage a major bleeding event.

PAGE 3 OF 5 PHARMACISTS’ EDITION

VOLUME 12-06

Decision Highlights - The anticoagulant activity of dabigatran is through direct inhibition of thrombin. - There is no reversal agent for dabigatran if there is a major bleed. - Since renal impairment can increase bleeding risk, renal function should be

regularly monitored. - In a pre-planned subgroup analysis the benefit of dabigatran 150 mg twice daily,

compared with adjusted dose warfarin, was primarily observed in centres that failed to achieve adequate INR control.

Criteria Updates: Xeloda®, Gleevec® The following products were reviewed by the Cancer Systemic Therapy Policy Committee (CSTPC) and will be listed with the following new criteria, effective June 1, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Xeloda® (capecitabine)

150mg Tab 500mg Tab

02238453 02238454

DNP DNP

E(SFC) E(SFC)

HLR HLR

Criteria As a single agent or in combination with HER2 directed therapy (e.g. lapatinib or trastuzumab) as one line of therapy in patients with advanced or metastatic breast cancer (MBC) who have an ECOG performance status of 0-2. For any one patient, a capecitabine-based regimen may only be used as one line of therapy for the treatment of MBC

As a single agent in patients who have documented evidence of metastatic colorectal cancer, with an ECOG performance status of 0-2, who choose not to receive combination chemotherapy (5-FU/LV/irinotecan) and/or are unable to tolerate first line therapy. This includes patients who are chemotherapy naive or who have progressed 6 months after completion of adjuvant 5-FU/LV therapy

For adjuvant treatment of patients with stage III (Dukes’ C) colon cancer and ECOG status 0-1 when prescribed by an oncologist

Requests must be from an oncologist or a prescriber with a specialty in oncology, and approval will be granted for three months, to be reviewed as required; in stage III colon cancer, coverage approved for 6 months

PAGE 4 OF 5 PHARMACISTS’ EDITION

VOLUME 12-06

Criteria updates continued…

Product Strength DIN Prescriber Benefit Status MFR

Gleevec® (imatinib)

100mg Tab 400mg Tab

02253275 02253283

DNP DNP

E(SFC) E(SFC)

NVR NVR

Criteria As a single agent for adult patients with a histological diagnosis of localized primary Gastrointestinal Stromal Tumors (GIST) (KIT(CD-117)-positive) following surgical complete resection and at a high risk of recurrence

- Risk of recurrence is dependent on location, size, and mitotic rate. Specific parameters for considering adjuvant treatment after resection of GIST along the gastrointestinal tract may include but are not limited to:

o Gastric: any tumor >3cm where the mitotic rate is >5/50 high powered fields (HPFs). Adjuvant treatment could be considered where the mitotic rate is <5HPFs and tumor >10cm

o Duodenal, small bowel, peritoneal, colorectal: any tumor where mitotic rate is >5HPFs; any tumor >5cm in size

o Coverage duration: 36 months For the treatment of chronic myelogenous leukemia (CML), as a single agent, in

patients who have documented evidence of Philadelphia chromosome positive CML, with an ECOG performance status of 0-2 and who:

- Are in blast crisis, accelerated phase, or chronic phase OR - As a secondary treatment in patients who demonstrate a hematologic

relapse or cytogenetic progression after interferon-alpha (INF-a) therapy - Coverage duration: 1 year

Requests for other indications will be reviewed on a case by case basis Written request of an oncologist required

Non-Insured Products The following products were reviewed by the Canadian Drug Expert Committee (CDEC), and were not recommended to be listed as insured benefits under the Nova Scotia Pharmacare Programs.

Product Strength DIN Prescriber Benefit Status MFR

Toctino® (alitretinoin)

10mg Cap 30mg Cap

02337630 02337649

N/A N/A

Not insured Not insured

ACT ACT

Decision Highlights Alitretinoin is an immunomodulator and anti-inflammatory agent. Alitretinoin is associated with a risk of teratogenicity and adherence to the Toctino

Pregnancy Prevention Program in the drug monograph is important. In one double-blind, RCT in patients with severe hand eczema refractory to topical

corticosteroids, the percentage of patients achieving a physician global assessment of “clear” or “almost clear” was statistically significantly higher for alitretinoin 30mg compared to placebo.

PAGE 5 OF 5 PHARMACISTS’ EDITION

VOLUME 12-06

Non-Insured Products continued… The following product was not recommended to be listed as a benefit, however, will be funded through the Cystic Fibrosis (CF) Clinic at the IWK and the QEII Health Sciences Centre, effective June 1, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Cayston® (aztreonam)

75mg/vial Inhalation Sol

02329840

N/A

Not insured

GIL

Decision Highlights Aztreonam is a monobactam antibiotic. Aztreonam for inhalation has a Health Canada indication for the management of CF patients with chronic pulmonary Pseudomonas aeruginosa infections.

Aztreonam for inhalation solution is approved for the treatment of chronic pulmonary Pseudomonas aeruginosa infections when used as cyclic treatment (28 day cycles) in patients with moderate to severe cystic fibrosis (CF) and deteriorating clinical condition despite treatment with inhaled tobramycin.

Transition Fees for the period of April 1, 2012 to March 31, 2013 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.75 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

06/2012

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Coverage of Dabigatran (Pradax®)

P A T I E N T I N F O R M A T I O N

PATIENT SURNAME

PATIENT GIVEN NAME

HEALTH CARD NUMBER

DATE OF BIRTH

PATIENT ADDRESS

D O S E R E Q U E S T E D

Pradax® 110mg bid Pradax

® 150mg bid

D I A G N O S T I C I N F O R M A T I O N

DIAGNOSIS *Only insured for non-valvular atrial fibrillation (AF) in patients with a CHADS2 score of ≥ 1

Non-valvular atrial fibrillation (AF) CHADS2 score: ___________________

*The CHADS2 score is an algorithm for predicting the risk of stroke in patients with AF. The score assigns points for various risk factors, as follows: 1 point for congestive heart failure, hypertension, age ≥ 75 yrs, and diabetes; 2 points for history of stroke or TIA. The score = sum of points (range 0-6)

Renal Function Tests:

Serum creatinine [SCr]: ___________________ µmol/L Date: ___________________

Creatinine clearance [CrCl]: ___________________ mL/min Date: ___________________

Recommended Dosing in AF (Refer to monograph for complete dosing information):

CrCI < 30mL/min: Pradax® use is contraindicated CrCI 30-49mL/min: Pradax

® 110mg bid

CrCI ≥ 50mL/min: Pradax® 150mg bid

Age > 80 years: Pradax

® 110mg bid

M E D I C A T I O N H I S T O R Y

Agents tried: Dose, length of therapy, and outcome: (i.e. inadequate anticoagulation*, etc.)

Warfarin _________________________________________________________

Other ______________________________ _________________________________________________________

* Please provide the percentage of INR testing results that are outside the desired INR range.

If warfarin has not been tried, please indicate the reason why:

Warfarin contraindicated _____________________________________________________________________________________________

Other ____________________________________________________________________________________________________________ ____________________________________________________________________________________________________________ PHYSICIAN NAME & ADDRESS:

CPSNS # PHYSICIAN SIGNATURE DATE

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1 Fax: (902) 468-9402

NOTE: The Exception Status Drug Request Form for Pradax® is available on the Nova Scotia

Pharmacare website at: www.gov.ns.ca/health/Pharmacare/info_pro/exception_status_drugs.asp

PRADAX® (dabigatran) INFORMATION INDICATION: On October 26, 2010, Health Canada approved dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Dabigatran etexilate (Pradax®) is the first of a new class of oral anticoagulants to reach the market. It is a direct thrombin inhibitor. With a more targeted mechanism of anticoagulation, dabigatran offers several potential clinical advantages over warfarin therapy, including obviating the need for routine monitoring; a faster onset and offset of action; no required dietary restrictions for patients; and few drug interactions. Anticoagulation agents are associated with a risk of bleeding complications. Bleeding in patients treated with warfarin can be managed with the administration of vitamin K but for the new anticoagulants there is no established specific antidote for reversal of the anticoagulation effect. CDEC RECOMMENDATION: On June 22, 2011, CADTH released the CDEC recommendation on dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular AF. The Canadian Drug Expert Committee (CDEC) recommends that dabigatran be listed for the prevention of stroke and systemic embolism in patients with atrial fibrillation meeting one of the following criteria:

- Patients in whom warfarin is indicated but who fail to achieve adequate international normalized ratio (INR) control, despite monitored warfarin treatment, such as with: regular INR testing, dosage adjustment according to a validated nomogram, and patient education. Patients who fail to achieve adequate INR control should be referred to an anticoagulation management service, if available. Or

- Patients who have a history of a serious hypersensitivity reaction to warfarin. PRECAUTIONS: Bleeding is typically the main safety issue of concern with all anticoagulants, including dabigatran. In RE-LY, the major randomized controlled trial (RCT) comparing dabigatran with warfarin, the risk of severe bleeding was reduced with the lower 110mg dose of dabigatran compared with adjusted-dose warfarin, but there was no such reduction with the higher, 150mg dose. However, there was evidence that in elderly patients there was no reduction in severe bleeding risk at either dose versus warfarin, and in the post-marketing period there was some evidence from case reports that elderly patients and/or those with severe renal impairment are at risk for serious bleeding events. MONITORING: Kidney function should be assessed in all patients prior to beginning dabigatran therapy. Patients with severe kidney impairment (i.e. CrCL<30 mL/min) should not take dabigatran. While on treatment, kidney function should be assessed in clinical situations where a decline in kidney function is suspected. Such situations include low blood volume, dehydration and when certain medications are taken at the same time. In elderly patients (> 75 years) or in patients with moderate kidney impairment, kidney function should be assessed at least once a year.

JULY 2012 • VOLUME 12-07 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Exception Status Benefits Criteria Update: Xarelto® Criteria Update: Sutent® New Diabetic Products – PRP Non-Insured Products Pharmacare Reimbursement Changes to Generic Drug Pricing New Products Added to Reimbursement List – PRP Standardization of Package Sizes Pharmacare Reimbursement Price (PRP) Transition Fees Included with this Bulletin Prescriber List Reimbursement List

Nova Scotia Formulary Updates New Exception Status Benefits The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and will be listed as exception status benefits, with the following criteria, effective July 3, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Visanne® (dienogest)

2mg Tab 02374900 DNP E(SF) BAY

Criteria For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly hormonal options are either ineffective or cannot be used

Decision Highlights

Dienogest is a progestin. Dienogest has a Health Canada indication for the

management of pelvic pain associated with endometriosis. In two randomized controlled trials (RCTs) included in the

systematic review, dienogest was superior to placebo (study A32473), and non-inferior to leuprolide (study AU19), in reducing pelvic pain in patients with endometriosis.

PAGE 2 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

New Exception Status Benefits continued…

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Xgeva® (denosumab)

120mg/1.7mL Sol 02368153 DNP E(SFC) AGA

Criteria As a single agent for the prevention of skeletal related events (SREs) for metastatic castrate resistant prostate cancer (CRPC) patients with one or more documented bone metastases and ECOG performance status (PS) 0-2

Decision Highlights Xgeva® (denosumab) is a human lgG2 monoclonal antibody that binds to human RANKL, a transmembrane (soluble protein) essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.

In three double-blind randomized controlled trials (RCTs) in patients with bony metastases secondary to solid tumours, denosumab was superior (study 103 and study 136) or non-inferior (study 244) to zoledronic acid for outcomes related to skeletal-related events (composite of fracture, spinal cord compression, and the need for surgery or radiation therapy of symptomatic bone metastases).

The following product was reviewed by the Pan-Canadian Oncology Drug Review (pCODR) and will be listed as an exception status benefit, with the following criteria, effective July 3, 2012.

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Votrient® (pazopanib)

200mg Tab 02352303 DNP E(SFC) GSK

Criteria As an alternate single agent first line treatment for patients with documented evidence of histologically confirmed advanced or metastatic clear cell renal cell carcinoma (RCC) who have an ECOG performance status (PS) of 0 or 1 and are unable to tolerate sunitinib

Decision Highlights Pazopanib is an orally administered, multi-target tyrosine kinase inhibitor. The pCODR systematic review included one double-blind, randomized controlled

trial (Study VEG105192, Sternberg 2010) comparing pazopanib with placebo in patients with advanced and/or metastatic renal cell carcinoma who were treatment naïve or who had received one prior cytokine-based systemic therapy.

PAGE 3 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

Criteria Update: Xarelto® The following product was reviewed by the Canadian Drug Expert Committee (CDEC) and will be listed with the following new criteria and applicable criteria codes, effective July 3, 2012.

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Xarelto® (rivaroxaban)

10mg Tab 02316986 DNP E(SF) BAY

Criteria For the prophylaxis of venous thromboembolism following total knee replacement surgery for up to 14 days, as an alternative to low molecular weight heparins [Criteria Code 14]

For the prophylaxis of venous thromboembolism following total hip replacement surgery for up to 35 days, as an alternative to low molecular weight heparins [Criteria Code 35]

Decision Highlights The Canadian Drug Expert Committee (CDEC) noted the following factors: - Similar costs of enoxaparin and rivaroxaban - Evolving clinical practice - The Health Canada recommended duration of treatment of 35 days for

rivarobaxan after elective total hip replacement surgery Criteria Update: Sutent® The following product was reviewed by the Cancer Systemic Therapy Policy Committee (CSTPC) and will be listed with the following new criteria, effective July 3, 2012.

PRODUCT STRENGTH DIN/PIN PRESCRIBER BENEFIT STATUS MFR

Sutent® (sunitinib)

12.5mg Cap 25mg Cap 50mg Cap

02280795 02280809 02280817

DNP DNP DNP

E(SFC) E(SFC) E(SFC)

PFI PFI PFI

Criteria As a single agent first line treatment in patients with documented evidence of histologically confirmed advanced or metastatic clear cell renal cell carcinoma (RCC) who have an ECOG performance status of 0 or 1. In any one patient all of the following conditions must be met:

- Sunitinib may be a first line option - Sunitinib may not be used after another tyrosine kinase inhibitor

(i.e., sorafenib or pazopanib) as sequential therapy - In the event of severe toxicity, a switch to another tyrosine kinase inhibitor

(i.e., sorafenib or pazopanib) may be allowed As a single agent for the treatment of advanced gastrointestinal stromal tumor

(GIST) patients after failure of imatinib due to intolerance or resistance Coverage approved for 9 months with reassessment

Decision Highlights Sunitinib malate is a small molecule that inhibits multiple receptor tyrosine kinases, some of which are implicated in tumour growth, pathologic angiogenesis, and metastatic progression of cancer.

Sutent is indicated for the treatment of metastatic renal cell carcinoma (MRCC) of clear cell histology. Approval of MRCC is based on statistically significant progression free survival in patients with good performance status (ECOG 0-1).

PAGE 4 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

New Diabetic Products - PRP The following products are new listings to the Nova Scotia Formulary, effective July 3, 2012. The benefit status and PRP within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT DIN/PIN PRP PRESCRIBER BENEFIT STATUS MFR

Contour® NEXT Blood Glucose Test Strips (50’s) 97799460 0.7400 DNP SFD BDD Contour® NEXT Blood Glucose Test Strips (100’s) 97799459 0.6989 DNP SFD BDD

Non-Insured Products The following product was reviewed by the Canadian Drug Expert Committee (CDEC), and was not recommended to be listed as an insured benefit under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Ozurdex® (dexamethasone)

0.7mg Intravitreal Implant

02363445 N/A Not Insured ALL

Decision Highlights Ozurdex® is available as a biodegradable polymer matrix implant containing 700mcg of dexamethasone for intravitreal injection

Dexamethasone intravitreal implant has a Health Canada indication for the treatment of macular edema following central retinal vein occlusion

The product monograph includes a warning that no more than two consecutive injections should be used, and an interval of approximately six months should be allowed between the two injections

The proportion of patients achieving a greater than or equal to 15-letter improvement in best corrected visual acuity which was assessed using the Early Treatment of Diabetic Retinopathy Study visual acuity chart was statistically higher for dexamethasone 700 mcg than for sham-treated patients at days 30 and 60, but not thereafter (days 90 and 180)

The proportion of patients experiencing a loss of greater than or equal to 15 letters, or meeting the criteria for legal blindness at day 180, was not statistically significantly different between dexamethasone 700 mcg and sham: 14% versus 20%, and 23% versus 29%, respectively.

PAGE 5 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

Pharmacare Reimbursement Changes to Generic Drug Pricing The province has developed a plan to get fair drug prices for Nova Scotians and to slow the rapid growth of spending on drugs through Pharmacare. As a result the price of generic drugs changed under the Pharmacare Programs on July 1, 2011. The third phase of the change is July 1, 2012, and generic prices are being reduced to 35% of the cost of the equivalent brand drug. Some generic drugs have exceptions to the Maximum Reimbursable Price (MRP) formula, and their MRP is also included in the Reimbursement List. Included with this bulletin is the Reimbursement List with the pricing for the Pharmacare Programs. It contains the MRP and Pharmacare Reimbursement Price (PRP) for applicable drugs. A copy of the Reimbursement List is also available online at www.nspharmacare.ca. For the products on the Reimbursement List, unless otherwise indicated, the MRP is effective August 1, 2012. Manufacturers will begin selling their products at the new lower price effective July 1, 2012. As a result of the changes, the following products will no longer be eligible benefits as of August 1, 2012:

DIN PRODUCT DIN PRODUCT

02352737 Amoxicillin 250mg chew tab 02247889 ratio-Meloxicam 7.5mg tab

02263130 Apo-Ciproflox 0.3% oph sol 02248031 ratio-Meloxicam 15mg tab

02231702 pms-Bromocriptine 2.5mg tab 02270927 ratio-Mirtazapine 30mg tab

02236949 pms-Bromocriptine 5mg cap 02343282 Nabumetone 500mg tab 02361299 Clonidine 0.025mg tab 02308681 ratio-Pantoprazole 20mg DR tab

02361302 Clonidine 0.1mg tab 02308703 ratio-Pantoprazole 40mg DR tab

01913786 Nu-Clonidine 0.1mg tab 02365529 Jamp-Pioglitazone 30mg Tab

02361310 Clonidine 0.2mg tab 02365537 Jamp-Pioglitazone 45mg Tab

01913220 Nu-Clonidine 0.2mg tab 02311704 ratio-Quetiapine 25mg tab

00027243 Dihydroergotamine 1mg/mL inj 02311712 ratio-Quetiapine 100mg tab

02249391 RAN-Fentanyl 25mcg/hr patch 02311747 ratio-Quetiapine 200mg tab

02249413 RAN-Fentanyl 50mcg/hr patch 02311755 ratio-Quetiapine 300mg tab

02249421 RAN-Fentanyl 75mcg/hr patch 02287692 ratio-Ramipril 1.25mg cap

02249448 RAN-Fentanyl 100mcg/hr patch 02287706 ratio-Ramipril 2.5mg cap

02260891 ratio-Gabapentin 300mg cap 02287714 ratio-Ramipril 5mg cap

PAGE 6 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

Changes to Generic Drug Pricing Continued…

DIN PRODUCT DIN PRODUCT

02287722 ratio-Ramipril 10mg cap 02257858 Sandoz Sotalol 160mg tab

02311194 ratio-Ramipril 15mg cap 02243023 ratio-Temazepam 15mg cap

00828688 ratio-Ranitidine 300mg tab 02243024 ratio-Temazepam 30mg cap

02245787 ratio-Sertraline 25mg cap 02231683 MYLAN-Trazodone 50mg tab

02245788 ratio-Sertraline 50mg cap 02231684 MYLAN-Trazodone 100mg tab

02245789 ratio-Sertraline 100mg cap 02140047 ratio-Valproic 250mg cap

02247068 ratio-Simvastatin 10mg tab 02242686 Taro-Warfarin 6mg tab

02247069 ratio-Simvastatin 20mg tab 02344106 Warfarin 7.5mg tab

02247070 ratio-Simvastatin 40mg tab 02247071 ratio-Simvastatin 80mg tab

New Products Added to Reimbursement List PRP The following products now have a PRP, effective August 1, 2012. The PRP within the Nova Scotia Pharmacare Program is indicated.

PRODUCT DIN

PRP (EFFECTIVE AUGUST 1, 2012)

PRESCRIBER BENEFIT STATUS MFR

lansoprazole 15mg cap Apo-Lansoprazole 15mg DR cap 02293811 0.3500 DNP E APX Lansoprazole 15mg DR cap 02357682 0.3500 DNP E SAS MYLAN-Lansoprazole 15mg DR cap 02353830 0.3500 DNP E MYL Novo-Lansoprazole 15mg DR cap 02280515 0.3500 DNP E TEV Prevacid 15mg cap 02165503 0.3500 DNP E ABB pantoprazole 20mg EC tab Apo-Pantoprazole 20mg DR tab 02292912 0.3538 DNP E APX Pantoloc 20mg DR tab 02241804 0.3538 DNP E NYC RAN-Pantoprazole 20mg DR tab 02305038 0.3538 DNP E RAN Sandoz Pantoprazole 20mg DR tab 02301075 0.3538 DNP E SDZ Teva-Pantoprazole 20mg DR tab 02285479 0.3538 DNP E TEV

PAGE 7 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

Standardization of Package Sizes In order to ensure claims are paid correctly, pharmacists are reminded that the Pharmacare Programs have developed guidelines for the standardization of package sizes. Please use the following guidelines when calculating quantities for each claim and ensure your cost per unit is correct in your system.

FORM QUANTITY FORM QUANTITY

Aeosols Per dose Nasal sprays Per dose

Capsules Per capsule Nebules Per mL

Creams Per gram Ointments Per gram

Enemas Per mL Oral contraceptives As 21 or 28 Gels Per gram Ostomy supplies Per item (e.g. 20 pouches)

Inhalers Per dose Patches Per patch

Insulin Per mL Powders Per gram

Kits Per kit Powder injectables Per vial

Lancets Per lancet Suppositories Per suppository

Liquid injectables Per mL Tablets Per tablet

Liquids (excluding methadone)

Per mL

Testing strips Per testing strip

Liquid methadone Per mg

FORM QUANTITY

Package/Kits of more than one drug (e.g., HP-Pac®, Monistat 3 Dual-Pack®, Didrocal®)

Per package

Packages of blood glucose testing strips with built-in meter (e.g., Sidekick® Blood Glucose Testing System)

Per test strip

The majority of calls received regarding billing involve the following products:

Humira® - Claims should be billed by mL, and not by syringes (i.e., one syringe is 0.8mL). Simponi® - Claims should be billed per mL, and not by syringe (i.e., one syringe is 0.5mL). Miacalcin® and generics – Claims should be billed per dose not by package or bottle (i.e., one box

is 28 doses). Didrocal® kit and generics – Claims should be billed per kit and not number of tablets (i.e., one box

is one kit).

PAGE 8 OF 8 PHARMACISTS’ EDITION

VOLUME 12-07

Pharmacare Reimbursement Price (PRP) PRP is the ‘special’ maximum price assigned to:

certain groups of drugs that are similar in therapeutic effect; specific services for which coverage is established; certain unit dose and special delivery formats that are also available in less expensive bulk formats;

and certain supplies that are used for the same function.

The PRP is the maximum amount the Pharmacare Program reimburses providers for one unit of a drug (tablet, capsule, mL, etc.) supply or service. In the case of methadone, one unit is a milligram. According to the current Tariff Agreement between the Department of Health and Wellness and the Pharmacy Association of Nova Scotia, when a PRP applies, pharmacies are reimbursed the PRP plus a 6% mark up (to a maximum of $250), plus the dispensing fee and the transition fee. Providers may charge the beneficiary the portion of their Actual Acquisition Cost (AAC) that exceeds the PRP, but are not permitted to charge the beneficiary any excess mark-up, transition fee or dispensing fee beyond what is set out in the Tariff Agreement. Any extra cost is not counted toward the beneficiary’s annual maximum copayment or annual maximum deductible. A complete list of current MRP and PRP and can be found on the Reimbursement List on the Pharmacare website at www.nspharmacare.ca. Transition Fees for the period of April 1, 2012 to March 31, 2013 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.75 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

PRESCRIBER LIST JULY 2012

PHYSICIANS

SURNAME TOWN/CITY CPSNS AAL ALI, ABDULLA S 13820 ABBASIAN, ALI SYDNEY 14003 ABBASS, ALLAN A HALIFAX 11867 ABDEL ATY, AMR N TRURO 15753 ABDELGADIR, IBRAHIM M ANTIGONISH 15710 ABEL, RACHEL MIRA ROAD 13484 ABENHEIMER, MARTIN S SYDNEY 6313 ABEYSEKERA, R M AMHERST 10449 ABIDI, SABINA HALIFAX 12384 ABONOWARA, ABDULGANI HALIFAX 13826 ABRAHAM, ROBERT HAMMONDS PLAINS 7645 ABRAHAM, SUMA R TRURO 14001 ABRIEL, DAVID L MAHONE BAY 6371 ABU-WASEL, BASSAM HALIFAX 15643 ABUD, LELY MAHONE BAY 14322 ACHENBACH, JILLIAN M HALIFAX 14623 ACKERMANN, MICHAEL J SHERBROOKE 7806 ACOTT, PHILIP D HALIFAX 10757 ACTON, DAVID C KENTVILLE 7903 ADAMS, HELIKA D SHUBENACADIE 6094 ADAMS, JAMES H DARTMOUTH 4530 ADAMSON, HENRY HALIFAX 7930 ADDIE, BRIAN F EASTERN PASSAGE 13014 ADELASOYE, OLUREMI F NEW GLASGOW 15193 AFZAL, SAMINA HALIFAX 15772 AGO, C T HALIFAX 12606 * AHMAD, AMER R WINDSOR 8002 AHMAD, ASMA R HALIFAX 11192 AHMAD, KHALIL DARTMOUTH 6419 AHMAD, SIRAJ HALIFAX 2893 AHMED, AHMED A HALIFAX 14876 AHMED, TAHIRA S HALIFAX 8129 AIKMAN, PETER J HALIFAX 11875 AINAMO, JYRI S KINGSTON 10743 AIRES, LIANA HALIFAX 12385 AKHTAR, SYED N DARTMOUTH 2610 AKINLAJA, AYODEJI - O SYDNEY 15803 AKINSOLA, OLUWATOSIN A SYDNEY 15497 AL BUGAMI, METEB M HALIFAX 14396 AL KARMI, RANI N SYDNEY 15222 AL-DHAMIN, AMMAR S HALIFAX 15424 AL-KUWAITI, NOORA H 14729 AL-MANAHI, RASHA N NEW GLASGOW 15735 AL-NASSAR, RAFID S NEW GLASGOW 15727 AL-SHAMI, EMAN YARMOUTH 15440 ALAGHBAND-RAD, JAVAD HALIFAX 14290 ALAM, MAHMOOD HALIFAX 15755 ALANSARI, NABEEL M CHARLOTTETOWN 15680 ALAS, JUAN P SPRINGHILL 12598 ALBISTON, BRIGIT J BRIDGEWATER 13927 ALDA, MARTIN HALIFAX 12049 ALDRIDGE, DAVID J SYDNEY 11966 ALEXANDER, DAVID I HALIFAX 4551 ALEXIADIS, MARIA HALIFAX 7820 ALI, IDRIS M HALIFAX 7524 ALI, IMTIAZ S HALIFAX 10890 ALI, JAVED E SYDNEY 10745 ALI, SYED Z SYDNEY 14757 ALIAN, WAEL ABD E 13832 ALJIFFRY, MURAD VERDUN 13662 ALLAN, PATRICIA L ANTIGONISH 6540 * ALLANACH, WILLIAM W 11631 ALLEN, ALEXANDER C HALIFAX 4406

SURNAME TOWN/CITY CPSNS ALLEN, CHRISTOPHER T HALIFAX 4626 ALLEN, DOUGLAS L HALIFAX 4576 ALLEN, MAUREEN A ANTIGONISH 12065 ALLEN, VICTORIA M HALIFAX 10776 ALOYSIUS, JEYARANEE HALIFAX 13532 ALRAYES, ZEYAD DARTMOUTH 15770 ALTENKIRK, GARY B TRURO 12100 ALVAREZ, CARLOS A PICKERING 15379 * ALWAYN, IAN P HALIFAX 14599 ALZAIDI, ABDULAZIZ 12904 ALZRIGHE, MOHAMED DARTMOUTH 13428 AMIR-KHALKHALI, BAHARAK HALIFAX 12391 AMIRAULT, JOHN D HALIFAX 4678 AMIT, MINOLI N ANTIGONISH 6267 ANDERSON, CHARLES C UPPER TANTALLON 6803 ANDERSON, DAVID R HALIFAX 10655 ANDERSON, K ERIC C HALIFAX 12122 ANDERSON, KAREN E HALIFAX 7211 ANDERSON, PETER A HALIFAX 6986 ANDREA, GLENN C HALIFAX 10287 ANDREW, MELISSA K HALIFAX 12658 ANDREWS, DAVID M HALIFAX 3337 ANNAMALAI, SIVAKUMAR SYDNEY 14882 ANSARI, SHOAIB R SYDNEY 14544 ANTONY, S SHEET HARBOUR 13764 APOSTOLIDES, COSTA HALIFAX 12123 AQUINO, EMMANUEL P DARTMOUTH 23 ARAB, MARTHA A HALIFAX 11056 ARCHIBALD, CURTIS HALIFAX 14125 ARCHIBALD, GREGORY C HALIFAX 12371 ARCHIBALD, J FRED HALIFAX 4543 ARCHIBALD, JOHN DAVID NEW GLASGOW 3560 ARCHIBALD, JOHN M SYDNEY 4226 * ARCHIBALD, SHAUNA M HALIFAX 13502 ARMSON, BRIAN A HALIFAX 6363 ARMSTRONG, DUNCAN S HALIFAX 4950 ARORA, GAGAN AMHERST 14813 ARSENAULT, WILLIAM E LABRADOR CITY 15437 ASHFAQ, SIRAJUDDIN HALIFAX 3307 ASHOUR, IMAN 13355 ASHTON, BRIAN D BEDFORD 11076 ASIM, HAMMAD H MIRA ROAD 13702 ASPIN, JOHN D HALIFAX 12898 ATIA, JOHN N AMHERST 15064 ATIYAH, ABDULRAZZAK O NEW WATERFORD 10778 ATKINSON, BRADLEY C SHEET HARBOUR 10859 ATKINSON, CHRISTINA M DARTMOUTH 12525 ATKINSON, SUSAN M HALIFAX 10249 ATKINSON, VICTORIA E 12659 AUCOIN, JOSEPH C CHETICAMP 3030 AUCOIN, MARCEL D CHETICAMP 11506 AUDAIN, COLIN V HALIFAX 14113 AUDAIN, VINCENT P HALIFAX 3363 AVERY, CHANDRA M HALIFAX 14479 AWALT, ERIN J HALIFAX 13835 AWAN, SHAHID I AMHERST 6620 AWWAD, BAHAA E ANTIGONISH 15742 AYLMER, ANNE P HALIFAX 7699 AYLMER, DAVID A TRURO 10332 AYOUB, HAIFA H GUYSBOROUGH 15159 AZER, RAED NEW WATERFORD 11516 AZIZ, SAHAR DARTMOUTH 14104 BADI, FATHI F DARTMOUTH 15459

* Refer to a page 22 for alternate Pharmacare prescriber number. 2

SURNAME TOWN/CITY CPSNS BADLEY, BERNARD W HALIFAX 5027 BADRELDIN, MOHAMED 12532 BAGNELL, ALEXA L HALIFAX 13453 BAGNELL, PHILIP SCOTT HALIFAX 11632 BAHL, GAURAV HALIFAX 15213 * BAILLY, GREGORY G HALIFAX 11633 BAINS, RAVINDER S HALIFAX 12660 BAKOWSKY, VOLODKO S HALIFAX 11077 BALSER, ERIC F MIDDLETON 12076 BALYS, RICHARD L DARTMOUTH 14222 BANCE, MANOHAR L HALIFAX 12588 BANDER, MAREK S DIGBY 10294 BANJO, OLUFEMI YARMOUTH 15673 BANKS, JOHN V DARTMOUTH 6556 BANKS, MICHAEL R HALIFAX 3558 BARCLAY, SPENCER L TRENTON 3891 BARKOVA, EVA HALIFAX 14408 BARKWELL, ROBERT G ANNAPOLIS ROYAL 11732 BARNES, DAVID C HALIFAX 7067 BARNES, PENELOPE J HALIFAX 10389 BARRY, ANNE E KENTVILLE 6818 * BARSS, DAVID H BRIDGEWATER 4395 BARTON, WILLIAM F DARTMOUTH 4085 BASECQZ, GUY NEW GLASGOW 15705 BASKETT, ROGER J HALIFAX 11634 BASKETT, THOMAS F HALIFAX 6071 BASS, STEPHANIE MUSQ HARBOUR 13278 BASTA, MAGDY N HALIFAX 11763 BATA, IQBAL R HALIFAX 7662 BATA, NAZLIN I HALIFAX 7458 BAUER, CHRISTOPHER A WOLFVILLE 15391 BAXTER, EDITH M HALIFAX 13580 BAXTER, MARY L DARTMOUTH 12538 BEATON, BLAINE G LUNENBURG 7166 BEAUPRIE, IAN G HALIFAX 7762 BEDARD, RICHARD J SYDNEY 4566 BEED, STEPHEN D ENFIELD 8086 BEGIN, PAUL A OXFORD 6931 BELEN, JAIME O INVERNESS 3950 BELL, BARBARA A GUYSBOROUGH 12490 BELL, DAVID G HALIFAX 6920 BELL, HELEN F TRURO 4970 BELL, MARILYNNE L HALIFAX 4863 BELLIVEAU, ADELE M DARTMOUTH 10067 BELLIVEAU, DANIEL J HALIFAX 12566 BENDOR-SAMUEL, R L HALIFAX 12115 BENNE, MARGARET E GREENFIELD 14310 BENNE, TOBIAS H GREENFIELD 14311 BENNETT, MARK S INVERNESS 10234 BENSTEAD, TIMOTHY J HALIFAX 7091 BENT, ALFRED E BROOKFIELD 13800 BENT, KEVIN P HALIFAX 12053 BENTLEY, JAMES R HALIFAX 10886 BERESFORD, J P HALIFAX 4712 BERGER, CHRISTOPHER W BEDFORD 12344 BERGHUIS, HAROLD P TRURO 11184 BERGIN, DEIRDRE B BEDFORD 12884 BERGIN, FIONA A HALIFAX 10079 BERGIN, SIOBHAN M DARTMOUTH 10618 BERMAN, JASON HALIFAX 13915 BERNARD, ANDRE M HALIFAX 14134 BERNSTEIN, MARK L HALIFAX 14220 BERRY, ROBERT F HALIFAX 11078 BESSENYEI, ANETT HALIFAX 14703 BEST, ROBERT A LOWER SACKVILLE 15354 BETHUNE, DREW C HALIFAX 6401 BETHUNE, GRAEME H HALIFAX 4745 * BEUKES, E GERHARD DIGBY 15399 BEVERIDGE, WILLIAM K KENTVILLE 7986 BEYDOUN, HUSSEIN HALIFAX 11244

SURNAME TOWN/CITY CPSNS BEZUHLY, MICHAEL HALIFAX 13279 BHALLA, SUMEER K 14625 BHAN, VIRENDER HALIFAX 7700 BHANOT, RAJ MOUNT UNIACKE 7628 BHASKARA, SREENIVASA M LOWER SACKVILLE 10944 BHATIA, ANUJ TORONTO 15144 BHATTACHARJEE, D NORTH SYDNEY 2862 BHATTACHARYYA, AMAL DARTMOUTH 2238 BIDDULPH, MICHAEL PLEASANTVILLE 13018 BIENKOWSKI, HALINA J AMHERST 8105 BIENKOWSKI, KRZYSZTOF AMHERST 7585 BIERNACKA, MAGDALENA T NEW GLASGOW 14062 BILO, JOHN M KENTVILLE 11885 BILSKI-PIOTROWSKI, M P HALIFAX 10476 BIRD, RODERICK A SYDNEY 4064 BIRD, SALLY J HALIFAX 14867 BIRNIE, WILLIAM A HALIFAX 6833 BISHOP, ALLEN J KENTVILLE 6009 BISSON, GAIL M SYDNEY 6770 BLACK, JOHN D DIGBY 4382 BLACK, KAREN J HALIFAX 11080 BLACK, KATHARINE A DARTMOUTH 10988 BLACKADAR, ANDREW LIVERPOOL 13388 BLACKIE, BARBARA J HALIFAX 11886 BLAIKIE, PETER G PUGWASH 10477 BLAIR, DAVID M TRURO 6097 BLAIR, WILLIAM H BARRINGTON PASS 6264 BLAKE, KIM HALIFAX 11760 BLANCHARD, MARK C HALIFAX 12442 BLASZKOW-PORANEK, B HALIFAX 7883 BLINN, ALAIN J METEGHAN CENTRE 15671 BLOIS, BEAU TRURO 15162 BLOOM, NANCY A HALIFAX 14577 BLOOM, SETH A HALIFAX 14367 BOBADILLA-MARTINEZ, J C AMHERST 12572 BOILEAU, LOUIS O HALIFAX 13417 BOLIVAR, PATRICIA E KENTVILLE 11410 BOLLEDDULA, KRISHNA P HALIFAX 14058 BONANG, LISA M MUSQ HARBOUR 10781 BOND, DAVID M DARTMOUTH 15183 BONNINGTON, SIMON P ANNAPOLIS ROYAL 15210 BOOD, TIMOTHY W HALIFAX 7186 BOOTH, A WILLIAM ANTIGONISH 6893 BOOTH, JOHN P 15637 BORGAONKAR, JOY N HALIFAX 11977 BORST, SJOERD A HALIFAX 15346 BORTOLUSSI, ROBERT A HALIFAX 4880 BOSMA, MARK A HALIFAX 12395 BOTROUS, MARY BEDFORD 15045 BOTTEN, DAVID L HALIFAX 12936 BOUCHER, CHARLES B PORT HAWKESBURY 4998 BOUDREAU, ANDRE DANIEL DARTMOUTH 14794 BOUDREAU, CINDY L YARMOUTH 6897 BOUDREAU, D TODD STELLARTON 13706 BOURKE, KEVIN E HALIFAX 7321 BOUTILIER, CAROL M GLACE BAY 7138 BOUTILIER, NICOLE A WESTVILLE 12882 BOUTILIER, ROBERT G FALL RIVER 11635 BOUZAYEN, RENDA HALIFAX 12511 BOWDEN, LOIS A PORT WILLIAMS 7703 BOWDRIDGE, GILDA A HALIFAX 10351 BOWEN, A SCOTT L AMHERST 12891 BOWER, NEIL L TRURO 7777 BOWES, DAVID M HALIFAX 13842 BOWES, VERNON F HALIFAX 2775 BOWIE, DENNIS M HALIFAX 4059 * BOYD, GORDON J HALIFAX 10782 BRADLEY, BILL R DARTMOUTH 10279 BRADLEY, CHRISTINE 13581 BRADY, JOLENE N HALIFAX 13179

* Refer to a page 22 for alternate Pharmacare prescriber number. 3

SURNAME TOWN/CITY CPSNS BRAKE, DAVID J SYDNEY 10082 BRAKE, JONATHAN A EASTERN PASSAGE 14380 BREITLING, MAGNUS K HALIFAX 15383 BRENNAN, ELIZABETH B ANTIGONISH 10419 BRENNAN, MICHAEL B ANTIGONISH 10070 BRENNAN, PETER G HALIFAX 10357 BRENNER, IRA SHAG HARBOUR 14511 BRIEN, DONALD M MIRA ROAD 11997 BRISSEAU, GUY F HALIFAX 10771 BRNA, PAULA M DARTMOUTH 13086 BROCK, JO-ANN K HALIFAX 13285 BRODAREC, IVAN YARMOUTH 10672 BROMLEY, PETER J LOWER SACKVILLE 10783 BROOKS, ANN BEDFORD 7092 BROOKS, JANE C MIDDLETON 12003 BROOKS, SIMON A BEDFORD 7080 BROSKY, GERALD M HALIFAX 7671 BROWN, BASIL S HALIFAX 2870 BROWN, CHARLES A KENTVILLE 2406 BROWN, DONALD C HALIFAX 5008 BROWN, MICHAEL PETER HALIFAX 13390 BROWN, ROBERT L HALIFAX 2137 BROWN, TIMOTHY HALIFAX 12129 BROWN, WANDA G TRURO 8123 BROWN, WAYNE C MUSQ HARBOUR 4203 BROWNSTONE, ROBERT M HALIFAX 12534 BRUNET, AILEEN S DARTMOUTH 14203 BRYDIE, ALAN O HALIFAX 13380 BRYDIE, SARAH E HALIFAX 14294 BUCHHOLZ, KENNETH P ANNAPOLIS ROYAL 6212 * BUCKLEY, NIALL J WINDSOR 7794 BUDDEN, HEIDI L SYDNEY 13554 BUDUHAN, GORDON HALIFAX 15105 BUFFETT, BERNARD R NEILS HARBOUR 6911 BUFFETT, LAWRENCE M DARTMOUTH 2266 BUHARIWALLA, FAROKH R SYDNEY 6729 BULAJIC, RANKA B MIRA ROAD 15421 BULLOCK, GRAHAM L HALIFAX 8097 BULLOCK, MARTIN J HALIFAX 11393 BURCH, KAREN A KENTVILLE 14600 BURDEN, GEORGE M ELMSDALE 4957 BURGE, FREDERICK I HALIFAX 8102 BURGESS, GINA M HALIFAX 10084 BURGESS, LORRAINE T KENTVILLE 7319 BURKE, BRIAN J PORT WILLIAMS 10085 BURKE, JOHN W HALIFAX 11786 BURNETT, RALPH H YARMOUTH 3860 BURNS LACHANCE, J HAMMONDS PLAINS 14247 BURNS, A GEORGE LOUISBOURG 12242 BURNS, EMMA C HALIFAX 14136 BURNSTEIN, MATTHEW D HALIFAX 6752 BURRELL, STEVEN C HALIFAX 11249 BURRILL, RANDY S PICTOU 6802 BURTON, ELIZABETH A HALIFAX 14137 BUSAHMEN, WALEED E DARTMOUTH 15457 BUSH, ROBERT P TATAMAGOUCHE 10087 BUSSEY, CHRISTY C HALIFAX 14414 BUSTIN, ROBIN G BERWICK 6204 BUTLER, CLAY K GLACE BAY 10657 BUTLER, CRAIG R 12666 BUTLER, GREGORY J CANNING 6129 BUTLER, TREVOR KENTVILLE 12667 BUTT, ROBINETTE D HAMMONDS PLAINS 13196 BUZAID, AMIN SYDNEY 14883 CADEGAN, PERRY K GLACE BAY 4526 CAIN, EDWARD J HALIFAX 4924 CAIN, MICHELLE R YARMOUTH 11197 CAINES, JUDY S HALIFAX 4790 CAJEE, ISMAIL HALIFAX 10696 CALKIN, CYNTHIA V HALIFAX 10785

SURNAME TOWN/CITY CPSNS CALNEN, CHARLOTTE A HALIFAX 12668 CALVERLEY, VIRGINIA C HALIFAX 7148 CAMERON, CATHERINE J SCOTSBURN 7596 CAMERON, ESTELLE E SYDNEY 4828 CAMERON, IAN A SHERBROOKE 4996 CAMERON, JEAN M ANTIGONISH 7404 CAMERON, KENNETH M DARTMOUTH 4962 CAMERON, MARIANNE C HALIFAX 14653 CAMERON, STEWART M HALIFAX 7748 CAMPBELL, DONALD M DARTMOUTH 4055 CAMPBELL, GENEVIEVE M DARTMOUTH 6678 CAMPBELL, GLENN R HALIFAX 11889 CAMPBELL, JOHN M 12398 CAMPBELL, MARY-ANNE SYDNEY 7335 CAMPBELL, SAMUEL G HALIFAX 11499 CANETE, YURI C CORNER BROOK 15209 CARBYN, KEVIN M HALIFAX 10484 CAREY, AIDAN G LOWER SACKVILLE 7459 CARPENTER, FREDERICK J TRURO 6243 CARR, BRENDAN S HALIFAX 10381 CARREY, NORMAND J HALIFAX 11501 CARRILLO, MONICA SYDNEY 13266 CARROLL, JULIA M TORONTO 15500 CARSLEY, HOLLY H TATAMAGOUCHE 13496 CARTER, ALEXANDRA J HALIBUT BAY 14782 CARTER, JOHN E HALIFAX 12487 CARTER, LORNA J DARTMOUTH 6190 CARVER, DANIEL J HALIFAX 7320 CASEY, J STEPHANIE HALIFAX 6773 CASEY, PATRICK J HALIFAX 11636 CASSIDY, BEVERLEY D WOLFVILLE 10464 CASSIDY, KERI-LEIGH HALIFAX 12912 CELIKER, MAHMUT Y HALIFAX 15779 CEPICA ANGEL, DENISA FALL RIVER 13019 CHALATI, BACHAR TRURO 13140 CHALMERS, RONALD A TRURO 4058 CHALONER, WOUNA M SHELBURNE 12589 CHAMPION, JEFFREY A DARTMOUTH 7170 CHANDLER, JAMES D YARMOUTH 7706 CHANDLER, JULIE E YARMOUTH 7502 CHAO, ERIC D HAMMONDS PLAINS 15428 CHARBONNEAU, REBECCA 14630 CHARLEBOIS, PAUL B HALIFAX 13212 CHATURVEDI, PRABHAT K GLACE BAY 3252 CHAWLA, RAKESH HAMMONDS PLAINS 13696 CHAWLA, VISHAL HALIFAX 12670 CHEAH, KEE S BEDFORD 3833 CHEEVERS, PAUL M YARMOUTH 13689 * CHEHIL, SONIA HALIFAX 11891 CHEN, ROBERT HALIFAX 11379 CHENG, CALVINO K HALIFAX 13973 CHENG, NATALIE Y DARTMOUTH 15488 CHENGAPA, VINNIE K HALIFAX 10369 CHERNIN, ANDREA L HAMMONDS PLAINS 10152 CHEVERIE, DONALD J DARTMOUTH 6850 CHIASSON, JOHN D ANTIGONISH 6117 CHIASSON, MEREDITH D FALL RIVER 14111 CHIASSON, MICHEL T CHETICAMP 13124 CHILDS, CHRISTOPHER M BEDFORD 3288 CHISHOLM, B T HALIFAX 10601 CHISHOLM, JANICE D HALIFAX 12399 CHISHOLM, KENNETH C HALIFAX 7567 CHOBOTUK, TARA D 14632 CHOKSHI, RASHMIKANT G SYDNEY 2981 CHOW, CARLYLE S BADDECK 3035 CHOW, LINDA Y HALIFAX 12074 CHOWDHURY, DHIMAN HALIFAX 11591 CHOWDHURY, SMRITI HALIFAX 11587 CHRISTIANS, NEIL J SYDNEY 13507 CHRISTIE, KEVIN 13910

* Refer to a page 22 for alternate Pharmacare prescriber number. 4

SURNAME TOWN/CITY CPSNS CHRISTIE, SEAN D HALIFAX 11414 CHUI, SAI-TAO LOWER SACKVILLE 2723 CHUN, SAMUEL S DARTMOUTH 11561 CHURCH, CHRISTOPHER L BRIDGEWATER 10758 CHURCH, RHONDA L BRIDGEWATER 10937 CIACH, MICHELLE BEDFORD 14141 CLAGUE, NICHOLAS P TRURO 10934 CLARK, ALEXANDER J HALIFAX 15152 * CLARK, DONALD F KENTVILLE 11531 CLARKE, ADAM C KENTVILLE 11893 CLARKE, BARRY S HALIFAX 7633 CLARKE, BRIAN A HALIFAX 13585 CLARKE, DAVID B HALIFAX 11566 CLARKE, GREGORY V KENTVILLE 12335 CLARKE, JAMES R HALIFAX 12672 CLARKE, KAREN A HALIFAX 7733 CLIFTON, NEIL A ANTIGONISH 12619 CLONEY, JACQUELINE F LOWER SACKVILLE 4959 CLORY, MICHAEL B BEDFORD 10698 CLOUTIER, LOUISE WOLFVILLE 4416 COADY, CATHERINE M HALIFAX 10254 COAKLEY, ARTHUR G BADDECK 11491 COGSWELL, ESTHER M KENTVILLE 10787 COHEN, ROBERT E SYDNEY 3862 COISH, CHARLES NORTH SYDNEY 12554 COLE, BASILON C NEW GLASGOW 6603 COLE, ELIZABETH M WINDSOR 11976 COLES, CHAD P HALIFAX 11640 COLES, JOYCE K HATCHETT LAKE 14226 COLLICUTT, JAMES A SYDNEY 11025 COLLINS, JAMES A PORT HAWKESBURY 4556 COLP, JEFFREY N HATCHET LAKE 10489 COLTER, KIMBERLEY A DARTMOUTH 11087 COLWELL, BRUCE D HALIFAX 11234 COLWELL, JOHN R BRIDGEWATER 12639 COMEAU, ALBAN L SAULNIERVILLE 4995 * CONNELL, CATHY A HALIFAX 8106 CONNELLY, ALAN B KENTVILLE 3572 CONNIDIS, STEPHANIE A HALIFAX 10402 CONNORS, LORI A BEDFORD 13847 CONRAD, SARAH L LUNENBURG 14693 CONROD, CHERYL K SYDNEY 7588 CONTER, HOWARD S HALIFAX 7109 CONYERS, ROOP ANNAPOLIS ROYAL 14553 COOK, CHRISTOPHER T TRURO 13460 COOK, MICHAEL W TRURO 4565 COOK, STEVEN T TRURO 3861 COOKEY, BENEDICT J DARTMOUTH 4063 COOLEN, JILLIAN D HALIFAX 14251 COONAN, THOMAS J HALIFAX 4480 COOPER ROSEN, ETHEL G DARTMOUTH 6505 COOPER, PHILLIP W ANTIGONISH 10963 COOPER, ROBERT J PICTOU 12476 * CORKUM, THOMAS P DARTMOUTH 3719 CORMIER, ALANA M HAMMONDS PLAINS 14798 CORSTEN, PETER GERARD HALIFAX 11088 COSH, SARAH M LIVERPOOL 14804 COTE, M CHRISTENA HALIFAX 7324 COTTREAU, ALISON M YARMOUTH 7349 COUBAN, STEPHEN HALIFAX 11560 COUPER, JANET A HEAD ST MARG BAY 10554 COUTURE, DOMINIQUE J YARMOUTH 10582 COUTURE, SOPHIE HALIFAX 13968 COVERT, ALAN A HALIFAX 3698 COVERT, CAROLINE R HALIFAX 14063 COVERT, SABRINA K KENTVILLE 13023 COVINGTON, NANCY I HALIFAX 4547 COX, CHRISTOPHER P HALIFAX 14477 COX, J JOSEPH SYDNEY 13563 COX, JAFNA L HALIFAX 10252

SURNAME TOWN/CITY CPSNS COX, JAMIE R FALMOUTH 13467 COX, KAREN A CHESTER 12921 COX, KATHARINE S TRURO 4670 CRAGG, FRANK J SYDNEY 7747 CRAIG, CATHERINE M DARTMOUTH 11159 CRAIG, PATRICIA A NEW GLASGOW 10007 CRAM, JENNIFER E ANNAPOLIS ROYAL 14868 CRASWELL, DONALD F MIDDLETON 3342 * CRAWFORD, KIM R LIVERPOOL 6952 CRAWLEY, FRANCES J WINDSOR 7602 CREIGHTON, DAVID A DARTMOUTH 6990 CREIGHTON, PAULA GLACE BAY 13137 CRITCHLEY, CAROL A MIRA ROAD 4820 CROCKER, JOHN F HALIFAX 2629 CRON, CHARLES C HALIFAX 3583 CROOKS, BRUCE N HALIFAX 13135 CROOKS, HARRIS G HATCHET LAKE 4521 CROSBIE, STEPHEN H NORTH SYDNEY 7575 CROSBY, AMANDA R STILLWATER LAKE 14634 CROSBY, JEAN D SYDNEY 6121 CROSKERRY, PATRICK G GLEN HAVEN 7090 CROWELL, DENISE M HALIFAX 13045 CROWELL, RICHARD H HALIFAX 6223 CRUESS, ALAN F HALIFAX 13217 CRUZ, ARTURO M DARTMOUTH 6815 CUDMORE, DAVID P ANTIGONISH 6376 CULLIGAN, W BRENT HALIFAX 12400 CUMMINGS, ELIZABETH A HALIFAX 11177 CURLEY, MICHAEL A HALIFAX 13292 CURLEY, WILLIAM F TRURO 10895 CURRIE, THOMAS B SYDNEY 11332 CURRY, PHILIP L SYDNEY RIVER 7408 CURRY, STEPHEN A HALIFAX 10642 CURTIS, GARY M TRURO 3037 CURTIS, HEATHER A HALIFAX 13293 CURTIS, JOHN C BEDFORD 4913 CURTIS, JOYCE B HALIFAX 4766 CURWIN, JULIE M SYDNEY 12871 CUSSEN, MICHAEL J NEWPORT 7034 CUTLER, SUSAN E NEW GLASGOW 14635 CWAJNA, WLADYSLAWA HALIFAX 10791 D'ANJOU, CATHERINE M HALIFAX 13848 D'ARCY, DIANE L HALIFAX 7537 D'ENTREMONT, JULITE L BRIDGEWATER 14638 D'ENTREMONT, LIONEL J METEGHAN CENTRE 4767 D'EON, JACQUELINE R PUBNICO 10491 D'INTINO, ANNE F SYDNEY 6510 D'INTINO, YOLANDA M SYDNEY 6852 DABBOUR, SAM HALIFAX 13024 DAHN, UWE HALIFAX 15703 DAKIN HACHE, KELLY A HALIFAX 12401 DAMACEN, HARVEY HALIFAX 14859 DARVESH, SULTAN HALIFAX 7965 DAS, BIJON HALIFAX 12673 * DAUPHINEE-BENTLEY, P K PARRSBORO 14109 DAVEY, COLIN F LOWER SACKVILLE 10021 DAVID, YASMINE HALIFAX 3318 DAVIDSON, DION L KENTVILLE 13945 DAVIS, DONNA J HALIFAX 10792 DAVIS, GEORGE R DARTMOUTH 4463 DAVIS, IAN R HALIFAX 11869 DAVIS, JOANN E HALIFAX 11257 DAVIS, MARY L HALIFAX 11193 DAVIS, PHILIP J WEST PENNANT 3699 DAWOOD, ISIS HALIFAX 13757 DAYAL-GOSINE, LYSTRA R HALIFAX 3229 DE BOER, CORNELIS TRURO 11324 DE SAINT SARDOS, A G BRIDGEWATER 14759 DE, SABE K BEDFORD 12402 DEARMAN, LISA M WOLFVILLE 10094

* Refer to a page 22 for alternate Pharmacare prescriber number. 5

SURNAME TOWN/CITY CPSNS DEBAIE, DARALYN M HALIFAX 14636 DECOSTE, REBECCA HALIFAX 12403 DELANEY, SUSAN M DARTMOUTH 12404 DELISLE, ISABELLE M HALIFAX 7637 DELIU, ENVER HALIFAX 12575 DELVA, M DIANNE HALIFAX 14516 DELVA, NICHOLAS J HALIFAX 14275 DEMCOE, ALISTAIR R 14706 DEMIAN, HANY A HALIFAX 14593 DEMPSEY, IAN M DARTMOUTH 11534 DEMPSTER, JEFFREY J HALIFAX 12548 DEROCHE, STEVEN A PETIT DE GRAT 15688 DESHWAL, NATASHA A BEDFORD 11258 DESORMEAU, LEON M ANTIGONISH 6318 DESORMEAUX, YVON ELMSDALE 12944 DESROSIERS, JACQUES G HALIFAX 7469 * DEVARAJAN, S HALIFAX 10365 DEVEAU, JOEY METEGHAN CENTRE 15150 DEVITT, JAMES H HAMMONDS PLAINS 12353 * DHAR, NEELMA HALIFAX 7549 DHARA, ARUNDHATI HALIFAX 15173 DHAWAN, BALCHANDRA YARMOUTH 15439 DIAS, E BERNICE GLACE BAY 11377 DIAZ, PEDRO E LOWER SACKVILLE 13816 DICKIESON, ANDREW W HALIFAX 12137 DICKINSON, JOHN D HALIFAX 11558 * DICKSON, GENA E BERWICK 7062 DIEFENBACH, KATHRYN L AYLESFORD 6209 DILL, ALAN S ANNAPOLIS ROYAL 3580 DINGLE, MARGARET A HALIFAX 4958 DINI, EZIO M HALIFAX 12991 DIPCHAND, CHRISTINE S HALIFAX 10795 DIQUINZIO, CLAUDIO HALIFAX 10001 DOANE, FRANK R HALIFAX 4827 DOBEK, ISABELLA CHESTER 10297 DOBEK, LUKE HALIFAX 14224 DOBSON, DIANA C NORTH SYDNEY 4242 DOBSON, GREGORY R HALIFAX 11837 DOBSON, REBECCA L HALIFAX 6652 DOCHEV, ATANAS BRIDGEWATER 14270 DODD, FAITH SYDNEY 14519 DOLHANTY, DOROTHY A MIRA ROAD 10099 DONKERVOORT, LAURA V LONDON 15074 DOOLEY, JOSEPH M HALIFAX 6365 DORAN, WILLIAM WOLFVILLE 13433 DORREEN, MARK S HALIFAX 12237 DOUCET, ALBERT D LIVERPOOL 4705 DOUCET, ROBYN T HALIFAX 15231 DOUCETTE, PAUL B DARTMOUTH 12358 DOUGLAS, ANDREW C PICTOU 6361 DOW, MICHELLE M METEGHAN CENTRE 7571 DOYLE, CRYSTAL R FALL RIVER 15049 DOYLE, MARY A SYDNEY 7194 DRAKE, WENDY T HATCHET LAKE 11416 DRAPEAU, DENNIS J HALIFAX 12406 DRUCKER, ARIK M HALIFAX 13027 DRYSDALE, SCOTT M HALIFAX 10100 DRYSDALE-BUHR, C L HALIFAX 7135 DU TOIT, DANIEL J BRIDGEWATER 15435 DUFFY, ANNE C HALIFAX 11384 DUGAS, GISELLE J METEGHAN CENTRE 14329 DUGAS, ISABELLE SYDNEY 12989 DUGGAN, MARY C HEBRON 3960 DUKE, STEPHEN M DARTMOUTH 14266 DUNBAR, MICHAEL J HALIFAX 10495 DUNN, MICHAEL V KENTVILLE 7772 DUNN, REX S SYDNEY 4942 DUPERE, DAVID HAMMONDS PLAINS 11097 DURLING, RONALD R PETITE RIVIERE 4379 DYACK, SARAH GLEN HAVEN 12524

SURNAME TOWN/CITY CPSNS DYKEMAN, M T DARTMOUTH 7898 DZIERZANOWSKI, MARTIN TRURO 12408 DZIEWALTOWSKA, B S HALIFAX 10578 EARLE, LYNDA M LIVERPOOL 13557 EASTON, ALEXANDER S HALIFAX 13537 EDGAR, DAWN C HALIFAX 10056 EDGAR, PHILIP A YARMOUTH 10258 EDMONDS, DIANE E PLEASANTVILLE 11725 EGAR, SUSANNE E INVERNESS 14964 EISENER, BEVERLEY M DARTMOUTH 6233 EL-BATNIGI, NEMER HALIFAX 13075 EL-HAWARY, RON HALIFAX 13963 EL-NAGGAR, WALID HALIFAX 14805 EL-ZUBEIDI, WASSIM NEW GLASGOW 14419 ELKOUT, LOTFIA HALIFAX 13827 ELLERKER, MARK R GLACE BAY 12272 ELLERKER, STEPHANIE P GLACE BAY 12274 ELLIOTT, CHRISTOPHER R NEW GLASGOW 4207 * ELLIOTT, DAVID C HALIFAX 6447 ELLIS, CATHERINE L HATCHET LAKE 10498 ELLIS, STEPHEN D TRURO 10796 ELLSMERE, JAMES C HALIFAX 12139 ELMEZUGHI, AHMED S HANWELL 15065 ELNAGAR, ISLAM S HALIFAX 14597 ENGLISH, KELTIE J LOWER SACKVILLE 7682 ENRIGHT, WILLIAM M WINDSOR 6498 EPSTEIN, IAN L HALIFAX 13593 ERNEST, GARY P LIVERPOOL 6238 ESPINAL MONTOYA, V H SYDNEY 14584 ESSER, MICHAEL HALIFAX 14767 ETCHES, SELENE M HALIFAX 13594 ETTEHAD DABAGH, M PARRSBORO 15725 EVANS, MICHAEL D HALIFAX 7354 EWING, KAREN D BASS RIVER 11340 FAHIM, MOHAMMAD NEW GLASGOW 14298 FAIRFIELD, SONIA SYDNEY 14150 FALVEY, DENIS M ROSE BAY 4843 FARINA, DANA M HALIFAX 11420 FARINHOLT, HEIDI-MARIE A TRENTON 15669 FAROOQ, MOHAMMAD SYDNEY 4396 FARRELL, E STEPHEN NEW WATERFORD 4630 FARRELL, GERALD E NEW GLASGOW 6193 FARRELL, SCOTT A HALIFAX 7756 FASHIR, BAROUDI M SYDNEY 13796 FASHORANTI, O O PUGWASH 10984 FAY, DONALD F HALIFAX 6262 FELDERHOF, CATHARINA A PICTOU 4528 FELDERHOF, RICHARD P MERIGOMISH 3721 FELTMATE, MARY F TRURO 12874 * FERGUSON, CRAIG A BRIDGEWATER 12374 FERGUSON, G BRIAN AMHERST 6216 FERGUSON, JEANNE M ROSS FERRY 11694 FERGUSON, LINDA M TRURO 7976 FERGUSON, MURDO TRURO 8090 FERGUSON-LOSIER, N M DARTMOUTH 10798 FERNANDEZ, CONRAD V HALIFAX 10866 FERNANDEZ, LOUIS A HALIFAX 4273 FEWER, KAREN A MIDDLE MUSQ 11544 FIELD, DEANNA J TRURO 13923 FIELD, SIMON W HALIFAX 13167 FIELDUS, WARREN HALIFAX 13595 FIGUEROA PEREZ, M DARTMOUTH 13791 FILLITER, BRUCE D DARTMOUTH 4550 FINKE, STEFAN HALIFAX 15385 FINKLE, SIMON NEIL HALIFAX 11262 FINLAYSON, ALEXANDER M HALIFAX 7006 FINLAYSON, LAURA A BEDFORD 7253 FINLEY, G ALLEN HALIFAX 7059 FINLEY, JOHN P HALIFAX 4861 FINNAMORE, RYAN E HALIFAX 13759

* Refer to a page 22 for alternate Pharmacare prescriber number. 6

SURNAME TOWN/CITY CPSNS FINNEGAN, MARTIN M MONCTON 10192 FITZ-CLARKE, JOHN R HALIFAX 11052 FITZGERALD, JAMES M LOWER SACKVILLE 3866 FLAVELLE, SHAUNA C HALIFAX 14428 FLECKENSTEIN, MARTIN H NEW MINAS 7579 FLEETWOOD, IAN G HALIFAX 12960 FLEMING, MICHAEL FALL RIVER 4981 FLEMMING, BRUCE K HALIFAX 4896 FLETCHER, MARK A DARTMOUTH 11024 FLINN, ROGER M PORT WILLIAMS 3708 FLYNN, MICHAEL S HALIFAX 7156 FOLEY, ANITA A GUYSBOROUGH 4533 FOLEY, BRIAN SYDNEY 8153 FOLINSBEE, CATHERINE D TRURO 6837 FORAN, JOCELYN PORT WILLIAMS 11908 FORBES, CYNTHIA A FALL RIVER 13184 FORBES, JOHN G WESTVILLE 4692 FOROUZESH, BAHRAM SYDNEY 15442 FORSHNER, DAVID D PUGWASH 4187 FORT, STEPHEN HALIFAX 13377 FORWARD, KEVIN R HALIFAX 7734 FOSTER, D LYNETTE BEDFORD 14834 FOUAD, MAGDY A NEW GLASGOW 10432 FOX, HILDA M FALL RIVER 4179 FOX, JONATHAN R FALL RIVER 11789 FOX, ROY A WAVERLEY 4140 FOX, SCOTT 13656 FOYLE, ANNETTE FALL RIVER 4719 FOYLE, CATHARINE DARTMOUTH 14877 FRABONI, THERESA L HALIFAX 12382 FRAGER, GERALDINE HALIFAX 11334 FRAGOSO, ZAIDA LOWER SACKVILLE 13001 FRASER, HUGHIE F CONQUERALL MILLS 15201 FRASER, JAMES D HALIFAX 10615 FRASER, JOHN R HALIFAX 4889 FRASER, LOUIS H WINDSOR 11984 FRASER, MARGARET A SYDNEY 14731 FRASER, MARY-ANNE ENFIELD 7841 FRASER, ROBERT B HALIFAX 7933 FRASER, RONALD I TRURO 11402 FRASER, ZACHARY R DARTMOUTH 4717 FREER, JANYA M HALIFAX 15507 FRETER, SUSAN H HALIFAX 12306 FRIEL, PATRICK H YARMOUTH 6547 FRIZZLE, TENA A AMHERST 12574 FUHRMANN, MARLENE B ANTIGONISH 6736 FULLER, PENELOPE J ANTIGONISH 7246 FUREY, ELIZABETH A HALIFAX 14433 FUREY, WILLIAM SCOTT HALIFAX 13597 FYNN, JOHN K AMHERST 14252 GADIR, YOUSIF HAMMONDS PLAINS 12469 GAGNON, LINDA L DARTMOUTH 6870 GAJEWSKI, JERZY B HALIFAX 7302 GALLACHER, WILLIAM HALIFAX 8083 GALLAGHER, KATHLEEN M BEDFORD 8019 GALLANT, CHRISTOPHER J DARTMOUTH 7256 GALLANT, PAULA M KENTVILLE 10049 GALLANT, STEVE J ANTIGONISH 8038 GALLIVAN, GLENN G ANTIGONISH 10290 GALLIVAN, MICHAEL P GLACE BAY 7222 GAMMELL, LISA SYDNEY 13301 GANDHI, KARAMCHAND J BRIDGEWATER 3465 GARCIA DEL BUSTO, ELENA BADDECK 14687 GARDNER, ANGUS J SYDNEY 4042 GARDNER, MARTIN J HALIFAX 6196 GARVEY, BRIAN M CANNING 4450 GASKIN, DAVID A HALIFAX 13265 GASS, DAVID A HALIFAX 4884 GATIEN, JOHN G HALIFAX 3641 GAZIT, VERED HALIFAX 15117

SURNAME TOWN/CITY CPSNS GEBRE-HEYWOT, TSEDALE GRAND LAKE 11339 GEE, SHIRL A HAMMONDS PLAINS 11269 GELDENHUYS, LAURETTE HALIFAX 12097 GELLRICH, PASCAL HALIFAX 14753 GENGE, ROLAND J BADDECK 4356 GEORGE, RONALD B HALIFAX 12677 GEORGE, SHAUN R BERWICK 10280 GEORGE, STAN P HALIFAX 12876 GERGES, MAGED F HALIFAX 14250

GERMANUS, FATEN S BARRINGTON PASSAGE 15739

GHAFFARI, SEYED R BRIDGEWATER 14906 GHANEM, YAZAN M PICTOU 14881 GHENEA, IRINA NORTH SYDNEY 12555 * GIACOMANTONIO, CARMAN HALIFAX 10105 GIACOMANTONIO, JAMES M HALIFAX 6112 GIACOMANTONIO, N HALIFAX 11243 GIBBON, STEPHEN B HALIFAX 4049 GIBSON, RICHARD J DARTMOUTH 6276 GIFFIN, BARRY D MIDDLE MUSQ 7389 GILL, RICHARD K HALIFAX 4758 GILLESPIE, LAURIE H YARMOUTH 14330 GILLIATT, ERICA P HALIFAX 10107 GILLIS, AMY E STELLARTON 13598 GILLIS, AMY E HALIFAX 14874 GILLIS, GRANT G HALIFAX 10801 * GILLIS, JOHN M DARTMOUTH 12636 GILLIS, L JANE HALIFAX 13391 GILLIS, LISA A EASTERN PASSAGE 13575 GILMOUR, DONNA T HALIFAX 12245 GINN, JOHN L DARTMOUTH 11241 GINTHER, DAVID G HALIFAX 7994 GIORNO, ANDREW M SYDNEY 14979 GLASGOW, DANIEL F SYDNEY 4585 GLASGOW, MICHAEL J TATAMAGOUCHE 7370 GLAUDE, SIMON-PIERRE SYDNEY FORKS 15644 GLAZEBROOK, KATHERINE HALIFAX 11100 GLAZEBROOK, MARK A HALIFAX 11101 GOBRAN, GEHAD HALIFAX 13514 GODDARD, PETER AYLESFORD 2781 GODDARD, TOM A WOLFVILLE 11961 GODKIN, TIMOTHY A HALIFAX 11827 GOLD, ELISABETH HALIFAX 7785 GOLDCHTAUB, VALERI NEW GLASGOW 14808 GOODINE, GRANT A LAWRENCETOWN 6948 GOODMAN, MARNI NEW MINAS 13419 GOODWIN, JANICE R DARTMOUTH 10108 GORDON, ALFRED DARTMOUTH 5146 GORDON, ANN K KENTVILLE 15380 GORDON, EDWARD G DARTMOUTH 11533 GORDON, JANET E HALIFAX 11488 GORDON, KEVIN E HALIFAX 7708 GORMAN, MARY C ANTIGONISH 6630 GORMAN, WAYNE M YARMOUTH 4057 GOSSE, G CRAIG BEDFORD 6999 GOW, NINA M HALIFAX 7802 GOWAN, SUSAN E HALIFAX 6686 GRACIE, GLEN A SYDNEY 4048 GRADA, ATEF HALIFAX 15759 GRADSTEIN, JANNEKE S AMHERST 14285 GRADSTEIN, ROETKA HALIFAX 14384 GRAHAM, CHRISTOPHER H HALIFAX 6742 GRAHAM, DAVID J GLEN MARGARET 4615 GRAHAM, JOHANNA H HALIFAX 10502 GRAHAM, JOHN P UPPER TANTALLON 6090 GRAHAM, ROBERT D TRURO 4973 GRANDY, ELWOOD C WINDSOR 6526 GRANT, DAVID A KENTVILLE 6525 GRANT, DOUGLAS A HALIFAX 11649 GRANT, IAN A HALIFAX 11811

* Refer to a page 22 for alternate Pharmacare prescriber number. 7

SURNAME TOWN/CITY CPSNS GRANT, JOHN D WOLFVILLE 7359 GRANTMYRE, JOHN E HALIFAX 6528 GRAVEN, MICHAEL A HALIFAX 13716 GRAVES, GILLIAN R HALIFAX 6030 GRAY, ALLISON J HALIFAX 12543 GRAY, CHRISTOPHER J HALIFAX 12678 GRAY, GERALD E HALIFAX 4515 GREEN, PETER J HALIFAX 11270 GREEN, ROBERT S HALIFAX 11613 GREGOIRE, MARIE-CLAUDE HALIFAX 13603 GREGOIRE, TRIXIE L HALIFAX 13121 GREGOR, RONALD D HALIFAX 3746 GREGUS, VOJTECH DARTMOUTH 10289 GRIFFIN, LESLIE B HALIFAX 11102 GRIFFIN, LISA J BEDFORD 13730 GRIMSHAW, ROBERT N HALIFAX 10299 GROSS, MICHAEL HALIFAX 7278 GRUCHY, STEVEN E HALIFAX 13922 GUBITZ, GORDON HALIFAX 11528 GUERIN, JOHN M HALIFAX 15681 * GUNDOGAN, MUNIRE HALIFAX 14249 GUNN, DAVID LIVERPOOL 13303 GUNN, ROBERT F KENTVILLE 4659 GUPTA, JAGDISH S SYDNEY 2964 GUPTA, REKHA HALIFAX 6152 GUPTILL, JONI E DARTMOUTH 14604 * GUPTILL, M ELIZABETH BRIDGEWATER 4991 GURUSAMY, DEEPA COLDBROOK 14103 GUY, TREVOR J SYDNEY 13856 HAASE, DAVID A HALIFAX 6790 HABIB, EMAD 12523 HABIBA, AYMAN A SYDNEY 14587 HACHE, A JOHN HALIFAX 12680 HACK, IMRAN NEW GLASGOW 6249 HACKMANN, THOMAS HALIFAX 10057 HACKSHAW, CHRISTIAN M MAHONE BAY 14607 HADDAD, SUSAN J BEDFORD 15121 HADLAW, VIOLETTA A PORT WILLIAMS 10638 HAFIDH, MAKY SYDNEY 14235 HAIDER, UMAR HALIFAX 12949 HAIGH, DONALD DARTMOUTH 11620 HAJEK, TOMAS HALIFAX 13551 HALDANE, DAVID J HALIFAX 7068 HALEEM, SAIMA MIRA ROAD 13681 HALEES, WALID Y ANTIGONISH 14752 HALIK, JERRY J YARMOUTH 10008 HALL, ALLEN H CARLETON 1346 HALL, RICHARD I HALIFAX 6950 HALL, STEPHANIE DARTMOUTH 13149 HALPERIN, SCOTT A HALIFAX 6843 HAMILTON, GILLIAN R HALIFAX 12413 HAMILTON, JOHN R ANTIGONISH 6462 * HAMILTON, KEITH R HALIFAX 6202 HAMILTON, LINDA D HALIFAX 11427 HAMILTON, ROGER D WOLFVILLE 10568 HAMM, CHARLES P KENTVILLE 13079 HAMMEL, KENNETH H NEW GLASGOW 13952 HAMSON, ANDREW C HALIFAX 10315 HANADA, EDWIN Y HALIFAX 11428 HANCOCK FRIESEN, C L HALIFAX 11829 HANCOCK, CAROLINE A ANNAPOLIS ROYAL 11830 HANCOCK, JENNIFER N HALIFAX 13987 HANLEY, W ERIC HALIFAX 6996 HANLY, JOHN G HALIFAX 7356 HANNA, ADALA HALIFAX 15349 HANNA, MARY H HALIFAX 15491 HANSON, SONYA DARTMOUTH 12479 HANSPAL, RAJVINDER S SYDNEY 15093 HAQ, SHEIRA NEW WATERFORD 13128 HAQUE, SHAMIM ANTIGONISH 14878

SURNAME TOWN/CITY CPSNS HARDING, ROY A WINDSOR JUNCTION 8128 HARLESS, WILLIAM W SYDNEY 15675 HAROON, BABAR A HALIFAX 15360 HARRIGAN, LYNNE A KENTVILLE 7615 HARRIS, ANDREW S HALIFAX 11430 HARRIS, COLIN J KENTVILLE 13606 HARRISON, DEAN AMHERST 13164 HART, RENEE S DARTMOUTH 12887 HART, ROBERT D HALIFAX 12415 HARVEY, WILLIAM L ELMSDALE 11650 HASAN, AZRA SYDNEY 14154 HASEGAWA, WANDA S HALIFAX 14008 HASSAN, ABDALLA A BRIDGEWATER 11812 HASSAN, ANSAR 11904 HASSAN, SAMEH M DARTMOUTH 14836 HATCHETTE, TODD F HALIFAX 11970 HATFIELD, PETER W HALIFAX 8067 HATHEWAY, RONALD J BRIDGEWATER 7279 HAWKINS, ANN E HALIFAX 6029 HAWORTH, DAMIAN J HAMMONDS PLAINS 13276 HAYDEN, DAVID S BRIDGEWATER 11108 HAYES, VONDA M HALIFAX 3735 HAYNE, ORMILLE A HALIFAX 2763 HAZELTON, LARA D HALIFAX 11109 HEATHCOTE, JOHN G HALIFAX 13665 HEBB, ARTHUR M DARTMOUTH 5167 HEBB, MATTHEW O 13037 HECKLER, LISA V HALIFAX 14688 HEEDE, SANTA HALIFAX 15706 HEELAN, JOHN A HALIFAX 10372 HEFFERNAN, LEROY P KENTVILLE 3292 HEGARTY, RAYMOND ANTIGONISH 12503 * HEIKAL, RUBY BEDFORD 14044 HEISLER, BENJAMIN E KENTVILLE 11272 HELYER, LUCY K HALIFAX 12249 HEMANI, RAZI H YARMOUTH 15701 HENDERSON, J DAVID TRURO 13506 HENDERSON, JANE M HALIFAX 7558 HENDY, AYMAN M HALIFAX 15738 HENNEBERRY, RYAN J WAVERLEY 12683 HENNENFENT, BRETT W LUNENBURG 11625 HENTELEFF, HARRY J HALIFAX 11215 HENZLER, DIETRICH HALIFAX 14520 HERGETT, SUSAN C WOLFVILLE 10109 HERING, RAMM HALIFAX 14446 HERMAN, SHAUNA P STILLWATER LAKE 14157 HERMANN, LAURA L WINNIPEG 14689 HERNANDEZ, MARIA D AMHERST 13677 HERNANDEZ, PAUL HALIFAX 11354 HEUGHAN, DAVID M BADDECK 14691 HEWINS, EDWARD A KENTVILLE 10068 HEWLETT, THOMAS J SYDNEY 10902 HICKCOX, SAMUEL E HALIFAX 13983 HICKEY, D PAUL NORTH SYDNEY 3908 HICKEY, JOHN S ANTIGONISH 4255 HICKEY, MICHAEL A HALIFAX 15657 HICKS, SHAWN D HALIFAX 15487 HIGGINS, TERRANCE F HALIFAX 3557 HILLIARD, JENNIFER Y KENTVILLE 15084 HILLIS, MICHAEL T PORT WILLIAMS 10930 HILLYARD, JEREMY W ANTIGONISH 11489 HIMMELMAN, DONALD W PLEASANTVILLE 3814 * HINDLER, LIONEL R SHUBENACADIE 10670 HIPWELL, ALEXANDER E DARTMOUTH 6704 HIRSCH, DAVID J HALIFAX 6645 HIRSCH, GREGORY M HALIFAX 11342 HOFFMAN, DANIEL B PICTOU 8016 HOFNER, GRAZYNA W TRURO 10807 HOLLAND, STEWART DARTMOUTH 4434 HOLLENHORST, HELMUT HALIFAX 13763

* Refer to a page 22 for alternate Pharmacare prescriber number. 8

SURNAME TOWN/CITY CPSNS HOLMES, ANDREW I BADDECK 11007 HONG, PAUL HALIFAX 13673 HOOGERBOORD, C PRINCE ALBERT 15629 HOPKINS, GARY W DARTMOUTH 7529 HORNE, S GABRIELLE HALIFAX 11154 HORNER, GORDON W DARTMOUTH 4593 HORREY, KATHLEEN A HALIFAX 12148 * HORTON, NATALIE L YARMOUTH 10210 HORTON, ROBERT P HALIFAX 10948 HOSEIN, JALAL WELLINGTON 4075 HOSKIN-MOTT, ANN E HALIFAX 6176 HOUCK, LESLIE V TRURO 12946 HOUSTOUN, ANNE HALIFAX 7130 HOWARD, JANE A ANTIGONISH 14211 HOWARD, JANET L DARTMOUTH 6716 HOWARD, JASON J HALIFAX 14873 HOWATT, ERIC B KENTVILLE 7036 HOWE, DAVID H PARRSBORO 11520 HOWLETT, TODD C DARTMOUTH 11029 HUANG, WEEI-YUARN HALIFAX 13921 HUBER, ADAM M HALIFAX 12383 HUBLALL, RONALD V YARMOUTH 15206 HUDEC, MARY-ANN HALIFAX 10312 HUGHES, DANIEL M HALIFAX 6720 HUMAYUN, MUHAMMAD DARTMOUTH 4180 * HUMPHREY, ANDREW B HALIFAX 10111 HUNG, ORLANDO R HALIFAX 7225 HURLEY, KATRINA F HALIFAX 13039 HUSSAIN, KHALID M SYDNEY 13396 HUSSEIN, ABIR H YARMOUTH 15726 HUSSEIN, MOHAMED SYDNEY 13209 HUTCHISON, MARY E NORTH SYDNEY 4541 HYDORN, THOMAS G AMHERST 7510 HYMAN, MICHAEL P GRANVILLE FERRY 12608 HYNDMAN, JOHN C HALIFAX 4173 IBRAHIM, WAEL STELLARTON 15484 IGNACIO, BAYANI S SYDNEY MINES 2823 IGNACIO, EUGENE E SYDNEY MINES 6894 IGOE, MICHAEL P NORTH SYDNEY 7426 IKEDE, AJIROGHO E DARTMOUTH 14432 ILES, SIAN E HALIFAX 6846 IMRAN, S ALI HALIFAX 12473 IMRIE, DAVID D HALIFAX 3754 ING, VINCENT W HALIFAX 2747 INGARFIELD, HEATHER L HALIFAX 10877 INGHAM, ANDREW B HALIFAX 11980 IQBAL, MIRZA N YARMOUTH 14976 IRWIN, MANDI R HALIFAX 14741 ISAC, FOUAD A YARMOUTH 4611 ISSEKUTZ, ANDREW C HALIFAX 6037 ISSEKUTZ, THOMAS B HALIFAX 6306 IZZARD, J BRAD DARTMOUTH 11655 JABEEN, SHAIFTA BEDFORD 13474 JACKMAN, CHRISTOPHER S HALIFAX 14253 JACKSON, PETER D SYDNEY 5583 JACKSON, SIMON D HALIFAX 10240 JACOBS, ROBERT J NEILS HARBOUR 13974 JAIN, SHERRY HALIFAX 14262 JALA, VIKRAM R NEW GLASGOW 14611 JAMES, SHERRY L LOWER SACKVILLE 13861 JAMIESON, CHRISTOPHER HALIFAX 11525 JANGAARD, KRISTA A HALIFAX 10703 JANKE, EDWIN M YARMOUTH 6173 JANSEN, GREGORY W BRIDGEWATER 7301 JARVIE, ANDREW HALIFAX 13801 JARVIS, CARL W HALIFAX 10808 * JARVIS, JOLENE E HUBBARDS 13225 JAYABARATHAN, AJANTHA HALIFAX 10264 JAZRAWI, BASHAR L STELLARTON 15495 JEANS-MINGO, L AULAYNE NEW GLASGOW 7406

SURNAME TOWN/CITY CPSNS JEFFREY, CAM A TRURO 13646 JELLEMA, DICK HEAD ST MARG BAY 11331 JENKINS, JOHN T LUNENBURG 10507 JEYAKUMAR, ALWIN HALIFAX 14057 JHA, UMESH C HALIFAX 4778 * JHIRAD, RONEN H MIRA ROAD 15130 JIWANI, ALMAS A BERWICK 14328 JOHNSON, ALPHONSE J HALIFAX 3094 JOHNSON, ERNEST B HALIFAX 1887 JOHNSON, HEATHER O BRIDGEWATER 12492 JOHNSON, JOHN K HALIFAX 11777 JOHNSON, KEVIN W BRIDGEWATER 12491 JOHNSON, KRISTINE A HALIFAX 11364 JOHNSON, LIANE B HALIFAX 11277 JOHNSON, PAUL M HALIFAX 11433 JOHNSTON, BARBARA L HALIFAX 7293 JOHNSTON, CHRISTOPHER FALL RIVER 13482 * JOHNSTON, DAVID G HALIFAX 6955 JOHNSTON, DENNIS W HALIFAX 5179 JOHNSTON, J MARK KENTVILLE 11656 JOHNSTON, MICHAEL R HALIFAX 14321 JOHNSTONE, JAMES E HALIFAX 14730 JOLLIMORE, JASON V TRURO 12152 JOLLYMORE, BRIAN D WOLFVILLE 8120 JOLLYMORE, GEORGE C CHESTER 2093 * JONASSON, JAMES D KINGSTON 15039 JONES, BRENT D HALIFAX 13242 JONES, BRONWEN A BLACK POINT 10026 JONES, CHRISTOPHER T HALIFAX 15642 JONES, GORDON R HALIFAX 4474 JONES, HEATHER D HALIFAX 13252 JONES, LORI M HALIFAX 14989 JONES, SARAH D UPPER TANTALLON 14434 JONES-LOCKE, DIANA C TRURO 8063 JONY, LOUAI TRURO 12481 JORGENSEN, SALLY MAHONE BAY 7740 JOSEPH, MARY K CANNING 12515 JOSEPH, PAUL K HALIFAX 7851 JOSEPHSON, E BRUCE HALIFAX 11761 JOSHI, CHANGULANDA NEW GLASGOW 13432 JOST, ELLEN HALIFAX 13721 * JOTA, JOSE M WESTVILLE 15077 JOY, ANDREA E EASTERN PASSAGE 11833 JOY, GRAHAM A EASTERN PASSAGE 11112 JOYCE, BRENDA M HALIFAX 7922 JUNEK, WADE HALIFAX 6299 JURGA, MILAN ANTIGONISH 11630 KADIR, NAJEEB A AMHERST 13807 KAHWASH, EIAD D HALIFAX 14802 KAIPRATH, SOUMINI NEW GLASGOW 13529 KAISER, STEPHANIE HALIFAX 13161 KAJETANOWICZ, ANDRZEJ SYDNEY 10442 KAJETANOWICZ, DANUTA M SYDNEY RIVER 8070 KALER, SHARONA A HALIFAX 14718 KALYAN, SANGEETA BRIDGEWATER 15147 KANAAN, HASSAN D SYDNEY 15100 KANAGASABAI, SIVAKUMAR COLDBROOK 15729 KANELLAKOS, GEORGE W HALIFAX 13240 KAPILAN, PRIYADHARSINI M BEDFORD 13803 KAPUR, FARAH FALL RIVER 11371 KAPUR, SANDEEP HALIFAX 10864 KARANWAL, DEREK A ALBERT BRIDGE 15783 KARIVELIL, JOSHY A SPRINGHILL 14317 KASINA, RAFAL A WINDSOR 7714 KAUL, SANJEEV AMHERST 14218 KAWCHUK, JANET HALIFAX 8028 KAWCHUK, TERRY P HALIFAX 7076 KAZIMIRSKI, JUDITH C FALMOUTH 3601 KAZIMIRSKI, MARK WINDSOR 3602 KEATING, M-M HALIFAX 14161

* Refer to a page 22 for alternate Pharmacare prescriber number. 9

SURNAME TOWN/CITY CPSNS KEELER, JOHN E SHELBURNE 6898 KEENAN, ROBERT J HALIFAX 14853 KELLAND, ALISON A CHESTER 4646 KELLS, CATHERINE M HALIFAX 7709 KELLY, CATHERINE L LUNENBURG 6592 KELLY, COLLEEN M HALIFAX 7755 KENT, BLAINE A HALIFAX 11659 KEOUGH, VALERIE J HALIFAX 12154 KEOUGH-RYAN, TAMMY M HALIFAX 11279 KESHEN, AARON HALIFAX 13610 KEW, ANDREA K HALIFAX 12688 KHALIFA, ABDUL M PORT MORIEN 2567 KHALIL, HISHAM A BEDFORD 15236 * KHALIL, TAREK H HALIFAX 14851 KHAN, ASIF A NEW GLASGOW 15353 KHAN, FAREEHA S ESKASONI 13865 KHAN, M NAEEM HALIFAX 12881 KHAN, MUHAMMAD A SYDNEY RIVER 13864 KHAN, SYMA A HALIFAX 15329 KHODADAD, KIAN K SYDNEY 15676 KHOROVETS, ANDREI HALIFAX 14579 KIBERD, BRYCE A HALIFAX 10734 KIDWAI, BAKHTIAR J HALIFAX 12993 KIESER, KATHARINA E HALIFAX 11662 KILCOLLINS, CALVIN T WINDSOR 4552 KILLEEN, RONALD A LOWER SACKVILLE 4517 KIM, EUISEOK HALIFAX 14992 KING, DAVID B HALIFAX 3995 KING, ELIZABETH A ANNAPOLIS ROYAL 13274 KING, YVONNE KENTVILLE 6001 KINLEY, C EDDY HALIFAX 7453 KINLEY, JACQUELINE L HALIFAX 13152 KINNEAR, HILARY A DARTMOUTH 11910 KINSLEY, GRANT CHURCH POINT 13771 KIRBY, JEFFREY C HALIFAX 4920 KIRBY, RONALD L HALIFAX 4482 * KIRBY, SARAH HALIFAX 10941 KIRK, DUNCAN GRANT STELLARTON 4228 KIRKPATRICK, DAVID A HALIFAX 6084 KIRKPATRICK, JOHN H NORTH SYDNEY 6529 KIRMANI, SALEEM AMHERST 15133 KIS, JOANNA HALIFAX 13828 KISHTA, WALEED E HALIFAX 15180 KITAMURA, KELLY M HALIFAX 11403 KLASSEN, BRIAN D 11437 KLASSEN, DENNIS R HALIFAX 12287 KLIMEK, MAREK 10641 KLONOWSKA, M-T DARTMOUTH 10444 KLONOWSKA-PHILLIPS, M E DARTMOUTH 13198 KLYNSTRA, SANDRA J BOUTILIERS POINT 6877 KNIGHT, DEBORAH C DARTMOUTH 4914 * KNOTT, Z MAREK SYDNEY MINES 10355 KODAGODA, DAYANANDA SYDNEY 11604 KOHLSMITH, DOUGLAS J SYDNEY MINES 7257 KOILPILLAI, CHRISTIANSEN HALIFAX 6588 KOLLER, KATALIN E HALIFAX 13310 KOLYSHER, PAULA L HALIFAX 11913 KOOKA, DARA M GLACE BAY 3480 KORMOS, ARPAD 3085 LIMASSOL 13774 KOSHI, EDVIN HALIFAX 12691 KOVACS, GEORGE HALIFAX 8084 KOWALCZYK, EARL S HALIFAX 15658 KOZEL, VITIA V TRURO 10238 * KOZOUSEK, VLADIMIR HALIFAX 7504 KRAWCZYK, JOHN G NEW GLASGOW 13450 KROL-LASS, JUSTYNA AMHERST 14512 KRONFLI, RISK N BEDFORD 10676 KRUEGER-NAUG, A M R HALIFAX 14164 KUMAR-CHUGH, PREM HALIFAX 7042 KUNCHERIA, JOY NORTH SYDNEY 10764

SURNAME TOWN/CITY CPSNS KUTCHER, STAN P HALIFAX 11229 KWAPISZ, MYRON M HALIFAX 14333 KWASNIK, ANNE M NEW GLASGOW 13449 KYDD, RICHARD W BRIDGEWATER 6219 KYSELA, ALENIA R YARMOUTH 15185 LACAS, ALETHEA D HALIFAX 15176 LACUESTA, GINA A HALIFAX 12052 LAFKOVICI, VLADIMIR BEAR RIVER 10460 LAFLEUR, EDITH P DARTMOUTH 12158 LAFONTAINE, ISABELLE SYDNEY 15740 LAFRANCE, MONIQUE S INVERNESS 12157 LAKOSHA, HESHAM HALIFAX 12514 LAMBETH, MICHELLE A DARTMOUTH 12083 LANG, BIANCA HALIFAX 6779 LANG, H BENNO HALIFAX 10816 LANG, MARIA T UPPER TANTALLON 7430 LANGDON, REX L HALIFAX 5208 * LANGE, JENNIFER A SYDNEY 13866 LANGILLE, DONALD B HALIFAX 4371 LANGILLE, KENNETH R AYLESFORD 15741 * LANGLEY, CHRISTINE E BEDFORD 10627 LANGLEY, JOANNE M HALIFAX 7944 LANGLEY, RICHARD G HALIFAX 10037 LANGLEY, STEPHANIE A NORTH SYDNEY 11283 LAPPIN, SUSAN F LOWER SACKVILLE 7551 LARKIN, TARA L NEW GLASGOW 15095 LAROCHE, G ROBERT HALIFAX 6397 LARSON, ALFHILD J HALIFAX 13518 LARYEA, MARIE A HALIFAX 12418 LASKOWSKI, ALEXANDRA M HALIFAX 12376 LASKOWSKI, DEREK HALIFAX 12560 LASSEY, STEVE PICTOU 11802 LATOUR, ANNE H SYDNEY 11841 LAUGHREN, JAMES J 14685 LAUNCELOTT, GORDON O HALIFAX 6032 LAURIA-HORNER, BIANCA A HALIFAX 7075 LAVALLEY, WILLIAM G CHESTER 7515 LAW, ANNI E BADDECK 7065 LAW, JOHN A HALIFAX 11230 LAW, JOYCE 14167 LAWAL, WAHEED O SYDNEY 15674 LAWAND, CHRISTOPHER M SYDNEY 13868 LAWEN, JOSEPH G HALIFAX 4967 LAWLESS, JILL M TIMBERLEA 13748 LAWRENCE, GILLIAN AMHERST 2742 LAZARIC, DANIEL M PORT WILLIAMS 11117 LAZIER, LORRAINE L FALMOUTH 10124 LAZOVSKIS, JURIS SYDNEY 13220 LEAHEY, J LORNE HALIFAX 6323 LEAHEY, SHELAGH M YARMOUTH 4512 LEAHY, JAMES R WINDSOR 6093 LEBLANC, CONSTANCE H HALIFAX 7741 LEBLANC, JOHN C HALIFAX 7991 LEBLANC, MARTIN R HALIFAX 13869 LEBLANC, RAYMOND P HALIFAX 6033 LEBLANC, ROBIN B DARTMOUTH 11664 LEBRUN, GERALD P HALIFAX 3328 LECKEY, NAIDA L LOWER SACKVILLE 10981 LECKEY, RICHARD N BEDFORD 11118 LEDDIN, DESMOND J HALIFAX 7749 LEE, GEORGE T HALIFAX 10237 LEE, MIN S HALIFAX 12160 LEE, PETER C DARTMOUTH 12161 LEE, PETER T NEW GLASGOW 6211 LEE, TONY C HALIFAX 15712 LEE, WILLIAM R DARTMOUTH 6293 LEE, WINIFRED W DARTMOUTH 12133 LEFEBVRE, GUY CALEDONIA 11618 LEFEL, OLEG YARMOUTH 15227 LEGARE, JEAN-FRANCOIS HALIFAX 11285

* Refer to a page 22 for alternate Pharmacare prescriber number. 10

SURNAME TOWN/CITY CPSNS LEGAY, DOUGLAS A DARTMOUTH 7030 LEGERE, PAUL W YARMOUTH 8049 LEHMANN, CHRISTIAN HALIFAX 14316 LEIGHTON, MARGARET M HALIFAX 4831 LEIGHTON, ROSS K HALIFAX 6876 LENNOX, A SCOTT BRIDGEWATER 14780 LESSARD, PIERRE L CANNING 11359 LEVERMAN, JENNIFER L HALIFAX 13470 LEWANDOWSKI, ROBERT L GLACE BAY 12006 LEWINGTON, DANIELLE C HACKETTS COVE 12101 LEWINGTON, RICHARD B HACKETTS COVE 12102 LEWIS, LORRAINE N DARTMOUTH 7325 LEWIS, VALERIE L HALIFAX 10583 LEY, DAVID C RESERVE MINES 10819 LEYENAAR, LAURINA K ROTHESAY 13870 LIBBUS, YVONNE E SYDNEY 10820 LIGHTFOOT, CHRISTOPHER HALIFAX 13871 LINCOLN, MAXIMILLIAN C NEW GLASGOW 15096 LINDENER, MARGO HALIFAX 7136 LINDENSMITH, JORIN M DARTMOUTH 12420 LITTLEJOHN, PETER W NEW WATERFORD 4299 LITZ, D SHARON HALIFAX 6369 LIVINGSTON, PATRICIA L HALIFAX 7879 LIVINGSTONE, JAMES B BRIDGEWATER 6189 LIWSKI, ROBERT S HALIFAX 13313 LLOYD, R GRAYSON PORT WILLIAMS 13615 LO, CHARLES D HALIFAX 6312 LO, FRANK L HALIFAX 6329 LOANE, THOMAS D HALIFAX 6403 LOCKE, TREVOR A TRURO 8064 LODGE, RICHARD HALIFAX 12311 LOGAN, HEATHER 12693 LOGAN, KARL J HALIFAX 15198 LOGAN, VANCE H W. PORTERS LAKE 6134 LOK, RAYMOND T INVERNESS 6601 LOOK, DIDIER S HALIFAX 13872 LOPEZ BLANCO, A V SYDNEY 15390 LORENZ, KONSTANTIN HALIFAX 14341 LOSHAJ, RYVE TRURO 14314 LOVE, MICHAEL P HALIFAX 13150 LOVERIDGE, PETER L GLENWOOD 4309 LOWE, WILLIAM M COLDBROOK 6012 LOWRY, BRIGITTE H NEW WATERFORD 11726 LUDMAN, MARK D HALIFAX 13258 * LUTWICK, RENEE E BEDFORD 7124 LYMBURNER, DANA L BEDFORD 15002 LYNCH, MARY E HALIFAX 6524 LYNK, ANDREW D SYDNEY 6539 LYNK, MARY E NEW WATERFORD 3919 LYONS, BRIAN J YARMOUTH 10938 M-SHENDEREY, INNA YARMOUTH 15135 MACAULAY, ANDRIA J TRURO 13461 MACAULAY, BRUCE D HALIFAX 11120 MACAULAY, PETER M COLE HARBOUR 7328 MACAULAY, ROBERT J BEDFORD 12239 MACCARA, ANNE S PICTOU 6341 MACCARA, MELANIE L NEW GLASGOW 10129 MACCORMICK, ELIZABETH SYDNEY MINES 6374 MACCORMICK, KEITH R WOLFVILLE 7565 MACCORMICK, RONALD E SYDNEY 4997 MACCORMICK, SHAUN A TRURO 6710 MACDONALD, ALLAN S SYDNEY 2099 MACDONALD, ANGUS C BADDECK 2096 MACDONALD, CARLA DARTMOUTH 11598 MACDONALD, DANIEL J TATAMAGOUCHE 13873 MACDONALD, DAVID A HALIFAX 12162 MACDONALD, DIANNE D HALIFAX 4963 MACDONALD, DONALD G SHEET HARBOUR 7159 MACDONALD, H PAUL STELLARTON 3880 MACDONALD, ILDIKO L BEDFORD 12542

SURNAME TOWN/CITY CPSNS MACDONALD, J GERARD AMHERST 6131 MACDONALD, JENNIFER L TRURO 13192 MACDONALD, JENNIFER L LIVERPOOL 13151 MACDONALD, JOANNE L HALIFAX 7924 MACDONALD, JOHN W DARTMOUTH 3569 MACDONALD, JON K NEW GLASGOW 4821 MACDONALD, KAREN A ANTIGONISH 12892 MACDONALD, KAREN A HALIFAX 6899 MACDONALD, MARION N STELLARTON 4446 MACDONALD, NANCY L HALIFAX 6322 MACDONALD, NONI E HALIFAX 12209 MACDONALD, PAUL J SYDNEY 7834 MACDONALD, RHEA C INVERNESS 13617 MACDONALD, SCOTT M FALL RIVER 13489 MACDONALD, SHANNON L HALIFAX 13046 MACDONALD, WILLIAM M NORTH SYDNEY 6342 MACDOUGALL, ALEXANDER HALIFAX 13479 MACDOUGALL, BRADLEY D WESTVILLE 15005 MACDOUGALL, CATHERINE HALIFAX 6913 MACDOUGALL, PETER C HALIFAX 12324 MACDOUGALL, RYAN F HALIFAX 14439 MACDOUGALL, STEVEN G MIRA ROAD 6719 MACDUFF, BLAIR A ANTIGONISH 14006 MACEACHERN, JOHN R BERWICK 6004 MACEACHERN, RON T NEW GLASGOW 12842 MACFARLANE, AMY E FALL RIVER 14036 MACFARLANE, ROBYN J HALIFAX 14061 MACGIBBON, S LOIS BEDFORD 14831 * MACGILLIVRAY, B JEAN ANTIGONISH 14288 MACGREGOR, JANICE M HALIFAX 10011 MACHEL, TERESA M WINDSOR 7463 MACHEL, WIESLAW J WINDSOR 7833 MACIEL-MIRANDA, JESUS A HALIFAX 15749 MACINNIS, BRIAN L BERWICK 6821 MACINNIS, MAUDE PORT HASTINGS 14671 MACINTOSH, BERNARD H NORTH SYDNEY 14440 MACINTOSH, DONALD G HALIFAX 12261 * MACINTOSH, REBECCA F HALIFAX 12253 * MACINTYRE, JANET K HALIFAX 12422 MACINTYRE, LISA A FALL RIVER 10521 MACKAY, IAN E TRURO 13619 MACKAY, ROSE L SYDNEY 12694 MACKAY, THOMAS J HALIFAX 15063 * MACKEAN, GERALD L HALIFAX 4661 MACKEAN-RIPLEY, SUSAN DARTMOUTH 14650 MACKENZIE, MICHAEL A ANTIGONISH 6241 MACKENZIE, ROBERT J ALBERT BRIDGE 14170 MACKILLOP, JAMES H SYDNEY 6680 MACKINNON, DAVID A MIDDLETON 4975 MACKINNON, HEATHER A HALIFAX 7783 MACKNIGHT, CHRIS R HALIFAX 10131 * MACLACHLAN, A JAMES PICTOU 12911 MACLACHLAN, DIANE E GLACE BAY 14800 MACLACHLAN, JOHN R WOLFVILLE 4708 MACLACHLAN, RICHARD HALIFAX 4378 MACLEAN, ALEX HALIFAX 14388 MACLEAN, C BERNARD INVERNESS 1892 MACLEAN, DAPHNE A ANTIGONISH 13917 MACLEAN, DAVID S DARTMOUTH 15128 MACLEAN, GREGOR W NEW GLASGOW 7331 MACLEAN, JAMES D GLACE BAY 13875 MACLEAN, MICHELE HALIFAX 12352 MACLEAN, MOIRA J BEDFORD 15716 MACLEAN, PAUL D MIDDLETON 4060 MACLEAN, RHONDA A HALIFAX 12423 MACLEAN, STEPHEN W BEDFORD 11394 MACLEAN-FRASER, ERIN ANTIGONISH 14497 MACLELLAN, DAWN L HALIFAX 11444 MACLELLAN, ROCHELLE LOWER SACKVILLE 14530 MACLENNAN, MARTIN T DARTMOUTH 11982

* Refer to a page 22 for alternate Pharmacare prescriber number. 11

SURNAME TOWN/CITY CPSNS MACLEOD, ALISON D KENTVILLE 13620 MACLEOD, SUSAN E SYDNEY 14522 MACLEOD, WAYNE HALIFAX 12496 MACMANUS, BRIAN J HALIFAX 6918 MACMULLIN, ELWOOD C SYDNEY 4994 MACNAUGHTON, JANET E WOLFVILLE 6917 MACNEIL, DAVID R BEDFORD 7342 MACNEIL, DOROTHY E SYDNEY 6271 MACNEIL, IAIN P ELMSDALE 7954 MACNEIL, MALCOLM L ARICHAT 6516 MACNEIL, MARY V HALIFAX 11567 * MACNEIL, MEAGAN A HALIFAX 14652 MACNEILL, JAMES R HALIFAX 3874 MACNEILL, JUDITH L HALIFAX 10523 MACNEILL, KARA E NEW GLASGOW 13047 MACNEILL, ROBERT B BEN EOIN 6571 MACPHEE, SHANNON DARTMOUTH 12867 MACPHERSON, MARILYN P TRURO 10685 MACPHERSON, RAYMA D DARTMOUTH 6375 MACQUARRIE, DONALD C HALIFAX 13315 MACQUARRIE, KIRK J HALIFAX 10826 MACQUARRIE, ROBYN M HEAD OF CHEZZ 14172 MACVICAR, G NEIL ALBERT BRIDGE 8041 MADER, JUDITH A HALIFAX 10352 MADHVANI, ASHWIN K YARMOUTH 6045 MADIGAN, MAUREEN A PORT WILLIAMS 13701 MAGEE, J FERGALL HALIFAX 14028 MAGEE, KIRK HALIFAX 11373 MAGUIRE, HUGH P TRURO 11074 MAHANEY, GORDON R DARTMOUTH 3875 MAHAR, ROBERT K HALIFAX 4944 MAHARAJ, MANDAT SYDNEY 10440 MAHDI, GAMAL E HALIFAX 15083 MAHENDRARAJAH, RANJINI GUYSBOROUGH 13743 MAHER, LAUREN H WEYMOUTH 14598 MAHMOUD-AHMED, A S SYDNEY 14223 MAIANSKI, IRIT R HALIFAX 14879 MAIANSKI, ZIV HALIFAX 15320 MAIDMENT, P DIANE EAST LAHAVE 10524 MAILMAN, TIMOTHY L HALIFAX 10827 MAJAESS, GEORGE G HALIFAX 7568 MAKHAN, WINSTON M STELLARTON 3724 MAKKAR, NINA TRURO 11125 MALAK, EMAD Y DARTMOUTH 14271 MALAN, J ETIENNE NEW GLASGOW 14854 MALDONADO GONZALEZ, D HALIFAX 15652 MALEKI, BABAK HALIFAX 13316 MALIAKKAL, RITA K L'ARDOISE 14869 MALIK, HATIM G SYDNEY 3387 MALIK, SAIRA DARTMOUTH 10603 MALIK, SHAHID L SYDNEY 13487 MALLERY, LAURIE H HALIFAX 10250 MALLOY, SUSAN J HALIFAX 7340 MALONEY, PAUL A ANTIGONISH 14902 MALONEY, WILLIAM J HALIFAX 7172 MALTBY, CATHERINE C PORT WILLIAMS 7691 MANCHIA, MIRKO HALIFAX 15175 MANGAT, NAVDEEP DIGBY 15009 MANKAVIL KOVILVEETIL, A HALIFAX 15648 MANN, COLIN G BRIDGEWATER 8026 MANN, OLGA E HALIFAX 4857 MANN, OTTO HALIFAX 4069 MANNING, J DAVID HALIFAX 10286 MANOS, DARIA HALIFAX 12696 MANOS, SARAH H HALIFAX 13080 MANSOOR, SAMINA SYDNEY 15141 MARAIS, ABRAHAM J YARMOUTH 14071 MARCHAND, DEBORAH J PORT HAWKESBURY 6814 MARCHE, JANET E HALIFAX 12513 MARE, FRANS YARMOUTH 15695

SURNAME TOWN/CITY CPSNS MARIER, GISELE BRIDGEWATER 10525 MARIOTTI, CARLO U HALIFAX 11666 MARSH, LORNE A HALIFAX 4918 * MARSHALL, ARTHUR D BRIDGEWATER 11289 MARSHALL, CINDY LOWER SACKVILLE 10526 MARSHALL, GENA M HALIFAX 11290 MARSTERS, DAVID W PORT WILLIAMS 4822 MARTEL, ROBERT F GRAND PRE 6511 MARTELL, DAVID R LUNENBURG 11667 MARTIN, KARYN L HALIFAX 14174 MARVAL-OSPINO, HEIZER HALIFAX 13878 MASON, WILLIAM F HALIFAX 1895 MASOUMI-RAVANDI, M BROOKFIELD 14481 MASSOUD, EMAD A HALIFAX 11357 MATEOS-CORRAL, DIMAS HALIFAX 15410 MATHESON, HUGH B HALIFAX 6520 MATHESON, LESLIE J HALIFAX 6751 MATHESON, TIMOTHY HAMMONDS PLAINS 14175 MATHISEN, BRIT L BRIDGEWATER 7314 MATSUSAKI, RONALD H DIGBY 14550 MATZ, ALEXANDER M YARMOUTH 12600 MAWDSLEY, SCOTT D DARTMOUTH 11291 MAXAN, EMILY E HALIFAX 14176 MAXNER, CHARLES E HALIFAX 6762 MAYER, A LISL HALIFAX 10830 MAYER, KRISTINE L SYDNEY RIVER 11442 MAYNES, DOUGLAS F HALIFAX 3879 MCADOO, KERI K NEW MINAS 11808 MCALLISTER, AMY L BEDFORD 15012 MCARTHUR, ALASTAIR KENTVILLE 7201 MCASLAN, K LYNN HALIFAX 6642 MCAULEY, PAUL MAHONE BAY 7358 MCBEATH, RODERICK I KENTVILLE 6172 MCBRIDE, GRAEME N DARTMOUTH 15013 MCCANN, D BURTON HALIFAX 7782 MCCARTHY, JOHN-PAUL KENTVILLE 13879 MCCARTHY, LEANNE S HALIFAX 13880 MCCARTHY, STEPHEN C TRURO 6228 MCCARVILLE, CLIFFORD DARTMOUTH 10831 MCCLELLAND, BRUCE BEDFORD 10693 MCCORMICK, KATE M DARTMOUTH 7536 MCCORMICK, SAMUEL A ANNAPOLIS ROYAL 14864 MCCORMICK, WILLIAM O LOWER SACKVILLE 6331 MCCRACKEN, L JOAN WOLFVILLE 4730 MCCROSSIN, J MURRAY AMHERST 10438 MCCULLOCH, DONNA M HALIFAX 10566 MCCURDY, JEFFREY D HALIFAX 14442 MCDONALD, ANDREA J HALIFAX 11651 MCDONALD, GORDON J 13882 MCDONALD, LINDSAY 14443 MCDONALD, LORI J HALIFAX 14484 MCFARLANE, BRIAN A PUGWASH 13817 MCGIBNEY, KIERON D TRURO 15186 * MCGORY, RODNEY W SYDNEY RIVER 13048 MCGRAIL, J SIMON DARTMOUTH 13967 MCGRATH, FIONA M HALIFAX 11758 MCGUIRE, PAUL B KINGSTON 4231 MCINTOSH, MARION C SYDNEY RIVER 2777 MCINTYRE, ALLAN J HALIFAX 4680 MCINTYRE, PAUL F HALIFAX 4735 MCKEEN, DOLORES M HALIFAX 11555 MCKELVEY, J ROGER DARTMOUTH 13154 MCKENNA, CHRISTINE J HALIFAX 12372 MCKENNA, PATRICIA J ANTIGONISH 4061 MCKENNEY, RODERICK N TRURO 8130 MCKEOUGH, MICHEL F SYDNEY MINES 6553 MCKIGGAN, JOHN J HALIFAX 2341 MCKINNON, GENEVIEVE HALIFAX 13883 MCLAUGHLIN, MICHAEL A DARTMOUTH 12348 MCLAUGHLIN, ROBYN A HALIFAX 13903

* Refer to a page 22 for alternate Pharmacare prescriber number. 12

SURNAME TOWN/CITY CPSNS MCLEAN, ANGUS D PORT WILLIAMS 10141 MCLEAN, JAMES R HUBBARDS 10303 MCLEOD, LYNNE HALIFAX 11445 MCLEOD, R BRUCE PORT WILLIAMS 7673 MCLERNON, SARAH L TANTALLON 13375 MCMAHON, LYNNE E DOMINION 12167 MCMILLAN, DOUGLAS D HALIFAX 13262 MCMILLAN, MERLE K KENTVILLE 14286 MCMULLEN, MARK A TANTALLON 11925 MCMULLEN, SARAH HALIFAX 14344 MCNAB, JOHN W FALL RIVER 4988 MCNALLY, CATHERINE E KENTVILLE 13123 MCNALLY, GREGORY T HEBBVILLE 7866 MCNEELY, P DANIEL HALIFAX 11669 MCNEIL, JOHN O TRURO 7151 MCNEIL, KEVIN S GLACE BAY 6220 MCNEIL, NANCY L DARTMOUTH 11446 MCNEIL, SHELLY A HALIFAX 11128 MCNEILL, LAURIE K BRIDGEWATER 13416 * MCPARLAND, COLUMBA HALIFAX 10636 MCPHEE, DERRICK M HALIFAX 10586 MCPHERSON, JOHN W CAMBRIDGE STN 14490 MCROBERT, ELIZABETH HALIFAX 7843 MCTIMONEY, MICHELLE HALIFAX 11712 MCVEIGH, SONJA A FERGUSONS COVE 14237 MCVEY, JENNIFER HALIFAX 12700 MEADOWS-YOUNGER, M TRURO 13906 MEARS, PAUL DARTMOUTH 13049 MEEHAN, CATHERYNE N PORTUGUESE COVE 14267 MENARD, PATRICIA A ANTIGONISH 10587 MENDEZ, IVAR M HALIFAX 11194 MENG, CHEN BRIDGEWATER 12429 MERCER, CHRISTINA L BERWICK 11670 MERRIMEN, JENNIFER L GLEN HAVEN 13053 MERRITT, ROBERT B PORTERS LAKE 8089 MERRYWEATHER, R J CANNING 12440 MERSHATI, A DARTMOUTH 11701 MIAN, IRFAN TORONTO 11476 MICHAEL, LILIANE F BEDFORD 14353 MICHAEL, ROGER T HALIFAX 3086 MIDGLEY, PETER I CHARLOTTETOWN 12430 MIGAS, MARIA HALIFAX 14537 MILBURN, CHRISTOPHER SYDNEY 12369 MILES, GRAHAM C ANTIGONISH 6947 MILLER, MERVYN D SYDNEY 11375 MILLER, ROBERT A HALIFAX 6072 MILLER, ROBERT A HALIFAX 11751 MILLER, ROBERT M HALIFAX 4787 MILLER, STEPHEN G FALL RIVER 10834 MILLIGAN, SCOTT R SYDNEY 11926 MILLIKEN, HEATHER I DARTMOUTH 11813 MILLIKEN, JACQUELINE H BRIDGEWATER 3471 MILLS, PHILIP J DARTMOUTH 11214 MILNE, ANDREW D HALIFAX 13319 MILNE, DAVID G HAMMONDS PLAINS 13199 MILNE, P RONALD HALIFAX 14083 * MINDRUM, CHRISTA R NEW MINAS 15397 MINDRUM, MICHAEL PORT WILLIAMS 15411 MINODIN, MIKE O BEDFORD 13478 MINOR, SAMUEL F BEDFORD 14217 MISHRA, ACHAL CANNING 15791 MISHRA, ADITYA V HALIFAX 6919 MISHRA, HARSH V HALIFAX 6714 MISTRY, DIPAN N HALIFAX 15677 MITCHELL, ALEXANDER D DARTMOUTH 13051 MITCHELL, DAVID A ANTIGONISH 7160 MITCHELL, MICHAEL J HALIFAX 6845 MITCHELL, VICTORIA P HALIFAX 6478 MOELLER, JEREMY J DARTMOUTH 13623 MOGAN, NORAH K LIVERPOOL 12855

SURNAME TOWN/CITY CPSNS MOHAMED, AHMED YARMOUTH 13508 MOHAMED, ISMAIL S HALIFAX 15441 MOHANDAS, RAJENDER ANTIGONISH 7659 MOHSIN, HINA BEDFORD 12895 MOKASHI, ARATI HALIFAX 13389 MOLINARI, MICHELE HALIFAX 13994 MONG, IRENE E BEDFORD 15640 MONTGOMERIE, HUGH S ELMSDALE 3546 MONTGOMERY, GAGE B ELMSDALE 6385 MONTGOMERY, KATHY P HALIFAX 6827 MOON, JENNI HALIFAX 11043 MOORE, IRENE M AYLESFORD 6787 MOORHOUSE, PAIGE A HALIFAX 13043 MORASH, ANGELA H HALIFAX 14473 MORASH, GARRY W LIVERPOOL 4840 MORGAN, MATTHEW E BEDFORD 12703 MORGAN, NEAL BRIDGEWATER 14614 MORGAN, PAUL F PORT WILLIAMS 11769 MORIARTY, MARY F DARTMOUTH 4824 MORLEY, CHARLOTTE M HALIFAX 7581 MORRIS, DAVID P HALIFAX 12970 MORRIS, IAN HALIFAX 4697 MORRIS, KELLY A AMHERST 14664 MORRIS, STEVEN F HALIFAX 10414 MORRISON, DEBRA HALIFAX 10319 MORRISON, EARL G MARION BRIDGE 10900 MORRISON, JASON M HALIFAX 14861 MORRISON, NANCY J HALIFAX 7570 MORSE, DAVID W LUNENBURG 15134 * MORSE, EWART A BRIDGEWATER 4062 * MORZYCKI, WOJCIECH HALIFAX 10705 MOSES, BRIAN G YARMOUTH 13624 MOSHER, PAMELA J HALIFAX 15499 MOSS, CHRISTOPHER J TATAMAGOUCHE 7193 MOSS, PHILIPPA A TATAMAGOUCHE 7701 MOUNTAIN, ANITA D HALIFAX 13625 MUGGAH, JENNIFER J PORT WILLIAMS 6081 MUHSIN, MUNIR HALIFAX 15094 MUIR, AVA J DARTMOUTH 14180 MUIR, JOHN G HALIFAX 7443 MUIR, SARAH A HALIFAX 10239 MUISE, ROLAND J YARMOUTH 4689 MUISE, THOMAS A YARMOUTH 7150 MUKHI, ALFIN N HALIFAX 13918 MULHALL, DAVID R KENTVILLE 7677 MULHERIN, MICHAEL T PORT WILLIAMS 11293 MULLAN, ROBERT D KENTVILLE 6354 MULLAN, TERENCE J BEDFORD 7562 MULLEN, TIMOTHY J HALIFAX 15666 MULLINS, ROSALIND J HALIFAX 13626 MULROY, LIAM A HALIFAX 7580 MUNRO, ALISTAIR EASTERN PASSAGE 6319 MUNROE, TANYA M TRURO 12289 MUNSHI, AUTAR K SYDNEY 6453 MURAD, KHULOOD J SYDNEY 14539 MURAD, MOAZZAM SYDNEY 13386 MURDOCH, JOHN L DARTMOUTH 6910 MURPHY, CHERYL L HALIFAX 12173 MURPHY, CHRISTOPHER YARMOUTH 13393 MURPHY, GEORGE F LOWER SACKVILLE 6847 MURPHY, JOANNE S HALIFAX 8088 MURPHY, KARMA N YARMOUTH 13947 MURPHY, MICHELE G ANTIGONISH 3928 MURPHY, NADIA L KENTVILLE 13886 MURPHY, NANCY HALIFAX 11451 MURPHY, PAUL F SYDNEY 4716 MURPHY, THOMAS B YARMOUTH 3355 MURRAY, JOCK A HALIFAX 10907 MURRAY, JOHN G TRURO 2687 MURRAY, JONATHAN A AVONPORT 13697

* Refer to a page 22 for alternate Pharmacare prescriber number. 13

SURNAME TOWN/CITY CPSNS MURRAY, KENNETH R NEILS HARBOUR 3873 MURRAY, KERRY A KINGSTON 13627 MURRAY, KIM P DARTMOUTH 6728 MURRAY, MICHAEL R TRURO 6887 MURRAY, ROYA R TRURO 6718 MURRAY, SCOTT J HALIFAX 7437 MURRAY, SHAWN K HALIFAX 11132 MUSGRAVE, BRUCE L KENTVILLE 15401 MUTHIAH, KARUPPAN PERTH-ANDOVER 13742 MUTHU, M SARAVANA DARTMOUTH 10463 MUTHU, SARASA ANTIGONISH 10584 MYATT, GERALD L BEDFORD 4945 MYATT, GREGORY A MIRA ROAD 10027 NABI, NAEEM U BEDFORD 15189 NADEEM, SYED N HALIFAX 13434 NADER, NABIL AMHERST 12499 * NADOUR, JALAA TRURO 14580 NAEEM, MEHMOODA NORTH SYDNEY 14886 NAGIAH, THEEPA S DARTMOUTH 14031 NAGPAL, SABINA HALIFAX 14677 NANJI, AMIN A HALIFAX 14026 NAPIER, ROBERT LUKE HALIFAX 14503 NAQVI, MAHMOOD ALI MIRA ROAD 5317 NASEEM, IRAM I SYDNEY RIVER 13718 NASH, MICHAEL B KENTVILLE 13733 NASSAR, BASSAM A HALIFAX 8096 NASSER, JOSEPH G HALIFAX 7870 NATARAJAN, NANDINI M HALIFAX 13462 NATHAN, VIJI WINDSOR 13746 NAULT, YVONNE D ST PETERS 10329 NEILSON, GRAINNE E HALIFAX 10893 NESTEL, ANTHONY W BRIDGEWATER 11985 NESTEL, MAGDALENA D BRIDGEWATER 11986 NETTE, FARRELL L KENTVILLE 13629 NEU, ROLF-DIETER HALIFAX 4233 NEUMANN, ANNA BEDFORD 14181 NEWCOMB, PAULETTE F BEDFORD 7560 NEWHOOK, TRACY L KENTVILLE 11672 NEWTON, PAUL X BRIDGEWATER 4992 NGAN, JOHNSON C HALIFAX 7063 NICHOLS, BLAIR A WOLFVILLE 4539 NICHOLSON, BRIAN M ANTIGONISH 11673 NICHOLSON, DANIEL J MINEVILLE 6912 NICHOLSON, JENNIFER M UPPER LAHAVE 15089 NICHOLSON, JOHN D DARTMOUTH 10146 NICHOLSON, RAE A PICTOU 3576 NICOLELA, MARCELO T HALIFAX 12034 NOLAN, MAUREEN C HALIFAX 10868 NORMAN, BRIAN P HALIFAX 14287 NORMAN, RICHARD W TANTALLON 4936 NORMORE, WAYNE J BEDFORD 11329 NORTHGRAVE, STACEY A SYDNEY 11674 NOVIKOVA, OLGA ANTIGONISH 13523 NOWLAN, CLAIRE N EASTERN PASSAGE 11983 NTAMBAZI, MATTHEW YARMOUTH 14930 NUNN, DAVID J KENTVILLE 7710 NUNN, ROBERT T HALIFAX 7346 NUTH, LAURA L DARTMOUTH 10452 O'BLENES, STACY B HALIFAX 11133 O'BRIEN, BRIAN D HALIFAX 15056 * O'BRIEN, BRIAN J GLACE BAY 4629 O'BRIEN, DANIEL M HALIFAX 7661 O'BRIEN, DAVID A DARTMOUTH 12175 O'BRIEN, M KATHLEEN HALIFAX 10055 O'CONNELL, JENNIFER M HAMMONDS PLAINS 14413 O'CONNOR, JOHN F DARTMOUTH 3360 O'DONOVAN, CLAIRE M HALIFAX 10635 O'GRADY, PATRICK G NORTH SYDNEY 10147 O'HEARN, BRUCE M HALIFAX 4234 O'MALLEY, VINCENT P KENTVILLE 7882

SURNAME TOWN/CITY CPSNS O'NEIL, BARBARA A NEW GERMANY 12434 O'NEIL, LEONARD S HALIFAX 4940 O'NEILL, CARMEN A BRIDGEWATER 7729 O'NEILL, MARIE-THERESE HALIFAX 10373 O'NEILL, MARY C HALIFAX 12273 O'NEILL, MICHELLE E SYDNEY 12705 O'SULLIVAN, EOGHAN F SHELBURNE 11031 OEI, IEN T SYDNEY 6602 OGUNTADE, JOHN A YARMOUTH 15422 OKAFOR, LIVINUS O NEW GLASGOW 14783 OLIVER, ROBERT A DARTMOUTH 4844 OMOTO, DANIEL M SYDNEY 14974 OPITZ, SILKE A KENTVILLE 14513 ORLIK, BENJAMIN C HALIFAX 13889 * ORLIK, HERBERT HALIFAX 4118 ORNSTEIN, AMY HALIFAX 13472 ORR, ANDREW C HALIFAX 7467 ORRELL, KEVIN G MIRA ROAD 6338 ORRELL, LIAM F SYDNEY 6895 ORRELL, SEAN E SYDNEY 6207 ORTIZ, ANA M DARTMOUTH 12615 ORTIZ-ALVAREZ, OLIVA ANTIGONISH 13790 ORTIZ-DOMINQUEZ, T A HALIFAX 14702 OSINOWO, ADEGBOYEGA AMHERST 15777 OTLEY, ANTHONY R HALIFAX 10580 OWEN, STEPHEN M BRIDGEWATER 4867 OXNER, JAMES H DARTMOUTH 3554 OXNER, WILLIAM M HALIFAX 11134 OZERE, CHRISTOPHER P DARTMOUTH 10031 PACIS, RUTH B DARTMOUTH 11779 PADMORE, DAVE E TRURO 10871 PADMOS, M ANDREW OTTAWA 11999 PAHIL, RAJBIR S SYDNEY 12247 PAJER, KATHLEEN A HALIFAX 15720 PALETA, JOHN HUBBARDS 15195 PALETZ, JUSTIN L HALIFAX 7017 PALMER, BRUCE W KENTVILLE 6519 PANEK, ROMUALD HALIFAX 10749 PARISH, BARBARA M BERWICK 10228 PARK, THOMAS R NEW GLASGOW 4953 PARKASH, RAJENDER HALIFAX 3976 PARKASH, RATIKA HALIFAX 13694 PARKASH, RAVI HALIFAX 12218 PARKASH, SANDHYA HALIFAX 13062 PARKER, DEBORAH J HALIFAX 14182 PARMINDER, RANJIT K SYDNEY RIVER 4211 PARSONS, ARTHUR H HALIFAX 3356 PASTERNAK, SYLVIA HALIFAX 12438 PATEL, NAVINCHANDRA LOUISBOURG 4219 PATEL, SUNIL T HALIFAX 12282 PATERSON, ROBERT A DARTMOUTH 7093 PATRICK, WARD D HALIFAX 11173 PATTERSON, MICHAEL D KENTVILLE 14004 PAULICK, BILL C YARMOUTH 10276 PEALING, ROBERT D GREENFIELD 15463 PEARCE, PATRICIA A HALIFAX 4639 * PEIN, CHO Y LOWER SACKVILLE 2387 PELLEY, LORRAINE V SHUBENACADIE 11541 PELLOW, TANYA R HALIFAX 12707 PELTEKIAN, KEVORK M HALIFAX 7972 PENN, JEFFREY R TRURO 10998 PENNELL, MARK L WOLFVILLE 11395 PENNEY, LYNETTE S HALIFAX 14498 PENNOCK, KEVIN STILLWATER LAKE 13357 PEREIRA, ETHEL E HALIFAX 5324 PEREIRA, LEO V ANTIGONISH 7849 PERES, AMOS HALIFAX 13162 PERK, MASIS TRURO 10576 PESTELL, DEBBIE L BEDFORD 15215 * PETERS, CURT S HALIFAX 13634

* Refer to a page 22 for alternate Pharmacare prescriber number. 14

SURNAME TOWN/CITY CPSNS PETERS, LAURA M GRAND LAKE 11362 PETERS, SUSAN NEW GLASGOW 15160 PETERSEN, AGNIESZKA E MIRA ROAD 15682 PETRIE, DANIEL W HALIFAX 14450 PETRIE, DAVID A HALIFAX 8054 PETROPOLIS, PETER N HALIFAX 6972 PHILLIPS, BRUCE A TRURO 10149 PHILLIPS, STEPHEN J HALIFAX 7473 PHILLIPS, WAYNE L WOLFVILLE 4235 PHILPOTT, STEPHANIE L SHUBENACADIE 12541 PHOTOPOULOS, SPIRO HALIFAX 12849 PICCININI, HELENA P HALIFAX 10766 PICKETT, BRYAN M BEDFORD 12332 PICKETT, GWYNEDD E HALIFAX 14809 PICKETT, WAYNE E BEDFORD 10150 PIERCE, MARIANNE E HALIFAX 14745 PILLAI, N G INVERNESS 2871 PITTMAN, CARLA E DARTMOUTH 12307 PLAXTON, E KIM HALIFAX 6693 PLUTA, PAUL L PORT HAWKESBURY 10042 POGOSYAN, MARYNA ROTHESAY 14024 POHLMANN-EDEN, B HALIFAX 14586 POIRIER, ANGELA M HALIFAX 10340 POLLETT, HARRY F NORTH SYDNEY 2873 PONNAMBALAM, CHRIS DARTMOUTH 7908 PONTON-BELTRAN, C AMHERST 12118 PORTER, GEOFFREY A HALIFAX 12526 POTTLE, M KENT HALIFAX 6932 POTTLE, ROBERT A DARTMOUTH 10416 POULOS, PETER H NORTH SYDNEY 6343 POULOS, ROBERT KIRK DARTMOUTH 10043 POWELL, KIMBERLEY D KENTVILLE 11298 POWER, MICHAEL T HAMMONDS PLAINS 12180 POYAH, PENELOPE S HALIFAX 13326 PRABHU, UMESH H YARMOUTH 10458 PREMACHANDRA, PALLIYAGE M

BARRINGTON PASSAGE 15106

PREMSAGAR, S HALIFAX 13173 PREMSAGAR, VICKESH HALIFAX 13226 PRETTY, BRUCE R PROSPECT BAY 4097 PRICE, JUDY M HALIFAX 13058 PRICE, NANCY A PORT WILLIAMS 7723 PRICE, VICTORIA E HALIFAX 13761 PRINGLE, CHRISTOPHER HALIFAX 10323 PRINSLOO, ETIENNE SYDNEY 13766 PROCTOR, IRMA J BRIDGEWATER 10756 PROKAI, KAREN A HALIFAX 11845 PROPPER, LUKAS HALIFAX 13437 PROPPEROVA, IVA HALIFAX 14186 PSOOY, BRIAN J HALIFAX 11679 PUGH, CHERYL P BRIDGEWATER 13498 PUGH, J CHRISTIAN BRIDGEWATER 13495 PUGSLEY, DONALD C BROOKFIELD 6214 PUPPALA, VENKATA K SYDNEY 15158 PURDY, KERRI S HALIFAX 13892 PURDY, R ALLAN HALIFAX 4909 PUTHENPARUMPIL, JACOB HALIFAX 13378 QUINN, BRYAN B SYDNEY 4351 QURAISHI, A HALIFAX 13362 RAAFAT, SAWSAN ANTIGONISH 14309 RAFFERTY, JAMES L CALEDONIA 12208 RAFIE, IHSAN YARMOUTH 15048 RAFIQ, SURAIYA TRURO 13234 RAFUSE, PAUL E HALIFAX 10701 RAGHAVAN, SAI L PORTERS LAKE 10689 RAHMAN, FAISAL ANTIGONISH 13700 RAHMAN, ZIA LITTLE BROOK 15156 RAHNAVARDI, KATAYOUN DARTMOUTH 14621 RAICHE-MARSDEN, M D DARTMOUTH 10537 RAIZAH, ABDULLAH F HALIFAX 13829

SURNAME TOWN/CITY CPSNS RAJARAMAN, MURALI M HALIFAX 7840 RAJARATHNA, MALLIKA P SPRINGHILL 14107 RAJDA, MALGORZATA HALIFAX 10620 RAJDA, MIROSLAW HALIFAX 10654 RAMER, SARAH A HALIFAX 12445 RAMESSAR, ELENA YARMOUTH 14084 RAMESSAR, JOHN A YARMOUTH 13174 RAMSEY, MICHAEL S HALIFAX 3682 RAMSEY, SUZANNE E HALIFAX 10539 RANDELL, L CHRISTOPHER YARMOUTH 12250 RANJI, MOSTAFA BERWICK 15477 RANSOM, THOMAS P HALIFAX 12845 RAO, SANJAY K KENTVILLE 15664 RAPPARD, SCOTT C DARTMOUTH 7306 RASHID, MOHSIN HALIFAX 12045 RASIC, DANIEL T HALIFAX 14390 RASTIKERDAR, ALI DARTMOUTH 15501 RATUSHNY, JEFFREY V BRIDGEWATER 14454 RAYMOND, ESTHER R MAHONE BAY 11225 RAYSON, DANIEL HALIFAX 10063 READ, ROBERT M HALIFAX 5339 REARDON, GERALD P HALIFAX 4370 REARDON, PATRICK M HALIFAX 4469 REBELLO, ROSARIO HALIFAX 12312 REBELO, RAUL A GLACE BAY 3662 RECEVEUR, DARRYN S HALIFAX 15388

REHAN, FOUZIA MUSQUODOBOIT HARBOUR 14078

REHMAN, WASEEMA SYDNEY 14090 REID, DANIEL S DARTMOUTH 3547 * RENAULT, PAUL S HALIFAX 6512 RENDON, RICARDO A HALIFAX 12650 REX, GREGORY HALIFAX 13144 REYNOLDS, JASON H BEDFORD 12183 REYNOLDS, PAUL E HALIFAX 6758 RHEAUME, DORIANNE E HALIFAX 12582 RICHARDSON, C GLEN HALIFAX 11457 * RIDEOUT, ANDREA N HALIFAX 13442 RIDEOUT, CAROLYN M ANTIGONISH 12950 RIDHA, MAHMOUD H HALIFAX 14556 RIDING, TIMOTHY J BRIDGEWATER 13991 RIIVES, MAI L HALIFAX 11593 * RILEY, CHRISTINE A HALIFAX 7192 RILEY, MARK E SHELBURNE 6826 RING, MELANIE S BEDFORD 7815 RITCEY, SUSAN G MIRA ROAD 10236 RITCHIE, JULIA ANTIGONISH 12859 RITENOUR, RUSTY J HALIFAX 13328 RITTENBERG, DAVID A HALIFAX 13480 RITTENBERG, PAULA V HALIFAX 13475 RITTER, JOHN A SYDNEY 12553 RIVAS, JUAN H LOWER SACKVILLE 12926 RIZK, SOHA R DARTMOUTH 15197 ROBBINS, MEGAN 13329 ROBERTS, DELYTH M HAMMONDS PLAINS 10153 ROBERTS, KENNETH F HALIFAX 14457 ROBERTSON, C 12447 ROBERTSON, HEATHER E BRIDGEWATER 7240 ROBERTSON, JILL D HALIFAX 14459 ROBERTSON, NANCY L BEDFORD 7696 ROBINSON, DALE K MONCTON 13533 ROBINSON, K SUE HALIFAX 7397 ROBINSON, KATHERINE A HALIFAX 7988 ROBITAILLE, JOHANE M HALIFAX 11568 ROCKER, GRAEME M HALIFAX 10876 ROCKWOOD, KENNETH J HALIFAX 10256 ROGERS, JAMIE B TRURO 10155 ROGERS, JOHN C SYDNEY 7784 * ROHLAND, TERRY A PUBNICO 4960 RONDEAU, RONALD L OXFORD 4676 *

* Refer to a page 22 for alternate Pharmacare prescriber number. 15

SURNAME TOWN/CITY CPSNS ROPER, FIONA M BEDFORD 6567 ROSE, HEATHER P WEST PENNANT 12185 ROSENBERG, EDWIN M HALIFAX 2404 ROSS, ANDREW A HALIFAX 7676 ROSS, BARBARA J PORT WILLIAMS 10763 ROSS, DAWN L HALIFAX 6537 ROSS, EDWARD C DARTMOUTH 3347 ROSS, JOHN A HALIFAX 8079 ROSS, JONATHAN G BEDFORD 15153 ROSS, VALERIE A HALIFAX 7556 ROWE, DONALD G TRURO 10233 ROWE, JUDY A HALIFAX 11661 ROWICKA, MARGARET D HALIFAX 10156 ROWICKA, MONIKA M NEW GLASGOW 14714 ROXBURGH, BRIAN M SYDNEY 7263 ROY, ARUP MICHAEL NEW GLASGOW 15486 ROY, GREGORY L DARTMOUTH 4525 * RUBENS, MARK J DARTMOUTH 7738 RUBIO-REYES, CARLOS A AMHERST 12570 RUDD, MICHAEL W KENTVILLE 12647 RUDDY, JAMES KENTVILLE 11791 RUGGLES, LESLEY ANTIGONISH 7519 RUTLEDGE, ROBERT D HALIFAX 10952 RUZICKOVA, MARTINA HALIFAX 12982 RYAN, MICHAEL T MIRA ROAD 6780 SAAD, EMILE BEAVER BANK 13806 SADEK, IRENE HALIFAX 10884 SADEK, JOSEPH A HALIFAX 12304 SADLER, LAURA K UPPER TANTALLON 14472 SADLER, MARGOT C ANTIGONISH 10159 SADLER, ROBERT MARK HALIFAX 7566 SAHA, AMAL K HALIFAX 13558 SALAH, JOAN C NORTH SYDNEY 12712 SALAMEH, MUWAFFAQ ANTIGONISH 14304 SALAT, PETER KENTVILLE 13781 SALAZAR, S RAMON WOLFVILLE 13747 SALIH, RASHA HALIFAX 12614 SALSMAN, KENNETH R AYLESFORD 14509 SAMAD, ARIF HALIFAX 10647 SAMPSON, MARIA T HALIFAX 12004 SAMPSON, MARK E SYDNEY 8027 SANDERS, DAVID H DARTMOUTH 2605 SAPP, GEORGE A CHESTER 2617 SAPP, HEIDI L HALIFAX 11140 SAPP, JOHN L HALIFAX 11141 SARDIWALLA, ISMAIL SYDNEY 14925 SARIC, AMRA HALIFAX 13132 SARIC, DJEMSO DARTMOUTH 13564 SARWAL, SHAILINI R HALIFAX 12361 SAUNDERS, W DAVID HALIFAX 6927 SAVA, CRISTINA M NEW GLASGOW 14352 SAVA, CRISTINA M NEW GLASGOW 14352 SAVVOPOULOS, S DARTMOUTH 12713 SAWLER, MARGARET R WAVERLEY 12341 * SAXON, MICHELE P MIDDLETON 14658 SCHAFFNER, JOHN P PORT WILLIAMS 4694 * SCHALLER, GERALD H HALIFAX 4522 SCHEFFLER, MATTHIAS HALIFAX 15375 SCHELEW, BENJAMIN L HALIFAX 8125 SCHERBARTH, SANDRA E SYDNEY 12448 SCHLECH, WALTER F HALIFAX 6316 SCHLOSSER, GISELA E TATAMAGOUCHE 13126 SCHMIDT, MATTHIAS H HALIFAX 11539 SCHMIDT, MICHAEL K HALIFAX 14521 SCHMIT, PIERRE J HALIFAX 14056 SCHNARE, KEVIN P NEW GLASGOW 7168 SCHOFFER, KERRIE L HALIFAX 12187 SCHWARTZ, STACEY A HALIFAX 7940 SCHWARZ, ROBERT D HALIFAX 4789 SCOTT, DONALD J BRIDGEWATER 3843

SURNAME TOWN/CITY CPSNS SCOTT, HEATHER M HALIFAX 10592 SCOTT, JEFFREY W HALIFAX 10664 SCOTT, ROBERT C NEW MINAS 10949 SCOTT, TRACY A HALIFAX 11213 * SCOVIL, ROBERT J HUBLEY 6725 SCOVIL, SUSAN J BEDFORD 15431 SEAMAN, DONALD M KENTVILLE 5413 SEAMAN, JAMES G KENTVILLE 3720 SEAMAN, SARAH J DARTMOUTH 13064 SEAMONE, C HALIFAX 6410 SEBASTIAN, A MIRA ROAD 12450 SEBASTIAN, MALEAKAL S NEW GLASGOW 2832 SEETHARAMDOO, P LOWER SACKVILLE 4041 SEGATO, PETER M WOLFVILLE 14068 SEKULA, ZYGMUNT P HALIFAX 10029 SEMENOV, IGOR AMHERST 15449 SEMSAR, ALIREZA SPRINGHILL 15170 SENTHILLMOHAN, S PORT HAWKESBURY 12381 SEQUEIRA, S PREM NEW GLASGOW 14236 SERS, ROBERT N ANTIGONISH 4671 SETAYESH, A RAMIN MUSQ HARBOUR 14573 SETHI, SHILPA MIDDLE MUSQ 15448 SHAABAN, HANI MIRA ROAD 12552 SHAARBAF, RAID HALIFAX 14089 SHAFFELBURG, MICHAEL KENTVILLE 11142 SHAHEEN, UZMA YARMOUTH 13562 SHAHI, BAHRAM NEW GLASGOW 15184 SHANKAR, JAI J HALIFAX 15350 SHARMA, SHIKHI TRURO 13719 SHARMA, SUSHIL K TRURO 13235 SHARRATT, GEOFFREY P HALIFAX 10737 SHATSHAT, SOUAD M HALIFAX 11461 SHAW, EMILY J HALIFAX 13334 SHAWWA, ALLAM A HALIFAX 12377 SHEA, SARAH E HALIFAX 7125 SHEEHAN, STEPHEN D HAMMONDS PLAINS 8020 SHEEHY, DAVID N SHUBENACADIE 6711 SHEHZAD, ANEES A SYDNEY 13065 SHEN, KHALED A TRURO 14345 SHEPPARD, DUANE G DARTMOUTH 11972 SHERIDAN, WILLIAM J HALIFAX 7039 SHETTAR, C YARMOUTH 12903 SHETTY, BANAKESARI N YARMOUTH 10744 SHIH, WARREN DARTMOUTH 10846 SHIMON, LAITH D SYDNEY 11612 SHIRLEY, MARGARET A BRIDGEWATER 8060 SHIVAKUMAR, SUDEEP S HALIFAX 13335 SHORT, CHRISTINE HALIFAX 11143 SHOULDICE, ELIZABETH 13885 SHRAFAT, NADEEM SYDNEY 13754 SHUBA, LESYA M HALIFAX 12453 SHUKLA, ROMESH C HALIFAX 4905 SHUKLA, SHASHI P HALIFAX 6040 SHULLAIH, ZAKI O SYDNEY 14478 SIBLEY, STEPHANIE R KINGSTON 15659 SIDDIQUI, MUGHINA A ANTIGONISH 14361 SIDHOM, MARY HALIFAX 10746 SILBURT, BRUCE S HALIFAX 12088 SILVER, M MARGARET ANTIGONISH 4663 SILVER, MICHAEL E ANTIGONISH 10162 SIMMS, MATTHEW HALIFAX 13336 SIMPSON, CHARLES D HALIFAX 6723 SIMPSON, CHARLES D HALIFAX 13641 SINCLAIR, MICHAEL G KENTVILLE 13712 SINGH, JAGMOHAN K TRURO 10999 SINGH, JASPAL KENTVILLE 8140 SINGH, SARBAN HALIFAX 12569 SINGH, SARBJIT TRURO 10164 SINGLETON, KATHLEEN HALIFAX 10633 SINHA, DINESH P HALIFAX 3848

* Refer to a page 22 for alternate Pharmacare prescriber number. 16

SURNAME TOWN/CITY CPSNS SIVAKUMAR, SARASWATI SYDNEY 14620 SIVANANTH, P KENTVILLE 13751 SJAUS, ANA HALIFAX 13066 SKIDMORE, DAVID L HALIFAX 13775 SKINNER, EDISON B PICTOU 5376 SLATER, JENNIFER L HALIFAX 14736 SLAYTER, IAN M ANTIGONISH 13443 * SLIPP, FRANK E TRURO 3570 SMITH, AARON C WESTVILLE 14747 SMITH, ANDREW NEIL DARTMOUTH 12455 SMITH, CATHRYN L WINDSOR 6458 SMITH, CHERYL D SCOTSBURN 11700 * SMITH, CORTNEY M HALIFAX 14195 SMITH, DAVID Y TRURO 4400 SMITH, DEBORAH J HALIFAX 6614 SMITH, ERIC J HATCHET LAKE 10060 SMITH, JAMIE A 14754 SMITH, JOHN D MINEVILLE 4818 SMITH, MATTHEW 14462 SMITH, MURDOCK A SYDNEY 3339 * SMITH, PAULA F POINT EDWARD 7804 SMITH, PETER K DARTMOUTH 7202 * SMITH, PHILIP M SYDNEY 7120 SMITH, PRESTON A HALIFAX 14342 SMITH, SHANE A HALIFAX 15143 SNAIR, PATTI J HALIFAX 13755 SNEDDON, KADRE A BEDFORD 15420 SNOW, STEPHANIE L HALIFAX 13899 SNOW, WILLIAM M SYDNEY 3701 SODER, CHRISTIAN M HALIFAX 6180 SOKOLENKO, MARINA HALIFAX 12106 SOLIMAN, EHAB STELLARTON 12203 SOMERS, PATRICK A HALIFAX 12265 SOMMER, MARKUS PORT WILLIAMS 14371 SOMMERFREUND, RAFI D LONDON 15418 SOMMERS, JACK G BEDFORD 4337 SOMMERS, JANET M TRURO 13839 SOMMERS, RYAN B TRURO 14209 SONIER, PAUL W CHETICAMP 12057 SOOCHAN, DIANA C HALIFAX 14712 SORHAINDO, MARK A FALL RIVER 11705 SOROKA, STEVEN D HALIFAX 12271 SOTO-MORENO, L YARMOUTH 15715 SOUDEK, DUSAN DARTMOUTH 7945 SOUSSOU, DAVID GLACE BAY 14890 SPENCER, GORDON J GLACE BAY 10550 SPICER, FINLAY R HALIFAX 7333 SPIESS, STEVEN D LOWER SACKVILLE 10728 SPRACKLIN, ANN E BRIDGEWATER 11944 SRIRANGARAJAN, R PORT HAWKESBURY 13405 SRIVATSA, KOUSTHUB K TRURO 14919 SSEGUYA-LWANGA, D SYDNEY 13208 ST PETERS, CRAIG B HALIFAX 11145 STACEY, COOPER B DARTMOUTH 14499 * STALKER, ROBERT E HALIFAX 4823 STANISH, WILLIAM D HALIFAX 3564 STARODUB, JAMES P HALIFAX 15692 STEELE, CURTIS A HALIFAX 7848 STEELE, LEONE DARTMOUTH 8068 STEEVES, ALEXANDER L MAHONE BAY 3702 STEEVES, BRIAN R ANTIGONISH 3884 STEIN, JOHN D HALIFAX 15069 STENDER, MARK W HALIFAX 12050 STERN, RICHARD B PORT WILLIAMS 6053 STEVENS, SARAH C HALIFAX 7609 *

STEWART, GRAHAM M UPPER KENNETCOOK 11360

STEWART, JACQUELINE HALIFAX 15627 STEWART, JAMES A LUNENBURG 6568 STEWART, JOHN W DARTMOUTH 2153

SURNAME TOWN/CITY CPSNS STEWART, KEIR M HALIFAX 11850 STEWART, ROBERT L HALIFAX 13642 STINSON, DORA A HALIFAX 4362 STODDART, TODD A BRIDGEWATER 11946 STOKES, AIDAN HALIFAX 3752 STOKES, ROBERT BADDECK 4560 STONE, CATHERINE M DARTMOUTH 15768 STONE, R CRAIG SYDNEY 10230 STRASFELD, MAURICE NEW GLASGOW 12333 STRAUB, DEBORAH NEW GLASGOW 10710 STRONG, JULIE K HALIFAX 6767 STURGE, CECIL C VALLEY 13737 STURMY, STEPHEN P ANTIGONISH 4535 STYLES, JANET K HALIFAX 13900 STYLES, JANET K HALIFAX 13900 SUBHANI, KHAJA N HALIFAX 3597 SULLIVAN, JOHN A HALIFAX 4238 SULLIVAN, JOHN H CANSO 4612 SULLIVAN, TANIA T ANTIGONISH 13367 SULLIVAN, WAYNE H HALIFAX 4386 SUNDARARAJAN, K WOLFVILLE 15460 SUNDIN, JAN O BRIDGEWATER 10663 SURETTE, JOEL Y YARMOUTH 13338 SUTHERLAND, GEORGE ANTIGONISH 6748 SUTTON, COLIN G GRAND LAKE 11556 SUTTON, EVELYN D HALIFAX 7689 SWAIN, ANN E PORT WILLIAMS 11465 SWICA, LESZEK STELLARTON 10555 SWIFT, ALEXANDER HALIFAX 13156 SWIFT, ELENA R BEDFORD 13143 SWINAMER, DEANNA L HALIFAX 12298 SZCZESNY, KRYSTIAN M AMHERST 7411 SZERB, JENNIFER J HALIFAX 6904 SZUDEK, EWA A HALIFAX 7884 T'IEN, WALLACE DARTMOUTH 7084 TAHA, DORIS MIRA ROAD 15111 TAIANI, E JOHN NEW MINAS 4979 TAIT, GLENDON R HALIFAX 15414 TALBALLA, HALA HALIFAX 15778 TALLON, JOHN M HALIFAX 11605 TAN, ALEXANDER HALIFAX 12720 TANTON, RONALD T HALIFAX 4635 TARAKJI, AHMAD R YARMOUTH 13671 TARGETT, MATTHEW M KENTVILLE 14466 TATLIDIL, CUNEYT DARTMOUTH 13069 TAYLOR CLARKE, R PORT WILLIAMS 11687 TAYLOR, BRETT W HALIFAX 11503 TAYLOR, GRETTA LUNENBURG 13214 TAYLOR, J E SCOTT BEDFORD 6923 TAYLOR, JOHNATHAN DARTMOUTH 13810 TAYLOR, LINDSAY E HALIFAX 15190 TAYLOR, ROSEMARIE A LOWER SACKVILLE 4807 TAYLOR, STEVEN MARK HALIFAX 12858 TAYLOR, TRUDY A HALIFAX 13654 TEEHAN, MICHAEL D HALIFAX 6974 TEODORESCU, OTILIA HALIFAX 13493 THANAMAYOORAN, S SYDNEY 12839 THERIAULT, DIANE M DARTMOUTH 7498 THERIAULT, P SCOTT HALIFAX 10190 THOMPSON, DEBORAH L HALIFAX 4781 THOMPSON, KAREN M PORT WILLIAMS 15697 THOMPSON, KRISTA L UPPER TANTALLON 11220 THOMPSON, SUSAN E RIVERVIEW 11204 THOMSON, CAROLYN J HALIFAX 8107 THONI, ANDREA J E. LAWRENCETOWN 12594 THORNE, SUSAN F LIVERPOOL 10166 THURGOOD, ANN HALIFAX 11178 TIBBO, PHILIP G HALIFAX 10605 TILLEY, DAVID L HALIFAX 7629 TITLE, LAWRENCE M HALIFAX 10320

* Refer to a page 22 for alternate Pharmacare prescriber number. 17

SURNAME TOWN/CITY CPSNS TO, DINH VU DARTMOUTH 13421 TOBIN, CHERYL LEANNE SYDNEY 15647 TODD, CRYSTAL F NEW MINAS 13341 TODD, ROBERT J SYDNEY 12722 TOLBA, MARWAN STELLARTON 13210 TOMA, TAMER S DARTMOUTH 15196 TOMLINSON, H MARY M DARTMOUTH 8147 TOMS, DAVID A CHARLOTTETOWN 13107 TOP, KARINA A HALIFAX 13860 TOPLACK, CHRISTINA M WOLFVILLE 10972 TOPP, TREVOR J HALIFAX 10405 TOREN, ANDREW J HALIFAX 15646 TOROK, MARIA T BEDFORD 14510 TOWNSEND, CLARENCE NEW GLASGOW 13767 TRAGER, MORRIS E HALIFAX 4252 TRAVERS, ANDREW H HALIFAX 13492 TREMAINE, ROBERT D HALIFAX 6522 TRENHOLM, ARTHUR D HALIFAX 3714 TRENHOLM, J ANDREW I HALIFAX 11469 TRITES, JONATHAN R HALIFAX 12599 * TRUEMAN, GILLIAN M BERWICK 6086

TUCKER, JOHN H PORTUGAL COVE - ST PHILIPS 12544

TUGWELL, BARNA D HALIFAX 13440 TULIPAN, TANYA M HALIFAX 14819 TURNBULL, GEOFFREY K HALIFAX 6496 TURNER, CHARLES G WINDSOR 4825 TUTERT, MARGARET L MOUNT UNIACKE 6840 TWEED, ANNE E MAHONE BAY 4616 TYNSKI, GREGORY F KENTVILLE 7561 UDOLU, OWHOEDE J SYDNEY 15408 UHER, RUDOLF HALIFAX 15766 UHOEGBU, CHIMDI U SYDNEY 15723 UREN, KELLY J KENTVILLE 14022 URSULIAK, ZENOVIA J HUBBARDS 12723 USMAN, MUHAMMAD SYDNEY 14483 VAIR, DONALD B HALIFAX 6246 VAKHARIA, NARENDRA R HALIFAX 10851 VALEEVA, LILIYA SHELBURNE 14920 VAN AARDT, RENIER G TRURO 11796 VAN BOXEL, PAUL J AMHERST 12583 VAN EYK, NANCY A HALIFAX 13732 VAN ONSELEN, EUGENE SAULNIERVILLE 13939 VAN ZANTEN, SANDER J HALIFAX 7993 VANAST, WALTER J LERY 14279 VANDENHOF, MICHIEL C HALIFAX 6206 VANDORPE, ROBERT A HALIFAX 6694 VARMA, DIVYA J DARTMOUTH 11689 VATS, ARUN R GREENWOOD 10660 VAUGHAN, PETER W HALIFAX 12990 VEASEY, DUNCAN A CENTREVILLE 14347 VEASEY, JACK B EASTERN PASSAGE 13097 VEERASSAMY, SHALINI HALIFAX 14202 VEINOT NASH, JANET L HALIFAX 6091 VELJKOVIC, ANDREA N KENTVILLE 13647 VENUGOPAL, VIKRAM DARTMOUTH 10420 VERMA, BHARTI HALIFAX 7022 VERRYN STUART, IAN T KENTVILLE 4664 VERSNICK, ERIC J TRURO 11470 VICIAN, MICHAEL HALIFAX 15781 VIENNEAU, THERESA L NEW GLASGOW 13990 VINCENT, FRANKLYN A HALIFAX 13714 VINCER, MICHAEL J HALIFAX 6791 VIRICK, MOHAN S BLACKETTS LAKE 2160 VITALE, WILLIAM R HALIFAX 6474 VLATTEN, ARNIM HALIFAX 13344 VOHRA, MANOJ VALLEY 7828 WADDEN, ANN M DARTMOUTH 6916 WADDEN, MICHAEL R KENTVILLE 11314 WADDEN, ROBERT A HALIFAX 10174

SURNAME TOWN/CITY CPSNS WAJEEH, MOHAMMED YARMOUTH 13185 WAJSTAUB, SANDRA SYDNEY 15661 WALENTYNOWICZ, M A HALIFAX 11163 WALKER, HARMANNUS C GLACE BAY 4613 WALKER, JANET A HALIFAX 11147 WALLACE, TIMOTHY AMHERST 13715 WALLING, KEITH E LOWER SACKVILLE 2538 WALLING, SIMON A HALIFAX 10367 WALSH, MARK J HALIFAX 11691 WALSH, NOREEN M HALIFAX 7422 WAMBULWA, CHARLES M SHELBURNE 15118 WANLESS, IAN R HALIFAX 14066 WARREN, ANDREW E HALIFAX 11496 WARREN, JOANN L TRURO 12357 WARREN, KATHERINE J WINDSOR 11471 WARREN, RICHARD DARTMOUTH 13402 WASILEWSKI, LESZEK J E. LAWRENCETOWN 12591 WATSON, ADRIENNE N HALIFAX 13788 WATSON, ANDREW C MAHONE BAY 3093 WATSON, KRISTA P MAHONE BAY 13148 WATSON, MARY-LYNN HALIFAX 8047 WATSON, MATTHEW T DARTMOUTH 12604 WATSON, WADE T HALIFAX 13926 WATSON-CREED, G B DARTMOUTH 13976 WATSON-JESSOME, JANE HALIFAX 13392 WATT, DOUGLAS A SYDNEY MINES 6907 WATT, GARTH B HALIFAX 11198 WATTS, PETER W KENTVILLE 3801 WAWER, ANDREW R NORTH SYDNEY 6732 * WAWER, URSULA B BEDFORD 7825 * WAWRZYSZYN, BENIGNA HALIFAX 10680 WAWRZYSZYN, JANUSZ SYDNEY 7204 WEAGLE, EVERETT D BRIDGEWATER 7792 WEAVER, DONALD F HALIFAX 12975 WEBSTER, DAVID M YARMOUTH 10675 WEBSTER, SUSAN D DARTMOUTH 10271 WEEREN, CHRISTOPHER G HALIFAX 10558 WELCH, JOHN PHILIP HALIFAX 2863 WELLS, PHILIP J STEWIACKE 7913 WELLWOOD, ALISON M WOLFVILLE 14502 WELLWOOD, HEATHER M WOLFVILLE 4376 WENNING, JOAN B HALIFAX 6114 WERNER, DIETRICH BRIDGEWATER 14239 WERTLEN, WINSTON G YARMOUTH 12299 * WESCOTT, DON D ANTIGONISH 12026 WEST, KENNETH A HALIFAX 10990

WEST, MICHAEL L HALIFAX 7989

WESTBY, DONALD M WEYMOUTH 6662 WHATLEY, GORDON S HALIFAX 6422 WHITBY, DAVID HALIFAX 2167 WHITE, CELINA D AMHERST 6400 WHITE, DARRELL J HALIFAX 11073 WHITE, KIMBERLEY D HALIFAX 12899 WHITE, MAUREEN E HALIFAX 7366 WHITE, MICHAEL L BEDFORD 4645 WHITE, ROSEMARY A HALIFAX 4380 WHITEHEAD, MICHAEL J KAMLOOPS 15807 WHYNOT, LESLEY M HAMMONDS PLAINS 11158 WHYTE, LAURA M SYDNEY 15081 WHYTE, ROBIN HALIFAX 10330 WIEBE, ALISON W DARTMOUTH 12021 WIEDER, JANA HALIFAX 7195 WIGHTMAN, HOWARD A KENTVILLE 6530 WIGNALL, GEOFFREY R 12728 WILE, IONA WINDSOR 10018 WILKE, DEREK R HALIFAX 11149 WILKIE, ALLAN V PORT WILLIAMS 12038 WILLIAMS, ALBERT R HALIFAX 13345 WILLIAMS, GEOFFREY S HALIFAX 13071

* Refer to a page 22 for alternate Pharmacare prescriber number. 18

SURNAME TOWN/CITY CPSNS WILLIAMS, JASON G HALIFAX 12464 WILLIAMS, JULIE HALIFAX 13400 WILLIAMS, LACI A HALIFAX 15033 WILLIAMS, LARA J HALIFAX 13346 WILLIAMS, STACEY P HALIFAX 12199 WILLIAMS, TRACEY L TRURO 12200 WILSON, DAVID H SHELBURNE 6414 WILSON, DIANE B LUNENBURG 11626 WILSON, EVA ADRIANA HALIFAX 14722 WILSON, KENNETH L HALIFAX 6245 WILSON, RODNEY D HALIFAX 11740 WINSOR, WENDY A HALIFAX 13535 WISNIOWSKI, LEO E BEDFORD 10740 WITTER, TOBIAS HALIFAX 14351 WOJCIK, RONALD W HAMMONDS PLAINS 7129 WONG, DANIEL 12201 WONG, DAVE SYDNEY 11695 WONG, JILL M HALIFAX 12193 WONG, KENNY K HALIFAX 11953 WONG, KIM HALIFAX 15618 WONG, LORI ANN HALIFAX 11809 WOO, DANIEL KENTVILLE 12730 WOOD, DAVID C HALIFAX 7421 WOOD, ELLEN P HALIFAX 12020 WOOD, JEREMY R HALIFAX 7086 WOOD, LORI A HALIFAX 12527 WOOD, WILLIAM C BRIDGEWATER 12220 * WOODFORD, TIMOTHY J LIVERPOOL 6934 WOODS, ERIC R YARMOUTH 6908 WORKMAN, STEPHEN R HALIFAX 11203 WORNELL, PHILIP A TRURO 12465 WORTH, GLEN G SYDNEY 10207 WREN, PATRICIA L HALIFAX 6407 WRIGHT, ALISTAIR S HALIFAX 13904 WRIGHT, BRUCE A BRIDGEWATER 7711 WRIGHT, S ELIZABETH BEDFORD 12531 WU, KWONG Y HALIFAX 6083 WURSTER, CHARLES L FALL RIVER 11955

SURNAME TOWN/CITY CPSNS WYBENGA, MILTON P BROOKFIELD 7357 WYMAN, CHESTER R YARMOUTH 3563 XU, ZHAOLIN HALIFAX 10573 YABSLEY, REGINALD H HALIFAX 2828 YAFAI, ABDUL-AZIZ KINGSTON 4604 YAMADA, DREW C HALIFAX 14470 YANCHAR, NATALIE L HALIFAX 12078 YAZER, ERIKA E HALIFAX 14936 YAZER, HAROLD HALIFAX 3709 YEADON, DEREK E WINDSOR 4602 YEE, KENNY Y BARRINGTON PASS. 10996 YEPES, HORACIO SYDNEY 13361 YEUNG, GORDON K HALIFAX 13905 YHAP, MARGARET C HALIFAX 4503 YOELL, CHRISTOPHER W NEW MINAS 10858 YOSHIDA, LIANNE M HALIFAX 13494 YOU, CHOONG K HALIFAX 3772 YOUNG, DAVID C HALIFAX 11765 YOUNG, GORDON V PICTOU 4223 YOUNG, MICHAEL J HALIFAX 12234 YOUNIS, TALLAL H HALIFAX 13515 YUNG, JASON D DARTMOUTH 12466 ZAMAN, KHAWAR-UZ DARTMOUTH 10762 ZAREMBA, EWELINA HALIFAX 14723 ZAREMBA, JOZEF AMHERST 10650 ZBUK, RANDALL S HALIFAX 14726 ZED, JOANNA M HALIFAX 7781 ZEMERLI, FATIMA Z SYDNEY 14397 ZHANG, LU HALIFAX 13707 ZILBERT, ARTHUR W DARTMOUTH 4389 ZINCK, M SUZANNE HALIFAX 13989 ZITNER, DAVID HALIFAX 4241 ZIVIC-DELIU, LJILJANA HALIFAX 13553 ZWICKER, CHRISTINE L PORTERS LAKE 11232 ZWICKER, DANIEL M LUNENBURG 4548 ZWICKER, DEBORAH A SYDNEY 11151 ZWICKER, HOLLY J UPPER TANTALLON 11473

* Refer to page 22 for alternate Pharmacare prescriber number. 19

MIDWIVES

SURNAME

PRESCRIBER TOWN/CITY

NUMBER

ASHE, AMANDA ANTIGONISH 2 * CHISHOLM, KELLY DARTMOUTH 4 * DIETZE, MAREN LUNENBURG 1 * NIBLETT, LESLIE F BRIDGEWATER 3 * SMITH, MARIE C ANTIGONISH 13 *

* Refer to page 22 for alternate Pharmacare prescriber number. 20

NURSE PRACTITIONERS

SURNAME

PROVIDER TOWN/CITY

NUMBER

ANDERSON, MARY A INVERNESS 720999 BENNETT, C RENATE CALEDONIA 722688 BENOIT, MARY R HALIFAX 716831 BILLARD, ARLENE GLACE BAY 728347 BLOIS, DEBORAH PARRSBORO 716883 BRACE, LENORA PICTOU 727529 BROOKS, ELAINE HALIFAX 719148 BURGESS, CARLA HALIFAX 725610 CAISSIE, VIRGINIA E ADVOCATE HBR 734683 * CAMERON, HOLLY M PARRSBORO 733479 CAMPBELL, CAROLYN HALIFAX 732779 CAMPBELL, TRUDY HALIFAX 729559 CARTWRIGHT, LOIS NEILS HARBOUR 727237 CHAPMAN, KRISTINA HALIFAX 732304 CHUBBS, DAWN O BRIDGEWATER 729855 CLEVELAND, C A UPPER TANTALLON 728934 COCKERSELL, KEITH HALIFAX 726244 CORBETT, DIANNE YARMOUTH 732280 COULTER, LYNN HALIFAX 717468 CURRIE, BARBARA HALIFAX 724553 D'ENTREMONT, D PUBNICO 723502 DAY, CONSTANCE DIGBY 727784 DEMAINE, DAPHNE DIGBY 733654 DICKS, DEBORAH MUSQ, HARBOUR 718179 DUKE, SANDRA HALIFAX 727896 EDGECOMBE, NANCY HALIFAX 731523 EDWARDS, JO-ANN HALIFAX 725096 ELLIS, ERICA SPRINGHILL 729695 FAIRBANKS-SMITH, H RIVER HEBERT 729880 FORREST, JENNIFER LOWER SACKVILLE 727298 GARDEN-JAYASINGHE, J LANTZ 724009 GIFFIN, LORRI BRIDGEWATER 726083 GILBERT, LILLA HALIFAX 732220 GORMAN, NICOLE E BEDFORD 733677 GRANT, DONNA HALIFAX 723558 GREEK, SHANNON BEDFORD 731311 GREENE, CARLA SPRINGHILL 728871 HART, DEBORAH LEITCHES CREEK 729988 HARVEY, JACINTA M BERWICK 719783 HEBERT, KIM FLETCHERS LAKE 722784 HENDRIKSEN, J M BADDECK 725417 HICKEY, DEANA SHELBURNE 729007 HIRSCH, GERALYNN HALIFAX 719144 HODGSON, ELIZABETH HALIFAX 717847 HUQ, SALINA MIDDLE SACKVILLE 730621 * INGS, DAVID JASON SYDNEY 729444 KELLY, NIKKI M HALIFAX 729636 KENNEDY, SHERYL HALIFAX 732325 KETTLE, SONIA HAMMONDS PLAINS 727677 KNICKLE, KRISSINDA A LUNENBURG 729085 KNICKLE, KRISTA LUNENBURG 727256 LAMARCHE, KIM FREEPORT 728963 LANDRY, DAVID HALIFAX 726953 LANE, TRICIA HALIFAX 728879 LAWLOR, DIANA STILLWATER LAKE 726144 LEBLANC, MEGAN G MIDDLE W. PUBNICO 731724 LEGG, KAREN MIDDLE SACKVILLE 725254

SURNAME

PROVIDER TOWN/CITY

NUMBER

LOVE, ANNETTE HALIFAX 730718 LOWE, DAWN WINDSOR 729116 MACCALLUM, KIMBERLY DARTMOUTH 726974 MACDONALD, DARA LEE NEW GLASGOW 724184 MACDONALD, G L CLARKS HARBOUR 733145 MACDONALD, LENA M ANTIGONISH 728483 MACDONALD, NANCY J CHESTER 729882 MACEACHERN, CLARE M MABOU 724720 MACISAAC, JANET PORT HAWKESBURY 716862 MACKAY, MICHELLE HAMMONDS PLAINS 727655 MACLEAN, KRISTAL PICTOU 727294 MACPHERSON, DARLA SACKVILLE 728028 MACRAE, HELEN FREEPORT 719963 MCCOWAN, SUSAN T HALIFAX 729587 MCGRAY, SHEILA J NEWPORT 718357 MCKEE, D BEVERLY WOLFVILLE 731807 MCNAMARA, CHRISTINA HALIFAX 726229 MCNAMARA-MORSE, D L MIDDLETON 726489 MEAGHER, ANDELA D HALIFAX 726471 MILLER, CAROLE-ANN HALIFAX 730408 MILLER, LYNN PUGWASH 726049 MISENER, CATHERINE HALIFAX 720151 MISNER, DEBBEE COLDBROOK 722259 MITCHELL, CAROLYN BRIDGEWATER 728359 MURPHY, RALEEN HALIFAX 731829 NEARING, SHANNON HALIFAX 721891 NEWTON, KIMBERLY J TATAMAGOUCHE 730467 NICHOLS, NATALIE DARTMOUTH 722227 O'CONNELL, TERRILEE METEGHAN CENTRE 730274 OLDFORD, DEBORAH DARTMOUTH 723924 PHALEN-KELLY, KELLY J BEDFORD 725360 PLANETTA, CYNTHIA SYDNEY 720682 RIIS, JENNIFER T NEW GERMANY 730062 ROACH, DEBORAH A GLACE BAY 721406 RUTHERFORD, MARILYN STILLWATER LAKE 731400 SAILE, AXEL S LUNENBURG 730455 SAMSON GAGNON, B L'ARDOISE 728286 SANREGRET, TAMBREY DIGBY 733413 SEYMOUR, FRANCES ADVOCATE HARBOUR 727069 SMITH, CHERYL AMHERST 721194 SNIDER, KAREN FREEPORT 730457 STEEVES, RICKY S PARRSBORO 734730 STODDART, MELISSA E AYLESFORD 731062 STOREY, SANDRA L HALIFAX 730043 TAYLOR, PAULA HAMMONDS PLAINS 722367 THIBEAU, MELANIE Z HEBRON 728231 TINNING, AMANDA HALIFAX 732355 TONER, SANDRA GEORGES RIVER 723718 VENEDAM-MARCHAND, C ANTIGONISH 724485 WELCHER, SOHANI HALIFAX 726424 WHITE-YOUNG, LEEANN MIDDLETON 729608 WITHROW, KAREN HALIFAX 730171 WOOD, MARSHA HAMMONDS PLAINS 721622 YATES, GILLIAN PROSPECT 719141 YEATES, PAULA HALIFAX 726671 YOUNG, DALE P ANNAPOLIS ROYAL 729604

NOTE: To become an authorized Nurse Practitioner under the Nova Scotia Pharmacare Programs, a practitioner must be licensed with the College of Registered Nurses of Nova Scotia and part of a valid “Collaborative Practice Agreement”.

* Refer to page 22 for alternate Pharmacare prescriber number. 21

PRESCRIBING OPTOMETRISTS

SURNAME

PROVIDER TOWN/CITY

NUMBER

AMBIZAS, HELEN SYDNEY 50174 BAIRD, MICHAEL H LOWER SACKVILLE 50164 BALDOCK, ALAN J AMHERST 50146 BAYER, CHERYL YARMOUTH 50216 BLACKMORE, STEPHANIE DARTMOUTH 50220 BOUDREAU, LUC AMHERST 50222 BUCHANAN-DORRANCE, J HALIFAX 50152 BURNS, BARRY A PORT HAWKESBURY 50115 CAREW, ALPHONSE S LOWER SACKVILLE 50107 CARTON, TOM LUNENBURG 50194 CHAFE, JOHN R SYDNEY 50117 CHOW, FREDDIE K HALIFAX 50185 CHUTE, MARK T ELMSDALE 50170 COX, M AVILA BEDFORD 50160 CULLEN, ANDREA SYDNEY 50221 CURRIE, DEBRA A LOWER SACKVILLE 50137 D'ENTREMONT, NAOMI STE-ANNE-DU-RUISS 50231 DAVIS, CARL W HALIFAX 50108 DEBLY, MIRIAM J HALIFAX 50132 DECOSTE, JOLENE ANTIGONISH 50179 DENMAN, MARNI HALIFAX 50225 DOBBELSTEYN, DAVID M HALIFAX 50058 DOBSON, ANGELA C BEDFORD 50144 DOMAN, CAROL A BEDFORD 50186 DUFFEY, MICHAEL P MIDDLETON 50060 FLEMING, JOHN SYDNEY 50062 FLYNN, KRISTA WOLFVILLE 50203 FRENCH, VICTORIA HALIFAX 50209 FURFARO, MELISSA ANTIGONISH 50235 GAGNON, PAUL J GREENWOOD 50224 * GALLIE, LEAH HALIFAX 50208 GAUDET, PAULA M LOWER SACKVILLE 50142 GILLAM, DAVID TRURO 50118 GRAY, PAUL J HALIFAX 50066 HAWKINS, K ANDREA ELMSDALE 50169 ISABELLE, GLENN D MAHONE BAY 50070 KEPES, MARK HALIFAX 50232 KILLORAN, JODY A DARTMOUTH 50183 KINNEY, BRETT MIDDLETON 50205 LACEY, LISA M YARMOUTH 50195 LAI, ELIZABETH BEDFORD 50207 LANDRY, REMI DIEPPE 50227 LANG, GAETAN L HALIFAX 50124 LAVANDIER, ANDRE BRIDGEWATER 50143 * LAWRENCE, THOMAS D BRIDGEWATER 50072 LEGER, JEAN - GUY SPRINGHILL 50131 LEVESQUE, YVES LIVERPOOL 50145 LU, CHARLES C DARTMOUTH 50157 MACDONALD, RHETLAND HALIFAX 50198 MACDONNELL, DEIDRE L HALIFAX 50187 MACDOUGALL, HEATHER TRURO 50111

SURNAME

PROVIDER TOWN/CITY

NUMBER

MACDUFF, J REID WINDSOR 50079 MACINNIS, SHAUN DARTMOUTH 50210 MACKINNON, LAWRENCE NEW GLASGOW 50121 MACLEOD, JOHN G NEW GLASGOW 50080 MAILLET, JULIE HALIFAX 50215 MAILLET, TIM UPPER TANTALLON 50196 MAKARAN, ROSEMARY RIVERVIEW 50190 MALIK, PAMELA BRIDGEWATER 50082 MANCHANDA, AMITPAL DARTMOUTH 50128 MANDELMAN, TOBY BEDFORD 50083 MARTIN, JUDY A SPRYFIELD 50085 MCCARTHY, IAN AMHERST 50214 MCGINTY, EUAN HAMMONDS PLAINS 50226 MCINTOSH, SCOTT DARTMOUTH 50191 MCKAY, SHARI L SYDNEY 50189 MCKEE, KATHERINE T WOLFVILLE 50155 MCMANUIS, CATHERINE YARMOUTH 50086 * MCMULLIN, LAURA DARTMOUTH 50234 MOORE, SUZANNE HALIFAX 50181 MUNRO, JILLIAN WOLFVILLE 50239 NAUGLE, MICHAEL MONCTON 50223 NEARING, MEGAN HALIFAX 50233 OULAHEN, MICHAEL G DARTMOUTH 50112 PARKASH, RAMAN HALIFAX 50184 PERRY, CRYSTAL HALIFAX 50213 POTHIER, SHELDON J WOLFVILLE 50113 POTTER, CHARLOTTE M NEW GLASGOW 50201 POTTLE, J THOMAS NORTH SYDNEY 50094 RAY, JANET E FALL RIVER 50095 READY, SARAH FALL RIVER 50236 REID, MELANIE NEW GLASGOW 50228 * REID, NATHAN NEW GLASGOW 50229 * RICHARD, SERGE MONCTON 50158 ROHLAND, GUY A YARMOUTH 50211 RYBA, EDWARD J SYDNEY 50098 SAMPSON, JOHANNA L ST PETERS 50126 SAMSON, NATHANIEL SYDNEY 50200 SANGSTER, JEFFREY O HALIFAX 50161 SAYWOOD, ANGELA K FALL RIVER 50202 SCOTT, ALLISON HALIFAX 50204 SEALE, ROBBI K YARMOUTH 50154 SHEPPARD, ERIN L BEDFORD 50188 SMIT, HENRY M TRURO 50100 SMITH, JACQUELYN HALIFAX 50178 SMITH, RYAN LANTZ 50238 TELSTAD, LYLE SCOTSBURN 50193 WAGG, RAYMOND P NEW GLASGOW 50102 WEBBER, ANDREW J FALL RIVER 50182 WILKINSON, SARA DIGBY 50192 WILSON, DAVID JOHN UPPER TANTALLON 50237 WINSLADE, TIMOTHY C WOLFVILLE 50105

22

ALTERNATE PRESCRIBER NUMBERS

The College of Physicians and Surgeons of Nova Scotia (CPSNS) license number is generally used as the physician prescriber number when billing the Pharmacare Programs. However, for some physicians, an alternative number has been assigned and should be used for Pharmacare billing purposes. SURNAME TOWN/CITY AGO, C

PRESCRIBER NUMBER

HALIFAX 5678081 ALLAN, PATRICIA ANTIGONISH 6542 ALVAREZ, CARLOS PICKERING 6470 ARCHIBALD, JOHN SYDNEY 5386 BAHL, GAURAV HALIFAX 152130 BARRY, ANNE KENTVILLE 898 BETHUNE, GRAEME HALIFAX 5365 BOWIE, DENNIS HALIFAX 4059A BUCHHOLZ, KENNETH ANNAPOLIS ROYAL 16212 CHEEVERS, PAUL YARMOUTH 13889 CLARK, ALEXANDER HALIFAX 4390 COMEAU, ALBAN SAULNIERVILLE 4955 COOPER, ROBERT PICTOU 4956 CRASWELL, DONALD MIDDLETON 15342 DAS, BIJON HALIFAX 126730 DESROSIERS, JACQUES HALIFAX 546 DEVITT, JAMES HAMMONDS PLAINS 9749 DICKINSON, JOHN HALIFAX 8012 ELLIOTT, CHRISTOPHER NEW GLASGOW 42077 FELTMATE, MARY TRURO 6393 GHENEA, IRINA NORTH SYDNEY 8205 GILLIS, GRANT HALIFAX 10808 GUERIN, JOHN HALIFAX 156810 GUPTILL, JONI DARTMOUTH 6386 HAMILTON, JOHN ANTIGONISH 5428 HEGARTY, RAYMOND ANTIGONISH 4298 HIMMELMAN, DONALD PLEASANTVILLE 5036 HORREY, KATHLEEN HALIFAX 9777 HUMAYUN, MUHAMMAD DARTMOUTH 306176 HUQ, SALINA MIDDLE SACKVILLE 30621 JARVIS, CARL HALIFAX 10801 JHA, UMESH HALIFAX 5239 JOHNSTON, C FALL RIVER 13982 JOLLYMORE, GEORGE CHESTER 5407 JOST, ELLEN HALIFAX 7175 KHALIL, HISHAM BEDFORD 15581 KIRBY, RONALD HALIFAX 529 KNIGHT, DEBORAH DARTMOUTH 49142 KOZEL, VITIA TRURO 10038 LANGDON, REX HALIFAX 15208 LANGILLE, KENNETH AYLESFORD 4538

SURNAME TOWN/CITY LUDMAN, MARK

PRESCRIBER NUMBER

HALIFAX 7704 MACDONALD, KAREN ANTIGONISH 6899A MACDONALD, KAREN HALIFAX 6899 MACGIBBON, S LOIS BEDFORD 148310 MACINTOSH, DONALD HALIFAX 12264 MACINTOSH, REBECCA HALIFAX 6610 MACKAY, THOMAS HALIFAX 3781 MACKNIGHT, CHRIS HALIFAX 8253 MACNEIL, MARY HALIFAX 8014 MARSH, LORNE HALIFAX 5368 MCGIBNEY, KIERON TRURO 151860 MCMANUIS, CATHERINE YARMOUTH 41 MCNEILL, LAURIE BRIDGEWATER 2634 MILNE, P RONALD HALIFAX 7635 MORSE, DAVID LUNENBURG 3878 MORSE, EWART BRIDGEWATER 5372 NADER, NABIL AMHERST 12499A O'BRIEN, BRIAN HALIFAX 4915 ORLIK, BENJAMIN HALIFAX 138890 PEARCE, PATRICIA HALIFAX 1639 PESTELL, DEBBIE BEDFORD 152150 REID, DANIEL DARTMOUTH 13574 RICHARDSON, C GLEN HALIFAX 11457A RIIVES, MAI HALIFAX 7311 ROGERS, JOHN SYDNEY 7784A RONDEAU, RONALD OXFORD 46761 ROY, GREGORY DARTMOUTH 5252 SAWLER, MARGARET WAVERLEY 123410 SCHAFFNER, JOHN PORT WILLIAMS 5758 SCOTT, TRACY HALIFAX 8076 SLAYTER, IAN ANTIGONISH 4401 SMITH, CHERYL SCOTSBURN 8053 SMITH, MURDOCK SYDNEY 5256 SMITH, PETER DARTMOUTH 17200 STACEY, COOPER DARTMOUTH 4969 STEVENS, SARAH HALIFAX 7600A TRITES, JONATHAN HALIFAX 104853 WAWER, ANDREW NORTH SYDNEY 5219 WAWER, URSULA BEDFORD 17825 WERTLEN, WINSTON YARMOUTH 1973 WOOD, WILLIAM BRIDGEWATER 4838

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 1 of 83

Generic Name and Strength DIN Brand MFR MRP PRPacebutolol HCl 100mg tab 02286246 Acebutolol 100mg tab SAS 0.1175

02147602 Apo-Acebutolol 100mg tab APX 0.117502237885 MYLAN-Acebutolol (Type S) 100mg tab MYL 0.117502237721 MYLAN-Acebutolol 100mg tab MYL 0.117502204517 Novo-Acebutolol 100mg tab TEV 0.117502165546 Nu-Acebutolol 100mg tab NXP 0.117501926543 Sectral 100mg tab (discontinued) SAV 0.1175

acebutolol HCl 200mg tab 02286254 Acebutolol 200mg tab SAS 0.176202147610 Apo-Acebutolol 200mg tab APX 0.176202237886 MYLAN-Acebutolol (Type S) 200mg tab MYL 0.176202237722 MYLAN-Acebutolol 200mg tab MYL 0.176202204525 Novo-Acebutolol 200mg tab TEV 0.176202165554 Nu-Acebutolol 200mg tab NXP 0.176201926551 Sectral 200mg tab SAV 0.1762

acebutolol HCl 400mg tab 02286262 Acebutolol 400mg tab SAS 0.350702147629 Apo-Acebutolol 400mg tab APX 0.350702237887 MYLAN-Acebutolol (Type S) 400mg tab MYL 0.350702237723 MYLAN-Acebutolol 400mg tab MYL 0.350702204533 Novo-Acebutolol 400mg tab TEV 0.350702165562 Nu-Acebutolol 400mg tab NXP 0.350701910167 Rhotral 400mg tab SDZ 0.350701926578 Sectral 400mg tab SAV 0.3507

acetaminophen 325mg & oxycodone 5mg tab

02324628 Apo-Oxycodone/Acet 5/325mg tab APX 0.1285

01916548 Endocet tab BRI 0.128502361361 Oxycodone/Acet 5/325mg tab SAS 0.128501916475 Percocet tab BRI 0.128500608165 ratio-Oxycocet tab TEV 0.128502307898 Sandoz-Oxycodone Acet tab SDZ 0.1285

acetazolamide 250mg tab 00545015 Acetazolamide tablets 250mg AAP 0.1343acetylcysteine 200mg/mL inj 02243098 Acetylcysteine 200mg/mL inj SDZ 0.6800

02091526 Mucomyst 200mg/mL inj WLS 0.6800acetylsalicylic acid 325mg EC tab 00010332 Entrophen 325mg EC tab PDP 0.0280

00216666 Novasen 325mg EC tab TEV 0.028002284529 pms-ASA 325mg EC tab PMS 0.0280

acetylsalicylic acid 650mg EC tab 00010340 Entrophen 650mg EC tab PDP 0.035200229296 Novasen 650mg EC tab TEV 0.0352

acetylsalicylic acid 330mg, butalbital 50mg, caffeine 40mg & codeine phosphate 15mg cap

00176192 Fiorinal C1/4 cap NVR 0.6446

00608203 ratio-Tecnal C1/4 cap TEV 0.6446acetylsalicylic acid 330mg, butalbital 50mg, caffeine 40mg & codeine phosphate 30mg cap

00176206 Fiorinal C1/2 cap NVR 0.7896

00608181 ratio-Tecnal C1/2 cap TEV 0.7896

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 2 of 83

Generic Name and Strength DIN Brand MFR MRP PRPacetylsalicylic acid 330mg, butalbital 50mg & caffeine 40mg cap

00226327 Fiorinal cap NVR 0.6014

00608238 ratio-Tecnal cap TEV 0.6014acyclovir 200mg tab 02286556 Acyclovir 200mg tab SAS 0.6397

02207621 Apo-Acyclovir 200mg tab APX 0.639702242784 MYLAN-Acyclovir 200mg tab MYL 0.639702285959 Novo-Acyclovir 200mg tab TEV 0.639702197405 Nu-Acyclovir 200mg tab NXP 0.639702078627 ratio-Acyclovir 200mg tab TEV 0.639700634506 Zovirax 200mg tab GSK 0.6397

acyclovir 400mg tab 02286564 Acyclovir 400mg tab SAS 1.270002207648 Apo-Acyclovir 400mg tab APX 1.270002242463 MYLAN-Acyclovir 400mg tab MYL 1.270002285967 Novo-Acyclovir 400mg tab TEV 1.270002197413 Nu-Acyclovir 400mg tab NXP 1.270002078635 ratio-Acyclovir 400mg tab TEV 1.270001911627 Zovirax 400mg tab GSK 1.2700

acyclovir 800mg tab 02286572 Acyclovir 800mg tab SAS 1.774202207656 Apo-Acyclovir 800mg tab APX 1.774202242464 MYLAN-Acyclovir 800mg tab MYL 1.774202285975 Novo-Acyclovir 800mg tab TEV 1.774202197421 Nu-Acyclovir 800mg tab NXP 1.774202078651 ratio-Acyclovir 800mg tab TEV 1.774201911635 Zovirax 800mg tab GSK 1.7742

adalimumab 50mg/mL inj (exception status)

02258595 Humira 40mg/0.8mL inj ABB 969.8815

alendronate 10mg tab (exception status) 02248728 Apo-Alendronate 10mg tab APX 0.698102201011 Fosamax 10mg tab FRS 0.698102270129 MYLAN-Alendronate 10mg tab MYL 0.698102288087 Sandoz Alendronate 10mg tab SDZ 0.698102247373 Teva-Alendronate 10mg tab TEV 0.6981

alendronate 40mg tab (exception status) 02258102 CO Alendronate 40mg tab COB 3.055702201038 Fosamax 40mg tab FRS 3.0557

alendronate 70mg tab (exception status) 02352966 Alendronate 70mg tab SAS 3.520102299712 Alendronate-FC 70mg tab PHL 3.520102248730 Apo-Alendronate 70mg tab APX 3.520102258110 CO Alendronate 70mg tab COB 3.520102245329 Fosamax 70mg tab FRS 3.520102286335 MYLAN-Alendronate 70mg tab MYL 3.520102284006 pms-Alendronate-FC 70mg tab PMS 3.520102275279 ratio-Alendronate 70mg tab (discontinued) TEV 3.520102288109 Sandoz Alendronate 70mg tab SDZ 3.520102261715 Teva-Alendronate 70mg tab TEV 3.5201

allopurinol 100mg tab 00402818 Zyloprim 100mg tab AAP 0.0846allopurinol 200mg tab 00479799 Zyloprim 200mg tab AAP 0.1411

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 3 of 83

Generic Name and Strength DIN Brand MFR MRP PRPallopurinol 300mg tab 00402796 Zyloprim 300mg tab AAP 0.2306alprazolam 0.25mg tab 02349191 Alprazolam 0.25mg tab SAS 0.0760

00865397 Apo-Alpraz 0.25mg tab APX 0.076002137534 MYLAN-Alprazolam 0.25mg tab MYL 0.076001913484 Teva-Alprazolam 0.25mg tab TEV 0.076000548359 Xanax 0.25mg tab PFI 0.0760

alprazolam 0.5mg tab 02349205 Alprazolam 0.5mg tab SAS 0.092000865400 Apo-Alpraz 0.5mg tab APX 0.092002137542 MYLAN-Alprazolam 0.5mg tab MYL 0.092001913492 Teva-Alprazolam 0.5mg tab TEV 0.092000548367 Xanax 0.5mg tab PFI 0.0920

amantadine HCl 100mg cap 02139200 MYLAN-Amantadine 100mg cap MYL 0.517901990403 pms-Amantadine 100mg cap PMS 0.5179

amantadine HCl 10mg/mL o/l 02022826 pms-Amantadine 10mg/mL syrup PMS 0.1005amcinonide 0.1% cr 02192284 Cyclocort 0.1% cr STI 0.1953

02247098 ratio-Amcinonide 0.1% cr TEV 0.195302246714 Taro-Amcinonide 0.1% cr TAR 0.1953

amcinonide 0.1% lot 02192276 Cyclocort 0.1% lot STI 0.271402247097 ratio-Amcinonide 0.1% lot TEV 0.2714

amcinonide 0.1% oint 02192268 Cyclocort 0.1% oint STI 0.377602247096 ratio-Amcinonide 0.1% oint TEV 0.3776

amiloride 5mg tab 02249510 Midamor 5mg tab AAP 0.29485-aminosalicylic acid 400mg tab 01997580 Asacol 400mg tab WNC 0.4039

02171929 Novo-5-ASA 400mg EC tab TEV 0.4039amiodarone 200mg tab 02364336 Amiodarone 200mg tab SAS 0.7206

02246194 Apo-Amiodarone 200mg tab APX 0.720602036282 Cordarone 200mg tab WAY 0.720602240604 MYLAN-Amiodarone 200mg tab MYL 0.720602245781 phl-Amiodarone 200mg tab PHL 0.720602242472 pms-Amiodarone 200mg tab PMS 0.720602240071 ratio-Amiodarone 200mg tab TEV 0.720602243836 Sandoz Amiodarone 200mg tab SDZ 0.720602239835 Teva-Amiodarone 200mg tab TEV 0.7206

amitriptyline 10mg tab 00335053 Elavil 10mg tab AAP 0.0721amitriptyline 25mg tab 00335061 Elavil 25mg tab AAP 0.1314amitriptyline 50mg tab 00335088 Elavil 50mg tab AAP 0.2547amitriptyline 75mg tab 00754129 Elavil 75mg tab AAP 0.3943amlodipine 5mg tab 02331284 Amlodipine 5mg tab SAS 0.4486

02273373 Apo-Amlodipine 5mg tab APX 0.448602297485 CO Amlodipine 5mg tab COB 0.448602280132 GD-Amlodipine 5mg tab GMD 0.448602331071 Jamp-Amlodipine 5mg tab JPC 0.448602357194 Jamp-Amlodipine 5mg tab JPC 0.448602371715 Mar-Amlodipine 5mg tab MAR 0.4486

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 4 of 83

Generic Name and Strength DIN Brand MFR MRP PRPamlodipine 5mg tab 02362651 MINT-Amlodipine 5mg tab MNT 0.4486

02272113 MYLAN-Amlodipine 5mg tab MYL 0.448600878928 Norvasc 5mg tab PFI 0.448602326779 phl-Amlodipine 5mg tab PHL 0.448602284065 pms-Amlodipine 5mg tab PMS 0.448602321858 RAN-Amlodipine 5mg tab RAN 0.448602259605 ratio-Amlodipine 5mg tab TEV 0.448602284383 Sandoz Amlodipine 5mg tab SDZ 0.448602357712 Septa-Amlodipine 5mg tab SPT 0.448602250497 Teva-Amlodipine 5mg tab TEV 0.4486

amlodipine 10mg tab 02331292 Amlodipine 10mg tab SAS 0.665902273381 Apo-Amlodipine 10mg tab APX 0.665902297493 CO Amlodipine 10mg tab COB 0.665902280140 GD-Amlodipine 10mg tab GMD 0.665902331098 Jamp-Amlodipine 10mg tab JPC 0.665902357208 Jamp-Amlodipine 10mg tab JPC 0.665902371723 Mar-Amlodipine 10mg tab MAR 0.665902362678 MINT-Amlodipine 10mg tab MNT 0.665902272121 MYLAN-Amlodipine 10mg tab MYL 0.665900878936 Norvasc 10mg tab PFI 0.665902326787 phl-Amlodipine 10mg tab PHL 0.665902284073 pms-Amlodipine 10mg tab PMS 0.665902321866 RAN-Amlodipine 10mg tab RAN 0.665902259613 ratio-Amlodipine 10mg tab TEV 0.665902284391 Sandoz Amlodipine 10mg tab SDZ 0.665902357720 Septa-Amlodipine 10mg tab SPT 0.665902250500 Teva-Amlodipine 10mg tab TEV 0.6659

amlodipine 5mg & atorvastatin 10mg tab 02273233 Caduet 5/10mg tab PFI 1.031002362759 GD-Amlodipine/Atorvastatin 5/10mg tab GMD 1.0310

amlodipine 5mg & atorvastatin 20mg tab 02273241 Caduet 5/20mg tab PFI 1.176602362767 GD-Amlodipine/Atorvastatin 5/20mg tab GMD 1.1766

amlodipine 5mg & atorvastatin 40mg tab 02273268 Caduet 5/40mg tab PFI 1.231202362775 GD-Amlodipine/Atorvastatin 5/40mg tab GMD 1.2312

amlodipine 5mg & atorvastatin 80mg tab 02273276 Caduet 5/80mg tab PFI 1.231202362783 GD-Amlodipine/Atorvastatin 5/80mg tab GMD 1.2312

amlodipine 10mg & atorvastatin 10mg tab 02273284 Caduet 10/10mg tab PFI 1.248302362791 GD-Amlodipine/Atorvastatin 10/10mg tab GMD 1.2483

amlodipine 10mg & atorvastatin 20mg tab 02273292 Caduet 10/20mg tab PFI 1.393902362805 GD-Amlodipine/Atorvastatin 10/20mg tab GMD 1.3939

amlodipine 10mg & atorvastatin 40mg tab 02273306 Caduet 10/40mg tab PFI 1.448502362813 GD-Amlodipine/Atorvastatin 10/40mg tab GMD 1.4485

amlodipine 10mg & atorvastatin 80mg tab 02273314 Caduet 10/80mg tab PFI 1.448502362821 GD-Amlodipine/Atorvastatin 10/80mg tab GMD 1.4485

amoxicillin & enzyme inhibitor 125mg/5mL susp

02243986 Apo-Amoxi Clav 125mg/5mL susp APX 0.0517

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 5 of 83

Generic Name and Strength DIN Brand MFR MRP PRPamoxicillin & enzyme inhibitor 125mg/5mL susp

01916882 Clavulin-125F 125mg/5mL susp GSK 0.0517

02244646 ratio-Aclavulanate 125mg/5mL susp TEV 0.0517amoxicillin & enzyme inhibitor 250mg/5mL susp

02243987 Apo-Amoxi Clav 250mg/5mL susp APX 0.0869

01916874 Clavulin-250F 250mg/5mL susp GSK 0.086902244647 ratio-Aclavulanate 250mg/5mL susp TEV 0.0869

amoxicillin & enzyme inhibitor 400mg/5mL susp

02288559 Apo-Amoxi Clav 400mg/5mL susp APX 0.1969

02238830 Clavulin-400 400mg/5mL susp GSK 0.1969amoxicillin & enzyme inhibitor 250mg tab 02243350 Apo-Amoxi Clav 250mg tab APX 0.9375amoxicillin & enzyme inhibitor 500mg tab 02243351 Apo-Amoxi Clav 500mg tab APX 0.6673

01916858 Clavulin-500F 500mg tab GSK 0.667302243771 ratio-Aclavulanate 500mg tab TEV 0.6673

amoxicillin & enzyme inhibitor 875mg tab 02245623 Apo-Amoxi Clav 875mg tab APX 0.777102238829 Clavulin-875 (875mg) tab GSK 0.777102248138 Novo-Clavamoxin-875 (875mg) tab TEV 0.777102247021 ratio-Aclavulanate 875mg tab TEV 0.7771

amoxicillin 250mg cap 02352710 Amoxicillin 250mg cap SAS 0.175000628115 Apo-Amoxi 250mg cap APX 0.175002238171 MYLAN-Amoxicillin 250mg cap MYL 0.175000406724 Novamoxin 250mg cap TEV 0.175000865567 Nu-Amoxi 250mg cap NXP 0.175002230243 pms-Amoxicillin 250mg cap PMS 0.1750

amoxicillin 500mg cap 02352729 Amoxicillin 500mg cap SAS 0.341700628123 Apo-Amoxi 500mg cap APX 0.341702238172 MYLAN-Amoxicillin 500mg cap MYL 0.341700406716 Novamoxin 500mg cap TEV 0.341700865575 Nu-Amoxi 500mg cap NXP 0.341702230244 pms-Amoxicillin 500mg cap PMS 0.3417

amoxicillin 250mg chewable tab 02036355 Novamoxin 250mg chew tab TEV 0.6156amoxicillin 25mg/mL o/l 02352745 Amoxicillin 125mg susp SAS 0.0353

02352761 Amoxicillin Sugar-Reduced 25mg/mL o/l SAS 0.035300628131 Apo-Amoxi 25mg/mL o/l APX 0.035300628131 Apo-Amoxi Sugar Free 25mg/mL o/l APX 0.035300452149 Novamoxin 25mg/mL o/l TEV 0.035301934171 Novamoxin Sugar-Reduced 25mg/mL o/l TEV 0.035300865540 Nu-Amoxi 25mg/mL o/l NXP 0.035302230245 pms-Amoxicillin 25mg/mL o/l PMS 0.0353

amoxicillin 50mg/mL o/l 02352753 Amoxicillin 250mg susp SAS 0.054002352788 Amoxicillin Sugar-Reduced 50mg/mL o/l SAS 0.054000628158 Apo-Amoxi 50mg/mL o/l APX 0.054000628158 Apo-Amoxi Sugar Free 50mg/mL o/l APX 0.054000452130 Novamoxin 50mg/mL o/l TEV 0.054001934163 Novamoxin Sugar-Reduced 50mg/mL o/l TEV 0.0540

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 6 of 83

Generic Name and Strength DIN Brand MFR MRP PRPamoxicillin 50mg/mL o/l 00865559 Nu-Amoxi 50mg/mL o/l NXP 0.0540

02230246 pms-Amoxicillin 50mg/mL o/l PMS 0.0540ampicillin 250mg cap 00020877 Novo-Ampicillin 250mg cap TEV 0.3796ampicillin 500mg cap 00020885 Novo-Ampicillin 500mg cap TEV 0.7091anagrelide 0.5mg cap (exception status) 02236859 Agrylin 0.5mg cap SHI 2.6361

02253054 MYLAN-Anagrelide 0.5mg cap MYL 2.636102260107 Sandoz Anagrelide 0.5mg cap SDZ 2.6361

atenolol 25mg tab 02247182 phl-Atenolol 25mg tab PHL 0.094602246581 pms-Atenolol 25mg tab PMS 0.0946

atenolol 50mg tab 00773689 Apo-Atenol 50mg tab APX 0.206902255545 CO Atenolol 50mg tab COB 0.206902367564 Jamp-Atenolol 50mg tab JPC 0.206902371987 Mar-Atenolol 50mg tab MAR 0.206902368021 MINT-Atenol 50mg tab MNT 0.206902146894 MYLAN-Atenolol 50mg tab MYL 0.206900886114 Nu-Atenol 50mg tab NXP 0.206902238316 phl-Atenolol 50mg tab PHL 0.206902237600 pms-Atenolol 50mg tab PMS 0.206902267985 RAN-Atenol 50mg tab RAN 0.206902171791 ratio-Atenolol 50mg tab TEV 0.206902231731 Sandoz Atenolol 50mg tab SDZ 0.206902039532 Tenormin 50mg tab AZE 0.206901912062 Teva-Atenolol 50mg tab TEV 0.2069

atenolol 100mg tab 00773697 Apo-Atenol 100mg tab APX 0.340102255553 CO Atenolol 100mg tab COB 0.340102367572 Jamp-Atenolol 100mg tab JPC 0.340102371995 Mar-Atenolol 100mg tab MAR 0.340102368048 MINT-Atenol 100mg tab MNT 0.340102147432 MYLAN-Atenolol 100mg tab MYL 0.340100886122 Nu-Atenol 100mg tab NXP 0.340102238318 phl-Atenolol 100mg tab PHL 0.340102237601 pms-Atenolol 100mg tab PMS 0.340102267993 RAN-Atenolol 100mg tab RAN 0.340102171805 ratio-Atenolol 100mg tab TEV 0.340102231733 Sandoz Atenolol 100mg tab SDZ 0.340102039540 Tenormin 100mg tab AZE 0.340101912054 Teva-Atenolol 100mg tab TEV 0.3401

atenolol 50mg & chlorthalidone 25mg tab 02248763 Apo-Atenidone 50/25mg tab APX 0.319502049961 Tenoretic 50/25mg tab AZE 0.319502302918 Teva-Atenolol/Chlorthalidone 50/25mg tab TEV 0.3195

atenolol 100mg & chlorthalidone 25mg tab 02248764 Apo-Atenidone 100/25mg tab APX 0.523602049988 Tenoretic 100/25mg tab AZE 0.523602302926 Teva-Atenolol/Chlorthalidone 100/25mg tab TEV 0.5236

atorvastatin 10mg tab 02295261 Apo-Atorvastatin 10mg tab APX 0.5824

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 7 of 83

Generic Name and Strength DIN Brand MFR MRP PRPatorvastatin 10mg tab 02348705 Atorvastatin 10mg tab (SAS) SAS 0.5824

02310899 CO Atorvastatin 10mg tab COB 0.582402288346 GD-Atorvastatin 10mg tab GMD 0.582402373203 MYLAN-Atorvastatin 10mg tab MYL 0.582402302675 Novo-Atorvastatin 10mg tab TEV 0.582402313448 pms-Atorvastatin 10mg tab PMS 0.582402313707 RAN-Atorvastatin 10mg tab RAN 0.582402350297 ratio-Atorvastatin 10mg tab TEV 0.582402324946 Sandoz Atorvastatin 10mg tab SDZ 0.5824

atorvastatin 20mg tab 02295288 Apo-Atorvastatin 20mg tab APX 0.728002348713 Atorvastatin 20mg tab (SAS) SAS 0.728002310902 CO Atorvastatin 20mg tab COB 0.728002288354 GD-Atorvastatin 20mg tab GMD 0.728002373211 MYLAN-Atorvastatin 20mg tab MYL 0.728002302683 Novo-Atorvastatin 20mg tab TEV 0.728002313456 pms-Atorvastatin 20mg tab PMS 0.728002313715 RAN-Atorvastatin 20mg tab RAN 0.728002350319 ratio-Atorvastatin 20mg tab TEV 0.728002324954 Sandoz Atorvastatin 20mg tab SDZ 0.7280

atorvastatin 40mg tab 02295296 Apo-Atorvastatin 40mg tab APX 0.782602348721 Atorvastatin 40mg tab (SAS) SAS 0.782602310910 CO Atorvastatin 40mg tab COB 0.782602288362 GD-Atorvastatin 40mg tab GMD 0.782602373238 MYLAN-Atorvastatin 40mg tab MYL 0.782602302691 Novo-Atorvastatin 40mg tab TEV 0.782602313464 pms-Atorvastatin 40mg tab PMS 0.782602313723 RAN-Atorvastatin 40mg tab RAN 0.782602350327 ratio-Atorvastatin 40mg tab TEV 0.782602324962 Sandoz Atorvastatin 40mg tab SDZ 0.7826

atorvastatin 80mg tab 02295318 Apo-Atorvastatin 80mg tab APX 0.782602348748 Atorvastatin 80mg tab (SAS) SAS 0.782602310929 CO Atorvastatin 80mg tab COB 0.782602288370 GD-Atorvastatin 80mg tab GMD 0.782602373246 MYLAN-Atorvastatin 80mg tab MYL 0.782602302713 Novo-Atorvastatin 80mg tab TEV 0.782602313472 pms-Atorvastatin 80mg tab PMS 0.782602313758 RAN-Atorvastatin 80mg tab RAN 0.782602350335 ratio-Atorvastatin 80mg tab TEV 0.782602324970 Sandoz Atorvastatin 80mg tab SDZ 0.7826

azathioprine 50mg tab 02242907 Apo-Azathioprine 50mg tab APX 0.336602343002 Azathioprine 50mg tab SAS 0.336600004596 Imuran 50mg tab GSK 0.336602231491 MYLAN-Azathioprine 50mg tab MYL 0.336602236819 Teva-Azathioprine 50mg tab TEV 0.3366

azithromycin 250mg tab (exception status) 02247423 Apo-Azithromycin 250mg tab APX 1.7290

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 8 of 83

Generic Name and Strength DIN Brand MFR MRP PRPazithromycin 250mg tab (exception status) 02330881 Azithromycin 250mg tab SAS 1.7290

02255340 CO Azithromycin 250mg tab COB 1.729002274531 GD-Azithromycin 250mg tab GMD 1.729002278359 MYLAN-Azithromycin 250mg tab MYL 1.729002267845 Novo-Azithromycin 250mg tab TEV 1.729002278588 phl-Azithromycin 250mg tab PHL 1.729002261634 pms-Azithromycin 250mg tab PMS 1.729002275287 ratio-Azithromycin 250mg tab TEV 1.729002265826 Sandoz Azithromycin 250mg tab SDZ 1.729002212021 Zithromax 250mg tab PFI 1.7290

azithromycin 600mg tab (exception status) 02330911 Azithromycin 600mg tab SAS 6.000002256088 CO Azithromycin 600mg tab COB 6.000002261642 pms-Azithromycin 600mg tab PMS 6.000002231143 Zithromax 600mg tab PFI 6.0000

azithromycin pos 100mg/5mL susp (exception status)

02315157 Novo-Azithromycin Pediatric 100mg/5mL susp TEV 0.3956

02274388 pms-Azithromycin POS 100mg/5mL susp PMS 0.395602332388 Sandoz Azithromycin POS 100mg/5mL susp SDZ 0.395602223716 Zithromax POS 100mg/5mL susp PFI 0.3956

azithromycin pos 200mg/5mL susp (exception status)

02315165 Novo-Azithromycin Pediatric 200mg/5mL susp TEV 0.5604

02274396 pms-Azithromycin POS 200mg/5mL susp PMS 0.560402332396 Sandoz Azithromycin POS 200mg/5mL susp SDZ 0.560402223724 Zithromax POS 200mg/5mL susp PFI 0.5604

baclofen 10mg tab 02139332 Apo-Baclofen 10mg tab APX 0.240302287021 Baclofen 10mg tab SAS 0.240300455881 Lioresal 10mg tab NVR 0.240302088398 MYLAN-Baclofen 10mg tab MYL 0.240302136090 Nu-Baclo 10mg tab NXP 0.240302236963 phl-Baclofen 10mg tab PHL 0.240302063735 pms-Baclofen 10mg tab PMS 0.240302236507 ratio-Baclofen 10mg tab TEV 0.2403

baclofen 20mg tab 02139391 Apo-Baclofen 20mg tab APX 0.467602287048 Baclofen 20mg tab SAS 0.467600636576 Lioresal DS 20mg tab NVR 0.467602088401 MYLAN-Baclofen 20mg tab MYL 0.467602136104 Nu-Baclo 20mg tab NXP 0.467602236964 phl-Baclofen 20mg tab PHL 0.467602063743 pms-Baclofen 20mg tab PMS 0.467602236508 ratio-Baclofen 20mg tab TEV 0.4676

beclomethasone dipropionate 50mcg/dose aqueous nasal spray

02238796 Apo-Beclo 50mcg/dose aq nasal sp APX 0.0613

02172712 MYLAN-Beclo 50mcg/dose aq nasal sp MYL 0.061302238577 Nu-Beclomethasone 50mcg/dose aq nasal sp NXP 0.0613

benazepril 5mg tab 02290332 Benazepril 5mg tab AAP 0.6051

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 9 of 83

Generic Name and Strength DIN Brand MFR MRP PRPbenazepril 5mg tab 00885835 Lotensin 5mg tab NVR 0.6051benazepril 10mg tab 02290340 Benazepril 10mg tab AAP 0.7156

00885843 Lotensin 10mg tab NVR 0.7156benazepril 20mg tab 02273918 Benazepril 20mg tab AAP 0.8210

00885851 Lotensin 20mg tab NVR 0.8210benztropine mesylate 2mg tab 00426857 Apo-Benztropine 2mg tab APX 0.0503

00587265 pms-Benztropine 2mg tab PMS 0.0503benzydamine 0.15% oral rinse (exception status)

02239044 Apo-Benzydamine 0.15% oral rinse (discontinued) APX 0.0290

02310422 Novo-Benzydamine 0.15% oral rinse TEV 0.029002229777 pms-Benzydamine 0.15% oral rinse PMS 0.0290

betahistine 16mg tab (exception status) 02374757 CO Betahistine 16mg tab COB 0.177002280191 Novo-Betahistine 16mg tab TEV 0.177002243878 Serc 16mg tab SPH 0.1770

betahistine 24mg tab (exception status) 02374765 CO Betahistine 24mg tab COB 0.304002280205 Novo-Betahistine 24mg tab TEV 0.393302247998 Serc 24mg tab SPH 0.3933

betamethasone 6mg/mL inj 02237835 Betaject 6mg/mL inj SDZ 9.530000028096 Celestone soluspan 6mg/mL inj SCH 9.5300

betamethasone & gentamicin oph/otic sol 00682217 Garasone oph/otic sol SCH 1.201202244999 Sandoz Pentasone oph/otic sol SDZ 1.2012

betamethasone 17 valerate 0.05% cr 00716618 Betaderm 0.05% cr TAR 0.059602357860 Celestoderm-V/2 0.05% cr VAL 0.0596

betamethasone 17 valerate 0.1% cr 00716626 Betaderm 0.1% cr TAR 0.088902357844 Celestoderm-V 0.1% cr VAL 0.0889

betamethasone dipropionate 0.05% cr 00323071 Diprosone 0.05% cr SCH 0.204801925350 Taro-Sone 0.05% cr TAR 0.2048

betamethasone dipropionate 0.05% glycol cr

00688622 Diprolene 0.05% glycol cr SCH 0.5187

00849650 ratio-Topilene 0.05% glycol cr TEV 0.5187betamethasone dipropionate 0.05% glycol lot

00862975 Diprolene 0.05% glycol lot SCH 0.5620

01927914 ratio-Topilene 0.05% glycol lot TEV 0.5620betamethasone dipropionate 0.05% glycol oint

00629367 Diprolene 0.05% glycol oint SCH 0.5187

00849669 ratio-Topilene 0.05% glycol oint TEV 0.5187betamethasone dipropionate 0.05% lot 00417246 Diprosone 0.05% lot SCH 0.1980

00809187 ratio-Topisone 0.05% lot TEV 0.1980betamethasone dipropionate 0.05% oint 00344923 Diprosone 0.05% oint SCH 0.2152

00805009 ratio-Topisone 0.05% oint TEV 0.2152bethamethasone dipropionate 0.05% & salicylic acid 2% lot

00578428 Diprosalic 0.05%/2% lot SCH 0.4228

02245688 ratio-Topisalic 0.05%/2% lot TEV 0.4228bicalutamide 50mg tab 02296063 Apo-Bicalutamide 50mg tab APX 2.3188

02325985 Bicalutamide 50mg tab AHC 2.3188

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 10 of 83

Generic Name and Strength DIN Brand MFR MRP PRPbicalutamide 50mg tab 02184478 Casodex 50mg tab AZE 2.3188

02274337 CO Bicalutamide 50mg tab COB 2.318802357216 Jamp-Bicalutamide 50mg tab JPC 2.318802302403 MYLAN-Bicalutamide 50mg tab MYL 2.318802270226 Novo-Bicalutamide 50mg tab TEV 2.318802275589 pms-Bicalutamide 50mg tab PMS 2.318802371324 RAN-Bicalutamide 50mg Tab RAN 2.318802277700 ratio-Bicalutamide 50mg tab TEV 2.318802276089 Sandoz Bicalutamide 50mg tab SDZ 2.3188

bisoprolol 5mg tab 02256134 Apo-Bisoprolol 5mg tab APX 0.139102267470 Novo-Bisoprolol 5mg tab TEV 0.139102302632 pms-Bisoprolol 5mg tab PMS 0.139102247439 Sandoz Bisoprolol 5mg tab SDZ 0.1391

bisoprolol 10mg tab 02256177 Apo-Bisoprolol 10mg tab APX 0.203002267489 Novo-Bisoprolol 10mg tab TEV 0.203002302640 pms-Bisoprolol 10mg tab PMS 0.203002247440 Sandoz Bisoprolol 10mg tab SDZ 0.2030

bosentan 62.5mg tab (exception status) 02244981 Tracleer 62.5mg tab ACT 69.6338bosentan 125mg tab (exception status) 02244982 Tracleer 125mg tab ACT 69.6338brimonidine 0.2% oph sol 02236876 Alphagan 0.2% oph sol ALL 1.1550

02260077 Apo-Brimonidine 0.2% oph sol APX 1.155002246284 pms-Brimonidine 0.2% oph sol PMS 1.155002243026 ratio-Brimonidine 0.2% oph sol TEV 1.155002305429 Sandoz Brimonidine 0.2% oph sol SDZ 1.1550

bromazepam 1.5mg tab 02177153 Apo-Bromazepam 1.5mg tab APX 0.0693bromazepam 3mg tab 02177161 Apo-Bromazepam 3mg tab APX 0.0525

00518123 Lectopam 3mg tab HLR 0.052502230584 Novo-Bromazepam 3mg tab TEV 0.0525

bromazepam 6mg tab 02177188 Apo-Bromazepam 6mg tab APX 0.076700518131 Lectopam 6mg tab HLR 0.076702230585 Novo-Bromazepam 6mg tab TEV 0.0767

bromocriptine mesylate 2.5mg tab 02087324 Apo-Bromocriptine 2.5mg tab APX 0.9782bromocriptine mesylate 5mg cap 02230454 Apo-Bromocriptine 5mg cap APX 1.4644budesonide 64mcg/dose aqueous nasal spray

02241003 MYLAN-Budesonide 64mcg/mL aq nasal spray MYL 0.0843

02231923 Rhinocort 64mcg/mL aq nasal spray AZE 0.0843bupropion 100mg SR tab 02325373 pms-Bupropion 100mg SR tab PMS 0.2167

02285657 ratio-Bupropion 100mg SR tab TEV 0.216702275074 Sandoz Bupropion 100mg SR tab SDZ 0.2167

bupropion 150mg SR tab 02313421 pms-Bupropion 150mg SR tab PMS 0.323602285665 ratio-Bupropion 150mg SR tab TEV 0.323602275082 Sandoz Bupropion 150mg SR tab SDZ 0.323602237825 Wellbutrin 150mg SR tab BVL 0.3236

buspirone HCl 10mg tab 02211076 Apo-Buspirone 10mg tab APX 0.3798

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 11 of 83

Generic Name and Strength DIN Brand MFR MRP PRPbuspirone HCl 10mg tab 00603821 Buspar 10mg tab (discontinued) BRI 0.3798

02231492 Novo-Buspirone 10mg tab TEV 0.379802207672 Nu-Buspirone 10mg tab NXP 0.379802230942 pms-Buspirone 10mg tab PMS 0.3798

butorphanol 10mg/mL nasal sp 02242504 Apo-Butorphanol nasal sp APX 3.7683cabergoline 0.5mg tab (exception status) 02301407 CO Cabergoline 0.5mg tab COB 10.5238

02242471 Dostinex 0.5mg tab SQI 10.5238calcitonin 200iu/dose nasal spray (exception status)

02247585 Apo-Calcitonin 200iu/dose nasal spray APX 1.7254

02240775 Miacalcin 200iu/dose nasal spray NVR 1.725402261766 Sandoz Calcitonin NS 200iu/dose nasal spray SDZ 1.7254

candesartan 8mg tab 02365359 Apo-Candesartan 8mg tab APX 0.410002239091 Atacand 8mg tab AZE 0.410002376539 CO Candesartan 8mg tab COB 0.410002326965 Sandoz Candesartan 8mg tab SDZ 0.410002366312 Teva-Candesartan 8mg tab TEV 0.4100

candesartan 16mg tab 02365367 Apo-Candesartan 16mg tab APX 0.410002239092 Atacand 16mg tab AZE 0.410002376547 CO Candesartan 16mg tab COB 0.410002326973 Sandoz Candesartan 16mg tab SDZ 0.410002366320 Teva-Candesartan 16mg tab TEV 0.4100

candesartan 32mg tab 02311658 Atacand 32mg tab AZE 0.419302376555 CO Candesartan 32mg tab COB 0.419302366339 Teva-Candesartan 32mg tab TEV 0.4193

captopril 12.5mg tab 00893595 Apo-Capto 12.5mg tab APX 0.106002163551 MYLAN-Captopril 12.5mg tab MYL 0.106001942964 Novo-Captoril 12.5mg tab TEV 0.106001913824 Nu-Capto 12.5mg tab NXP 0.1060

captopril 25mg tab 00893609 Apo-Capto 25mg tab APX 0.150000546283 Capoten 25mg tab BRI 0.150002163578 MYLAN-Captopril 25mg tab MYL 0.150001942972 Novo-Captoril 25mg tab TEV 0.150001913832 Nu-Capto 25mg tab NXP 0.1500

captopril 50mg tab 00893617 Apo-Capto 50mg tab APX 0.279500546291 Capoten 50mg tab (discontinued) BRI 0.279502163586 MYLAN-Captopril 50mg tab MYL 0.279501942980 Novo-Captoril 50mg tab TEV 0.279501913840 Nu-Capto 50mg tab NXP 0.2795

captopril 100mg tab 00893625 Apo-Capto 100mg tab APX 0.519802163594 MYLAN-Captopril 100mg tab MYL 0.519801942999 Novo-Captoril 100mg tab TEV 0.519801913859 Nu-Capto 100mg tab NXP 0.519802230206 pms-Captopril 100mg tab PMS 0.5198

carbamazepine 200mg tab 00402699 Apo-Carbamazepine 200mg tab (discontinued) APX 0.079500010405 Tegretol 200mg tab NVR 0.0795

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 12 of 83

Generic Name and Strength DIN Brand MFR MRP PRPcarbamazepine 200mg tab 00782718 Teva-Carbamazepine 200mg tab TEV 0.0795carbamazepine 100mg chewable tab 02231542 pms-Carbamazepine 100mg chewable tab PMS 0.0572

02261855 Sandoz Carbamazepine 100mg chewable tab SDZ 0.057202244403 Taro-Carbamazepine 100mg chewable tab TAR 0.057200369810 Tegretol 100mg chewable tab NVR 0.0572

carbamazepine 200mg chewable tab 02231540 pms-Carbamazepine 200mg chewable tab PMS 0.112802261863 Sandoz Carbamazepine 200mg chewable tab SDZ 0.112802244404 Taro-Carbamazepine 200mg chewable tab TAR 0.112800665088 Tegretol 200mg chewable tab NVR 0.1128

carbamazepine 200mg cr tab 02241882 MYLAN-Carbamazepine 200mg CR tab MYL 0.140102231543 pms-Carbamazepine 200mg CR tab PMS 0.140102261839 Sandoz Carbamazepine 200mg CR tab SDZ 0.140100773611 Tegretol 200mg CR tab NVR 0.1401

carbamazepine 400mg cr tab 02241883 MYLAN-Carbamazepine 400mg CR tab MYL 0.280102231544 pms-Carbamazepine 400mg CR tab PMS 0.280102261847 Sandoz Carbamazepine 400mg CR tab SDZ 0.280100755583 Tegretol 400mg CR tab NVR 0.2801

carvedilol 3.125mg tab (exception status) 02247933 Apo-Carvedilol 3.125mg tab APX 0.472802364913 Carvedilol 3.125mg tab SAS 0.472802347512 MYLAN-Carvedilol 3.125mg tab MYL 0.472802248752 phl-Carvedilol 3.125mg tab PHL 0.472802245914 pms-Carvedilol 3.125mg tab PMS 0.472802268027 RAN-Carvedilol 3.125mg tab RAN 0.472802252309 ratio-Carvedilol 3.125mg tab TEV 0.472802338068 Zym-Carvedilol 3.125mg tab ZYM 0.4728

carvedilol 6.25mg tab (exception status) 02247934 Apo-Carvedilol 6.25mg tab APX 0.472802364921 Carvedilol 6.25mg tab SAS 0.472802347520 MYLAN-Carvedilol 6.25mg tab MYL 0.472802248753 phl-Carvedilol 6.25mg tab PHL 0.472802245915 pms-Carvedilol 6.25mg tab PMS 0.472802268035 RAN-Carvedilol 6.25mg tab RAN 0.472802252317 ratio-Carvedilol 6.25mg tab TEV 0.472802338092 Zym-Carvedilol 6.25mg tab ZYM 0.4728

carvedilol 12.5mg tab (exception status) 02247935 Apo-Carvedilol 12.5mg tab APX 0.472802364948 Carvedilol 12.5mg tab SAS 0.472802347555 MYLAN-Carvedilol 12.5mg tab MYL 0.472802248754 phl-Carvedilol 12.5mg tab PHL 0.472802245916 pms-Carvedilol 12.5mg tab PMS 0.472802268043 RAN-Carvedilol 12.5mg tab RAN 0.472802252325 ratio-Carvedilol 12.5mg tab TEV 0.472802338106 Zym-Carvedilol 12.5mg tab ZYM 0.4728

carvedilol 25mg tab (exception status) 02247936 Apo-Carvedilol 25mg tab APX 0.472802364956 Carvedilol 25mg tab SAS 0.472802347571 MYLAN-Carvedilol 25mg tab MYL 0.472802248755 phl-Carvedilol 25mg tab PHL 0.4728

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 13 of 83

Generic Name and Strength DIN Brand MFR MRP PRPcarvedilol 25mg tab (exception status) 02245917 pms-Carvedilol 25mg tab PMS 0.4728

02268051 RAN-Carvedilol 25mg tab RAN 0.472802252333 ratio-Carvedilol 25mg tab TEV 0.472802338114 Zym-Carvedilol 25mg tab ZYM 0.4728

cefadroxil 500mg cap 02240774 Apo-Cefadroxil 500mg cap APX 0.842102235134 Novo-Cefadroxil 500mg cap TEV 0.8421

cefazolin sodium 500mg/vial inj 02108119 Cefazolin Sodium 500mg/vial inj TEV 4.000002308932 Cefazolin Sodium 500mg/vial inj SDZ 4.0000

cefazolin sodium 1g/vial inj 02297205 Cefazolin Sodium 1g/vial inj APX 6.000002108127 Cefazolin Sodium 1g/vial inj TEV 6.000002308959 Cefazolin Sodium 1g/vial inj SDZ 6.0000

cefprozil 125mg/5mL o/l 02293943 Apo-Cefprozil 125mg/5mL o/l APX 0.059302347261 Auro-Cefprozil 125mg/5mL Susp ARO 0.059302163675 Cefzil 125mg/5mL o/l BRI 0.059302329204 RAN-Cefprozil 125mg/5mL o/l RAN 0.059302303426 Sandoz Cefprozil 125mg/5mL o/l SDZ 0.0593

cefprozil 250mg/5mL o/l 02293951 Apo-Cefprozil 250mg/5mL o/l APX 0.118502347288 Auro-Cefprozil 250mg/5mL Susp ARO 0.118502163683 Cefzil 250mg/5mL o/l BRI 0.118502293579 RAN-Cefprozil 250mg/5mL o/l RAN 0.118502303434 Sandoz Cefprozil 250mg/5mL o/l SDZ 0.1185

cefprozil 250mg tab 02292998 Apo-Cefprozil 250mg tab APX 0.606402347245 Auro-Cefprozil 250mg tab ARO 0.606402163659 Cefzil 250mg tab BRI 0.606402293528 RAN-Cefprozil 250mg tab RAN 0.606402302179 Sandoz Cefprozil 250mg tab SDZ 0.6064

cefprozil 500mg tab 02293005 Apo-Cefprozil 500mg tab APX 1.189102347253 Auro-Cefprozil 500mg tab ARO 1.189102163667 Cefzil 500mg tab BRI 1.189102293536 RAN-Cefprozil 500mg tab RAN 1.189102302187 Sandoz Cefprozil 500mg tab SDZ 1.1891

ceftriaxone 0.25g/vial inj 02292866 Ceftriaxone 0.25g/vial inj APX 7.525000657387 Rocephin 0.25g/vial inj HLR 7.5250

ceftriaxone 1g/vial inj 02292874 Ceftriaxone 1g/vial inj (APX) APX 12.495002292270 Ceftriaxone 1g/vial inj (SDZ) SDZ 12.495000657417 Rocephin 1g/vial inj (discontinued) HLR 12.4950

ceftriaxone 2g/vial inj 02292882 Ceftriaxone 2g/vial inj (APX) APX 24.140002292289 Ceftriaxone 2g/vial inj (SDZ) SDZ 24.1400

cefuroxime axetil 250mg tab 02244393 Apo-Cefuroxime 250mg tab APX 0.723702344823 Auro-Cefuroxime 250mg tab ARO 0.723702212277 Ceftin 250mg tab GSK 0.723702242656 ratio-Cefuroxime 250mg tab TEV 0.7237

cefuroxime axetil 500mg tab 02244394 Apo-Cefuroxime 500mg tab APX 1.433702344831 Auro-Cefuroxime 500mg tab ARO 1.4337

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 14 of 83

Generic Name and Strength DIN Brand MFR MRP PRPcefuroxime axetil 500mg tab 02212285 Ceftin 500mg tab GSK 1.4337

02242657 ratio-Cefuroxime 500mg tab TEV 1.4337celecoxib 100mg cap 02239941 Celebrex 100mg cap PFI 0.2625celecoxib 200mg cap 02239942 Celebrex 200mg cap PFI 0.5250cephalexin monohydrate 25mg o/l 00342106 Novo-Lexin 125mg/5mL susp TEV 0.0860cephalexin monohydrate 50mg o/l 00342092 Novo-Lexin 250mg/5mL susp TEV 0.1351cephalexin monohydrate 250mg tab 00768723 Apo-Cephalex 250mg tab APX 0.2250

00583413 Novo-Lexin 250mg tab TEV 0.225000865877 Nu-Cephalex 250mg tab NXP 0.2250

cephalexin monohydrate 500mg tab 00768715 Apo-Cephalex 500mg tab APX 0.450000583421 Novo-Lexin 500mg tab TEV 0.450000865885 Nu-Cephalex 500mg tab NXP 0.4500

cetirizine 10mg tab (exception status) 02231603 APC-Cetirizine 10mg tab APX 0.408302231603 Apo-Cetirizine 10mg tab APX 0.408302315955 Extra Strength Allergy Relief 10mg tab PDP 0.408302223554 Reactine 10mg tab JNJ 0.4083

chlordiazepoxide HCl 5mg & clidinium Br 2.5mg cap

00618454 Apo-Chlorax 5mg/2.5mg cap APX 0.2231

00115630 Librax 5mg/2.5mg cap VLN 0.2231chloroquine phosphate 250mg tab 00021261 Novo-Chloroquine 250mg tab TEV 0.4020chlorpromazine 25mg/mL inj 00743518 Chlorpromazine 25mg/mL inj SDZ 1.1100cilazapril 1mg tab 02291134 Apo-Cilazapril 1mg tab APX 0.2492

02350963 Cilazapril 1mg tab SAS 0.249201911465 Inhibace 1mg tab (discontinued) HLR 0.249202283778 MYLAN-Cilazapril 1mg tab MYL 0.249202266350 Novo-Cilazapril 1mg tab TEV 0.249202280442 pms-Cilazapril 1mg tab PMS 0.2492

cilazapril 2.5mg tab 02291142 Apo-Cilazapril 2.5mg tab APX 0.251302350971 Cilazapril 2.5mg tab SAS 0.251301911473 Inhibace 2.5mg tab HLR 0.251302283786 MYLAN-Cilazapril 2.5mg tab MYL 0.251302266369 Novo-Cilazapril 2.5mg tab TEV 0.251302280450 pms-Cilazapril 2.5mg tab PMS 0.2513

cilazapril 5mg tab 02291150 Apo-Cilazapril 5mg tab APX 0.291902350998 Cilazapril 5mg tab SAS 0.291901911481 Inhibace 5mg tab HLR 0.291902283794 MYLAN-Cilazapril 5mg tab MYL 0.291902266377 Novo-Cilazapril 5mg tab TEV 0.291902280469 pms-Cilazapril 5mg tab PMS 0.2919

cilazapril 5mg & hydrochlorothiazide 12.5mg tab

02284987 Apo-Cilazapril/HCTZ 5mg/12.5mg tab APX 0.4170

02181479 Inhibace Plus 5mg/12.5mg tab HLR 0.417002313731 Novo-Cilazapril/HCTZ 5mg/12.5mg tab TEV 0.4170

cimetidine 200mg tab 00584215 Apo-Cimetidine 200mg tab APX 0.0860cimetidine 300mg tab 00487872 Apo-Cimetidine 300mg tab APX 0.0860

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 15 of 83

Generic Name and Strength DIN Brand MFR MRP PRPcimetidine 300mg tab 02227444 MYLAN-Cimetidine 300mg tab MYL 0.0860

00865818 Nu-Cimet 300mg tab NXP 0.0860cimetidine 400mg tab 00600059 Apo-Cimetidine 400mg tab APX 0.1350

02227452 MYLAN-Cimetidine 400mg tab MYL 0.135000865826 Nu-Cimet 400mg tab NXP 0.1350

cimetidine 600mg tab 00600067 Apo-Cimetidine 600mg tab APX 0.170202227460 MYLAN-Cimetidine 600mg tab MYL 0.170200865834 Nu-Cimet 600mg tab NXP 0.1702

cimetidine 800mg tab 00749494 Apo-Cimetidine 800mg tab APX 0.2530ciprofloxacin 0.3% oph sol (exception status)

01945270 Ciloxan 0.3% oph sol ALC 0.7920

02253933 pms-Ciprofloxacin 0.3% oph sol PMS 0.7920ciprofloxacin 250mg tab (exception status) 02229521 Apo-Ciproflox 250mg tab APX 0.8660

02155958 Cipro 250mg tab BAY 0.866002353318 Ciprofloxacin 250mg tab SAS 0.866002247339 CO Ciprofloxacin 250mg tab COB 0.866002317427 MINT-Ciprofloxacin 250mg tab MNT 0.866002245647 MYLAN-Ciprofloxacin 250mg tab MYL 0.866002161737 Novo-Ciprofloxacin 250mg tab TEV 0.866002248437 pms-Ciprofloxacin 250mg tab PMS 0.866002303728 RAN-Ciproflox 250mg tab RAN 0.866002246825 ratio-Ciprofloxacin 250mg tab TEV 0.866002248756 Sandoz Ciprofloxacin 250mg tab SDZ 0.8660

ciprofloxacin 500mg tab (exception status) 02229522 Apo-Ciproflox 500mg tab APX 0.977002155966 Cipro 500mg tab BAY 0.977002353326 Ciprofloxacin 500mg tab SAS 0.977002247340 CO Ciprofloxacin 500mg tab COB 0.977002317435 MINT-Ciprofloxacin 500mg tab MNT 0.977002245648 MYLAN-Ciprofloxacin 500mg tab MYL 0.977002161745 Novo-Ciprofloxacin 500mg tab TEV 0.977002248438 pms-Ciprofloxacin 500mg tab PMS 0.977002303736 RAN-Ciproflox 500mg tab RAN 0.977002246826 ratio-Ciprofloxacin 500mg tab TEV 0.977002248757 Sandoz Ciprofloxacin 500mg tab SDZ 0.9770

ciprofloxacin 750mg tab (exception status) 02229523 Apo-Ciproflox 750mg tab APX 1.789102155974 Cipro 750mg tab BAY 1.789102353334 Ciprofloxacin 750mg tab SAS 1.789102247341 CO Ciprofloxacin 750mg tab COB 1.789102317443 MINT-Ciprofloxacin 750mg tab MNT 1.789102245649 MYLAN-Ciprofloxacin 750mg tab MYL 1.789102161753 Novo-Ciprofloxacin 750mg tab TEV 1.789102248439 pms-Ciprofloxacin 750mg tab PMS 1.789102303744 RAN-Ciproflox 750mg tab RAN 1.789102246827 ratio-Ciprofloxacin 750mg tab TEV 1.789102248758 Sandoz Ciprofloxacin 750mg tab SDZ 1.7891

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 16 of 83

Generic Name and Strength DIN Brand MFR MRP PRPcitialopram 10mg tab 02273543 phl-Citalopram 10mg tab PHL 0.4464

02270609 pms-Citalopram 10mg tab PMS 0.4464citalopram 20mg tab 02246056 Apo-Citalopram 20mg tab APX 0.4661

02239607 Celexa 20mg tab VLH 0.466102353660 Citalopram 20mg tab SAS 0.466102306239 Citalopram-Odan 20mg tab ODN 0.466102248050 CO Citalopram 20mg tab COB 0.466102313405 Jamp-Citalopram 20mg tab JPC 0.466102371898 Mar-Citalopram 20mg tab MAR 0.466102304686 MINT-Citalopram 20mg tab MNT 0.466102246594 MYLAN-Citalopram 20mg tab MYL 0.466102293218 Novo-Citalopram 20mg tab TEV 0.466102248944 phl-Citalopram 20mg tab PHL 0.466102248010 pms-Citalopram 20mg tab PMS 0.466102285622 RAN-Citalo 20mg tab RAN 0.466102252112 ratio-Citalopram 20mg tab TEV 0.466102248170 Sandoz Citalopram 20mg tab SDZ 0.466102355272 Septa-Citalopram 20mg tab SPT 0.4661

citalopram 40mg tab 02246057 Apo-Citalopram 40mg tab APX 0.466102239608 Celexa 40mg tab VLH 0.466102353679 Citalopram 40mg tab SAS 0.466102306247 Citalopram-Odan 40mg tab ODN 0.466102248051 CO Citalopram 40mg tab COB 0.466102313413 Jamp-Citalopram 40mg tab JPC 0.466102371901 Mar-Citalopram 40mg tab MAR 0.466102304694 MINT-Citalopram 40mg tab MNT 0.466102246595 MYLAN-Citalopram 40mg tab MYL 0.466102293226 Novo-Citalopram 40mg tab TEV 0.466102248945 phl-Citalopram 40mg tab PHL 0.466102248011 pms-Citalopram 40mg tab PMS 0.466102285630 RAN-Citalo 40mg tab RAN 0.466102252120 ratio-Citalopram 40mg tab TEV 0.466102248171 Sandoz Citalopram 40mg tab SDZ 0.466102355280 Septa-Citalopram 40mg tab SPT 0.4661

clarithromycin 250mg tab (exception status)

02274744 Apo-Clarithromycin 250mg tab APX 0.5770

01984853 Biaxin BID 250mg tab ABB 0.577002248856 MYLAN-Clarithromycin 250mg tab MYL 0.577002247573 pms-Clarithromycin 250mg tab PMS 0.577002361426 RAN-Clarithromycin 250mg tab RAN 0.577002247818 ratio-Clarithromycin 250mg tab TEV 0.577002266539 Sandoz Clarithromycin 250mg tab SDZ 0.5770

clarithromycin 500mg tab (exception status)

02274752 Apo-Clarithromycin 500mg tab APX 1.6292

02126710 Biaxin BID 500mg tab ABB 1.6293

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 17 of 83

Generic Name and Strength DIN Brand MFR MRP PRPclarithromycin 500mg tab (exception status)

02248857 MYLAN-Clarithromycin 500mg tab MYL 1.6293

02247574 pms-Clarithromycin 500mg tab PMS 1.629302361434 RAN-Clarithromycin 500mg tab RAN 1.629302247819 ratio-Clarithromycin 500mg tab TEV 1.629302266547 Sandoz Clarithromycin 500mg tab SDZ 1.6293

clindamycin 150mg/mL (bulk) inj 02230535 Clindamycin 150mg/mL (bulk) inj SDZ 3.325000260436 Dalacin C Phos 150mg/mL (bulk) inj PFI 3.3250

clindamycin 150mg cap 02245232 Apo-Clindamycin 150mg cap APX 0.329400030570 Dalacin C 150mg cap PFI 0.329402258331 MYLAN-Clindamycin 150mg cap MYL 0.329402241709 Teva-Clindamycin 150mg cap TEV 0.3294

clindamycin 300mg cap 02245233 Apo-Clindamycin 300mg cap APX 0.658802182866 Dalacin C 300mg cap PFI 0.658802258358 MYLAN-Clindamycin 300mg cap MYL 0.658802241710 Novo-Clindamycin 300mg cap TEV 0.6588

clindamycin 150mg/mL inj 02230540 Clindamycin 150mg/mL inj SDZ 3.325000260436 Dalacin C Phos 150mg/mL inj PFI 3.3250

clindamycin 1% top sol 00582301 Dalacin T 1% top sol PFI 0.226002266938 Taro-Clindamycin 1% top sol TAR 0.2260

clobazam 10mg tab 02244638 Apo-Clobazam 10mg tab APX 0.153802221799 Frisium 10mg tab OVN 0.153802238334 Novo-Clobazam 10mg tab TEV 0.153802244474 pms-Clobazam 10mg tab PMS 0.1538

clobetasol 17-propionate 0.05% cr 02213265 Dermovate 0.05% cr TPH 0.227902024187 MYLAN-Clobetasol 0.05% cr MYL 0.227902093162 Novo-Clobetasol 0.05% cr TEV 0.227902309521 pms-Clobetasol 0.05% cr PMS 0.227902232191 pms-Clobetasol 0.05% cr (discontinued) PMS 0.227901910272 ratio-Clobetasol 0.05% cr TEV 0.227902245523 Taro-Clobetasol 0.05% cr TAR 0.2279

clobetasol 17-propionate 0.05% oint 02213273 Dermovate 0.05% oint TPH 0.227902026767 MYLAN-Clobetasol 0.05% oint MYL 0.227902126192 Novo-Clobetasol 0.05% oint TEV 0.227902309548 pms-Clobetasol 0.05% oint PMS 0.227902232193 pms-Clobetasol 0.05% oint (discontinued) PMS 0.227901910280 ratio-Clobetasol 0.05% oint TEV 0.227902245524 Taro-Clobetasol 0.05% oint TAR 0.2279

clobetasol 17-propionate 0.05% scalp lot 02213281 Dermovate 0.05% scalp lot TPH 0.199002216213 Gen-Clobetasol 0.05% scalp lot MYL 0.199002232195 pms-Clobetasol 0.05% scalp lot PMS 0.199001910299 ratio-Clobetasol 0.05% scalp lot TEV 0.199002245522 Taro-Clobetasol 0.05% scalp lot TAR 0.1990

clomipramine 10mg tab 00330566 Anafranil 10mg tab ORX 0.129002040786 Apo-Clomipramine 10mg tab APX 0.1290

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 18 of 83

Generic Name and Strength DIN Brand MFR MRP PRPclomipramine 10mg tab 02244816 CO Clomipramine 10mg tab COB 0.1290clomipramine 25mg tab 00324019 Anafranil 25mg tab ORX 0.1758

02040778 Apo-Clomipramine 25mg tab APX 0.175802244817 CO Clomipramine 25mg tab COB 0.1758

clomipramine 50mg tab 00402591 Anafranil 50mg tab ORX 0.323702040751 Apo-Clomipramine 50mg tab APX 0.323702244818 CO Clomipramine 50mg tab COB 0.3237

clonazepam 0.5mg tab 02177889 Apo-Clonazepam 0.5mg tab APX 0.069402270641 CO Clonazepam 0.5mg tab COB 0.069402230950 MYLAN-Clonazepam 0.5mg tab MYL 0.069402239024 Novo-Clonazepam 0.5mg tab TEV 0.069402236948 phl-Clonazepam-R 0.5mg tab PHL 0.069402048701 pms-Clonazepam 0.5mg tab PMS 0.069402207818 pms-Clonazepam-R 0.5mg tab PMS 0.069402103656 ratio-Clonazepam 0.5mg tab (discontinued) TEV 0.069400382825 Rivotril 0.5mg tab HLR 0.069402233960 Sandoz Clonazepam 0.5mg tab SDZ 0.069402345676 Zym-Clonazepam 0.5mg tab ZYM 0.0694

clonazepam 1mg tab 02145235 phl-Clonazepam 1mg tab PHL 0.148702048728 pms-Clonazepam 1mg tab PMS 0.1487

clonazepam 2mg tab 02177897 Apo-Clonazepam 2mg tab APX 0.119602270676 CO Clonazepam 2mg tab COB 0.119602230951 MYLAN-Clonazepam 2mg tab MYL 0.119602239025 Novo-Clonazepam 2mg tab TEV 0.119602145243 phl-Clonazepam 2mg tab PHL 0.119602048736 pms-Clonazepam 2mg tab PMS 0.119602103737 ratio-Clonazepam 2mg tab (discontinued) TEV 0.119600382841 Rivotril 2mg tab HLR 0.119602233985 Sandoz Clonazepam 2mg tab SDZ 0.119602303337 Zym-Clonazepam 2mg tab ZYM 0.1196

clonidine HCl 0.025mg tab 02248732 Apo-Clonidine 0.025mg tab APX 0.152300519251 Dixarit 0.025mg tab BOE 0.152302304163 Novo-Clonidine 0.025mg tab TEV 0.1523

clonidine HCl 0.1mg tab 00868949 Apo-Clonidine 0.1mg tab APX 0.135800259527 Catapres 0.1mg tab BOE 0.135802046121 Novo-Clonidine 0.1mg tab TEV 0.1358

clonidine HCl 0.2mg tab 00868957 Apo-Clonidine 0.2mg tab (discontinued) APX 0.242400291889 Catapres 0.2mg tab BOE 0.242402046148 Novo-Clonidine 0.2mg tab TEV 0.2424

clopidogrel 75mg tab (exception status) 02252767 Apo-Clopidogrel 75mg tab APX 0.920602303027 CO Clopidogrel 75mg tab COB 0.920602351536 MYLAN-Clopidogrel 75mg tab MYL 0.920602238682 Plavix 75mg tab BRI 0.920602348004 pms-Clopidogrel 75mg tab PMS 0.9206

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 19 of 83

Generic Name and Strength DIN Brand MFR MRP PRPclopidogrel 75mg tab (exception status) 02359316 Sandoz Clopidogrel 75mg tab SDZ 0.9206

02293161 Teva-Clopidogrel 75mg tab TEV 0.9206clorazepate dipotassium 3.75mg cap 00860689 Apo-Clorazepate 3.75mg cap APX 0.1476clorazepate dipotassium 7.5mg cap 00860700 Apo-Clorazepate 7.5mg cap APX 0.1810clorazepate dipotassium 15mg cap 00860697 Apo-Clorazepate 15mg cap APX 0.3259clotrimazole 1% cr 02150867 Canesten 1% cr YNO 0.0884

00812382 Clotrimaderm 1% cr TAR 0.0884clotrimazole 1% vag cr 02150891 Canesten 1% vag cr YNO 0.1750

00812366 Clotrimaderm 1% vag cr TAR 0.1750clotrimazole 2% vag cr 02150905 Canesten 2% vag cr YNO 0.3500

00812374 Clotrimaderm 2% vag cr TAR 0.3500cloxacillin 250mg cap 00337765 Novo-Cloxin 250mg cap TEV 0.3515cloxacillin 500mg cap 00337773 Novo-Cloxin 500mg cap TEV 0.6646cloxacillin 25mg/mL o/l 00337757 Novo-Cloxin 25mg/mL o/l TEV 0.0855cromoglycate sodium 1% unit dose inh sol 02046113 pms-Sodium Cromoglycate 1% neb sol PMS 1.5392cromoglycate sodium 2% nasal sol 01950541 Rhinaris-CS Anti-Allergic nasal mist PMS 0.5292cromoglycate sodium 2% oph sol 02009277 Cromolyn 2% oph sol PDP 0.9500

02230621 Opticrom 2% oph sol ALL 0.9500cyanocobalamin 100mcg/mL inj 02241500 Vitamin B12 100mcg/mL inj SDZ 1.4500cyclobenzaprine HCl 10mg tab 02177145 Apo-Cyclobenzaprine 10mg tab APX 0.3727

02348853 Auro-Cyclobenzaprine 10mg tab ARO 0.372702287064 Cyclobenzaprine 10mg tab SAS 0.372702231353 MYLAN-Cyclobenzaprine 10mg tab MYL 0.372702080052 Novo-Cycloprine 10mg tab TEV 0.372702171848 Nu-Cyclobenzaprine 10mg tab NXP 0.372702249359 phl-Cyclobenzaprine 10mg tab PHL 0.372702212048 pms-Cyclobenzaprine 10mg tab PMS 0.3727

cyclosporine 25mg cap (exception status) 02150689 Neoral 25mg cap NVR 1.305002247073 Sandoz Cyclosporine 25mg cap SDZ 1.3050

cyclosporine 50mg cap (exception status) 02150662 Neoral 50mg cap NVR 2.545002247074 Sandoz Cyclosporine 50mg cap SDZ 2.5450

cyclosporine 100mg cap (exception status)

02150670 Neoral 100mg cap NVR 5.090002242821 Sandoz Cyclosporine 100mg cap SDZ 5.0900

cyclosporine 100mg/mL o/l (exception status)

02244324 Apo-Cyclosporine 100mg/mL o/l APX 3.7708

02150697 Neoral 100mg/mL o/l NVR 3.7708cyproterone 50mg tab 00704431 Androcur 50mg tab PMS 1.5283

02245898 Cyproterone 50mg tab AAP 1.5283dasatinib 50mg cap (exception status) 02293137 Sprycel 50mg cap BRI 78.0658dasatinib 100mg cap (exception status) 02320193 Sprycel 100mg cap BRI 154.4823deferasirox 125mg tab (exception status) 02287420 Exjade 125mg tab for susp NVR 11.0714deferasirox 250mg tab (exception status) 02287439 Exjade 250mg tab for susp NVR 22.1421deferasirox 500mg tab (exception status) 02287447 Exjade 500mg tab for susp NVR 44.2850deferoxamine 500mg/vial inj 01981242 Desferal 500mg/vial inj NVR 7.4800

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 20 of 83

Generic Name and Strength DIN Brand MFR MRP PRPdeferoxamine 500mg/vial inj 02241600 Desferrioxamine 500mg/vial inj HOS 7.4800

02242055 pms-Deferoxamine 500mg/vial inj PMS 7.4800desipramine 10mg tab 02216248 Apo-Desipramine 10mg tab APX 0.9900desipramine 25mg tab 02216256 Apo-Desipramine 25mg tab APX 0.3804desipramine 50mg tab 02216264 Apo-Desipramine 50mg tab APX 0.6704desipramine 75mg tab 02216272 Apo-Desipramine 75mg tab APX 0.8915desipramine 100mg tab 02216280 Apo-Desipramine 100mg tab APX 0.8915desmopressin 0.1mg tab (exception status)

02284030 Apo-Desmopressin 0.1mg tab APX 0.4626

00824305 DDAVP 0.1mg tab FEI 0.462602287730 Novo-Desmopressin 0.1mg tab TEV 0.462602304368 pms-Desmopressin 0.1mg tab PMS 0.4626

desmopressin 0.2mg tab (exception status)

02284049 Apo-Desmopressin 0.2mg tab APX 0.9251

00824143 DDAVP 0.2mg tab FEI 0.925102287749 Novo-Desmopressin 0.2mg tab TEV 0.925102304376 pms-Desmopressin 0.2mg tab PMS 0.9251

desmopressin 60mcg SL tab (exception status)

02284995 DDAVP Melt 60mcg SL tab FEI 0.4626

desmopressin 120mcg SL tab (exception status)

02285002 DDAVP Melt 120mcg SL tab FEI 0.9251

desogestrel 150mcg and ethiny estradiol 30mcg tab (21)

02317192 Apri 21 tab 21 day APX 0.5436

02042487 Marvelon 21 tab 21 day ORG 0.5436desogestrel 150mcg and ethiny estradiol 30mcg tab (28)

02317206 Apri 28 tab 28 day APX 0.4077

02042479 Marvelon 28 tab 28 day ORG 0.4077desonide 0.05% cr 02229315 pms-Desonide 0.05% cr PMS 0.3349desonide 0.05% oint 02229323 pms-Desonide 0.05% oint PMS 0.3177dexamethasone 0.5mg tab 02261081 Apo-Dexamethasone 0.5mg tab APX 0.1095

01964976 pms-Dexamethasone 0.5mg tab PMS 0.1095dexamethasone 0.75mg tab 01964968 pms-Dexamethasone 0.75mg tab PMS 0.4500dexamethasone 4mg tab 02250055 Apo-Dexamethasone 4mg tab APX 0.4265

00489158 Dexasone 4mg tab VLN 0.426501964070 pms-Dexamethasone 4mg tab PMS 0.4265

dexamethasone 4mg/mL inj 01977547 Dexamethasone 4mg/mL inj CYI 1.606000664227 Dexamethasone 4mg/mL inj SDZ 1.6060

dexamethasone 0.1% oph/otic sol 00739839 Sandoz Dexamethasone 0.1% oph/otic sol SDZ 1.4060dexamethasone, framycetin sulfate & gramicidin oph/otic sol

02247920 Sandoz Opticort oph/otic sol SDZ 0.9800

02224623 Sofracort oph/otic sol SAV 0.9800diazepam 5mg tab 00362158 Apo-Diazepam 5mg tab APX 0.0650

00013285 Valium 5mg tab HLR 0.0650diazepam 10mg tab 00405337 Apo-Diazepam 10mg tab APX 0.0867diazepam 5mg/mL inj 00399728 Diazepam 5mg/mL inj SDZ 0.7850

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 21 of 83

Generic Name and Strength DIN Brand MFR MRP PRPdiclofenac sodium 25mg EC tab 00839175 Apo-Diclo 25mg EC tab APX 0.1094

00808539 Novo-Difenac 25mg EC tab TEV 0.109400886017 Nu-Diclo 25mg EC tab NXP 0.109402302616 pms-Diclofenac 25mg EC tab PMS 0.109402261952 Sandoz Diclofenac 25mg EC tab SDZ 0.1094

diclofenac sodium 50mg EC tab 00839183 Apo-Diclo 50mg EC tab APX 0.233302352397 Diclofenac Sodium 50mg tab SAS 0.233300808547 Novo-Difenac 50mg EC tab TEV 0.233300886025 Nu-Diclo 50mg EC tab NXP 0.233302302624 pms-Diclofenac 50mg EC tab PMS 0.233302261960 Sandoz Diclofenac 50mg EC tab SDZ 0.233300514012 Voltaren 50mg EC tab NVR 0.2333

diclofenac sodium 75mg SR tab 02162814 Apo-Diclo 75mg SR tab APX 0.350002352400 Diclofenac Sodium 75mg SR tab SAS 0.350002158582 Novo-Difenac 75mg SR tab TEV 0.350002231504 pms-Diclofenac 75mg SR tab PMS 0.350002261901 Sandoz Diclofenac 75mg SR tab SDZ 0.350000782459 Voltaren 75mg SR tab NVR 0.3500

diclofenac sodium 100mg SR tab 02091194 Apo-Diclo 100mg SR tab APX 0.578802048698 Novo-Difenac 100mg SR tab TEV 0.578802231505 pms-Diclofenac 100mg SR tab PMS 0.578802261944 Sandoz Diclofenac 100mg SR tab SDZ 0.578800590827 Voltaren 100mg SR tab NVR 0.5788

diclofenac sodium 50mg supp 02231506 pms-Diclofenac 50mg supp PMS 0.467002261928 Sandoz Diclofenac 50mg supp SDZ 0.467000632724 Voltaren 50mg supp NVR 0.4670

diclofenac sodium 100mg supp 02231508 pms-Diclofenac 100mg supp PMS 0.628602261936 Sandoz Diclofenac 100mg supp SDZ 0.628600632732 Voltaren 100mg supp NVR 0.6286

diflunisal 250mg tab 02039486 Apo-Diflunisal 250mg tab APX 0.175002048493 Novo-Diflunisal 250mg tab TEV 0.1750

diflunisal 500mg tab 02039494 Apo-Diflunisal 500mg tab APX 0.3500dihydroergotamine 1mg/mL inj 02241163 Dihydroergotamine 1mg/mL inj SDZ 3.7933diltiazem 120mg CD cap 02230997 Apo-Diltiaz 120mg CD cap APX 0.5174

02097249 Cardizem 120mg CD cap BVL 0.517402370611 CO Diltiazem CD 120mg cap COB 0.517402242538 Novo-Diltazem 120mg CD cap TEV 0.517402231052 Nu-Diltiaz 120mg CD cap NXP 0.517402355752 pms-Diltiazem CD 120mg cap PMS 0.517402229781 ratio-Diliazem 120mg CD cap TEV 0.517402243338 Sandoz Diltiazem 120mg CD cap SDZ 0.5174

diltiazem 180mg CD cap 02230998 Apo-Diltiaz 180mg CD cap APX 0.686902097257 Cardizem 180mg CD cap BVL 0.686902370638 CO Diltiazem CD 180mg cap COB 0.6869

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 22 of 83

Generic Name and Strength DIN Brand MFR MRP PRPdiltiazem 180mg CD cap 02242539 Novo-Diltazem 180mg CD cap TEV 0.6869

02231053 Nu-Diltiaz 180mg CD cap NXP 0.686902355760 pms-Diltiazem CD 180mg cap PMS 0.686902229782 ratio-Diliazem 180mg CD cap TEV 0.686902243339 Sandoz Diltiazem 180mg CD cap SDZ 0.6869

diltiazem 240mg CD cap 02230999 Apo-Diltiaz 240mg CD cap APX 0.911102097265 Cardizem 240mg CD cap BVL 0.911102370646 CO Diltiazem CD 240mg cap COB 0.911102242540 Novo-Diltazem 240mg CD cap TEV 0.911102231054 Nu-Diltiaz 240mg CD cap NXP 0.911102355779 pms-Diltiazem CD 240mg cap PMS 0.911102229783 ratio-Diliazem 240mg CD cap TEV 0.911102243340 Sandoz Diltiazem 240mg CD cap SDZ 0.9111

diltiazem 300mg CD cap 02229526 Apo-Diltiaz 300mg CD cap APX 1.138802097273 Cardizem 300mg CD cap BVL 1.138802370654 CO Diltiazem CD 300mg cap COB 1.138802242541 Novo-Diltazem 300mg CD cap TEV 1.138802355787 pms-Diltiazem CD 300mg cap PMS 1.138802229784 ratio-Diliazem 300mg CD cap TEV 1.138802243341 Sandoz Diltiazem 300mg CD cap SDZ 1.1388

diltiazem 120mg ER cap 02291037 Apo-Diltiaz TZ 120mg ER cap APX 0.298702370441 CO Diltiazem T 120mg cap COB 0.298702271605 Novo-Diltiazem HCL 120mg ER cap TEV 0.298702245918 Sandoz Diltiazem T 120mg ER cap SDZ 0.298702231150 Tiazac 120mg ER cap BVL 0.2987

diltiazem 180mg ER cap 02291045 Apo-Diltiaz TZ 180mg ER cap APX 0.404502370492 CO Diltiazem T 180mg cap COB 0.404502271613 Novo-Diltiazem HCL 180mg ER cap TEV 0.404502245919 Sandoz Diltiazem T 180mg ER cap SDZ 0.404502231151 Tiazac 180mg ER cap BVL 0.4045

diltiazem 240mg ER cap 02291053 Apo-Diltiaz TZ 240mg ER cap APX 0.536502370506 CO Diltiazem T 240mg cap COB 0.536502271621 Novo-Diltiazem HCL 240mg ER cap TEV 0.536502245920 Sandoz Diltiazem T 240mg ER cap SDZ 0.536502231152 Tiazac 240mg ER cap BVL 0.5365

diltiazem 300mg ER cap 02291061 Apo-Diltiaz TZ 300mg ER cap APX 0.660702370514 CO Diltiazem T 300mg cap COB 0.660702271648 Novo-Diltiazem HCL 300mg ER cap TEV 0.660702245921 Sandoz Diltiazem T 300mg ER cap SDZ 0.660702231154 Tiazac 300mg ER cap BVL 0.6607

diltiazem 360mg ER cap 02291088 Apo-Diltiaz TZ 360mg ER cap APX 0.808902370522 CO Diltiazem T 360mg cap COB 0.808902271656 Novo-Diltiazem HCL 360mg ER cap TEV 0.808902245922 Sandoz Diltiazem T 360mg ER cap SDZ 0.808902231155 Tiazac 360mg ER cap BVL 0.8089

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 23 of 83

Generic Name and Strength DIN Brand MFR MRP PRPdiltiazem HCl 30mg tab 00771376 Apo-Diltiaz 30mg tab APX 0.1866

00862924 Novo-Diltazem 30mg tab TEV 0.186600886068 Nu-Diltiaz 30mg tab NXP 0.1866

diltiazem HCl 60mg tab 00771384 Apo-Diltiaz 60mg tab APX 0.327300862932 Novo-Diltazem 60mg tab TEV 0.327300886076 Nu-Diltiaz 60mg tab NXP 0.3273

dimenhydrinate 10mg/mL IV inj 00392731 Dimenhydrinate 10mg/mL IV amp SDZ 0.3520dimenhydrinate 50mg/mL IM inj 00392537 Dimenhydrinate 50mg/mL IM inj SDZ 1.1500

00013579 Gravol I 50mg/mL IM inj CHU 1.1500dimethyl sulfoxide 500mg/g (50%) irr sol 02243231 Dimethyl Sulfoxide 50% irr sol SDZ 1.1840

00493392 Rimso 50% irr sol BCH 1.1840dipyridamole 25mg tab 00895644 Apo-Dipyridamole-FC 25mg tab APX 0.2633dipyridamole 50mg tab 00895652 Apo-Dipyridamole-FC 50mg tab APX 0.2932dipyridamole 75mg tab 00895660 Apo-Dipyridamole-FC 75mg tab APX 0.4397divalproex sodium 125mg tab 02239698 Apo-Divalproex 125mg tab APX 0.1032

00596418 Epival 125mg tab ABB 0.103202239701 Novo-Divalproex 125mg tab TEV 0.103202239517 Nu-Divalproex 125mg tab NXP 0.1032

divalproex sodium 250mg tab 02239699 Apo-Divalproex 250mg tab APX 0.185500596426 Epival 250mg tab ABB 0.185502239702 Novo-Divalproex 250mg tab TEV 0.185502239518 Nu-Divalproex 250mg tab NXP 0.1855

divalproex sodium 500mg tab 02239700 Apo-Divalproex 500mg tab APX 0.371100596434 Epival 500mg tab ABB 0.371102239703 Novo-Divalproex 500mg tab TEV 0.371102239519 Nu-Divalproex 500mg tab NXP 0.3711

dobutamine 12.5mg/mL inj 02242010 Dobutamine 12.5mg/mL inj SDZ 1.4885domperidone maleate 10mg tab 02103613 Apo-Domperidone 10mg tab APX 0.0832

02350440 Domperidone 10mg tab SAS 0.083202278669 MYLAN-Domperidone 10mg tab MYL 0.083202231477 Nu-Domperidone 10mg tab NXP 0.083202236466 pms-Domperidone 10mg tab PMS 0.083202268078 RAN-Domperidone 10mg tab RAN 0.083201912070 ratio-Domperidone 10mg tab TEV 0.083202157195 Teva-Domperidone 10mg tab TEV 0.0832

dorzolamide HCI 2% oph sol 02316307 Sandoz Dorzolamide 2% oph sol SDZ 1.327902216205 Trusopt 2% oph sol MSD 1.3279

dorzolamide HCI 2% & timolol maleate 0.5% oph sol

02299615 Apo-Dorzo-Timop 2%/0.5% oph sol APX 2.0097

02240113 Cosopt 2%/0.5% oph sol MSD 2.009702344351 Sandoz Dorzolamide/Timolol 2%/0.5% oph sol SDZ 2.0097

doxazosin 1mg tab 02240588 Apo-Doxazosin 1mg tab APX 0.198901958100 Cardura-1 1mg tab PFI 0.198902240498 MYLAN-Doxazosin 1mg tab MYL 0.1989

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 24 of 83

Generic Name and Strength DIN Brand MFR MRP PRPdoxazosin 1mg tab 02242728 Novo-Doxazosin 1mg tab TEV 0.1989

02244527 pms-Doxazosin 1mg tab PMS 0.1989doxazosin 2mg tab 02240589 Apo-Doxazosin 2mg tab APX 0.2385

01958097 Cardura-2 2mg tab PFI 0.238502240499 MYLAN-Doxazosin 2mg tab MYL 0.238502242729 Novo-Doxazosin 2mg tab TEV 0.238502244528 pms-Doxazosin 2mg tab PMS 0.2385

doxazosin 4mg tab 02240590 Apo-Doxazosin 4mg tab APX 0.310201958119 Cardura-4 4mg tab PFI 0.310202240500 MYLAN-Doxazosin 4mg tab MYL 0.310202242730 Novo-Doxazosin 4mg tab TEV 0.310202244529 pms-Doxazosin 4mg tab PMS 0.3102

doxepin HCl 10mg cap 02049996 Apo-Doxepin 10mg cap APX 0.188900024325 Sinequan 10mg cap ERF 0.1889

doxepin HCl 25mg cap 02050005 Apo-Doxepin 25mg cap APX 0.214001913425 Novo-Doxepin 25mg cap TEV 0.214000024333 Sinequan 25mg cap ERF 0.2140

doxepin HCl 50mg cap 02050013 Apo-Doxepin 50mg cap APX 0.292301913433 Novo-Doxepin 50mg cap TEV 0.292300024341 Sinequan 50mg cap ERF 0.2923

doxepin HCl 75mg cap 02050021 Apo-Doxepin 75mg cap APX 0.430201913441 Novo-Doxepin 75mg cap TEV 0.430200400750 Sinequan 75mg cap ERF 0.4302

doxepin HCl 100mg cap 02050048 Apo-Doxepin 100mg cap APX 0.516001913468 Novo-Doxepin 100mg cap TEV 0.516000326925 Sinequan 100mg cap ERF 0.5160

doxepin HCl 150mg cap 01913476 Novo-Doxepin 150mg cap TEV 1.1507doxycycline 100mg cap 00740713 Apo-Doxy 100mg cap APX 0.5949

02351234 Doxycycline 100mg cap SAS 0.594900725250 Novo-Doxylin 100mg cap TEV 0.594902044668 Nu-Doxycycline 100mg cap NXP 0.594900024368 Vibramycin 100mg cap PFI 0.5949

doxycycline 100mg tab (Vibra-tabs) 00874256 Apo-Doxy 100mg tab APX 0.586002351242 Doxycycline 100mg tab SAS 0.586002158574 Novo-Doxylin 100mg tab TEV 0.5860

enalapril 2.5mg tab 02020025 Apo-Enalapril 2.5mg tab APX 0.273702291878 CO Enalapril 2.5mg tab COB 0.273702300036 MYLAN-Enalapril 2.5mg tab MYL 0.273702300680 Novo-Enalapril 2.5mg tab TEV 0.273702352230 RAN-Enalapril 2.5mg tab RAN 0.273702299933 Sandoz Enalapril 2.5mg tab SDZ 0.273700851795 Vasotec 2.5mg tab FRS 0.2737

enalapril 5mg tab 02019884 Apo-Enalapril 5mg tab APX 0.323902291886 CO Enalapril 5mg tab COB 0.3239

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 25 of 83

Generic Name and Strength DIN Brand MFR MRP PRPenalapril 5mg tab 02300044 MYLAN-Enalapril 5mg tab MYL 0.3239

02233005 Novo-Enalapril 5mg tab TEV 0.323902352249 RAN-Enalapril 5mg tab RAN 0.323902299941 Sandoz Enalapril 5mg tab SDZ 0.323900708879 Vasotec 5mg tab FRS 0.3239

enalapril 10mg tab 02019892 Apo-Enalapril 10mg tab APX 0.389102291894 CO Enalapril 10mg tab COB 0.389102300052 MYLAN-Enalapril 10mg tab MYL 0.389102233006 Novo-Enalapril 10mg tab TEV 0.389102352257 RAN-Enalapril 10mg tab RAN 0.389102299968 Sandoz Enalapril 10mg tab SDZ 0.389100670901 Vasotec 10mg tab FRS 0.3891

enalapril 20mg tab 02019906 Apo-Enalapril 20mg tab APX 0.469602291908 CO Enalapril 20mg tab COB 0.469602300060 MYLAN-Enalapril 20mg tab MYL 0.469602233007 Novo-Enalapril 20mg tab TEV 0.469602352265 RAN-Enalapril 20mg tab RAN 0.469602299976 Sandoz Enalapril 20mg tab SDZ 0.469600670928 Vasotec 20mg tab FRS 0.4696

enalapril 5mg & hydrochlorothiazide 12.5mg tab

02352923 Apo-Enalapril Maleate/HCTZ 5/12.5mg tab APX 0.4941

02300222 Novo-Enalapril/HCTZ 5/12.5mg tab TEV 0.4941enalapril 10mg & hydrochlorothiazide 25mg tab

02352931 Apo-Enalapril Maleate/HCTZ 10/25mg tab APX 0.6108

02300230 Novo-Enalapril/HCTZ 10/25mg tab TEV 0.610800657298 Vaseretic 10/25mg tab FRS 0.6108

entacapone 200mg tab (exception status) 02243763 Comtan 200mg tab NVR 0.568702380005 Sandoz Entacapone 200mg tab SDZ 0.568702375559 Teva-Entacapone 200mg tab TEV 0.5687

erythromycin base 250mg cap 00726672 Apo-Erythro-EC 250mg cap AAP 0.423200607142 ERYC 250mg cap PFI 0.4232

erythromycin base 333mg cap 01925938 Apo-Erythro-EC 333mg cap AAP 0.470000873454 ERYC 333mg cap PFI 0.4700

erythromycin ethylsuccinate 600mg tab 00637416 Erythro-ES 600mg tab AAP 0.3649erythromycin ethylsuccinate 40mg/mL o/l 00605859 Novo-Rythro EES 200mg/5mL susp TEV 0.0923erythromycin ethylsuccinate 80mg/mL o/l 00652318 Novo-Rythro EES 400mg/5mL susp TEV 0.1398erythropoeietin 2,000iu/mL inj (exception status)

02231583 Eprex 1,000iu/0.5mL syringe inj JAN 30.9225

erythropoeietin 4,000iu/mL inj (exception status)

02231584 Eprex 2,000iu/0.5mL syringe inj JAN 61.8450

erythropoeietin 10,000iu/mL inj (exception status)

02231585 Eprex 3,000iu/0.3mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02231586 Eprex 4,000iu/0.4mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02243400 Eprex 5,000iu/0.5mL syringe inj JAN 154.6125

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 26 of 83

Generic Name and Strength DIN Brand MFR MRP PRPerythropoeietin 10,000iu/mL inj (exception status)

02243401 Eprex 6,000iu/0.6mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02243403 Eprex 8,000iu/0.8mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02231587 Eprex 10,000iu/mL syringe inj JAN 154.6125

erythropoeietin 40,000iu/mL inj (exception status)

02243239 Eprex 20,000iu/0.5mL syringe inj JAN 600.5258

erythropoeietin 40,000iu/mL inj (exception status)

02288680 Eprex 30,000iu/0.75mL syringe inj JAN 600.5258

erythropoeietin 40,000iu/mL inj (exception status)

02240722 Eprex 40,000iu/mL syringe inj JAN 450.3944

estradiol 50mcg/day patch (exception status)

02244000 Estradot 50mcg/day patch NVR 2.4125

02246967 Sandoz Estradiol Derm 50mcg/day patch SDZ 2.4125estradiol 75mcg/day patch (exception status)

02244001 Estradot 75mcg/day patch NVR 2.5875

02246968 Sandoz Estradiol Derm 75mcg/day patch SDZ 2.5875estradiol 100mcg/day patch (exception status)

02244002 Estradot 100mcg/day patch NVR 2.7375

02246969 Sandoz Estradiol Derm 100mcg/day patch SDZ 2.7375etanercept 25mg powder for inj (exception status)

02242903 Enbrel 25mg Pdr for inj AGA 200.1325

etanercept 50mg/mL inj (exception status) 02274728 Enbrel 50mg/mL inj AGA 400.2650etidronate 200mg tab 02248686 CO Etidronate 200mg tab COB 0.4997

02245330 MYLAN-Etidronate 200mg tab MYL 0.4997etidronic disodium 400mg & calcium carbonate 500mg tab, sequential kit (exception status)

02263866 CO Etidrocal sequential kit COB 19.9900

02176017 Didrocal sequential kit WNC 19.990002353210 Etidrocal Kit SAS 19.990002247323 MYLAN-Eti-Cal Carepac sequential kit MYL 19.990002324199 Novo-Etidrocal sequential kit TEV 19.9900

etodolac 200mg cap 02232317 Etodolac 200mg cap AAP 0.3500etodolac 300mg cap 02232318 Etodolac 300mg cap AAP 0.3500everolimus 2.5mg tab (exception status) 02369257 Afinitor 2.5mg tab NVR 201.8100everolimus 5mg tab (exception status) 02339501 Afinitor 5mg tab NVR 201.8100everolimus 10mg tab (exception status) 02339528 Afinitor 10mg tab NVR 201.8100famciclovir 125mg tab 02292025 Apo-Famciclovir 125mg tab APX 1.3940

02305682 CO Famciclovir 125mg tab COB 1.394002229110 Famvir 125mg tab NVR 1.394002278081 pms-Famciclovir 125mg tab PMS 1.394002278634 Sandoz Famciclovir 125mg tab SDZ 1.3940

famciclovir 250mg tab 02292041 Apo-Famciclovir 250mg tab APX 1.873302305690 CO Famciclovir 250mg tab COB 1.873302229129 Famvir 250mg tab NVR 1.873302278103 pms-Famciclovir 250mg tab PMS 1.8733

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 27 of 83

Generic Name and Strength DIN Brand MFR MRP PRPfamciclovir 250mg tab 02278642 Sandoz Famciclovir 250mg tab SDZ 1.8733famciclovir 500mg tab 02292068 Apo-Famciclovir 500mg tab APX 2.4260

02305704 CO Famciclovir 500mg tab COB 2.426002177102 Famvir 500mg tab NVR 2.426002278111 pms-Famciclovir 500mg tab PMS 2.426002278650 Sandoz Famciclovir 500mg tab SDZ 2.4260

famotidine 20mg tab 01953842 Apo-Famotidine 20mg tab APX 0.180002351102 Famotidine 20mg tab SAS 0.180002196018 MYLAN-Famotidine 20mg tab MYL 0.180002022133 Novo-Famotidine 20mg tab TEV 0.180002024195 Nu-Famotidine 20mg tab NXP 0.180000710121 Pepcid 20mg tab FRS 0.1800

famotidine 40mg tab 01953834 Apo-Famotidine 40mg tab APX 0.360002351110 Famotidine 40mg tab SAS 0.360002196026 MYLAN-Famotidine 40mg tab MYL 0.360002022141 Novo-Famotidine 40mg tab TEV 0.360002024209 Nu-Famotidine 40mg tab NXP 0.360000710113 Pepcid 40mg tab FRS 0.3600

famotidine 10mg/mL inj 02247745 Famotidine Omega 10mg/mL inj OMG 1.9850famotidine 10mg/mL inj (pf) 02247735 Famotidine Omega (PF) 10mg/mL inj OMG 1.6740felodipine 5mg tab (Plendil) 00851779 Plendil 5mg tab AZE 0.4620

02280264 Sandoz Felodipine 5mg tab SDZ 0.4620felodipine 10mg tab (Plendil) 00851787 Plendil 10mg tab AZE 0.6733

02280272 Sandoz Felodipine 10mg tab SDZ 0.6733felodipine 5mg tab (Renedil) 02221993 Renedil 5mg tab SAV 0.4620

02280264 Sandoz Felodipine 5mg tab SDZ 0.4620felodipine 10mg tab (Renedil) 02222000 Renedil 10mg tab SAV 0.6733

02280272 Sandoz Felodipine 10mg tab SDZ 0.6733fenofibrate 67mg cap 02243180 Apo-Feno-Micro 67mg cap APX 0.4325

02243551 Novo-Fenofibrate Micronized 67mg cap TEV 0.4325fenofibrate 100mg tab 02246859 Apo-Feno-Super 100mg tab APX 0.5407

02356570 Fenofibrate-S 100mg tab SAS 0.540702241601 Lipidil Supra 100mg tab SPH 0.540702289083 Novo-Fenofibrate S 100mg tab TEV 0.540702288044 Sandoz Fenofibrate S 100mg tab SDZ 0.5407

fenofibrate 160mg tab 02246860 Apo-Feno-Super 160mg tab APX 0.436202356589 Fenofibrate-S 160mg tab SAS 0.436202241602 Lipidil Supra 160mg tab SPH 0.436202289091 Novo-Fenofibrate S 160mg tab TEV 0.436202288052 Sandoz Fenofibrate S 160mg tab SDZ 0.4362

fenofibrate 200mg cap 02239864 Apo-Feno-Micro 200mg cap APX 0.381202286092 Fenofibrate Micro 200mg cap SAS 0.381202146959 Lipidil Micro 200mg cap SPH 0.381202240210 MYLAN-Fenofibrate Micro 200mg cap MYL 0.3812

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 28 of 83

Generic Name and Strength DIN Brand MFR MRP PRPfenofibrate 200mg cap 02243552 Novo-Fenofibrate Micronized 200mg cap TEV 0.3812

02273551 pms-Fenofibrate Micro 200mg cap PMS 0.381202250039 ratio-Fenofibrate MC 200mg cap TEV 0.3812

fentanyl 12mcg/hr patch (exception status) 02341379 pms-Fentanyl MTX 12mcg/hr patch PMS 2.230002330105 RAN-Fentanyl MTX 12mcg/hr patch RAN 2.230002311925 ratio-Fentanyl 12mcg/hr patch TEV 2.230002327112 Sandoz Fentanyl 12mcg/hr patch SDZ 2.2300

fentanyl 25mcg/hr patch (exception status) 02275813 Duragesic MAT 25mcg/hr patch JAN 4.023602314630 Novo-Fentanyl 25mcg/hr patch TEV 4.023602341387 pms-Fentanyl MTX 25mcg/hr patch PMS 4.023602330113 RAN-Fentanyl MTX 25mcg/hr patch RAN 4.023602282941 ratio-Fentanyl 25mcg/hr patch TEV 4.023602327120 Sandoz Fentanyl 25mcg/hr patch SDZ 4.0236

fentanyl 50mcg/hr patch (exception status) 02275821 Duragesic MAT 50mcg/hr patch JAN 7.571902314649 Novo-Fentanyl 50mcg/hr patch TEV 7.571902341395 pms-Fentanyl MTX 50mcg/hr patch PMS 7.571902330121 RAN-Fentanyl MTX 50mcg/hr patch RAN 7.571902282968 ratio-Fentanyl 50mcg/hr patch TEV 7.571902327147 Sandoz Fentanyl 50mcg/hr patch SDZ 7.5719

fentanyl 75mcg/hr patch (exception status) 02275848 Duragesic MAT 75mcg/hr patch JAN 10.649802314657 Novo-Fentanyl 75mcg/hr patch TEV 10.649802341409 pms-Fentanyl MTX 75mcg/hr patch PMS 10.649802330148 RAN-Fentanyl MTX 75mcg/hr patch RAN 10.649802282976 ratio-Fentanyl 75mcg/hr patch TEV 10.649802327155 Sandoz Fentanyl 75mcg/hr patch SDZ 10.6498

fentanyl 100mcg/hr patch (exception status)

02275856 Duragesic MAT 100mcg/hr patch JAN 13.2559

02314665 Novo-Fentanyl 100mcg/hr patch TEV 13.255902341417 pms-Fentanyl MTX 100mcg/hr patch PMS 13.255902330156 RAN-Fentanyl MTX 100mcg/hr patch RAN 13.255902282984 ratio-Fentanyl 100mcg/hr patch TEV 13.255902327163 Sandoz Fentanyl 100mcg/hr patch SDZ 13.2559

finasteride 5mg tab 02365383 Apo-Finasteride 5mg tab APX 0.653102354462 CO Finasteride 5mg tab COB 0.653102355043 Finasteride 5mg tab AHC 0.653102357224 Jamp-Finasteride 5mg tab JPC 0.653102356058 MYLAN-Finasteride 5mg tab MYL 0.653102348500 Novo-Finasteride 5mg tab TEV 0.653102310112 pms-Finasteride 5mg tab PMS 0.653102010909 Proscar 5mg tab FRS 0.653102371820 RAN-Finasteride 5mg tab RAN 0.653102306905 ratio-Finasteride 5mg tab TEV 0.653102322579 Sandoz Finasteride 5mg tab SDZ 0.6531

flecainide 50mg tab 02275538 Flecainide 50mg tab AAP 0.429201966197 Tambocor 50mg tab MDS 0.4292

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 29 of 83

Generic Name and Strength DIN Brand MFR MRP PRPflecainide 100mg tab 02275546 Flecainide 100mg tab AAP 0.8585

01966200 Tambocor 100mg tab MDS 0.8585floctafenine 200mg tab 02244680 Floctafenine 200mg tab AAP 0.1167floctafenine 400mg tab 02244681 Floctafenine 400mg tab AAP 0.2333fluconazole 50mg tab 02237370 Apo-Fluconazole 50mg tab APX 1.8066

02281260 CO Fluconazole 50mg tab COB 1.806602245292 MYLAN-Fluconazole 50mg tab MYL 1.806602236978 Novo-Fluconazole 50mg tab TEV 1.806602245643 pms-Fluconazole 50mg tab PMS 1.8066

fluconazole 100mg tab 02237371 Apo-Fluconazole 100mg tab APX 3.204802281279 CO Fluconazole 100mg tab COB 3.204802245293 MYLAN-Fluconazole 100mg tab MYL 3.204802236979 Novo-Fluconazole 100mg tab TEV 3.204802245644 pms-Fluconazole 100mg tab PMS 3.2048

fluconazole 150mg cap 02241895 Apo-Fluconazole 150mg cap APX 7.072502282348 pms-Fluconazole 150mg cap PMS 7.0725

flunarizine 5mg cap 02246082 Flunarizine 5mg cap AAP 0.7817fluocinonide 0.05% cr 02161923 Lidex 0.05% cr VAL 0.1616

00716863 Lyderm 0.05% cr TPH 0.1616fluocinonide 0.05% gel 02236997 Lyderm 0.05% gel TPH 0.3418

02161974 Topsyn 0.05% gel MDS 0.3418fluocinonide 0.05% oint 02161966 Lidex 0.05% oint VAL 0.1771

02236996 Lyderm 0.05% oint TPH 0.1771fluorometholone 0.1% oph sol 00247855 FML Liquifilm 0.1% oph sol ALL 1.7900

02238568 pms-Fluorometholone 0.1% oph sol PMS 1.7900fluoxetine 10mg cap 02216353 Apo-Fluoxetine 10mg cap APX 0.8650

02242177 CO Fluoxetine 10mg cap COB 0.865002286068 Fluoxetine 10mg cap SAS 0.865002380560 MINT-Fluoxetine 10mg cap MNT 0.865002237813 MYLAN-Fluoxetine 10mg cap MYL 0.865002192756 Nu-Fluoxetine 10mg cap NXP 0.865002223481 phl-Fluoxetine 10mg cap PHL 0.865002177579 pms-Fluoxetine 10mg cap PMS 0.865002018985 Prozac 10mg cap LIL 0.865002241371 ratio-Fluoxetine 10mg cap TEV 0.865002243486 Sandoz Fluoxetine 10mg cap SDZ 0.865002216582 Teva-Fluoxetine 10mg cap TEV 0.865002302659 Zym-Fluoxetine 10mg cap ZYM 0.8650

fluoxetine 20mg cap 02216361 Apo-Fluoxetine 20mg cap APX 0.643802242178 CO Fluoxetine 20mg cap COB 0.643802286076 Fluoxetine 20mg cap SAS 0.643802380579 MINT-Fluoxetine 20mg cap MNT 0.643802237814 MYLAN-Fluoxetine 20mg cap MYL 0.643802192764 Nu-Fluoxetine 20mg cap NXP 0.6438

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 30 of 83

Generic Name and Strength DIN Brand MFR MRP PRPfluoxetine 20mg cap 02223503 phl-Fluoxetine 20mg cap PHL 0.6438

02177587 pms-Fluoxetine 20mg cap PMS 0.643800636622 Prozac 20mg cap LIL 0.643802241374 ratio-Fluoxetine 20mg cap TEV 0.643802243487 Sandoz Fluoxetine 20mg cap SDZ 0.643802216590 Teva-Fluoxetine 20mg cap TEV 0.643802302667 Zym-Fluoxetine 20mg cap ZYM 0.6438

fluphenazine decanoate 25mg/mL inj 02091275 pms-Fluphenazine 25mg/mL inj (discontinued) PMS 4.6320flurbiprofen 50mg tab 00647942 Ansaid 50mg tab (discontinued) PFI 0.1750

01912046 Apo-Flurbiprofen 50mg tab APX 0.175002100509 Novo-Flurprofen 50mg tab TEV 0.175002020661 Nu-Flurbiprofen 50mg tab NXP 0.1750

flurbiprofen 100mg tab 00600792 Ansaid 100mg tab (discontinued) PFI 0.303901912038 Apo-Flurbiprofen 100mg tab APX 0.303902100517 Novo-Flurprofen 100mg tab TEV 0.303902020688 Nu-Flurbiprofen 100mg tab NXP 0.3039

flutamide 250mg tab 02238560 Apo-Flutamide 250mg tab APX 1.353000637726 Euflex 250mg tab SCH 1.353002230089 Novo-Flutamide 250mg tab TEV 1.353002230104 pms-Flutamide 250mg tab PMS 1.3530

fluvoxamine 50mg tab 02231329 Apo-Fluvoxamine 50mg tab APX 0.300002255529 CO Fluvoxamine 50mg tab COB 0.300001919342 Luvox 50mg tab SPH 0.300002239953 Novo-Fluvoxamine 50mg tab TEV 0.300002231192 Nu-Fluvoxamine 50mg tab NXP 0.300002240682 pms-Fluvoxamine 50mg tab PMS 0.300002218453 ratio-Fluvoxamine 50mg tab TEV 0.3000

fluvoxamine 100mg tab 02231330 Apo-Fluvoxamine 100mg tab APX 0.539202255537 CO Fluvoxamine 100mg tab COB 0.539201919369 Luvox 100mg tab SPH 0.539202239954 Novo-Fluvoxamine 100mg tab TEV 0.539202231193 Nu-Fluvoxamine 100mg tab NXP 0.539202240683 pms-Fluvoxamine 100mg tab PMS 0.539202218461 ratio-Fluvoxamine 100mg tab TEV 0.5392

fosinopril 10mg tab 02266008 Apo-Fosinopril 10mg tab APX 0.304902331004 Jamp-Fosinopril 10mg tab JPC 0.304901907107 Monopril 10mg tab BRI 0.304902262401 MYLAN-Fosinopril 10mg tab MYL 0.304902294524 RAN-Fosinopril 10mg tab RAN 0.304902247802 Teva-Fosinopril 10mg tab TEV 0.3049

fosinopril 20mg tab 02266016 Apo-Fosinopril 20mg tab APX 0.366602331012 Jamp-Fosinopril 20mg tab JPC 0.366601907115 Monopril 20mg tab BRI 0.366602262428 MYLAN-Fosinopril 20mg tab MYL 0.366602294532 RAN-Fosinopril 20mg tab RAN 0.3666

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 31 of 83

Generic Name and Strength DIN Brand MFR MRP PRPfosinopril 20mg tab 02247803 Teva-Fosinopril 20mg tab TEV 0.3666furosemide 20mg tab 00396788 Apo-Furosemide 20mg tab APX 0.0373

02351420 Furosemide 20mg tab SAS 0.037302224690 Lasix 20mg tab SAV 0.037300337730 Novo-Semide 20mg tab TEV 0.0373

furosemide 40mg tab 00362166 Apo-Furosemide 40mg tab APX 0.055802351439 Furosemide 40mg tab SAS 0.055802224704 Lasix 40mg tab SAV 0.055800337749 Novo-Semide 40mg tab TEV 0.0558

furosemide 80mg tab 00707570 Apo-Furosemide 80mg tab APX 0.122002351447 Furosemide 80mg tab SAS 0.122000765953 Novo-Semide 80mg tab TEV 0.1220

gabapentin 100mg cap 02244304 Apo-Gabapentin 100mg cap APX 0.146002321203 Auro-Gabapentin 100mg cap ARO 0.146002256142 CO Gabapentin 100mg cap COB 0.146002353245 Gabapentin 100mg cap SAS 0.146002285819 GD-Gabapentin 100mg cap GMD 0.146002248259 MYLAN-Gabapentin 100mg cap MYL 0.146002084260 Neurontin 100mg cap PFI 0.146002246314 phl-Gabapentin 100mg cap PHL 0.146002243446 pms-Gabapentin 100mg cap PMS 0.146002319055 RAN-Gabapentin 100mg cap RAN 0.146002260883 ratio-Gabapentin 100mg cap (discontinued) TEV 0.146002244513 Teva-Gabapentin 100mg cap TEV 0.1460

gabapentin 300mg cap 02244305 Apo-Gabapentin 300mg cap APX 0.355302321211 Auro-Gabapentin 300mg cap ARO 0.355302256150 CO Gabapentin 300mg cap COB 0.355302353253 Gabapentin 300mg cap SAS 0.355302285827 GD-Gabapentin 300mg cap GMD 0.355302248260 MYLAN-Gabapentin 300mg cap MYL 0.355302084279 Neurontin 300mg cap PFI 0.355302246315 phl-Gabapentin 300mg cap PHL 0.355302243447 pms-Gabapentin 300mg cap PMS 0.355302319063 RAN-Gabapentin 300mg cap RAN 0.355302244514 Teva-Gabapentin 300mg cap TEV 0.3553

gabapentin 400mg cap 02244306 Apo-Gabapentin 400mg cap APX 0.423302321238 Auro-Gabapentin 400mg cap ARO 0.423302256169 CO Gabapentin 400mg cap COB 0.423302353261 Gabapentin 400mg cap SAS 0.423302285835 GD-Gabapentin 400mg cap GMD 0.423302248261 MYLAN-Gabapentin 400mg cap MYL 0.423302084287 Neurontin 400mg cap PFI 0.423302246316 phl-Gabapentin 400mg cap PHL 0.423302243448 pms-Gabapentin 400mg cap PMS 0.423302319071 RAN-Gabapentin 400mg cap RAN 0.4233

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 32 of 83

Generic Name and Strength DIN Brand MFR MRP PRPgabapentin 400mg cap 02260905 ratio-Gabapentin 400mg cap TEV 0.4233

02244515 Teva-Gabapentin 400mg cap TEV 0.4233gabapentin 600mg tab 02293358 Apo-Gabapentin 600mg tab APX 0.6350

02285843 GD-Gabapentin 600mg tab GMD 0.635002239717 Neurontin 600mg tab PFI 0.635002248457 Teva-Gabapentin 600mg tab TEV 0.6350

gabapentin 800mg tab 02293366 Apo-Gabapentin 800mg tab APX 0.846702285851 GD-Gabapentin 800mg tab GMD 0.846702239718 Neurontin 800mg tab PFI 0.846702247346 Teva-Gabapentin 800mg tab TEV 0.8467

galantamine 8mg ER cap (exception status)

02339439 MYLAN-Galantamine ER 8mg cap MYL 1.7451

02316943 PAT-Galantamine ER 8mg cap PPH 1.745102266717 Reminyl ER 8mg cap JAN 1.745102377950 Teva-Galantamine ER 8mg cap TEV 1.7451

galantamine 16mg ER cap (exception status)

02339447 MYLAN-Galantamine ER 16mg cap MYL 1.7451

02316951 PAT-Galantamine ER 16mg cap PPH 1.745102266725 Reminyl ER 16mg cap JAN 1.745102377969 Teva-Galantamine ER 16mg cap TEV 1.7451

galantamine 24mg ER cap (exception status)

02339455 MYLAN-Galantamine ER 24mg cap MYL 1.7451

02316978 PAT-Galantamine ER 24mg cap PPH 1.745102266733 Reminyl ER 24mg cap JAN 1.745102377977 Teva-Galantamine ER 24mg cap TEV 1.7451

gemfibrozil 300mg cap 01979574 Apo-Gemfibrozil 300mg cap APX 0.171700599026 Lopid 300mg cap PFI 0.171702185407 MYLAN-Gemfibrozil 300mg cap MYL 0.171702241704 Novo-Gemfibrozil 300mg cap TEV 0.171702058456 Nu-Gemfibrozil 300mg cap NXP 0.171702239951 pms-Gemfibrozil 300mg cap PMS 0.1717

gemfibrozil 600mg tab 01979582 Apo-Gemfibrozil 600mg tab APX 0.515702230476 MYLAN-Gemfibrozil 600mg tab MYL 0.515702142074 Novo-Gemfibrozil 600mg tab TEV 0.515702058464 Nu-Gemfibrozil 600mg tab NXP 0.515702230183 pms-Gemfibrozil 600mg tab PMS 0.5157

gentamicin 40mg/mL inj 02242652 Gentamicin 40mg/mL inj SDZ 2.9650gentamicin 0.3% oph oint 02230888 Sandoz Gentamicin 0.3% oph oint SDZ 1.5000gentamicin 0.3% oph sol 00512192 Garamycin 0.3% oph sol SCH 0.4060

02229440 Sandoz Gentamicin 0.3% oph sol SDZ 0.4060gentamicin 0.3% otic sol 00512184 Garamycin 0.3% otic sol SCH 1.0320

02229441 Sandoz Gentamicin 0.3% otic sol SDZ 1.0320gliclazide 80mg tab 02245247 Apo-Gliclazide 80mg tab APX 0.1304

00765996 Diamicron 80mg tab SEV 0.130402287072 Gliclazide 80mg tab SAS 0.1304

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 33 of 83

Generic Name and Strength DIN Brand MFR MRP PRPgliclazide 80mg tab 02229519 MYLAN-Gliclazide 80mg tab MYL 0.1304

02238103 Novo-Gliclazide 80mg tab TEV 0.1304gliclazide MR 30mg tab 02242987 Diamicron MR 30mg tab SEV 0.1524

02297795 Gliclazide MR 30mg tab AAP 0.1524glucose testing strips 97799824 Accu-Chek Advantage (100) BOM 0.7400

97799823 Accu-Chek Advantage (50) BOM 0.740097799814 Accu-Chek AVIVA (100) BOM 0.740097799815 Accu-Chek AVIVA (50) BOM 0.740097799962 Accu-Chek Compact (102) BOM 0.740097799963 Accu-Chek Compact (51) BOM 0.740097799497 Accu-Chek Mobile BG Test Strip Cassette (100) BOM 0.740097799496 Accu-Chek Mobile BG Test Strip Cassette (50) BOM 0.740097799748 Ascensia Breeze 2 Disc (100) BDD 0.740097799749 Ascensia Breeze 2 Disc (50) BDD 0.740097799702 Ascensia Contour (100) BDD 0.740097799703 Ascensia Contour (50) BDD 0.740097799465 BGStar Test Strips (100) SAV 0.675097799464 BGStar Test Strips (50) SAV 0.740097799459 Contour NEXT BG Test Strips (100) BDD 0.698997799460 Contour NEXT BG Test Strips (50) BDD 0.740097799564 EZ Oracle (100) THI 0.738197799829 FreeStyle (100) MID 0.733597799827 FreeStyle (50) MID 0.740097799597 FreeStyle Lite (100) MID 0.733597799596 FreeStyle Lite (50) MID 0.740097799770 iTest (50) AUT 0.691097799458 MyGlucoHealth Glucose Test Strips (50) EHS 0.673097799583 NovaMax (100) NBM 0.740097799584 NovaMax (50) NBM 0.740097799582 On-Call Plus (100) ACO 0.630097799580 On-Call Plus (25) ACO 0.700097799581 On-Call Plus (50) ACO 0.670097799475 One Touch Verio Test Strips (100) LFS 0.694397799476 One Touch Verio Test Strips (50) LFS 0.740097799976 One-Touch (100) LFS 0.738197799977 One-Touch (50) LFS 0.740097799982 One-Touch FastTake (100) LFS 0.738197799983 One-Touch FastTake (50) LFS 0.740097799985 One-Touch Ultra (100) LFS 0.738197799986 One-Touch Ultra (50) LFS 0.740097799840 Precision Xtra (100) MID 0.732597799841 Precision Xtra (50) MID 0.740097799451 Rapid Response Blood Glucose Test Strip (50) BTX 0.710097799478 Rightest GS100 Test Strips (100) BNM 0.558097799479 Rightest GS100 Test Strips (50) BNM 0.5730

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 34 of 83

Generic Name and Strength DIN Brand MFR MRP PRPglucose testing strips 97799601 Sidekick Blood Glucose HOM 0.4444

97799532 TRUEtest (100) HOM 0.574197799531 TRUEtest (50) HOM 0.574297799602 TrueTrack (100) HOM 0.385997799603 TrueTrack (50) HOM 0.4444

glyburide 2.5mg tab 01913654 Apo-Glyburide 2.5mg tab APX 0.039302224550 Diabeta 2.5mg tab SAV 0.039302350459 Glyburide 2.5mg tab SAS 0.039300808733 MYLAN-Glybe 2.5mg tab MYL 0.039302020734 Nu-Glyburide 2.5mg tab NXP 0.039301900927 ratio-Glyburide 2.5mg tab TEV 0.039302248008 Sandoz Glyburide 2.5mg tab SDZ 0.039301913670 Teva-Glyburide 2.5mg tab TEV 0.0393

glyburide 5mg tab 01913662 Apo-Glyburide 5mg tab APX 0.068302224569 Diabeta 5mg tab SAV 0.068300720941 Euglucon 5mg tab PMS 0.068302350467 Glyburide 5mg tab SAS 0.068300808741 MYLAN-Glybe 5mg tab MYL 0.068302020742 Nu-Glyburide 5mg tab NXP 0.068302236734 pms-Glyburide 5mg tab PMS 0.068301900935 ratio-Glyburide 5mg tab TEV 0.068302248009 Sandoz Glyburide 5mg tab SDZ 0.068301913689 Teva-Glyburide 5mg tab TEV 0.0683

granisetron 1 mg tab (exception status) 02308894 Granisetron 1mg tab AAP 14.647502185881 Kytril 1mg tab HLR 14.6475

haloperidol 0.5mg tab 00396796 Apo-Haloperidol 0.5mg tab APX 0.036000363685 Novo-Peridol 0.5mg tab TEV 0.0360

haloperidol 1mg tab 00396818 Apo-Haloperidol 1mg tab APX 0.061400363677 Novo-Peridol 1mg tab TEV 0.0614

haloperidol 2mg tab 00396826 Apo-Haloperidol 2mg tab APX 0.105000363669 Novo-Peridol 2mg tab TEV 0.1050

haloperidol 5mg tab 00396834 Apo-Haloperidol 5mg tab APX 0.148700363650 Novo-Peridol 5mg tab TEV 0.1487

haloperidol 10mg tab 00463698 Apo-Haloperidol 10mg tab APX 0.133000713449 Novo-Peridol 10mg tab TEV 0.1330

haloperidol LA 50mg/mL inj 02130297 Haloperidol LA 50mg/mL inj SDZ 7.3600haloperidol LA 100mg/mL inj 02130300 Haloperidol LA 100mg/mL inj SDZ 14.7167hydralazine HCl 10mg tab 00441619 Apo-Hydralazine 10mg tab APX 0.1347hydralazine HCl 25mg tab 00441627 Apo-Hydralazine 25mg tab APX 0.2314hydralazine HCl 50mg tab 00441635 Apo-Hydralazine 50mg tab APX 0.3633hydrochlorothiazide 12.5mg tab 02327856 Apo-Hydro 12.5mg tab APX 0.0322

02274086 pms-Hydrochlorothiazide 12.5mg tab PMS 0.0322hydrochlorothiazide 25mg tab 00326844 Apo-Hydro 25mg tab APX 0.0257

02360594 Hydrochlorothiazide 25mg tab SAS 0.0257

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 35 of 83

Generic Name and Strength DIN Brand MFR MRP PRPhydrochlorothiazide 25mg tab 02247386 pms-Hydrochlorothiazide 25mg tab PMS 0.0257

00021474 Teva-Hydrochlorothiazide 25mg tab TEV 0.0257hydrochlorothiazide 50mg tab 00312800 Apo-Hydro 50mg tab APX 0.0358

02360608 Hydrochlorothiazide 50mg tab SAS 0.035800021482 Novo-Hydrazide 50mg tab TEV 0.035802247387 pms-Hydrochlorothiazide 50mg tab PMS 0.0358

hydrochlorothiazide 100mg tab 00644552 Apo-Hydro 100mg tab APX 0.1232hydrochlorothiazide 50mg & amiloride HCl 5mg tab

00784400 Apo-Amilzide 50mg/5mg tab APX 0.1293

02257378 MYLAN-Amilazide 50mg/5mg tab (discontinued) MYL 0.129301937219 Novamilor 50mg/5mg tab TEV 0.129300886106 Nu-Amilzide 50mg/5mg tab NXP 0.1293

hydrochlorothiazide 25mg & spironolactone 25mg tab

00180408 Aldactazide 25/25mg tab PFI 0.1108

00613231 Novo-Spirozine 25/25mg tab TEV 0.1078hydrochlorothiazide 50mg & spironolactone 50mg tab

00594377 Aldactazide 50/50mg tab PFI 0.2281

00657182 Novo-Spirozine 50/50mg tab TEV 0.2281hydrochlorothiazide 25mg & triamterene 50mg tab

00441775 Apo-Triazide 25/50mg tab APX 0.0608

00532657 Novo-Triamzide 25/50mg tab TEV 0.060800865532 Nu-Triazide 25/50mg tab NXP 0.0608

hydrocortisone & antiinfectives oph oint 02242485 Sandoz Cortimyxin oph oint SDZ 3.6143hydrocortisone 0.5% oint 02128446 Anodan-HC 0.5% oint ODN 0.4130

00505773 Anusol-HC 0.5% oint JNJ 0.413002247691 Sandoz Anuzinc HC 0.5% oint SDZ 0.4130

hydrocortisone 10mg supp 02236399 Anodan-HC 10mg supp ODN 0.607500476285 Anusol-HC 10mg supp JNJ 0.607502242798 Sandoz Anuzinc HC 10mg supp SDZ 0.6075

hydrocortisone valerate 0.2% cr 02242984 Hydroval 0.2% cr TPH 0.1212hydrocortisone, framycetin sulfate & cinchocaine HCl oint

02247322 Proctol oint ODN 0.5960

02223252 Proctosedyl oint AXC 0.596002226383 ratio-Proctosone oint TEV 0.596002242527 Sandoz Proctomyxin HC oint SDZ 0.5960

hydrocortisone, framycetin sulfate & cinchocaine HCl supp

02247882 Proctol supp ODN 0.7925

02223260 Proctosedyl supp AXC 0.792502226391 ratio-Proctosone supp TEV 0.792502242528 Sandoz Proctomyxin HC supp SDZ 0.7925

hydrocortisone, pramoxine oint 00505781 Anugesic-HC oint JNJ 0.731702234466 Proctodan-HC oint ODN 0.731702247692 Sandoz Anuzinc HC Plus oint SDZ 0.7317

hydrocortisone, pramoxine supp 00476242 Anugesic-HC supp JNJ 1.087502240851 Proctodan-HC supp ODN 1.087502242797 Sandoz Anuzinc HC Plus supp SDZ 1.0875

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 36 of 83

Generic Name and Strength DIN Brand MFR MRP PRPhydromorphone 2mg/mL inj 00627100 Dilaudid 2mg/mL inj PFR 1.1380

02145901 Hydromorphone 2mg/mL inj SDZ 1.1380hydromorphone 10mg/mL inj 00622133 Dilaudid HP 10mg/mL inj PFR 2.7500

02145928 Hydromorphone HP 10mg/mL inj SDZ 2.7500hydromorphone 20mg/mL inj 02146118 Dilaudid HP Plus 20mg/mL inj PFR 4.5100

02145936 Hydromorphone HP 20mg/mL inj SDZ 4.5100hydromorphone 50mg/mL inj 02145863 Dilaudid XP 50mg/mL inj PFR 13.1500

02146126 Hydromorphone HP 50mg/mL inj SDZ 13.1500hydromorphone 1mg/mL oral sol 00786535 Dilaudid 1mg/mL oral sol PFR 0.0665

01916386 pms-Hydromorphone 1mg/mL oral sol PMS 0.0665hydromorphone HCl 1mg tab 00705438 Dilaudid 1mg tab PFR 0.0950

00885444 pms-Hydromorphone 1mg tab PMS 0.095902319403 Teva-Hydromorphone 1mg tab TEV 0.0959

hydromorphone HCl 2mg tab 00125083 Dilaudid 2mg tab PFR 0.141700885436 pms-Hydromorphone 2mg tab PMS 0.141702319411 Teva-Hydromorphone 2mg tab TEV 0.1417

hydromorphone HCl 4mg tab 00125121 Dilaudid 4mg tab PFR 0.224000885401 pms-Hydromorphone 4mg tab PMS 0.224002319438 Teva-Hydromorphone 4mg tab TEV 0.2240

hydromorphone HCl 8mg tab 00786543 Dilaudid 8mg tab PFR 0.352800885428 pms-Hydromorphone 8mg tab PMS 0.352802319446 Teva-Hydromorphone 8mg tab TEV 0.3528

hydroxychloroquine 200mg tab 02246691 Apo-Hydroxyquine 200mg tab APX 0.262002252600 MYLAN-Hydroxychloroquine 200mg tab MYL 0.262002017709 Plaquenil 200mg tab SAV 0.2620

hydroxyurea 500mg cap 02247937 Apo-Hydroxyurea 500mg cap (discontinued) APX 1.020300465283 Hydrea 500mg cap BRI 1.020302343096 Hydroxyurea 500mg cap SAS 1.020302242920 MYLAN-Hydroxyurea 500mg cap MYL 1.0203

hydroxyzine HCl 10mg cap (exception status)

00646059 Apo-Hydroxyzine 10mg cap APX 0.1116

00738824 Novo-Hydroxyzin 10mg cap TEV 0.1116hydroxyzine HCl 25mg cap (exception status)

00646024 Apo-Hydroxyzine 25mg cap APX 0.1425

00738832 Novo-Hydroxyzin 25mg cap TEV 0.1425hydroxyzine HCl 50mg cap (exception status)

00646016 Apo-Hydroxyzine 50mg cap APX 0.2068

00738840 Novo-Hydroxyzin 50mg cap TEV 0.2068ibuprofen 300mg tab 00441651 Apo-Ibuprofen 300mg tab APX 0.1087

02242632 Motrin IB 300mg tab JNJ 0.1087ibuprofen 400mg tab 00506052 APC-Ibuprofen 400mg tab APX 0.0372

00506052 Apo-Ibuprofen 400mg tab APX 0.037202317338 Jamp-Ibuprofen 400mg tab JPC 0.037202242658 Motrin IB 400mg tab JNJ 0.037200629340 Novo-Profen 400mg tab TEV 0.0372

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 37 of 83

Generic Name and Strength DIN Brand MFR MRP PRPibuprofen 600mg tab 00585114 Apo-Ibuprofen 600mg tab APX 0.1313

00629359 Novo-Profen 600mg tab TEV 0.131302020726 Nu-Ibuprofen 600mg tab NXP 0.1313

idoxuridine 0.1% sol 02237187 Sandoz Idoxuridine 0.1% sol SDZ 4.9900imatinib 100mg tab (exception status) 02253275 Gleevec 100mg tab NVR 29.5926imatinib 100mg tab (exception status) 02253283 Gleevec 400mg tab NVR 118.3702imipramine 25mg tab 00312797 Imipramine 25mg tab AAP 0.2682imipramine 50mg tab 00326852 Imipramine 50mg tab AAP 0.5232indomethacin 25mg cap 00611158 Apo-Indomethacin 25mg cap (discontinued) APX 0.0871

00337420 Novo-Methacin 25mg cap TEV 0.087100865850 Nu-Indo 25mg cap NXP 0.0871

indomethacin 50mg cap 00611166 Apo-Indomethacin 50mg cap (discontinued) APX 0.151100337439 Novo-Methacin 50mg cap TEV 0.151100865869 Nu-Indo 50mg cap NXP 0.1511

indomethacin 50mg supp 02231799 Sandoz Indomethacin 50mg supp SDZ 0.8400indomethacin 100mg supp 01934139 ratio-Indomethacin 100mg supp TEV 0.8920

02231800 Sandoz Indomethacin 100mg supp SDZ 0.8920infliximab 100mg IV inj (exception status) 02244016 Remicade 100mg pdr for inj SCH 1019.9000ipratropium bromide 200mcg/mL & salbutamol 1mg/mL unit dose inh sol (exception status)

02231675 Combivent UD inh sol BOE 0.2936

02272695 MYLAN-Combo Sterinebs UD inh sol MYL 0.293602243789 ratio-IPRA SAL UD inh sol TEV 0.2936

ipratropium bromide 125mcg/mL unit dose inh sol (2mL) (exception status)

02231135 pms-Ipratropium 125mcg/mL UD inh sol PMS 0.1579

02097176 ratio-Ipratropium 125mcg/mL UD inh sol TEV 0.1579ipratropium bromide 250mcg/mL inh sol (20mL) (exception status)

02126222 Apo-Ipravent 250mcg/mL inh sol (20mL) APX 0.3157

02239131 MYLAN-Ipratropium 250mcg/mL inh sol (20mL) MYL 0.315702210479 Novo-Ipramide 250mcg/mL inh sol (20mL) TEV 0.315702231136 pms-Ipratropium 250mcg/mL inh sol (20mL) PMS 0.3157

ipratropium bromide 250mcg/mL unit dose inh sol (1mL) (exception status)

02216221 MYLAN-Ipratropium 250mcg/mL UD inh sol(1mL) MYL 0.3157

02231244 pms-Ipratropium 250mcg/mL UD inh sol (1mL) PMS 0.315702097168 ratio-Ipratropium 250mcg/mL UD inh sol (1mL) TEV 0.3157

ipratropium bromide 250mcg/mL unit dose inh sol (2mL) (exception status)

02216221 MYLAN-Ipratropium 250mcg/mL UD inh sol(2mL) MYL 0.3157

02231245 pms-Ipratropium 250mcg/mL UD inh sol (2mL) PMS 0.315702097168 ratio-Ipratropium 250mcg/mL UD inh sol (2mL) TEV 0.3157

ipratropium bromide 0.3% nasal spray (21mcg/dose)

02163705 Atrovent 0.3% nasal spray BOE 0.0508

02239627 pms-Ipratropium 0.3% nasal spray PMS 0.0508ipratropium bromide 0.6% nasal spray (42mcg/dose)

02246084 Apo-Ipravent 0.6% nasal spray APX 0.1355

02163713 Atrovent 0.6% nasal spray BOE 0.1355irbesartan 75mg tab 02237923 Avapro 75mg tab BRI 0.4234

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 38 of 83

Generic Name and Strength DIN Brand MFR MRP PRPirbesartan 75mg tab 02328070 CO Irbesartan 75mg tab COB 0.4234

02372347 Irbesartan 75mg tab SAS 0.423402317060 pms-Irbesartan 75mg tab PMS 0.423402316390 ratio-Irbesartan 75mg tab TEV 0.423402328461 Sandoz Irbesartan 75mg SDZ 0.423402315971 Teva-Irbesartan 75mg tab TEV 0.4234

irbesartan 150mg tab 02237924 Avapro 150mg tab BRI 0.423402328089 CO Irbesartan 150mg tab COB 0.423402372371 Irbesartan 150mg tab SAS 0.423402317079 pms-Irbesartan 150mg tab PMS 0.423402316404 ratio-Irbesartan 150mg tab TEV 0.423402328488 Sandoz Irbesartan 150mg tab SDZ 0.423402315998 Teva-Irbesartan 150mg tab TEV 0.4234

irbesartan 300mg tab 02237925 Avapro 300mg tab BRI 0.423402328100 CO Irbesartan 300mg tab COB 0.423402372398 Irbesartan 300mg tab SAS 0.423402317087 pms-Irbesartan 300mg tab PMS 0.423402316412 ratio-Irbesartan 300mg tab TEV 0.423402328496 Sandoz Irbesartan 300mg tab SDZ 0.423402316005 Teva-Irbesartan 300mg tab TEV 0.4234

irbesartan 150mg & hydrochlorothiazide 12.5mg tab

02241818 Avalide 150/12.5mg tab BRI 0.4234

02357399 CO Irbesartan/HCT 150/12.5mg tab COB 0.423402372886 Irbesartan/HCTZ 150/12.5mg tab SAS 0.423402328518 pms-Irbesartan-HCTZ 150/12.5 mg tab PMS 0.423402363208 RAN-Irbesartan HCTZ 150/12.5mg tab RAN 0.423402330512 ratio-Irbesartan HCTZ 150/12.5 mg tab TEV 0.423402337428 Sandoz Irbesartan HCT 150/12.5mg tab SDZ 0.423402316013 Teva-Irbesartan/HCTZ 150/12.5mg tab TEV 0.4234

irbesartan 300mg & hydrochlorothiazide 12.5mg tab

02241819 Avalide 300/12.5mg tab BRI 0.4234

02357402 CO Irbesartan/HCT 300/12.5mg tab COB 0.423402372894 Irbesartan/HCTZ 300/12.5mg tab SAS 0.423402328526 pms-Irbesartan-HCTZ 300/12.5 mg tab PMS 0.423402363216 RAN-Irbesartan HCTZ 300/12.5mg tab RAN 0.423402330520 ratio-Irbesartan HCTZ 300/12.5 mg tab TEV 0.423402337436 Sandoz Irbesartan HCT 300/12.5mg tab SDZ 0.423402316021 Teva-Irbesartan/HCTZ 300/12.5mg tab TEV 0.4234

irbesartan 300mg & hydrochlorothiazide 25mg tab

02280213 Avalide 300/25mg tab BRI 0.4206

02357410 CO Irbesartan/HCT 300/25mg tab COB 0.420602372908 Irbesartan/HCTZ 300/25mg tab SAS 0.420602328534 pms-Irbesartan-HCTZ 300/25 mg tab PMS 0.420602363224 RAN-Irbesartan HCTZ 300/25mg tab RAN 0.420602330539 ratio-Irbesartan HCTZ 300/25 mg tab TEV 0.420602337444 Sandoz Irbesartan HCT 300/25mg tab SDZ 0.4206

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 39 of 83

Generic Name and Strength DIN Brand MFR MRP PRPirbesartan 300mg & hydrochlorothiazide 25mg tab

02316048 Teva-Irbesartan/HCTZ 300/25mg tab TEV 0.4206

isosorbide dinitrate 5mg SL tab 00670944 ISDN 5mg tab AAP 0.0674isosorbide dinitrate 10mg tab 00441686 ISDN 10mg tab AAP 0.0397isosorbide dinitrate 30mg tab 00441694 ISDN 30mg tab AAP 0.0930isosorbide mononitrate 60mg SR tab 02272830 Apo-ISMN 60mg SR tab APX 0.3523

02126559 Imdur 60mg ER tab AZE 0.352302301288 pms-ISMN 60mg SR tab PMS 0.3523

isotretinoin 10mg cap 00582344 Accutane 10mg cap HLR 0.931302257955 Clarus 10mg cap MYL 0.9313

isotretinoin 40mg cap 00582352 Accutane 40mg cap HLR 1.900302257963 Clarus 40mg cap MYL 1.9003

ketoconazole 2% cr 02245662 Ketoderm 2% cr TPH 0.3166ketoconazole 200mg tab 02237235 Apo-Ketoconazole 200mg tab APX 0.9393

02231061 Novo-Ketoconazole 200mg tab TEV 0.939302122197 Nu-Ketocon 200mg tab NXP 0.9393

ketoprofen 50mg cap 00790427 Apo-Keto 50mg cap AAP 0.1750ketoprofen 50mg EC tab 00790435 Apo-Keto-E 50mg EC tab AAP 0.1750ketoprofen 100mg EC tab 00842664 Apo-Keto-E 100mg EC tab AAP 0.3500ketoprofen 200mg SR tab 02172577 Ketoprofen SR 200mg EC tab AAP 0.7000ketorolac 30mg/mL inj 02239944 Ketorolac 30mg/mL inj SDZ 4.3000ketorolac 0.5% oph sol 01968300 Acular 0.5% oph sol ALL 1.6000

02245821 Apo-Ketorolac 0.5% oph sol APX 1.600002247461 ratio-Ketorolac 0.5% oph sol TEV 1.6000

ketotifen fumarate 1mg tab 02230730 Novo-Ketotifen 1mg tab TEV 1.672200577308 Zaditen 1mg tab TEV 1.6722

ketotifen fumarate 1mg/5mL syr 02176084 Novo-Ketotifen 1mg/5mL inj TEV 0.1330lactulose 667mg/mL o/l (exception status) 02242814 Apo-Lactulose 667mg/mL o/l APX 0.0145

02295881 Jamp-Lactulose 667mg/mL o/l JPC 0.014500854409 ratio-Lactulose 667mg/mL o/l TEV 0.014502331551 Teva-Lactulose 667mg/mL o/l TEV 0.0145

lamotrigine 25mg tab 02245208 Apo-Lamotrigine 25mg tab APX 0.131002142082 Lamictal 25mg tab GSK 0.131002343010 Lamotrigine 25mg tab SAS 0.131002265494 MYLAN-Lamotrigine 25mg tab MYL 0.131002248232 Novo-Lamotrigine 25mg tab TEV 0.131002246897 pms-Lamotrigine 25mg tab PMS 0.131002243352 ratio-Lamotrigine 25mg tab TEV 0.1310

lamotrigine 100mg tab 02245209 Apo-Lamotrigine 100mg tab APX 0.522902142104 Lamictal 100mg tab GSK 0.522902343029 Lamotrigine 100mg tab SAS 0.522902265508 MYLAN-Lamotrigine 100mg tab MYL 0.522902248233 Novo-Lamotrigine 100mg tab TEV 0.522902246898 pms-Lamotrigine 100mg tab PMS 0.5229

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 40 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlamotrigine 100mg tab 02243353 ratio-Lamotrigine 100mg tab TEV 0.5229lamotrigine 150mg tab 02245210 Apo-Lamotrigine 150mg tab APX 0.7706

02142112 Lamictal 150mg tab GSK 0.770602343037 Lamotrigine 150mg tab SAS 0.770602265516 MYLAN-Lamotrigine 150mg tab MYL 0.770602248234 Novo-Lamotrigine 150mg tab TEV 0.770602246899 pms-Lamotrigine 150mg tab PMS 0.770602246963 ratio-Lamotrigine 150mg tab TEV 0.7706

lancets 97799689 Abbott Thin (200) MID 0.044597799691 Abbott Thin 28g (100) MID 0.050097799494 Accu-Chek Fastclix Lancets (102) BOM 0.050097799495 Accu-Chek Fastclix Lancets (204) BOM 0.050097799817 Accu-Chek Multiclix (102) BOM 0.050097799816 Accu-Chek Multiclix (204) BOM 0.050097799946 Accu-Chek Softclix (100) BOM 0.050097799945 Accu-Chek Softclix (200) BOM 0.050097799942 Accu-Chek Softclix Pro (200) BOM 0.050097799917 Ascensia Microlet BDD 0.050097799918 Ascensia Microlet (100) BDD 0.050097799882 BD Ultra-Fine 33g (100) BTD 0.050097799466 BGStar Lancets (100) SAV 0.050097799540 EZ Health (100) THI 0.050097799825 Finger Stix (200) BDD 0.050097799826 FreeStyle (100) MID 0.050097799766 iTest 28g (100) AUT 0.046597799767 iTest 33g (100) AUT 0.040497799592 Medlance Plus Lite 25g (200) MPD 0.050097799591 Medlance Plus Universal 21G (200) MPD 0.050097799810 MPD Thin MPD 0.031897799807 MPD Ultra Thin (100) MPD 0.031897799501 One Touch Delica (100) LFS 0.050097799765 One-Touch Sure Soft (200) LFS 0.050097799970 One-Touch Ultra Soft (100) LFS 0.050097799948 Safe-T-Pro (200) BOM 0.0500

lansoprazole 15mg cap (exception status) 02293811 Apo-Lansoprazole 15mg DR cap APX 0.350002357682 Lansoprazole 15mg DR cap SAS 0.350002353830 MYLAN-Lansoprazole 15mg DR cap MYL 0.350002280515 Novo-Lansoprazole 15mg DR cap TEV 0.350002165503 Prevacid 15mg cap ABB 0.3500

lansoprazole 30mg cap (exception status) 02293838 Apo-Lansoprazole 30mg DR cap APX 0.700002357690 Lansoprazole 30mg DR cap SAS 0.700002353849 MYLAN-Lansoprazole 30mg DR cap MYL 0.700002280523 Novo-Lansoprazole 30mg DR cap TEV 0.700002165511 Prevacid 30mg cap ABB 0.7000

latanopost 50mcg/mL oph sol 02296527 Apo-Latanoprost 0.005% oph sol APX 3.8542

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 41 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlatanopost 50mcg/mL oph sol 02254786 CO Latanoprost 0.005% oph sol COB 3.8542

02373041 GD-Lantanoprost 0.005% oph sol GMD 3.854202231493 Xalatan 0.005% oph sol PFI 3.8542

leflunomide 10mg tab (exception status) 02256495 Apo-Leflunomide 10mg tab APX 3.759702241888 Arava 10mg tab SAV 3.759702351668 Leflunomide 10mg tab SAS 3.759702319225 MYLAN-Leflunomide 10mg tab MYL 3.759702261251 Novo-Leflunomide 10mg tab TEV 3.759702288265 pms-Leflunomide 10mg tab PMS 3.759702283964 Sandoz Leflunomide 10mg tab SDZ 3.7597

leflunomide 20mg tab (exception status) 02256509 Apo-Leflunomide 20mg tab APX 3.759702241889 Arava 20mg tab SAV 3.759702351676 Leflunomide 20mg tab SAS 3.759702319233 MYLAN-Leflunomide 20mg tab MYL 3.759702261278 Novo-Leflunomide 20mg tab TEV 3.759702288273 pms-Leflunomide 20mg tab PMS 3.759702283972 Sandoz Leflunomide 20mg tab SDZ 3.7597

letrozole 2.5 tab 02231384 Femara 2.5mg tab NVR 2.066202338459 Letrozole 2.5mg tab (AHC) AHC 2.066202348969 Letrozole 2.5mg tab (COB) COB 2.066202347997 Letrozole 2.5mg tab (TEV) TEV 2.066202373424 Mar-Letrozole 2.5mg tab MAR 2.066202322315 MED-Letrozole 2.5mg tab GMP 2.066202372169 Myl-Letrozole 2.5mg tab MYL 2.066202309114 pms-Letrozole 2.5mg tab PMS 2.066202372282 RAN-Letrozole 2.5mg tab RAN 2.066202344815 Sandoz Letrozole 2.5mg tab SDZ 2.0662

levetiracetam 250mg tab (exception status)

02285924 Apo-Levetiracetam 250mg tab APX 0.8000

02375249 Auro-Levetiracetam 250mg tab ARO 0.800002274183 CO Levetiracetam 250mg tab COB 0.800002247027 Keppra 250mg tab UCB 0.800002353342 Levetiracetam 250mg tab SAS 0.800002296101 pms-Levetiracetam 250mg tab PMS 0.8000

levetiracetam 500mg tab (exception status)

02285932 Apo-Levetiracetam 500mg tab APX 0.9750

02375257 Auro-Levetiracetam 500mg tab ARO 0.975002274191 CO Levetiracetam 500mg tab COB 0.975002247028 Keppra 500mg tab UCB 0.975002353350 Levetiracetam 500mg tab SAS 0.975002296128 pms-Levetiracetam 500mg tab PMS 0.9750

levetiracetam 750mg tab (exception status)

02285940 Apo-Levetiracetam 750mg tab APX 1.3500

02375265 Auro-Levetiracetam 750mg tab ARO 1.350002274205 CO Levetiracetam 750mg tab COB 1.3500

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 42 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlevetiracetam 750mg tab (exception status)

02247029 Keppra 750mg tab UCB 1.3500

02353369 Levetiracetam 750mg tab SAS 1.350002296136 pms-Levetiracetam 750mg tab PMS 1.3500

levobunolol HCl 0.25% oph sol 02031159 ratio-Levobunolol 0.25% oph sol TEV 1.914302241715 Sandoz Levobunolol 0.25% oph sol (discontinued) SDZ 1.9143

levobunolol HCl 0.5% oph sol 00637661 Betagan 0.5% oph sol ALL 1.151502237991 pms-Levobunolol 0.5% oph sol PMS 1.151502031167 ratio-Levobunolol 0.5% oph sol TEV 1.151502241716 Sandoz Levobunolol 0.5% oph sol SDZ 1.1515

levodopa 100mg & carbidopa 10mg tab 02195933 Apo-Levocarb 100/10mg tab APX 0.187702244494 Novo-Levocarbidopa 100/10mg tab TEV 0.187702182831 Nu-Levocarb 100/10mg tab NXP 0.187700355658 Sinemet 100/10mg tab FRS 0.1877

levodopa 100mg & carbidopa 25mg tab 02195941 Apo-Levocarb 100/25mg tab APX 0.280302244495 Novo-Levocarbidopa 100/25mg tab TEV 0.280302182823 Nu-Levocarb 100/25mg tab NXP 0.280300513997 Sinemet 100/25mg tab FRS 0.2803

levodopa 250mg & carbidopa 25mg tab 02195968 Apo-Levocarb 250/25mg tab APX 0.312902244496 Novo-Levocarbidopa 250/25mg tab TEV 0.312900328219 Sinemet 250/25mg tab FRS 0.3129

levodopa 100mg & carbidopa 25mg cr tab 02272873 Apo-Levocarb CR 100/25mg tab AAP 0.556202028786 Sinemet CR 100/25mg tab FRS 0.5562

levodopa 200mg & carbidopa 50mg cr tab 02245211 Levocarb CR 200/50mg tab AAP 1.085000870935 Sinemet CR 200/50mg tab FRS 1.0850

levofloxacin 250mg tab (exception status) 02284707 Apo-Levofloxacin 250mg tab APX 1.853802315424 CO Levofloxacin 250mg tab COB 1.853802236841 Levaquin 250mg tab JAN 1.853802313979 MYLAN-Levofloxacin 250mg tab MYL 1.853802248262 Novo-Levofloxacin 250mg tab TEV 1.853802284677 pms-Levofloxacin 250mg tab PMS 1.853802298635 Sandoz Levofloxacin 250mg tab SDZ 1.8538

levofloxacin 500mg tab (exception status) 02284715 Apo-Levofloxacin 500mg tab APX 2.112502315432 CO Levofloxacin 500mg tab COB 2.112502236842 Levaquin 500mg tab JAN 2.112502313987 MYLAN-Levofloxacin 500mg tab MYL 2.112502248263 Novo-Levofloxacin 500mg tab TEV 2.112502284685 pms-Levofloxacin 500mg tab PMS 2.112502298643 Sandoz Levofloxacin 500mg tab SDZ 2.1125

levonorgestrel 0.10mg & ethinyl estradiol 0.02mg tab (21)

02236974 Alesse 21 Day WAY 0.4636

02298538 Aviane 21 Day APX 0.4636levonorgestrel 0.10mg & ethinyl estradiol 0.02mg tab (28)

02236975 Alesse 28 Day WAY 0.3477

02298546 Aviane 28 Day APX 0.3477

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 43 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlevonorgestrel 0.15mg & ethinyl estradiol 0.03mg tab (21)

02042320 Min-Ovral 21 Day WAY 0.4636

02295946 Portia 21 Day APX 0.4636levonorgestrel 0.15mg & ethinyl estradiol 0.03mg tab (28)

02042339 Min-Ovral 28 Day WAY 0.3477

02295954 Portia 28 Day APX 0.3477lidocaine 5% oint 02083795 Lidodan 5% oint ODN 0.3967

00001961 Xylocaine 5% oint AZE 0.3967linezolid 600mg tab 02243684 Zyvoxam 600mg tab PFI 78.2560lisinopril 5mg tab 02217481 Apo-Lisinopril 5mg tab APX 0.2100

02271443 CO Lisinopril 5mg tab COB 0.210002361531 Jamp-Lisinopril 5mg tab JPC 0.210002274833 MYLAN-Lisinopril 5mg tab MYL 0.210002285061 Novo-Lisinopril (Type P) 5mg tab TEV 0.210002285118 Novo-Lisinopril (Type Z) 5mg tab TEV 0.210002292203 pms-Lisinopril 5mg tab PMS 0.210000839388 Prinivil 5mg tab FRS 0.210002294230 RAN-Lisinopril 5mg tab RAN 0.210002256797 ratio-Lisinopril P 5mg tab TEV 0.210002299879 ratio-Lisinopril Z 5mg tab TEV 0.210002289199 Sandoz Lisinopril 5mg tab SDZ 0.210002049333 Zestril 5mg tab AZE 0.2100

lisinopril 10mg tab 02217503 Apo-Lisinopril 10mg tab APX 0.252202271451 CO Lisinopril 10mg tab COB 0.252202361558 Jamp-Lisinopril 10mg tab JPC 0.252202274841 MYLAN-Lisinopril 10mg tab MYL 0.252202285126 Novo-Lisinopril Z 10mg tab TEV 0.252202292211 pms-Lisinopril 10mg tab PMS 0.252200839396 Prinivil 10mg tab FRS 0.252202294249 RAN-Lisinopril 10mg tab RAN 0.252202256800 ratio-Lisinopril P 10mg tab TEV 0.252202299887 ratio-Lisinopril Z 10mg tab TEV 0.252202289202 Sandoz Lisinopril 10mg tab SDZ 0.252202285088 Teva-Lisinopril (Type P) 10mg tab TEV 0.252202049376 Zestril 10mg tab AZE 0.2522

lisinopril 20mg tab 02217511 Apo-Lisinopril 20mg tab APX 0.303202271478 CO Lisinopril 20mg tab COB 0.303202361566 Jamp-Lisinopril 20mg tab JPC 0.303202274868 MYLAN-Lisinopril 20mg tab MYL 0.303202285134 Novo-Lisinopril Z 20mg tab TEV 0.303202292238 pms-Lisinopril 20mg tab PMS 0.303200839418 Prinivil 20mg tab FRS 0.303202294257 RAN-Lisinopril 20mg tab RAN 0.303202256819 ratio-Lisinopril P 20mg tab TEV 0.303202299895 ratio-Lisinopril Z 20mg tab TEV 0.3032

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 44 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlisinopril 20mg tab 02289229 Sandoz Lisinopril 20mg tab SDZ 0.3032

02285096 Teva-Lisinopril (Type P) 20mg tab TEV 0.303202049384 Zestril 20mg tab AZE 0.3032

lisinopril 10mg & hydrochlorothiazide 12.5mg tab

02261979 Apo-Lisinopril/HCTZ 10/12.5mg tab APX 0.3001

02362945 Lisinopril/HCTZ 10/12.5mg (Type Z) tab SAS 0.300102297736 MYLAN-Lisinopril/HCTZ 10/12.5mg tab MYL 0.300102302136 Novo-Lisinopril/HCTZ (Type P) 10/12.5mg tab TEV 0.300102301768 Novo-Lisinopril/HCTZ (Type Z) 10/12.5mg tab TEV 0.300102108194 Prinzide 10/12.5mg tab FRS 0.300102302365 Sandoz Lisinopril HCT 10/12.5mg tab SDZ 0.300102103729 Zestoretic 10/12.5mg tab AZE 0.3001

lisinopril 20mg & hydrochlorothiazide 12.5mg tab

02261987 Apo-Lisinopril/HCTZ 20/12.5mg tab APX 0.3605

02362953 Lisinopril/HCTZ 20/12.5mg (Type Z) tab SAS 0.360502297744 MYLAN-Lisinopril/HCTZ 20/12.5mg tab MYL 0.360502302144 Novo-Lisinopril/HCTZ (Type P) 20/12.5mg tab TEV 0.360500884413 Prinzide 20/12.5mg tab FRS 0.360502302373 Sandoz Lisinopril HCT 20/12.5mg tab SDZ 0.360502301776 Teva-Lisinopril/HCTZ (Type Z) 20/12.5mg tab TEV 0.360502045737 Zestoretic 20/12.5mg tab AZE 0.3605

lisinopril 20mg & hydrochlorothiazide 25mg tab

02261995 Apo-Lisinopril/HCTZ 20/25mg tab APX 0.3605

02362961 Lisinopril/HCTZ 20/25mg (Type Z) tab SAS 0.360502297752 MYLAN-Lisinopril/HCTZ 20/25mg tab MYL 0.360502302152 Novo-Lisinopril/HCTZ (Type P) 20/25mg tab TEV 0.360502301784 Novo-Lisinopril/HCTZ (Type Z) 20/25mg tab TEV 0.360502302381 Sandoz Lisinopril HCT 20/25mg tab SDZ 0.360502045729 Zestoretic 20/25mg tab AZE 0.3605

lithium 300mg SR tab 02266695 Lithmax SR 300mg tab AAP 0.2708lithium 150mg cap (Carbolith) 02242837 Apo-Lithium Carbonate 150mg cap APX 0.0422

00461733 Carbolith 150mg cap VLN 0.042202216132 pms-Lithium Carbonate 150mg cap PMS 0.0422

lithium 300mg cap (Carbolith) 02242838 Apo-Lithium Carbonate 300mg cap APX 0.044300236683 Carbolith 300mg cap VLN 0.044302216140 pms-Lithium Carbonate 300mg cap PMS 0.0443

lithium 600mg cap 02011239 Carbolith 600mg cap VLN 0.153002216159 pms-Lithium Carbonate 600mg cap PMS 0.1530

lithium 150mg cap (Lithane) 02242837 Apo-Lithium Carbonate 150mg cap APX 0.042202013231 Lithane 150mg cap ERF 0.0422

lithium 300mg cap (Lithane) 02242838 Apo-Lithium Carbonate 300mg cap APX 0.044300406775 Lithane 300mg cap ERF 0.0443

loperamide 2mg caplet 02212005 Apo-Loperamide 2mg caplet APX 0.125502183862 Imodium 2mg caplet JNJ 0.125502132591 Novo-Loperamide 2mg caplet TEV 0.1255

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 45 of 83

Generic Name and Strength DIN Brand MFR MRP PRPloperamide 2mg caplet 02228351 pms-Loperamide 2mg caplet PMS 0.1255

02257564 Sandoz Loperamide 2mg caplet SDZ 0.1255loperamide HCl 0.2mg/mL o/l 02016095 pms-Loperamide 0.2mg/mL o/l PMS 0.0988loratadine 10mg tab (exception status) 02243880 APC-Loratadine 10mg tab APX 0.6267

02243880 Apo-Loratadine 10mg tab APX 0.626700782696 Claritin 10mg tab SCH 0.6267

lorazepam 0.5mg tab 00655740 Apo-Lorazepam 0.5mg tab APX 0.035902041413 Ativan 0.5mg tab WAY 0.035902351072 Lorazepam 0.5mg tab SAS 0.035900711101 Novo-Lorazem 0.5mg tab TEV 0.035900728187 pms-Lorazepam 0.5mg tab PMS 0.0359

lorazepam 1mg tab 00655759 Apo-Lorazepam 1mg tab APX 0.044702041421 Ativan 1mg tab WAY 0.044702351080 Lorazepam 1mg tab SAS 0.044700637742 Novo-Lorazem 1mg tab TEV 0.044700728195 pms-Lorazepam 1mg tab PMS 0.0447

lorazepam 2mg tab 00655767 Apo-Lorazepam 2mg tab APX 0.069902041448 Ativan 2mg tab WAY 0.069902351099 Lorazepam 2mg tab SAS 0.069900637750 Novo-Lorazem 2mg tab TEV 0.069900728209 pms-Lorazepam 2mg tab PMS 0.0699

lorazepam 4mg/mL inj 02243278 Lorazepam 4mg/mL inj SDZ 2.9900losartan 25mg tab 02379058 Apo-Losartan 25mg tab APX 0.4407

02354829 CO Losartan 25mg tab COB 0.440702182815 Cozaar 25mg tab FRS 0.440702368277 MYLAN-Losartan 25mg tab MYL 0.440702309750 pms-Losartan 25mg tab PMS 0.440702313332 Sandoz Losartan 25mg tab SDZ 0.440702380838 Teva-Losartan 25mg tab TEV 0.4407

losartan 50mg tab 02353504 Apo-Losartan 50mg tab APZ 0.440702354837 CO Losartan 50mg tab COB 0.440702182874 Cozaar 50mg tab FRS 0.440702368285 MYLAN-Losartan 50mg tab MYL 0.440702309769 pms-Losartan 50mg tab PMS 0.440702313340 Sandoz Losartan 50mg tab SDZ 0.440702357968 Teva-Losartan 50mg tab TEV 0.4407

losartan 100mg tab 02353512 Apo-Losartan 100mg tab APX 0.440702354845 CO Losartan 100mg tab COB 0.440702182882 Cozaar 100mg tab FRS 0.440702368293 MYLAN-Losartan 100mg tab MYL 0.440702309777 pms-Losartan 100mg tab PMS 0.440702313359 Sandoz Losartan 100mg tab SDZ 0.440702357976 Teva-Losartan 100mg tab TEV 0.4407

losartan 50mg & hydrochlorothiazide 12.5mg tab

02371235 Apo-Losartan/HCTZ 50/12.5mg tab APX 0.4407

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 46 of 83

Generic Name and Strength DIN Brand MFR MRP PRPlosartan 50mg & hydrochlorothiazide 12.5mg tab

02230047 Hyzaar 50/12.5mg tab FRS 0.4407

02378078 MYLAN-Losartan HCTZ 50/12.5mg tab MYL 0.440702313375 Sandoz Losartan HCT 50/12.5mg tab SDZ 0.440702358263 Teva-Losartan/HCTZ 50/12.5mg tab TEV 0.5036

losartan 100mg & hydrochlorothiazide 12.5mg tab

02371243 Apo-Losartan HCTZ 100/12.5mg tab APX 0.4314

02297841 Hyzaar 100/12.5mg tab FRS 0.431402378086 MYLAN-Losartan HCTZ 100/12.5mg tab MYL 0.431402362449 Sandoz Losartan HCT 100/12.5mg tab SDZ 0.431402377144 Teva-Losartan/HCTZ 100/12.5mg tab TEV 0.4314

losartan 100mg & hydrochlorothiazide 25mg tab

02371251 Apo-Losartan HCTZ 100/25mg tab APX 0.4407

02241007 Hyzaar DS 100/25mg tab FRS 0.440702378094 MYLAN-Losartan HCTZ 100/25mg tab MYL 0.440702313383 Sandoz Losartan HCT DS 100/25mg tab SDZ 0.440702377152 Teva-Losartan/HCTZ 100/25mg tab TEV 0.4407

lovastatin 20mg tab 02220172 Apo-Lovastatin 20mg tab APX 0.723102248572 CO Lovastatin 20mg tab COB 0.723102353229 Lovastatin 20mg tab SAS 0.723100795860 Mevacor 20mg tab FRS 0.723102243127 MYLAN-Lovastatin 20mg tab MYL 0.723102246542 Novo-Lovastatin 20mg tab TEV 0.723102246013 pms-Lovastatin 20mg tab PMS 0.723102245822 ratio-Lovastatin 20mg tab TEV 0.723102247056 Sandoz Lovastatin 20mg tab SDZ 0.7231

lovastatin 40mg tab 02220180 Apo-Lovastatin 40mg tab APX 1.320802248573 CO Lovastatin 40mg tab COB 1.320802353237 Lovastatin 40mg tab SAS 1.320800795852 Mevacor 40mg tab FRS 1.320802243129 MYLAN-Lovastatin 40mg tab MYL 1.320802246543 Novo-Lovastatin 40mg tab TEV 1.320802246014 pms-Lovastatin 40mg tab PMS 1.320802245823 ratio-Lovastatin 40mg tab TEV 1.320802247057 Sandoz Lovastatin 40mg tab SDZ 1.3208

loxapine 5mg tab 02230837 Xylac 5mg tab PMS 0.0751loxapine 10mg tab 02230838 Xylac 10mg tab PMS 0.1249loxapine 25mg tab 02230839 Xylac 25mg tab PMS 0.1936loxapine 50mg tab 02230840 Xylac 50mg tab PMS 0.2582maprotiline 25mg tab 02158612 Novo-Maprotiline 25mg tab TEV 0.5687maprotiline 50mg tab 02158620 Novo-Maprotiline 50mg tab TEV 1.0769maprotiline 75mg tab 02158639 Novo-Maprotiline 75mg tab TEV 1.4707medroxyprogesterone acetate 2.5mg tab 02244726 Apo-Medroxy 2.5mg tab APX 0.0642

02221284 Novo-Medrone 2.5mg tab TEV 0.064200708917 Provera 2.5mg tab PFI 0.0642

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 47 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmedroxyprogesterone acetate 5mg tab 02244727 Apo-Medroxy 5mg tab APX 0.1270

02221292 Novo-Medrone 5mg tab TEV 0.127000030937 Provera 5mg tab PFI 0.1270

medroxyprogesterone acetate 10mg tab 02277298 Apo-Medroxy 10mg tab APX 0.257702221306 Novo-Medrone 10mg tab TEV 0.257700729973 Provera 10mg tab PFI 0.2577

medroxyprogesterone acetate 100mg tab 02267640 Apo-Medroxy 100mg tab APX 1.205700030945 Provera 100mg tab PFI 1.2057

medroxyprogesterone acetate 150mg/mL inj

00585092 Depo-Provera 150mg/mL inj PFI 22.0000

02322250 Medroxyprogesterone Acetate 150mg/mL inj SDZ 22.0000mefenamic acid 250mg cap 02229452 Apo-Mefenamic 250mg cap AAP 0.5412megestrol 40mg tab 02195917 Megestrol 40mg tab AAP 1.0929megestrol 160mg tab 02195925 Megestrol 160mg tab AAP 4.6254meloxicam 7.5mg tab 02248973 Apo-Meloxicam 7.5mg tab APX 0.2804

02250012 CO Meloxicam 7.5mg tab COB 0.280402353148 Meloxicam 7.5mg tab SAS 0.280402242785 Mobicox 7.5mg tab BOE 0.280402255987 MYLAN-Meloxicam 7.5mg tab MYL 0.280402258315 Novo-Meloxicam 7.5mg tab TEV 0.280402248607 phl-Meloxicam 7.5mg tab PHL 0.280402248267 pms-Meloxicam 7.5mg tab PMS 0.2804

meloxicam 15mg tab 02248974 Apo-Meloxicam 15mg tab APX 0.323502250020 CO Meloxicam 15mg tab COB 0.323502353156 Meloxicam 15mg tab SAS 0.323502242786 Mobicox 15mg tab BOE 0.323502255995 MYLAN-Meloxicam 15mg tab MYL 0.323502248608 phl-Meloxicam 15mg tab PHL 0.323502248268 pms-Meloxicam 15mg tab PMS 0.323502258323 Teva-Meloxicam 15mg tab TEV 0.3235

metformin HCl 500mg tab 02167786 Apo-Metformin 500mg tab APX 0.083402257726 CO Metformin 500mg tab COB 0.083402099233 Glucophage 500mg tab SAV 0.083402378620 Mar-Metformin 500mg tab MAR 0.083402242794 Metformin 500mg tab MEL 0.083402353377 Metformin 500mg tab SAS 0.083402378841 Metformin 500mg tab MAR 0.083402148765 MYLAN-Metformin 500mg tab MYL 0.083402045710 Novo-Metformin 500mg tab TEV 0.083402162822 Nu-Metformin 500mg tab NXP 0.083402223562 pms-Metformin 500mg tab PMS 0.083402269031 RAN-Metformin 500mg tab RAN 0.083402242974 ratio-Metformin 500mg tab TEV 0.083402246820 Sandoz Metformin FC 500mg tab SDZ 0.0834

metformin HCl 850mg tab 02229785 Apo-Metformin 850mg tab APX 0.1205

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 48 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmetformin HCl 850mg tab 02257734 Co Metformin 850mg tab COB 0.1205

02162849 Glucophage 850mg tab SAV 0.120502378639 Mar-Metformin 850mg tab MAR 0.120502353385 Metformin 850mg tab SAS 0.120502378868 Metformin 850mg tab MAR 0.120502229656 MYLAN-Metformin 850mg tab MYL 0.120502230475 Novo-Metformin 850mg tab TEV 0.120502229517 Nu-Metformin 850mg tab NXP 0.120502242589 pms-Metformin 850mg tab PMS 0.120502269058 RAN-Metformin 850mg tab RAN 0.120502242931 ratio-Metformin 850mg tab TEV 0.120502246821 Sandoz Metformin FC 850mg tab SDZ 0.1205

methotrexate 2.5mg tab 02182963 Apo-Methotrexate 2.5mg tab APX 0.632502170698 Methotrexate 2.5mg tab WAY 0.632502244798 ratio-Methotrexate Sodium 2.5mg tab TEV 0.6325

methotrimeprazine 2mg tab 02238403 Apo-Methoprazine 2mg tab APX 0.0685methotrimeprazine 5mg tab 02238404 Apo-Methoprazine 5mg tab APX 0.0991methotrimeprazine 25mg tab 02238405 Apo-Methoprazine 25mg tab APX 0.2547methotrimeprazine 50mg tab 02238406 Apo-Methoprazine 50mg tab APX 0.3857methyldopa 125mg tab 00360252 Methyldopa 125mg tab AAP 0.1074methyldopa 250mg tab 00360260 Methyldopa 250mg tab AAP 0.1555methyldopa 500mg tab 00426830 Methyldopa 500mg tab AAP 0.2753methylphenidate 10mg tab 02249324 Apo-Methylphenidate 10mg tab APX 0.1271

00584991 pms-Methylphenidate 10mg tab PMS 0.127100005606 Ritalin 10mg tab NVR 0.1271

methylphenidate 20mg tab 02249332 Apo-Methylphenidate 20mg tab APX 0.235900585009 pms-Methylphenidate 20mg tab PMS 0.235900005614 Ritalin 20mg tab NVR 0.2359

methylphenidate 18mg ER tab 02315068 Novo-Methylphenidate ER-C 18mg tab TEV 1.4276methylphenidate 27mg ER tab 02315076 Novo-Methylphenidate ER-C 27mg tab TEV 1.6475methylphenidate 36mg ER tab 02315084 Novo-Methylphenidate ER-C 36mg tab TEV 1.8674methylphenidate 54mg ER tab 02315092 Novo-Methylphenidate ER-C 54mg tab TEV 2.3072methylphenidate 20mg SR tab 02266687 Apo-Methylphenidate 20mg SR tab APX 0.2820

00632775 Ritalin 20mg SR tab NVR 0.282002320312 Sandoz Methylphenidate 20mg SR tab SDZ 0.2820

methylprednisolone acetate 40mg/vial inj 01934333 Depo-Medrol 40mg/mL inj PFI 4.515002245407 Methylprednisolone Acetate 40mg/mL inj SDZ 4.5150

methylprednisolone acetate 80mg/vial inj 01934341 Depo-Medrol 80mg/mL inj PFI 6.990002245408 Methylprednisolone Acetate 80mg/mL inj SDZ 6.9900

methylprednisolone acetate 40mg/vial inj (pf)

00030759 Depo-Medrol 40mg/mL inj (PF) PFI 4.7250

02245400 Methylprednisolone Acetate 40mg/mL inj (PF) SDZ 4.7250methylprednisolone acetate 80mg/vial inj (pf)

00030767 Depo-Medrol 80mg/mL inj (PF) PFI 9.0300

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 49 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmethylprednisolone acetate 80mg/vial inj (pf)

02245406 Methylprednisolone Acetate 80mg/mL inj (PF) SDZ 9.0300

methylprednisolone sodium succinate 40mg/vial inj

02231893 Methylprednisolone Sod. Succ. 40mg/vial inj TEV 4.2966

methylprednisolone sodium succinate 125mg/vial inj

02231894 Methylprednisolone Sod. Succ. 125mg/vial inj TEV 9.3500

methylprednisolone sodium succinate 500mg/vial inj

02231895 Methylprednisolone Sod Succ 500mg/vial inj TEV 22.2002

00030678 Solu-Medrol 500mg/vial inj PFI 22.2002methylprednisolone sodium succinate 1g/vial inj

02241229 Methylprednisolone Sod Succ 1g/vial inj TEV 31.0000

00036137 Solu-Medrol 1g/vial inj PFI 31.0000metoclopramide HCl 5mg tab 00842826 Apo-Metoclop 5mg tab (discontinued) APX 0.0556

02143275 Nu-Metoclopramide 5mg tab NXP 0.055602230431 pms-Metoclopramide 5mg tab PMS 0.0556

metoclopramide HCl 10mg tab 00842834 Apo-Metoclop 10mg tab (discontinued) APX 0.058302143283 Nu-Metoclopramide 10mg tab NXP 0.058302230432 pms-Metoclopramide 10mg tab PMS 0.0583

metoclopramide HCl 1mg o/l 02230433 pms-Metoclopramide 1mg/mL liq PMS 0.0486metoprolol tartrate 50mg tab 00618632 Apo-Metoprolol 50mg tab APX 0.0940

00749354 Apo-Metoprolol-L 50mg tab APX 0.094000397423 Lopresor 50mg tab NVR 0.094002350394 Metoprolol Film-Coated 50mg tab SAS 0.094002174545 MYLAN-Metoprolol (Type L) 50mg tab MYL 0.094000865605 Nu-Metop 50mg tab NXP 0.094002230803 pms-Metoprolol-L 50mg tab PMS 0.094002354187 Sandoz Metoprolol (Type L) 50mg tab SDZ 0.094002247875 Sandoz Metoprolol (Type L) 50mg tab SDZ 0.094000648035 Teva-Metoprolol 50mg tab TEV 0.0940

metoprolol tartrate 100mg tab 00618640 Apo-Metoprolol 100mg tab APX 0.205000751170 Apo-Metoprolol-L 100mg tab APX 0.205000397431 Lopresor 100mg tab NVR 0.205002350408 Metoprolol Film-Coated 100mg tab SAS 0.205002174553 MYLAN-Metoprolol (Type L) 100mg tab MYL 0.205000865613 Nu-Metop 100mg tab NXP 0.205002230804 pms-Metoprolol-L 100mg tab PMS 0.205002354195 Sandoz Metoprolol (Type L) 100mg tab SDZ 0.205002247876 Sandoz Metoprolol (Type L) 100mg tab SDZ 0.205000648043 Teva-Metoprolol 100mg tab TEV 0.2050

metoprolol tartrate 100mg SR tab 02285169 Apo-Metoprolol 100mg SR tab APX 0.124800658855 Lopresor 100mg SR tab NVR 0.124802303396 Sandoz Metoprolol 100mg SR tab SDZ 0.1248

metoprolol tartrate 200mg SR tab 02285177 Apo-Metoprolol 200mg SR tab APX 0.249900534560 Lopresor 200mg SR tab NVR 0.249902303418 Sandoz Metoprolol 200mg SR tab SDZ 0.2499

metronidazole 250mg tab 00545066 Metronidazole 250mg tab AAP 0.0749

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 50 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmexiletine 100mg cap 02230359 Novo-Mexiletine 100mg cap TEV 1.0203mexiletine 200mg cap 02230360 Novo-Mexiletine 200mg cap TEV 1.3663miconazole 2% vag cr 02231106 Micozole 2% vag cr TAR 0.1511

02084309 Monistat 7 2% vag cr JNJ 0.1511midazolam 1mg/mL inj 02240285 Midazolam 1mg/mL inj SDZ 0.7800midazolam 5mg/mL inj 02240286 Midazolam 5mg/mL inj SDZ 4.1000midodrine 2.5mg tab 02278677 Midodrine 2.5mg tab AAP 0.3665midodrine 5mg tab 02278685 Midodrine 5mg tab AAP 0.6109minocycline HCl 50mg cap 02084090 Apo-Minocycline 50mg cap APX 0.3064

02173514 Minocin 50mg cap (discontinued) STI 0.306402287226 Minocycline 50mg cap SAS 0.306402230735 MYLAN-Minocycline 50mg cap MYL 0.306402108143 Novo-Minocycline 50mg cap TEV 0.306402294419 pms-Minocycline 50mg cap PMS 0.306402237313 Sandoz Minocycline 50mg cap SDZ 0.3064

minocycline HCl 100mg cap 02084104 Apo-Minocycline 100mg cap APX 0.591202287234 Minocycline 100mg cap SAS 0.591202230736 MYLAN-Minocycline 100mg cap MYL 0.591202108151 Novo-Minocycline 100mg cap TEV 0.591202294427 pms-Minocycline 100mg cap PMS 0.591202237314 Sandoz Minocycline 100mg cap SDZ 0.5912

mirtazapine 30mg tab 02286629 Apo-Mirtazapine 30mg tab APX 0.455702370689 Mirtazapine 30mg tab SAS 0.455702256118 MYLAN-Mirtazapine 30mg tab MYL 0.455702259354 Novo-Mirtazapine 30mg tab TEV 0.455702252279 phl-Mirtazapine 30mg tab PHL 0.455702248762 pms-Mirtazapine 30mg tab PMS 0.455702243910 Remeron 30mg tab ORG 0.455702250608 Sandoz Mirtazapine 30mg tab SDZ 0.455702325187 Zym-Mirtazapine 30mg tab ZYM 0.4557

mirtazapine 15mg RD tab 02299801 Auro-Mirtazapine OD 15mg tab ARO 0.140602279894 Novo-Mirtazapine 15mg OD tab TEV 0.140602248542 Remeron 15mg RD tab ORG 0.1406

mirtazapine 30mg RD tab 02299828 Auro-Mirtazapine OD 30mg tab ARO 0.281202279908 Novo-Mirtazapine 30mg OD tab TEV 0.281202248543 Remeron 30mg RD tab ORG 0.2812

mirtazapine 45mg RD tab 02299836 Auro-Mirtazapine OD 45mg tab ARO 0.421802279916 Novo-Mirtazapine 45mg OD tab TEV 0.421802248544 Remeron 45mg RD tab ORG 0.4218

misoprostol 100mcg tab 02244022 Misoprostol 100mcg tab AAP 0.2804misoprostol 200mcg tab 02244023 Misoprostol 200mcg tab AAP 0.4669moclobemide 100mg tab 02232148 Apo-Moclobemide 100mg tab APX 0.2520

02239746 Novo-Moclobemide 100mg tab TEV 0.252002237111 Nu-Moclobemide 100mg tab NXP 0.2520

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 51 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmoclobemide 150mg tab 02232150 Apo-Moclobemide 150mg tab APX 0.2120

00899356 Manerix 150mg tab MVL 0.212002239747 Novo-Moclobemide 150mg tab TEV 0.212002237112 Nu-Moclobemide 150mg tab NXP 0.2120

moclobemide 300mg tab 02240456 Apo-Moclobemide 300mg tab APX 0.416402166747 Manerix 300mg tab MVL 0.416402239748 Novo-Moclobemide 300mg tab TEV 0.4164

mometasone 0.1% cr 00851744 Elocom 0.1% cr SCH 0.526202367157 Taro-Mometasone 0.1% cr TAR 0.5262

mometasone 0.1% lot 00871095 Elocom 0.1% lot SCH 0.312402266385 Taro-Mometasone 0.1% lot TAR 0.3124

mometasone 0.1% oint 00851736 Elocom 0.1% oint SCH 0.270102248130 ratio-Mometasone 0.1% oint TEV 0.270102264749 Taro-Mometasone 0.1% oint TAR 0.2701

montelukast 4mg granules (exception status)

02358611 Sandoz Montelukast 4mg granules SDZ 0.1276

02247997 Singulair 4mg/pkt granules FRS 0.1276montelukast 4mg chewable tab (exception status)

02354977 pms-Montelukast 4mg chewtab PMS 0.5104

02330385 Sandoz Montelukast 4mg chewtab SDZ 0.510402243602 Singulair 4mg chewtab FRS 0.510402355507 Teva-Montelukast 4mg chewtab TEV 0.5104

montelukast 5mg chewable tab (exception status)

02354985 pms-Montelukast 5mg chewtab PMS 0.5635

02330393 Sandoz Montelukast 5mg chewtab SDZ 0.563502238216 Singulair 5mg chewtab FRS 0.563502355515 Teva-Montelukast 5mg chewtab TEV 0.5635

montelukast 10mg tab (exception status) 02374609 Apo-Montelukast 10mg tab APX 0.827602368226 MYLAN-Montelukast 10mg tab MYL 0.827602373947 pms-Montelukast FC 10mg tab PMS 0.827602328593 Sandoz Montelukast 10mg tab SDZ 0.827602238217 Singulair 10mg tab FRS 0.827602355523 Teva-Montelukast 10mg tab TEV 0.8276

morphine sulfate 15mg SR tab 02350815 Morphine SR 15mg tab SAS 0.231702015439 MS Contin 15mg SR tab PFR 0.231702302764 Novo-Morphine 15mg SR tab TEV 0.231702244790 Sandoz Morphine 15mg SR tab SDZ 0.2317

morphine sulfate 30mg SR tab 02350890 Morphine SR 30mg tab SAS 0.350002014297 MS Contin 30mg SR tab PFR 0.350002302772 Novo-Morphine 30mg SR tab TEV 0.350002244791 Sandoz Morphine 30mg SR tab SDZ 0.3500

morphine sulfate 60mg SR tab 02350912 Morphine SR 60mg tab SAS 0.616702014300 MS Contin 60mg SR tab PFR 0.616702302780 Novo-Morphine 60mg SR tab TEV 0.616702245286 pms-Morphine Sulfate 60mg SR tab (discontinued) PMS 0.6167

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 52 of 83

Generic Name and Strength DIN Brand MFR MRP PRPmorphine sulfate 60mg SR tab 02244792 Sandoz Morphine 60mg SR tab SDZ 0.6167morphine sulfate 100mg SR tab 02350920 Morphine SR 100mg tab SAS 0.9401

02014319 MS Contin 100mg SR tab PFR 0.940102302799 Novo-Morphine 100mg SR tab TEV 0.9401

morphine sulfate 200mg SR tab 02350947 Morphine SR 200mg tab SAS 1.747902014327 MS Contin 200mg SR tab PFR 1.747902302802 Novo-Morphine 200mg SR tab TEV 1.7479

morphine sulfate 10mg/mL inj 00392588 Morphine Sulfate 10mg/mL inj SDZ 0.9900morphine sulfate 15mg/mL inj 00392561 Morphine Sulfate 15mg/mL inj SDZ 1.0050mupirocin 2% oint 01916947 Bactroban 2% oint GSK 0.3453

02279983 Taro-Mupirocin 2% oint TAR 0.3453nabilone 0.5mg cap (exception status) 02256193 Cesamet 0.5mg cap VLN 1.0859

02380900 pms-Nabilone 0.5mg cap PMS 1.085902358085 RAN-Nabilone 0.5mg cap RAN 1.085902384884 Teva-Nabilone 0.5mg cap TEV 1.0859

nabilone 1mg cap (exception status) 00548375 Cesamet 1mg cap VLN 2.171802380919 pms-Nabilone 1mg cap PMS 2.171802358093 RAN-Nabilone 1mg cap RAN 2.171802384892 Teva-Nabilone 1mg cap TEV 2.1718

nabumetone 500mg tab 02238639 Apo-Nabumetone 500mg tab APX 0.175002244563 MYLAN-Nabumetone 500mg tab MYL 0.175002240867 Novo-Nabumetone 500mg tab TEV 0.1750

nabumetone 750mg tab 02240868 Novo-Nabumetone 750mg tab TEV 0.3500nadolol 40mg tab 00782505 Apo-Nadol 40mg tab APX 0.2465

02126753 Novo-Nadolol 40mg tab TEV 0.2465nadolol 80mg tab 00782467 Apo-Nadol 80mg tab APX 0.3515

02126761 Novo-Nadolol 80mg tab TEV 0.3515nadolol 160mg tab 00782475 Apo-Nadol 160mg tab APX 1.2046naproxen 125mg tab 00522678 Apo-Naproxen 125mg tab APX 0.0781naproxen 250mg tab 00522651 Apo-Naproxen 250mg tab APX 0.1068

02350750 Naproxen 250mg tab SAS 0.106800865648 Nu-Naprox 250mg tab NXP 0.106800565350 Teva-Naproxen 250mg tab TEV 0.1068

naproxen 375mg tab 00600806 Apo-Naproxen 375mg tab APX 0.145802350769 Naproxen 375mg tab SAS 0.145800865656 Nu-Naprox 375mg tab NXP 0.145800627097 Teva-Naproxen 375mg tab TEV 0.1458

naproxen 500mg tab 00592277 Apo-Naproxen 500mg tab APX 0.211002350777 Naproxen 500mg tab SAS 0.211000865664 Nu-Naprox 500mg tab NXP 0.211000589861 Teva-Naproxen 500mg tab TEV 0.2110

naproxen 250mg EC tab 02246699 Apo-Naproxen 250mg EC tab APX 0.143402162792 Naprosyn-E 250mg EC tab HLR 0.143402350785 Naproxen 250mg EC tab SAS 0.1434

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 53 of 83

Generic Name and Strength DIN Brand MFR MRP PRPnaproxen 250mg EC tab 02243312 Novo-Naprox 250mg EC tab TEV 0.1434naproxen 375mg EC tab 02246700 Apo-Naproxen 375mg EC tab APX 0.1880

02243432 MYLAN-Naproxen 375mg EC tab MYL 0.188002162415 Naprosyn-E 375mg EC tab HLR 0.188002350793 Naproxen 375mg EC tab SAS 0.188002294702 pms-Naproxen 375mg EC tab PMS 0.188002243313 Teva-Naproxen-EC 375mg tab TEV 0.1880

naproxen 500mg EC tab 02246701 Apo-Naproxen 500mg EC tab APX 0.339602241024 MYLAN-Naproxen 500mg EC tab MYL 0.339602162423 Naprosyn-E 500mg EC tab HLR 0.339602350807 Naproxen 500mg EC tab SAS 0.339602243314 Novo-Naprox 500mg EC tab TEV 0.339602294710 pms-Naproxen 500mg EC tab PMS 0.3396

naproxen 750mg SR tab 02177072 Apo-Naproxen 750mg SR tab (discontinued) APX 0.453302162466 Naprosyn 750mg SR tab HLR 0.4533

naproxen sodium 275mg tab 02162725 Anaprox 275mg tab HLR 0.175000784354 Apo-Napro-Na 275mg tab APX 0.175002351013 Naproxen Sodium 275mg tab SAS 0.175000778389 Teva-Naproxen Sodium 275mg tab TEV 0.1750

naproxen sodium 550mg tab 02162717 Anaprox DS 550mg tab HLR 0.350001940309 Apo-Napro-Na DS 550mg tab APX 0.350002351021 Naproxen Sodium DS 550mg tab SAS 0.350002026600 Teva-Naproxen Sodium DS 550mg tab TEV 0.3500

naproxen 500mg supp 02017237 pms-Naproxen 500mg supp PMS 0.9639naratriptan 1mg tab (exception status) 02237820 Amerge 1mg tab GSK 7.7950

02314290 Novo-Naratriptan 1mg tab TEV 7.7950naratriptan 2.5mg tab (exception status) 02237821 Amerge 2.5mg tab GSK 6.1438

02314304 Novo-Naratriptan 2.5mg tab TEV 6.143802322323 Sandoz Naratriptan 2.5mg tab SDZ 6.1438

nifedipine 5mg cap 00725110 Nifedipine 5mg cap AAP 0.3992nifedipine 10mg tab 00755907 Nifedipine 10mg tab AAP 0.5292nifedipine 30mg ER tab 02155907 Adalat XL 30mg tab BAY 0.6171

02349167 MYLAN-Nifedipine 30mg ER tab MYL 0.6171nifedipine 60mg ER tab 02155990 Adalat XL 60mg tab BAY 0.9374

02321149 MYLAN-Nifedipine 60mg ER tab MYL 0.9374nilotinib 150mg cap (exception status) 02368250 Tasigna 150mg cap NVR 29.5926nilotinib 200mg cap (exception status) 02315874 Tasigna 200mg cap NVR 42.0054nitrofurantoin 50mg cap 02231015 Novo-Furantoin 50mg cap TEV 0.3984nitroglycerin 0.4mg/dose pumpspray 02231441 Nitrolingual 0.4mg/dose pumpspray SAV 0.0423

02238998 Rho-Nitro 0.4mg/dose pumpspray SDZ 0.0423nizatidine 150mg cap 02220156 Apo-Nizatidine 150mg cap APX 0.1800

00778338 Axid 150mg cap MMT 0.180002240457 Novo-Nizatidine 150mg cap TEV 0.180002177714 pms-Nizatidine 150mg cap PMS 0.1800

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 54 of 83

Generic Name and Strength DIN Brand MFR MRP PRPnizatidine 300mg cap 02220164 Apo-Nizatidine 300mg cap APX 0.3600

00778346 Axid 300mg cap MMT 0.360002240458 Novo-Nizatidine 300mg cap TEV 0.360002177722 pms-Nizatidine 300mg cap PMS 0.3600

norfloxacin 400mg tab (exception status) 02229524 Apo-Norflox 400mg tab APX 0.793402269627 CO Norfloxacin 400mg tab COB 0.793402237682 Novo-Norfloxacin 400mg tab TEV 0.793402246596 pms-Norfloxacin 400mg tab PMS 0.7934

nortriptyline 10mg cap 02223511 Apo-Nortriptyline 10mg cap APX 0.078700015229 Aventyl 10mg cap PHL 0.078702231781 Novo-Nortriptyline 10mg cap TEV 0.078702223139 Nu-Nortriptyline 10mg cap NXP 0.078702177692 pms-Nortriptyline 10mg cap PMS 0.0787

nortriptyline 25mg cap 02223538 Apo-Nortriptyline 25mg cap APX 0.158300015237 Aventyl 25mg cap PHL 0.158302231782 Novo-Nortriptyline 25mg cap TEV 0.158302223147 Nu-Nortriptyline 25mg cap NXP 0.158302177706 pms-Nortriptyline 25mg cap PMS 0.1583

nystatin 100,000iu o/l 02194201 ratio-Nystatin 100,000iu/mL oral drops TEV 0.0740octreotide 50mcg/mL inj 02248639 Octreotide Acetate Omega 50mcg/mL inj HOS 1.7815

00839191 Sandostatin 50mcg/mL inj NVR 1.7815octreotide 100mcg/mL inj 02248640 Octreotide Acetate Omega 100mcg/mL inj HOS 3.3635

00839205 Sandostatin 100mcg/mL inj NVR 3.3635octreotide 200mcg/mL inj 02248642 Octreotide Acetate Omega 200mcg/mL inj HOS 6.4687

02049392 Sandostatin 200mcg/mL inj NVR 6.4687octreotide 500mcg/mL inj 02248641 Octreotide Acetate Omega 500mcg/mL inj HOS 15.8060

00839213 Sandostatin 500mcg/mL inj NVR 15.8060ofloxacin 300mg tab (exception status) 02231531 Ofloxacin 300mg tab AAP 1.6625ofloxacin 400mg tab (exception status) 02231532 Ofloxacin 400mg tab AAP 1.6625ofloxacin 0.3% oph sol (exception status) 02248398 Apo-Ofloxacin 0.3% oph sol APX 0.8561

02143291 Ocuflox 0.3% oph sol ALL 0.856102252570 pms-Ofloxacin 0.3% oph sol PMS 0.8561

olanzapine 2.5mg tab (exception status) 02281791 Apo-Olanzapine 2.5mg tab APX 0.629002337878 MYLAN-Olanzapine 2.5mg tab MYL 0.629002372819 Olanzapine 2.5mg tab SAS 0.629002303116 pms-Olanzapine 2.5mg tab PMS 0.629002310341 Sandoz Olanzapine 2.5mg tab SDZ 0.629002276712 Teva-Olanzapine 2.5mg tab TEV 0.629002229250 Zyprexa 2.5mg tab LIL 0.6290

olanzapine 5mg tab (exception status) 02281805 Apo-Olanzapine 5mg tab APX 1.258002337886 MYLAN-Olanzapine 5mg tab MYL 1.258002372827 Olanzapine 5mg tab SAS 1.258002303159 pms-Olanzapine 5mg tab PMS 1.258002310368 Sandoz Olanzapine 5mg tab SDZ 1.2580

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 55 of 83

Generic Name and Strength DIN Brand MFR MRP PRPolanzapine 5mg tab (exception status) 02276720 Teva-Olanzapine 5mg tab TEV 1.2580

02229269 Zyprexa 5mg tab LIL 1.2580olanzapine 7.5mg tab (exception status) 02281813 Apo-Olanzapine 7.5mg tab APX 1.8871

02337894 MYLAN-Olanzapine 7.5mg tab MYL 1.887102372835 Olanzapine 7.5mg tab SAS 1.887102303167 pms-Olanzapine 7.5mg tab PMS 1.887102310376 Sandoz Olanzapine 7.5mg tab SDZ 1.887102276739 Teva-Olanzapine 7.5mg tab TEV 1.887102229277 Zyprexa 7.5mg tab LIL 1.8871

olanzapine 10mg tab (exception status) 02281821 Apo-Olanzapine 10mg tab APX 2.516102337908 MYLAN-Olanzapine 10mg tab MYL 2.516102372843 Olanzapine 10mg tab SAS 2.516102303175 pms-Olanzapine 10mg tab PMS 2.516102310384 Sandoz Olanzapine 10mg tab SDZ 2.516102276747 Teva-Olanzapine 10mg tab TEV 2.516102229285 Zyprexa 10mg tab LIL 2.5161

olanzapine 15mg tab (exception status) 02281848 Apo-Olanzapine 15mg tab APX 3.774102337916 MYLAN-Olanzapine 15mg tab MYL 3.774102372851 Olanzapine 15mg tab SAS 3.774102303183 pms-Olanzapine 15mg tab PMS 3.774102310392 Sandoz Olanzapine 15mg tab SDZ 3.774102276755 Teva-Olanzapine 15mg tab TEV 3.774102238850 Zyprexa 15mg tab LIL 3.7741

olanzapine ODT 5mg tab (exception status)

02360616 Apo-Olanzapine ODT 5mg tab APX 1.2511

02327562 CO Olanzapine ODT 5mg tab COB 1.251102352974 Olanzapine ODT 5mg tab SAS 1.251102303191 pms-Olanzapine ODT 5mg tab PMS 1.251102327775 Sandoz Olanzapine ODT 5mg tab SDZ 1.251102321343 Teva-Olanzapine OD 5mg tab TEV 1.251102243086 Zyprexa Zydis 5mg tab LIL 1.2511

olanzapine ODT 10mg tab (exception status)

02360624 Apo-Olanzapine ODT 10mg tab APX 2.5000

02327570 CO Olanzapine ODT 10mg tab COB 2.500002352982 Olanzapine ODT 10mg tab SAS 2.500002303205 pms-Olanzapine ODT 10mg tab PMS 2.500002327783 Sandoz Olanzapine ODT 10mg tab SDZ 2.500002321351 Teva-Olanzapine OD 10mg tab TEV 2.500002243087 Zyprexa Zydis 10mg tab LIL 2.5000

olanzapine ODT 15mg tab (exception status)

02360632 Apo-Olanzapine ODT 15mg tab APX 3.7489

02327589 CO Olanzapine ODT 15mg tab COB 3.748902352990 Olanzapine ODT 15mg tab SAS 3.748902303213 pms-Olanzapine ODT 15mg tab PMS 3.748902327791 Sandoz Olanzapine ODT 15mg tab SDZ 3.7489

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 56 of 83

Generic Name and Strength DIN Brand MFR MRP PRPolanzapine ODT 15mg tab (exception status)

02321378 Teva-Olanzapine OD 15mg tab TEV 3.7489

02243088 Zyprexa Zydis 15mg tab LIL 3.7489olanzapine ODT 20mg tab (exception status)

02360640 Apo-Olanzapine ODT 20mg tab APX 5.9376

02327597 CO Olanzapine ODT 20mg tab COB 5.937602327805 Sandoz Olanzapine ODT 20mg tab SDZ 5.937602321386 Teva-Olanzapine OD 20mg tab TEV 5.937602243089 Zyprexa Zydis 20mg tab LIL 5.9376

omeprazole 10mg cap 02119579 Losec 10mg cap AZE 0.385002329425 MYLAN-Omeprazole 10mg cap MYL 0.385002296438 Sandoz Omeprazole 10mg cap SDZ 0.3850

omeprazole 20mg cap 02245058 Apo-Omeprazole 20mg cap APX 0.770000846503 Losec 20mg cap AZE 0.770002329433 MYLAN-Omeprazole 20mg cap MYL 0.770002348691 Omeprazole 20mg cap SAS 0.770002320851 pms-Omeprazole 20mg cap PMS 0.770002296446 Sandoz Omeprazole 20mg cap SDZ 0.7700

omeprazole 10mg cap/tab 02230737 Losec 10mg tab AZE 0.385002329425 MYLAN-Omeprazole 10mg cap MYL 0.3850

omeprazole 20mg cap/tab 02245058 Apo-Omeprazole 20mg cap APX 0.770002190915 Losec 20mg tab AZE 0.770002329433 MYLAN-Omeprazole 20mg cap MYL 0.770002295415 Novo-Omeprazole Delayed-Release 20mg tab TEV 0.770002348691 Omeprazole 20mg cap SAS 0.770002310260 pms-Omeprazole DR 20mg tab PMS 0.770002374870 RAN-Omeprazole 20mg tab RAN 0.770002260867 ratio-Omeprazole 20mg tab TEV 0.7700

ondansetron 4mg tab (exception status) 02288184 Apo-Ondansetron 4mg tab APX 3.577802296349 CO Ondansetron 4mg tab COB 3.577802313685 Jamp-Ondansetron 4mg tab JPC 3.577802371731 Mar-Ondansetron 4mg tab MAR 3.577802305259 MINT- Ondansetron 4mg tab MNT 3.577802297868 MYLAN-Ondansetron 4mg tab MYL 3.577802264056 Novo-Ondansetron 4mg tab TEV 3.577802306212 Ondansetron-Odan 4mg tab ODN 3.577802278618 phl-Ondansetron 4mg tab PHL 3.577802258188 pms-Ondansetron 4mg tab PMS 3.577802312247 RAN-Ondansetron 4mg tab RAN 3.577802278529 ratio-Ondansetron 4mg tab TEV 3.577802274310 Sandoz Ondansetron 4mg tab SDZ 3.577802213567 Zofran 4mg tab GSK 3.5778

ondansetron 8mg tab (exception status) 02288192 Apo-Ondansetron 8mg tab APX 7.155502296357 CO Ondansetron 8mg tab COB 7.155502313693 Jamp-Ondansetron 8mg tab JPC 7.1555

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 57 of 83

Generic Name and Strength DIN Brand MFR MRP PRPondansetron 8mg tab (exception status) 02371758 Mar-Ondansetron 8mg tab MAR 7.1555

02305267 MINT-Ondansetron 8mg tab MNT 7.155502297876 MYLAN-Ondansetron 8mg tab MYL 7.155502306220 Ondansetron-Odan 8mg tab ODN 7.155502278626 phl-Ondansetron 8mg tab PHL 7.155502258196 pms-Ondansetron 8mg tab PMS 7.155502312255 RAN-Ondansetron 8mg tab RAN 7.155502278537 ratio-Ondansetron 8mg tab TEV 7.155502274329 Sandoz Ondansetron 8mg tab SDZ 7.155502264064 Teva-Ondansetron 8mg tab TEV 7.155502213575 Zofran 8mg tab GSK 7.1555

ondansetron 4mg ODT tab (exception status)

02239372 Zofran 4mg ODT tab GSK 3.5778

ondansetron 8mg ODT tab (exception status)

02239373 Zofran 8mg ODT tab GSK 7.1555

ondansetron 4mg/5mL o/l (exception status)

02291967 Ondansetron 4mg/5mL o/l AAP 1.5856

02229639 Zofran 4mg/5mL o/l GSK 1.5856orciprenaline 2mg/mL syr 02236783 Apo-Orciprenaline 2mg/mL syr APX 0.0574oxazepam 15mg tab 00402745 Apo-Oxazepam 15mg tab APX 0.0560oxazepam 30mg tab 00402737 Apo-Oxazepam 30mg tab APX 0.0764oxcarbazepine 150mg tab (exception status)

02284294 Apo-Oxcarbazepine 150mg tab APX 0.6209

02242067 Trileptal 150mg tab NVR 0.6209oxcarbazepine 300mg tab (exception status)

02284308 Apo-Oxcarbazepine 300mg tab APX 1.2414

02242068 Trileptal 300mg tab NVR 1.2414oxcarbazepine 600mg tab (exception status)

02284316 Apo-Oxcarbazepine 600mg tab APX 2.4826

02242069 Trileptal 600mg tab NVR 2.4826oxybutynin 5mg tab 02163543 Apo-Oxybutynin 5mg tab APX 0.1508

02230800 MYLAN-Oxybutynin 5mg tab MYL 0.150802230394 Novo-Oxybutynin 5mg tab TEV 0.150802158590 Nu-Oxybutyn 5mg tab NXP 0.150802350238 Oxybutynin 5mg tab SAS 0.150802240550 pms-Oxbytynin 5mg tab PMS 0.1508

oxybutynin 1mg/mL o/l 02223376 pms-Oxybutynin 1mg/mL o/l PMS 0.1183oxycodone 5mg tab (Supeudol) 02319977 pms-Oxycodone 5mg tab PMS 0.1776

00789739 Supeudol 5mg tab SDZ 0.1776oxycodone 10mg tab (Supeudol) 02319985 pms-Oxycodone 10mg tab PMS 0.2760

00443948 Supeudol 10mg tab SDZ 0.2760oxycodone 5mg tab (Oxy-IR) 02231934 Oxy-IR 5mg tab PFR 0.1776

02319977 pms-Oxycodone 5mg tab PMS 0.1776oxycodone 10mg tab (Oxy-IR) 02240131 Oxy-IR 10mg tab PFR 0.2760

02319985 pms-Oxycodone 10mg tab PMS 0.2760oxycodone 20mg tab 02240132 Oxy-IR 20mg tab PFR 0.4538

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 58 of 83

Generic Name and Strength DIN Brand MFR MRP PRPoxycodone 20mg tab 02319993 pms-Oxycodone 20mg tab PMS 0.4538pantoprazole 20mg EC tab (exception status)

02292912 Apo-Pantoprazole 20mg DR tab APX 0.3538

02241804 Pantoloc 20mg DR tab NYC 0.353802305038 RAN-Pantoprazole 20mg DR tab RAN 0.353802301075 Sandoz Pantoprazole 20mg DR tab SDZ 0.353802285479 Teva-Pantoprazole 20mg DR tab TEV 0.3538

pantoprazole 40mg EC tab (exception status)

02292920 Apo-Pantoprazole 40mg DR tab APX 0.7076

02300486 CO Pantoprazole 40mg DR tab COB 0.707602299585 MYLAN-Pantoprazole 40mg DR tab MYL 0.707602229453 Pantoloc 40mg DR tab NYC 0.707602370808 Pantoprazole 40mg tab SAS 0.707602307871 pms-Pantoprazole 40mg DR tab PMS 0.707602305046 RAN-Pantoprazole 40mg DR tab RAN 0.707602301083 Sandoz Pantoprazole 40mg DR tab SDZ 0.707602285487 Teva-Pantoprazole 40mg DR tab TEV 0.7076

paroxetine 20mg tab 02240908 Apo-Paroxetine 20mg tab APX 0.632002262754 CO Paroxetine 20mg tab COB 0.632002248013 MYLAN-Paroxetine 20mg tab MYL 0.632002282852 Paroxetine 20mg tab SAS 0.632001940481 Paxil 20mg tab GSK 0.632002248451 phl-Paroxetine 20mg tab PHL 0.632002247751 pms-Paroxetine 20mg tab PMS 0.632002247811 ratio-Paroxetine 20mg tab TEV 0.632002269430 Sandoz Paroxetine 20mg tab SDZ 0.632002248557 Teva-Paroxetine 20mg tab TEV 0.6320

paroxetine 30mg tab 02240909 Apo-Paroxetine 30mg tab APX 0.671402262762 CO Paroxetine 30mg tab COB 0.671402248014 MYLAN-Paroxetine 30mg tab MYL 0.671402282860 Paroxetine 30mg tab SAS 0.671401940473 Paxil 30mg tab GSK 0.671402248452 phl-Paroxetine 30mg tab PHL 0.671402247752 pms-Paroxetine 30mg tab PMS 0.671402247812 ratio-Paroxetine 30mg tab TEV 0.671402269449 Sandoz Paroxetine 30mg tab SDZ 0.671402248558 Teva-Paroxetine 30mg tab TEV 0.6714

penicillin V potassium 300mg tab 00642215 Apo-Pen VK 300mg tab APX 0.071000021202 Novo-Pen-VK 300mg tab TEV 0.071000717568 Nu-Pen VK 300mg tab NXP 0.0710

penicillin V potassium 60mg/mL o/l 00642231 Apo-Pen VK 60mg/mL o/l APX 0.047200391603 Novo-Pen-VK 60mg/mL o/l TEV 0.0472

pentoxifylline 400mg tab (exception status)

02230090 Apo-Pentoxifylline 400mg SR tab APX 0.584602221977 Trental 400mg tab SAV 0.5846

perphenazine 4mg tab 00335126 Perphenazine 4mg tab AAP 0.0823

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 59 of 83

Generic Name and Strength DIN Brand MFR MRP PRPpethidine 50mg/mL inj 00725765 Meperidine 50mg/mL inj SDZ 0.9600pethidine 75mg/mL inj 00725757 Meperidine 75mg/mL inj SDZ 1.0100pethidine 100mg/mL inj 00725749 Meperidine 100mg/mL inj SDZ 1.0700phenylephrine 10mg/mL inj 02241980 Neo-Synephrine 10mg/mL inj HOS 4.4300

01953583 Phenylephrine 10mg/mL inj SDZ 4.4300phenytoin 25mg/mL susp 00023450 Dilantin-125 25mg/mL susp PFI 0.0311

02250896 Taro-Phenytoin 25mg/mL susp TAR 0.0311pimozide 2mg tab 02245432 Apo-Pimozide 2mg tab APX 0.3093

00313815 Orap 2mg tab PHL 0.3093pimozide 4mg tab 02245433 Apo-Pimozide 4mg tab APX 0.4136

00313823 Orap 4mg tab PHL 0.4136pindolol 5mg tab 00755877 Apo-Pindol 5mg tab APX 0.2050

00869007 Novo-Pindol 5mg tab TEV 0.205000886149 Nu-Pindol 5mg tab NXP 0.205002231536 pms-Pindolol 5mg tab PMS 0.205002261782 Sandoz Pindolol 5mg tab SDZ 0.205000417270 Visken 5mg tab NVR 0.2050

pindolol 10mg tab 00755885 Apo-Pindol 10mg tab APX 0.350000869015 Novo-Pindol 10mg tab TEV 0.350000886009 Nu-Pindol 10mg tab NXP 0.350002231537 pms-Pindolol 10mg tab PMS 0.350002261790 Sandoz Pindolol 10mg tab SDZ 0.350000443174 Visken 10mg tab NVR 0.3500

pindolol 15mg tab 00755893 Apo-Pindol 15mg tab APX 0.507800869023 Novo-Pindol 15mg tab TEV 0.507800886130 Nu-Pindol 15mg tab NXP 0.507802231539 pms-Pindolol 15mg tab PMS 0.507802261804 Sandoz Pindolol 15mg tab SDZ 0.507800417289 Visken 15mg tab NVR 0.5078

pioglitazone 15mg tab (exception status) 02242572 Actos 15mg tab LIL 0.832402302942 Apo-Pioglitazone 15mg tab APX 0.832402302861 CO Pioglitazone 15mg tab COB 0.832402326477 MINT-Pioglitazone 15mg tab MNT 0.832402298279 MYLAN-Pioglitazone 15mg tab MYL 0.832402274914 Novo-Pioglitazone 15mg tab TEV 0.832402307669 phl-Pioglitazone 15mg tab PHL 0.832402303124 pms-Pioglitazone 15mg tab PMS 0.832402301423 ratio-Pioglitazone 15mg tab TEV 0.832402297906 Sandoz Pioglitazone 15mg tab SDZ 0.832402320754 Zym-Pioglitazone 15mg tab ZYM 0.8324

pioglitazone 30mg tab (exception status) 02242573 Actos 30mg tab LIL 1.166202302950 Apo-Pioglitazone 30mg tab APX 1.166202302888 CO Pioglitazone 30mg tab COB 1.166202326485 MINT-Pioglitazone 30mg tab MNT 1.1662

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 60 of 83

Generic Name and Strength DIN Brand MFR MRP PRPpioglitazone 30mg tab (exception status) 02298287 MYLAN-Pioglitazone 30mg tab MYL 1.1662

02274922 Novo-Pioglitazone 30mg tab TEV 1.166202307677 phl-Pioglitazone 30mg tab PHL 1.166202339587 Pioglitazone 30mg tab AHC 1.166202303132 pms-Pioglitazone 30mg tab PMS 1.166202301431 ratio-Pioglitazone 30mg tab TEV 1.166202297914 Sandoz Pioglitazone 30mg tab SDZ 1.166202320762 Zym-Pioglitazone 30mg tab ZYM 1.1662

pioglitazone 45mg tab (exception status) 02242574 Actos 45mg tab LIL 1.753502302977 Apo-Pioglitazone 45mg tab APX 1.753502302896 CO Pioglitazone 45mg tab COB 1.753502326493 MINT-Pioglitazone 45mg tab MNT 1.753502298295 MYLAN-Pioglitazone 45mg tab MYL 1.753502274930 Novo-Pioglitazone 45mg tab TEV 1.753502307723 phl-Pioglitazone 45mg tab PHL 1.753502339595 Pioglitazone 45mg tab AHC 1.753502303140 pms-Pioglitazone 45mg tab PMS 1.753502301458 ratio-Pioglitazone 45mg tab TEV 1.753502297922 Sandoz Pioglitazone 45mg tab SDZ 1.753502320770 Zym-Pioglitazone 45mg tab ZYM 1.7535

piroxicam 10mg cap 00642886 Apo-Piroxicam 10mg cap APX 0.321100695718 Novo-Pirocam 10mg cap TEV 0.321100865761 Nu-Pirox 10mg cap NXP 0.3211

piroxicam 20mg cap 00642894 Apo-Piroxicam 20mg cap APX 0.519600695696 Novo-Pirocam 20mg cap TEV 0.519600865788 Nu-Pirox 20mg cap NXP 0.5196

piroxicam 20mg supp 02154463 pms-Piroxicam 20mg supp PMS 2.2329polymixin b sulfate, neomycin sulfate & gramicidin oph/otic sol

00807435 Optimyxin Plus oph/otic sol SDZ 0.8230

polymyxin b sulfate, neomycin sulfate & hydrocortisone otic sol

01912828 Cortisporin otic sol GSK 1.1400

02230386 Sandoz Cortimyxin otic sol SDZ 1.1400potassium chloride 1.33mEq/mL o/l 80024360 K-10 1.33mEq/mL o/l GSK 0.0158

02238604 pms-Potassium Chloride 1.33mEq/mL o/l PMS 0.0158pramipexole 0.25mg tab 02292378 Apo-Pramipexole 0.25mg tab APX 0.3680

02297302 CO Pramipexole 0.25mg tab COB 0.368002237145 Mirapex 0.25mg tab BOE 0.368002269309 Novo-Pramipexole 0.25mg tab TEV 0.368002290111 pms-Pramipexole 0.25mg tab PMS 0.368002315262 Sandoz Pramipexole 0.25mg tab SDZ 0.3680

pramipexole 1mg tab 02292394 Apo-Pramipexole 1mg tab APX 0.736002297329 CO Pramipexole 1mg tab COB 0.736002237146 Mirapex 1mg tab BOE 0.736002269325 Novo-Pramipexole 1mg tab TEV 0.736002290146 pms-Pramipexole 1mg tab PMS 0.7360

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 61 of 83

Generic Name and Strength DIN Brand MFR MRP PRPpramipexole 1mg tab 02315289 Sandoz Pramipexole 1mg tab SDZ 0.7360pramipexole 1.5mg tab 02292408 Apo-Pramipexole 1.5mg tab APX 0.7360

02297337 CO Pramipexole 1.5mg tab COB 0.736002237147 Mirapex 1.5mg tab BOE 0.736002269333 Novo-Pramipexole 1.5mg tab TEV 0.736002290154 pms-Pramipexole 1.5mg tab PMS 0.736002315297 Sandoz Pramipexole 1.5mg tab SDZ 0.7360

pravastatin 10mg tab 02243506 Apo-Pravastatin 10mg tab APX 0.567002248182 CO Pravastatin 10mg tab COB 0.567002330954 Jamp-Pravastatin 10mg tab JPC 0.567002317451 MINT-Pravastatin 10mg tab MNT 0.567002257092 MYLAN-Pravastatin 10mg tab MYL 0.567002247008 Novo-Pravastatin 10mg tab TEV 0.567002244350 Nu-Pravastatin 10mg tab NXP 0.567002249766 phl-Pravastatin 10mg tab PHL 0.567002247655 pms-Pravastatin 10mg tab PMS 0.567000893749 Pravachol 10mg tab BRI 0.567002356546 Pravastatin 10mg tab SAS 0.567002284421 RAN-Pravastatin 10mg tab RAN 0.567002247856 Sandoz Pravastatin 10mg tab SDZ 0.5670

pravastatin 20mg tab 02243507 Apo-Pravastatin 20mg tab APX 0.668902248183 CO Pravastatin 20mg tab COB 0.668902330962 Jamp-Pravastatin 20mg tab JPC 0.668902317478 MINT-Pravastatin 20mg tab MNT 0.668902257106 MYLAN-Pravastatin 20mg tab MYL 0.668902247009 Novo-Pravastatin 20mg tab TEV 0.668902244351 Nu-Pravastatin 20mg tab NXP 0.668902249774 phl-Pravastatin 20mg tab PHL 0.668902247656 pms-Pravastatin 20mg tab PMS 0.668900893757 Pravachol 20mg tab BRI 0.668902356554 Pravastatin 20mg tab SAS 0.668902284448 RAN-Pravastatin 20mg tab RAN 0.668902247857 Sandoz Pravastatin 20mg tab SDZ 0.6689

pravastatin 40mg tab 02243508 Apo-Pravastatin 40mg tab APX 0.805702248184 CO Pravastatin 40mg tab COB 0.805702330970 Jamp-Pravastatin 40mg tab JPC 0.805702317486 MINT-Pravastatin 40mg tab MNT 0.805702257114 MYLAN-Pravastatin 40mg tab MYL 0.805702247010 Novo-Pravastatin 40mg tab TEV 0.805702244352 Nu-Pravastatin 40mg tab NXP 0.805702249782 phl-Pravastatin 40mg tab PHL 0.805702247657 pms-Pravastatin 40mg tab PMS 0.805702222051 Pravachol 40mg tab BRI 0.805702356562 Pravastatin 40mg tab SAS 0.805702284456 RAN-Pravastatin 40mg tab RAN 0.8057

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 62 of 83

Generic Name and Strength DIN Brand MFR MRP PRPpravastatin 40mg tab 02247858 Sandoz Pravastatin 40mg tab SDZ 0.8057prazosin HCl 1mg tab 00882801 Apo-Prazo 1mg tab APX 0.1371

01934198 Novo-Prazin 1mg tab TEV 0.137101913794 Nu-Prazo 1mg tab NXP 0.1371

prazosin HCl 2mg tab 00882828 Apo-Prazo 2mg tab APX 0.186201934201 Novo-Prazin 2mg tab TEV 0.186201913808 Nu-Prazo 2mg tab NXP 0.1862

prazosin HCl 5mg tab 00882836 Apo-Prazo 5mg tab APX 0.256001934228 Novo-Prazin 5mg tab TEV 0.256001913816 Nu-Prazo 5mg tab NXP 0.2560

prednisolone acetate 0.12% oph susp 00299405 Pred Mild 0.12% oph susp ALL 1.345001916181 Sandoz Prednisolone 0.12% oph susp SDZ 1.3450

prednisolone acetate 1% oph susp 00301175 Pred Forte 1% oph susp ALL 1.940000700401 ratio-Prednisolone 1% oph susp TEV 1.940001916203 Sandoz Prednisolone 1% oph susp SDZ 1.9400

prednisolone sodium phosphare 1mg/mL o/l

02230619 Pediapred oral sol SAV 0.0936

02245532 pms-Prednisolone oral sol PMS 0.0936prednisone 1mg tab 00598194 Apo-Prednisone 1mg tab APX 0.1072

00271373 Winpred 1mg tab VLN 0.1072prednisone 5mg tab 00312770 Apo-Prednisone 5mg tab APX 0.0401

00021695 Novo-Prednisone 5mg tab TEV 0.0401prednisone 50mg tab 00550957 Apo-Prednisone 50mg tab APX 0.1735

00232378 Novo-Prednisone 50mg tab TEV 0.1735primidone 125mg tab 00399310 Primidone 125mg tab AAP 0.0600primidone 250mg tab 00396761 Primidone 250mg tab AAP 0.0944prochlorperazine 5mg tab 00886440 Apo-Prochlorazine 5mg tab APX 0.1659prochlorperazine 10mg tab 00886432 Apo-Prochlorazine 10mg tab APX 0.2025prochlorperazine 5mg/mL inj 00789747 Prochlorperazine 5mg/mL inj SDZ 1.0450procyclidine HCl 5mg tab 00587354 pms-Procyclidine 5mg tab PMS 0.1396procyclidine HCl 0.5mg/mL o/l 00587362 pms-Procyclidine 0.5mg/mL elx PMS 0.2730propafenone 150mg tab 02243324 Apo-Propafenone 150mg tab APX 0.4227

02245372 MYLAN-Propafenone 150mg tab MYL 0.422702294559 pms-Propafenone 150mg tab PMS 0.422702343053 Propafenone 150mg tab SAS 0.422700603708 Rythmol 150mg tab ABB 0.4227

propafenone 300mg tab 02243325 Apo-Propafenone 300mg tab APX 0.745002245373 MYLAN-Propafenone 300mg tab MYL 0.745002294575 pms-Propafenone 300mg tab PMS 0.745002343061 Propafenone 300mg tab SAS 0.745000603716 Rythmol 300mg tab ABB 0.7450

propranolol 10mg tab 00402788 Apo-Propranolol 10mg tab APX 0.019200496480 Novo-Pranol 10mg tab TEV 0.0192

propranolol 20mg tab 00663719 Apo-Propranolol 20mg tab APX 0.0346

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 63 of 83

Generic Name and Strength DIN Brand MFR MRP PRPpropranolol 20mg tab 00740675 Novo-Pranol 20mg tab TEV 0.0346propranolol 40mg tab 00402753 Apo-Propranolol 40mg tab APX 0.0348

00496499 Novo-Pranol 40mg tab TEV 0.0348propranolol 80mg tab 00402761 Apo-Propranolol 80mg tab APX 0.0585

00496502 Novo-Pranol 80mg tab TEV 0.0585propranolol 120mg tab 00504335 Apo-Propranolol 120mg tab APX 0.3091quetiapine 25mg tab 02313901 Apo-Quetiapine 25mg tab APX 0.1779

02316080 CO Quetiapine 25mg tab COB 0.177902330415 Jamp-Quetiapine 25mg tab JPC 0.177902307804 MYLAN-Quetiapine 25mg tab MYL 0.177902284235 Novo-Quetiapine 25mg tab TEV 0.177902299054 phl-Quetiapine 25mg tab PHL 0.177902296551 pms-Quetiapine 25mg tab PMS 0.177902353164 Quetiapine 25mg tab SAS 0.177902313995 Sandoz Quetiapine 25mg tab SDZ 0.177902236951 Seroquel 25mg tab AZE 0.1779

quetiapine 100mg tab 02313928 Apo-Quetiapine 100mg tab APX 0.474602316099 CO Quetiapine 100mg tab COB 0.474602330423 Jamp-Quetiapine 100mg tab JPC 0.474602307812 MYLAN-Quetiapine 100mg tab MYL 0.474602284243 Novo-Quetiapine 100mg tab TEV 0.474602299062 phl-Quetiapine 100mg tab PHL 0.474602296578 pms-Quetiapine 100mg tab PMS 0.474602353172 Quetiapine 100mg tab SAS 0.474602314002 Sandoz Quetiapine 100mg tab SDZ 0.474602236952 Seroquel 100mg tab AZE 0.4746

quetiapine 200mg tab 02313936 Apo-Quetiapine 200mg tab APX 0.953002316110 CO Quetiapine 200mg tab COB 0.953002330458 Jamp-Quetiapine 200mg tab JPC 0.953002307839 MYLAN-Quetiapine 200mg tab MYL 0.953002284278 Novo-Quetiapine 200mg tab TEV 0.953002299089 phl-Quetiapine 200mg tab PHL 0.953002296594 pms-Quetiapine 200mg tab PMS 0.953002353199 Quetiapine 200mg tab SAS 0.953002314010 Sandoz Quetiapine 200mg tab SDZ 0.953002236953 Seroquel 200mg tab AZE 0.9530

quetiapine 300mg tab 02313944 Apo-Quetiapine 300mg tab APX 1.390602316129 CO Quetiapine 300mg tab COB 1.390602330466 Jamp-Quetiapine 300mg tab JPC 1.390602307847 MYLAN-Quetiapine 300mg tab MYL 1.390602284286 Novo-Quetiapine 300mg tab TEV 1.390602299097 phl-Quetiapine 300mg tab PHL 1.390602296608 pms-Quetiapine 300mg tab PMS 1.390602353202 Quetiapine 300mg tab SAS 1.390602314029 Sandoz Quetiapine 300mg tab SDZ 1.3906

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 64 of 83

Generic Name and Strength DIN Brand MFR MRP PRPquetiapine 300mg tab 02244107 Seroquel 300mg tab AZE 1.3906quinine sulfate 200mg cap 00021008 Novo-Quinine 200mg cap TEV 0.2481quinine sulfate 300mg cap 00021016 Novo-Quinine 300mg cap TEV 0.3893rabeprazole 10mg EC tab 02345579 Apo-Rabeprazole 10mg EC tab APX 0.2341

02243796 Pariet 10mg EC tab JAN 0.234102310805 pms-Rabeprazole 10mg EC tab PMS 0.234102356511 Rabeprazole EC 10mg tab SAS 0.234102298074 RAN-Rabeprazole 10mg EC tab RAN 0.234102314177 Sandoz Rabeprazole 10mg EC tab SDZ 0.234102296632 Teva-Rabeprazole-EC 10mg tab TEV 0.2341

rabeprazole 20mg EC tab 02345587 Apo-Rabeprazole 20mg EC tab APX 0.468202243797 Pariet 20mg EC tab JAN 0.468202310813 pms-Rabeprazole 20mg EC tab PMS 0.468202356538 Rabeprazole EC 20mg tab SAS 0.468202298082 RAN-Rabeprazole 20mg EC tab RAN 0.468202314185 Sandoz Rabeprazole 20mg EC tab SDZ 0.468202296640 Teva-Rabeprazole-EC 20mg tab TEV 0.4682

raloxifene 60mg tab (exception status) 02279215 Apo-Raloxifene 60mg tab APX 0.845702239028 Evista 60mg tab LIL 0.845702312298 Novo-Raloxifene 60mg tab TEV 0.845702358921 pms-Raloxifene 60mg tab PMS 0.8457

ramipril 1.25mg cap/tab 02221829 Altace 1.25mg cap SAV 0.242702251515 Apo-Ramipril 1.25mg cap APX 0.242702295482 CO Ramipril 1.25mg cap COB 0.242702331101 Jamp-Ramipril 1.25mg cap JPC 0.242702301148 MYLAN-Ramipril 1.25mg cap MYL 0.242702295369 pms-Ramipril 1.25mg cap PMS 0.242702310503 RAN-Ramipril 1.25mg cap RAN 0.242702291398 Sandoz Ramipril 1.25mg tab SDZ 0.2427

ramipril 2.5mg cap/tab 02221837 Altace 2.5mg cap SAV 0.280002251531 Apo-Ramipril 2.5mg cap APX 0.280002295490 CO Ramipril 2.5mg cap COB 0.280002331128 Jamp-Ramipril 2.5mg cap JPC 0.280002301156 MYLAN-Ramipril 2.5mg cap MYL 0.280002247917 pms-Ramipril 2.5mg cap PMS 0.280002374846 Ramipril 2.5mg cap SAS 0.280002310511 RAN-Ramipril 2.5mg cap RAN 0.280002291401 Sandoz Ramipril 2.5mg tab SDZ 0.280002247945 Teva-Ramipril 2.5mg cap TEV 0.2800

ramipril 5mg cap/tab 02221845 Altace 5mg cap SAV 0.280002251574 Apo-Ramipril 5mg cap APX 0.280002295504 CO Ramipril 5mg cap COB 0.280002331136 Jamp-Ramipril 5mg cap JPC 0.280002301164 MYLAN-Ramipril 5mg cap MYL 0.280002247918 pms-Ramipril 5mg cap PMS 0.2800

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 65 of 83

Generic Name and Strength DIN Brand MFR MRP PRPramipril 5mg cap/tab 02374854 Ramipril 5mg cap SAS 0.2800

02310538 RAN-Ramipril 5mg cap RAN 0.280002291428 Sandoz Ramipril 5mg tab SDZ 0.280002247946 Teva-Ramipril 5mg cap TEV 0.2800

ramipril 10mg cap/tab 02221853 Altace 10mg cap SAV 0.354602251582 Apo-Ramipril 10mg cap APX 0.354602295512 CO Ramipril 10mg cap COB 0.354602331144 Jamp-Ramipril 10mg cap JPC 0.354602301172 MYLAN-Ramipril 10mg cap MYL 0.354602247919 pms-Ramipril 10mg cap PMS 0.354602374862 Ramipril 10mg cap SAS 0.354602310546 RAN-Ramipril 10mg cap RAN 0.354602291436 Sandoz Ramipril 10mg tab SDZ 0.354602247947 Teva-Ramipril 10mg cap TEV 0.3546

ramipril 15mg cap 02281112 Altace 15mg cap SAV 0.813202325381 Apo-Ramipril 15mg cap APX 0.8132

ramipril 2.5mg & hydrochlorothiazide 12.5mg tab

02283131 Altace HCT 2.5/12.5mg tab SAV 0.2250

02342138 pms-Ramipril-HCTZ 2.5/12.5mg tab PMS 0.2250ramipril 5mg & hydrochlorothiazide 12.5mg tab

02283158 Altace HCT 5/12.5mg tab SAV 0.2263

02342146 pms-Ramipril-HCTZ 5/12.5mg tab PMS 0.2263ramipril 5mg & hydrochlorothiazide 25mg tab

02283174 Altace HCT 5/25mg tab SAV 0.2263

02342162 pms-Ramipril-HCTZ 5/25mg tab PMS 0.2263ramipril 10mg & hydrochlorothiazide 12.5mg tab

02283166 Altace HCT 10/12.5mg tab SAV 0.2865

02342154 pms-Ramipril-HCTZ 10/12.5mg tab PMS 0.2865ramipril 10mg & hydrochlorothiazide 25mg tab

02283182 Altace HCT 10/25mg tab SAV 0.2865

02342170 pms-Ramipril-HCTZ 10/25mg tab PMS 0.2865ranitidine 150mg tab 00733059 Apo-Ranitidine 150mg tab APX 0.1800

02248570 CO Ranitidine 150mg tab COB 0.180002367378 Myl-Ranitidine 150mg tab MYL 0.180002207761 MYLAN-Ranitidine 150mg tab MYL 0.180000828564 Novo-Ranidine 150mg tab TEV 0.180000865737 Nu-Ranit 150mg tab NXP 0.180002242453 pms-Ranitidine 150mg tab PMS 0.180002336480 RAN-Ranitidine 150mg tab RAN 0.180002353016 Ranitidine 150mg tab SAS 0.180000828823 ratio-Ranitidine 150mg tab TEV 0.180002243229 Sandoz Ranitidine 150mg tab SDZ 0.180002212331 Zantac 150mg tab GSK 0.1800

ranitidine 300mg tab 00733067 Apo-Ranitidine 300mg tab APX 0.360002248571 CO Ranitidine 300mg tab COB 0.360002367386 Myl-Ranitidine 300mg tab MYL 0.3600

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 66 of 83

Generic Name and Strength DIN Brand MFR MRP PRPranitidine 300mg tab 02207788 MYLAN-Ranitidine 300mg tab MYL 0.3600

00828556 Novo-Ranidine 300mg tab TEV 0.360000865745 Nu-Ranit 300mg tab NXP 0.360002242454 pms-Ranitidine 300mg tab PMS 0.360002336502 RAN-Ranitidine 300mg tab RAN 0.360002353024 Ranitidine 300mg tab SAS 0.360002243230 Sandoz Ranitidine 300mg tab SDZ 0.360002212358 Zantac 300mg tab GSK 0.3600

ranitidine 25mg/mL inj 02256711 Ranitidine 25mg/mL inj SDZ 1.331002212366 Zantac 25mg/mL inj GSK 1.3310

ranitidine 15mg/mL o/l 02280833 Apo-Ranitidine 15mg/mL o/l APX 0.093202242940 Novo-Ranidine 15mg/mL o/l TEV 0.093202212374 Zantac 15mg/mL o/l (discontinued) GSK 0.0932

rifampin 150mg cap 02091887 Rifadin 150mg cap SAV 0.655200393444 Rofact 150mg cap VLN 0.6552

rifampin 300mg cap 02092808 Rifadin 300mg cap SAV 1.031100343617 Rofact 300mg cap VLN 1.0311

risedronate 5mg tab (exception status) 02242518 Actonel 5mg tab WNC 1.389702298376 Teva-Risedronate 5mg tab TEV 1.3897

risedronate 30mg tab (exception status) 02239146 Actonel 30mg tab WNC 9.003302298384 Teva-Risedronate 30mg tab TEV 9.0033

risedronate 35mg tab (exception status) 02246896 Actonel 35mg tab WNC 4.130002353687 Apo-Risedronate 35mg tab APX 4.130002357984 MYLAN-Risedronate 35mg tab MYL 4.130002302209 pms-Risedronate 35mg tab PMS 4.130002319861 ratio-Risedronate 35mg tab TEV 4.130002370255 Risedronate 35mg tab SAS 4.130002327295 Sandoz-Risedronate 35mg tab SDZ 4.130002298392 Teva-Risedronate 35mg tab TEV 4.1300

risperidone 0.25mg tab 02282119 Apo-Risperidone 0.25mg tab APX 0.184002282585 CO Risperidone 0.25mg tab COB 0.184002359529 Jamp-Risperidone 0.25mg tab JPC 0.184002371766 Mar-Risperidone 0.25mg tab MAR 0.184002359790 MINT Risperidone 0.25mg tab MNT 0.184002282240 MYLAN-Risperidone 0.25mg tab MYL 0.184002282690 Novo-Risperidone 0.25mg tab TEV 0.184002258439 phl-Risperidone 0.25mg tab PHL 0.184002252007 pms-Risperidone 0.25mg tab PMS 0.184002280906 RAN-Risperidone 0.25mg tab RAN 0.184002328305 RBX-Risperidone 0.25mg tab RAN 0.184002240551 Risperdal 0.25mg tab JAN 0.184002356880 Risperidone 0.25mg tab SAS 0.184002303655 Sandoz Risperidone 0.25mg tab SDZ 0.1840

risperidone 0.5mg tab 02282127 Apo-Risperidone 0.5mg tab APX 0.3082

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 67 of 83

Generic Name and Strength DIN Brand MFR MRP PRPrisperidone 0.5mg tab 02282593 CO Risperidone 0.5mg tab COB 0.3082

02359537 Jamp-Risperidone 0.5mg tab JPC 0.308202371774 Mar-Risperidone 0.5mg tab MAR 0.308202359804 MINT Risperidone 0.5mg tab MNT 0.308202282259 MYLAN-Risperidone 0.5mg tab MYL 0.308202264188 Novo-Risperidone 0.5mg tab TEV 0.308202258447 phl-Risperidone 0.5mg tab PHL 0.308202252015 pms-Risperidone 0.5mg tab PMS 0.308202280914 RAN-Risperidone 0.5mg tab RAN 0.308202328313 RBX-Risperidone 0.5mg tab RAN 0.308202240552 Risperdal 0.5mg tab JAN 0.308202356899 Risperidone 0.5mg tab SAS 0.308202303663 Sandoz Risperidone 0.5mg tab SDZ 0.3082

risperidone 1mg tab 02282135 Apo-Risperidone 1mg tab APX 0.425802282607 CO Risperidone 1mg tab COB 0.425802359545 Jamp-Risperidone 1mg tab JPC 0.425802371782 Mar-Risperidone 1mg tab MAR 0.425802359812 MINT Risperidone 1mg tab MNT 0.425802282267 MYLAN-Risperidone 1mg tab MYL 0.425802264196 Novo-Risperidone 1mg tab TEV 0.425802258455 phl-Risperidone 1mg tab PHL 0.425802252023 pms-Risperidone 1mg tab PMS 0.425802280922 RAN-Risperidone 1mg tab RAN 0.425802328321 RBX-Risperidone 1mg tab RAN 0.425802025280 Risperdal 1mg tab JAN 0.425802356902 Risperidone 1mg tab SAS 0.425802279800 Sandoz Risperidone 1mg tab SDZ 0.4258

risperidone 2mg tab 02282143 Apo-Risperidone 2mg tab APX 0.850002282615 CO Risperidone 2mg tab COB 0.850002359553 Jamp-Risperidone 2mg tab JPC 0.850002371790 Mar-Risperidone 2mg tab MAR 0.850002359820 MINT-Risperidone 2mg tab MNT 0.850002282275 MYLAN-Risperidone 2mg tab MYL 0.850002264218 Novo-Risperidone 2mg tab TEV 0.850002258463 phl-Risperidone 2mg tab PHL 0.850002252031 pms-Risperidone 2mg tab PMS 0.850002280930 RAN-Risperidone 2mg tab RAN 0.850002328348 RBX-Risperidone 2mg tab RAN 0.850002025299 Risperdal 2mg tab JAN 0.850002356910 Risperidone 2mg tab SAS 0.850002279819 Sandoz Risperidone 2mg tab SDZ 0.8500

risperidone 3mg tab 02282151 Apo-Risperidone 3mg tab APX 1.275102282623 CO Risperidone 3mg tab COB 1.275102359561 Jamp-Risperidone 3mg tab JPC 1.275102371804 Mar-Risperidone 3mg tab MAR 1.2751

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 68 of 83

Generic Name and Strength DIN Brand MFR MRP PRPrisperidone 3mg tab 02359839 MINT Risperidone 3mg tab MNT 1.2751

02282283 MYLAN-Risperidone 3mg tab MYL 1.275102264226 Novo-Risperidone 3mg tab TEV 1.275102258471 phl-Risperidone 3mg tab PHL 1.275102252058 pms-Risperidone 3mg tab PMS 1.275102280949 RAN-Risperidone 3mg tab RAN 1.275102328364 RBX-Risperidone 3mg tab RAN 1.275102025302 Risperdal 3mg tab JAN 1.275102356929 Risperidone 3mg tab SAS 1.275102279827 Sandoz Risperidone 3mg tab SDZ 1.2751

risperidone 4mg tab 02282178 Apo-Risperidone 4mg tab APX 1.700102282631 CO Risperidone 4mg tab COB 1.700102359588 Jamp-Risperidone 4mg tab JPC 1.700102371812 Mar-Risperidone 4mg tab MAR 1.700102359847 MINT Risperidone 4mg tab MNT 1.700102282291 MYLAN-Risperidone 4mg tab MYL 1.700102264234 Novo-Risperidone 4mg tab TEV 1.700102258498 phl-Risperidone 4mg tab PHL 1.700102252066 pms-Risperidone 4mg tab PMS 1.700102280957 RAN-Risperidone 4mg tab RAN 1.700102328372 RBX-Risperidone 4mg tab RAN 1.700102025310 Risperdal 4mg tab JAN 1.700102356937 Risperidone 4mg tab SAS 1.700102279835 Sandoz Risperidone 4mg tab SDZ 1.7001

risperidone ODT 1mg tab 02291789 pms-Risperidone ODT 1mg tab PMS 0.772702247705 Risperdal M-tab (1mg) JAN 0.7727

risperidone ODT 2mg tab 02291797 pms-Risperidone ODT 2mg tab PMS 1.52802247706 Risperdal M-tab (2mg) JAN 1.5280

risperidone ODT 3mg tab 02370697 pms-Risperidone ODT 3mg tab PMS 2.291302268086 Risperdal M-tab (3mg) JAN 2.2913

risperidone ODT 4mg tab 02370700 pms-Risperidone ODT 4mg tab PMS 3.063802268094 Risperdal M-tab (4mg) JAN 3.0638

risperidone 1mg/mL o/l 02280396 Apo-Risperidone 1mg/mL o/l APX 0.480202279266 pms-Risperidone 1mg/mL o/l PMS 0.480202236950 Risperdal 1mg/mL o/l JAN 0.4802

rituximab 10mg/mL inj (exception status) 02241927 Rituxan 10mg/mL inj HLR 55.6063rivastigmine 1.5mg cap (exception status) 02336715 Apo-Rivastigmine 1.5mg cap APX 0.9121

02242115 Exelon 1.5mg cap NVR 0.912102332809 MYLAN-Rivastigmine 1.5mg cap MYL 0.912102305984 Novo-Rivastigmine 1.5mg cap TEV 0.912102306034 pms-Rivastigmine 1.5mg cap PMS 0.912102311283 ratio-Rivastigmine 1.5mg cap TEV 0.912102324563 Sandoz Rivastigmine 1.5mg cap SDZ 0.9121

rivastigmine 3mg cap (exception status) 02336723 Apo-Rivastigmine 3mg cap APX 0.9121

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 69 of 83

Generic Name and Strength DIN Brand MFR MRP PRPrivastigmine 3mg cap (exception status) 02242116 Exelon 3mg cap NVR 0.9121

02332817 MYLAN-Rivastigmine 3mg cap MYL 0.912102305992 Novo-Rivastigmine 3mg cap TEV 0.912102306042 pms-Rivastigmine 3mg cap PMS 0.912102311291 ratio-Rivastigmine 3mg cap TEV 0.912102324571 Sandoz Rivastigmine 3mg cap SDZ 0.9121

rivastigmine 4.5mg cap (exception status) 02336731 Apo-Rivastigmine 4.5mg cap APX 0.912102242117 Exelon 4.5mg cap NVR 0.912102332825 MYLAN-Rivastigmine 4.5mg cap MYL 0.912102306018 Novo-Rivastigmine 4.5mg cap TEV 0.912102306050 pms-Rivastigmine 4.5mg cap PMS 0.912102311305 ratio-Rivastigmine 4.5mg cap TEV 0.912102324598 Sandoz Rivastigmine 4.5mg cap SDZ 0.9121

rivastigmine 6mg cap (exception status) 02336758 Apo-Rivastigmine 6mg cap APX 0.912102242118 Exelon 6mg cap NVR 0.912102332833 MYLAN-Rivastigmine 6mg cap MYL 0.912102306026 Novo-Rivastigmine 6mg cap TEV 0.912102306069 pms-Rivastigmine 6mg cap PMS 0.912102311313 ratio-Rivastigmine 6mg cap TEV 0.912102324601 Sandoz Rivastigmine 6mg cap SDZ 0.9121

rizatriptan 5mg tab (exception status) 02379651 Mar-Rizatriptan 5mg tab MAR 5.187002240520 Maxalt 5mg tab FRS 5.1870

rizatriptan 10mg tab (exception status) 02379678 Mar-Rizatriptan 10mg tab MAR 5.187002240521 Maxalt 10mg tab FRS 5.1870

rizatriptan ODT 5mg tab (exception status) 02374730 CO Rizatriptan ODT 5mg tab COB 5.187002240518 Maxalt RPD 5mg wafers FRS 5.187002379198 MYLAN-Rizatriptan ODT 5mg tab MYL 5.187002351870 Sandoz Rizatriptan ODT 5mg tab SDZ 5.1870

rizatriptan ODT 10mg tab (exception status)

02374749 CO Rizatriptan ODT 10mg tab COB 5.1870

02240519 Maxalt RPD 10mg wafers FRS 5.187002379201 MYLAN-Rizatriptan ODT 10mg tab MYL 5.187002351889 Sandoz Rizatriptan ODT 10mg tab SDZ 5.1870

ropinirole 0.25mg tab 02316846 CO Ropinirole 0.25mg tab COB 0.099302326590 pms-Ropinirole 0.25mg tab PMS 0.099302232565 ReQuip 0.25mg tab GSK 0.099302353040 Ropinirole 0.25mg tab SAS 0.0993

ropinirole 1mg tab 02316854 CO Ropinirole 1mg tab COB 0.397402326612 pms-Ropinirole 1mg tab PMS 0.397402232567 ReQuip 1mg tab GSK 0.397402353059 Ropinirole 1mg tab SAS 0.3974

ropinirole 2mg tab 02316862 CO Ropinirole 2mg tab COB 0.437102326620 pms-Ropinirole 2mg tab PMS 0.437102232568 ReQuip 2mg tab GSK 0.437102353067 Ropinirole 2mg tab SAS 0.4371

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 70 of 83

Generic Name and Strength DIN Brand MFR MRP PRPropinirole 5mg tab 02316870 CO Ropinirole 5mg tab COB 1.2034

02326639 pms-Ropinirole 5mg tab PMS 1.203402232569 ReQuip 5mg tab NVR 1.203402353075 Ropinirole 5mg tab SAS 1.2034

rosuvastatin 10mg tab 02337983 Apo-Rosuvastatin 10mg tab APX 0.476002339773 CO Rosuvastatin 10mg tab COB 0.476002247162 Crestor 10mg tab AZE 0.476002381273 MYLAN-Rosuvastatin 10mg tab MYL 0.476002378531 pms-Rosuvastatin 10mg tab PMS 0.476002382652 RAN-Rosuvastatin 10mg tab RAN 0.476002338734 Sandoz Rosuvastatin 10mg tab SDZ 0.476002354616 Teva-Rosuvastatin 10mg tab TEV 0.4760

rosuvastatin 20mg tab 02337991 Apo-Rosuvastatin 20mg tab APX 0.595002339781 CO Rosuvastatin 20mg tab COB 0.595002247163 Crestor 20mg tab AZE 0.595002381281 MYLAN-Rosuvastatin 20mg tab MYL 0.595002378558 pms-Rosuvastatin 20mg tab PMS 0.595002382660 RAN-Rosuvastatin 20mg tab RAN 0.595002338742 Sandoz Rosuvastatin 20mg tab SDZ 0.595002354624 Teva-Rosuvastatin 20mg tab TEV 0.5950

rosuvastatin 40mg tab 02338009 Apo-Rosuvastatin 40mg tab APX 0.696502339803 CO Rosuvastatin 40mg tab COB 0.696502247164 Crestor 40mg tab AZE 0.696502381303 MYLAN-Rosuvastatin 40mg tab MYL 0.696502378566 pms-Rosuvastatin 40mg tab PMS 0.696502382679 RAN-Rosuvastatin 40mg tab RAN 0.696502338750 Sandoz Rosuvastatin 40mg tab SDZ 0.696502354632 Teva-Rosuvastatin 40mg tab TEV 0.6965

salbutamol 100mcg/dose oral inh 02232570 Airomir 100mcg/dose oral inh MDS 0.032502245669 Apo-Salvent CFC Free 100mcg/dose oral inh APX 0.032502241497 Ventolin HFA 100mcg/dose oral inh GSK 0.0325

salbutamol 5mg/mL inh sol (exception status)

02069571 pms-Salbutamol 5mg/mL inh sol 10mL PMS 0.3511

00860808 ratio-Salbutamol 5mg/mL inh sol 10mL TEV 0.351102154412 Sandoz Salbutamol 5mg/mL inh sol 10mL SDZ 0.351102213486 Ventolin 5mg/mL inh sol 10mL GSK 0.3511

salbutamol 2mg tab 02146843 Apo-Salvent 2mg tab APX 0.1274salbutamol 4mg tab 02146851 Apo-Salvent 4mg tab APX 0.2134salbutamol 0.5mg/mL unit dose inh sol (exception status)

02208245 pms-Salbutamol 0.5mg/mL UD inh sol PMS 0.0293

02239365 ratio-Salbutamol 0.5mg/mL UD inh sol TEV 0.0293salbutamol 1mg/mL unit dose inh sol (exception status)

01926934 MYLAN-Salbutamol 1mg/mL UD inh sol MYL 0.0585

02208229 pms-Salbutamol 1mg/mL UD inh sol PMS 0.058501986864 ratio-Salbutamol 1mg/mL UD inh sol TEV 0.0585

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 71 of 83

Generic Name and Strength DIN Brand MFR MRP PRPsalbutamol 1mg/mL unit dose inh sol (exception status)

02213419 Ventolin 1mg/mL UD inh sol GSK 0.0585

salbutamol 2mg/mL unit dose inh sol (exception status)

02173360 MYLAN-Salbutamol 2mg/mL UD inh sol MYL 0.1170

02208237 pms-Salbutamol 2mg/mL UD inh sol PMS 0.117002239366 ratio-Salbutamol 2mg/mL UD inh sol TEV 0.117002213427 Ventolin 2mg/mL UD inh sol GSK 0.1170

scopolamine 20mg/mL inj 02229868 Hyoscine Butylbromide 20mg/mL inj SDZ 4.5150selegiline 5mg tab 02230641 Apo-Selegiline 5mg tab APX 0.7030

02231036 MYLAN-Selegiline 5mg tab MYL 0.703002068087 Novo-Selegiline 5mg tab TEV 0.703002230717 Nu-Selegiline 5mg tab NXP 0.7030

sertraline 25mg cap 02238280 Apo-Sertraline 25mg cap APX 0.281402287390 CO Sertraline 25mg cap COB 0.281402273683 GD-Sertraline 25mg cap GMD 0.281402242519 MYLAN-Sertraline 25mg cap MYL 0.281402240485 Novo-Sertraline 25mg cap TEV 0.281402245824 phl-Sertraline 25mg cap PHL 0.281402244838 pms-Sertraline 25mg cap PMS 0.281402374552 RAN-Sertraline 25mg cap RAN 0.281402245159 Sandoz Sertraline 25mg cap SDZ 0.281402353520 Sertraline 25mg cap SAS 0.281402132702 Zoloft 25mg cap PFI 0.2814

sertraline 50mg cap 02238281 Apo-Sertraline 50mg cap APX 0.562802287404 CO Sertraline 50mg cap COB 0.562802273691 GD-Sertraline 50mg cap GMD 0.562802242520 MYLAN-Sertraline 50mg cap MYL 0.562802240484 Novo-Sertraline 50mg cap TEV 0.562802245825 phl-Sertraline 50mg cap PHL 0.562802244839 pms-Sertraline 50mg cap PMS 0.562802374560 RAN-Sertraline 50mg cap RAN 0.562802245160 Sandoz Sertraline 50mg cap SDZ 0.562802353539 Sertraline 50mg cap SAS 0.562801962817 Zoloft 50mg cap PFI 0.5628

sertraline 100mg cap 02238282 Apo-Sertraline 100mg cap APX 0.589802287412 CO Sertraline 100mg cap COB 0.589802273705 GD-Sertraline 100mg cap GMD 0.589802242521 MYLAN-Sertraline 100mg cap MYL 0.589802245826 phl-Sertraline 100mg cap PHL 0.589802244840 pms-Sertraline 100mg cap PMS 0.589802374579 RAN-Sertraline 100mg cap RAN 0.589802245161 Sandoz Sertraline 100mg cap SDZ 0.589802353547 Sertraline 100mg cap SAS 0.589802240481 Teva-Sertraline 100mg cap TEV 0.589801962779 Zoloft 100mg cap PFI 0.5898

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 72 of 83

Generic Name and Strength DIN Brand MFR MRP PRPsildenafil 20mg tab 02319500 ratio-Sildenafil-R 20mg tab TEV 7.4399

02279401 Revatio 20mg tab PFI 7.4399simvastatin 5mg tab 02247011 Apo-Simvastatin 5mg tab APX 0.3600

02248103 CO Simvastatin 5mg tab COB 0.360002331020 Jamp-Simvastatin 5mg tab JPC 0.360002375036 Mar-Simvastatin 5mg tab MAR 0.360002372932 MINT-Simvastatin 5mg tab MNT 0.360002246582 MYLAN-Simvastatin 5mg tab MYL 0.360002281546 phl-Simvastatin 5mg tab PHL 0.360002269252 pms-Simvastatin 5mg tab PMS 0.360002329131 RAN-Simvastatin 5mg tab RAN 0.360002284723 Simvastatin 5mg tab SAS 0.360002250144 Teva-Simvastatin 5mg tab TEV 0.360000884324 Zocor 5mg tab FRS 0.3600

simvastatin 10mg tab 02247012 Apo-Simvastatin 10mg tab APX 0.708102248104 CO Simvastatin 10mg tab COB 0.708102331039 Jamp-Simvastatin 10mg tab JPC 0.708102375044 Mar-Simvastatin 10mg tab MAR 0.708102372940 MINT-Simvastatin 10mg tab MNT 0.708102246583 MYLAN-Simvastatin 10mg tab MYL 0.708102250152 Novo-Simvastatin 10mg tab TEV 0.708102281554 phl-Simvastatin 10mg tab PHL 0.708102269260 pms-Simvastatin 10mg tab PMS 0.708102329158 RAN-Simvastatin 10mg tab RAN 0.708102247828 Sandoz Simvastatin 10mg tab SDZ 0.708102284731 Simvastatin 10mg tab SAS 0.708100884332 Zocor 10mg tab FRS 0.7081

simvastatin 20mg tab 02247013 Apo-Simvastatin 20mg tab APX 0.875102248105 CO Simvastatin 20mg tab COB 0.875102331047 Jamp-Simvastatin 20mg tab JPC 0.875102375052 Mar-Simvastatin 20mg tab MAR 0.875102372959 MINT-Simvastatin 20mg tab MNT 0.875102246737 MYLAN-Simvastatin 20mg tab MYL 0.875102250160 Novo-Simvastatin 20mg tab TEV 0.875102281562 phl-Simvastatin 20mg tab PHL 0.875102269279 pms-Simvastatin 20mg tab PMS 0.875102329166 RAN-Simvastatin 20mg tab RAN 0.875102247830 Sandoz Simvastatin 20mg tab SDZ 0.875102284758 Simvastatin 20mg tab SAS 0.875100884340 Zocor 20mg tab FRS 0.8751

simvastatin 40mg tab 02247014 Apo-Simvastatin 40mg tab APX 0.875102248106 CO Simvastatin 40mg tab COB 0.875102331055 Jamp-Simvastatin 40mg tab JPC 0.875102375060 Mar-Simvastatin 40mg tab MAR 0.875102372967 MINT-Simvastatin 40mg tab MNT 0.8751

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 73 of 83

Generic Name and Strength DIN Brand MFR MRP PRPsimvastatin 40mg tab 02246584 MYLAN-Simvastatin 40mg tab MYL 0.8751

02281570 phl-Simvastatin 40mg tab PHL 0.875102269287 pms-Simvastatin 40mg tab PMS 0.875102329174 RAN-Simvastatin 40mg tab RAN 0.875102247831 Sandoz Simvastatin 40mg tab SDZ 0.875102284766 Simvastatin 40mg tab SAS 0.875102250179 Teva-Simvastatin 40mg tab TEV 0.875100884359 Zocor 40mg tab FRS 0.8751

simvastatin 80mg tab 02247015 Apo-Simvastatin 80mg tab APX 0.875102248107 CO Simvastatin 80mg tab COB 0.875102331063 Jamp-Simvastatin 80mg tab JPC 0.875102375079 Mar-Simvastatin 80mg tab MAR 0.875102246585 MYLAN-Simvastatin 80mg tab MYL 0.875102281589 phl-Simvastatin 80mg tab PHL 0.875102269295 pms-Simvastatin 80mg tab PMS 0.875102329182 RAN-Simvastatin 80mg tab RAN 0.875102247833 Sandoz Simvastatin 80mg tab SDZ 0.875102284774 Simvastatin 80mg tab SAS 0.875102250187 Teva-Simvastatin 80mg tab TEV 0.875102240332 Zocor 80mg tab FRS 0.8751

sodium aurothiomalate 10mg/mL inj 01927620 Myochrysine 10mg/mL inj SAV 9.660002245456 Sodium Aurothiomalate 10mg/mL inj SDZ 9.6600

sodium aurothiomalate 25mg/mL inj 02245457 Sodium Aurothiomalate 25mg/mL inj SDZ 11.7100sodium aurothiomalate 50mg/mL inj 01927604 Myochrysine 50mg/mL inj SAV 18.2100

02245458 Sodium Aurothiomalate 50mg/mL inj SDZ 18.2100sodium chloride, hypertonic 5% oph sol 00750824 MURO-128 5% oph sol BSH 0.5633

02245735 Sandoz Sodium Chloride 5% oph sol SDZ 0.5633sorafenib 200mg tab (exception status) 02284227 Nexavar 200mg tab BAY 48.8928sotalol 80mg tab 02210428 Apo-Sotalol 80mg tab APX 0.2966

02270625 CO Sotalol 80mg tab COB 0.296602229778 MYLAN-Sotalol 80mg tab MYL 0.296602231181 Novo-Sotalol 80mg tab TEV 0.296602200996 Nu-Sotalol 80mg tab NXP 0.296602238326 pms-Sotalol 80mg tab PMS 0.296602084228 ratio-Sotalol 80mg tab TEV 0.296602257831 Sandoz Sotalol 80mg tab SDZ 0.5932

sotalol 160mg tab 02167794 Apo-Sotalol 160mg tab APX 0.227302270633 CO Sotalol 160mg tab COB 0.227302229779 MYLAN-Sotalol 160mg tab MYL 0.227302231182 Novo-Sotalol 160mg tab TEV 0.227302163772 Nu-Sotalol 160mg tab NXP 0.227302238327 pms-Sotalol 160mg tab PMS 0.227302084236 ratio-Sotalol 160mg tab TEV 0.2273

spironolactone 25mg tab 00028606 Aldactone 25mg tab PFI 0.1057

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 74 of 83

Generic Name and Strength DIN Brand MFR MRP PRPspironolactone 25mg tab 00613215 Novo-Spiroton 25mg tab TEV 0.1057spironolactone 100mg tab 00285455 Aldactone 100mg tab PFI 0.2461

00613223 Novo-Spiroton 100mg tab TEV 0.2461sucralfate 1g tab 02125250 Apo-Sucralfate 1g tab APX 0.1924

02045702 Novo-Sucralate 1g tab TEV 0.192402134829 Nu-Sucralfate 1g tab NXP 0.192402100622 Sulcrate 1g tab AXC 0.1924

sufentanil citrate 50mcg/mL inj 02244147 Sufentanil Citrate 50mcg/mL inj SDZ 6.8300sulfamethoxazole 400mg & trimethoprim 80mg tab

00445274 Apo-Sulfatrim 400/80mg tab APX 0.0482

00510637 Novo-Trimel 400/80mg tab TEV 0.048200865710 Nu-Cotrimox 400/80mg tab NXP 0.0482

sulfamethoxazole 800mg & trimethoprim 160mg tab

00445282 Apo-Sulfatrim 800/160mg DS tab APX 0.1221

00510645 Novo-Trimel 800/160mg DS tab TEV 0.122100865729 Nu-Cotrimox 800/160mg DS tab NXP 0.1221

sulfamethoxazole 40mg & trimethoprim 8mg/mL o/l

00726540 Novo-Trimel 40/8mg susp TEV 0.0929

sulfinpyrazone 200mg tab 00441767 Sulfinpyrazone 200mg tab AAP 0.3252sulindac 150mg tab 00778354 Apo-Sulin 150mg tab APX 0.3500

00745588 Novo-Sundac 150mg tab TEV 0.350002042576 Nu-Sulindac 150mg tab NXP 0.3500

sulindac 200mg tab 00778362 Apo-Sulin 200mg tab APX 0.350000745596 Novo-Sundac 200mg tab TEV 0.350002042584 Nu-Sulindac 200mg tab NXP 0.3500

sumatriptan 50mg tab (exception status) 02268388 Apo-Sumatriptan 50mg tab APX 7.135002257890 CO Sumatriptan 50mg tab COB 7.135002212153 Imitrex DF 50mg tab GSK 7.135002268914 MYLAN-Sumatriptan 50mg tab MYL 7.135002286823 Novo-Sumatriptan DF 50mg tab TEV 7.135002256436 pms-Sumatriptan 50mg tab PMS 7.135002263025 Sandoz Sumatriptan 50mg tab SDZ 7.135002286521 Sumatriptan 50mg tab SAS 7.1350

sumatriptan 100mg tab (exception status) 02268396 Apo-Sumatriptan 100mg tab APX 7.860002257904 CO Sumatriptan 100mg tab COB 7.860002212161 Imitrex DF 100mg tab GSK 7.860002268922 MYLAN-Sumatriptan 100mg tab MYL 7.860002239367 Novo-Sumatriptan 100mg tab TEV 7.860002286831 Novo-Sumatriptan DF 100mg tab TEV 7.860002256444 pms-Sumatriptan 100mg tab PMS 7.860002263033 Sandoz Sumatriptan 100mg tab SDZ 7.860002286548 Sumatriptan 100mg tab SAS 7.8600

sumatriptan 12mg/mL inj (exception status)

02212188 Imitrex 6mg/0.5mL inj GSK 61.7200

02361698 Sumatriptan SUN 6mg/0.5mL inj TAR 61.7200

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 75 of 83

Generic Name and Strength DIN Brand MFR MRP PRPsunitinib 25mg cap (exception status) 02280809 Sutent 25mg cap PFI 137.0402sunitinib 50mg cap 02280817 Sutent 50mg cap PFI 274.0807tamoxifen citrate 10mg tab 00812404 Apo-Tamox 10mg tab APX 0.1750

02088428 MYLAN-Tamoxifen 10mg tab MYL 0.175000851965 Novo-Tamoxifen 10mg tab TEV 0.1750

tamoxifen citrate 20mg tab 00812390 Apo-Tamox 20mg tab APX 0.350002089858 MYLAN-Tamoxifen 20mg tab MYL 0.350002048485 Nolvadex-D 20mg tab AZE 0.350000851973 Novo-Tamoxifen 20mg tab TEV 0.3500

telmisartan 40mg tab 02240769 Micardis 40mg tab BOE 0.395402376717 MYLAN-Telmisartan 40mg tab MYL 0.395402375958 Sandoz Telmisartan 40mg tab SDZ 0.395402320177 Teva-Telmisartan 40mg tab TEV 0.3954

telmisartan 80mg tab 02240770 Micardis 80mg tab BOE 0.395402376725 MYLAN-Telmisartan 80mg tab MYL 0.395402375966 Sandoz Telmisartan 80mg tab SDZ 0.395402320185 Teva-Telmisartan 80mg tab TEV 0.3954

telmisartan 80mg & hydrochlorothiazide 12.5mg tab

02244344 Micardis Plus 80/12.5mg tab BOE 0.3954

02373564 MYLAN-Telmisartan HCTZ 80/12.5mg tab MYL 0.395402330288 Teva-Telmisartan HCTZ 80/12.5mg tab TEV 0.3954

telmisartan 80mg & hydrochlorothiazide 25mg tab

02318709 Micardis Plus 80/25mg tab BOE 0.3954

02373572 MYLAN-Telmisartan HCTZ 80/25mg tab MYL 0.395402379252 Teva-Telmisartan HCTZ 80/25mg tab TEV 0.3954

temazepam 15mg cap 02225964 Apo-Temazepam 15mg cap APX 0.069902244814 CO Temazepam 15mg cap COB 0.069902230095 Novo-Temazepam 15mg cap TEV 0.069900604453 Restoril 15mg cap ORX 0.0699

temazepam 30mg cap 02225972 Apo-Temazepam 30mg cap APX 0.084702244815 CO Temazepam 30mg cap COB 0.084702230102 Novo-Temazepam 30mg cap TEV 0.084700604461 Restoril 30mg cap ORX 0.0847

temozolomide 100mg cap (exception status)

02241095 Temodal 100mg cap SCH 160.9560

temozolomide 140mg cap (exception status)

02312794 Temodal 140mg cap SCH 225.3400

temozolomide 250mg cap (exception status)

02241096 Temodal 250mg cap SCH 402.3800

tenoxicam 20mg tab 02230661 Tenoxicam 20mg tab AAP 0.7000terazosin 1mg tab 02234502 Apo-Terazosin 1mg tab APX 0.2616

00818658 Hytrin 1mg tab ABB 0.261602233047 Nu-Terazosin 1mg tab NXP 0.261602243518 pms-Terazosin 1mg tab PMS 0.261602218941 ratio-Terazosin 1mg tab TEV 0.2616

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 76 of 83

Generic Name and Strength DIN Brand MFR MRP PRPterazosin 1mg tab 02350475 Terazosin 1mg tab SAS 0.2616

02230805 Teva-Terazosin 1mg tab TEV 0.2616terazosin 2mg tab 02234503 Apo-Terazosin 2mg tab APX 0.3325

00818682 Hytrin 2mg tab ABB 0.332502233048 Nu-Terazosin 2mg tab NXP 0.332502243519 pms-Terazosin 2mg tab PMS 0.332502218968 ratio-Terazosin 2mg tab TEV 0.332502350483 Terazosin 2mg tab SAS 0.332502230806 Teva-Terazosin 2mg tab TEV 0.3325

terazosin 5mg tab 02234504 Apo-Terazosin 5mg tab APX 0.451500818666 Hytrin 5mg tab ABB 0.451502233049 Nu-Terazosin 5mg tab NXP 0.451502243520 pms-Terazosin 5mg tab PMS 0.451502218976 ratio-Terazosin 5mg tab TEV 0.451502350491 Terazosin 5mg tab SAS 0.451502230807 Teva-Terazosin 5mg tab TEV 0.4515

terazosin 10mg tab 02234505 Apo-Terazosin 10mg tab APX 0.660900818674 Hytrin 10mg tab ABB 0.660902233050 Nu-Terazosin 10mg tab NXP 0.660902243521 pms-Terazosin 10mg tab PMS 0.660902218984 ratio-Terazosin 10mg tab TEV 0.660902350505 Terazosin 10mg tab SAS 0.660902230808 Teva-Terazosin 10mg tab TEV 0.6609

terbinafine 250mg tab (exception status) 02239893 Apo-Terbinafine 250mg tab APX 1.852602320134 Auro-Terbinafine 250mg tab ARO 1.852602254727 CO Terbinafine 250mg tab COB 1.852602031116 Lamisil 250mg tab NVR 1.852602242503 MYLAN-Terbinafine 250mg tab MYL 1.852602240346 Novo-Terbinafine 250mg tab TEV 1.852602294273 pms-Terbinafine 250mg tab PMS 1.852602262177 Sandoz Terbinafine 250mg tab SDZ 1.852602353121 Terbinafine 250mg tab SAS 1.8526

testosterone cypionate 100mg/mL inj 00030783 Depo-Testosterone 100mg/mL inj PFI 2.358002246063 Testosterone Cypionate 100mg/mL inj SDZ 2.3580

testosterone undercanoate 40mg cap 00782327 Andriol 40mg cap SCH 0.705002322498 pms-Testosterone 40mg cap PMS 0.7050

tetracycline 250mg cap 00580929 Tetracycline 250mg cap AAP 0.0713theophylline 200mg SR tab 02230086 Novo-Theophyl SR 200mg tab TEV 0.1350theophylline 300mg SR tab 02230087 Novo-Theophyl SR 300mg tab TEV 0.1817thiamine (vit B1) 100mg/mL inj 02193221 Thiamiject 100mg/mL inj (OMG) OMG 1.1880

02243525 Thiamine 100mg/mL inj CYI 1.1880tiaprofenic acid 200mg tab 02136112 Apo-Tiaprofenic 200mg tab APX 0.2333

02179679 Novo-Tiaprofenic 200mg tab TEV 0.2333tiaprofenic acid 300mg tab 02136120 Apo-Tiaprofenic 300mg tab APX 0.3257

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 77 of 83

Generic Name and Strength DIN Brand MFR MRP PRPtiaprofenic acid 300mg tab 02179687 Novo-Tiaprofenic 300mg tab TEV 0.3257

02146886 Nu-Tiaprofenic 300mg tab NXP 0.3257ticlopidine 250mg tab (exception status) 02237701 Apo-Ticlopidine 250mg tab APX 0.4398

02239744 MYLAN-Ticlopidine 250mg tab MYL 0.439802236848 Novo-Ticlopidine 250mg tab TEV 0.439802243587 Sandoz Ticlopidine 250mg tab (discontinued) SDZ 0.439802343045 Ticlopidine 250mg tab SAS 0.4398

timolol maleate 0.25% oph gel 02242275 Timolol Maleate-EX 0.25% oph gel SDZ 2.592002171880 Timoptic-XE 0.25% oph gel FRS 2.5920

timolol maleate 0.5% oph gel 02242276 Timolol Maleate-EX 0.5% oph gel SDZ 2.730002171899 Timoptic-XE 0.5% oph gel FRS 2.7300

timolol maleate 0.25% oph sol 00755826 Apo-Timop 0.25% oph sol APX 0.967800893773 MYLAN-Timolol 0.25% oph sol (discontinued) MYL 0.967802083353 pms-Timolol 0.25% oph sol PMS 0.967802166712 Sandoz Timolol 0.25% oph sol SDZ 0.9678

timolol maleate 0.5% oph sol 00755834 Apo-Timop 0.5% oph sol APX 1.275400893781 MYLAN-Timolol 0.5% oph sol (discontinued) MYL 1.275402083345 pms-Timolol 0.5% oph sol PMS 1.275402166720 Sandoz Timolol 0.5% oph sol SDZ 1.275400451207 Timoptic 0.5% oph sol FRS 1.2754

timolol maleate 5mg tab 00755842 Apo-Timol 5mg tab APX 0.164901947796 Novo-Timol 5mg tab TEV 0.164902044609 Nu-Timolol 5mg tab NXP 0.1649

timolol maleate 10mg tab 00755850 Apo-Timol 10mg tab APX 0.257201947818 Novo-Timol 10mg tab TEV 0.257202044617 Nu-Timolol 10mg tab NXP 0.2572

timolol maleate 20mg tab 00755869 Apo-Timol 20mg tab APX 0.500501947826 Novo-Timol 20mg tab TEV 0.5005

tizanidine 4mg tab (exception status) 02259893 Apo-Tizanidine 4mg tab APX 0.368602272059 MYLAN-Tizanidine 4mg tab MYL 0.368602239170 Zanaflex 4mg tab SQI 0.3686

tobramycin 10mg/mL inj 02241209 Tobramycin 10mg/mL inj SDZ 2.3150tobramycin 40mg/mL inj 02241210 Tobramycin 40mg/mL inj SDZ 3.2100tobramycin 0.3% oph sol 02239577 pms-Tobramycin 0.3% oph sol (discontinued) PMS 0.5948

02241755 Sandoz Tobramycin 0.3% oph sol SDZ 0.594800513962 Tobrex 0.3% oph sol ALC 0.5948

tolbutamide 500mg tab 00312762 Tolbutamide 500mg tab AAP 0.1182topiramate 25mg tab (exception status) 02279614 Apo-Topiramate 25mg tab APX 0.4379

02345803 Auro-Topiramate 25mg tab ARO 0.437902287765 CO Topiramate 25mg tab COB 0.437902315645 MINT-Topiramate 25mg tab MNT 0.437902263351 MYLAN-Topiramate 25mg tab MYL 0.437902248860 Novo-Topiramate 25mg tab TEV 0.437902271184 phl-Topiramate 25mg tab PHL 0.4379

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 78 of 83

Generic Name and Strength DIN Brand MFR MRP PRPtopiramate 25mg tab (exception status) 02262991 pms-Topiramate 25mg tab PMS 0.4379

02260050 SandozTopiramate 25mg tab SDZ 0.437902230893 Topamax 25mg tab JAN 0.437902356856 Topiramate 25mg tab SAS 0.437902325136 Zym-Topiramate 25mg tab ZYM 0.4379

topiramate 100mg tab (exception status) 02279630 Apo-Topiramate 100mg tab APX 0.830002345838 Auro-Topiramate 100mg tab ARO 0.830002287773 CO Topiramate 100mg tab COB 0.830002315653 MINT-Topiramate 100mg tab MNT 0.830002263378 MYLAN-Topiramate 100mg tab MYL 0.830002248861 Novo-Topiramate 100mg tab TEV 0.830002271192 phl-Topiramate 100mg tab PHL 0.830002263009 pms-Topiramate 100mg tab PMS 0.830002260069 Sandoz Topiramate 100mg tab SDZ 0.830002230894 Topamax 100mg tab JAN 0.830002356864 Topiramate 100mg tab SAS 0.830002325144 Zym-Topiramate 100mg tab ZYM 0.8300

topiramate 200mg tab (exception status) 02279649 Apo-Topiramate 200mg tab APX 1.239502345846 Auro-Topiramate 200mg tab ARO 1.239502287781 CO Topiramate 200mg tab COB 1.239502315661 MINT-Topiramate 200mg tab MNT 1.239502263386 MYLAN-Topiramate 200mg tab MYL 1.239502248862 Novo-Topiramate 200mg tab TEV 1.239502271206 phl-Topiramate 200mg tab PHL 1.239502263017 pms-Topiramate 200mg tab PMS 1.239502267837 Sandoz Topiramate 200mg tab SDZ 1.239502230896 Topamax 200mg tab JAN 1.239502356872 Topiramate 200mg tab SAS 1.239502325152 Zym-Topiramate 200mg tab ZYM 1.2395

trazodone 50mg tab 02147637 Apo-Trazodone 50mg tab APX 0.077502165384 Nu-Trazodone 50mg tab NXP 0.077502236941 phl-Trazodone 50mg tab PHL 0.077501937227 pms-Trazodone 50mg tab PMS 0.077502144263 Teva-Trazodone 50mg tab TEV 0.077502348772 Trazodone 50mg tab SAS 0.0775

trazodone 100mg tab 02147645 Apo-Trazodone 100mg tab APX 0.138502165392 Nu-Trazodone 100mg tab NXP 0.138502236942 phl-Trazodone 100mg tab PHL 0.138501937235 pms-Trazodone 100mg tab PMS 0.138502144271 Teva-Trazodone 100mg tab TEV 0.138502348780 Trazodone 100mg tab SAS 0.1385

trazodone 150mg tab 02147653 Apo-Trazodone 150mg tab APX 0.203502165406 Nu-Trazodone-D 150mg tab NXP 0.203502144298 Teva-Trazodone 150mg tab TEV 0.203502348799 Trazodone 150mg tab SAS 0.2035

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 79 of 83

Generic Name and Strength DIN Brand MFR MRP PRPtriamcinolone acetonide 0.1% oral paste 01964054 Oracort 0.1% Paste TAR 0.9267triamcinolone 10mg/mL inj 01999761 Kenalog-10 10mg/mL inj WSQ 2.6760

02229540 Triamcinolone 10mg/mL inj SDZ 2.6760triamcinolone 40mg/mL inj 01999869 Kenalog-40 40mg/mL inj WSQ 4.7700

01977563 Triamcinolone 40mg/mL inj CYI 4.770002229550 Triamcinolone 40mg/mL inj SDZ 4.7700

trifluoperazine 1mg tab 00345539 Trifluoperazine 1mg tab AAP 0.1454trifluoperazine 2mg tab 00312754 Trifluoperazine 2mg tab AAP 0.1908trifluoperazine 5mg tab 00312746 Trifluoperazine 5mg tab AAP 0.2526trifluoperazine 10mg tab 00326836 Trifluoperazine 10mg tab AAP 0.3028trifluridine 1% oph sol 02248529 Sandoz Trifluridine 1% oph sol SDZ 3.0387

00687456 Viroptic 1% oph sol THR 3.0387trimebutine 200mg tab 00803499 Modulon 200mg tab AXC 0.5680

02245664 Trimebutine 200mg tab AAP 0.5680trimethoprim 100mg tab 02243116 Trimethoprim 100mg tab AAP 0.2785trimethoprim 200mg tab 02243117 Trimethoprim 200mg tab AAP 0.5722trimipramine 12.5mg tab 00740799 Trimipramine 12.5mg tab AAP 0.2339trimipramine 25mg tab 00740802 Trimipramine FCT 25mg tab AAP 0.3012trimipramine 50mg tab 00740810 Trimipramine 50mg tab AAP 0.5896trimipramine 75mg cap 02070987 Trimipramine 75mg cap AAP 0.7936trimipramine 100mg tab 00740829 Trimipramine 100mg tab AAP 1.0061tryptophan 500mg tab (exception status) 02248538 Apo-Tryptophan 500mg tab APX 0.3563

02240333 ratio-Tryptophan 500mg tab TEV 0.356302029456 Tryptan 500mg tab VLN 0.3563

tryptophan 1g tab (exception status) 02248539 Apo-Tryptophan 1g tab APX 0.712602237250 ratio-Tryptophan 1g tab TEV 0.712600654531 Tryptan 1g tab VLN 0.7126

tryptophan 500mg cap (exception status) 02248540 Apo-Tryptophan 500mg cap APX 0.356302240334 ratio-Tryptophan 500mg cap TEV 0.356300718149 Tryptan 500mg cap VLN 0.3563

ursodiol 250mg tab (exception status) 02273497 pms-Ursodiol C 250mg tab PMS 0.911902238984 Urso 250mg tab AXC 0.9119

ursodiol 500mg tab (exception status) 02273500 pms-Ursodiol C 500mg tab PMS 1.729802245894 Urso DS 500mg tab AXC 1.7298

ustekinumab 90mg/mL inj (exception status)

02320673 Stelara 45mg/0.5mL syringe inj JAN 9414.7620

valacyclovir 500mg tab 02295822 Apo-Valacyclovir 500mg tab APX 1.187402331748 CO-Valacyclovir 500mg tab COB 1.187402351579 MYLAN-Valacyclovir 500mg tab MYL 1.187402298457 pms-Valacyclovir 500mg tab PMS 1.187402219492 Valtrex 500mg tab GSK 1.1874

valproic acid 250mg cap 02238048 Apo-Valproic 250mg cap APX 0.194700443840 Depakene 250mg cap ABB 0.194702184648 MYLAN-Valproic 250mg cap MYL 0.1947

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 80 of 83

Generic Name and Strength DIN Brand MFR MRP PRPvalproic acid 250mg cap 02100630 Novo-Valproic 250mg cap TEV 0.1947

02237830 Nu-Valproic 250mg cap NXP 0.194702230768 pms-Valproic 250mg cap PMS 0.1947

valproic acid 500mg EC cap 02218321 Novo-Valproic 500mg EC cap TEV 0.519702229628 pms-Valproic 500mg EC cap PMS 0.5197

valproic acid 50mg/mL syr 02238370 Apo-Valproic 50mg/mL syr APX 0.040600443832 Depakene 50mg/mL syr ABB 0.040602236807 pms-Valproic 50mg/mL syr PMS 0.040602140063 ratio-Valproic 50mg/mL syr TEV 0.0406

valsartan 40mg tab 02337487 CO Valsartan 40mg tab COB 0.407502270528 Diovan 40mg tab NVR 0.407502363062 RAN-Valsartan 40mg tab RAN 0.407502356740 Sandoz Valsartan 40mg tab SDZ 0.407502356643 Teva-Valsartan 40mg tab TEV 0.4075

valsartan 80mg tab 02337495 CO Valsartan 80mg tab COB 0.418802244781 Diovan 80mg tab NVR 0.418802363100 RAN-Valsartan 80mg tab RAN 0.418802356759 Sandoz Valsartan 80mg tab SDZ 0.418802356651 Teva-Valsartan 80mg tab TEV 0.4188

valsartan 160mg tab 02337509 CO Valsartan 160mg tab COB 0.419802244782 Diovan 160mg tab NVR 0.419802363119 RAN-Valsartan 160mg tab RAN 0.419802356767 Sandoz Valsartan 160mg tab SDZ 0.419802356678 Teva-Valsartan 160mg tab TEV 0.4198

valsartan 320mg tab 02337517 CO Valsartan 320mg tab COB 0.408002289504 Diovan 320mg tab NVR 0.408002356775 Sandoz Valsartan 320mg tab SDZ 0.408002356686 Teva-Valsartan 320mg tab TEV 0.4080

valsartan 80mg & hydrochlorothiazide 12.5mg tab

02241900 Diovan-HCT 80/12.5mg tab NVR 0.4176

02373734 MYLAN-Valsartan HCTZ 80/12.5mg tab MYL 0.417602356694 Sandoz Valsartan/HCT 80/12.5mg tab SDZ 0.417602356996 Teva-Valsartan/HCTZ 80/12.5mg tab TEV 0.4176

valsartan 160mg & hydrochlorothiazide 12.5mg tab

02241901 Diovan-HCT 160/12.5mg tab NVR 0.4190

02373742 MYLAN-Valsartan HCTZ 160/12.5mg tab MYL 0.419002356708 Sandoz Valsartan/HCT 160/12.5mg tab SDZ 0.419002357003 Teva-Valsartan/HCTZ 160/12.5mg tab TEV 0.4190

valsartan 160mg & hydrochlorothiazide 25mg tab

02246955 Diovan-HCT 160/25mg tab NVR 0.4179

02373750 MYLAN-Valsartan HCTZ 160/25mg tab MYL 0.417902356716 Sandoz Valsartan/HCT 160/25mg tab SDZ 0.417902357011 Teva-Valsartan/HCTZ 160/25mg tab TEV 0.4179

valsartan 320mg & hydrochlorothiazide 12.5mg tab

02308908 Diovan-HCT 320/12.5mg tab NVR 0.4204

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 81 of 83

Generic Name and Strength DIN Brand MFR MRP PRPvalsartan 320mg & hydrochlorothiazide 12.5mg tab

02373769 MYLAN-Valsartan HCTZ 320/12.5mg tab MYL 0.4204

02356724 Sandoz Valsartan/HCT 320/12.5mg tab SDZ 0.420402357038 Teva-Valsartan/HCTZ 320/12.5mg tab TEV 0.4204

valsartan 320mg & hydrochlorothiazide 25mg tab

02308916 Diovan-HCT 320/25mg tab NVR 0.4179

02373777 MYLAN-Valsartan HCTZ 320/25mg tab MYL 0.417902356732 Sandoz Valsartan/HCT 320/25mg tab SDZ 0.417902357046 Teva-Valsartan/HCTZ 320/25mg tab TEV 0.4179

vancomycin HCI 500mg/vial inj 02230191 Sterile Vancomycin HCI 500mg/vial inj HOS 33.689302342855 Val-Vanco 500mg/vial inj VAL 33.6893

vancomycin HCI 1g/vial inj 02230192 Sterile Vancomycin HCI 1g/vial inj HOS 64.004202342863 Val-Vanco 1000mg/vial inj VAL 64.0042

vancomycin 500mg/vial inj 02241820 pms-Vancomycin 500mg/vial inj PMS 33.6893vancomycin 1g/vial inj 02241821 pms-Vancomycin 1g/vial inj PMS 64.0042venlafaxine 37.5mg ER cap 02331683 Apo-Venlafaxine 37.5mg XR cap APX 0.3178

02304317 CO Venlafaxine 37.5mg XR cap COB 0.317802237279 Effexor 37.5mg XR cap WAY 0.317802360020 GD-Venlafaxine XR 37.5mg cap GMD 0.317802310279 MYLAN-Venlafaxine 37.5mg XR cap MYL 0.317802278545 pms-Venlafaxine 37.5mg XR cap PMS 0.317802380072 RAN-Venlafaxine 37.5mg XR cap RAN 0.317802273969 ratio-Venlafaxine 37.5mg XR cap TEV 0.317802310317 Sandoz Venlafaxine 37.5mg XR cap SDZ 0.317802275023 Teva-Venlafaxine XR 37.5mg cap TEV 0.317802354713 Venlafaxine 37.5mg XR cap SAS 0.3178

venlafaxine 75mg ER cap 02331691 Apo-Venlafaxine 75mg XR cap APX 0.635602304325 CO Venlafaxine 75mg XR cap COB 0.635602237280 Effexor 75mg XR cap WAY 0.635602360039 GD-Venlafaxine XR 75mg cap GMD 0.635602310287 MYLAN-Venlafaxine 75mg XR cap MYL 0.635602275031 Novo-Venlafaxine 75mg XR cap TEV 0.635602278553 pms-Venlafaxine 75mg XR cap PMS 0.635602380080 RAN-Venlafaxine 75mg XR cap RAN 0.635602273977 ratio-Venlafaxine 75mg XR cap TEV 0.635602310325 Sandoz Venlafaxine 75mg XR cap SDZ 0.635602354721 Venlafaxine 75mg XR cap SAS 0.6356

venlafaxine 150mg ER cap 02331705 Apo-Venlafaxine 150mg XR cap APX 0.671002304333 CO Venlafaxine 150mg XR cap COB 0.671002237282 Effexor 150mg XR cap WAY 0.671002360047 GD-Venlafaxine XR 150mg cap GMD 0.671002310295 MYLAN-Venlafaxine 150mg XR cap MYL 0.671002278561 pms-Venlafaxine 150mg XR cap PMS 0.671002380099 RAN-Venlafaxine 150mg XR cap RAN 0.671002273985 ratio-Venlafaxine 150mg XR cap TEV 0.6710

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 82 of 83

Generic Name and Strength DIN Brand MFR MRP PRPvenlafaxine 150mg ER cap 02310333 Sandoz Venlafaxine 150mg XR cap SDZ 0.6710

02275058 Teva-Venlafaxine XR 150mg cap TEV 0.671002354748 Venlafaxine 150mg XR cap SAS 0.6710

verapamil HCl 80mg tab 00782483 Apo-Verap 80mg tab APX 0.273502237921 MYLAN-Verapamil 80mg tab MYL 0.273500886033 Nu-Verap 80mg tab NXP 0.2735

verapamil HCl 120mg tab 00782491 Apo-Verap 120mg tab APX 0.425002237922 MYLAN-Verapamil 120mg tab MYL 0.425000886041 Nu-Verap 120mg tab NXP 0.4250

verapamil 180mg SR tab 02246894 Apo-Verap 180mg SR tab APX 0.542401934317 Isoptin 180mg SR tab ABB 0.542402210355 MYLAN-Verapamil 180mg SR tab MYL 0.5424

verapamil 240mg SR tab 02246895 Apo-Verap 240mg SR tab APX 0.723300742554 Isoptin 240mg SR tab ABB 0.723302210363 MYLAN-Verapamil 240mg SR tab MYL 0.723302211920 Novo-Veramil 240mg SR tab TEV 0.723302237791 pms-Verapamil 240mg SR tab PMS 0.7233

warfarin 1mg tab 02242924 Apo-Warfarin 1mg tab APX 0.111401918311 Coumadin 1mg tab BRI 0.111402244462 MYLAN-Warfarin 1mg tab MYL 0.111402265273 Novo-Warfarin 1mg tab TEV 0.111402242680 Taro-Warfarin 1mg tab TAR 0.111402344025 Warfarin 1mg tab SAS 0.1114

warfarin 2mg tab 02242925 Apo-Warfarin 2mg tab APX 0.117801918338 Coumadin 2mg tab BRI 0.117802244463 MYLAN-Warfarin 2mg tab MYL 0.117802265281 Novo-Warfarin 2mg tab TEV 0.117802242681 Taro-Warfarin 2mg tab TAR 0.117802344033 Warfarin 2mg tab SAS 0.1178

warfarin 2.5mg tab 02242926 Apo-Warfarin 2.5mg tab APX 0.094301918346 Coumadin 2.5mg tab BRI 0.094302244464 MYLAN-Warfarin 2.5mg tab MYL 0.094302265303 Novo-Warfarin 2.5mg tab TEV 0.094302242682 Taro-Warfarin 2.5mg tab TAR 0.094302344041 Warfarin 2.5mg tab SAS 0.0943

warfarin 3mg tab 02245618 Apo-Warfarin 3mg tab APX 0.146002240205 Coumadin 3mg tab BRI 0.146002287498 MYLAN-Warfarin 3mg tab MYL 0.146002265311 Novo-Warfarin 3mg tab TEV 0.146002242683 Taro-Warfarin 3mg tab TAR 0.146002344068 Warfarin 3mg tab SAS 0.1460

warfarin 4mg tab 02242927 Apo-Warfarin 4mg tab APX 0.146002007959 Coumadin 4mg tab BRI 0.146002244465 MYLAN-Warfarin 4mg tab MYL 0.1460

REIMBURSEMENT LIST - August 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective August 1, 2012 Page 83 of 83

Generic Name and Strength DIN Brand MFR MRP PRPwarfarin 4mg tab 02265338 Novo-Warfarin 4mg tab TEV 0.1460

02242684 Taro-Warfarin 4mg tab TAR 0.146002344076 Warfarin 4mg tab SAS 0.1460

warfarin 5mg tab 02242928 Apo-Warfarin 5mg tab APX 0.094501918354 Coumadin 5mg tab BRI 0.094502244466 MYLAN-Warfarin 5mg tab MYL 0.094502265346 Novo-Warfarin 5mg tab TEV 0.094502242685 Taro-Warfarin 5mg tab TAR 0.094502344084 Warfarin 5mg tab SAS 0.0945

warfarin 6mg tab 02240206 Coumadin 6mg tab BRI 0.175302287501 MYLAN-Warfarin 6mg tab MYL 0.1753

warfarin 7.5mg tab 02287528 MYLAN-Warfarin 7.5mg tab MYL 0.188702242697 Taro-Warfarin 7.5mg tab TAR 0.3014

warfarin 10mg tab 02242929 Apo-Warfarin 10mg tab APX 0.169501918362 Coumadin 10mg tab BRI 0.169502244467 MYLAN-Warfarin 10mg tab MYL 0.169502242687 Taro-Warfarin 10mg tab TAR 0.169502344114 Warfarin 10mg tab SAS 0.1695

zolmitriptan 2.5mg tab (exception status) 02369036 MYLAN-Zolmitriptan 2.5mg tab MYL 4.800802324229 pms-Zolmitriptan 2.5mg tab PMS 4.800802362988 Sandoz Zolmitriptan 2.5mg tab SDZ 4.800802313960 Teva-Zolmitriptan 2.5mg tab TEV 4.800802238660 Zomig 2.5mg tab AZE 4.8008

zolmitriptan ODT 2.5mg tab (exception status)

02324768 pms-Zolmitriptan ODT 2.5mg tab PMS 4.8008

02362996 Sandoz Zolmitriptan ODT 2.5mg tab SDZ 4.800802342545 Teva-Zolmitriptan OD 2.5mg tab TEV 4.800802243045 Zomig Rapimelt 2.5mg tab AZE 4.8008

zopiclone 5mg tab 02245077 Apo-Zopiclone 5mg tab APX 0.223102271931 CO Zopiclone 5mg tab COB 0.223102216167 Imovane 5mg tab SAV 0.223102296616 MYLAN-Zopiclone 5mg tab MYL 0.223102251450 Novo-Zopiclone 5mg tab TEV 0.223102294052 phl-Zopiclone 5mg tab PHL 0.223102243426 pms-Zopiclone 5mg tab PMS 0.223102267918 RAN-Zopiclone 5mg tab RAN 0.223102246534 ratio-Zopiclone 5mg tab TEV 0.223102257572 Sandoz Zopiclone 5mg tab SDZ 0.223102344122 Zopiclone 5mg tab SAS 0.2231

AUGUST 2012 • VOLUME 12-08 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Exception Status Benefits New Product Non-Insured Products New Ostomy Products Pharmacists’ Guide – Important Reminders Understanding Generic Drugs Palliative Home Care Drug Coverage Program Transition Fees Appendix I – Lantus® Information

Nova Scotia Formulary Updates New Exception Status Benefits The following product will be listed as an exception status benefit, with the following criteria, effective August 1, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Lantus® (insulin glargine)

100u/mL vial 100u/mL cartridge 100u/mL 3mL Solostar prefilled disposable pen

02245689 02251930 02294338

DNP DNP DNP

E (SF) E (SF) E (SF)

SAV SAV SAV

Criteria For the treatment of patients who have been diagnosed with type 1 or type 2 diabetes requiring insulin and are currently taking NPH and/or premix insulin daily at optimal dosing for at least three months AND

Have experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management OR

Have documented severe or continuing systemic or local allergic reaction to existing insulin

For more Lantus® information, please refer to Appendix I.

PAGE 2 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

New Product The following product was reviewed by the Canadian Drug Expert Committee (CDEC) and was recommended to be listed as an open benefit in the Nova Scotia Formulary, effective August 1, 2012.

Product Strength DIN Prescriber Benefit Status MFR

Asmanex® (mometasone furoate)

200mcg/act Twisthaler 400mcg/act Twisthaler

02243595 02243596

DNP DNP

SF SF

FRS FRS

Decision Highlights Mometasone furoate is an inhaled corticosteroid with anti-inflammatory properties. Mometasone furoate has a Health Canada indication for the prophylactic

management of steroid-responsive bronchial asthma in patients 12 years of age and older.

Based on the systematic review, mometasone demonstrated similar or greater efficacy compared with other available inhaled corticosteroids based on improvements in lung function tests and symptom scores and reductions in rescue medication use.

Non-Insured Products The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and were not recommended to be listed as insured benefits under the Nova Scotia Pharmacare Programs.

Product Strength DIN Prescriber Benefit Status MFR

Gelnique® (oxybutynin chloride)

100mg/g Gel 02366150 N/A Not Insured WTS

Decision Highlights Oxybutynin chloride is an antispasmodic, anticholinergic agent. Oxybutynin chloride gel has a Health Canada indication for the treatment of

overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

The Committee considered the comparative clinical benefit of oxybutynin chloride gel to be uncertain because of the absence of any randomized controlled trials (RCTs) that directly compare it with other pharmacological treatments for overactive bladder.

There are no RCTs comparing the incidence of anticholinergic adverse effects (such as cognitive and neurological) between oxybutynin chloride gel and other oxybutynin products, particularly in the elderly.

PAGE 3 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

Non-Insured Products Continued…

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Benlysta® (belimumab)

120mg/5mL vial 400mg/20mL vial

02370050 02370069

N/A N/A

Not Insured Not Insured

GSK GSK

Decision Highlights Belimumab is a fully human monoclonal antibody, classified as an immunosuppressant.

Belimumab has a Health Canada indication for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) when used in combination with standard therapy.

Trials provided no evidence that belimumab alters the risk of organ damage, improves quality of life, or allows for a reduction in prednisone dose.

In two randomized controlled trials (C1056 and C1057), the proportion of responders was statistically significantly higher for belimumab groups than for placebo at 52 weeks, but not at 76 weeks in the trial that extended beyond one year.

The following product was not recommended to be listed as a benefit, however, will be funded through the HIV Program at the QEII Health Sciences Centre (VG site).

Product Strength DIN Prescriber Benefit Status MFR

Complera® (emtricitabine/rilpivirine/ tenofovir)

200mg/25mg/300mg Tab

02374129

N/A

Not Insured

GIL

New Ostomy Products The following products are new listings to the Nova Scotia Formulary, effective August 1, 2012.

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Esteem + Closed Pouch 95098119 416700 DNP SFC CON

Esteem + Closed Pouch 95098118 416701 DNP SFC CON

Esteem + Closed Pouch 95098117 416702 DNP SFC CON

Esteem + Closed Pouch 95098116 416703 DNP SFC CON

Esteem + Closed Pouch 95098115 416704 DNP SFC CON

Esteem + Closed Pouch 95098114 416705 DNP SFC CON

Esteem + Closed Pouch 95098113 416706 DNP SFC CON

Esteem + Closed Pouch 95098112 416707 DNP SFC CON

PAGE 4 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

New Ostomy Products Continued…

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Esteem + Closed Pouch 95098111 416708 DNP SFC CON

Esteem + Closed Pouch 95098110 416709 DNP SFC CON

Esteem + Closed Pouch 95098109 416710 DNP SFC CON

Esteem + Closed Pouch 95098108 416711 DNP SFC CON

Esteem + Closed Pouch 95098107 416712 DNP SFC CON

Esteem + Closed Pouch 95098106 416713 DNP SFC CON

Esteem + Closed Pouch 95098105 416714 DNP SFC CON

Esteem + Closed Pouch 95098104 416715 DNP SFC CON

Esteem + Drainable Pouch

95098103 416719 DNP SFC CON

Esteem + Drainable Pouch

95098102 416725 DNP SFC CON

Esteem + Drainable Pouch

95098101 416729 DNP SFC CON

Esteem + Drainable Pouch

95098100 416733 DNP SFC CON

Esteem + Drainable Pouch

95098099 416737 DNP SFC CON

Esteem + Drainable Pouch

95098098 416739 DNP SFC CON

Esteem + Drainable Pouch

95098097 416741 DNP SFC CON

Esteem + Drainable Pouch

95098096 416743 DNP SFC CON

Esteem + Drainable Pouch

95098095 416745 DNP SFC CON

Esteem + Drainable Pouch

95098094 416747 DNP SFC CON

Esteem + Drainable Pouch

95098093 416749 DNP SFC CON

Esteem + Drainable Pouch

95098092 416751 DNP SFC CON

Esteem + Closed Pouch 95098091 416718 DNP SFC CON

Esteem + Closed Pouch 95098090 416721 DNP SFC CON

Esteem + Closed Pouch 95098089 416724 DNP SFC CON

Esteem + Closed Pouch 95098088 416728 DNP SFC CON

Esteem + Closed Pouch 95098087 416732 DNP SFC CON

Esteem + Closed Pouch 95098086 416736 DNP SFC CON

Esteem + Closed Pouch 95098082 416742 DNP SFC CON

Esteem + Drainable Pouch

95098084 416738 DNP SFC CON

PAGE 5 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

New Ostomy Products Continued…

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Esteem + Drainable Pouch

95098083 416740 DNP SFC CON

Esteem + Drainable Pouch

95098081 416744 DNP SFC CON

Esteem + Drainable Pouch

95098080 416746 DNP SFC CON

Esteem + Drainable Pouch

95098079 416748 DNP SFC CON

Esteem + Drainable Pouch

95098078 416750 DNP SFC CON

Natura + Drainable Pouch

95098077 416415 DNP SFC CON

Natura + Drainable Pouch

95098076 416416 DNP SFC CON

Natura + Drainable Pouch

95098075 416417 DNP SFC CON

Natura + Drainable Pouch

95098074 416420 DNP SFC CON

Natura + Drainable Pouch

95098073 416423 DNP SFC CON

Natura + Drainable Pouch

95098072 416418 DNP SFC CON

Natura + Drainable Pouch

95098071 416421 DNP SFC CON

Natura + Drainable Pouch

95098070 416424 DNP SFC CON

Natura + Drainable Pouch

95098069 416472 DNP SFC CON

Natura + Drainable Pouch

95098068 416419 DNP SFC CON

Natura + Drainable Pouch

95098067 416422 DNP SFC CON

Natura + Closed Pouch 95098066 416400 DNP SFC CON

Natura + Closed Pouch 95098065 416401 DNP SFC CON

Natura + Closed Pouch 95098064 416402 DNP SFC CON

Natura + Closed Pouch 95098063 416403 DNP SFC CON

Natura + Closed Pouch 95098062 416404 DNP SFC CON

Natura + Closed Pouch 95098061 416405 DNP SFC CON

Natura + Closed Pouch 95098060 416406 DNP SFC CON

Natura + Closed Pouch 95098059 416407 DNP SFC CON

Natura + Closed Pouch 95098058 416408 DNP SFC CON

Natura + Closed Pouch 95098057 416409 DNP SFC CON

Natura + Closed Pouch 95098056 416410 DNP SFC CON

PAGE 6 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

New Ostomy Products Continued…

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Natura + Closed Pouch 95098055 416411 DNP SFC CON

Natura + Closed Pouch 95098054 416412 DNP SFC CON

Natura + Closed Pouch 95098053 416413 DNP SFC CON

Pharmacists’ Guide – Important Reminders Conditions of Provider Participation A provider shall:

determine that the prescription is for the use of the eligible beneficiary, respect the Pharmacare Programs as the insurer of last resort, which involves determining to

the best of their knowledge that the beneficiary is not entitled to drug benefits under the Workers’ Compensation Act, from the Royal Canadian Mounted Police, from the Department of National Defense, from Veterans Affairs Canada, under any other Act of the Legislature or the Parliament of Canada, or under any statute of any jurisdiction either within or outside of Canada,

dispense all prescriptions in accordance with the directions of the prescriber, Pharmacare rules and regulations, and all applicable pharmacy legislation,

submit claims to the Pharmacare Programs in an approved manner (CPhA Pharmacy Claims Standard),

bill the Pharmacare Programs according to the current Tariff Agreement, collect all applicable copayments and/or deductibles, be subject to audit, ensuring the Pharmacare Programs are being billed correctly and benefits are

provided according to the rules and regulations of the Programs. Reimbursement of Copayments for Seniors with Private Drug Coverage including Public Service Health Care Plan (PSHCP) Seniors who are not eligible to join Pharmacare because they have drug coverage through a private benefit plan may be eligible to have their drug copayments reimbursed. If the copayments a senior pays to their private insurance exceed the amount of annual maximum premium plus annual maximum copayment they would have paid if they were enrolled in Seniors’ Pharmacare, they may request a reimbursement of the difference. For the program year 2012-2013, the amount is $806 ($424 for premium plus a maximum of $382 for copayment) but may be less if the senior would have qualified for a reduced premium. Only drugs and supplies listed as benefits under the Seniors’ Pharmacare Program are included in the copayment reimbursement calculation.

PAGE 7 OF 7 PHARMACISTS’ EDITION

VOLUME 12-08

Reimbursement of Copayments for Seniors with Private Drug Coverage (including PSHCP) continued… Seniors who seek reimbursement should contact the Pharmacare office, providing the original receipts and/or the explanation of benefits from the private insurer, within one year of the date the product was dispensed at the pharmacy. Submissions for consideration of reimbursement must also include the senior’s Nova Scotia Health Card number, name, phone number, and address. This must be submitted within 90 days of the end of the program year, March 31st. The private benefit plan continues to be the primary insurer. Understanding Generic Drugs The Canadian Agency for Drugs and Technologies and Health (CADTH) has developed handouts for both patients and health professionals, which help to answer common questions about generic drugs. You can access these handouts through the following links: http://www.cadth.ca/resources/generics Generic Drugs: Your Questions Answered: http://www.cadth.ca/en/resources/generics/your-questions-answered Similarities and Differences Between Brand Name and Generic Drugs: http://www.cadth.ca/en/resources/generics/similarities What are Bioavailability and Bioequivelance?: http://www.cadth.ca/media/pdf/Generic_prof_supplement_en.pdf Palliative Home Care Drug Coverage Program In the February 2012 Pharmacare News Bulletin, we provided details of the Palliative Home Care Drug Coverage Program. This program was effective February 1, 2012, and covers the full cost of drugs intended for use in end-of-life care at home. A complete list of the eligible medication is now available on the members only section of the Pharmacy Association of Nova Scotia (PANS) website. After April 1, 2012, only those medications that are on the list will be paid under the program. Pharmacies are also reminded that:

A valid prescription is required for medication that can be purchased over-the-counter, and an official prescription receipt is required for reimbursement

The program does not provide coverage for any supplies or medical equipment. Please contact Pharmaceutical Services at 902-424-1596 with any questions regarding this program. Transition Fees for the period of April 1, 2012 to March 31, 2013 According to Section 6 of the Tariff Agreement, the provider is entitled to bill a transition fee up to $0.75 per prescription. Transition fees are to be submitted with the dispensing fee. There will be no retroactive payment of transition fees.

Appendix I

Lantus® Information

Insulin glargine (Lantus®) is a recombinant human insulin analog that provides long-acting controlled release of insulin over 24 hours without a pronounced peak. Insulin glargine is indicated for once-daily administration in the treatment of patients with type 1 and type 2 diabetes requiring basal insulin. Insulin glargine was reviewed by the National Common Drug Review (CDR) in 2009. Ongoing reviews of the evidence support the CDR report.

No studies have found statistically or clinically significant differences in Hemoglobin A1C between insulin glargine and NPH insulin in patients with either type 1 or type 2 diabetes.

No studies have found significant differences between insulin glargine and NPH insulin in the incidence of severe symptomatic hypoglycemia.

Studies vary in findings for incidence of overall and nocturnal hypoglycemia. Some evidence shows that significantly fewer patients with type 2 diabetes using insulin glargine experienced nocturnal hypoglycemia. However, many of these studies have design flaws, including lack of randomization.

No studies have found significant differences in quality of life associated with different insulins in patients with type 2 diabetes; for patients with type 1 diabetes results are inconsistent.

Insulin glargine is significantly more expensive than NPH insulin.

NPH insulin should be the first choice for patients with type 1 or type 2 diabetes requiring basal insulin. Although the evidence is limited and inconsistent, insulin analogues may offer some advantage over other types of insulin for some people in specific circumstances, such as in patients experiencing significant nocturnal hypoglycemia while using NPH insulin. For this reason, the Nova Scotia Pharmacare Program has decided to add Lantus® to the Nova Scotia Formulary under special authorization with specific criteria required for coverage. The criteria are:

- For the treatment of patients who have been diagnosed with type 1 or type 2

diabetes requiring insulin and are currently taking NPH and/or premix insulin daily at optimal dosing for at least three months

AND - Have experienced unexplained nocturnal hypoglycemia at least once a month

despite optimal management.

OR - Have documented severe or continuing systemic or local allergic reaction

to existing insulin. 

SEPTEMBER 2012 • VOLUME 12-09 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Exception Status Benefits

Criteria Updates: Pegasys RBV®, Pegetron® and Pegetron® Redipen Injection

Criteria Update: Afinitor®

New Diabetic Product

Understanding Generic Drugs

Palliative Home Care Drug Coverage Program

Included with this Bulletin

Request for Coverage of Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) Form

Nova Scotia Formulary Updates

New Exception Status Benefits The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and will be listed as exception status benefits, with the following criteria, effective September 1, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Xarelto® (rivaroxaban)

15mg Tab 20mg Tab

02378604 02378612

DNP DNP

E (SF) E (SF)

BAY BAY

Criteria Inclusion Criteria: At-risk1 patients with non-valvular atrial fibrillation (AF) who require rivaroxaban for the prevention of stroke and systemic embolism AND in whom:

- Anticoagulation is inadequate2 following a reasonable trial3 on warfarin; OR

- Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)

Exclusion Criteria:

Patients with impaired renal function4 (creatinine clearance or estimated glomerular filtration rate < 30 mL/min) OR ≥ 75 years of age and without documented stable renal function5 OR hemodynamically significant rheumatic valvular heart disease6, especially mitral stenosis; OR prosthetic heart valves

PAGE 2 OF 6 PHARMACISTS’ EDITION

VOLUME 12-09

New Exception Status Benefits cont’d…

Criteria 1) At-risk patients with non-valvular atrial fibrillation are defined as those with a CHADS2 score of ≥ 1. Although the ROCKET-AF trial included patients with higher CHADS2 scores (≥ 2), other landmark studies with the other newer oral anticoagulants demonstrated a therapeutic benefit in patients with a CHADS2 score of 1. Prescribers may consider an antiplatelet regimen or oral anticoagulation for patients with a CHADS2 score of 1.

2) Inadequate anticoagulation is defined as INR testing results that are outside the desired INR range for at least 35% of the tests during the monitoring period (i.e. adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).

3) A reasonable trial on warfarin is defined as at least two months of therapy. 4) Since renal impairment can increase bleeding risk, renal function should be

regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see Xarelto® (rivaroxaban) Product Monograph).

5) Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate of 30-49 mL/min for 15mg once daily dosing or ≥ 50 mL/min for 20mg once daily dosing that is maintained for at least 3 months.

6) There is currently no data to support that rivaroxaban provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves, so rivaroxaban is not recommended in these populations.

* Please Note: Patients starting rivaroxaban should have ready access to appropriate medical services to manage a major bleeding event.

Decision Highlights Rivaroxaban is an anticoagulant that directly inhibits Factor Xa. Rivaroxaban has a new Health Canada indication for prevention of stroke and

systemic embolism in patients with non-valvular atrial fibrillation. In the ROCKET-AF study, the proportion of patients in the per-protocol population

who experienced a primary outcome event was numerically lower for rivaroxaban (2.7%) than for warfarin (3.4%), and rivaroxaban was determined to be non-inferior to warfarin.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Incivek® (telaprevir)

375mg Tab 02371553 DNP E (SF) VTX

Criteria For the treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon α (PegIFNα/ribavirin (RBV)), if the following criteria are met:

- Detectable levels of hepatitis C virus (HCV) RNA prior to treatment - Fibrosis stage of F2, F3, or F4 as determined by a biopsy or fibroscan

where available or for patients who are assessed to have significant disease in the professional experience of a hepatologist or a prescriber with a specialty in hepatitis

- Patient not co-infected with HIV - One course treatment only (12 weeks duration)

PAGE 3 OF 6 PHARMACISTS’ EDITION

VOLUME 12-09

New Exception Status Benefits cont’d…

Decision Highlights Telaprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1 in combination with PegIFNα/RBV.

In five RCTs, a statistically significantly higher percentage of telaprevir-treated patients achieved a sustained virologic response (SVR) compared with placebo.

The Committee concluded that the balance of benefits and harms suggests that patients with higher fibrosis scores should be a priority for treatment.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Victrelis® (boceprevir) Victrelis Triple® (boceprevir/ribavirin peginterferon alfa-2b)

200mg Cap 200mg Cap / 200mg Cap / 80mcg Inj 200mg Cap / 200mg Cap / 100mcg Inj 200mg Cap / 200mg Cap / 120mcg Inj 200mg Cap / 200mg Cap / 150mcg Inj

02370816 02371448 02371456 02371464 02371472

DNP DNP DNP DNP DNP

E (SF) E (SF) E (SF) E (SF) E (SF)

FRS FRS FRS FRS FRS

Criteria For the treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon α (PegIFNα/ribavirin (RBV)), if the following criteria are met:

- Detectable levels of hepatitis C virus (HCV) RNA prior to treatment - Fibrosis stage of F2, F3, or F4 as determined by a biopsy or fibroscan

where available or for patients who are assessed to have significant disease in the professional experience of a hepatologist or a prescriber with a specialty in hepatitis

- Patient not co-infected with HIV - One course of treatment only (up to 44 weeks duration)

Decision Highlights Boceprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1. Boceprevir is the first direct-acting antiviral agent approved by Health Canada for the

treatment of chronic hepatitis C genotype 1 infection, in combination with PegIFNα/RBV in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous therapy.

In three double-blind, RCTs comparing placebo with boceprevir, both in combination with PegIFNα/ribavirin, a statistically significantly higher percentage of boceprevir-treated patients achieved a sustained virologic response; the benefit of boceprevir was observed both in treatment-naive patients, and patients who had either not had an adequate response or had relapsed after previous PegIFNα/ribavirin therapy.

PAGE 4 OF 6 PHARMACISTS’ EDITION

VOLUME 12-09

Criteria Updates: Pegasys® RBV, Pegetron® and Pegetron® Redipen Injection/Capsule Effective September 1, 2012, the criteria for Pegasys® RBV Injection/Tablet, Pegetron® and Pegetron® Redipen Injection/Capsule will change to the following:

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Pegasys RBV® (peginterferon alfa-2a and ribavirin)

180mcg/mL Inj / 200mg Tab 180mcg/0.5mL Inj / 200mg Tab 180mcg/0.5mL Inj / 200mg Tab

02253410 02253429 00999450

DNP DNP DNP

E E E

HLR HLR HLR

Criteria For the treatment of hepatitis C in patients who are treatment naive, upon the written request of a hepatologist or prescriber with a specialty in hepatitis

A 24 week period will initially be approved at which time a further request will be required documenting the patient’s response. If a positive response occurs, coverage can be continued for an additional 24 weeks (48 weeks total)

As combination therapy with new protease inhibitors (i.e., boceprevir or telaprevir); futility rules being enforced. Patients should stop all therapy (both protease inhibitor and PegIFNα/RBV) if hepatitis C virus levels are:

- with boceprevir, ≥ 100 IU/mL at 12 weeks or detectable at 24 weeks - with telaprevir, ≥ 1,000 IU/mL at 4 weeks or 12 weeks, or detectable at 24

weeks

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Pegetron® Redipen (peginterferon alfa-2b and ribavirin) Pegetron® (peginterferon alfa-2b and ribavirin)

80mcg/0.5mL Inj / 200mg Cap 100mcg/0.5mL Inj / 200mg Cap 120mcg/0.5mL Inj / 200 mg Cap 150mcg/0.5mL Inj / 200mg Cap 50mcg/mL Inj / 200mg Cap 80mcg/mL Inj / 200mg Cap 100mcg/mL Inj / 200mg Cap 120mcg/mL Inj / 200 mg Cap 150mcg/mL Inj / 200mg Cap

02254581 02254603 02254638 02254646 02246026 02246027 02246028 02246029 02246030

DNP DNP DNP DNP DNP DNP DNP DNP DNP

E E E E E E E E E

FRS FRS FRS FRS FRS FRS FRS FRS FRS

PAGE 5 OF 6 PHARMACISTS’ EDITION

VOLUME 12-09

Criteria Updates cont’d…

Criteria For the treatment of hepatitis C in patients who are treatment naive, upon the written request of a hepatologist or prescriber with a specialty in hepatitis

A 24 week period will initially be approved at which time a further request will be required documenting the patient’s response. If a positive response occurs, coverage can be continued for an additional 24 weeks (48 weeks total)

As combination therapy with new protease inhibitors (i.e., boceprevir or telaprevir); futility rules being enforced. Patients should stop all therapy (both protease inhibitor and PegIFNα/RBV) if hepatitis C virus levels are:

- with boceprevir, ≥ 100 IU/mL at 12 weeks or detectable at 24 weeks - with telaprevir, ≥ 1,000 IU/mL at 4 weeks or 12 weeks, or detectable at 24

weeks Criteria Update: Afinitor® The following coverage criteria has been updated effective September 1, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Afinitor® (everolimus)

2.5mg Tab 5mg Tab 10mg Tab

02369257 02339501 02339528

DNP DNP DNP

E (SFC) E (SFC) E (SFC)

NVR NVR NVR

Criteria As a single agent for metastatic renal cell carcinoma (RCC) patients with documented clear cell histology who have a Karnofsky performance status 70% or higher after progression or intolerance to the VEGF multi-targeted tyrosine kinase inhibitors (TKIs), (e.g., sunitinib, pazopanib and/or sorafenib)

New Diabetic Product The following product is a new listing to the Nova Scotia Formulary, effective September 1, 2012. The benefit status within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT DIN/PIN PRODUCT NUMBER PRESCRIBER BENEFIT

STATUS MFR

Ulticare Pen Needles 32g x 4mm

97799440

00543

DNP

SFC

DRX

PAGE 6 OF 6 PHARMACISTS’ EDITION

VOLUME 12-09

Understanding Generic Drugs The Canadian Agency for Drugs and Technologies and Health (CADTH) has developed handouts for both patients and health professionals, which help to answer common questions about generic drugs. You can access these handouts through the following links: http://www.cadth.ca/en/resources/generics Generic Drugs: Your Questions Answered: http://www.cadth.ca/en/resources/generics/your-questions-answered Similarities and Differences Between Brand Name and Generic Drugs: http://www.cadth.ca/en/resources/generics/similarities What are Bioavailability and Bioequivalence?: http://www.cadth.ca/media/pdf/Generic_prof_supplement_en.pdf Palliative Home Care Drug Coverage Program In the February 2012 Pharmacare News Bulletin, we provided details of the Palliative Home Care Drug Coverage Program. This program was effective February 1, 2012, and covers the full cost of drugs intended for use in end-life care at home. A complete list of the eligible medications is now available on the members only section of the Pharmacy Association of Nova Scotia (PANS) website. After April 1, 2012, only those medications that are on the list will be paid under the program. Pharmacies are also reminded that:

A valid prescription is required for medications that can be purchased over-the-counter, and an official prescription receipt is required for reimbursement.

The program does not provide coverage for any supplies or medical equipment.

Please contact Pharmaceutical Services at 902-424-1596 with any questions regarding the program.

SEPTEMBER 2012 • VOLUME 12-10 PHARMACISTS’ EDITION

Included with this Bulletin

Request for Coverage of Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) Form

Telaprevir (Incivek®) Claim Cost Exceeding $9,999.99 Currently pharmacy software systems do not allow for the online transmission of claims over $9,999.99. With the recent addition of Telaprevir (Incivek®) routine claims will likely exceed this amount. In order to allow for online adjudication the claim must be divided and processed as two separate transactions as follows:

The first transaction should be submitted using the DIN 02371553. The quantity should be adjusted to ensure the total cost of the claim, including ingredient cost, dispensing fee and mark up, does not exceed $9,999.99.

A second claim can be transmitted for the remaining quantity using the PIN 00999627. This PIN will pay ingredient cost only.

The copayment and deductible will be applied to both claims for beneficiaries enrolled in Seniors’ and Family Pharmacare Programs.

This process should only be used when the total claim for Incivek® as written by the prescriber will exceed $9,999.

Patients will still require exception status approval prior to claim being paid online. Please contact the Pharmacare office with any questions at: 496-7001 or 1-800-305-5026. Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) Form Please be advised that there was an error in the Request for Coverage of Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) form for atrial fibrillation which was provided with a recent Pharmacare Bulletin. Specifically the dose of Xarelto® was indicated to be twice daily, instead of once daily. The corrected form is attached for your use and is posted on the Pharmacare website, www.nspharmacare.ca.

We apologize for any inconvenience.

09/2012

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Coverage of Dabigatran (Pradax®) or Rivaroxaban (Xarelto®)

P A T I E N T I N F O R M A T I O N

PATIENT SURNAME

PATIENT GIVEN NAME

HEALTH CARD NUMBER

DATE OF BIRTH

PATIENT ADDRESS

D O S E R E Q U E S T E D

Pradax® 110mg bid Pradax

® 150mg bid Xarelto

® 15mg once daily Xarelto

® 20mg once daily

D I A G N O S T I C I N F O R M A T I O N

Diagnosis: *Only insured for non-valvular atrial fibrillation (AF) in patients with a CHADS2 score of ≥ 1

Non-valvular atrial fibrillation (AF) CHADS2 score: ___________________

*The CHADS2 score is an algorithm for predicting the risk of stroke in patients with AF. The score assigns points for various risk factors, as follows: 1 point for congestive heart failure, hypertension, age ≥ 75 yrs, and diabetes; 2 points for history of stroke or TIA. The score = sum of points (range 0-6)

Renal Function Tests:

Serum creatinine [SCr]: ___________________ µmol/L Date: ___________________

Creatinine clearance [CrCl]: ___________________ mL/min Date: ___________________

Selected notes regarding dosing in AF (Refer to monograph for complete dosing information):

CrCI < 30mL/min: - Pradax® use is contraindicated

- Xarelto® use is contraindicated

CrCI 30-49mL/min: - Pradax® 110mg bid

- Xarelto® 15 mg once daily

CrCI ≥ 50mL/min: - Pradax® 150mg bid

- Xarelto® 20 mg once daily

Age > 80 years: - Pradax® 110mg bid

- Xarelto® 20 mg or 15 mg once daily as appropriate

M E D I C A T I O N H I S T O R Y

Agents tried: Dose, length of therapy, and outcome: (i.e. inadequate anticoagulation*, etc.)

Warfarin _________________________________________________________

Other ______________________________ _________________________________________________________

* Please provide the percentage of INR testing results that are outside the desired INR range.

If warfarin has not been tried, please indicate the reason why:

Warfarin contraindicated _____________________________________________________________________________________________

Other ____________________________________________________________________________________________________________ ____________________________________________________________________________________________________________ PHYSICIAN NAME & ADDRESS:

CPSNS # PHYSICIAN SIGNATURE DATE

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1 Fax: (902) 468-9402

NOVEMBER 2012 • VOLUME 12-11 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

New Exception Status Benefit Levemir

Coverage of Antiviral Therapies for Influenza-Like Illness (ILI) Criteria Update – Infliximab Criteria Update – Capecitabine Hp-Pac Benefit Status Xamiol® Gel Name Change New Products – MRP New Diabetic Product – PRP Nova Scotia Formulary Included with this Bulletin: Pharmacists’ Guide 2012

Nova Scotia Formulary Updates New Exception Status Benefit The following product will be listed as an exception status benefit with the following criteria, effective November 1, 2012.

PRODUCT STRENGTH DIN PRESCRIBER BENEFIT STATUS MFR

Levemir® (insulin detemir)

100u/mL Penfill

02271842 DNP E (SF) NNO

Criteria - for the treatment of patients who have been diagnosed with Type 1 or Type 2 diabetes requiring insulin and have previously taken NPH and/or premix insulin daily at optimal dosing

AND - have experienced unexplained nocturnal

hypoglycemia at least once a month despite optimal management

OR - have documented severe or continuing systemic

or local allergic reaction to existing insulin(s) Coverage of Antiviral Therapies for Influenza-Like Illness (ILI) Please be reminded that coverage for antiviral therapies for influenza (oseltamivir, zanamivir) is available to Pharmacare recipients who are long-term care residents, according to established coverage criteria and provincial guidelines for use. The provincial 2012–2013 Guide to Influenza Control for Long-Term Care Facilities and Adult Residential Centers is available at: http://novascotia.ca/hpp/cdpc/info-for-professionals.asp.

PAGE 2 OF 3 PHARMACISTS’ EDITION

VOLUME 12-11

Criteria Update – Infliximab Please note that effective November 1, 2012, the criteria for infliximab (Remicade®) will be updated to include the treatment of ankylosing spondylitis, with the following criteria:

- for the treatment of patients with moderate to severe ankylosing spondylitis (e.g., Bath AS Disease Activity Index (BASDAI) score ≥ 4 on 10 point scale) who: · have axial symptoms** and who have failed to respond to the sequential use of at least 2

NSAIDs at the optimum dose for a minimum period of 3 months observation, or in whom NSAIDs are contraindicated OR

· have peripheral symptoms and who have failed to respond to, or have contraindications to, the sequential use of at least 2 NSAIDs at the optimum dose for a minimum period of 3 months observation and have had an inadequate response to an optimal dose or maximal tolerated dose of a DMARD

- must be prescribed by a rheumatologist or prescriber with a specialty in rheumatology - requests for renewal must include information showing the beneficial effects of the treatment,

specifically: · a decrease of at least 2 points on the BASDAI scale, compared with the pre-treatment score;

OR · patient and expert opinion of an adequate clinical response as indicated by a significant

functional improvement (measured by outcomes such as HAQ or "ability to return to work") ** Patients with recurrent uveitis (2 or more episodes within 12 months) as a complication of axial disease, do not require a trial of 2 NSAIDs. Initial Coverage Duration and Maximum Dosage approved: Infliximab – initial coverage period 6 months, maximum dose 5mg/kg at 0, 2, and 6 weeks then every 6-8 weeks thereafter and not in combination with other anti-TNF agents

Criteria Update – Capecitabine in Colon and Rectal Cancer Please note that effective November 1, 2012, the criteria for capecitabine (Xeloda®) in colon and rectal cancer will change to the following: Neo-Adjuvant and Adjuvant – Colon and Rectal Cancer

- neo-adjuvant treatment of stage II or stage III rectal cancer as a single agent prior to radiotherapy and/or concurrent with radiotherapy

- adjuvant treatment of stage II or stage III rectal cancer as a single agent and/or concurrent with radiotherapy

- adjuvant treatment of stage III colon cancer as a single agent - adjuvant treatment of stage III colon or rectal cancer as part of the XELOX (CAPOX) regimen as an

alternative to infusional 5-FU in the FOLFOX regimen Metastatic Colorectal Cancer

- first line single agent as an alternative to combination chemotherapy - alternative to the infusional 5-FU in the FOLFOX regimen as part of the XELOX (CAPOX) regimen

PAGE 3 OF 3 PHARMACISTS’ EDITION

VOLUME 12-11

Hp-Pac Benefit Status H. pylori regimens insured in the Pharmacare Programs are limited to one week of therapy. Currently the pharmacist selects a criteria code for the Hp-Pac indicating the prescription is for a one week therapy. However, in some cases, the code has been used multiple times, allowing for payment of a longer course of therapy, and this has resulted in pharmacy audit recoveries. Effective November 1, 2012, in lieu of a criteria code, a limit of one package (1 week therapy) per year will be instituted. Claims after the one week fill will be rejected. If a patient fails the therapy, an alternative therapy should be selected. Exceptional cases can be reviewed by the Pharmacare office upon request. Xamiol® Gel Name Change Please note that the brand name of Xamiol® gel has changed to Dovobet® gel. There is no change in the product’s DIN or formulation. The exception status criteria will remain the same. New Products – MRP The following products will be reinstated as benefits on the Nova Scotia Formulary, effective December 1, 2012, with the indicated MRP.

PRODUCT DIN/PIN MRP PRESCRIBER BENEFIT STATUS MFR

Lipitor® 10mg Tab 02230711 0.5824 DNP SF PFI Lipitor® 20mg Tab 02230713 0.7280 DNP SF PFI Lipitor® 40mg Tab 02230714 0.7826 DNP SF PFI Lipitor® 80mg Tab 02243097 0.7826 DNP SF PFI

New Diabetic Product – PRP The following product is a new listing to the Nova Scotia Formulary, effective November 1, 2012. The benefit status and PRP within the Nova Scotia Pharmacare Programs is indicated.

PRODUCT DIN/PIN PRP PRESCRIBER BENEFIT STATUS MFR

OneTouch® Delica® Lancets 30G 97799431 0.0500 DNP SFD LFS

Nova Scotia Formulary The Nova Scotia Formulary is available on the Nova Scotia Pharmacare website (www.nspharmacare.ca) in PDF and is updated on a monthly basis. Please avoid using any previous publications, including any printed versions of the Formulary or the “Blue Book” as these are now significantly out of date.

Pharmacare Programs

Pharmacists’ Guide

November 2012

This guide provides information on the Nova Scotia Pharmacare Programs, but it does not replace either the Fair Drug Pricing Act or its regulations.

NOVEMBER 2012 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

TABLE OF CONTENTS

ADMINISTRATION ......................................................................................................................... 1

PROVIDER REGISTRATION ........................................................................................................................................ 1 CONDITIONS OF PROVIDER PARTICIPATION ............................................................................................................... 2

PROGRAMS AND FUNDING ............................................................................................................ 3 NOVA SCOTIA SENIORS’ PHARMACARE PROGRAM ................................................................................................... 3 NOVA SCOTIA FAMILY PHARMACARE PROGRAM ....................................................................................................... 6 DRUG ASSISTANCE FOR CANCER PATIENTS ............................................................................................................. 7 NOVA SCOTIA DIABETES ASSISTANCE PROGRAM ..................................................................................................... 8 MULTIPLE SCLEROSIS COPAYMENT ASSISTANCE ...................................................................................................... 9 UNDER 65 – LONG TERM CARE (LTC) PHARMACARE PLAN .................................................................................... 10 DEPARTMENT OF COMMUNITY SERVICES – PHARMACARE BENEFITS ....................................................................... 11 PALLIATIVE CARE PROGRAM ................................................................................................................................. 12

BENEFITS AND EXCLUSIONS ....................................................................................................... 14 NOVA SCOTIA SENIORS’ PHARMACARE, FAMILY PHARMACARE, DIABETES ASSISTANCE PROGRAM, DRUG

ASSISTANCE FOR CANCER PATIENTS & COMMUNITY SERVICES PHARMACARE ONLY ............................................... 14 ALL PHARMACARE PROGRAMS ................................................................................................... 15

EXCEPTION STATUS DRUGS ................................................................................................................................... 15 AUTOMATIC ADJUDICATION OF ESD ...................................................................................................................... 16 USE OF CRITERIA CODES ....................................................................................................................................... 16 COVERAGE OF NURSE PRACTITIONER AND OPTOMETRIST PRESCRIBED BENEFITS ................................................... 17 COVERAGE OF MIDWIFE PRESCRIBED BENEFITS ..................................................................................................... 17 PHARMACIST PRESCRIBING ................................................................................................................................... 18 COVERAGE OF CONTINUED CARE PRESCRIPTIONS .................................................................................................. 19 INSURED PROFESSIONAL SERVICES ....................................................................................................................... 20 THE NOVA SCOTIA FORMULARY ............................................................................................................................. 24 BENEFIT REVIEW PROCESS ................................................................................................................................... 24

PRICING PROCEDURES ............................................................................................................... 26 TARIFF AGREEMENT .............................................................................................................................................. 26 PHARMACARE REIMBURSEMENT ............................................................................................................................ 26 PRODUCT SHORTAGES .......................................................................................................................................... 27 QUANTITATIVE LIMITS ............................................................................................................................................ 27 STANDARDIZATION OF PACKAGE SIZES .................................................................................................................. 29 BILLING FOR METHADONE ORAL LIQUID ................................................................................................................. 29 COMPOUNDED PRODUCTS ..................................................................................................................................... 29

BILLING THE PHARMACARE PROGRAM ........................................................................................ 31 CLAIM INFORMATION FOR ONLINE ADJUDICATION ................................................................................................... 31 PRESCRIBER NUMBERS ......................................................................................................................................... 31 RESPONSE CODES ................................................................................................................................................ 32 BILLING OF CLAIMS WITH COST EXCEEDING $9,999.99 .......................................................................................... 32 MANUAL CLAIMS ................................................................................................................................................... 34 ADJUSTMENTS ...................................................................................................................................................... 35 MEDICATIONS RETURNED TO STOCK ...................................................................................................................... 36 REIMBURSEMENT FOR UNRETURNABLE PRODUCTS ................................................................................................ 37 PAYMENTS AND STATEMENTS ................................................................................................................................ 39

AUDIT ....................................................................................................................................... 40 PHARMACARE AUDIT ............................................................................................................................................. 40 PHARMACARE PRESCRIPTION AUDIT RECOVERY PROCEDURES ............................................................................... 40

NOVEMBER 2012 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

APPENDIX I ................................................................................................................................ 43

PHARMACARE TARIFF AGREEMENT ........................................................................................................................ 43 APPENDIX II ............................................................................................................................... 50

PHARMACARE CONFIRMATION OF AGREEMENT FORM ............................................................................................. 50 APPENDIX III .............................................................................................................................. 51

PROVIDER APPEALS REGULATIONS ........................................................................................................................ 51 APPENIX IV ............................................................................................................................... 57

NOTICE OF APPEAL BY PROVIDER .......................................................................................................................... 57

NOVEMBER 2012 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Information on the following Pharmacare programs may also be found at the web address: www.nspharmacare.ca MSI Registration (Health Cards, new residents) Local Calls: 496-7008 P.O. Box 500, Halifax, NS B3J 2S1 Toll Free: 1-800-563-8880 Nova Scotia Seniors’ Pharmacare Program Local Calls: 429-6565 or 496-7002 P.O. Box 9322, Halifax, NS B3K 6A1 Toll Free: 1-800-544-6191 Nova Scotia Family Pharmacare Program Local Calls: 496-5667 P.O. Box 500, Halifax, NS B3J 2S1 Toll Free: 1-877-330-0323 Nova Scotia Department of Community Services Toll Free: 1-877-424-1177 P.O. Box 500, Halifax, NS B3J 2T7 Nova Scotia Diabetes Assistance Program Local Calls: 496-7001 P.O. Box 500, Halifax, NS B3J 2S1 Toll Free: 1-800-305-5026 Drug Assistance for Cancer Patients Local Calls: 496-7001 Nova Scotia Pharmacare Programs Toll Free: 1-800-305-5026 P.O. Box 500, Halifax, NS B3J 2T7 Palliative Care Program Local Calls: 424-1596 c/o Pharmaceutical Services, Fax: 424-0605 Nova Scotia Department of Health and Wellness P.O. Box 488, Halifax NS B3J 2R8 Low Income Pharmacare for Children Local Calls: 424-1269 Nova Scotia Department of Community Services Toll Free: 1-866-424-1269 P.O. Box 696, Halifax, NS B3J 2T7 Under 65 – LTC Pharmacare Plan Local Calls: 496-7001 Nova Scotia Pharmacare Programs Toll Free: 1-800-305-5026 P.O. Box 500, Halifax, NS B3J 2S1 Nova Scotia Prescription Monitoring Program Local Calls: 496-7123 P.O. Box 2200, Halifax, NS B3J 3C6 Toll Free: 1-877-476-7767 General e-mail: [email protected] www.nspmp.ca Pharmacare Audit Local Calls: 496-7030, 496-7122, 496-7511 P.O. Box 500, Halifax, NS B3J 2S1 Toll Free: 1-800-563-8880 Dalhousie MS Research Unit Phone: 422-7817 University Ave, Halifax, NS B3H 1B7

Pharmacy Claims Inquiries regarding claims, benefits, eligibility and exception status drugs

LLooccaall CCaallllss:: 449966--77000011

TToollll FFrreeee:: 11--880000--330055--55002266 FFaaxx:: 446688--99440022

Our representatives are available Monday to Friday, 8:00 a.m. to 5:00 p.m.

NOVEMBER 2012 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Addiction Services Phone: 424-5623 P.O. Box 896, Dartmouth, NS B2Y 3Z6 Nova Scotia College of Pharmacists Phone: 422-8528 1559 Brunswick Street, Suite 220 Halifax, NS B3J 2G1 General e-mail: [email protected] www.nspharmacists.ca Pharmacy Association of Nova Scotia Phone: 422-9583 170 Cromarty Drive, Suite 225 Dartmouth, NS B3B 0G1 www.pans.ns.ca Public Health Local Calls: 424-4807 Nova Scotia Department of Health and Wellness Toll Free: 1-866-231-3882 P.O. Box 488, Halifax NS B3J 2R8 http://www.gov.ns.ca/hpp/contacts/phs-offices.asp

NOVEMBER 2012 1 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

ADMINISTRATION

Provider Registration Nova Scotia Pharmacare Programs P.O. Box 500, Halifax, NS B3J 2S1 Local calls: 496-7001 Toll free: 1-877-305-5026 Fax: 468-9402 A “Provider” is a pharmacy licensed under the Pharmacy Act that has entered into an agreement with the Minister respecting the tariff and has been designated as a provider or in a class of providers. Pharmacy providers must be licensed with the Nova Scotia College of Pharmacists. New providers and providers who have changed ownership are required to complete the following forms provided by Pharmacare:

Registration of the Pharmacy form, providing information to establish the pharmacy as an authorized provider of pharmaceutical services under the Pharmacare Programs.

Confirmation of Agreement form, as acceptance of the Tariff Agreement. MSI Provider Business Arrangement form, authorizing direct payment to the pharmacy’s account. Provider Accreditation Application form, to request accreditation of the pharmacy’s software package and

to accept the Terms and Conditions of MSI Provider Accreditation. Certification of Responsibility for Electronic Claims Submission form, to accept legal responsible and

liability for the accuracy and validity of all claims submitted to Medavie Blue Cross via telecommunications.

PHARMACY CLOSING OR TRANSFERRING OWNERSHIP As indicated in the Tariff Agreement between the Pharmacy Association of Nova Scotia and the Nova Scotia Department of Health and Wellness, if your pharmacy is closing or changing ownership, it is your responsibility to notify our office within 30 days in advance of transfer/closing. This information will be retained in confidence. A close-out prescription audit is required. You may contact our office at [email protected] or (902) 496-7560, 496-7190, and 496-7107 or toll free at 1-800-536-8880 ext 7560, 7190, or 7107. Upon registration, a new pharmacy is provided with some key information, including:

Pharmacy provider number Business arrangement number Nova Scotia Formulary Tariff Agreement Reimbursement List List of College of Physicians and Surgeons of Nova Scotia (CPSNS) numbers for physicians in Nova

Scotia and lists of other authorized prescribers. Recent Pharmacare News Bulletins Requests for Adjustment forms Nova Scotia Pharmacare Programs Pharmacists’ Guide Nova Scotia Seniors’ Pharmacare Program Information Booklet

NOVEMBER 2012 2 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Conditions of Provider Participation A Provider shall:

determine that the prescription is for the use of the eligible beneficiary, respect the Pharmacare Programs as the insurer of last resort, which involves determining to the best of

their knowledge that the beneficiary is not entitled to drug benefits under the Workers’ Compensation Act, from the Royal Canadian Mounted Police, from the Department of National Defence, from Veterans Affairs Canada, under any other Act of the Legislature or the Parliament of Canada, or under any statute of any jurisdiction either within or outside of Canada,

dispense all prescriptions in accordance with the directions of the prescriber, Pharmacare rules and regulations, and all applicable pharmacy legislation,

submit claims to the Pharmacare Programs in an approved manner (CPhA Pharmacy Claims Standard), bill the Pharmacare Programs according to the current Tariff Agreement, collect all applicable copayments and/or deductibles, be subject to audit, ensuring the Pharmacare Programs are being billed correctly and benefits are

provided according to the rules and regulations of the Programs.

NOVEMBER 2012 3 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

PROGRAMS AND FUNDING

Nova Scotia Seniors’ Pharmacare Program The Nova Scotia Seniors’ Pharmacare Program is a provincial drug insurance plan that assists seniors with the cost of their prescription drugs. Seniors are not obligated to join the Seniors’ Pharmacare Program, and not every senior is eligible to join. The following general information applies to the Seniors’ Pharmacare Program. This information is subject to change at any time. The Pharmacare News Bulletins, which are mailed to pharmacies and can be accessed on the Nova Scotia Pharmacare Programs website at www.nspharmacare.ca, provide pharmacies with information on changes to the program.

Eligibility The Nova Scotia Seniors’ Pharmacare Program is offered to permanent Nova Scotia residents who;

have a valid Nova Scotia Health Card number; and are at least 65 years old; do not already have prescription drug coverage through Veterans Affairs Canada, Non-insured Health

Benefits, Nova Scotia Family Pharmacare, or any other public or private benefit plan that covers medication and supplies after age 65.

Enrollment Pharmacare sends an information package approximately three months prior to the 65th birthday of an eligible resident of Nova Scotia. If a senior wishes to join the Seniors’ Pharmacare Program, they must return completed documentation within 90 days of the first day of the month of their 65th birthday. Seniors become eligible for Pharmacare on the first day of the month of their 65th birthday, but only if Pharmacare has received the proper documentation to register, and any required premium payment prior to this date.

Benefits The benefits for the Seniors’ Pharmacare Program are indicated in the Nova Scotia Formulary with an “S” in the benefit status column. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information.

Premium for Seniors Who Apply Late If a senior does not apply for Pharmacare coverage within 90 days of the first day of the month in which they turn age 65, or decides to leave Pharmacare, but then wants to join later; they will be subject to the late entry penalty, which means they will:

have to wait 90 days for coverage to begin once accepted into Pharmacare and have to pay one and a half times the premium for five years.

Seniors Whose Drug Coverage (Private or Public) Ceases Any senior providing proof of continuous prescription drug coverage or proof of enrollment in the Nova Scotia Family Pharmacare Program since becoming 65 years of age is exempt from the late entry penalty if they enroll in Seniors’ Pharmacare after the eligibility date (age 65). The senior must return a completed application form along with proof of other drug coverage from age 65 within 90 days of the first day of the month that the other drug coverage was terminated. If a senior just moved to Nova Scotia, they must first apply for and receive a Nova Scotia Health Card before they can register with the Program. They must return a completed application form within 90 days of receiving their Nova Scotia Health Card.

Identification Card All individuals registered for MSI have a personalized Nova Scotia Health Card. This card is also used to identify beneficiaries in the Seniors’ Pharmacare Program. Seniors enrolled in the Seniors’ Pharmacare program must present their health card to the provider at the time of prescription purchase to have their prescription processed under Pharmacare. The card can only be used by the person whose name appears on the card.

NOVEMBER 2012 4 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Public Service Health Care Plan (PSHCP) Members The Public Service Health Care Plan (PSHCP) provides primary drug coverage to their members who do not receive the Guaranteed Income Supplement (GIS). The Seniors’ Pharmacare Program provides coverage to PSHCP members who receive the GIS. If a senior has drug coverage under the PSHCP, payment of claims by PSHCP will be determined as follows: The PSHCP provides primary drug coverage to their members who do not receive the GIS. If the copayment amount a senior pays to PSHCP exceeds the amount of annual maximum premium plus annual maximum copayment they would have paid if they were enrolled in Seniors’ Pharmacare, they may request a reimbursement of the difference for any of the drug benefits covered by the Seniors’ Pharmacare Program. (See section on “Reimbursement of Copayments for Seniors with Private Drug Coverage (including PSHCP)”). The Seniors’ Pharmacare Program provides primary drug coverage to PSHCP members who receive the GIS. Seniors receiving the GIS from the federal government can apply to the Seniors’ Pharmacare Program (see section on “Enrollment”) and do not have to pay a premium for coverage. A copayment of 30% for drug benefits still applies. If you would like to learn more about the Guaranteed Income Supplement (GIS) from the federal government, please visit www.hrsdc.gc.ca/en/isp/pub/oas/gismain.shtml.

Reimbursement of Copayments for Seniors with Private Drug Coverage (including PSHCP) Seniors who are not eligible to join Pharmacare because they have drug coverage through a private benefit plan may be eligible to have their drug copayments reimbursed. If the copayments a senior pays to their private insurance exceed the amount of annual maximum premium plus annual maximum copayment they would have paid if they were enrolled in Seniors’ Pharmacare, they may request a reimbursement of the difference. For the program year 2012-2013, the amount is $806 ($424 for premium plus a maximum of $382 for copayment) but may be less if the senior would have qualified for a reduced premium. Only drugs and supplies listed as benefits under the Seniors’ Pharmacare Program are included in the copayment reimbursement calculation. Seniors who seek reimbursement should contact the Pharmacare office, providing the original receipts and the explanation of benefits from the private insurer and may be submitted to Pharmacare anytime during the fiscal year, but no later than June 30, which is 90 days after the end of that fiscal year. Submissions for consideration of reimbursement must also include the senior’s Nova Scotia Health Card number, name, phone number, and address. The private benefit plan continues to be primary insurer.

Premiums The maximum premium to join the Seniors' Pharmacare Program for the program year 2012-2013 is $424. Seniors receiving the Guaranteed Income Supplement (GIS) from the federal government do not have to pay a premium for coverage. Seniors not receiving the GIS must pay a premium for Pharmacare coverage. However, some low income seniors who do not receive the GIS may qualify for reduced premiums. Eligibility for a reduced premium is automatically determined when the Seniors' Pharmacare Program verifies seniors’ income with the Canada Revenue Agency. Copayment Beneficiaries in the Seniors’ Pharmacare Program are required to pay a copayment of 30% of the prescription cost up to an annual maximum copayment of $382. Beneficiaries have the option of paying the annual maximum copayment amount in monthly or annual instalments directly to the Seniors’ Pharmacare Program, similar to their premium payments. However, beneficiaries may choose to pay their copayment on every prescription to the pharmacy. Once the annual maximum copayment of $382 has been reached, Seniors’ Pharmacare will pay the full cost of prescriptions that are covered under the Program until the end of the program year, March 31st. If the beneficiary chooses to pay the annual maximum copayment of $382 for the Program year, there will be no reimbursement for any portion of $382 that was not used within the year.

NOVEMBER 2012 5 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

No beneficiary in the program will pay more than $382 in copayments each year. The exception to this is when: The senior wants the brand name drug, which is more expensive than the generic; or The drug or supply costs more than the maximum amount Seniors’ Pharmacare will cover; or The drug prescribed is not covered by Seniors’ Pharmacare.

In these circumstances, the senior is responsible for the additional costs and the amounts paid do not go toward the annual maximum copayment. Billing Claims are submitted on-line using the Nova Scotia Health Card number as the beneficiary’s identification number. Professional fees and mark-ups are paid according to the Pharmacare Tariff Agreement. If a senior chooses to pay their copayment at the pharmacy with each prescription, the Pharmacare on-line adjudication system calculates the amount of copayment to be billed for each prescription and automatically stops copayment requirements when the senior has reached the annual copayment maximum.

NOVEMBER 2012 6 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Nova Scotia Family Pharmacare Program The Nova Scotia Family Pharmacare Program (NSFP) is available to all Nova Scotia residents who are not currently enrolled in another Pharmacare Program (except Drug Assistance for Cancer Patients). Residents may also enrol in NSFP as secondary insurance if they already have private insurance. There are no upfront costs or premiums when registering with NSFP. Annual copayment and deductible maximums are determined by family size and income. The following general information applies to NSFP. This information is subject to change at any time. The Pharmacare News Bulletins, which are mailed to pharmacies and can be accessed on the Nova Scotia Pharmacare Programs website at www.nspharmacare.ca, provide pharmacies with recent changes to the program.

Eligibility To be eligible, the individual must be a permanent Nova Scotia resident AND have a valid Nova Scotia Health Card number. The family members must also agree to provide family size information and annual family income verification through Canada Revenue Agency (CRA). The individual is not eligible if currently receiving drug coverage though:

The Nova Scotia Seniors’ Pharmacare Program; The Nova Scotia Diabetes Assistance Program; Under 65 – Long Term Care Pharmacare Plan; or any Department of Community Services Pharmacare Benefits.

Enrollment Residents of Nova Scotia must complete and submit the registration form. Enrollment in the program is by families. Re-enrollment packages will be sent out to families enrolled in NSFP. Each family must register by April 1st of each year. NSFP Registration forms can be found on the Nova Scotia Family Pharmacare Programs website: www.nspharmacare.ca. Benefits NSFP benefits are indicated with an “F” in the benefit status column of the Nova Scotia Formulary. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information.

Identification Card All individuals registered for MSI have a Nova Scotia Health Card. This card is also used for NSFP. Individuals enrolled in the NSFP must present their Nova Scotia Health Card to the provider at the time of prescription purchase to have their prescriptions processed under Pharmacare. The card can only be used by the person whose name appears on the card.

Billing Eligible prescription claims for the NSFP beneficiaries are submitted on-line to the Pharmacare Programs and are adjudicated according to the beneficiary’s deductible and copayment level. An electronic response is returned to the pharmacy. The beneficiary pays the copayment and deductible component to the pharmacy and Pharmacare reimburses the pharmacy for any portion covered by NSFP.

Copayment and Deductible All beneficiaries who are enrolled in the NSFP program will be required to pay a part of the cost of medications or supplies covered under the program. The Family Pharmacare coverage starts on the first day of the month the person joins. The Nova Scotia Health Card is also the Pharmacare Card. Each family member must show their Nova Scotia Health Card at the pharmacy when they have a prescription filled. The family will be required to cost share the Program. The first 20 percent of every prescription is applied towards the annual family copayment maximum. The remaining 80 percentage of the total will be applied against the annual family deductible.

NOVEMBER 2012 7 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

When the total deductible is paid, the beneficiaries continue to pay 20 percent per prescription until the annual copayment is also paid in full. When both the annual maximum copayment and the annual maximum deductible are paid, Pharmacare will pay the approved cost of the medications that are covered under the Family Pharmacare Program until the end of the program year, which is March 31st. Contact the Pharmacare office for the copayment and deductible balance. The annual maximum copayment and deductible are specific to each family and depend on family size and income. Each family will receive a letter with their family annual maximum copayment and annual maximum deductible. Beneficiaries can determine their initial out of pocket expense using the on-line calculator at: www.nspharmacare.ca. Drug Assistance for Cancer Patients Drug Assistance for Cancer Patients provides income-based assistance to Nova Scotia residents to help defray the cost of approved cancer-related benefits. Eligibility To be eligible, an individual must:

be an eligible resident of Nova Scotia and have a valid Nova Scotia Health Card number; not be eligible for any other drug coverage, except Nova Scotia Family Pharmacare; have a diagnosis of cancer; have a gross family income of no more than $15,720; provide a copy of the most recent Income Tax Notice of Assessment or Reassessment from Canada

Revenue Agency (CRA) for the cancer patient, their parent(s) or guardian(s), spouse or common-law partner; and

agree to family income verification from the CRA Notice of Assessment or Reassessment. Enrollment Beneficiaries wishing to apply for coverage should contact Drug Assistance for Cancer Patients at the contact numbers provided at the beginning of this document. Additional information and application forms can be found on the Nova Scotia Pharmacare Programs website at: www.nspharmacare.ca. Benefits A “C” in the benefit status column of the Nova Scotia Formulary indicates benefits covered under Drug Assistance for Cancer Patients. Benefits include categories such as chemotherapeutic agents, pain medications, antiemetic agents, laxatives for use with chronic opioid therapy. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information. Other agents that are directly related to the beneficiary’s cancer therapy can be considered by the Pharmacare Office upon receipt of a written request from the prescriber. Billing/Copayment Claims are submitted on-line using the Nova Scotia Health Card number as the beneficiary’s identification number. Professional fees and mark-ups are paid according to the Pharmacare Tariff Agreement. Beneficiaries do not pay a copayment.

NOVEMBER 2012 8 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Nova Scotia Diabetes Assistance Program The Nova Scotia Diabetes Assistance Program (NSDAP) is a provincial drug plan that helps to pay for certain prescribed medications and supplies used to manage diabetes. Effective April 1, 2010, the NSDAP will no longer be accepting new beneficiaries. Existing beneficiaries of the NSDAP are required to re-register by April 1 each year in order to remain in the program. Anyone newly diagnosed with diabetes who is a member of a family currently enrolled in the NSDAP will be covered.

Eligibility The NSDAP is offered to permanent residents of Nova Scotia who:

have a valid Nova Scotia Health Card number; are under age 65; have a confirmed diagnosis of diabetes; agree to provide family size information; agree to family income verification through Canada Revenue Agency (CRA); and do not already have coverage through Veterans Affairs Canada, Nova Scotia Family Pharmacare, or any

other drug insurance plan for medications and supplies for diabetes.

Enrollment Residents of Nova Scotia must complete and submit the registration form. Enrollment in the program is by families. Re-enrollment packages will be sent out to families enrolled in NSDAP. Each family must re-enrol by April 1st of each year. Registration forms are on the Nova Scotia Pharmacare Programs website at: www.nspharmacare.ca.

Benefits A “D” in the benefit status column of the Nova Scotia Formulary indicates benefits available under the NSDAP. Standard benefits include:

insulin and analogues, oral blood glucose lowering drugs blood glucose test strips, needles, syringes, and lancets.

The program does not cover:

medications - or supplies taken or used for other medical conditions, such as blood pressure or heart problems

blood glucose monitors, insulin pumps, and pump supplies. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Nova Scotia Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information.

Identification Card Upon registration, beneficiaries in the NSDAP are provided with a letter confirming their enrollment and family deductible. All individuals registered for MSI have a Nova Scotia Health Card. This card is also used for the NSDAP. Individuals enrolled in the NSDAP must present their Health Card to the provider at the time of prescription purchase to have their prescriptions processed under Pharmacare. The card can be used only by the person whose name appears on the card. Billing Eligible prescription claims for the NSDAP clients are submitted on-line to the Pharmacare Programs and are adjudicated according to the beneficiary’s copayment and deductible level. An electronic response is returned to the pharmacy. The beneficiary pays the copayment and deductible component to the pharmacy and Pharmacare reimburses the pharmacy for any portion covered by the NSDAP. Beneficiaries can determine their initial out of pocket expense using the on-line calculator at: www.nspharmacare.ca.

NOVEMBER 2012 9 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Copayment and Deductible All beneficiaries who are enrolled in the NSDAP program will be required to pay a part of the cost of prescriptions for medications or supplies covered under the program. Beneficiaries are required to pay 20% of the total cost of each prescription as a copayment. The balance of the total prescription cost will also be paid by the beneficiary but will be applied against the annual family deductible. The annual family deductible resets on April 1st of each year. Once a beneficiary pays the deductible portion of the prescription cost they will only be required to pay the 20% copayment. Note: There is no copayment maximum in NSDAP. The deductible is specific to each family and depends on family size and income. Each family will receive a letter with their family copayment and deductible requirements. Multiple Sclerosis Copayment Assistance This Pharmacare Program provides copayment assistance for select multiple sclerosis (MS) drugs to eligible residents who meet the established disease state criteria, have private insurance coverage for these drugs, and are required to pay a copayment as part of their drug coverage. Eligibility To be eligible for copayment assistance the beneficiaries must:

be a permanent resident of Nova Scotia with a valid Nova Scotia Health Card number; have drug coverage for the specified MS drugs, but be required to pay a copayment as part of the

coverage; be managed by the Dalhousie Multiple Sclerosis Research Unit (DMSRU); meet the DMSRU guidelines for MS disease-modifying therapy.

Enrollment When eligibility is confirmed the DMSRU sends a written notification of eligibility to Pharmacare. The DMSRU also sends written notification and information on billing processes to the provider that will be filling eligible prescriptions. Benefits For a prescription to be eligible for copayment assistance, it must be for the following:

Glatiramer acetate (Copaxone®) or Interferon-beta-1a (Avonex® or Rebif®) or Interferon-beta-1b (Betaseron®)

and be: written by a neurologist/nurse practitioner at the DMSRU or the MS satellite clinic in Sydney; and dispensed by a Pharmacare provider

Billing Pharmacare reimburses either the eligible beneficiary or the provider. An eligible beneficiary or the provider must submit their receipt for the copayment, along with the completed MS Copayment Reimbursement Form (available from Pharmacare) to Pharmacare. Copayment Pharmacare reimburses the eligible resident or provider for the copayment minus a user fee per prescription equal to the maximum professional fee negotiated in the Tariff Agreement between the Department of Health and Wellness and the Pharmacare Association of Nova Scotia (PANS). Where the eligible resident has reached the annual maximum under their drug insurance plan, and is required to pay the full amount of the prescription, Pharmacare reimburses the full amount of the prescription minus the applicable user fee for the remainder of the year.

NOVEMBER 2012 10 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Under 65 – Long Term Care (LTC) Pharmacare Plan The Under 65 – LTC Pharmacare Plan provides drug coverage for long-term care residents under age 65 who have no drug insurance. Eligibility To be eligible the individual must:

be a resident of Nova Scotia with a valid Nova Scotia Health Card number; be under age 65; be a regular bed resident of a long-term care facility; and not have access to, or coverage under, another public or private drug plan.

Enrollment Upon admission of an eligible resident, the long term care facility shall provide written notification to the program administrator for the Pharmacare Programs to enroll the resident in the Under 65 – LTC Pharmacare Plan. Facsimile notification is acceptable. The following information must be provided by the facility:

Facility name and address Name and number for facility contact Name of resident Resident’s date of birth Resident’s Nova Scotia Health Card number Date of admission Date of discharge (where applicable)

The program administrator for the Pharmacare Programs will confirm that the resident has a valid Health Card number and set up the resident as a beneficiary of the Under 65 – LTC Pharmacare Plan. Benefits The Under 65 – LTC Pharmacare Plan benefits are indicated with an “F” in the benefit status column of the Nova Scotia Formulary. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information. Billing/Copayment Eligible prescription claims for these beneficiaries are submitted on-line to Pharmacare. The long term care facilities notify their respective pharmacy providers when eligible individuals have been enrolled as beneficiaries in the Under 65 – LTC Pharmacare Plan. The resident identification number for the plan is the resident’s Nova Scotia Health Card number. Beneficiaries of the Under 65 – LTC Pharmacare Plan are not charged a premium, copayment, or deductible.

NOVEMBER 2012 11 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Department of Community Services – Pharmacare Benefits

The Department of Community Services provides prescription drug coverage to eligible beneficiaries.

Eligibility Please refer to the table below for information on eligibility for programs of the Department of Community Services.

Enrollment Low Income Pharmacare for Children Program: Application forms are available by calling toll free 1-877-424-1269 or on the Community Services web-page at http://gov.ns.ca/coms/families/PharmacareforChildren.html.

For all other Programs: Pharmacare is considered a benefit that is available to individuals/families once they meet the specific program eligibility criteria. If an individual does not have prescription coverage and requires assistance with the cost of drugs, they can be referred to the toll free 1-877-424-1177 or access information on the Community Services web-page at: http://gov.ns.ca/coms/index.html.

Benefits The Community Services Pharmacare benefits are indicated with an “F” in the benefit status column of the Nova Scotia Formulary. Some medications are considered exception status drugs and require a prescriber’s request for approval. These exception status drugs are indicated by “E” next to the program covered in the benefit status column of the Formulary. Please refer to the “Exception Status Drugs” section of this guide for more information.

Drugs not listed as benefits in the Nova Scotia Formulary or drugs not approved for exception status coverage are not covered.

Identification Card All beneficiaries and their dependants with Pharmacare coverage through the Department of Community Services must provide their Nova Scotia Health Card as their identification card.

Billing/Copayment Please refer to the table below for copayment arrangements by program.

Department of Community Services Pharmacare Benefits

PROGRAM WHO IS ELIGIBLE PREMIUM DEDUCTIBLE COPAYMENT

Income Assistance As determined by the Department of Community Services Assessment

NO NO $5.00

Income Assistance: Copayment Exempt

Clients on Income Assistance who: - receive more than 3 prescriptions per month - have a permanent disability - take small dosage amounts on a regular Basis

NO NO NO

Income Assistance: Special Needs Pharmacare

Clients who do not qualify for Pharmacare under Income Assistance but have significant drug costs may qualify for payment and if deemed eligible, payment can only be made through a PO #

NO NO Variable

Income Assistance: Transitional Pharmacare

Clients who are no longer eligible for Income Assistance because of employment income may be eligible to receive transitional benefits for 1 year

NO NO $5.00

Low Income Pharmacare For Children (LIPC)

Children of families who receive the NS Child Benefit NO NO $5.00

Services for Persons with Disabilities

Clients with intellectual and physical disabilities and long term mental illness who qualify for support and services under the program.

NO NO NO

Children in Care Children who are placed outside their parent’s home. NO NO NO

NOVEMBER 2012 12 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Palliative Home Care Drug Coverage Program Effective February 1, 2012, the province introduced the Palliative Home Care Drug Coverage Program. This program covers the full cost of drugs intended for use in end of life care at home. In order to be eligible for the program, patients must reside in Nova Scotia and have a valid health card number. Eligibility will be determined by a palliative care nurse, nurse practitioner, or physician. Once patients are approved for coverage, the nurse, nurse practitioner, or physician will complete a Medication Authorization Form and forward it to the community pharmacy. This form lists all of the approved medication classifications that will be covered under the program for the patient. Only medications that are in the classifications on the form will be eligible. A valid prescription is required for medications that can be purchased over the counter. A sample form has been provided on the next page. The form also provides authorization for the pharmacy to bill the cost of the approved medications, and is good for six months from the date of issue. The pharmacy will bill the Department of Health and Wellness directly for all approved medications. Pharmacies will be reimbursed for the total cost submitted for any claims dated February 1, 2012 or later. Pharmacare pricing policies, such as PRP, will not apply and the drugs will not be subject to exception status criteria. There will be no cost to the patient for approved medications. In order to be reimbursed, pharmacies must complete the pharmacy contact information on the form and must submit a copy of the Medication Authorization Form, along with the original prescription receipts to:

Palliative Home Care Drug Coverage Program c/o Pharmaceutical Services, Department of Health and Wellness

PO Box 488 Halifax, NS

B3J 2R8

NOVEMBER 2012 13 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Palliative Home Care Drug Coverage Medication Authorization Form

NOVEMBER 2012 14 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

BENEFITS AND EXCLUSIONS

Seniors’ Pharmacare, Family Pharmacare, Diabetes Assistance Program, Drug Assistance for Cancer Patients & Community Services Pharmacare Only Benefits Benefits generally include:

Drugs requiring a prescription by law under Schedule F of the Food and Drugs Act, the Controlled Drug Substances Act, or Schedule I of the Drug Schedules Regulations to the Nova Scotia Pharmacy Act and that have been specifically included as a benefit for recipients of these Pharmacare Programs.

Non-prescription products specifically included on the benefit list (e.g., enteric coated ASA). Selected diabetic supplies including insulin, needles, lancets, and testing strips but not including glucose

testing meters, lancet devices, alcohol swabs, insulin pump, or pump supplies. Selected ostomy products for use by beneficiaries with ileostomy, colostomy, or urostomy.

Pharmacare News Bulletins are also an important source of information as they provide timely information on recent changes to the benefit list. Bulletins are mailed to pharmacies and can be accessed on the Nova Scotia Pharmacare Programs website at www.nspharmacare.ca. Please note that it usually takes several months for a new drug to be reviewed by the Canadian Drug Expert Committee (CDEC), the Atlantic Expert Advisory Committee (AEAC) and the Cancer Systemic Therapy Policy Committee (CSTPC). Benefit Exclusions Exclusions include but are not limited to:

prescriptions filled outside Nova Scotia; proprietary medicines and household remedies; non-prescription analgesics, antihistamines, vitamins, natural health products, mouth preparations, throat

preparations, nasal preparations, laxatives, antacids, and cough and cold preparations; artificial sweetening agents; dietary supplements and food products; soaps, cleaners, and shampoos, medicated or otherwise; supportive or physical aids/devices, mechanical or otherwise; prescription accessories, convalescent aids or other non-drug items of a similar nature; cosmetic, health and beauty aids; blood derivatives (Immune Serum Globulin for prophylaxis against infectious hepatitis or measles for

treatment of immune deficiency disease available from Public Health); vaccines and sera (most are available from Public Health); smoking cessation therapies; anti-obesity therapies; erectile dysfunction therapies; infertility therapies; antihistamines; therapies for environmental illness; drug products identified by trade names deemed to be inappropriate, confusing, and/or misleading; wound care products.

Note: A complete list of benefits is available in the Nova Scotia Formulary which details the benefit status of each medication.

ALL benefits require a prescription and must be dispensed as a prescription by an approved provider. The Nova Scotia Formulary provides “Prescriber Codes” which indicate the health care provider (physicians/dentists, nurse practitioners, pharmacists, midwives and prescribing optometrists) who is authorized to prescribe a specific drug product for payment under the Nova Scotia Pharmacare Programs.

NOVEMBER 2012 15 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

ALL PHARMACARE PROGRAMS

Exception Status Drugs Certain drugs are only eligible for coverage under the Pharmacare Programs when an individual meets criteria developed by the Atlantic or Canadian Expert Advisory Committees. A list of these drugs is included in the Nova Scotia Formulary as Appendix III, “Criteria for Coverage of Exception Status Drugs” and they are indicated by “E” in the benefit status column of the Formulary. For the Drug Assistance for Cancer Patients Program, the exception status drugs which can be considered for coverage are indicated by an asterisk (*) in Appendix III of the Nova Scotia Formulary. A copy of the standard request form, as well as specialized forms, is available on the Nova Scotia Pharmacare Programs website at: www.nspharmacare.ca. Forms may be added or changed at any time. To ensure up to date information please refer to the website. Requests for Coverage To request coverage, the prescriber should mail or fax a completed Request Form or letter to the Pharmacare office. Pharmacists may complete an exception status form on behalf of the beneficiary; however, the form must be signed by the prescriber. Prescribers may also contact the Pharmacare office and speak directly to a drug exception analyst or a pharmacist consultant to request coverage. The prescriber must provide the following information as part of the request:

beneficiary identification, including Nova Scotia Health Card number diagnosis drug requested criteria met, and other pertinent information.

Coverage for non-benefit drugs may also be considered for coverage in exceptional circumstances following a written request from the prescriber. Prescribers may also contact the Pharmacare office and speak directly to a pharmacist consultant to request coverage. Notification Beneficiaries are notified by a letter if the request is approved. Beneficiaries may bring this letter to the pharmacy to verify that coverage has been approved or the pharmacist may simply bill the claim on-line for immediate response. The prescriber is notified if coverage is authorized, if the request is refused because the criterion for coverage is not met, or if more information is required. Billing Once authorization is approved, the claim for the exception status drug is billed on-line to the Pharmacare Programs. Usual copayment and deductible rules apply. If the beneficiary has received the drug while awaiting authorization and the request is eventually approved, the beneficiary can seek reimbursement if the receipt is forwarded to the Pharmacare Office within six months of the date purchased. Likewise, coverage may also be backdated to a maximum of three months, or the first of the month of registration (whichever is less).

Every effort is made to process requests within 7 days. Requests of a more urgent nature are processed more quickly. Requests that do not meet defined criteria but warrant further review may take longer.

NOVEMBER 2012 16 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Automatic Adjudication of ESD Requests will be adjudicated automatically based on the age of the patient as follows:

Desmopressin (DDAVP® Tab, MELT Tab and generic brands) will not require prior approval, provided the claim is for a beneficiary who is under the age of 16

Mometasone nasal spray (Nasonex®) will not require prior approval, provided the claim is for a beneficiary aged 3 to 11

Tretinoin topical preparations will not require prior approval, provided the claim is for a beneficiary under the age of 30

The following drugs will be adjudicated automatically based on the beneficiary’s history: Cabergoline (Dostinex® 0.5mg Tablet & generic brands) Calcipotriol (Dovonex ®50mcg/g Ointment, Cream and 50mcg/mL Scalp Solution) Entacapone (Comtan® 200mg Tablet) Finasteride (Proscar® 5mg Tablet & generic brands) Fluconazole (Diflucan POS® 10mg/mL) Levodopa and carbidopa and entacapone (Stalevo® 50mg, 75mg, 100mg, 125mg, 150mg Tablet) Quinagolide (Norprolac® 0.025mg, 0.05mg, 0.075mg 0.15mg Tablet) Vigabatrin (Sabril® Sachet & Tablet) Levetiracetam (Keppra® Tablet)

Claims submitted that meet these criteria will pay; claims submitted that do not meet the criteria will be rejected with this message “CP” (Eligible for special authorization). If the claim is rejected, the prescriber can still submit a request to the Pharmacare office for consideration. Use of Criteria Codes Selected exception status drugs can be billed on-line without prior approval if criteria codes are provided during the billing process. The exception status drugs that have been assigned criteria codes are noted in the “Criteria for Coverage of Exception Status Drugs” (Appendix III) of the Nova Scotia Formulary. Criteria Codes Provided by Authorized Prescribers For most of the drugs that can be billed using criteria codes, the criteria codes are supplied directly by an authorized prescriber. By supplying a code, the prescriber is verifying that he or she is prescribing the drug for an indication approved under the Pharmacare Programs. The prescriber may provide the criteria code or diagnostic information on the prescription (instead of the actual code), or alternatively the pharmacist may confirm the code. Any situation that falls outside the criteria identified by the codes requires pre-approval and the procedure mentioned previously under “Requests for Coverage” must be followed. Rules for Using Criteria Codes

Criteria codes or diagnostic information may be provided by the prescriber or may be confirmed by the pharmacist.

When a criteria code is part of a verbally received prescription, the criteria code must be documented on the hard copy.

If diagnostic information is provided, it must be specific enough that the code is clearly identified (e.g., “patient had stroke on ASA” for ticlopidine therapy”).

If the therapy is long term and the code has been supplied correctly on the original prescription but not on the subsequent prescriptions, please reference the original prescription number on subsequent prescriptions. The original code must be easily located upon audit.

If appropriate information is not evident upon audit, monies will be recovered.

NOVEMBER 2012 17 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Billing To allow payment when using a criteria code, two codes are required: 1. The code ‘ED’ must be entered in the Intervention Code field when prescribed by a physician, nurse

practitioner, pharmacist, midwife, or optometrist. 2. The code ‘EA’ must be entered in the Intervention Code field when a continuing care prescription is written

by a pharmacist 3. The specific criteria code (01, 02, etc.) is entered in the Special Authorization Code field.

Prescriptions Filled Outside Nova Scotia The Pharmacare Program will not pay for prescriptions filled in a pharmacy outside Nova Scotia. However, exemptions may be considered on a case-by-case basis. For prescriptions filled outside of Canada, there is no reimbursement, emergency or otherwise. Beneficiaries traveling out of the province are advised to take adequate supplies of medications with them and to have adequate travel insurance. Coverage of Nurse Practitioner and Optometrist Prescribed Benefits The Nova Scotia Formulary contains a list of benefits which can be insured if prescribed by nurse practitioners or prescribing optometrists. This is indicated by the prescriber code assigned to each drug with “N” indicating it is insured when prescribed by an authorized nurse practitioner, and “O” indicating it is insured when prescribed by an authorized optometrist. The prescriber number assigned to a nurse practitioner or prescribing optometrist is required to be submitted as part of the claim. Claims Submission Claims for authorized nurse practitioner or optometrist prescribed benefits are to be billed to the Pharmacare Programs for real-time electronic adjudication as follows:

Claims must have the nurse practitioner or optometrist prescriber number in the Prescriber field (refer to the Canadian Pharmacists Association Pharmacy Claim Standard.) Prescriber numbers for nurse practitioners and prescribing optometrists are provided to pharmacies annually. New prescribers are published in monthly Pharmacare News Bulletins which are mailed to the pharmacies (also available on the Nova Scotia Pharmacare Programs website at www.nspharmacare.ca).

Claims must be submitted in accordance with the terms and conditions of the Nova Scotia Pharmacare

Tariff Agreement. Reimbursement will be in accordance with the payment rules of this agreement.

Claims submitted for drugs that are not eligible to be prescribed by authorized nurse practitioners or optometrists will be rejected with this message “CD” (Drug is not a benefit).

Coverage of Midwife Prescribed Benefits The Nova Scotia Formulary contains a list of benefits which can be insured if prescribed by midwives. This is indicated by the prescriber code assigned to each drug with “M” indicating it is insured when prescribed by an authorized midwife. The prescriber number assigned to a midwife is required to be submitted as part of the claim.

Claims Submission Prescriptions for midwife prescribed products are to be billed to the Pharmacare Program for real-time electronic adjudication as follows:

Claims must have the midwife prescribing number in the Prescriber field (refer to the Canadian Pharmacists Association Pharmacy Claim Standard.)

Claims must be submitted is accordance with the terms and conditions of the Nova Scotia Pharmacare Tariff Agreement. Reimbursement will be in accordance with the payment rules of the Agreement.

Please continue to refer to the Pharmacare News Bulletins (www.nspharmacare.ca) for updated information regarding the use of criteria codes.

NOVEMBER 2012 18 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Claims submitted for drugs that are not eligible to be prescribed by midwives will be rejected with the message “CD” (Drug is not a benefit).

Pharmacist Prescribing In January of 2010, the Nova Scotia legislature approved Regulations to the Pharmacy Act which authorized prescribing by pharmacists in Nova Scotia. Government approval of the regulations was contingent upon the NSCP developing Standards of Practice to provide structure and details as to how the prescribing activities will happen. The Standards of Practice - Prescribing of Drugs of Pharmacists were released by NSCP in January of 2011. As a result, pharmacists are now able to undertake prescribing of drugs in accordance with the standards, existing legislation, regulations, the Code of Ethics, agreements, other standards of practice, and policy directives relevant to pharmacy practice in Nova Scotia. Effective immediately, the list of drugs in the Nova Scotia Formulary that are benefits when prescribed by a pharmacist have been expanded to include all drugs that could be prescribed according to the standards. These products are only benefits when all prescribing standards are met. To reflect the broader prescribing capabilities of pharmacists, the Nova Scotia Formulary has been updated with the following prescriber codes:

D: Physicians and Dentists N: Nurse practitioners P: Pharmacists M: Midwives O: Optometrists

All claims must have a prescriber number in the Prescriber field. Until individual prescriber numbers are available for pharmacists when billing the Pharmacare Programs, all pharmacists will use 71111 as their prescriber ID number. Claims submitted for drugs that are not eligible to be prescribed by the type of prescriber indicated by the prescriber number submitted will be rejected with the message “CD” (Drug is not a benefit). Exception Status Drugs All Pharmacare policies will apply to pharmacist prescriptions including minimum days supply, special authorization requirements, etc. If a pharmacist is the prescriber of a medication that requires special authorization for payment, the pharmacist may submit a request for coverage for review. The request must clearly indicate:

That the pharmacist is the prescriber of the medication Pharmacist’s name and NSCP license number Pharmacy name and provider number Mailing address (for written confirmation of response) Clinical details clearly demonstrating how the beneficiary meets the coverage criteria

Written confirmation of the outcome of the review is provided to the prescriber of the medication. It is, therefore, very important that pharmacists provide an appropriate mailing address on each request that will ensure the confidential response is delivered to them or other designated pharmacy staff. A specialized form to collect the necessary information is posted on the Nova Scotia Pharmacare Programs website at: www.nspharmacare.ca. Requests can be faxed to 902-468-9402.

NOVEMBER 2012 19 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Coverage of Continued Care Prescriptions In a May 1, 2006, Professional Memorandum, the Nova Scotia College of Pharmacists provided details of the “Continued Care Prescriptions Agreement” between the Nova Scotia College of Pharmacists and the College of Physicians and Surgeons of Nova Scotia. The agreement authorizes pharmacists to extend existing prescriptions as continued care prescriptions (CCPs) provided certain conditions are met. Pharmacists may submit claims for CCPs to the Nova Scotia Pharmacare Programs for reimbursement provided:

The medication being continued is not benzodiazepine or a drug monitored by the Nova Scotia Prescription Monitoring Program.

The CCP is for an eligible benefit under the applicable Pharmacare Program. The pharmacist prescribing the CCP is licensed with the Nova Scotia College of Pharmacists. The physician who prescribed the original prescription being extended is licensed with the College of

Physicians and Surgeons of Nova Scotia. The patient has an immediate need for a prescription extension and the patient’s physician is unavailable

to provide refill authorization. The pharmacist is reasonably satisfied that the physician, if available, would provide the authorization. The medication to be continued is for a chronic or long-term condition. The patient has established a stable history with the medication (no recent changes to dosage/drug

therapy). The prescription is being extended in the same pharmacy where it originated and the patient is under the

current care of that pharmacy. The prescription has not previously been extended through a CCP. The amount of the medication provided does not exceed the previous amount prescribed or one month

(30 days), whichever is less. The CCP is documented in a manner that complies with all applicable legislation. It is assigned its own

prescription number and the prescription number of the prescription being extended must be noted on the CCP.

The pharmacist signs the CCP as the prescriber, thereby assuming full responsibility for the CCP. CCPs are retained by the pharmacy in compliance with all applicable legislation and are available for

Pharmacare audit (refer to the Audit Section for the prescription audit procedures that apply). As with any other prescription, the CCP should be documented on the patient’s medication profile. The primary care physician or physician providing overall care to the patient, if different from the prescribing physician, should be notified of the CCP as soon as reasonably possible. Claims Submission CCPs are to be billed to the Pharmacare Programs for real-time electronic adjudication as follows:

Claims must include the prescription number assigned to the CCP. All claims must have the pharmacist prescribing number in the Prescriber field (refer to the Canadian

Pharmacists Association Pharmacy Claim Standard). Until individual prescribing numbers are assigned all pharmacists will use the pharmacists’ prescribing number 71111.

Claims must have an “N” in the new/refill code field and an “EA” (pharmacist authorized off-hours claim) in

the Intervention/Exception Code field, and if required, the specific criteria code (01, 02, etc.) in the Special Authorization Code field (refer to the Canadian Pharmacists Association Pharmacy Claim Standard).

Claims submitted for drugs that are not authorized to be prescribed by pharmacists, that have the

pharmacist prescribing number 71111, do not have an “N” in the New/Refill code field and an “EA” (pharmacist authorized off-hours claim) in the Intervention/Exception Code field will be rejected, with the message “CD” (Drug is not a benefit).

Claims must be submitted in accordance with the terms and conditions of the Nova Scotia Pharmacare

Tariff Agreement. Reimbursement will be in accordance with the payment rules of this agreement.

NOVEMBER 2012 20 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Insured Professional Services Advanced Medication Review Service Advanced Medication Review Service (AMRS) – approximately one and one-half hours to complete - is an insured service under the Nova Scotia Seniors‘ Pharmacare Program. Pharmacies are required to complete the Pharmacy sign-up form and fax it to the Pharmacy Association of Nova Scotia (PANS) prior to offering the service to their patients.* It is important for the pharmacy to be registered for billing and audit purposes. To qualify for the program, beneficiaries must:

Be beneficiaries of the Nova Scotia Seniors’ Pharmacare Program. Agree with their pharmacist that they are a suitable candidate for the program. A signed consent form

and all documentation is to be kept on file in the pharmacy for at least three years for audit purposes. Not reside in a nursing home, home for special care, or be receiving medication in compliance packaging. Be taking 4 or more prescription medications; OR taking one of the following:

- methyldopa - indomethacin - cyclobenzaprine - diazepam - chlordiazepoxide - clorazepate - amitriptyline

Have at least one of the following diseases: - asthma - diabetes - hypertension - hyperlipidemia - congestive heart failure - chronic obstructive pulmonary disease - arthritis

Claims Submission Pharmacists may submit claims for AMRS to the Nova Scotia Pharmacare Programs for reimbursement provided the beneficiaries qualify according to the criteria above and:

One AMRS per beneficiary using PIN 93899999 in each benefit year, April 1st to March 31st. Pharmacists are permitted to prescribe the AMRS using the pharmacists‘ prescribing number 71111. The service fee for advanced medication review (Special Service Code ―”6”) will be subject to a PRP of

$150.00. The copayment will be applicable to this claim. The special service code ―”6” is only applicable to the Nova Scotia Seniors‘ Pharmacare Program.

The following CPhA Claims Standard field content is required on the claim:

CPhA Claim Standard Field

#

CPhA Claim Standard Field Name

Content

D.56.03 DIN/GP#/PIN 93899999 D.57.03 Special Service Code 006 (Drug utilization review) D.58.03 Quantity 000001 (one) D.61.03 Prescriber ID Prescriber number of the physician, nurse

practitioner or pharmacist who initiates the review

D.66.03 Drug Cost/Product Value DDDDD (dollar value - not adjudicated) D 67.03 Cost Upcharge DDDDD (dollar value - not adjudicated) D.68.03 Professional Fee DDDDD (dollar value - not adjudicated) D.72.03 Special Services Fee(s) 15000 ($150.00) PRP

* For more information, please contact the Pharmacy Association of Nova Scotia (PANS) at (902) 422-9583 or visit their website: www.pans.ns.ca for the Medication Review Forms under Membership.

NOVEMBER 2012 21 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Basic Medication Review Service Basic Medication Review Service (BMRS) – approximately 20 to 30 minutes to complete - is an insured service under all the Pharmacare Programs, except the Under 65 – LTC Program. To qualify for the program:

The individual must be a beneficiary of a Nova Scotia Pharmacare Program, except the Under 65 – LTC Program.

The beneficiary must agree with their pharmacist that they are a suitable candidate for the program and sign a consent form which, along with all other documentation, is to be kept on file in the pharmacy for at least three years for audit purposes.

The beneficiary must not reside in a nursing home, home for special care, or be receiving medication in compliance packaging.

The beneficiary must meet with the pharmacist for an in-person consultation. The beneficiary must be taking 3 or more prescription medications that are used for the treatment of

chronic conditions, and are covered by the Pharmacare Programs. The beneficiary must be provided with a comprehensive drug review list that is dated and authorized with

the pharmacist’s and the patient’s signatures. Claims Submission Pharmacists may submit claims for BMRS to the Nova Scotia Pharmacare Programs for reimbursement provided all the above criteria are met, and the beneficiary has received their comprehensive drug review list dated and authorized with the pharmacist’s and the patient’s signatures, and:

One BMRS per beneficiary using PIN 93899995 in each benefit year, April 1st to March 31st. Pharmacists are permitted to prescribe the BMRS using the pharmacists‘ prescribing number 71111. The service fee for basic medication review (Special Service Code ―003) is subject to a PRP of $52.50.

The copayment and/or deductible will be applicable to this claim. The following CPhA Claims Standard field content is required on the claim:

CPhA Claim

Standard Field #

CPhA Claim Standard Field Name

Content

D.56.03 DIN/GP#/PIN 93899995 D.57.03 Special Service Code 003 (pharmacist consultation) D.58.03 Quantity 000001 (one) D.61.03 Prescriber ID Prescriber number of the physician, nurse

practitioner or pharmacist who initiates the review

D.66.03 Drug Cost/Product Value DDDDD (dollar value - not adjudicated) D 67.03 Cost Upcharge DDDDD (dollar value - not adjudicated) D.68.03 Professional Fee DDDDD (dollar value - not adjudicated) D.72.03 Special Services Fee(s) 5250 ($52.50) PRP

Therapeutic Substitution Therapeutic substitution (TS) is an insured service under all the Pharmacare Programs. This is an eligible service only when it is in response to a Pharmacare policy such as Pharmacare Reimbursement Price (PRP), proton pump inhibitor (PPI) policy, etc. To qualify for the program:

The individual must be a beneficiary of a Nova Scotia Pharmacare Program. Give informed and voluntary consent as described in the Nova Scotia College of Pharmacist Standards of

Practice for Prescribing Drugs by Pharmacists. Pharmacists must comply with all applicable Nova Scotia College of Pharmacist Standards of Practice for Prescribing Drugs by Pharmacists. Documentation of consent, assessment, monitoring plan and notification to the prescriber of the medication that being substituted is to be kept on file in the pharmacy for at least three years for audit purposes.

The beneficiary must be taking a medication for which the Pharmacare Programs have specifically authorized therapeutic substitution. The list of products will be provided in Pharmacare News Bulletins

NOVEMBER 2012 22 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Claims Submission Pharmacists may submit claims for therapeutic substitution to the Nova Scotia Pharmacare Programs for reimbursement provided all the above criteria are met, and the beneficiary has signed consent authorizing the pharmacist to make the TS, and:

The following steps must be completed in order for the pharmacy to be reimbursed for the service. o The original claim for the prescription as written by the prescriber must be submitted to

Pharmacare and then reversed. o Submit a claim for therapeutic substitution using PIN 93899996, with the CPhA Claims Standard

field content below. The hard copy must reference the prescription numbers for the original claim and the modified claim.

o The claim for the new prescription with the changes made is submitted to Pharmacare. Pharmacists are permitted to prescribe the TS using the pharmacists’ prescribing number 71111. The service fee for therapeutic substitution (Special Service Code ―002) is subject to a PRP of $14.00.

The copayment and/or deductible will not be applied to this claim. Pharmacists may submit claims for TS to the Nova Scotia Pharmacare Programs for reimbursement provided all the above criteria are met, and the following CPhA Claims Standard field content is required on the claim:

CPhA Claim Standard Field

#

CPhA Claim Standard Field Name

Content

D.56.03 DIN/GP#/PIN 93899996 D.57.03 Special Service Code 002 (pharmacist intervention) D.58.03 Quantity 000001 (one) D.61.03 Prescriber ID 71111 D.66.03 Drug Cost/Product Value DDDDD (dollar value - not adjudicated) D 67.03 Cost Upcharge DDDDD (dollar value - not adjudicated) D.68.03 Professional Fee DDDDD (dollar value - not adjudicated) D.72.03 Special Services Fee(s) 2625 ($26.25) PRP

The claims adjudication system will only allow the submission of one PIN per beneficiary per day. If multiple services are required for the same beneficiary on the same day, manual claims should be submitted to the Pharmacare Programs. Prescription Adaptation Prescription adaptation (PA) is an insured service under all the Pharmacare Programs when it is performed as follows:

1. Refusal to fill a drug monitored by the Prescription Monitoring Program. 2. For a clinical reason to enhance patient outcomes such as dose, duration, adverse drug reaction, or

intolerance. Note: Changes in prescription quantity not related to a dose or duration change or changes in formulation are not insured PA services.

To qualify for the program: The individual must be a beneficiary of a Nova Scotia Pharmacare Program. The beneficiary must give informed and voluntary consent as described in the Nova Scotia College of

Pharmacist Standards of Practice for Prescribing Drugs by Pharmacists. Pharmacists must comply with all applicable Nova Scotia College of Pharmacist Standards of Practice for Prescribing Drugs by Pharmacists. Documentation of consent, assessment, monitoring plan, and notification to the prescriber of the medication that being adapted is to be kept on file in the pharmacy for at least three years for audit purposes.

Pharmacists submit an adverse drug reaction (ADR) report if PA is done for a clinical reason such as an adverse drug reaction or intolerance to a drug. A copy of the Health Canada ADR report is to be kept on file in the pharmacy for at least three years for audit purposes.

Claims Submission Pharmacists may submit claims for PA to the Nova Scotia Pharmacare Programs for reimbursement of refusal to fill a monitored drug provided all the above criteria are met, and:

NOVEMBER 2012 23 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

The following steps must be completed in order, on the same day, for the pharmacy to be reimbursed for the service.

o The original claim for the prescription as written by the prescriber must be submitted to Pharmacare and then reversed.

o Submit a claim for prescription adaptation fee using PIN 93899986, with the CPhA Claims Standard field content below. The hard copy must reference the prescription number for the original claim.

Pharmacists are permitted to prescribe the PA using the pharmacists’ prescribing number 71111. The service fee for prescription adaptation (Special Service Code ―1) is subject to a PRP of $14.00. The

copayment and/or deductible will not be applied to this claim.

The following CPhA Claims Standard field content is required on the claim:

CPhA Claim Standard Field

#

CPhA Claim Standard Field Name

Content

D.56.03 DIN/GP#/PIN 93899986 D.57.03 Special Service Code 1 (refusal to fill) D.58.03 Quantity 000001 (one) D.61.03 Prescriber ID 71111 D.66.03 Drug Cost/Product Value DDDDD (dollar value - not adjudicated) D 67.03 Cost Upcharge DDDDD (dollar value - not adjudicated) D.68.03 Professional Fee DDDDD (dollar value - not adjudicated) D.72.03 Special Services Fee(s) 1400 ($14.00) PRP

The claims adjudication system will only allow the submission of one PIN per beneficiary per day. If multiple services are required for the same beneficiary on the same day, manual claims should be submitted to the Pharmacare Programs. Pharmacists may submit claims for PA to the Nova Scotia Pharmacare Programs for reimbursement for a clinical reason to enhance patient outcomes provided all the above criteria are met, and:

The following steps must be completed in order, on the same day, for the pharmacy to be reimbursed for the service.

o The original claim for the prescription as written by the prescriber must be submitted to Pharmacare and then reversed.

o Submit a claim for prescription adaptation fee using PIN 93899985 and a quantity of 1 (one), with the CPhA Claims Standard field content below. The hard copy must reference the prescription numbers for the original claim and the modified claim.

o The claim for the new prescription with the changes made is submitted to Pharmacare Pharmacists are permitted to prescribe the PA using the pharmacists’ prescribing number 71111. The service fee for prescription adaptation (Special Service Code ―E) is subject to a PRP of $14.00. The

copayment and/or deductible will not be applied to this claim.

The following CPhA Claims Standard field content is required on the claim:

CPhA Claim Standard Field

#

CPhA Claim Standard Field Name

Content

D.56.03 DIN/GP#/PIN 93899985 D.57.03 Special Service Code E (claiming professional care service) D.58.03 Quantity 000001 (one) D.61.03 Prescriber ID 71111 D.66.03 Drug Cost/Product Value DDDDD (dollar value - not adjudicated) D 67.03 Cost Upcharge DDDDD (dollar value - not adjudicated) D.68.03 Professional Fee DDDDD (dollar value - not adjudicated) D.72.03 Special Services Fee(s) 1400 ($14.00) PRP

NOVEMBER 2012 24 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

The claims adjudication system will only allow the submission of one PIN per beneficiary per day. If multiple services are required for the same beneficiary on the same day, the following PINS have been established:

Second adaptation 93899983 Third adaptation 93899984

If more than three adaptations are required, manual claims should be submitted to the Pharmacare Programs. The Nova Scotia Formulary The Nova Scotia Formulary details which drugs are benefits under each Pharmacare Program. The Pharmacare News Bulletins provide pharmacies with recent changes to the Formulary. The Formulary and Bulletins may be accessed through the Nova Scotia Pharmacare Programs website at: www.nspharmacare.ca. The on-line Formulary (PDF) is updated monthly. Drugs which have been deemed non-benefits are also listed in the Formulary to indicate the entire range of agents available in a therapeutic class. The benefit column is blank for these agents. Drugs are listed according to the Anatomical Therapeutic Chemical (ATC) Classification System. The Formulary provides the following information for each drug:

name of each product manufactured (including dosage form and/or route and strength) authorized prescribers for each benefit whether a Maximum Reimbursable Price (MRP) applies whether a Pharmacare Reimbursement Price (PRP) applies benefit status (programs for which the product is a benefit) and exception drug status drug identification number (DIN) manufacturer interchangeability information (products grouped within a box are interchangeable).

Please refer to the Formulary for more information. Benefit Review Process The Nova Scotia Department of Health and Wellness relies on a number of different expert advisory committees to provide guidance regarding what drugs will be reimbursed under the public drug programs and under what conditions. To provide prescribers with information to better understand how benefit decisions are made, the following is a brief description of each committee. New Drugs to the Canadian Market New drugs to market and drugs with new indications are assessed through the national Common Drug Review (CDR). Through this process, an expert advisory committee known as the Canadian Drug Expert Committee (CDEC) reviews the new drug and makes a listing recommendation to publicly funded drug programs across the country (with the exception of Quebec). Each jurisdiction, such as Nova Scotia, must then make the final benefit listing and coverage decision. More information is available at www.cadth.ca.

Re-listing of Products From time to time discontinued products may be re-listed in the Formulary at the request of a manufacturer. Processes are in place to ensure that changes to the product since its discontinuation from the Formulary are reviewed accordingly.

Line Extensions The four Atlantic Provinces collaborate through the Atlantic Common Drug Review (ACDR) to review line extensions (e.g., new formats of strengths), review old funding decisions, and conduct drug class reviews. The Atlantic Expert Advisory Committee (AEAC), with experts in the fields of medicine and pharmacy, is involved in making a recommendation to the Nova Scotia Department of Health and Wellness. More information is available at www.gov.ns.ca/health/Pharmacare/committees/acdr.asp.

NOVEMBER 2012 25 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Generic Drugs The Nova Scotia Drugs and Therapeutics Committee reviews submissions from generic manufacturers to determine whether a pharmacist in Nova Scotia can use a generic brand if the prescription is written for a brand name product (interchangeability). The primary consideration is whether products are bioequivalent (produce similar blood levels as dictated by Health Canada guidelines) but other issues such as safety are also considered.

Cancer Drugs Nova Scotia has a Cancer Systemic Therapy Policy Committee (CSTPC) which advises the Department of Health and Wellness regarding the public funding of new cancer therapies. This committee includes membership from a wide variety of stakeholders including clinicians, cancer survivors, members of the public, economists, government, and a medical ethicist. More information available at: www.gov.ns.ca/health/cancer_drugs.

NOVEMBER 2012 26 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

PRICING PROCEDURES

Tariff Agreement The Nova Scotia Department of Health and Wellness negotiates with the Pharmacy Association of Nova Scotia to determine maximum professional fees, allowable mark-ups and definitions of the costs that pharmacies can charge for prescriptions covered under the Pharmacare Programs. A copy of the current Tariff Agreement is provided in Appendix I of this guide. Confirmation of Agreement The Confirmation of Agreement form (Appendix II) must be completed when a pharmacy opens or changes ownership, as well as when the usual and customary charge to cash customers changes. Pharmacare Reimbursement Drug costs billed to the Pharmacare Programs are reimbursed based on the following pricing categories:

Actual Acquisition Cost (AAC) Maximum Reimbursable Price (MRP) Pharmacare Reimbursement Price (PRP) Manufacturer’s List Price (MLP)

Actual Acquisition Costs (AAC) (AAC) are the net costs to the provider after deducting all rebates, allowances, free products, etc. No mark-up or buying profit is to be included in the calculation of the AAC. The ‘net cost’ to the provider is defined as the drug ingredient (or supply) costs based on the date of purchase and inventory flow, even though the current prices available may be lower or higher when the product is dispensed. Incentives for prompt payment (e.g., payment within 15 days up to a maximum of 2%) are not to be included in the calculation of the AAC. Maximum Reimbursable Price (MRP) MRP is the maximum reimbursable price established by the Pharmacare Programs for an interchangeable generic drug. MRP is applied to those drugs which are Pharmacare benefits, and have been deemed interchangeable (e.g., brand name drugs and their generic equivalents) The MRP is the maximum amount that the Pharmacare Programs will reimburse providers for one unit (tablet, capsule, millilitre, etc.) of a drug. For each interchangeable, generic drug category, a maximum reimbursable price per unit (e.g., tablet, capsule, and millilitre) is determined by calculating 35% of the cost of the equivalent brand name drug. Some generic drugs may have exceptions to the MRP formula and their MRP will also be included in the Reimbursement List. Exemptions to the MRP are available for beneficiaries who have experienced severe, life-threatening side effects with lower cost alternatives. A request must be received from the prescriber detailing the reaction. Collection of costs from beneficiaries for MRP drugs: Providers shall not charge any cost difference between the AAC of the drug and amount reimbursed by the Pharmacare Programs unless the beneficiary requests the higher priced drug. If the beneficiary requests the higher priced drug, the extra cost is not counted toward their annual maximum copayment or annual maximum deductible.

NOVEMBER 2012 27 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Pharmacare Reimbursement Price (PRP) PRP is the ‘special’ maximum price assigned to:

certain groups of drugs that are similar in therapeutic effect; specific services for which coverage is established; certain unit dose and special delivery formats that are also available in less expensive bulk formats; and certain supplies that are used for the same function; other products as determined by Pharmacare.

The PRP is the maximum amount the Pharmacare Program reimburses providers for one unit of a drug (tablet, capsule, millilitre, etc.) supply or service. In the case of methadone, one unit is a milligram. A complete list of current MRP and PRP can be found on the Reimbursement List on the Pharmacare website at www.nspharmacare.ca. Collection of costs from beneficiaries for PRP Drugs: Providers may charge the beneficiary the portion of their AAC that exceeds the PRP, but are not permitted to charge the beneficiary any excess mark-up, transition fee or dispensing fee beyond what is set out in the Tariff Agreement. Any extra cost is not counted toward the beneficiary’s annual maximum copayment or annual maximum deductible. Manufacturer’s List Price (MLP) Manufacturer’s list price is the manufacturer’s published price at which a drug or device is sold to a provider or wholesaler that does not include any mark-up for distribution. In all pricing categories, except AAC, the Pharmacare Programs will reimburse pharmacies the lesser of the amount submitted, or as applicable, MRP, MLP, or PRP. Product Shortages Interchangeable Products (non-PRP) In the event of the shortage of generic products on the Reimbursement List, the Pharmacare Programs can lift the MRP. This will allow for full reimbursement of the brand product, at MLP + 10.5%. Before this can be done, the shortage must be due to complete unavailability of all generic products in the interchangeable category, and be confirmed by the manufacturer, not the wholesaler level. The manufacturer must confirm a shortage before any changes are made to the reimbursement. Quantitative Limits Maximum Days Supply Pharmacies shall fill claims up to a maximum of 100 days supply if prescribed. However, Seniors’ Pharmacare Program beneficiaries traveling outside the province for more than 100 days will be allowed to obtain two prescriptions for the same medication before leaving Nova Scotia. Neither prescription shall exceed a 90 days supply (maximum 180 days supply for the two prescriptions). The usual copayment and pricing rules will apply to each of the prescriptions. This must be clearly documented on the prescription. The Pharmacare Programs will not pay multiple dispensing fees where the pharmacist dispenses a quantity less than the quantity prescribed. Therefore, more than one dispensing fee cannot be charged on a prescription when the original quantity is reduced and refills are generated, (even at the beneficiary’s request) unless the prescriber is contacted and the reduced quantity plus refills are authorized.

NOVEMBER 2012 28 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Minimum Days Supply The following is a list of ATC categories for which refill claims for drugs and products must be for a minimum of 28 days supply. Note: Injectables and compounded oral liquids that have been approved for an individual beneficiary within these ATC categories are exempt from the 28 day minimum supply policy. ATC CODE DESCRIPTOR

A02BA H2-Receptor Antagonists

A02BB Prostaglandins

A02BC Proton Pump Inhibitors

A02BX Other Drugs for Peptic Ulcer and Gastro-Esophageal Reflux Disease (GERD)

A09AA Enzyme Preparations

A10 Drugs Used for Diabetes

C01 Cardiac Therapy

C02 Antihypertensives

C03 Diuretics

C04 Peripheral Vasodilators

C07 Beta Blocking Agents

C08 Calcium Channel Blockers

C09 Agents Acting on the Renin-Angiotensin System

C10 Lipid Modifying Agents

G04BD Urinary Antispasmodics

G04CA Alpha Adrenoreceptor Antagonists

H03 Thyroid Therapy

M05 Drugs for Treatment of Bone Diseases

N06D Anti-Dementia Drugs

V07AY04 Insulin Syringes

V07AY05 Insulin Pen Needles

V07AY06 Diabetic Lancets The Pharmacare adjudication system will reject applicable Pharmacare claims for refills if the days supply is less than 28 days. The pharmacy will receive the message “DR” (Days supply lower than minimum allowable). Quantity Limits Quantity limits apply to certain Pharmacare benefits. Beneficiaries requiring quantities that exceed these limits must receive approval through the exception status request process. Applicable quantity limits: BENEFIT QUANTITY LIMIT TIME FRAME

AeroChamber® 1 12 month period April 1st to March 31st

Didrocal® and generics 6 12 month period April 1st to March 31st

Epipen®/Twinject 2 12 month period April 1st to March 31st

Medication Review Service 1 12 month period April 1st to March 31st

Proton Pump Inhibitors (PPI) 400 12 month period April 1st to March 31st

Xarelto® 14 12 month period April 1st to March 31st

Testosterone patches 120 Quarterly (Jan-Mar, Apr-Jul, etc.)

Triptans 18 Quarterly (Jan-Mar, Apr-Jul, etc.)

Pharmacies receive the response code “CM” (Patient is nearing quantity limit) when the benefit reaches 80% of the quantity limit.

Pharmacies receive the response code “CN” (Patient has reached quantity limit) when the beneficiary reaches 100% of the quantity limit

NOVEMBER 2012 29 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Pharmacies receive the response code “CO” (Patient is over quantity limit) when the claim rejects due to the quantity limit being previously met.

Standardization of Package Sizes In order to ensure claims are paid correctly, please use the following guidelines when calculating quantities for each claim and ensure your cost per unit is correct in your system. FORM QUANTITY FORM QUANTITY Aerosols Per dose Nasal sprays Per dose Capsules Per capsule Nebules Per ml Creams Per gram Ointments Per gram Enemas Per ml Oral contraceptives As 21 or 28 Gels Per gram Ostomy supplies Per item (e.g., 20 pouches)Inhalers Per dose Patches Per patch Insulins (vials, penfills, cartridges) Per ml Powders Per gram Kits Per kit Powder Injectables Per vial Lancets Per lancet Suppositories Per suppository Liquids Injectables Per ml Tablets Per tablet Liquids (except methadone) Per ml Testing strips Per testing strip Liquid methadone Per mg Other:

FORM QUANTITY

Package/Kits of more than one drug Per package (e.g., HP-Pac®, Monistat 3 Dual-Pack®, Didrocal®)

Packages of blood glucose testing strips with built-in meter

Per test strip (e.g., Sidekick® Blood Glucose Testing System)

Billing for Methadone Oral Liquid All claims for methadone oral liquid must be billed to the Nova Scotia Pharmacare Programs using the methadone compound PIN (00999734), regardless of the product you chose to use to prepare the oral liquid. Claims billed using the DINs for Metadol® 1mg/mL or 10mg/mL will be rejected. Beneficiaries who have been approved for Metadol® will automatically be approved for the methadone compound PIN (00999734). Methadone is to be billed to the Pharmacare Programs at MLP plus 10.5%. An MLP of $0.0050/mg has been established for methadone oral liquid. Compounded Products Anthralin Soft Paste PIN 00902063 0.05% PIN 00900907 0.1% PIN 00900915 0.2% Ingredients: Anthralin, Lassar’s paste (half strength) Anthralin Ointment PIN 00901105 0.2% PIN 00901113 0.4% Ingredients: Anthralin, emulsifying wax, mineral oil Disulfiram 250mg Capsule-PIN 00903079 Ingredients: disulfiram powder, gelatin capsules, lactose powder

NOVEMBER 2012 30 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Hydrocortisone Powder in Clotrimazole Cream (1% - 2.5%)-PIN 00999474* Ingredients: hydrocortisone powder, clotrimazole cream *Mixing hydrocortisone 1% cream with clotrimazole cream in equal parts will create a product of hydrocortisone 0.5% in ½ strength clotrimazole cream. This concentration is not insured under the Nova Scotia Pharmacare Programs and upon audit, any reimbursements for this compound will be recovered. LCD (Coal Tar) Preparations PIN 00358494 (any strength) PIN 00358495 (20% USP) Ingredients: LCD, petrolatum or hydrophilic ointment (lanolin, Eucerin®, Dermabase® etc.) Magic Mouthwash- PIN 00999022 Formulations: Diphenhydramine Syrup (Pediatric) 50mL Lidocaine Viscous 2% 25mL Attapulgite Suspension 25mL Diphenhydramine Syrup (Pediatric) 50mL Lidocaine Viscous 2% 25mL Magnesium/Aluminum Conc. Suspension 75mL Diphenhydramine Syrup (Pediatric) 50mL Attapulgite Suspension 50mL Diphenhydramine Syrup (Pediatric) 50mL Magnesium/Aluminum Suspension 50mL Methadone for Oral Liquid Compound-PIN 00999734 Ingredients: methadone, Tang® or similar product Salicylic Acid Ointment (any strength)-PIN 00900788 Ingredients: salicylic acid, white soft paraffin Tar Pomade-PIN 00901121 Ingredients: salicylic acid, coal tar solution, emulsifying ointment Uninsured Services Any service, such as compliance packaging, for which a tariff level has not been established, is an uninsured service under this agreement.

NOVEMBER 2012 31 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

BILLING THE PHARMACARE PROGRAM

Claim Information for Online Adjudication Claims to the Pharmacare Programs are transmitted in accordance with the Canadian Pharmacists Association (CPhA) Pharmacy Claim Standard, Version 03. Copies of the Standard can be obtained from: The Canadian Pharmacists Association 1785 Alta Vista Drive Ottawa, ON K1G 3Y6 Phone: (613) 523-7877 Fax: (613) 523-0445 The following are some important fields that are transmitted and adjudicated with each claim.

Pharmacy ID: number assigned by Pharmacare, Client ID, Client date of birth, Patient first and last name, Gender, Prescription number, Transaction date, DIN or assigned PIN, Quantity, Days supply, New or Repeat code, Number of refills, Prescriber ID, Drug cost, Mark-up, Professional fee, and Intervention and exception codes, if applicable (e.g., for on-line authorization of selected agents).

Prescriber Numbers

A physician’s assigned College of Physicians and Surgeons and Nova Scotia (CPSNS) number must be used when billing the Pharmacare Program.

Updated lists of physicians and their CPSNS numbers, as well as the billing numbers for optometrists and nurse practitioners who are authorized to prescribe to the Nova Scotia Pharmacare Programs, are provided to pharmacies by the Pharmacare office.

The “dummy” physician number of 9999 is only to be used when the prescriber is a medical resident without a CPSNS number or when a temporary prescriber number has not been assigned.

Out of province physicians should be indicated by the number 3333. The prescriber number 8888 is used for all dentists. The prescriber number 71111 is used for all pharmacists until individual prescribing numbers are

assigned.

NOVEMBER 2012 32 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Response Codes The following response codes below are commonly utilized by the Pharmacare Programs as per the Pharmacy Claims Standard. Please refer to the Claims Standard for a listing of all CPhA response codes.

30 – Carrier ID error 31 – Group ID number error 32 – Client ID error 34 – Patient DOB error 35 – Cardholder identity error 36 – Relationship error 37 – Patient first name error 38 – Patient last name error 40 – Patient gender error 56 – DIN error 58 – Quantity error 59 – Days supply error 61 – Prescriber ID error 62 – Product selection code error A1 – Claim too old A3 – Identical claim has been processed A6 – Submit manual claim A7 – Submit manual reversal A8 – No reversal made – original claim missing C2 – Services provided before effective date C4 – Coverage terminated before service C9 – Patient is not covered for drugs CD – Drug is not a benefit CM – Patient is nearing quantity limit CN – Patient has reached quantity limit CO – Patient is over quantity limit CP – Eligible for special authorization D1 – DIN is not a benefit DR – Days supply lower than minimum allowable MT – Drug/gender conflict indicated

Please note that the same DIN cannot be billed for a beneficiary twice on the same day. Payment will not be provided for the second prescription, generating a reject code of A3, “Identical claim has been processed”. Billing of Claims with Cost Exceeding $9,999.99 Currently pharmacy software systems do not allow for the online transmission of claims over $9,999.99. With the addition of newer high cost drugs, routine claims will likely exceed this amount. In order to allow for online adjudication claims that will exceed $9,999.99 must be divided and processed as two separate transactions as follows:

The first transaction should be submitted using the DIN for the product. The quantity should be adjusted to ensure the total cost of the claim, including ingredient cost, dispensing fee and mark up, does not exceed $9,999.99.

A second claim can be transmitted for the remaining quantity using the PIN assigned to the product. This PIN will pay ingredient cost only.

The copayment and deductible will be applied to both claims for beneficiaries enrolled in Seniors’, Community Service and Family Pharmacare Programs.

This process should only be used when the total claim for as written by the prescriber will exceed $9,999.99.

NOVEMBER 2012 33 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

The applicable DIN and PIN are listed below:

Incivek® (telaprevir) DIN 02371553, and PIN for the second claim 00999627

Patients will still require exception status approval prior to claims being paid online.

NOVEMBER 2012 34 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Manual Claims In very exceptional circumstances, or for providers who are not on-line, it may be necessary to bill the Pharmacare Programs utilizing a manual claim. Claims must be submitted within three months of the date of service. A charge of $0.25 per claim is deducted for each manual claim. This appears as a bottom line deduction on the payment statement. Manual Claim Form Sample The claim form consists of two parts, the Pharmacist Copy and MSI Copy. Below is the claim form with an explanation of the various fields.

PATIENT'S HEALTH NUMBER

A

PHARMACY NO

B

CLAIM NO. 000001

PATIENT'S NAME FIRST & SECOND NAME OF PHARMACY

SEX Y.O.B. SURNAME PRESCRIBING INITIALS / SURNAME DOCTOR PHARMACARE

P.O. BOX 500, HALIFAX, N.S. B3J 2S1

DETAILS OF COMPOUNDS / OSTOMY SUPPLIES ETC.

DATE PRESCRIPTION FILLED DAY MO. YR

C

DOCTOR NUMBER

D

PRESCRIPTION NO. DIN O/R REFILLS AUTH

QUANTITY DAYS SUPPLY

DRUG COST FEE MARK UP AMOUNT CHARGED

CO-PAY AMOUNT APPROVED

ADJ

E F G H I J K L M

I CERTIFY THAT THE ABOVE PRESCRIPTION(S) IS FOR THE SOLE USE OF THE PATIENT NAMED ABOVE WHO IS ELIGIBLE FOR BENEFITS UNDER THE MSI PHARMACARE PROGRAM.

X

I CERTIFY THIS TO BE A TRUE STATEMENT OF PRESCRIPTION(S) DISPENSED FOR THE PATIENT NAMED ABOVE.

A - Nova Scotia Health Card Number entered as follows 5555-555-555. B - Pharmacy Number as assigned by Pharmacare Program. C - Date entered numerically, e.g., 15.05.00 (= 15th of MAY 2000).

D - Prescriber number, e.g., 71111 for a pharmacist, 9999 for a medical resident, 8888 for a dentist. E - “O” for original or new prescription, “R” for refill. F - Refer to "Standardization of Package Sizes" in the guide. G - Drug cost (AAC, MRP or PRP). H - Professional fee. Do not put any mark-up in this field. I - Mark up (as per the Nova Scotia Pharmacare Tariff Agreement). J - Total cost of prescription. K - Amount of copayment charged to beneficiary, if applicable. LM - For Pharmacare use only.

NOVEMBER 2012 35 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Adjustments If a claim has been billed incorrectly on-line the pharmacist may, within 90 days of the original claim, reverse and resubmit the claim with the correct information. It is expected that pharmacists will check the response screen when claims are submitted to determine if the appropriate amount has been paid, instead of waiting to identify problems when the payment statement arrives. After 90 days, reversals and adjustments must be submitted on a Request for Adjustments Form (reference sample below). This form is also used for adjustments to manual claims. Adjustments to previously paid claims can be submitted up to a maximum of six months from the date of service. Pharmacare staff will make the necessary adjustments and these will appear on the next pharmacy statement. Should there be a problem, the request for adjustment will be returned to the pharmacy with an explanation.

NS PHARMACARE PROGRAMS - REQUEST FOR ADJUSTMENTS DATE: PHARMACY NAME: NUMBER:

PAYMENT STATE. DATE - ________________________

CLAIM NO. - ________________________

REFERENCE NO. - ________________________

HEALTH CARD NO. - ________________________

PRESCRIPTION NO. - ________________________

DATE RX DISPENSED - ________________________

CO-PAY CHARGED - ________________________

REASON FOR ADJUSTMENT

______________________________________________

______________________________________________

______________________________________________

______________________________________________

_________________________________________

PHARMACARE REPLY

________________________________

________________________________

________________________________

________________________________

________________________________

PAYMENT STATE. DATE - ________________________

CLAIM NO. - ________________________

REFERENCE NO. - ________________________

HEALTH CARD NO. - ________________________

PRESCRIPTION NO. - ________________________

DATE RX DISPENSED - ________________________

CO-PAY CHARGED - ________________________

REASON FOR ADJUSTMENT

______________________________________________

______________________________________________

______________________________________________

______________________________________________

______________________________________________

________________________________________

PHARMACARE REPLY

________________________________

________________________________

________________________________

________________________________

________________________________

________________________________

PAYMENT STATE. DATE - ________________________

CLAIM NO. - ________________________

REFERENCE NO. - ________________________

HEALTH CARD NO. - ________________________

PRESCRIPTION NO. - ________________________

DATE RX DISPENSED - ________________________

CO-PAY CHARGED - ________________________

REASON FOR ADJUSTMENT

______________________________________________

______________________________________________

______________________________________________

______________________________________________

______________________________________________

______________________________________________

PHARMACARE REPLY

________________________________

________________________________

________________________________

________________________________

________________________________

___________________ ____________

PAYMENT STATE. DATE - ________________________

CLAIM NO. - ________________________

REFERENCE NO. - ________________________

HEALTH CARD NO. - ________________________

PRESCRIPTION NO. - ________________________

DATE RX DISPENSED - ________________________

CO-PAY CHARGED - ________________________

REASON FOR ADJUSTMENT

______________________________________________

______________________________________________

______________________________________________

______________________________________________

______________________________________________

_____________________________________________

PHARMACARE REPLY

________________________________

________________________________

________________________________

________________________________

________________________________

________________________________

NOVEMBER 2012 36 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Medications Returned to Stock Pursuant to the guidelines set out in the “Return of Medication” policy of the Nova Scotia College of Pharmacists. Prescriptions that were billed to the Pharmacare Programs but never provided to the beneficiary must be credited to the Pharmacare Programs and reissued. Returned prescription medications should be credited to the Programs by using the “Statement of Returned Medications” form (reference sample below). The quantity, description, and total drug cost associated with each item must be provided. A restocking fee of 20% of the value of medications returned for reuse is allowed. A cheque for the net amount can be submitted with the form or the net amount will be deducted from a future payment statement.

NOVA SCOTIA MEDICAL SERVICES INSURANCE P.O. BOX 500, HALIFAX, N.S. B3J 2S1

STATEMENT OF RETURNED MEDICATION PHARMACY NUMBER DATE

PHARMACY NAME INSTITUTION NAME

ADDRESS ADDRESS

QUANTITY DESCRIPTION AMOUNT

CHECK √ ONE TOTAL

□ PAYMENT ENCLOSED FOR THE NET AMOUNT

□ DEDUCT THE NET AMOUNT FROM PAYMENT STATEMENT

LESS RESTOCKING FEE

NET AMOUNT �

I CERTIFY THIS TO BE AN ACCURATE STATEMENT OF THE MEDICATIONS DESTROYED AND OF THE AMOUNT DUE MSI FOR RETURNED MEDICATIONS RESTOCKED TO INVENTORY SIGNATURE OF PHARMACIST

I CERTIFY THIS TO BE AN ACCURATE STATEMENT OF MEDICATIONS EITHER RETURNED TO THE PHARMACY OR DESTROYED IN MY PRESENCE SIGNATURE OF ADMINISTRATOR OR DESIGNEE

NOVEMBER 2012 37 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Reimbursement for Unreturnable Products: Injectables and Ostomy Supplies As part of the Tariff Agreement negotiations, a process was developed to reimburse pharmacies for the cost of injectable medications and ostomy supplies that cannot be returned to the point of purchase. This process is intended to remove the financial risk for pharmacies who stock injectable medications and ostomy supplies for Pharmacare beneficiaries that are subsequently not needed, and cannot be returned to the point of purchase. This process will apply when the injectable medication or ostomy supply has been ordered for, and is an eligible benefit for a Pharmacare beneficiary. Pharmacies will be reimbursed for the AAC of the medication, provided it cannot be returned to the point of purchase for credit. Each request must also be accompanied by a fully completed “Request for Reimbursement Form”, with all required documentation, and will only be considered under the following conditions:

The provider is an approved Pharmacare provider and has been assigned a provider ID number. The product was ordered for a claimant who was an eligible resident and enrolled in a Pharmacare

Program at the time the product was ordered. The provider must provide the DIN/PIN, trade name, lot number, expiry date, and manufacturer of the

product and the health card number of the Pharmacare beneficiary. The provider must submit a copy of the prescription. The provider must submit a copy of the invoice showing the AAC of the product. The product was an eligible benefit in the Nova Scotia Formulary for the Pharmacare Program under

which the resident was a beneficiary at the time it was purchased. Note that exception status products are only eligible for reimbursement if the resident had been approved for them through the exception status approval process at the time the product was received.

The product is not eligible for return according to the policies of the wholesaler or manufacturer from which it was purchased.

The request for reimbursement is received within six (6) months of the date on the prescription. If the request qualifies for reimbursement, an adjustment will be applied on the next pharmacy statement. Should there be a problem the request for adjustment will be returned to the pharmacy with an explanation.

The process will be monitored on an ongoing basis to ensure the needs of all stakeholders are met. Please do not hesitate to contact the Pharmacare Programs if you have any questions or concerns.

NOVEMBER 2012 38 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

REQUEST FOR CREDIT INJECTABLES AND OSTOMY SUPPLIES

PHARMACY NAME: PROVIDER NUMBER: CONTACT PERSON:

PATIENT NAME:

HEALTH CARD NUMBER:

PRODUCT NAME:

DIN:

DATE PRODUCT WAS DISPENSED:

DATE OF REVERSAL:

(ATTACH COPY OF ORIGINAL PRESCRIPTION) DATE PRODUCT WAS PURCHASED:

MANUFACTURER:

(ATTACH COPY OF INVOICE) LOT NUMBER:

EXPIRY DATE:

TOTAL AMOUNT CLAIMED: $

I CERTIFY THAT THE ABOVE PRESCRIPTION WAS FOR THE SOLE USE OF THE PATIENT NAMED ABOVE WHO

IS ELIGIBLE FOR BENEFITS UNDER THE NOVA SCOTIA PHARMACARE PROGRAM. I CERTIFY THAT ALL

REASONABLE ATTEMPTS HAVE BEEN MADE TO RETURN THIS PRODUCT TO THE POINT OF PURCHASE

AND WERE UNSUCCESSFUL. X

PLEASE ATTACH:

A COPY OF THE ORIGINAL PRESCRIPTION A COPY OF THE INVOICE WITH DATE OF PURCHASE AND AAC

Please be advised that the only claims considered are those that cannot be returned to the point of purchase for credit. Requests for reimbursement will only be considered if submitted within six months of the date of service. Mail to: Nova Scotia Pharmacare Programs PO Box 500 Halifax, NS B3J 2S1

Or Fax: (902)468-9402

NOVEMBER 2012 39 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

Payments and Statements Payments to pharmacies are made every two weeks on a predetermined schedule and are deposited electronically into the appropriate account. The cut-off date, for claims to be included in the payment, is three days prior to the payment date. A payment statement is generated on the predetermined date and itemizes each claim paid.

A double asterisk beside a claim indicates that the amount paid is different from the amount claimed. Rejected claims are not included on the payment statement. Reversed claims are indicated by a zero amount claimed and a negative amount paid. Bottom line adjustments appear on the last page of the statement and are deducted from the total amount

owed to the pharmacy. These adjustments include a $0.03 per claim deduction which is forwarded to the Pharmacy Association of Nova Scotia, and may also include any charges recovered due to an audit, medications returned to stock, and deductions of $0.25 for each manual claim submitted.

Below is a sample of the Payment Statement Form:

Claim Number Reference Number Adjustment Codes Numbers are in sequence. This number should be quoted when you are If the amount paid is less than the amount corresponding with MSI — the number claimed an adjustment code will be entered. uniquely identifies each claim. — below is a list of the codes.

Pharmacy Number Day Mo. Year Page

NOVA SCOTIA MEDICAL SERVICES INSURANCE P.O. BOX 500, HALIFAX, NS B3J 2S1

CLAIM NUMBER

NAME

REFERENCE NUMBER

SERVICE REGISTRATION NO.

AMOUNT CLAIMED

AMOUNT PAID

ADJ.

DAY MO. YR.

Adjustment Codes

22 – Provider transaction data error A2 – Claim is post dated 32 – Patient Identification Information error A3 – Identical claim has been processed 52 – New/refill code error C2 – Service provided before effective date 56 – DIN error C4 – Coverage terminated before service 58 – Quantity error D1 – DIN not a benefit 59 – Days supply error TS – Trial Prescription error 61 – Prescriber ID error **-Payment reduced to comply with Tariff

Agreement 66 – Drug cost error

NOVEMBER 2012 40 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

AUDIT

Pharmacare Audit Pharmacare Audit P.O. Box 500, Halifax, NS B3J 2S1 Local calls: 496-7030 or 496-7511 Toll free: 1-800-563-8880 The MSI Monitoring department performs the following types of Pharmacare audits:

Pricing Audit Pricing audit consists of a review of prices and quantities submitted to ensure the Pharmacare Programs were billed correctly.

Prescription Audit

A prescription audit is conducted to determine if the provider has on file valid prescriptions to support claims paid. Detailed information associated with the prescription audit process can be found in the “Pharmacare Prescription Audit Recovery Procedures” below. The specified guidelines are applicable to all providers billing the Pharmacare Programs, including home health care suppliers, hospitals, long term care facilities, and dispensing physicians.

Prescription Verification

A percentage of prescriptions audited may be verified with the prescriber(s) to ensure that prescriptions were prescribed as claimed. For example, a diagnosis of Community Acquired Pneumonia (CAP) documented on the prescription by the pharmacist may be verified with the prescriber.

PHARMACARE PRESCRIPTION AUDIT RECOVERY PROCEDURES

Pharmacare Prescription Audit Recovery Procedures The purpose of the Pharmacare prescription audit is to confirm that the details of a prescription paid under the Pharmacare Programs comply with the corresponding prescription on file in the pharmacy and support overall effective operations of the Programs. Providers are audited on a regular basis. Specific audits may be conducted as warranted. In general, a sample consists of at least 100 prescriptions. The documentation to support the prescription claimed must be available for review during the on-site audit. For the calculation of an audit recovery, information subsequently solicited from or provided by the prescriber will not be used to support the prescription claimed; only the documentation available at the time of the audit will be considered.

NOVEMBER 2012 41 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

AUDIT FINDINGS ACTION 1. PATIENT’S NAME (i) First initial/first name or surname missing (ii) No patient name is indicated

Recover professional fee for original and any refills. Recover total amount paid for original and any refills.

2. DRUG NAME/PRODUCT NAME NOT INDICATED Recover total amount paid for original and any refills.

3. NO DRUG STRENGTH INDICATED WHERE MULTIPLE STRENGTHS EXIST.

Recover total amount paid for original and any refills.

4. NO QUANTITY OR NO DOSAGE DIRECTIONS INDICATED FOR DRUG PRESCRIBED.

Unless the quantity claimed is the only size manufactured and the package format is such that it cannot be divided (e.g., inhalers, insulins, and ophthalmic/otic products) recover professional fee(s) for original and any refills. If no quantity and no dosage directions indicated, recover total amount paid for original and any refills.

5. SMALLER QUANTITY CLAIMED THAN PRESCRIBED Recover excess professional fee(s).

6. LARGER QUANTITY CLAIMED THAN TOTAL QUANTITY PRESCRIBED

Unless the quantity claimed has been adjusted to comply with the minimum 28 days supply requirement regarding select products, recover excess drug cost for original and any refills.

7. AUTHORIZED SIGNATURE OF PRESCRIBER NOT PRESENT ON WRITTEN PRESCRIPTION

Recover professional fee(s) for original and any refills.

8. REFILLS FOR DRUG PRESCRIBED (i) More refills claimed than authorized by prescriber

(ii) Non-specific refill directions, e.g., “PRN”, and “1Year”

Recover total amount paid for excess refills. Recover total amount paid for any refills.

NOVEMBER 2012 42 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

AUDIT FINDINGS ACTION

9. MISSING PRESCRIPTION(S) (i) One or two prescriptions

(ii) Three or more prescriptions

Recover the professional fee for original(s) and any refills, if the prescriptions cannot be located during the on-site audit. Recover the total amount paid for original(s) and any refills associated with every missing prescription, if the prescriptions cannot be located during the on-site audit.

10. DIFFERENT DRUG CLAIMED THAN PRESCRIBED

Recover total amount paid for original and any refills (e.g., Hyderm® 1% Cream cannot be claimed if Cortate® 1% Cream is prescribed). Only products indicated as interchangeable in the Nova Scotia Formulary may be selected for interchangeability.

11. UNINSURED PRODUCT CLAIMED UNDER AN INSURED DIN/PIN

Recover total amount paid for original and any refills.

12. CRITERIA CODE OR DIAGNOSIS SUPPORTING PAYMENT NOT INDICATED ON PLAN EXCEPTION PRESCRIPTION CLAIMED WITH CRITERIA CODE.

Recover total amount paid for original and any refills.

13. NO PATIENT CONSENT AND DISCLOSURE FOR

PHARMACIST PRESCRIBED DRUGS AND SERVICES

Recover total amount paid for original and any refills.

Overall Findings Based on the overall audit findings, the audit sample size and audit time period may be increased to further determine the extent of infractions. The sample audit results may be extrapolated over all of the claims paid during the period from which the same was drawn for the purpose of calculating recovery. A percentage of prescriptions audited may be verified with the prescriber(s) to ensure the prescriptions were prescribed as claimed. The following examples: “Refill Rx #6234567”, “Refill Lanoxin® X 6”, “Refill all meds as before X 3”, all lack some components of a valid prescription, i.e., drug name, strength, quantity, or dosage directions. In order to avoid recoveries for invalid prescriptions, any missing or incomplete prescription information is to be verified prior to dispensing and added to the prescription. As well, any alteration of the original prescription is to be verified in a similar manner.

NOVEMBER 2012 43 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

APPENDIX I PHARMACARE TARIFF AGREEMENT

NOVEMBER 2012 44 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 45 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 46 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 47 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 48 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 49 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 50 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

APPENDIX II PHARMACARE CONFIRMATION OF AGREEMENT FORM

NOVEMBER 2012 51 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

APPENDIX III PROVIDER APPEALS REGULATIONS

NOVEMBER 2012 52 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 53 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 54 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 55 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 56 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

NOVEMBER 2012 57 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

APPENIX IV NOTICE OF APPEAL BY PROVIDER

NOVEMBER 2012 58 NOVA SCOTIA PHARMACARE PROGRAMS – PHARMACISTS’ GUIDE

DECEMBER 2012 • VOLUME 12-12 PHARMACISTS’ EDITION

Nova Scotia Formulary Updates

Update of Criteria and New ESD Form for Osteoporosis Therapies New Exception Status Benefits

- Brilinta® - Saphris®

Non-Insured Products - Resotran®

Included with this Bulletin: Pharmacare Payment Schedule Osteoporosis Form

Nova Scotia Formulary Updates Update of Criteria and New ESD Form for Osteoporosis Therapies Included in this bulletin is an updated form which can be used to request coverage of therapies for the treatment of osteoporosis. The form includes all therapies available on the formulary for this condition. The form and the criteria for coverage for oral bisphosphates has been adjusted to reflect current treatment and diagnostic methods. Coverage for oral bisphosphonates includes:

1. Current/Previous Fragility Fracture 2. On or Will be on Oral Prednisone for 3 months 3. High Ten Year Fracture Risk (>20%) as indicated by the radiologist on a

bone mineral density (BMD) report Note: Fracture risk tables are no longer provided on the form. Instead radiologists use the CAROC risk assessment tool to determine the 10 year fracture risk which considers BMD results as well as other patient factors. The radiologist typically indicates fracture risk on the returned BMD report. As a reminder, alendronate (10mg, 70mg), risedronate (5mg, 35mg), and alendronate/colecalciferal 70mg/5600IU (Fosavance®) are provided as first line therapies when a patient meets these criteria. Other therapies listed on the request form are insured when these agents are not tolerated or are contraindicated as per their specific criteria. Full coverage criteria for each agent have been previously published and are detailed in the Nova Scotia Formulary and in the Criteria for Exception Status Drugs documents available on the Pharmacare website http://www.gov.ns.ca/health/pharmacare.

PAGE 2 OF 3PHARMACISTS’ EDITION

VOLUME 12-12

New Exception Status Benefits The following products were reviewed by the Canadian Drug Expert Committee (CDEC) and will be listed as exception status benefits, with the following criteria, effective December 1, 2012.

PRODUCT STRENGTH DIN PRESCRIBERBENEFITSTATUS

MFR

Brilinta®(ticagrelor)

90mg Tab 02368544 DNP E (SF) AZE

Criteria - To be taken in combination with ASA 75 mg -150mg daily1 for patients with acute coronary syndrome (i.e. ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), or unstable angina (UA), as follows: STEMI2,3

STEMI patients undergoing primary percutaneous coronary intervention (PCI)

NSTEMI or UA2,3

Presence of high risk features irrespective of intent to perform revascularization: - High GRACE risk score (>140) - High TIMI risk score (5-7) - Second ACS within 12 months - Complex or extensive coronary artery disease e.g. diffuse three vessel

disease - Definite documented cerebrovascular or peripheral vascular disease - Previous CABG

ORUndergoing PCI + high risk angiographic anatomy4

- Coverage duration 12 months NOTE: Criteria Code 30 may be used for the initial 30 days coverage period, however a written request from the prescriber is also required to allow coverage for the remaining duration of treatment. 1 Co-administration of ticagrelor with high maintenance dose ASA (>150 mg daily) is not

recommended. 2 In the PLATO study more patients on ticagrelor experienced non CABG related major

bleeding than patients on clopidogrel, however, there was no difference between the rate of overall major bleeding, between patients treated with ticagrelor and those treated with clopidogrel. As with all other antiplatelet treatments the benefit/risk ratio of antithrombotic effect vs. bleeding complications should be evaluated.

3 Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment.

4 High risk angiographic anatomy is defined as any of the following: left main stenting, high risk bifurcation stenting (i.e., two-stent techniques), long stents 38 mm or overlapping stents, small stents 2.5 mm in patients with diabetes.

PAGE 3 OF 3PHARMACISTS’ EDITION

VOLUME 12-12

New Exception Status Benefits continued…

PRODUCT STRENGTH DIN PRESCRIBERBENEFITSTATUS

MFR

Saphris®(asenapine)

5mg SL Tab 10mg SL Tab

02374803 02374811

DNP DNP

E (SF) E (SF)

FRS FRS

Criteria For the acute treatment of manic or mixed episodes associated with bipolar I disorder as either:

Monotherapy, after a trial of lithium or divalproex sodium has failed, and trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response Co-therapy with lithium or divalproex sodium, after trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response

Decision Highlights Asenapine is an atypical antipsychotic agent available as a sublingual tablet. Health Canada approved asenapine for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia. It was recommended that asenapine not be insured for the treatment of schizophrenia. Asenapine failed to consistently demonstrate superiority in the five placebo-controlled trials; and in one of the three trials comparing olanzapine with asenapine, olanzapine was superior to asenapine based on the primary outcome and a number of secondary outcomes.

Non-Insured Products

The following product was reviewed by the Canadian Drug Expert Committee (CDEC) and was not recommended to be listed as an insured benefit under the Nova Scotia Pharmacare Programs.

PRODUCT STRENGTH DIN PRESCRIBERBENEFITSTATUS

MFR

Resotran®(prucalopride)

1mg Tab 2mg Tab

02377012 02377020

N/A N/A

Not Insured Not Insured

JAN JAN

Decision Highlights Prucalopride has a Health Canada indication for the treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. Given the uncertain clinical effectiveness in patients who had previously failed laxative therapy, the Canadian Drug Expert Committee noted that there was uncertainty regarding the cost-effectiveness of prucalopride. At the recommended daily doses, the cost of prucalopride ranges from $2.15 (1mg for adults > 65 years) to $3.30 (2mg daily for adults 65 years). Most oral laxatives cost < $1 a day.

NOVA SCOTIA PHARMACARE PROGRAMS

2013

CUT-OFF DATES, PAYMENT DATES & RUN NUMBERS

CUT-OFF DATE

RUN DATE

PAYMENTDATE

RUN #

CUT-OFF DATE

RUN DATE

PAYMENTDATE

RUN #

7-Jan-13 8-Jan-13 11-Jan-13 1 AI 8-Jul-13 9-Jul-13 12-Jul-13 1 GJ

21-Jan-13 22-Jan-13 25-Jan-13 1 AS 22-Jul-13 23-Jul-13 26-Jul-13 1 GT

4-Feb-13 5-Feb-13 8-Feb-13 1 BF 5-Aug-13 6-Aug-13 9-Aug-13 1 HG

18-Feb-13 19-Feb-13 22-Feb-13 1 BP 19-Aug-13 20-Aug-13 23-Aug-13 1 HQ

4-Mar-13 5-Mar-13 8-Mar-13 1 CF 2-Sep-13 3-Sep-13 6-Sep-13 1 IE

18-Mar-13 19-Mar-13 22-Mar-13 1 CP 16-Sep-13 17-Sep-13 20-Sep-13 1 IO

1-Apr-13 2-Apr-13 5-Apr-13 1 DE 30-Sep-13 1-Oct-13 4-Oct-13 1 JD

15-Apr-13 16-Apr-13 19-Apr-13 1 DO 14-Oct-13 15-Oct-13 18-Oct-13 1 JN

29-Apr-13 30-Apr-13 3-May-13 1 EC 28-Oct-13 29-Oct-13 1-Nov-13 1 KA

13-May-13 14-May-13 17-May-13 1 EM 11-Nov-13 12-Nov-13 15-Nov-13 1 KK

27-May-13 28-May-13 31-May-13 1 EW 25-Nov-13 26-Nov-13 29-Nov-13 1 KU

10-Jun-13 11-Jun-13 14-Jun-13 1 FJ 9-Dec-13 10-Dec-13 13-Dec-13 1 LJ

24-Jun-13 25-Jun-13 28-Jun-13 1 FT 18-Dec-12** 19-Dec-12** 27-Dec-12 1 LT

CLAIMS MUST BE RECEIVED BY 11:59 P.M. ON CUT-OFF DATE

TO ENSURE PROCESSING FOR THAT PAYMENT PERIOD.

PLEASE NOTE, THE ** INDICATES A DATE VARIATION

12/2012

Please Return Form To: Nova Scotia Pharmacare Department, P.O. Box 500, Halifax, NS B3J 2S1 FAX: (902) 468-9402

REQUEST FOR COVERAGE OF OSTEOPOROSIS THERAPY

P A T I E N T I N F O R M A T I O N

PATIENT'S SURNAME PATIENT'S GIVEN NAME HEALTH CARD NUMBER DATE OF BIRTH

PATIENT'S ADDRESS

D R U G R E Q U E S T E D

Alendronate ____mg (10mg, 70mg) Risedronate ____mg (5mg, 35mg)

Alendronate/Cholecalciferal 70mg/5600IU

Calcitonin Nasal Spray – for fracture pain x 3 months only

The following choices must be explained:

Raloxifene 60 mg Etidronate 200mg Etidronate/Calcium Kit 400mg/500mg

Denosumab 60mg/mL Zoledronic acid 5mg/100mL Calcitonin Nasal Spray - long term

Explanation:

D I A G N O S T I C I N F O R M A T I O N

Please indicate the clinical indication for oral bisphosphonate therapy. At least one of the following criteria must be fulfilled for coverage to be provided.

Previous/Current Fragility* Fracture (As per the 2010 Osteoporosis Canada (OC) Clinical Practice Guidelines, fractures of the skull, hands, feet and ankles are not considered fragility fractures)

On or will be on therapy with oral prednisone for 3 months. Once prednisone is stopped assess further need‡ for antiresorptive therapy

High 10 year fracture risk (>20%) as indicated by the radiologist on a BMD report

Exceptional circumstances predicting high 10 year fracture risk. Provide details below:

* Defined as a fracture that occurs as a result of minimal trauma such as a fall from standing height or less (at no greater than walking speed) or no identifiable trauma. The most common fragility fractures occur in the wrist, spine and hip.

‡The 2010 Canadian OC guidelines recommend that antiresorptive therapy be continued for at least the duration of the CS

therapy. The “at least” recognizes that fracture risk does not return to pretreatment levels immediately upon discontinuation of the CS. Antiresorptive therapy may be continued up to 18 months after stopping corticosteroids.

COMMENTS:

PHYSICIAN’S NAME & ADDRESS:

CPSNS #: _____________ _________________________________ ______________ PHYSICIAN'S SIGNATURE DATE

PAGE 1 OF 5

DISCONTINUED PRODUCTS

Discontinued Products in the Nova Scotia Formulary The respective manufacturers have given notification of the discontinuation of the products listed below. The products are already removed or marked as discontinued in the new Nova Scotia Formulary. They will continue to be insured until existing stock is depleted.

PRODUCT DIN MFR

Amoxicillin 250mg Chewtab 02352737 SAS APC-Loperamide 2mg tab 02212005 APX Apo-Bisacodyl 10mg supp 00754595 APX Apo-Cefaclor 250mg cap 02230263 APX Apo-Cefaclor 500mg cap 02230264 APX Apo-Cloxi 250mg cap 00618292 APX Apo-Cloxi 25mg/mL o/l 00644633 APX Apo-Cloxi 500mg cap 00618284 APX Apo-Haloperidol Liq 2mg/mL 00587702 APX Apo-Hydroxyurea 500mg Cap 02247937 APX Apo-Naproxen SR 750mg tab 02177072 APX Assura Easiclose Drainable 95098461 COL Assura Easiclose Drainable 95099062 COL Assura Easiclose Drainable 95098470 COL Assura Easiclose Drainable 95098474 COL Assura Easiclose Drainable 95098476 COL Assura E-E Wear 95099112 COL Assura E-E Wear Drainable 95099016 COL Assura E-E Wear Drainable 95099018 COL Assura E-E Wear Drainable 95099014 COL Assura E-E Wear Drainable 95099013 COL Assura Pediatric Closed 95098882 COL Assura Std Wear 95099089 COL Assura Std Wear Closed 95098900 COL Assura Std Wear Closed 95098890 COL Assura Std Wear Closed 95098896 COL Assura Std Wear Closed 95098904 COL Assura Std Wear Closed 95098897 COL Assura Std Wear Closed 95098892 COL

PAGE 2 OF 5

DISCONTINUED PRODUCTS

Discontinued products continued…

PRODUCT DIN MFR

Assura Std Wear Closed 95098893 COL Assura Std Wear Closed 95098891 COL Assura Std Wear Dr Easiclose 95098515 COL Assura Std Wear Drainable 95098949 COL Assura Std Wear Drainable 95098948 COL Assura Std Wear Drainable 95098947 COL Assura Std Wear Drainable 95098946 COL Assura Std Wear Drainable 95098964 COL Assura Std Wear Drainable 95098958 COL Assura Std Wear Drainable 95098957 COL Assura Std Wear Drainable 95098956 COL Assura Std Wear Drainable 95098955 COL Assura Std Wear Drainable 95098954 COL Assura Std Wear Drainable 95098953 COL Assura Std Wear Drainable 95098952 COL Assura Std Wear Drainable 95098951 COL Assura Std Wear Drainable 95098950 COL Assura Std Wear Drainable 95098961 COL Assura Std Wear Drainable 95098945 COL Assura Std Wear Drainable 95098944 COL Assura Std Wear Drainable 95098943 COL Assura Std Wear Drainable 95098942 COL Assura Std Wear Drainable 95098941 COL Assura Std Wear Drainable 95098940 COL Assura Std Wear Drainable 95098939 COL Assura Std Wear Drainable 95098938 COL Assura Std Wear Drainable 95098937 COL Assura Two-Piece Drainable 95099052 COL Assura Two-Piece Drainable 95099051 COL Assura Two-Piece Drainable 95099046 COL Assura Two-Piece Drainable 95099049 COL Assura Two-Piece Drainable 95099048 COL

PAGE 3 OF 5

DISCONTINUED PRODUCTS

Discontinued products continued…

PRODUCT DIN MFR

Assura Two-Piece Drainable 95099047 COL Bonamine 25mg tab 00220442 JNJ Cedocard-SR 20mg Tab 00740721 PAL Clonidine 0.025mg Tab 02361299 SAS Clonidine 0.1mg Tab 02361302 SAS Clonidine 0.2mg Tab 02361310 SAS Daypro 600mg cap 02027860 PFI Desocort 0.05% Lot 02115514 GAC Desocort 0.05% Oint 02115522 GAC Easiflex Closed 95098815 COL Easiflex Closed 95098817 COL Easiflex Closed 95098820 COL Easiflex Closed 95098819 COL Easiflex Drainable w Easiclose 95098830 COL Easiflex Drainable w Easiclose 95098834 COL Easiflex Drainable w Easiclose 95098833 COL Easiflex Drainable w Easiclose 95098487 COL Emo-Cort Scalp Sol 2.5% 00641154 GSK Gleevec 100mg Cap 02244725 NVR Livostin 0.5mg/mL oph sol 02131625 NVR Lopid 600mg tab 00659606 PFI Minocin 100mg cap 02173506 GSK Minocin 50mg Cap 02173514 STI Novo-Ferrogluc 300mg Tab 00021458 TEV PhylloContin 225mg tab 02014270 PFR PhylloContin 350mg tab 02014289 PFR pms-Bezafibrate 200mg tab 02240331 PMS pms-Buspirone 5mg tab 02230941 PMS pms-Chloral Hydrate 500mg cap 00811882 PMS pms-Clobetasol 0.05% Oint 02232193 PMS pms-Codeine 15mg tab 02243978 PMS pms-Dipivefrin 0.1% oph sol 02237868 PMS

PAGE 4 OF 5

DISCONTINUED PRODUCTS

Discontinued Products Continued…

PRODUCT DIN MFR

pms-Doxycycline 100mg cap 02289539 PMS pms-Doxycycline 100mg tab 02289466 PMS pms-Fluoxetine 20mg/5mL syr 02177595 PMS pms-Fluphenazine 100mg/mL inj 02241928 PMS pms-Fluphenazine 25mg/mL inj 02091275 PMS pms-Gentamicin 0.3% otic sol 02230889 PMS pms-Loxapine 25mg/mL oral concentrate 02239101 PMS pms-Moclobemide 300mg tab 02243219 PMS pms-Moclobemide 300mg tab 02243219 PMS pms-Morphine SR Sulfate 30mg tab 02245285 PMS pms-Morphine SR Sulfate 60mg tab 02245286 APX pms-Morphine SR Sulfate 100mg tab 02245287 PMS pms-Piroxicam 10mg cap 00836249 PMS pms-Selegiline 5mg tab 02238102 PMS pms-Tobramycin 0.3% Oph Sol 02239577 PMS ratio-Alendronate 70mg tab 02275279 TEV ratio-Clonazepam 0.5mg tab 02103656 TEV ratio-Clonazepam 2mg tab 02103737 TEV ratio-Cyclobenzaprine 10mg tab 02236506 TEV ratio-Enalapril 10mg tab 02300001 TEV ratio-Enalapril 2.5mg tab 02299984 TEV ratio-Enalapril 20mg tab 02300028 TEV ratio-Enalapril 5mg tab 02299992 TEV ratio-Gabapentin 100mg cap 02260883 TEV ratio-Gabapentin 300mg cap 02260891 TEV ratio-Gabapentin 600mg tab 02260913 TEV ratio-Gabapentin 800mg tab 02260921 TEV ratio-Minocycline 100mg cap 01914146 TEV ratio-Minocycline 50mg cap 01914138 TEV ratio-Morphine SR 15mg tab 02244790 TEV ratio-Pantoprazole 20mg tab 02308681 TEV ratio-Pantoprazole 40mg tab 02308703 TEV

PAGE 5 OF 5

DISCONTINUED PRODUCTS

Discontinued Products Continued…

PRODUCT DIN MFR

ratio-Pravastatin 10mg tab 02246930 TEV ratio-Pravastatin 20mg tab 02246931 TEV ratio-Pravastatin 40mg tab 02246932 TEV ratio-Quetiapine 100mg tab 02311712 TEV ratio-Quetiapine 200mg tab 02311747 TEV ratio-Quetiapine 25mg tab 02311704 TEV ratio-Quetiapine 300mg tab 02311755 TEV ratio-Quetiapine 300mg tab 02311755 TEV ratio-Ramipril 10mg cap 02287722 TEV ratio-Ramipril 15mg cap 02311194 TEV Ratio-Ramipril 5mg cap 02287714 TEV ratio-Sertraline 100mg cap 02245789 TEV ratio-Sertraline 25mg cap 02245787 TEV ratio-Sertraline 50mg cap 02245788 TEV ratio-Simvastatin 20mg tab 02247069 TEV ratio-Simvastatin 40mg tab 02247070 TEV ratio-Topiramate 100mg tab 02256835 TEV ratio-Topiramate 200mg tab 02256843 TEV ratio-Topiramate 25mg tab 02256827 TEV ratio-Trazodone 100mg tab 02277352 TEV ratio-Trazodone 150mg tab 02277360 TEV ratio-Trazodone 50mg tab 02277344 TEV ratio-Valproic Acid 250mg cap 02140047 TEV Rhinaris-F 25mcg/dose Nasal Mist 01927167 PMS Sandoz Levobunolol 0.25% oph sol 02241715 SDZ Sandoz Ticlopidine 250mg tab 02243587 SDZ Sensura Easiclose 95098396 COL Sensura Flex Dr Pouch 95098354 COL Stieva-A 0.025% sol 00578568 GSK Temodal 180mg Cap 02312816 SCH Timolol Maleate-EX 0.25% Oph Gel 02242275 PMS Timolol Maleate-EX 0.5% Oph Gel 02242276 PMS

REIMBURSEMENT LIST - January 1, 2012

NOVA SCOTIA PHARMACARE PROGRAMS

21

Key: 1. MRP = Maximum reimbursable price. The beneficiary is not to be charged any cost difference between the actual acquisition cost of the drug and the MRP.

2. PRP = Pharmacare reimbursement price. The beneficiary is always to be charged the cost difference between the actual acquisition cost of the drug and the PRP unless a PRP exception has been approved.

Version: NS Pharmacare Reimbursement List Effective January 1, 2012 Page 1 of 1

Generic Name and Strength DIN Brand MFR MRP PRPadalimumab 50mg/mL inj 02258595 Humira 40mg/0.8mL inj ABB 969.8815bosentan 62.5mg tab 02244981 Tracleer 62.5mg tab ACT 69.6338bosentan 125mg tab 02244982 Tracleer 125mg tab ACT 69.6338dasatinib 50mg cap 02293137 Sprycel 50mg cap BRI 78.0658dasatinib 100mg cap 02320193 Sprycel 100mg cap BRI 154.4823erythropoeietin 2,000iu/mL inj (exception status)

02231583 Eprex 1,000iu/0.5mL syringe inj JAN 30.9225

erythropoeietin 4,000iu/mL inj (exception status)

02231584 Eprex 2,000iu/0.5mL syringe inj JAN 61.8450

erythropoeietin 10,000iu/mL inj (exception status)

02231585 Eprex 3,000iu/0.3mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02231586 Eprex 4,000iu/0.4mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02243400 Eprex 5,000iu/0.5mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02243401 Eprex 6,000iu/0.6mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02243403 Eprex 8,000iu/0.8mL syringe inj JAN 154.6125

erythropoeietin 10,000iu/mL inj (exception status)

02231587 Eprex 10,000iu/mL syringe inj JAN 154.6125

erythropoeietin 40,000iu/mL inj (exception status)

02243239 Eprex 20,000iu/0.5mL syringe inj JAN 600.5258

erythropoeietin 40,000iu/mL inj (exception status)

02288680 Eprex 30,000iu/0.75mL syringe inj JAN 600.5258

erythropoeietin 40,000iu/mL inj (exception status)

02240722 Eprex 40,000iu/mL syringe inj JAN 450.3944

everolimus 2.5mg tab 02369257 Afinitor 2.5mg tab NVR 201.8100everolimus 5mg tab 02339501 Afinitor 5mg tab NVR 201.8100everolimus 10mg tab 02339528 Afinitor 10mg tab NVR 201.8100imatinib 100mg tab (exception status) 02253275 Gleevec 100mg tab NVR 29.5926imatinib 100mg tab (exception status) 02253283 Gleevec 400mg tab NVR 118.3702infliximab 100mg IV inj 02244016 Remicade 100mg pdr for inj SCH 1,019.9000nilotinib 150mg cap 02368250 Tasigna 150mg cap NVR 29.5926nilotinib 200mg cap 02315874 Tasigna 200mg cap NVR 42.0054rituximab 10mg/mL inj 02241927 Rituxan 10mg/mL inj HLR 55.6063sorafenib 200mg tab 02284227 Nexavar 200mg tab BAY 48.8928sunitinib 25mg cap 02280809 Sutent 25mg cap PFI 137.0402sunitinib 50mg cap 02280817 Sutent 50mg cap PFI 274.0807ustekinumab 90mg/mL inj 02320673 Stelara 45mg/0.5mL syringe inj JAN 9,414.7620

NOVA SCOTIA PHARMACARE PROGRAMS

2012

CUT-OFF DATES, PAYMENT DATES & RUN NUMBERS

CUT-OFF

DATE RUN DATE

PAYMENT DATE

RUN #

CUT-OFF DATE

RUN DATE

PAYMENT DATE

RUN #

9-Jan-12 10-Jan-12 13-Jan-12 9 AJ 9-Jul-12 10-Jul-12 13-Jul-12 9 GJ

23-Jan-12 24-Jan-12 27-Jan-12 9 AT 23-Jul-12 24-Jul-12 27-Jul-12 9 GT

6-Feb-12 7-Feb-12 10-Feb-12 9 BH 6-Aug-12 7-Aug-12 10-Aug-12 9 HH

20-Feb-12 21-Feb-12 24-Feb-12 9 BR 20-Aug-12 21-Aug-12 24-Aug-12 9 HR

5-Mar-12 6-Mar-12 9-Mar-12 9 CG 3-Sep-12 4-Sep-12 7-Sep-12 9 IE

19-Mar-12 20-Mar-12 23-Mar-12 9 CQ 17-Sep-12 18-Sep-12 21-Sep-12 9 IO

1-Apr-12** 2-Apr-12** 5-Apr-12** 9 DD 1-Oct-12 2-Oct-12 5-Oct-12 9 JE

16-Apr-12 17-Apr-12 20-Apr-12 9 DO 15-Oct-12 16-Oct-12 19-Oct-12 9 JO

30-Apr-12 1-May-12 4-May-12 9 ED 29-Oct-12 30-Oct-12 2-Nov-12 9 KB

14-May-12 15-May-12 18-May-12 9 EN 12-Nov-12 13-Nov-12 16-Nov-12 9 KL

28-May-12 29-May-12 1-Jun-12 9 FA 26-Nov-12 27-Nov-12 30-Nov-12 9 KV

11-Jun-12 12-Jun-12 15-Jun-12 9 FK 10-Dec-12 11-Dec-12 14-Dec-12 9 LJ

25-Jun-12 26-Jun-12 29-Jun-12 9 FU 19-Dec-12** 20-Dec-12** 28-Dec-12 9 LT

CLAIMS MUST BE RECEIVED BY 11:59 P.M. ON CUT-OFF DATE

TO ENSURE PROCESSING FOR THAT PAYMENT PERIOD.

PLEASE NOTE, THE ** INDICATES A DATE VARIATION

04/2011 Please Return Form To: Nova Scotia Pharmacare Department, P.O. Box 500, Halifax, NS B3J 2S1 FAX: (902) 468-9402

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

REQUEST FOR INSURED COVERAGE OF EXCEPTION STATUS DRUG (PHARMACIST VERSION)

PATIENT INFORMATION

PATIENT’S SURNAME

PATIENT’S GIVEN NAME HEALTH CARD NUMBER DATE OF BIRTH

PATIENT’S ADDRESS

DIAGNOSTIC/DRUG INFORMATION

DIAGNOSIS/INDICATION: REQUESTED DRUG NAME/DOSAGE REASON FOR REQUEST: EXPLAIN:

PHARMACIST INFORMATION

PHARMACIST SURNAME

FIRST NAME INITIAL PHONE: FAX:

STREET ADDRESS

CITY PROVINCE POSTAL CODE NSCP#:

PHARMACIST’S SIGNATURE:

DATE:

ARE YOU THE PRESCRIBER? YES